<SEC-DOCUMENT>0001213900-26-048090.txt : 20260427
<SEC-HEADER>0001213900-26-048090.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427171623
ACCESSION NUMBER:		0001213900-26-048090
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36848
		FILM NUMBER:		26902123

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		NON US STATE TERRITORY:  	ISRAEL
		PROVINCE COUNTRY:   	L3
		ZIP:			000000
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		NON US STATE TERRITORY:  	ISRAEL
		PROVINCE COUNTRY:   	L3
		ZIP:			000000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0287623-20f_checkcap.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:34 UTC 2026 -->
<html xmlns:chek="http://check-cap.com/20251231" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-19778">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-19779">&#9744;</ix:nonNumeric> <b>REGISTRATION STATEMENT PURSUANT TO
SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-19780">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-19781"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-19782">December&#160;31</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-19783">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-19784">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport" id="ixv-19785">&#9744;</ix:nonNumeric> <b>SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-19786">001-36848</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-76"><b>Check-Cap Ltd.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1.5pt solid">(Exact name of
the Registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-84"><b>Israel</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1.5pt solid">(Jurisdiction of
incorporation or organization)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-19787">29 Abba Hushi Avenue</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-19788">P.O. Box 1271</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-19789">Isfiya</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-19790">3009000</ix:nonNumeric> Mount Carmel, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-19791">Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1.5pt solid">(Address of principal
executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-19792">David Lontini</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chairman of the Board and
Interim Chief Executive Officer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check-Cap Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-19793">29 Abba Hushi Avenue</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-106">P.O. Box<br/> 1271</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-19794">Isfiya</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-19795">3009000</ix:nonNumeric> Mount Carmel, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-19796">Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone:
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-19797">+1 (647)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-19798">892-9516</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress" id="ixv-19799">david@londacorp.com</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="width: 2%">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="width: 2%">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-133"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares, par value NIS 48.00</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-138"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MBAI</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-19800">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of
each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <b>As of December&#160;31,
2025, the registrant had <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-19801">7,020,502</ix:nonFraction> ordinary shares outstanding, NIS 48.00 par value per share.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-19802">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-19803">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-19804">Yes</ix:nonNumeric> &#9746;&#160;&#160; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-19805">Yes</ix:nonNumeric> &#9746;&#160;&#160; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; Large Accelerated filer</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; Accelerated filer</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; <ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-19806">Non-accelerated filer</ix:nonNumeric></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-19807">&#9744;</ix:nonNumeric> Emerging growth company</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-19808">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-19809">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; <ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-19810">U.S. GAAP</ix:nonNumeric></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; International Financial Reporting<br/> Standards as issued by the International Accounting Standards Board</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; Other</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; Item 17 &#9744; Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-19811">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PAST FIVE YEARS)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent
to the distribution of the securities under a plan confirmed by a court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td colspan="2">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="2"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part I</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 9%">&#160;</td>
    <td style="width: 82%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identity of Directors, Senior Management and Advisers</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisers</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Statistics and Expected Timetable</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved.]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information On Our Company</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company Our History</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4A.</span></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and Prospects</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, patents and licenses, etc.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="width: 82%"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and senior management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation of Directors and Executive Officers</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders and Related Party Transactions</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements and Other Financial Information.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer and Listing</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets for Ordinary Shares</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange controls</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and paying agents</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by experts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td><a href="#a_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on display</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosure About Market Risk</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Other Than Equity Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="2"><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part II </span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 9%">&#160;</td>
    <td style="width: 82%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td><a href="#a_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Modifications to The Rights of Security Holders and Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td><a href="#a_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td><a href="#a_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16A.</span></td>
    <td><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Financial Expert.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16B.</span></td>
    <td><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16C.</span></td>
    <td><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16D.</span></td>
    <td><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemptions From The Listing Standards for Audit Committees.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16E.</span></td>
    <td><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases of Equity Securities By The Issuer and Affiliated Purchasers.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16F.</span></td>
    <td><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#8217;s Certifying Accountant.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16G.</span></td>
    <td><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16H.</span></td>
    <td><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16I.</span></td>
    <td><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16J.</span></td>
    <td><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policies.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16K.</span></td>
    <td><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_074">Part III</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 17.</span></td>
    <td><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 18.</span></td>
    <td><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 19.</span></td>
    <td><a href="#a_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_078">Signatures</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Check-Cap Ltd. (&#8220;Check-Cap&#8221;,
the &#8220;Company&#8221; or &#8220;we&#8221;) is a clinical stage medical diagnostics company with a limited operating history. On June&#160;6,
2023, Check-Cap announced that after further review of additional data and interaction with the Food and Drug Administration on a revised
pivotal study protocol together with the anticipated time and investment necessary to further develop the technology, it was reducing
its workforce significantly to reduce cash burn, concentrating its&#160; resources on essential research activities, discontinuing its
calibration studies, and evaluating and pursuing strategic options. As a result of its evaluation and pursuit of strategic options, on
August&#160;16, 2023, Check-Cap entered into a business combination agreement (the &#8220;Keystone BCA&#8221;) with Keystone Dental Holdings,
Inc. (&#8220;Keystone&#8221;), Capstone Dental PubCo, Inc (&#8220;PubCo&#8221;) and other direct, wholly owned subsidiaries of PubCo.
At its 2023 annual general meeting of shareholders, such business combination transactions did not receive the requisite majority required
for approval under Section 320 of the Israeli Companies Law 5759-1999. On December&#160;24, 2023, Check-Cap received a notice on behalf
of Keystone, terminating the Keystone BCA in light of the results. On March&#160;25, 2024, Check-Cap entered into a business combination
agreement (the &#8220;Apollo BCA&#8221;) with Apollo Technology Capital Corporation (formerly known as Nobul AI Corp.) (&#8220;Apollo&#8221;),
a private Ontario corporation (the &#8220;Check-Cap/Apollo Business Combination&#8221;). On September 12, 2025, Check-Cap entered into
an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with MBody AI Inc. (&#8220;MBody AI&#8221;), a Nevada corporation, and
CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Check-Cap (the &#8220;Merger Sub&#8221;), pursuant
to which <span style="font-family: Times New Roman, Times, Serif">Merger Sub will merge with and into MBody AI, with MBody AI surviving
as a wholly-owned subsidiary of Check-Cap</span> (the &#8220;Merger&#8221;). The Merger and a proposed reverse share split of Check-Cap&#8217;s
ordinary shares within a range of 1 for 2 to 1 for 100 were approved by Check-Cap&#8217;s shareholders on November 14, 2025. The exact
ratio of the reverse share split will be determined by further action of Check-Cap&#8217;s board of directors and will be effective on
a date to be determined by Check-Cap&#8217;s board of directors. <span style="font-family: Times New Roman, Times, Serif">The Merger
is expected to consummate in the first half of 2026; however, the timing of the completion of the Merger is subject to various conditions
and uncertainties, and there can be no assurance that the Merger will be completed within this timeframe or at all. Immediately after
the Merger, former MBody AI equityholders are expected to own approximately 90% of the issued and outstanding ordinary shares of the
combined company on a fully diluted basis, and former Check-Cap equityholders are expected to own approximately 10% of the issued and
outstanding ordinary shares of the combined company on a fully diluted basis. The combined company will change its name from &#8220;Check-Cap
Ltd.&#8221; to &#8220;MBody AI Ltd.&#8221; On December&#160;1, 2025, Check-Cap changed its ticker symbol from &#8220;CHEK&#8221; to &#8220;MBAI&#8221;
effective at the opening of trading on December&#160;2, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the effective time of
the closing of the Merger, the Apollo BCA will be terminated by mutual consent of the parties such that no termination fee will be due
to Apollo or Check-Cap. Upon the closing of the Merger, the loans made by Check-Cap to Apollo that are currently outstanding will be
converted into a 7.5% equity position in Apollo that will be owned by Check-Cap, and each of the related loan agreements between Check-Cap
and Apollo will be cancelled for no further consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise stated,
all of our financial information presented in this annual report has been prepared in accordance with generally accepted accounting principles
in the United States of America, or U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In this Annual Report on
Form 20-F, or the Annual Report, unless the context indicates otherwise, references to &#8220;NIS&#8221; are to the legal currency of
Israel, &#8220;U.S. dollars,&#8221; &#8220;$&#8221; or &#8220;dollars&#8221; are to United States dollars, and the terms &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our Company,&#8221; &#8220;our,&#8221; and &#8220;Check-Cap&#8221; refer to Check-Cap Ltd. Unless otherwise
indicated, U.S. dollar translation of NIS amounts presented in this Annual Report are translated using the rate of $1.00 = NIS 3.1870,
the exchange rate published by the U.S. Treasury&#8217;s official report on December&#160;31, 2025, and U.S. dollar translation of GBP
amounts presented in this Annual Report are translated using the rate of $1.00 = GBP 0.7912, based on the exchange rates published by
the U.S. Treasury&#8217;s official report on December&#160;31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF TRADE NAMES AND TRADEMARKS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Throughout this Annual Report,
we refer to various trademarks, service marks and trade names that we use in our business. The &#8220;CHECK-CAP&#8221; and &#8220;C-Scan&#8221;
trademarks and design logos are the property of Check-Cap Ltd. Other trademarks and service marks appearing in this Annual Report are
the property of their respective holders. We do not intend our use or display of other companies&#8217; tradenames, trademarks or service
marks to imply a relationship with, or endorsement or sponsorship of us by these other companies. Solely for convenience, trademarks
and trade names referred to in this Annual Report appear without the &#174; or TM symbols, but such references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor
to these trademarks and trade names.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report contains
forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our plans with respect to our
evaluation and pursuit of strategic options including the transactions contemplated by the Apollo BCA and the Merger Agreement, our ongoing
and planned product development and clinical trials and lack thereof; the timing of, and our ability to make, regulatory filings and
obtain and maintain regulatory approvals for our product candidates; our intellectual property position; the degree of clinical utility
of our products, particularly in specific patient populations; our ability to develop commercial functions; expectations regarding product
launch and revenue; our results of operations; cash needs; our ability to raise capital, including but not limited to capital raised
pursuant to our existing equity line of credit; financial condition, liquidity, prospects, growth and strategies; the industry in which
we operate; and the trends that may affect the industry or us. In addition, from time to time, we or our representatives have made or
may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements
made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially
from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results
to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors
summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report identifies
important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements, particularly
those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this Annual Report are not necessarily all
of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements.
Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Factors that could cause
our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our previously announced
    Merger Agreement with MBody AI and the proposed termination of the Apollo BCA upon the closing of the Merger, and our ability to
    consummate the Merger;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    integrate MBody AI&#8217;s business and operations following the closing of the Merger;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            ability to capitalize on the Ghost Kitchen franchise rights;</td>
</tr></table><div>



</div><p style="text-align: justify; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            ability to raise capital, including pursuant to our existing equity line of credit;</td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    compliance with The Nasdaq Capital Market LLC&#8217;s (&#8220;Nasdaq&#8221;) continued listing requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history of losses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our needs for additional
    capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue
    as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, timing,
    progress and results of our clinical trials and other product development efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on one product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical development,
    commercialization and market acceptance of C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to receive
    de novo classification or premarket approval and other regulatory approvals for C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    complete clinical trials and obtain desired performance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on single-source
    suppliers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve
    an acceptable cost of goods;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on third parties,
    such as for purposes of our clinical trials and clinical development and the manufacturing, marketing and distribution of C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    and maintain strategic partnerships and other corporate collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve
    reimbursement and coverage from government and private third-party payors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our
    business model and strategic plans for our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of protection
    we are able to establish and maintain for intellectual property rights covering C-Scan and our ability to operate our business without
    infringing the intellectual property rights of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive companies,
    technologies and our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current or future adverse
    developments with respect to financial institutions and associated liquidity risk;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable economic and
    market conditions, including uncertainties around the impact of inflation, cost of capital and the impact from the changes in economic
    policies and regulations, such as trade policies and tariffs;&#160;and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors referred
    to in &#8220;Item 3. Key Information - D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item
    5. Operating and Financial Review and Prospects&#8221;, as well as in this Annual Report generally.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All forward-looking statements
attributable to us or persons acting on our behalf speak only as of the date of this Annual Report and are expressly qualified in their
entirety by the cautionary statements included in this Annual Report. We undertake no obligations to update or revise forward-looking
statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In
evaluating forward-looking statements, you should consider these risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MARKET AND INDUSTRY DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Market data and certain
industry data and forecasts used throughout this Annual Report were obtained from internal company surveys, market research, consultant
surveys commissioned by the Company, publicly available information, reports of governmental agencies and industry publications and surveys.
Industry surveys, publications, consultant surveys commissioned by the Company and forecasts generally state that the information contained
therein has been obtained from sources believed to be reliable. However, this information may prove to be inaccurate because of the method
by which some of the data for the estimates is obtained or because this information cannot always be verified with complete certainty
due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations
and uncertainties. As a result, the market and industry data and forecasts included or incorporated by reference in this Annual Report,
and estimates and beliefs based on that data, may not be reliable. We have relied on certain data from third-party sources, including
internal surveys, industry forecasts and market research, which we believe to be reliable based on our management&#8217;s knowledge of
the industry. However, we have not ascertained the underlying economic assumptions relied upon therein. Forecasts are particularly likely
to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic
growth were used in preparing the forecasts we cite. Statements as to our market position are based to the best of our knowledge on the
most currently available data. While we are not aware of any misstatements regarding the industry data presented in this Annual Report,
our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the
heading &#8220;Risk Factors&#8221; in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Part
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
1. Identity of Directors, Senior Management and Advisers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Directors and Senior Management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Advisers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Auditors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
2. Offer Statistics and Expected Timetable</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
3. Key Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. </b>[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Capitalization and Indebtedness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Reasons for the Offer and Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Risk factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>In conducting our business,
we face many risks that may interfere with our business objectives. Some of these risks could materially and adversely affect our business,
financial condition and results of operations. In particular, we are subject to various risks resulting from changing economic, political,
industry, regulatory, business and financial conditions. The risks and uncertainties described below are not the only ones we face. Additional
risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our
business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>You should carefully
consider the following factors and other information in this Annual Report before you decide to invest in our ordinary shares. These
disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect us and our securities in the future.
References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to
whether or not such factors have occurred in the past or their likelihood of occurring in the future. If any of the risks referred to
below occur, our business, financial condition and results of operations could suffer. In any such case, the trading price of our ordinary
shares could decline, and you may lose all or part of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business is subject
to numerous risks and uncertainties, including those highlighted in the section titled &#8220;Risk Factors&#8221; immediately following
this summary. The principal factors and uncertainties that make investing in our ordinary shares risky, include, among others:</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Merger</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance of ordinary
    shares in connection with the Merger will substantially dilute the relative voting power of holders of Check-Cap ordinary shares
    prior to the closing of the Merger, and, as a result, such holders will exercise substantially less influence over the management
    and policies of the combined company following the consummation of the Merger;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred
    and expects to continue to incur substantial non-recurring transaction-related costs in connection with the Merger, including legal,
    accounting, regulatory filing, and other professional fees, which will be incurred regardless of whether the Merger is completed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may fail to
    realize the anticipated benefits of the Merger, including as a result of difficulties in integrating the operations and personnel
    of the two companies, failure to retain key employees, higher-than-expected integration or transaction costs, and unforeseen market
    or economic conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may become
    involved in securities class action litigation or shareholder derivative litigation in connection with the Merger, which could result
    in substantial costs, divert management&#8217;s attention and resources, and have a material adverse effect on the Company&#8217;s
    business, financial condition, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Merger is not completed
    for any reason, the Company will need to evaluate its strategic alternatives and will require significant additional funding in order
    to continue operations, and if such funding is not available on acceptable terms, the Company may be forced to significantly curtail
    or cease operations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Apollo BCA remains
    in effect and will not terminate unless and until the Merger closes, and the Company has outstanding other payables due to Apollo
    in the aggregate principal amount of approximately $1.4 million as of December 31, 2025, the conversion of which to equity in Apollo
    is contingent on the closing of the Merger. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Position</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a history of losses, may incur future losses and require additional funding in order to complete the development of our products
    and technology. If additional capital is not available and we cease the development of our products and technology or are obligated
    to relinquish rights to our intellectual property, we may not ever achieve profitability and be forced to liquidate; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not recover amounts
loaned to Apollo, and any equity interest in Apollo we ultimately hold may be illiquid and of uncertain value. The Company has made loans
to Apollo in the aggregate principal amount of approximately $16.3 million, which are to be exchanged for common shares representing
a 7.5% equity interest in Apollo, pursuant to an Exchange Agreement (defined below) and a BCA Termination Agreement dated September 12,
2025, by and between Apollo and the Company (the &#8220;BCA Termination Agreement&#8221;), conditioned on the closing of the Merger.
If the Merger does not close, the Exchange Agreement will not close and the Company may not recover these amounts. If the Merger closes,
the Company will hold a minority interest in a private company with no readily determinable fair value, and there can be no assurance
the Company will realize the carrying value, or any value, from such investment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to MBody AI&#8217;s Business and Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI has a limited
    operating history and an evolving business model, which makes it difficult to evaluate its future prospects and may adversely affect
    the MBody AI&#8217;s ability to achieve its business objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI currently relies
    on a limited number of customers, and the loss or reduction of business from any customer could materially adversely affect its results
    of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI&#8217;s operations
    depend on a small number of third-party vendors, deployment partners, and hardware suppliers, and any failure by its suppliers to
    deliver on schedule, in sufficient quantities, or at anticipated price points could delay customer implementations or impair revenue
    targets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI operates in regulated
    environments, including hospitality, gaming, and potentially healthcare, and regulatory requirements may change over time, differ
    by jurisdiction, or impose additional compliance costs that could adversely affect its ability to deploy its platform or expand into
    new markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI may face liability
    or compliance exposure related to the operation of autonomous systems, and the evolving regulatory landscape for artificial intelligence,
    robotics, and autonomous systems could impose additional obligations or restrict certain applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI has a history
    of operating losses since inception and may not achieve or sustain profitability, and will require additional capital to execute
    its business plan, which may not be available on acceptable terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI operates in a
    rapidly evolving and competitive market, and new technologies, business models, or competitors may emerge that could reduce demand
    for its platform or render its offerings less competitive; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MBody AI&#8217;s success
    depends on its ability to attract and retain key management and technical personnel, and the loss of key personnel or inability to
    attract additional talent could materially adversely affect its business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the ARC ELOC Facility</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is not possible to predict
    the actual number of shares we will sell under that certain Purchase Agreement&#160;&#160;(the &#8220;Purchase Agreement&#8221;)
    entered with ARC Group International Ltd. (&#8220;ARC&#8221;) on December 17, 2025 (the &#8220;ARC ELOC Facility&#8221;), or the
    actual gross proceeds resulting from those sales, and the total proceeds could be substantially less than the $30.0 million total
    commitment amount;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may require additional
    financing to sustain our operations beyond the Purchase Agreement, and such financing may not be available on acceptable terms, or
    at all, which could materially adversely affect our business, financial condition, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future sales and issuances
    of our ordinary shares, including pursuant to the Purchase Agreement, might result in significant dilution to existing shareholders
    and could cause the price of our ordinary shares to decline; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We undertake to seek shareholder
    approval to re-designate our ordinary shares as no-par value, and any delay or failure to complete the re-designation could limit
    our flexibility to issue shares under the Purchase Agreement and adversely affect our ability to raise capital.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Acquisition of Ghost Kitchen Franchise Rights
in New Jersey</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There can be no assurance
    that the Company will realize the anticipated benefits of the acquisition of Ghost Kitchen franchise rights in New Jersey, including
    generating revenue from the acquired operations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued 1,169,596
    ordinary shares as consideration for the acquisition of Ghost Kitchen franchise rights in New Jersey, and while the shares are subject
    to a two-year lock-up period and a voting agreement, the eventual availability of those shares for resale in the public market could
    adversely affect the price of our ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Historical Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although we received Food
    and Drug Administration (&#8220;FDA&#8221;) approval of our investigational device exemption (&#8220;IDE&#8221;) (including our IDE
    amended application) for our U.S. pivotal study, the most recent efficacy results from our studies did not meet the goal to proceed
    to the powered portion of the U.S. pivotal study, as such we cannot provide any assurance that we will ever be able to redesign such
    study or redeploy our technology into other potentially viable products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical failure can occur
    at any stage of clinical development, and we may not succeed in completing the development of our product. Any product we advance
    through clinical trials may require further clinical validation and may not have favorable results in later clinical trials or receive
    regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may face a number of
    challenges with respect to our commercialization efforts and may not succeed in the commercialization of our product, obtain required
    regulatory approvals or manufacture commercial quantities of C-Scan at an acceptable cost to enable us to generate significant revenues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited manufacturing
    experience and capabilities and if we are unable to scale up our manufacturing operations to develop our products, our growth could
    be limited and our business, financial condition and results of operations could be materially adversely affected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on sole or
    single source suppliers could harm our ability to conduct clinical trials and meet demand for our product in a timely manner or within
    our budget;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of any of our C-Scan
    Cap, C-Scan Track, C-Scan View or any new products and technology could result in product liability or similar claims that could
    be expensive to defend, damage our reputation and harm our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have historically depended
    on third parties to manage our clinical studies and trials, perform related data collection and analysis, and to enroll patients
    for our clinical trials, and, as a result, we may face costs and delays that are beyond our control;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently expect to
    sell our products mainly in the United States, Europe, Israel and Japan and, if we are unable to manage our operations in these territories,
    our business, financial condition and results of operations could be materially adversely affected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful
    in establishing and maintaining strategic partnerships, which could adversely affect our ability to develop and commercialize our
    products and technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A security breach or disruption
    or failure in a computer or communications systems could adversely affect us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or the third parties
    upon whom we depend may be adversely affected by natural disasters and/or health epidemics or pandemics and our business continuity
    and disaster recovery plans may not adequately protect us from a serious disaster; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder activism could
    result in potential operational disruption, divert our resources and management&#8217;s attention and have an adverse effect on our
    business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Regulations Applicable to Our Historical Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or our future manufacturers
    or distributors do not obtain and maintain the necessary regulatory clearances or approvals, or equivalent third country approvals
    in a specific country or region, we or our future distributors will not be able to market and sell C-Scan or future products in that
    country or region;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the indications for
    use or instructions for use for which the iodinated oral contrast medium is approved are not sufficiently broad to support its use
    throughout the C-Scan procedure, the FDA or the competent regulatory authorities in the European Union (&#8220;EU&#8221;) Member
    States and other foreign countries may consider that contrast agent is being used off-label;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of any future
    clinical trials may not support our product candidate requirements or intended use claims or may result in the discovery of adverse
    side effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if C-Scan or future
    products are cleared or approved by regulatory authorities or after obtaining CE Certificates from a notified body, modifications
    to C-Scan or future products may require new regulatory clearances or approvals, new CE Certificates, or may require us to recall
    or cease marketing it until the necessary clearances, approvals or CE Certificates are obtained;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our failure to comply with
    radiation safety or radio frequency regulations in a specific country or region could impair our ability to conduct our clinical
    trials, or commercially distribute and market C-Scan or any similar product in that country or region;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products may in the
    future be subject to product recalls that could harm our reputation, business and financial results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If C-Scan or future products
    cause or contribute to a death or a serious injury, or malfunction in such a way that causes or contributes to a death or serious
    injury, we will be subject to medical device reporting regulations, which can result in corrective actions or enforcement actions
    from regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business is subject
    to complex environmental and health legislation in various jurisdictions that may increase our costs and our risk of noncompliance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal and state privacy
    laws, and equivalent laws of third countries, may increase our costs of operation and expose us to civil and criminal sanctions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with
    the U.S. federal Anti-Kickback Statute and similar state and third-country laws, we could be subject to criminal and civil penalties
    and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third-country
    programs, which would have a material adverse effect on our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our failure to comply with
    the necessary regulatory approval regarding the use of radioactive materials could significantly impair our ability to develop, manufacture
    and/or sell C-Scan or similar products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to source and
    distribute our products profitably or at all could be harmed if new trade restrictions are imposed or existing trade restrictions
    become more burdensome.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Legacy Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to protect
    our intellectual property rights, our competitive position could be harmed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the medical device
    industry is litigious, we are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial
    damages or prohibit us from selling C-Scan or any similar products we may develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The steps we have taken
    to protect our intellectual property may not be adequate, which could have a material adverse effect on our ability to compete in
    the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third parties may challenge
    the validity of our issued patents or challenge patent applications in administrative proceedings before various patent offices which,
    if successful, could negatively affect our future business and financial performance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to initiate
    lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could
    cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on trademark protection
    to distinguish our products from the products of our competitors; however, if a third party is entitled to use our trademark, we
    could be forced to rebrand, which could result in loss of brand recognition and our ability to distinguish our products may be impaired,
    which could adversely affect our business; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to enforce
    covenants not to compete at all or, we may be unable to enforce them for the duration contemplated in our employment contracts and
    may, therefore, be unable to prevent competitors from benefiting from the expertise of some of our former employees involved in research
    and development activities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal offices,
    research and development facilities, our manufacturing sites and some of our suppliers are located in Israel and, therefore, our
    business, financial condition and results of operation may be adversely affected by political, economic and military instability
    in Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of
    the Israeli government grants we received for research and development expenditures related to our historical business, we are obligated
    to pay certain royalties on our revenues from our legacy products to the Israeli government. In addition, the terms of an Israeli
    government grant we received require us to satisfy specified conditions and to make additional payments in addition to repayment
    of the grants upon certain events;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your rights and responsibilities
    as a shareholder are governed by Israeli law, which differ in some material respects from the rights and responsibilities of shareholders
    of U.S. companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It may be difficult to
    enforce a judgment of a U.S. court against us, certain of our officers and directors or the Israeli experts named in this Annual
    Report in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on certain of our officers
    and directors and these experts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law
    and our amended articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when
    the terms of such a transaction are favorable to us and our shareholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may become subject to
    claims for payment of compensation for assigned service inventions by our current or former employees relating to our historical
    business, which could result in litigation and adversely affect our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Ownership of our Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incur and will continue
    to incur significant costs as a result of operating as a public company in the United States, and our management is required to devote
    substantial time to compliance initiatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to maintain
    effective internal control over financial reporting, the price of our ordinary shares may be adversely affected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to maintain
    compliance with Nasdaq&#8217;s continued listing requirements, which could result in the delisting of our ordinary shares from Nasdaq;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a foreign private
    issuer and, as a result, we are not subject to U.S. proxy rules and are subject to the Securities Exchange Act of 1934 reporting
    obligations that, to some extent, are more lenient and less frequent than those applicable to a U.S. issuer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a foreign private issuer,
    we are permitted, to follow, and follow certain home country corporate governance practices instead of otherwise applicable Nasdaq
    requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we lose our status as
    a foreign private issuer under the SEC&#8217;s rules, our compliance costs will increase;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange rate fluctuations
    between the U.S. dollar and the NIS and the Euro and inflation may negatively affect our earnings and we may not be able to hedge
    our currency exchange risks successfully;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never declared
    or paid a dividend and currently do not intend to pay cash dividends in the foreseeable future. Any return on investment may be limited
    to the value of our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If securities or industry
    analysts do not publish research or reports about us or our business or publish unfavorable research about us or our business, the
    price of our securities and their trading volume could decline;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our stock price has and
    may be subject to fluctuation, and purchasers of our securities could incur substantial losses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The trading market for
    our ordinary shares is not always active, liquid and orderly, which may inhibit the ability of our shareholders to sell ordinary
    shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have broad discretion
    in how we use the net proceeds from our financings, and we may not use these proceeds effectively; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business, operating
    results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments
    with respect to financial institutions and associated liquidity risk.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Risks Related to Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is a risk that we
    could be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the transactions related to our
    acquisition of all of the business operations and substantially all of the assets of Check-Cap LLC on May&#160;31, 2009 (the &#8220;Reorganization&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be eligible for
    tax benefits from government programs relating to our historical assets, which require us to meet certain conditions, including regarding
    the location of our property, plant and equipment and manufacturing in Israel. We can provide no assurance that we would continue
    to be eligible for such benefits and/or that any such benefits will not be terminated in the future; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is a risk that we
    may be classified as a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences
    to U.S. investors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Merger</b></span> </p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>The consummation
of the Merger is subject to the satisfaction of certain conditions, which may not be satisfied on a timely basis, if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2025, the Company entered into the Merger Agreement,
pursuant to which Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly owned subsidiary of the Company.
The Merger was approved by the Company&#8217;s shareholders on November 14, 2025. The consummation of the Merger remains subject to the satisfaction
or waiver of certain closing conditions, including, among others, that no governmental authority shall have issued any order preventing
the Merger, the expiration or termination of any applicable waiting periods under antitrust laws, the accuracy of representations and
warranties of each party, the performance by each party of its covenants and obligations in all material respects, and the absence of
a material adverse effect with respect to either party. We cannot assure you that all of the conditions will be satisfied or waived.
If the conditions are not satisfied or waived, the Merger will not occur or will be delayed, and we may lose some or all of the intended
benefits of the Merger. The Merger Agreement provides that either party may terminate the agreement if the Merger is not consummated
by June 30, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><b>Our shareholders
will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Company following
the consummation of the Merger.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Pursuant to the Merger Agreement, at the effective time of the Merger,
each share of MBody AI capital stock outstanding immediately prior to the effective time will be converted into the right to receive
ordinary shares of the Company such that, following the closing, the former MBody AI shareholders will own approximately 90% of the Company&#8217;s
outstanding share capital on a fully diluted and as-converted basis, and the Company&#8217;s shareholders prior to the closing will own approximately
10%. Accordingly, the issuance of ordinary shares to MBody AI&#8217;s shareholders pursuant to the Merger Agreement will significantly reduce
the relative voting power of each ordinary share held by the Company&#8217;s existing shareholders. Consequently, existing shareholders will
exercise substantially less influence over the management and policies of the Company than they did prior to the consummation of the
Merger.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>During the pendency of the Merger, the Company is subject to operating
restrictions and limitations on its ability to pursue alternative transactions, which could adversely affect its financial condition
and results of operations.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Merger Agreement contains covenants that restrict the Company&#8217;s
ability to operate its business during the period between signing and closing. During this interim period, the Company is required to
operate in the ordinary course of business and is subject to restrictions on, among other things, declaring dividends or distributions,
amending its organizational documents, issuing securities (subject to limited exceptions), making capital expenditures in excess of $50,000,
entering into material contracts, and acquiring or disposing of material assets, in each case without the prior written consent of MBody
AI. In addition, the Company is subject to a no-solicitation covenant under which it is prohibited from soliciting, initiating, encouraging,
or entering into certain transactions with third parties. The Company may consider a Superior Offer (as defined in the Merger Agreement),
subject to compliance with specific notice and procedural requirements. These restrictions may prevent the Company from pursuing other
opportunities that may arise or from taking actions that would otherwise be in the best interests of shareholders and may adversely affect
the Company&#8217;s financial condition and results of operations.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>The Company has incurred and expects to continue to incur substantial
transaction-related costs in connection with the Merger.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Company has incurred, and expects to continue to incur, a number
of non-recurring transaction-related costs associated with the Merger and the related transactions, which cannot be accurately estimated
at this time. These fees and costs have been, and will continue to be, substantial. Non-recurring transaction costs include, but are
not limited to, fees paid to legal, financial, and other advisors, SEC filing costs, printing costs, and other regulatory expenses. Additional
unanticipated costs may be incurred in the Company&#8217;s business, which may be higher than expected and could have a material adverse effect
on the Company&#8217;s financial condition and operating results.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Company may fail to realize the anticipated benefits of the
Merger.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The success of the Merger will depend on the Company&#8217;s ability to
achieve its business objectives following the closing, including successfully integrating MBody AI&#8217;s business and operations, retaining
key personnel, maintaining and expanding customer relationships, and raising the necessary capital to fund operations. The integration
of MBody AI&#8217;s business involves a number of risks, including difficulties in combining operations and personnel, the potential disruption
of each company&#8217;s ongoing business, the possible inability to maintain uniform standards, controls, policies, and procedures, and unanticipated
expenses and liabilities. If the Company is not able to achieve these objectives, the anticipated benefits of the Merger may not be realized
fully, may take longer to realize than expected, or may not be realized at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>MBody AI has a limited operating history and an evolving business
model, which makes it difficult to evaluate its prospects and may increase the risk that the Merger will not achieve its objectives.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">MBody AI was incorporated in October 2024 and has a limited operating
history. MBody AI&#8217;s business model is still evolving and its future success depends on, among other things, its ability to develop and
commercialize its robotics and artificial intelligence platform, attract and retain customers, and scale its operations. There can be
no assurance that MBody AI&#8217;s business strategy will be successful or that its technology and services will achieve broad market acceptance.
The Company has limited historical financial data on which to base its evaluation of MBody AI&#8217;s prospects, and MBody AI&#8217;s limited operating
history makes it difficult to predict future performance. If MBody AI&#8217;s business does not develop as expected, the Company may not realize
the anticipated benefits of the Merger and the Company&#8217;s business, financial condition, and results of operations could be materially
adversely affected.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Company may become involved in securities litigation or shareholder
derivative litigation in connection with the Merger, and this could divert the attention of management and harm the Company&#8217;s business.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Securities litigation or shareholder derivative litigation frequently
follows the announcement of certain significant business transactions. The Company may become involved in this type of litigation in
connection with the Merger and is currently involved in shareholder derivative litigation relating to the Apollo BCA. Litigation often
is expensive and diverts management&#8217;s attention and resources, which could adversely affect the business of the Company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>We are substantially dependent on our remaining key employees to
facilitate the consummation of the Merger and the transition of the Company&#8217;s business.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">As a result of our cash conservation activities, we maintain a significantly
reduced workforce. Our ability to successfully complete the Merger and integrate with MBody AI&#8217;s business operations depends in large
part on our ability to retain certain key personnel. Despite our efforts to retain these employees, one or more may terminate their employment
on short notice. The loss of the services of any of these employees could potentially harm our ability to complete the Merger, run our
day-to-day business operations, and fulfill our reporting obligations as a public company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>If the Merger is not completed, the Company will require significant
additional funding in order to continue operations, and if additional capital is not available, the Company may have to cease operations.</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Merger was approved by the Company&#8217;s shareholders on November
14, 2025. The consummation of the Merger remains subject to the satisfaction of certain customary closing conditions. There can be no
assurance that these conditions will be satisfied on a timely basis, if at all. If the Merger is not completed for any reason, the Company
will need to evaluate its strategic alternatives and will require significant additional funding in order to continue its operations.
The Company previously entered into the Keystone BCA in August 2023, which was terminated in December 2023 after failing to receive the
requisite shareholder approval, and the Apollo BCA in March 2024, which will be subsequently terminated upon closing of the Merger. The
Company has incurred significant costs in connection with each of these transactions. A failure to complete the Merger would further
deplete the Company&#8217;s limited resources. In addition, if the Merger Agreement is terminated under certain circumstances, the Company
may be required to pay MBody AI a termination fee of up to $2.5 million. If adequate additional financing on acceptable terms is not
available, the Company&#8217;s ability to continue to support its business growth and to respond to business challenges could be significantly
limited, and the Company may have to curtail or cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The termination of the Apollo BCA is contingent on the closing
of the Merger, and if the Merger is not completed, the Apollo BCA an the related loan agreements will remain in effect.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms
of the Merger Agreement and the BCA Termination Agreement, at the effective time of the closing of the Merger, the Apollo BCA will be terminated by mutual consent of
the parties such that no termination fee will be due to Apollo or the will remain in effect. In such event, the Company would need
to evaluate its options with respect to the Apollo BCA, which could include pursuing the transactions contemplated thereby,
negotiating a termination, or taking other actions, any of which could require the expenditure of additional resources and
management attention. There can be no assurance that the resolution of the Apollo BCA on terms favorable to the Company would be
achieved outside the context of the Merger.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to MBody AI&#8217;s Business
and Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI has a limited operating history
and an evolving business model, which makes it difficult to evaluate its future prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI was incorporated
in October 2024 and has a limited operating history as an embedded AI software and service company. As a result, there is limited historical
information upon which investors can evaluate its business, operating results, or future prospects. MBody AI&#8217;s business model,
technology platform, and go-to-market strategy continue to evolve, and there can be no assurance that its current approach will result
in sustainable growth or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI currently relies on a limited
number of customers, and the loss or reduction of business from any customer could materially adversely affect its results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI currently derives
a significant portion of its revenue from a small number of enterprise customers. While certain customer arrangements have multi-year
terms, some customer agreements may be terminable under certain circumstances. The loss of a customer, a reduction in deployment scope,
delays in implementation, or a failure to expand existing deployments could materially and adversely affect MBody AI&#8217;s revenue,
operating results, and business prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI&#8217;s platform is deployed through
a phased and evolving feature set, which may affect the timing and scope of customer adoption.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s platform
is deployed through a staged rollout of features, with certain capabilities delivered incrementally or provided to customers through
asynchronous analysis and reporting rather than fully integrated real-time operation. While this approach is intended to support ongoing
refinement and optimization of the platform, there can be no assurance that all planned features will be completed on schedule, fully
integrated, or deliver the anticipated operational benefits. Delays in development, integration challenges, or performance limitations
could affect customer satisfaction, the pace of deployment expansion, or the renewal of customer arrangements. MBody AI relies in part
on asynchronous deployment, data collection, and analysis, which in certain circumstances may limit customer adoption, expansion, or
perceived value of the platform.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI&#8217;s operations depend on third-party
vendors, deployment partners, and hardware suppliers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI does not manufacture
robots or autonomous hardware and relies on third-party vendors, integrators, and partners for hardware procurement, deployment, financing,
and maintenance. This comprehensive service model involves customized deployments and coordination with customer personnel. As a result,
MBody AI&#8217;s operations are subject to several material risks related to these third-party dependencies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Procurement and Inventory
Risk:</i> MBody AI is responsible for the procurement of third-party hardware to fulfill turnkey customer orders. Any failure by its
suppliers to deliver units on schedule, in sufficient quantities, or at anticipated price points could delay customer implementations,
increase deployment costs, or impair our ability to meet its revenue targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Integration and Technical
Compatibility:</i> MBody AI&#8217;s proprietary AI Orchestrator&#8482; must integrate with various types of third-party hardware to deliver
a &#8220;unified command layer&#8221;. Disruptions in technical relationships, changes to Original Equipment Manufacturer (OEM) firmware,
or lack of access to critical APIs could cause service failures, limit platform functionality, or hinder its ability to coordinate heterogeneous
robot fleets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Geopolitical and Supply
Chain Sensitivity:</i> Certain components or systems may be sourced from vendors located outside the United States, including in jurisdictions
subject to evolving trade policies, export controls, or geopolitical tensions. These factors could increase MBody AI&#8217;s deployment
costs, compress hardware margins, or result in supply chain delays that materially adversely affect its results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Dependence on Financing
and Maintenance Partners:</i> MBody AI&#8217;s business involves complex implementation and ongoing operational support. MBody AI relies
on third-party partners for hardware, parts and software updates. Any failure by these partners to perform could result in increased
costs, contractual disputes, reputational harm, or reduced demand for MBody AI&#8217;s offerings causing a material adverse effect on
its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI&#8217;s business involves complex
implementation and service delivery, which may expose it to operational risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s services
often involve customized deployments across customer facilities, coordination with customer personnel, and ongoing operational support.
These activities may involve unforeseen technical, logistical, or operational challenges. Failure to effectively manage deployments,
services, or customer expectations could result in increased costs, contractual disputes, reputational harm, or reduced demand for MBody
AI&#8217;s offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Adoption, ROI, and Budget Cycles
could adversely affect MBody AI&#8217;s revenue, growth, and operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Customer adoption, expansion,
and renewal of MBody AI&#8217;s platform may depend on customers achieving expected operational benefits and on customer budget cycles.
MBody AI&#8217;s customers may evaluate continued or expanded deployment of the Company&#8217;s platform based on perceived operational
savings, efficiency improvements, or return on investment. These evaluations may be influenced by customer-specific factors, including
budget cycles, capital allocation priorities, labor conditions, macroeconomic factors, and internal approval processes. Even if customers
are satisfied with MBody AI&#8217;s platform, delays in expansion decisions, reductions in deployment scope, or changes in customer priorities
could adversely affect MBody AI&#8217;s revenue, growth, and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dependence on Customer Facilities and Operating
Environments could delay deployments, increase costs, or affect the performance or scalability of MBody AI&#8217;s platform.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s deployments
depend on customer-controlled facilities and operating environments, which are outside of its control. MBody AI&#8217;s platform is deployed
within customer facilities and physical environments that are owned and operated by customers. Deployment timelines, system performance,
and operational outcomes may be affected by factors outside MBody AI&#8217;s control, including facility layout, network infrastructure,
physical access constraints, operational schedules, and coordination with customer personnel. Limitations or changes in customer-controlled
environments could delay deployments, increase costs, or affect the performance or scalability of MBody AI&#8217;s platform.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Integration with Third-Party Software and
Systems could increase deployment costs, delay implementations, or reduce customer satisfaction.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s platform
may require integration with third-party software systems used by customers, which may present technical and operational challenges.
Customer deployments of MBody AI&#8217;s platform may require integration with third-party software systems, including facility management,
scheduling, or reporting systems. Such integrations may involve technical complexity, reliance on third-party interfaces or application
programming interfaces, and coordination with customers or third-party vendors. Changes to third-party systems, integration delays, or
compatibility issues could increase deployment costs, delay implementations, or reduce customer satisfaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI operates in regulated environments
and may be subject to regulatory requirements that could increase costs or limit growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s customers
operate in regulated industries, including hospitality, gaming, and potentially healthcare and data centers. In certain jurisdictions,
deployment of autonomous systems may require regulatory approvals, licenses, or compliance with industry-specific rules, including gaming
or safety regulations. Regulatory requirements may change over time, differ by jurisdiction, or impose additional compliance costs, which
could adversely affect MBody AI&#8217;s ability to deploy its platform or expand into new markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI may face liability or compliance
exposure related to the operation of autonomous systems.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although MBody AI does not
manufacture hardware, it sells, procures, finances, and/or supports the deployment of third-party autonomous hardware in connection with
its software platform. MBody AI&#8217;s software influences the operation and coordination of autonomous systems deployed in customer
environments, and its involvement in hardware procurement, deployment, or ongoing services may increase its exposure to claims, investigations,
or regulatory scrutiny related to system performance, safety incidents, or operational failures, whether or not caused by its software.
Such matters could result in litigation, regulatory action, reputational harm, or increased insurance, indemnification, or compliance
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory landscape for artificial
intelligence, robotics, and autonomous systems is evolving and may adversely affect its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Laws and regulations governing
artificial intelligence, robotics, and autonomous systems are evolving in the United States and internationally. New or modified requirements
related to safety, accountability, transparency, data use, or deployment of AI-enabled systems could impose additional compliance obligations,
restrict certain applications, or increase regulatory oversight. Because MBody AI&#8217;s platform influences the operation and coordination
of autonomous systems deployed in physical environments, regulatory changes may require modifications to its technology, deployment practices,
or business model, increase operating costs, delay deployments, or limit market opportunities. Failure to comply with applicable or future
regulations could result in fines, penalties, litigation, or reputational harm, any of which could materially adversely affect its business,
financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI has a history of operating losses
and may not achieve or sustain profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI has incurred operating
losses since inception and expects to continue to incur expenses as it grows its operations, develops its platform, and expands customer
deployments. Although MBody AI may achieve profitability in future periods, there can be no assurance that it will do so or that profitability,
if achieved, will be sustainable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI will require additional capital
to execute its business plan, and such capital may not be available on acceptable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI expects to require
additional financing to fund its operations, growth initiatives, and platform development. There can be no assurance that additional
capital will be available when needed, on acceptable terms, or at all. Failure to obtain additional financing could materially adversely
affect MBody AI&#8217;s ability to continue operations or execute its business strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future financings may result in dilution
and could adversely affect shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI may raise capital
through equity issuances, convertible securities, debt financings, or other structured transactions. Such financings may result in significant
dilution to existing shareholders, impose restrictive covenants, or grant preferential rights to new investors. Market conditions, stock
price volatility, and Nasdaq compliance considerations may further limit financing alternatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI operates in a rapidly evolving
and competitive market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The markets for artificial
intelligence, automation, and autonomous systems are rapidly evolving and highly competitive. New technologies, business models, and
competitors may emerge that could reduce demand for MBody AI&#8217;s platform or render its offerings less competitive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>MBody AI&#8217;s success depends on its
ability to attract and retain key personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s future
success depends on the continued services of its management team and technical personnel. Competition for qualified employees is intense,
and the loss of key personnel or inability to attract additional talent could materially adversely affect its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If the Merger does not close, the debt-for-equity exchange with
Apollo will not close, the Apollo BCA will remain in effect, and approximately $16.3 million of loans to Apollo may not be recoverable.</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has made loans to Apollo in the aggregate principal amount
of approximately <b>$16.3</b> million (the &#8220;Apollo Loans&#8221;). On June 30, 2025, the Company and Apollo entered
into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) providing for the Apollo Loans to be exchanged for common shares representing
a 7.5% equity interest in Apollo. Closing of the Exchange Agreement is conditioned on the closing of the Merger. If the Merger does not
close, the Exchange Agreement will not close, the Company will continue to hold the Apollo Loans as receivables, recovery is uncertain,
and the Apollo BCA will remain in effect and may limit the Company&#8217;s flexibility to pursue alternative strategic transactions.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recognized the exchange effective November 14, 2025 following
98.01% shareholder approval of the Merger, based on management&#8217;s determination that the closing condition ceased to be substantive at
that date. As of December 31, 2025, the equity investment is carried at $6,525,000 under ASC 321, and a payable of approximately $1,400,000
remains outstanding to Apollo. Legal closing of the Exchange Agreement has not occurred. If the Merger closes and the Exchange Agreement
closes, the Company will hold an illiquid minority interest in a private company with no governance rights and no readily determinable
fair value, and there can be no assurance the Company will realize the carrying value, or any value, from the investment.</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Financial Position</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a history of losses, may
incur future losses and require additional funding in order to complete the development of our products and technology. If additional
capital is not available and we cease the development of our products and technology or are obligated to relinquish rights to our intellectual
property, we may not ever achieve profitability and be forced to liquidate.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a clinical and development-stage medical
diagnostics company with a limited operating history, and our operations have consumed substantial amounts of cash. We have historically
incurred net losses since we commenced operations in 2009. We incurred net income of $4.1 million in 2025, and net losses of $25.1 million
in 2024, and $17.6 million in 2023, respectively. As of December 31, 2025, our accumulated deficit was $165.9 million. On March 21, 2023,
we announced that following our internal assessment of the clinical data collected from the calibration studies until such date, we determined
that the most recent efficacy results from our calibration studies did not meet the goal to proceed to the powered portion of the U.S.
pivotal study and, as such, the initiation of the second part of the U.S. pivotal study that was expected in mid-2023 was also postponed.
On June 6, 2023, we announced that after further review of additional data and interaction with the FDA on a revised pivotal study protocol
together with the anticipated time and investment necessary to further develop the technology, we were reducing our workforce significantly
to reduce cash burn, concentrating our resources on essential research activities, discontinuing our calibration studies, and evaluating
and pursuing strategic options. As a result of our evaluation and pursuit of strategic options, on August 16, 2023, we entered into the
Keystone BCA. At our 2023 annual general meeting of shareholders, such business combination transactions did not receive the requisite
majority required for approval under Section 320 of the Israeli Companies Law 5759-1999. On December 24, 2023, we received a notice on
behalf of Keystone, terminating the Keystone BCA in light of the results. On March 25, 2024, we entered into a business combination agreement
with Apollo. In May 2024, we reimbursed Apollo $3,808,815 pursuant to the provisions of the Apollo BCA. On September 4, 2025, the Company
acquired certain assets relating to a Ghost Kitchen area representative business. On September 12, 2025, the Company entered into the
Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that we will need
substantial amounts of cash resources in order to complete the development of the products and technology derived from our intellectual
property so that we can find new or alternative ways to redeploy them into other existing or new products and technologies. We intend
to use our limited cash resources to support these efforts, including through the Business Combination. See Item 5B &#8220;Operating
and Financial Review and Prospects - Liquidity and Capital Resources - Sources of Liquidity.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, we may seek additional
funding through equity offerings, debt financings, collaborations, licensing arrangements or any other means. If we raise additional
funds by issuing equity securities, you may experience significant dilution of your ownership interest, and the newly issued securities
may have rights senior to those of the holders of our ordinary shares. In addition, the issuance of additional equity securities by us,
or the possibility of such issuance, may cause the market price of our ordinary shares to decline. Alternatively, if we raise funds by
obtaining loans from third parties, the terms of those financing arrangements may include negative covenants, may require us to grant
a lender a security interest in our assets or may include other restrictions on our business that could impair our operational flexibility,
and could also result in high interest expense. If we raise additional funds through collaborations, licensing arrangements or other
structured financing transactions, we may relinquish rights to certain of our technologies or products, grant security interests in our
assets or grant licenses to third parties on terms that are unfavorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securing additional financing
may divert our management&#8217;s attention from its day-to-day activities, which may adversely further delay and affect our ability
to complete the development of our products and technology and such additional financing may not be available to us on a timely basis
or on terms acceptable to us, or at all. Accordingly, the extent of our future operating losses, the timing or even the potential of
becoming profitable are highly uncertain, and we may never achieve or sustain profitability. Any of these factors could materially and
adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The issuance of ordinary shares in connection
with the Merger will substantially dilute the relative voting power of shareholders of Check-Cap prior to the closing of the Merger,
and, as a result, such shareholders prior to the closing of the Merger will exercise substantially less influence over the management
of the Company following the consummation of the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the closing of
the Merger, shareholders of Check-Cap prior to the closing of the Merger (the &#8220;Previous Shareholders&#8221;) are expected to own
approximately 10% of the Company&#8217;s outstanding share capital, on a fully diluted and as-converted basis, and the MBody AI shareholders
are expected to own approximately 90% of the Company&#8217;s outstanding share capital, on a fully-diluted and as-converted basis. Accordingly,
the issuance of ordinary shares to MBody AI&#8217;s shareholders pursuant to the Merger Agreement will significantly reduce the relative
voting power of each ordinary share held by the Previous Shareholders. Consequently, the Previous Shareholders will exercise substantially
less influence over the management and policies of the Company than they did prior to the consummation of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company has incurred and expects to
continue to incur substantial transaction-related costs in connection with the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has incurred,
and expects to continue to incur, a number of non-recurring transaction-related costs associated with the Merger and the related transactions,
which cannot be accurately estimated at this time. These fees and costs have been, and will continue to be, substantial. Non-recurring
transaction costs include, but are not limited to, fees paid to legal and other advisors, SEC filing costs and printing costs. Additional
unanticipated costs may be incurred in the Company&#8217;s business, which may be higher than expected and could have a material adverse
effect on the Company&#8217;s financial condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company may fail to realize the anticipated
benefits of the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The success of the Merger
and the related transactions will depend on the Company&#8217;s ability to achieve its business objectives and raise the necessary capital
to fund its operations. If the Company is not able to achieve these objectives, the anticipated benefits of the Merger and the related
transactions may not be realized fully, may take longer to realize than expected, or may not be realized at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company may become involved in securities
litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of management and
harm the Company&#8217;s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities litigation or
shareholder derivative litigation frequently follows the announcement of certain significant business transactions. The Company may become
involved in this type of litigation in connection with the Merger and is currently involved in shareholder derivative litigation relating
to the Apollo BCA. Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect
the business of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Merger is not completed, the Company
will require significant additional funding in order to continue operations, and if additional capital is not available, the Company
may have to cease operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Merger was approved
by the Company&#8217;s shareholders on November 14, 2025. The consummation of the Merger remains subject to the satisfaction of certain
customary closing conditions. There can be no assurance that these conditions will be satisfied on a timely basis, if at all. If the
Merger is not completed for any reason, the Company will need to evaluate its strategic alternatives and will require significant additional
funding in order to continue its operations. The Company previously entered into a business combination agreement with Apollo in March
2024, and the Company incurred significant costs in connection with that transaction, including the reimbursement of approximately $3.8
million to Apollo. A failure to complete the Merger would further deplete the Company&#8217;s limited resources. If adequate additional
financing on acceptable terms is not available, the Company&#8217;s ability to continue to support its business growth and to respond
to business challenges could be significantly limited, and the Company may have to curtail or cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our management and
board of directors have concluded that a substantial doubt is deemed to exist concerning our ability to continue as a going concern</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounting standards require
management to assess our ability to continue as a going concern for one year after the date the financial statements are issued. As discussed
in Note 2 to our consolidated financial statements, conditions exist that raise substantial doubt about our ability to continue as a
going concern for the one-year period from the date these financial statements are issued. Management&#8217;s plans to address these conditions
&#8212; principally the pending Merger and the ARC ELOC Facility &#8212; depend on external approvals and market conditions outside our
sole control and are not, under ASC 205-40, probable of alleviating that doubt. These conditions could materially adversely affect the
market price of our ordinary shares, our access to additional capital, our ability to complete the Merger, and our relationships with
counterparties and employees. If our plans do not materialize, we may be required to wind down operations or liquidate our assets, and
the values realized could be materially less than those reflected in our consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the ARC ELOC Facility</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is not possible to predict the actual
number of shares we will sell under the Purchase Agreement to ARC, or the actual gross proceeds resulting from those sales.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 17, 2025, we
entered into the Purchase Agreement with ARC, pursuant to which ARC has committed to purchase up to $30.0 million of our ordinary shares,
subject to certain limitations and conditions set forth in the Purchase Agreement. The ordinary shares that may be issued under the Purchase
Agreement may be sold by us to the ARC at our discretion from time to time over a three-year period commencing on the date of the Purchase
Agreement. We generally have the right to control the timing and amount of any sales of our ordinary shares to ARC under the Purchase
Agreement. Sales of our ordinary shares, if any, to ARC under the Purchase Agreement will depend upon market conditions and other factors.
We may ultimately decide to sell to ARC all, some or none of the ordinary shares that may be available for us to sell to ARC pursuant
to the Purchase Agreement. Because the purchase price per share to be paid by ARC for the ordinary shares that we may elect to sell to
ARC under the Purchase Agreement, if any, will fluctuate based on the market prices of ordinary shares during the applicable purchase
valuation period for each purchase made pursuant to the Purchase Agreement, it is not possible for us to predict, as of the date of this
annual report and prior to any such sales, the total number of ordinary shares that we will sell to ARC under the Purchase Agreement,
the purchase price per share that ARC will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds
that we will receive from those purchases by ARC under the Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investors who buy shares at different times
will likely pay different prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Purchase
Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to ARC. If and when
we do elect to sell ordinary shares to ARC pursuant to the Purchase Agreement, ARC may resell, some or none of such shares at any time
or from time to time in its discretion and at different prices. As a result, investors who purchase shares from ARC at different times
will likely pay different prices for those shares, and therefore, may experience different levels of dilution and in some cases substantial
dilution and different outcomes in their investment results. In addition, investors may experience a decline in the value of the shares
they purchase from ARC as a result of future sales made by us to ARC at prices lower than the prices such investors paid for their shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may require additional financing to
sustain our operations, and such financing may not be available on acceptable terms, or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The extent to which we rely
on ARC as a source of funding will depend on a number of factors, including the prevailing market price of our ordinary shares, our ability
to meet the conditions necessary to deliver Advance Notices (as defined in the Purchase Agreement) under the Purchase Agreement and the
extent to which we are able to secure funding from other sources. Regardless of the amount of funds we ultimately raise under the Purchase
Agreement, if any, we may continue to seek other sources of funding. Even if we were to sell to ARC the total commitment of $30.0 million
under the Purchase Agreement, we may still need additional capital to fully implement our business plan. There can be no assurance that
additional financing will be available on acceptable terms, or at all, and any inability to obtain such financing could materially adversely
affect our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales and issuances of our ordinary
shares or other securities might result in significant dilution and could cause the price of our ordinary shares to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To raise capital, including
pursuant to the Purchase Agreement, we may sell ordinary shares, convertible securities or other equity securities in one or more transactions
at prices and in a manner we determine from time to time. We may sell shares or other securities in any other offering at a price per
share that is less than the price per share paid by investors, and investors purchasing shares or other securities in the future could
have rights superior to existing shareholders. The price per share at which we sell additional ordinary shares, or securities convertible
or exchangeable into ordinary shares, in future transactions may be higher or lower than the price per share previously paid by investors.
Any sales of additional shares will dilute our shareholders. Sales of a substantial number of ordinary shares in the public market or
the perception that these sales might occur could depress the market price of our ordinary shares and could impair our ability to raise
capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market
price of our ordinary shares. In addition, the sale of substantial numbers of our ordinary shares could adversely impact their price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We undertake to seek shareholder approval
to re-designate our ordinary shares as no-par value, and there can be no assurance that such re-designation will be completed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares currently
have a nominal value of NIS 48.0 per share. Our board of directors undertakes that it will not seek to make calls on or forfeit the shares
offered at any time if the nominal amount per share has not been paid. We also undertake to include on the agenda for our next annual
general meeting of shareholders a proposal to amend our amended articles of association to re-designate the ordinary shares as no-par
value shares, subject to applicable law and shareholder approval. Any delay or failure to complete the re-designation could limit our
flexibility to issue ordinary shares, including under the Purchase Agreement, and could adversely affect our ability to raise capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to the Acquisition of Ghost Kitchen
Franchise Rights in New Jersey</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company may not realize the anticipated
benefits of the acquisition of Ghost Kitchen franchise rights in New Jersey, including generating revenue from the acquired Ghost Kitchen
area representative operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 4, 2025, the
Company entered into that certain &#160;Asset Purchase Agreement with Parea LLC (the &#8220;Parea APA&#8221;) to acquire certain assets
relating to a Ghost Kitchen area representative business for the State of New Jersey. The acquisition is intended to provide the Company
with a source of near-term revenue from franchise area representative operations. However, there can be no assurance that the Company
will successfully integrate the acquired assets, generate revenue from the Ghost Kitchen operations, or realize the anticipated benefits
of this acquisition. The Company&#8217;s ability to generate revenue from the acquired operations will depend on a number of factors,
including the performance of the Ghost Kitchen franchise system, the Company&#8217;s ability to manage area representative operations,
and prevailing market conditions in the New Jersey territory. If the Company is unable to generate expected revenue or if the Ghost Kitchen
franchise system experiences operational difficulties, the acquisition may not contribute to the Company&#8217;s financial performance
as anticipated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company issued 1,169,596 ordinary shares
as consideration for the Parea APA, and the eventual availability of those shares for resale in the public market could adversely affect
the price of our ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the Parea
APA, the Company issued 1,169,596 Ordinary Shares as consideration to the sellers. While these shares are subject to a two-year lock-up
period and a two-year voting agreement with the Company, upon expiration of the lock-up period the shares will become available for resale
in the public market. The resale of a significant number of these shares, or the perception that such resales may occur, could adversely
affect the market price of our ordinary shares. In addition, the issuance of the consideration shares resulted in dilution to existing
shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Historical Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although we received FDA approval of our
IDE (including our IDE amended application) for our U.S. pivotal study, the most recent efficacy results from our studies did not meet
the goal to proceed to the powered portion of the U.S. pivotal study, as such we cannot provide any assurance that we will ever be able
to redesign such study or redeploy our technology into other potentially viable products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We received FDA approval
of our IDE and our IDE amended application for our planned U.S. pivotal study. While we initiated the first part of the U.S. pivotal
study in May&#160;2022, the initiation of the powered portion of the U.S. pivotal study was dependent upon successful completion of the
calibration portion of the U.S. pivotal study. On March&#160;21, 2023, we announced that following our internal assessment of the clinical
data collected from the calibration studies until such date, we determined that the most recent efficacy results from our calibration
studies did not meet the goal to proceed to the powered portion of the U.S. pivotal study and, as such, the initiation of the second
part of the U.S. pivotal study that was expected in mid-2023 was also postponed. On June&#160;6, 2023, we announced that after further
review of additional data and interaction with the FDA on a revised pivotal study protocol together with the anticipated time and investment
necessary to further develop the technology, we were reducing our workforce significantly to reduce cash burn, concentrating our resources
on essential research activities, discontinuing our calibration studies, and evaluating and pursuing strategic options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In light of such developments,
we cannot provide any timeline or assurance of when, if ever, or whether we will be able to compile an IDE supplement for submission
to the FDA. There can be no assurance that the FDA would approve any such an IDE supplement or that we will be ever able to commence
or complete the powered portion of the U.S. pivotal study. Furthermore, even if we were able to redesign the study and submit such IDE
supplement, the FDA or other regulatory authority may require us to complete additional studies or satisfy other FDA or other regulatory
requests, which would further delay any further U.S. pivotal studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of the foregoing,
our ability to redesign our U.S. studies, complete the development of our products and technology for the redeployment into other potentially
viable products is inherently uncertain, and may take significant time to complete, if any such options are ever completed at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical failure can occur at any stage
of clinical development and we may not succeed in completing the development of our product. Any product we advance through clinical
trials may require further clinical validation and may not have favorable results in later clinical trials or receive regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical failure can occur
at any stage of clinical development, and we may not succeed in completing the development of our product. To date, we have performed
clinical studies with iterative versions of both scanning and non-scanning capsules, in conjunction with iterative versions of the C-Scan
Track, C-Scan View application. The C-Scan system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous
polyps, and other structural abnormalities. In addition, our clinical trials to date were conducted under differing protocols, while
using specific inclusion criteria and enrolling both average risk and high-risk patients (e.g., &#8220;enriched population&#8221;). Therefore,
our ability to identify potential problems and/or inefficiencies concerning current and future versions of C-Scan in advance of its use
in general and expanded groups of average risk patients has been limited and we cannot assure you that the actual clinical performance
will be satisfactory to support proposed indications, obtain regulatory approvals and gain clinical acceptance and adoption, or that
its use will not result in unanticipated complications. Although we continuously collect additional clinical data to improve reliability
of our products and technology, we cannot provide any assurance that such studies will yield favorable results. For example, we conducted
a study in Israel for which we initially enrolled both average risk and high-risk patients and subsequently shifted to enrollment of
only average risk patients commencing in May&#160;2022. The purpose of the additional study was to improve calibration of the C-Scan
system, in parallel to conducting the first stage of the U.S. pivotal study that was initiated in May&#160;2022. As part of the approved
amended IDE, we designed the U.S. pivotal study to include two stages: the first stage, aimed to support our C-Scan calibration among
the average risk population, which is intended to include up to 200 patients in the U.S.; and the second stage, which was intended to
include up to 800 subjects (400 in the U.S. and 400 in Israel), aimed to compare the performance of C-Scan to traditional colonoscopy
through a statistically powered and randomized study. The initiation of the powered portion of the U.S. pivotal study was dependent upon
successful completion of the calibration portion of the U.S. pivotal study. Because we determined that the efficacy results from our
calibration studies did not meet the goal to proceed to the powered portion of the U.S. pivotal study and discontinued further studies,
we reduced our workforce to preserve and concentrate our resources on essential research activities and evaluated and pursued strategic
options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, results from
laboratory, non-clinical and completed clinical studies, as well as results from any ongoing clinical trials may not always be indicative
of final clinical results. As such, any product we advance through clinical trials may require further clinical validation and may not
have favorable results in later clinical trials or receive regulatory approval. In addition, the results of clinical trials are subject
to human analyses and interpretation of the data accumulated, which could be affected by various errors due to, among others, lack of
sufficient clinical experience with C-Scan, assumptions used in the statistical analysis of results, interpretation errors in the analysis
of the clinical trials results, including the reconstructed images by C-Scan, or due to uncertainty in the actual efficacy of C-Scan
in its current clinical stage. Therefore, the safety and efficacy of C-Scan and the clinical results to date will require further independent
professional validation and require further clinical study. If C-Scan does not function as expected over time, we may not be able to
develop C-Scan at the rate or to the stage we desire, we could be subject to liability claims, our reputation may be harmed, C-Scan may
not achieve regulatory clearances, and C-Scan may not be widely adopted by healthcare providers and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face a number of challenges with
respect to our commercialization efforts and may not succeed in the commercialization of our product, obtain required regulatory approvals
or manufacture commercial quantities of C-Scan at an acceptable cost to enable us to generate significant revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since commencing our operations,
we focused on the research and development and limited clinical trials of C-Scan and then reduced investment in research and development
activities in anticipation of the initiation of our strategic development plan. Although we previously received a CE-certificate from
a notified body according to the EU Regulation 2017/745 on Medical Devices for the marketing and sale of C-Scan in the European Union,
valid until December&#160;1, 2026, we were unable to commence marketing and sales in the European Union and, to extent we are able to
redesign any study protocols or C-Scan, additional or new regulatory approval in Member States of the European Union, for instance from
the German Federal Office for Radiation Protection (Bundesamt f&#252;r Strahlenschutz, BfS) may be required before we are able to launch
any such redesigned studies or deploy redesigned products or technology. Furthermore, we may require additional regulatory certifications,
registrations and/or approvals from regulatory authorities in European jurisdictions outside the European Union, including with the UK
Medicines and Healthcare Products Regulatory Agency and the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra).
In Israel, we received approval from the Medical Devices and Accessories Division of the Israeli Ministry of Health, or AMAR, for the
marketing and sale of C-Scan in Israel, which was valid until December&#160;31, 2024. We have not received approvals in other jurisdictions,
including the United States, and there can be no assurance that we will be able to receive regulatory approvals to commence marketing
and sales for C-Scan in the foreseeable future or ever. Our ability to generate revenues and achieve profitability depends on our ability
to successfully complete the development of our C-Scan product, demonstrate sufficient clinical evidence, obtain required regulatory
approvals and commercial licenses, and manufacture commercial quantities of C-Scan at an acceptable cost to enable us to generate significant
revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The future success of our
business cannot be determined at this time, and, in light of recent developments, we do not anticipate generating any revenues from product
sales for the foreseeable future. In addition, we have no experience in commercializing C-Scan, so even if we are able to redesign such
clinical studies, we may face a number of challenges with respect to our commercialization efforts, including, among others, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have adequate
    financial or other resources to complete the development of our product, demonstrate adequate clinical results, attain required regulatory
    approvals and licensures, obtain adequate manufacturing and capacity and begin the commercialization efforts for C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to obtain or
    maintain required regulatory approvals and licensures for C-Scan in our target markets or may face adverse regulatory or legal actions
    relating to our system even if regulatory approval is obtained;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not demonstrate
    adequate clinical safety and clinical effectiveness results from our current or future versions of C-Scan, to support regulatory
    body approval or market acceptance and adoption;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may face ongoing limitations
    imposed by the Nuclear Regulatory Commission, or NRC, or other nuclear regulatory commissions in jurisdictions in which we intend
    to commercialize C-Scan in relation to the disposal of our C-Scan Cap in the sanitary system, such as requiring patients to retrieve
    our C-Scan Cap after use, which could impact engagement with clinical sites and enrollment pace in our clinical studies and make
    C-Scan less attractive;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to maintain
    an adequate supply chain due to reliance on single or sole suppliers for critical components and scale up the manufacture of C-Scan
    to commercial quantities at an adequate quality or at an acceptable cost;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to establish
    adequate sales, marketing and distribution channels;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare professionals
    and patients may not accept C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be aware of
    possible complications from the continued use of C-Scan because we have limited clinical experience with respect to the actual use
    of C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other technological breakthroughs
    in colorectal cancer, or CRC, screening, treatment and prevention may reduce the demand for C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the market for
    CRC screening, new alliances between existing market participants and the entrance of new market participants may interfere with
    our market penetration efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government and private
    third-party payors may not agree to provide coding, coverage and payment adequate to reimburse healthcare providers and patients
    for any or all of the purchase price in conjunction with clinical effectiveness of C-Scan, which may adversely affect healthcare
    providers&#8217; and patients&#8217; willingness to purchase C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty as to market
    demand may result in inefficient pricing of C-Scan; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to adequately
    protect our intellectual property or may face third-party claims of intellectual property infringement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we determine to resume
the development of C-Scan and are unable to meet any one or more of these challenges successfully, our ability to complete the development
of and effectively commercialize C-Scan could be limited, which in turn could have a material adverse effect on our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited manufacturing experience
and currently have no manufacturing capabilities. If we resume development of C-Scan and are unable to scale up our manufacturing operations
to develop our products, our growth could be limited and our business, financial condition and results of operations could be materially
adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have limited
resources, facilities and experience in manufacturing. Following the determination to discontinue our clinical studies and conserve our
resources, on September 8, 2023, we terminated our sub-lease agreement and service agreement with the sole supplier of the X-ray source
used in C-Scan pursuant to which we leased approximately 70 square meters of laboratory production space at the supplier premises and
independently produced the X-ray source using our own production employees. See &#8220;<i>Information on Our Company - Business - Manufacturing
and Suppliers.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have in the past, and
we may in the future, continue to face technical challenges to obtain, increase or adjust manufacturing capacity, including, among others,
equipment design and automation, material procurement and lower than expected yields and increased scrap costs, as well as challenges
related to maintaining quality control and assurance standards, manufacturing commercial quantities of products at an acceptable cost
and logistics associated with the handling of radioactive materials, such as was the case in our C-Scan Cap, which have resulted in and
could result in delays in our clinical trial and commercialization plans and lost revenue. We may be unable to establish or maintain
reliable, high-volume manufacturing capacity. Even if we can establish and maintain this capacity, the cost of doing so may increase
the cost of our products and reduce our ability to compete successfully. If we resume development of C-Scan and are unable to scale up
our manufacturing capabilities to meet market demand, or to achieve adequate product cost, our growth could be limited and our business,
financial condition and results of operations could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we received
and may receive in the future grants from the Government of the State of Israel through the Innovation Authority of the Ministry of Economy
and Industry (the &#8220;IIA&#8221;) for the financing of a portion of our research and development expenditures and to support the funding
of our transition from research and development to manufacturing, pursuant to the Encouragement of Research, Development and Technological
Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development Law 5744-1984),
or the Innovation Law. The terms of the IIA grants subject us to certain restrictions relating to (among other things) the transfer of
the manufacturing of IIA-funded products outside Israel. See &#8220;<i>Risk Factors - Risks Related to Our Operations in Israel - Pursuant
to the terms of the Israeli government grants we received for research and development expenditures, we are obligated to pay certain
royalties on our revenues to the Israeli government. In addition, the terms of Israeli government grants we received require us to satisfy
specified conditions and to make additional payments in addition to repayment of the grants upon certain events</i>.&#8221; Such restrictions
may impair our ability to outsource or transfer development or manufacturing activities with respect to any product or technology outside
of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our reliance on sole or single source suppliers
could harm our ability to conduct clinical trials and meet demand for our product in a timely manner or within budget.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have historically depended
on sole or single source suppliers for some of the components and materials necessary for the production of C-Scan. If we determine to
resume the development of C-Scan and are required to change the supplier of any of these key components, there may be a significant delay
in locating a suitable alternative manufacturer. In addition, we may be required to verify that the new manufacturer maintains facilities
and procedures that comply with FDA and other applicable quality standards and with all applicable regulations and guidelines. To the
extent we ever are able to redesign the clinical studies for submission to the FDA or other regulatory authorities or redeploy our technology
into other potentially viable products, we will be required to find new suppliers, which we may not be able to do in a timely manner.
The delays associated with the introduction of a new manufacturer for certain key components or new suppliers for certain materials,
could delay our ability to manufacture any redesigned products in a timely manner or within budget. Furthermore, in the event that the
manufacturer of a key component of any our products ceases operations or otherwise ceases to do business with us, we may not have access
to the information necessary to enable an alternative supplier to manufacture the component. The occurrence of any of these events could
harm our ability to complete the development of our products and meet demand in a timely manner or within budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of any of our C-Scan Cap, C-Scan
Track, C-Scan View or any new products and technology could result in product liability or similar claims that could be expensive to
defend, damage our reputation and harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business exposes us
to an inherent risk of potential product liability or similar claims related to the manufacturing, marketing and sale of medical devices.
The medical device industry has historically been litigious, and we face financial exposure to product liability or similar claims if
the use of any of our C-Scan Cap, C-Scan Track or C-Scan View were to cause or contribute to injury or death, including, without limitation,
harm to the body caused by the procedure or inaccurate diagnoses from the procedure that could affect treatment options. There is also
the possibility that defects in the design or manufacture of any of these products or any new products and technology we redesign or
redeploy might necessitate a product recall. We do not currently maintain product liability insurance. A product liability claim, regardless
of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction
and frustration, and a substantial diversion of management attention. A successful claim brought against us could have a material adverse
effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have historically depended on third
parties to manage our clinical studies and trials, perform related data collection and analysis, and to enroll patients for our clinical
trials, and, as a result, we may face costs and delays that are beyond our control.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have historically relied
on third parties, such as third-party clinical research organizations, or CROs, clinical investigators, clinical research coordinators,
physicians and clinical sites, to manage our clinical trials and perform data collection and analysis, and to enroll patients for our
clinical trials. Although we have and expect to continue to have contractual arrangements with these third parties, we control only certain
aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the
applicable protocol and legal, regulatory and scientific standards, and our reliance on such third parties does not relieve us of our
regulatory responsibilities. If such third parties fail to comply with applicable regulatory requirements, the clinical data generated
in our clinical trials may be deemed unreliable and regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications, which would delay the regulatory approval process. Furthermore, we may not be able to control the
amount and timing of resources that these parties devote to our studies and trials or the quality of these resources. In addition, our
engagement with clinical centers for conducting our clinical trial in the U.S depends upon site-specific licensing and regulatory requirements
associated with the X-ray technology within our C-Scan capsules related to nuclear regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If these third parties fail
to properly manage our studies and trials or enroll patients for our clinical trials, we will be unable to complete them at all or in
a satisfactory or timely manner, which could delay or prevent us from obtaining regulatory approvals for, or achieving market acceptance
of, our product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, termination
of relationships with third parties may result in delays, inability to enter into arrangements with alternative third parties or do so
on commercially reasonable terms. Switching or adding additional clinical sites involves additional cost and requires management time
and focus. In addition, there is a natural transition period when a new clinical site commences work. As a result, delays occur, which
can materially impact our ability to meet our desired clinical development timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may sell our products in the United
States, Europe, Israel and Japan and, if we are unable to manage our operations in these territories, our business, financial condition
and results of operations could be materially adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our headquarters and substantially
all of our operations and employees are presently located in Israel, but we may market our products in the United States, Europe, Israel
and Japan. Accordingly, we may be subject to risks associated with international operations, and our international sales and operations
may require significant management attention and financial resources. In addition, our international sales and operations may subject
us to risks inherent in international business activities, many of which are beyond our control and include, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    certification, registration and other regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customs
    clearance and shipping delays;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">import
    and export controls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
    restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple
    and possibly overlapping tax structures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    forecasting the results of our international operations and managing our inventory due to our reliance on third-party distributors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    laws and regulations, business and clinical practices, licensures, government and private third-party payor reimbursement policies
    and patient preferences;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    standards of intellectual property protection among countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing our international operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in penetrating markets in which our competitors&#8217; products are more established and achieving a competitive sale price for our
    product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">currency
    exchange rate fluctuations and foreign currency exchange controls and tax rates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    and economic instability, war or acts of terrorism or natural disasters, emergence of a pandemic, or other widespread health emergencies
    (or concerns over the possibility of such an emergency, including for example, the COVID-19 pandemic).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are unable to manage
our international operations effectively, our business, financial condition and results of operations could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in establishing
and maintaining strategic partnerships, which could adversely affect our ability to develop and commercialize our products and technology.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A part of our strategy is
to evaluate and, as deemed appropriate, enter into partnerships in the future when strategically attractive, including potentially with
major medical device companies. We face significant competition in seeking appropriate partners for our products and technology, and
the negotiation process is time-consuming and complex. Potential partners must view our products and technology as economically valuable
in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other
companies. Even if we are successful in our efforts to establish strategic partnerships, the terms that we agree upon may not be favorable
to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product is delayed
or sales of an approved product are disappointing. Any delay in entering into strategic partnership agreements for our products and technology
could delay the development and commercialization of any product candidates and reduce their competitiveness even if they reach the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, our strategic
partners may breach any future agreement with us, and we may not be able to adequately protect our rights under these agreements. Furthermore,
our strategic partners will likely negotiate for certain rights to control decisions regarding the development and commercialization
of our products and technology, and may not conduct those activities in the same manner as we would do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to establish
and maintain strategic partnerships, we will bear all the risks and costs related to the development and commercialization of our products
and technology, and we will need to seek additional significant financing, hire additional employees and otherwise develop expertise
which we do not have and for which we have not budgeted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A security breach or disruption or failure
of our computer or communications systems could adversely affect us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Despite the implementation
of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to
damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism, war, and telecommunication and
electrical failures. If such an event were to occur and interrupt our operations, it could result in a material disruption to our business.
To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets
or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of clinical
trial participants or employees or former employees, access to our clinical data, or disruption of the manufacturing process, we could
incur liability and the further development of our products and technology could be delayed. We may also be vulnerable to cyber-attacks
by hackers or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial
information and adversely affect our business or result in legal proceedings. Further, these cybersecurity breaches may inflict reputational
harm upon us that may result in decreased market value and erode public trust.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We or the third parties upon whom we depend
may be adversely affected by natural disasters, health epidemics or pandemics, and/or war and conflicts and our business continuity and
disaster recovery plans may not adequately protect us from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Natural disasters could
severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects.
If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our office,
manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract
manufacturers, subcontractors, suppliers, CROs, clinical sites, clinical investigators, clinical coordinators, third parties ongoing
activities and schedules or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue
our plans and business for a substantial period of time. See &#8220;<i>Risk Factors - Risks Related to Our Operations in Israel - Our
principal offices, research and development facilities our manufacturing sites and some of our suppliers are located in Israel and, therefore,
our business, financial condition and results of operation may be adversely affected by political, economic and military instability
in Israel</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>


</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal offices, research
and development facilities, manufacturing sites and certain key suppliers are located in Israel. As a result, our business, financial
condition and results of operations may be adversely affected by political, economic and military instability in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since October 2023, Israel
has experienced heightened and sustained armed conflict and security tensions, including military operations in Gaza, hostilities along
Israel&#8217;s northern border, missile and drone attacks, and broader regional instability involving neighboring states and non-state
actors. Although the intensity and geographic scope of these events have fluctuated, the situation remains unpredictable and could escalate
further or persist for an extended period. Past conflicts have disrupted commercial activity in Israel, and similar or more severe disruptions
could occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In particular, military
operations such as Operation Epic Fury and Israel&#8217;s ongoing actions against Hezbollah have heightened security risks in northern
Israel, including in areas near the Company&#8217;s headquarters, resulting at times in rocket alerts, air-defense activity, transportation
disruptions and temporary limitations on business operations. These conditions increase the risk of operational interruptions, employee
unavailability and logistical delays affecting facilities and personnel located in this region. These conditions have resulted, and may
continue to result, in a range of adverse effects on our operations, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Workforce
                                            availability constraints, including due to military service obligations of Israeli employees,
                                            restrictions on movement, safety concerns, or displacement of personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Disruptions
                                            to research, development and manufacturing activities, including temporary facility closures,
                                            reduced productivity, or delays in product development or commercialization;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Supply
                                            chain interruptions, including delays in the delivery of raw materials, components or finished
                                            goods, higher logistics and shipping costs, increased transit times, or the need to source
                                            alternative suppliers;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Infrastructure
                                            and operational risks, including disruptions to transportation networks, ports, utilities,
                                            communications or other critical infrastructure;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Increased
                                            operating expenses, including costs associated with security measures, insurance, employee
                                            support, facility hardening, redundancy planning and business continuity efforts;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Restrictions
                                            on trade or investment, including the impact of actual or potential sanctions, export control
                                            restrictions, trade embargoes, or changes in diplomatic relations between Israel and other
                                            countries;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Macroeconomic
                                            impacts, including volatility in the Israeli economy, currency fluctuations, interest rate
                                            changes, credit rating actions, inflationary pressures or reduced access to capital;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Reputational
                                            risks, including negative perceptions by customers, partners, investors or other stakeholders
                                            arising from our presence or activities in Israel, which could affect commercial relationships
                                            or demand for our products; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Insurance
                                            limitations, including increased premiums, exclusions or the unavailability of coverage for
                                            losses resulting from acts of war, terrorism or civil unrest.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our facilities, suppliers
or logistics partners in Israel were damaged, destroyed or rendered inoperable, or if we were required to suspend or significantly modify
operations there for any reason, we may not be able to replace such capacity, personnel or capabilities in a timely or cost-effective
manner, if at all. Any prolonged interruption could materially impair our ability to manufacture products, meet customer demand, execute
our growth strategy or maintain our competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, regional instability
could negatively affect global financial markets, international trade routes or investor confidence more broadly, which could further
adversely impact our business, liquidity or market valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholder activism could result in potential
operational disruption, divert our resources and management&#8217;s attention and have an adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shareholder activism, which
may arise in various forms and situations, could divert management&#8217;s attention from its current strategies, require us to incur
substantial legal, consulting, and public relations fees, and could result in potential operational disruption. For example, on September
29, 2023, Symetryx Corporation, a self-described family office based in Toronto, Canada (&#8220;Symetryx&#8221;) delivered a letter to
Check-Cap in which it demanded that Check-Cap convene an extraordinary general meeting of shareholders, the purpose of which would be
to dismiss all five then current members of the Check-Cap Board and to appoint five director nominees as proposed by Symetryx. It then
filed with the Haifa District Court (Economic Department) a claim against Check-Cap and its directors, to instruct Check-Cap to comply
with the resolutions that shall be adopted at the extraordinary general meeting convened by Symetryx. On November&#160;12, 2023, Check-Cap
and Symetryx reached a settlement under which Symetryx cancelled the extraordinary shareholders meeting that it purported to self-convene
and Check-Cap converted the extraordinary shareholder meeting Symetryx convened to an annual general meeting of shareholders held on
December&#160;18, 2023, where the five director nominees proposed by the shareholder were elected to the Board of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Perceived uncertainties
as to our future direction and control arising from shareholder activism may result in the loss of potential business opportunities and
may make it more difficult to attract and retain qualified employees, any of which could adversely affect our business and operating
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Regulations Applicable to
Our Historical Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or our future manufacturers or distributors
do not obtain and maintain the necessary regulatory clearances or approvals, or equivalent third country approvals in a specific country
or region, we or our future distributors will not be able to market and sell C-Scan or future products in that country or region.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To be able to market and
sell C-Scan or any future products in a specific country or region, we and/or our distributors must comply with the regulations of that
country or region. These regulations, and the time required for regulatory review, vary from country to country. Obtaining regulatory
approvals is expensive and time-consuming, and we cannot be certain that we or our distributors will receive regulatory approvals required
for C-Scan or any future products in each country or region in which we plan to market such products. We currently do not have a notified
body. If we modify C-Scan or any future products, we or our distributors may need to apply for new regulatory approvals, or a notified
body may need to review the planned changes before we are permitted to sell the respective products. We may not meet the quality and
safety standards required to maintain the authorizations that we or our distributors have received. If we or if permitted, our distributors
are unable to maintain our authorizations or CE Certificates in a particular country or region, we will no longer be able to sell C-Scan
and/or any potential future products in that country or region, and our ability to generate revenues will be materially and adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the indications for use or instructions
for use for which the iodinated oral contrast medium is approved are not sufficiently broad to support its use throughout the C-Scan
procedure, the FDA or the competent regulatory authorities in the European Union (EU) Member States and other foreign countries may consider
that contrast agent is being used off-label.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ingestion of C-Scan requires
the preparatory use of iodinated oral contrast medium to provide a coating for colonic imaging. We cannot be sure that the indications
for which iodinated oral contrast medium are approved in the United States, or in other countries is sufficiently broad to cover such
use. If the FDA or the competent regulatory authorities in other countries consider that iodinated oral contrast medium is not approved
for the purpose for which it is used with the system, we may be considered to promote the off-label use of the iodinated oral contrast
medium. Because the promotion of off-label use of drugs or medicinal products is prohibited in the United States, and in other countries,
we could face both related issues with the FDA and/or the competent authorities of and/or other countries. In these circumstances, the
FDA and/or the competent regulatory authorities and/or other countries may require us to obtain appropriate regulatory approvals for
the iodinated oral contrast medium prior to marketing C-Scan with such substances. Under such circumstances, should we fail to obtain
approval of the contrast agent for use with C-Scan, in a timely fashion, or at all, this could delay or prevent regulatory clearance
or approval of the C-Scan, and our business and financial condition will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The results of any future clinical trials
may not support our product candidate requirements or intended use claims or may result in the discovery of adverse side effects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if future clinical
trials are completed, we cannot be certain that their results will support our product requirements or intended use claims, which could
inhibit our marketing strategies, or that the FDA, foreign authorities or a notified body will agree with our conclusions regarding them.
Success in non-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot
be sure that clinical trials will replicate the results of prior trials. The clinical trial process may fail to demonstrate that C- Scan,
or any future products, are safe and effective for the desired or proposed indicated uses, which could cause us to abandon a product
and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions
and, ultimately, our ability to commercialize C-Scan, or any future products, and generate revenues. It is also possible that patients
enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if C-Scan or future products are cleared
or approved by regulatory authorities or after obtaining CE Certificates from a notified body, modifications to C-Scan or future products
may require new regulatory clearances or approvals, new CE Certificates, or may require us to recall or cease marketing it until the
necessary clearances, approvals or CE Certificates are obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once cleared, approved or
marketed, modifications to C-Scan or future products may require new regulatory approvals, clearances, including CE Certificates from
a notified body, 510(k) clearances or PMAs, or require us to recall or cease marketing the modified devices until these clearances or
approvals are obtained. Obtaining clearances and approvals, or new or amended CE Certificates for device modifications can be a time-consuming
process, and delays in obtaining required future clearances, approvals, or CE Certificates could adversely affect our ability to introduce
new or enhanced products in a timely manner, which in turn could harm our future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if C-Scan and future products are
cleared or approved by regulatory authorities or after obtaining CE Certificates from a notified body, if we or our suppliers fail to
comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products,
our products could be subject to restrictions or withdrawal from the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacturing processes,
reporting requirements, post-approval clinical data and promotional activities associated with any product for which we obtain clearance,
approval or CE Certificates, or equivalent third country approval will be subject to continuous regulatory review, oversight and periodic
inspections by the FDA other domestic and foreign regulatory authorities. If any adverse actions relating to the foregoing were to occur,
our reputation would be harmed, our product sales and profitability would suffer and we may not be able to generate revenue. Furthermore,
our key suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could
result in our failure to produce our products on a timely basis and in the required quantities, if at all. Even if regulatory clearance
or approval of a product is granted, or after obtaining CE Certificates, such clearance or approval, or CE Certificates may be subject
to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the
product and generate revenue from the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our failure to comply with radiation safety
or radio frequency regulations in a specific country or region could impair our ability to conduct our clinical trials, or commercially
distribute and market C-Scan or any similar product in that country or region.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan includes a small
X-ray source and wireless radio frequency transmitter and receiver and is therefore subject to equipment authorization requirements in
a number of countries and regions. In the United States, the EU and Japan, authorities often require advance clearance of all radiation
and radio frequency devices before they can be sold or marketed in these jurisdictions, subject to limited exceptions. Competent authorities
for such additional approval requirements include the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra) and the
German Federal Office for Radiation Protection (Bundesamt f&#252;r Strahlenschutz, BfS). Modifications to the approved C-Scan version
design and specifications may require new or further regulatory clearances or approvals before we are permitted to market and sell a
modified C-Scan version. If we are unable to obtain any required clearances or approvals from the authorities responsible for the radiation
as well as the radio frequency regulations in these and other jurisdictions, the sale or use of C-Scan or any similar product could be
prevented in these countries. Any such action could negatively affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products may in the future be subject
to product recalls that could harm our reputation, business and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and similar foreign
governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or
defects in design or manufacture or a public health/safety issue. In the case of the FDA, the authority to require a recall must be based
on an FDA finding that there is a reasonable probability that the device would cause injury or death. In addition, foreign governmental
bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated
or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling
defects or other deficiencies and issues. Once marketed, recalls of any of our products, including C-Scan, would divert managerial and
financial resources and have an adverse effect on our business, financial condition and results of operations. FDA requires that certain
classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain
certain records of recalls, even if they are not reportable to FDA. We may initiate voluntary recalls involving our products in the future
that we determine do not require us to notify the FDA. If the FDA disagrees with our determinations, they could require us to report
those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition,
the FDA could take enforcement action against us based on our failure to report the recalls when they were conducted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If C-Scan or future products cause or contribute
to a death or a serious injury, or malfunction in such a way that causes or contributes to a death or serious injury, we will be subject
to medical device reporting regulations, which can result in corrective actions or enforcement actions from regulatory authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we resume development
of C-Scan and obtain approval to commercialize our product, we expect that we will be required to conduct post-market testing and surveillance
to monitor the safety or effectiveness of our products, which is costly, and we must comply with medical device reporting requirements,
including the reporting of adverse events and malfunctions related to our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under FDA medical device
reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused
or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious
injury if the malfunction of our device (or any similar future product) were to recur. If we fail to investigate and report these events
to FDA within the required timeframes, or at all, the FDA could take enforcement action against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the EU MDR we will
now have to comply with the increased requirements of medical devices vigilance provisions. In particular, according to Art. 83 MDR,
we are required to have a post-market surveillance system in place in a manner that is proportionate to the risk class and appropriate
for the type of device, as an integral part of the quality management system. Depending on the devices&#8217; risk class, either a post
market surveillance report or a periodic safety update report, or PSUR, must be created and provided to the competent authority upon
request. The PSUR also has to be provided to a notified body. Furthermore, requirements on vigilance and incident reporting are increased
and market surveillance competencies of the authorities are strengthened.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, later discovery
of previously unknown problems with our products, including unanticipated adverse side effects or adverse side effects of unanticipated
severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the Quality System Regulations,
may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market,
voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute,
fines, suspension or withdrawal of regulatory approvals or CE Certificates, product seizures, injunctions or the imposition of civil
or criminal penalties. If any such adverse event results in legal action taken against us, it will require us to devote sufficient time
and capital to the matter, distract management from operating our business, and may harm our reputation. Any such occurrence would adversely
affect our business, financial condition and operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to complex environmental
and health legislation in various jurisdictions that may increase our costs and our risk of noncompliance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
and manufacturing processes, including through our service providers, involve the handling of potentially harmful radioactive and other
hazardous materials. Therefore, we and our service providers may be subject to various environmental, health and safety laws and regulations,
including governing the use, shipping, handling, storage and disposal of these materials, and we incur expenses related to compliance
with these laws and regulations. If we are found to have violated applicable environmental, health and safety laws, whether as a result
of human error, equipment failure or other causes, we could be held liable for damages, penalties and costs of remedial actions and could
be subject to work stoppages or delays, which could materially adversely affect our business, financial condition and results of operations.
The risk of contamination or injury from these materials cannot be eliminated. If an accident or release of any radioactive or other
hazardous material occurs, we could be held liable for resulting damages, including for investigation, remediation and monitoring of
the contamination, including the costs of which could be substantial. In addition, we may be required to pay damages or civil judgments
in respect of third-party claims, including those relating to personal injury (including exposure to radioactive materials) or contribution
claims. In the future, we could be subject to additional environmental requirements or existing environmental laws could become more
stringent, which could lead to greater compliance costs and increasing risks and penalties associated with violations. For example, changes
to, or restrictions on, permitting requirements or processes, hazardous or radioactive material storage or handling might require an
unplanned capital investment or relocation. If we or our service providers fail to comply with existing or new environmental laws or
regulations, our business, financial condition and results of operations could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Federal and state privacy laws, and equivalent
laws of third countries, may increase our costs of operation and expose us to civil and criminal sanctions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Health Insurance Portability
and Accountability Act of 1996, as amended, and the regulations that have been issued under it, to which we refer collectively as HIPAA,
and similar laws outside the United States, contain substantial restrictions and requirements with respect to the use and disclosure
of individuals&#8217; protected health information. The HIPAA privacy rules prohibit &#8220;covered entities,&#8221; such as healthcare
providers and health plans, from using or disclosing an individual&#8217;s protected health information, unless the use or disclosure
is authorized by the individual or is specifically required or permitted under the privacy rules. Under the HIPAA security rules, covered
entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability
of electronic protected health information maintained or transmitted by them or by others on their behalf. While we do not believe that
we are a covered entity under HIPAA, many of our customers may be covered entities subject to HIPAA. Such customers may require us to
enter into business associate agreements, which will obligate us to safeguard certain health information we obtain in the course of our
relationship with them, restrict the manner in which we use and disclose such information and impose liability on us for failure to meet
our contractual obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, under The Health
Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which was signed into law as part of the U.S. stimulus
package in February&#160;2009, certain of HIPAA&#8217;s privacy and security requirements are now also directly applicable to &#8220;business
associates&#8221; of covered entities and subject them to direct governmental enforcement for failure to comply with these requirements.
We may be deemed as a &#8220;business associate&#8221; of some of our customers. As a result, we may be subject as a &#8220;business
associate&#8221; to civil and criminal penalties for failure to comply with applicable privacy and security rule requirements. Moreover,
HITECH created a new requirement obligating &#8220;business associates&#8221; to report any breach of unsecured, individually identifiable
health information to their covered entity customers and imposes penalties for failing to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to HIPAA, most
U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical information, and many
U.S. states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards,
and data security breach notification requirements. These U.S. state laws, which may be even more stringent than the HIPAA requirements,
are not preempted by the federal requirements, and we are therefore required to comply with them to the extent they are applicable to
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These and other possible
changes to HIPAA or other U.S. federal or state laws or regulations, or comparable laws and regulations in countries where we conduct
business, could affect our business and the costs of compliance could be significant. Failure by us to comply with any of the standards
regarding patient privacy, identity theft prevention and detection, and data security may subject us to penalties, including civil monetary
penalties and in some circumstances, criminal penalties. In addition, such failure may damage our reputation and adversely affect our
ability to retain customers and attract new customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The protection of personal
data, particularly patient data, is subject to strict laws and regulations in many countries. The collection and use of personal health
data in the EU is governed by the General Data Protection Regulation Reg. EU 2016/679, which became applicable on May&#160;25, 2018,
or the GDPR. The GDPR imposes a number of requirements, including an obligation to seek the consent of individuals to whom the personal
data relate, the information that must be provided to the individuals, notification of data processing obligations to the competent national
data protection authorities of individual EU Member States and the security and confidentiality of the personal data. The GDPR also imposes
strict rules on the transfer of personal data out of the EU to the U.S. Failure to comply with the requirements of the GDPR and the related
national data protection laws of the EU Member States may result in fines and other administrative penalties and harm our business. We
may incur extensive costs in ensuring compliance with these laws and regulations, particularly if we are considered to be a data controller
within the meaning of the GDPR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with the U.S. federal
Anti-Kickback Statute and similar state and third-country laws, we could be subject to criminal and civil penalties and exclusion from
federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third-country programs, which would
have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A provision of the Social
Security Act, commonly referred to as the federal Anti-Kickback Statute, prohibits the knowing and willful offer, payment, solicitation
or receipt of any form of remuneration, directly or indirectly, in cash or in kind, to induce or reward the referring, ordering, leasing,
purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable, in whole or in part,
by Medicare, Medicaid or any other federal healthcare program. PPACA, among other things, clarified that a person or entity needs not
to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. Although there are a number of statutory
exemptions and regulatory safe harbors to the federal Anti- Kickback Statute protecting certain common business arrangements and activities
from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely
within an exemption or safe harbor may be subject to scrutiny. The federal Anti-Kickback Statute is very broad in scope and many of its
provisions have not been uniformly or definitively interpreted by existing case law or regulations. In addition, most of the states have
adopted laws similar to the federal Anti-Kickback Statute, and some of these laws are even broader than the federal Anti-Kickback Statute
in that their prohibitions may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply
regardless of the source of payment. Violations of the federal Anti-Kickback Statute may result in substantial criminal, civil or administrative
penalties, damages, fines and exclusion from participation in federal healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of our financial relationships
with healthcare providers, purchasers, and others who provide products or services to federal healthcare program beneficiaries are potentially
governed by the federal Anti-Kickback Statute and similar state laws. We believe our operations are in compliance with the federal Anti-Kickback
Statute and similar state laws. However, we cannot be certain that we will not be subject to investigations or litigation alleging violations
of these laws, which could be time-consuming and costly to us and could divert management&#8217;s attention from operating our business,
which in turn could have a material adverse effect on our business. In addition, if our arrangements were found to violate the federal
Anti- Kickback Statute or similar state laws, the consequences of such violations would likely have a material adverse effect on our
business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are other federal
and state laws that may affect our ability to operate, including the federal civil False Claims Act, which prohibits, among other things,
individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government
funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to
the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to
the federal government. PPACA amended the Social Security Act to provide that the government may assert that a claim including items
or services resulting from a violation of the federal Anti- Kickback Statute constitutes a false or fraudulent claim for purposes of
the federal civil False Claims Act. Moreover, we may be subject to other federal false claim laws, including, among others, federal criminal
healthcare fraud and false statement statutes that extend to non-government healthcare benefit programs. Moreover, there are analogous
state laws. Violations of these laws can result in substantial criminal, civil or administrative penalties, damages, fines and exclusion
from participation in federal healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Similar restrictions are
imposed by the national legislation of many third countries in which our medical devices will be marketed. Moreover, the provisions of
the Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and
their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international
organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase
in anti-bribery law enforcement activity by U.S. regulators, with more aggressive and frequent investigations and enforcement by both
the U.S. Securities and Exchange Commission and the Department of Justice. A determination that our operations or activities violated
United States or foreign laws or regulations could result in imposition of substantial fines, interruption of business, loss of supplier,
vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. In
addition, lawsuits brought by private litigants may also follow as a consequence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our failure to comply with the necessary
regulatory approval regarding the use of radioactive materials could significantly impair our ability to develop, manufacture and/or
sell C-Scan or similar products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacture of C-Scan
requires the use and storage of radioactive materials. In order to use such materials in the development and manufacture of C-Scan in
Israel, we are required to obtain a permit from the Israeli Commissioner for Environmental Radiation, or the Commissioner, pursuant to
the Israeli Pharmaceutical Regulations (Radioactive Elements and By-Products), 5740-1980. Should we fail to comply with the conditions
of our currently existing permit, the Commissioner would have authority to cancel our permit. Should the Commissioner determine that
our activities or facilities, or the activities or facilities adjacent to our premises, constitute a danger to the health and well-being
of a person, the public or the environment, the cancellation or suspension of our permit could be immediate and without prior notice.
Furthermore, we cannot guarantee the annual renewal of our permit and/or annual renewal subject to identical conditions, as the approval
of an annual application and the conditions thereof are at the discretion of the Commissioner. Similar requirements and regulations may
apply to the manufacture of C-Scan or similar products in other countries. Cancellation of or failure to renew our permit could have
materially adverse consequences on our ability to manufacture and sell our products and therefore on our ability to continue our business
and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to source and distribute our
products profitably or at all could be harmed if new trade restrictions are imposed or existing trade restrictions become more burdensome.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been significant
changes and proposed changes in recent years to U.S. trade policies, tariffs and treaties affecting imports. The Trump administration
has announced additional tariffs on imports from a number of countries. Such tariffs and any further legislation or actions taken by
the U.S. or other countries that restrict trade, such as additional tariffs, trade barriers, tax policies related to international commerce,
export controls, sanctions and investment restrictions, renegotiation of existing trade agreements with U.S. trading partners, and other
protectionist or retaliatory measures taken by such governments, could adversely impact our business, financial condition and results
of operations. If any forms of duties or tariffs are imposed on our products, we may be required to charge higher prices in the United
States than we expect, which may result in fewer customers and harm our operating performance. Alternatively, we or our contractors may
seek manufacturers and/or suppliers in countries not affected, or less affected by the tariffs, resulting in significant costs and disruption
to our operations and business. Our business could also be impacted by retaliatory trade measures taken by other countries in response
to existing or future tariffs, causing us to raise prices or make changes to our operations, any of which could materially harm our business,
financial condition and results of operations. Escalating trade tensions between the U.S. and other countries may also disrupt global
supply chains or result in significant price increases. The imposition of tariffs or other similar trade restrictions may also be inflationary,
which could cause the cost of inputs to increase. Volatile trade relations have also caused and may continue to cause significant volatility
in the global financial markets. Further, political tensions as a result of trade policies could reduce trade volume, investment, technological
exchange, and other economic activities between major international economies, resulting in a material adverse effect on global economic
conditions. Any of these developments could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Legacy Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect our intellectual
property rights, our competitive position could be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our success and ability
to compete depends in large part upon our ability to protect our intellectual property. Although we have patents issued in Israel, Europe,
United States, Japan, China, India, Hong Kong, Canada, South Korea, Brazil and Australia, we continue to file and prosecute in many of
the same countries and additional countries. We face several risks and uncertainties in connection with our intellectual property rights,
including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
    and future patent applications may not result in the issuance of patents or, if issued, may not be issued in a form that will be
    advantageous to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our issued
    patents may be challenged, invalidated or legally circumvented by third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our patents
    may not be upheld as valid and enforceable or prevent the development of competitive products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the eligibility
    of certain inventions related to diagnostic medicine, more specifically diagnostic methods and processes, for patent protection in
    the United States has been limited recently which may affect our ability to enforce our issued patents in the United States or may
    make it difficult to obtain broad patent protection going forward in the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the eligibility
    to protect methods for treating humans, which is available in the US, is generally not available in other countries, for example
    in Europe;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for a
    variety of reasons, we may decide not to file for patent protection on various improvements or additional features; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
    property protection and/or enforcement may be unavailable or limited in some countries where laws or law enforcement practices may
    not protect our proprietary rights to the same extent as the laws of the United States, the European Union, Canada or Israel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Consequently, our competitors
could develop, manufacture and sell products that directly compete with our products, which could decrease our sales and diminish our
ability to compete. In addition, competitors could attempt to develop their own competitive technologies that fall outside of our intellectual
property rights. If our intellectual property does not adequately protect us from our competitors&#8217; products and methods, our competitive
position could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the medical device industry is
litigious, we are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages
or prohibit us from selling C-Scan or any similar products we may develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is a substantial amount
of litigation over patent and other intellectual property rights in the medical device industry. Whether a product infringes a patent
involves complex legal and factual issues, the determination of which is often uncertain. Searches typically performed to identify potentially
infringed patents of third parties are often not conclusive and because patent applications can take many years to issue, there may be
applications now pending, which may later result in issued patents which our current or future products may infringe. In addition, our
competitors or other parties may assert that C-Scan or any similar products we may develop and the methods they employ may be covered
by patents held by them. If C-Scan, any similar products we may develop or any of their components infringes a valid patent, we could
be prevented from manufacturing or selling it unless we can obtain a license or redesign the product to avoid infringement. Third parties
may currently have, or may eventually be issued, patents on which our current or future products or technologies may infringe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, litigation
in which we are accused of infringement may cause negative publicity, adversely impact prospective customers, cause product shipment
delays, prohibit us from manufacturing, marketing or selling our current or future products, require us to develop non-infringing technology,
make substantial payments to third parties or enter into royalty or license agreements, which may not be available on acceptable terms,
or at all. If a successful claim of infringement were made against us and we could not develop non-infringing technology or license the
infringed or similar technology in a timely and cost-effective manner, our ability to generate significant revenues may be substantially
harmed and we could be exposed to significant liability. A court could enter orders that temporarily, preliminarily or permanently enjoin
us, our suppliers, distributors or our customers from making, using, selling, offering to sell or importing our current or future products,
or could enter an order mandating that we undertake certain remedial activities. Claims that we have misappropriated the confidential
information or trade secrets of third parties can have a similar negative impact on our reputation, business, financial condition or
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may also become involved
in litigation in connection with our brand name rights. We do not know whether others will assert that our brand name infringes their
trademark rights. In addition, names we choose for our products may be claimed to infringe names held by others. If we have to change
the names we use, we may experience a loss in goodwill associated with our brand name, customer confusion and a loss of sales. Infringement
and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate and could divert our management&#8217;s
attention from operating our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The steps we have taken to protect our
intellectual property may not be adequate, which could have a material adverse effect on our ability to compete in the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to patents,
we rely on confidentiality, non-compete, non-disclosure and assignment of inventions provisions, as appropriate, with our employees,
consultants, subcontractors, suppliers and clinical investigators to protect and otherwise seek to control access to, and distribution
of, our proprietary information. These measures may not be adequate to protect our intellectual property from unauthorized disclosure,
third-party infringement or misappropriation, for the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the agreements
    may be breached, may not provide the scope of protection we believe they provide or may be determined to be unenforceable, in part
    or in whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may
    have inadequate remedies for any breach;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proprietary
    information could be disclosed to our competitors; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to
    our trade secrets or disclose such technologies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If, for any of the above
reasons, our intellectual property is disclosed or misappropriated, it could harm our ability to protect our rights and could have a
material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, although our
employees and consultants have agreed to assign to us all rights to any intellectual property created in the scope of their employment
or engagement with us and most of our current employees and consultants, have agreed to waive their economic rights with respect to our
intellectual property, we cannot assure you that such claims will not be brought against us by current or former employees or consultants,
despite their contractual representations and obligations toward us, or by any of the medical and/or governmental institutions that employ
or engage such consultants, claiming alleged rights to our intellectual property or demanding remuneration in consideration for assigned
intellectual property rights, which could result in litigation and adversely affect our business, financial condition and results of
operations. See &#8220;<i>Risk Factors - Risks Related to Our Operations in Israel - We may become subject to claims for payment of compensation
for assigned service inventions by our current or former employees, which could result in litigation and adversely affect our business.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may challenge the validity
of our issued patents or challenge patent applications in administrative proceedings before various patent offices which, if successful,
could negatively affect our future business and financial performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Various patent offices,
including in the United States and Europe, provide administrative proceedings by which a third party can challenge the validity of an
issued patent or challenge an application that is being examined absent any threat of litigation. In some instances, including in the
United States, the administrative proceedings provide a more efficient and favorable forum to challenge our patents which may lead to
more opportunities for competitors to do so, particularly smaller competitors with limited resources. Moreover, the standards utilized
in these administrative proceedings, at least in the United States, provide certain legal advantages versus challenging the validity
of a patent in a district court. If a third party is successful in one of these administrative proceedings, the patent will no longer
be enforceable in the corresponding jurisdiction. In addition, we did not renew certain patents in pursuit of strategic options. With
this loss in patent rights, we will not be able to prevent third parties from offering identical or similar competing products which
may result in lower profits and a less substantial market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need to initiate lawsuits to protect
or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could cause us to lose some
of our intellectual property rights, which would harm our ability to compete in the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely on patents to protect
a portion of our intellectual property and our competitive position. Patent law relating to the scope of claims in the technology fields
in which we operate is still evolving and, consequently, patent positions in the medical device industry are generally uncertain. In
order to protect or enforce our patent rights, we may initiate patent and related litigation against third parties, such as infringement
suits or interference proceedings. Any lawsuits that we initiate could be expensive, take significant time and divert our management&#8217;s
attention from other business concerns and the outcome of litigation to enforce our intellectual property rights in patents, copyrights,
trade secrets or trademarks is highly unpredictable. Litigation also puts our patents and other registered intellectual property at risk
of being invalidated or interpreted narrowly and our patent applications at risk of not being issued. In addition, we may provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, including
attorney fees, if any, may not be commercially valuable. The occurrence of any of these events could have a material adverse effect on
our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on trademark protection to distinguish
our products from the products of our competitors; however, if a third party is entitled to use our trademark, we could be forced to
rebrand, which could result in loss of brand recognition and our ability to distinguish our products may be impaired, which could adversely
affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely on trademark protection
to distinguish our products from the products of our competitors. In jurisdictions where we have not registered our trademarks and logos
and are using them, and as permitted by applicable local law, we rely on common law trademark protection. Third parties may oppose our
trademark applications, or otherwise challenge our use of the trademarks, and may be able to use our trademarks in jurisdictions where
they are not registered or otherwise protected by law. If our trademarks are successfully challenged or if a third party is using confusingly
similar or identical trademarks in particular jurisdictions before we do, we may be prevented from using our brands and/or domain names
and/or could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote additional
resources to marketing new brands. If others are able to use our trademarks, our ability to distinguish our products may be impaired,
which could adversely affect our business. Further, we cannot assure you that competitors will not infringe upon our trademarks, or that
we will have adequate resources to enforce our trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to enforce covenants
not to compete at all or, we may be unable to enforce them for the duration contemplated in our employment contracts and may, therefore,
be unable to prevent competitors from benefiting from the expertise of some of our former employees involved in research and development
activities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We historically have entered
into non-compete agreements that prohibit our employees, if they cease working for us, from directly competing with us or working for
our competitors for a limited period of time following termination of employment. In many jurisdictions, courts are increasingly refusing
to enforce restrictions on competition by former employees or have interpreted them narrowly. For example, in Israel, where currently
all of our employees reside, courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate
that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which
have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or its intellectual
property. If we cannot demonstrate that harm would be caused to us, an Israeli court may refuse to enforce our non-compete restrictions
or reduce the contemplated period of non- competition such that we may be unable to prevent our competitors from benefiting from the
expertise of our former employees. A growing number of states in the U.S. have refused to enforce non-compete provisions in employment
contracts and the federal government has recently done the same. While employees may compete against us, they cannot use our trade secrets
and other confidential information. If that were to occur, we would have to prove such activities. Intellectual property litigation is
expensive, diverts management time and the results are uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal offices, research and development
facilities, our manufacturing sites and some of our suppliers are located in Israel and, therefore, our business, financial condition
and results of operation may be adversely affected by political, economic and military instability in Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal offices are
located in Israel. In addition, all of our employees are residents of Israel. Accordingly, political, economic and military conditions
in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have
taken place between Israel and its neighboring countries. Although Israel has entered into various agreements with Egypt, Jordan and
the Palestinian Authority, there has been an increase in unrest and terrorist activity, which began in September 2000 and continued with
varying levels of severity throughout 2025. Following the October 7, 2023 attacks by Hamas terrorists in Israel&#8217;s southern border,
Israel declared war against Hamas and since then, Israel has been involved in military conflicts with Hamas, Hezbollah, a terrorist organization
based in Lebanon, Syria and Iran, both directly and through proxies. Although a ceasefire between Israel and Hamas took effect on October
10, 2025, there is no assurance that this agreement will continue to be upheld. On February 28, 2026 the U.S. and Israel initiated air
strikes against Iranian military targets and leadership. Since then, retaliation by Iran against U.S. and Israeli interests in the Middle
East has been widespread. As of the date of the filing of this Annual Report on Form 20-F, military activity and hostilities continue
to escalate in the Middle East, and the situation throughout the region remains volatile, with the potential for continued escalation
into a broader and more sustained regional conflict.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, none of our facilities
or infrastructure, including our technology platform and IT system, have been damaged nor have our supply chains been significantly impacted
since the war broke out. However, a prolonged war could adversely impact our supply chain and our ability to ship products from Israel,
which could disrupt our operations. Our commercial insurance does not cover losses that may occur as a result of events associated with
war and terrorism, and the war and terrorism insurance we maintain may not be adequate to cover any losses we may incur associated with
armed conflicts and terrorist attacks. Although the Israeli government currently covers the reinstatement value of direct damages that
are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will
sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the past, the State of
Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel
and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition
or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also
adversely impact our business. Parties with whom we may do business could decline to travel to Israel during periods of heightened unrest
or tension. In addition, the political and security situation in Israel may result in parties with whom we may have agreements involving
performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure
provisions in such agreements. In addition, any hostilities involving Israel could have a material adverse effect on our facilities including
our corporate office or on the facilities of our local suppliers, in which event all or a portion of our inventory may be damaged, and
our ability to deliver products to customers could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, our operations
could also be disrupted by the obligations of personnel to perform military service. All our employees and independent contractors are
based in Israel. Some of our personnel in Israel may be obligated to perform annual military reserve duty in the Israel Defense Forces,
depending on their age and position in the army. Our operations could be disrupted by the absence of one or more of our executive officers
or key employees for a significant period due to military service and any significant disruption in our operations could harm our business.
The full impact on our workforce or business if some of our executive officers and employees are called upon to perform military service,
especially in times of national emergency, is difficult to predict. Our operations could be disrupted by the absence of a significant
number of employees related to military service, which could materially adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any hostilities involving
Israel, terrorist activities or political instability in the region or the interruption or curtailment of trade between Israel and its
present trading partners, or significant downturns in the economic or financial condition of Israel, could adversely affect our operations
and product development, cause our revenues to decrease and adversely affect our share price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, the Israeli
government has pursued, and continues to debate, significant changes to Israel&#8217;s judicial system. While the scope and timing of
these measures have evolved over time, and certain initiatives have been delayed, modified or suspended, the underlying issues remain
a source of political division and public controversy. In response to these developments, individuals, organizations and institutions,
both within and outside of Israel, have expressed concerns that actual or proposed changes to the judicial framework could negatively
affect Israel&#8217;s business environment, including through reduced willingness of foreign investors to invest or conduct business
in Israel, increased currency volatility, adverse actions or outlooks by credit rating agencies, higher interest rates, increased volatility
in securities markets, and other adverse macroeconomic effects. These developments could also adversely affect the Israeli labor market
or contribute to political instability or civil unrest. To the extent that any of these factors persist or intensify, they could have
a material adverse effect on our business, results of operations, financial condition and our ability to raise additional capital on
favorable terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pursuant to the terms of the Israeli government
grants we received for research and development expenditures, we are obligated to pay certain royalties on our revenues to the Israeli
government. In addition, the terms of Israeli government grant we received require us to satisfy specified conditions and to make additional
payments in addition to repayment of the grants upon certain events.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
efforts have been financed, in part, through funding from the IIA and the BIRD Foundation. We have received grants from the Government
of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of (i) our research and development expenditures
and (ii) a portion of the development of our manufacturing line, pursuant to the Innovation Law and related regulations and guidelines.
As of December&#160;31, 2025, we had received funding from the IIA and the BIRD Foundation in the total amount of approximately $5.6
million and $0.11 million, respectively. As of December&#160;31, 2025, we had not paid any royalties to the IIA and had a contingent
obligation to the IIA with respect to such funding in the amount of approximately $6.2 million. In addition, in January&#160;2021, we
received an IIA grant approval to support the funding of our transition from research and development to manufacturing. The final IIA
grant amounted to $620,000 (NIS 2.25 million) (along with a co-investment by us of the same amount), which we are not required to repay
to the IIA, subject to the terms and conditions set forth in the grant approval, of which we received approximately $0 (NIS 0) in 2025
and 2024, and $225,000 (NIS 816,075) in February&#160;2023. We may apply for additional IIA grants in the future; however, there is no
assurance that such applications will be approved in the amount requested or at all. Furthermore, the funds available for IIA grants
out of the annual budget of the State of Israel have been reduced in the past and may be further reduced in the future. We cannot predict
whether we will be entitled to any future grants, or the amounts of any such grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of the Innovation
Law as currently in effect, products developed with IIA funding are required to be manufactured in Israel, unless the IIA approved grant
program includes a pre-determined portion of manufacturing that may be performed outside Israel (as certain of our IIA approved grants
included). The approval of the IIA is required for the transferring of manufacturing outside Israel in excess of such pre-determined
portion (however, only a notice to the IIA, as opposed to approval, is required for the transfer outside Israel of up to 10% of the cumulative
manufacturing in excess of such pre-approved portion). If manufacturing of IIA-funded products is transferred outside Israel (following
IIA approval) in excess of the pre-determined percentage included in the grant approval, then the royalty repayment rate will be increased
by 1% with respect to the additional approved percentage to be manufactured outside Israel and the royalty repayment for the entire approved
program may be increased to up to three times the amount of the grants received, depending on the percentage manufactured outside Israel
(plus accrued interest). We may explore from time to time whether certain other components of C-Scan can be assembled outside of Israel.
For example, we may in the future explore whether it would be possible to assemble the capsule without the X-ray source in Israel and
have the X-ray source subsequently manufactured and assembled into C-Scan at a certified radioisotope production facility or at a distribution
center outside Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Over the years, we received
approval of grant applications that included a certain predetermined percentage of manufacturing to be performed outside of Israel of
the X-ray source but additional examination of these approvals and consequent manufacturing is required to determine liabilities to the
IIA, if any. IIA prior approval is also required for the transfer of IIA-funded know-how to a third party outside of Israel (including
by way of license), which we may not receive (and any such approval would typically be subject to payment of a redemption fee, calculated
according to a formula under the Innovation Law, which may be in the amount of up to six times the amount of the grants received less
paid royalties, if any, and depreciation, but no less than the total grants received), plus accrued interest. Even following the full
repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the Innovation Law and related regulations
and guidelines. The foregoing restrictions and requirements for payment may impair our ability to sell our technology assets outside
of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel.
Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology
or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to
pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
any of the conditions and restrictions imposed by the Innovation Law and related regulations and guidelines, or by the specific terms
under which we received the grants, we may be required to refund any grants previously received together with interest and penalties,
and, in certain circumstances, may be subject to criminal charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a shareholder
are governed by Israeli law, which differ in some material respects from the rights and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights and responsibilities
of the holders of our ordinary shares are governed by our amended articles of association and by Israeli law. These rights and responsibilities
differ in some material respects from the rights and responsibilities of shareholders in U.S. based corporations. In particular, a shareholder
of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations
towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting
at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s
authorized share capital, mergers and acquisitions and certain related party transactions requiring shareholder approval under Israeli
law. In addition, a controlling shareholder of an Israeli company or a shareholder who is aware that it possesses the power to determine
the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company or has other
powers towards the company, has a duty of fairness toward the company. There is limited case law available to assist us in understanding
the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations
and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a U.S. court against us, certain of our officers and directors or the Israeli experts named in this Annual Report in Israel or the
United States, to assert U.S. securities laws claims in Israel or to serve process on certain of our officers and directors and these
experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Israel.
A majority of our executive officers and directors are not residents of the United States, and a substantial portion of our assets are
located outside the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on
the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced
by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United States or to assert
U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation
of U.S. securities laws on the grounds that Israel is not the most appropriate forum in which to bring such a claim. In addition, even
if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law
is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that
addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may
not be able to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a
transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example,
a full tender offer for all of a public company&#8217;s issued and outstanding shares can only be completed if the acquirer receives
positive responses from the holders of at least 95% of the issued share capital and the approval of a majority of the offerees that do
not have a personal interest in the tender offer, unless at least 98% of the company&#8217;s outstanding shares are tendered. Furthermore,
the shareholders, including those who indicated their acceptance of the tender offer (unless the acquirer stipulated in its tender offer
that a shareholder that accepts the offer may not seek appraisal rights), may, at any time within six months following the completion
of the tender offer, petition an Israeli court for an appraisal right, to alter the consideration for the acquisition. In addition, a
statutory merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger
was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was
approved by the shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become subject to claims for payment
of compensation for assigned service inventions by our current or former employees, which could result in litigation and adversely affect
our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Patents
Law, 5727-1967, or the Patents Law, inventions conceived by an employee during the scope of his or her employment are regarded as &#8220;service
inventions&#8221; and are owned by the employer, absent a specific agreement between the employee and employer giving the employee service
invention rights. Section 134 of the Patents Law provides that if no agreement between an employer and an employee exists that prescribes
whether, to what extent, and on what conditions the employee is entitled to remuneration for his or her service inventions, then such
matters may, upon application by the employee, be decided by a government-appointed compensation and royalties committee established
under the Patents Law, or the Committee. Although our employees have agreed to assign to us all rights to any intellectual property created
in the scope of their employment and most of our current employees, including all those involved in the development of our intellectual
property, have agreed to waive their economic rights with respect to service inventions, we cannot assure you that claims will not be
brought against us by current or former employees demanding remuneration in consideration for assigned service inventions. If any such
claims were filed, we could potentially be required to pay remuneration to our current or former employees for such assigned service
inventions, or be forced to litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Ownership of our Ordinary
Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur and will continue to incur significant
costs as a result of operating as a public company in the United States, and our management is required to devote substantial time to
compliance initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a public company whose
securities are traded in the United States, we incur and will continue to incur significant legal, accounting and other expenses. The
Sarbanes-Oxley Act of 2002, as well as rules and regulations implemented by the U.S. Securities and Exchange Commission and the Nasdaq,
impose various requirements on public companies, including requiring the establishment and maintenance of effective disclosure and financial
controls. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Changes in the laws,
rules and regulations affecting public companies would result in increased costs to us as we respond to their requirements. These rules
and regulations could make it more difficult or more expensive for us to obtain certain types of insurance, including directors&#8217;
and officers&#8217; liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantial costs
to obtain or maintain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract
and retain qualified persons to serve on our Board of Directors, our Board committees or as executive officers. We cannot predict or
estimate the amount or timing of additional costs we may incur in order to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain effective internal
control over financial reporting, the price of our ordinary shares may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our internal control over
financial reporting may have weaknesses and conditions that could require correction or remediation, the disclosure of which may have
an adverse impact on the price of our ordinary shares. We are required to establish and maintain appropriate internal control over financial
reporting. Failure to establish those controls, or any failure of those controls once established, could adversely affect our public
disclosures regarding our business, prospects, financial condition or results of operations. In addition, management&#8217;s assessment
of internal control over financial reporting may identify weaknesses and conditions that need to be addressed in our internal control
over financial reporting or other matters that may raise concerns for investors. In addition, as a &#8220;non-accelerated filer,&#8221;
we are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting
firms provide an attestation report on the effectiveness of internal control over financial reporting. Decreased disclosures in our SEC
filings due to our status as a &#8220;non-accelerated filer&#8221; may make it harder for investors to analyze our results of operations
and financial prospects and may make our ordinary shares a less attractive investment. Any actual or perceived weaknesses and conditions
that need to be addressed in our internal control over financial reporting or disclosure of management&#8217;s assessment of our internal
control over financial reporting may have an adverse impact on the price of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to maintain compliance
with Nasdaq&#8217;s continued listing requirements, which could result in the delisting of our ordinary shares from the Nasdaq Capital
Market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nasdaq has established certain
standards for the continued listing of a security on Nasdaq. On September 3, 2025, we received a deficiency letter from the Nasdaq Listing
Qualifications Department notifying us that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires us to maintain
a minimum of $2,500,000 in shareholders&#8217; equity. The letter further stated that we had 45 calendar days, or by October 20, 2025,
to submit a plan to regain compliance with respect to the deficiency identified in the letter. We submitted the plan on October 20, 2025.
On January 30, 2026, we announced that we had regained compliance with Nasdaq&#8217;s minimum shareholders&#8217; equity requirement;
however, such compliance is conditional on our ability to maintain compliance on an ongoing basis. There can be no assurance that we
will be able to maintain compliance with Nasdaq&#8217;s continued listing requirements in the future. If we are delisted from Nasdaq,
our ordinary shares may be eligible for trading on an over-the-counter market in the United States. In the event that we are not able
to obtain a listing on another U.S. stock exchange or quotation service for our ordinary shares, it may be extremely difficult or impossible
for shareholders to sell their ordinary shares in the United States. Moreover, if we are delisted from Nasdaq, but obtain a substitute
listing for our ordinary shares in the United States, it will likely be on a market with less liquidity, and therefore, experience potentially
more price volatility than experienced on Nasdaq. Shareholders may not be able to sell their ordinary shares on any such substitute U.S.
market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result
of these factors, if our ordinary shares are delisted from Nasdaq, the price of our ordinary shares is likely to decline. A delisting
of our ordinary shares from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a
loss of confidence by investors, or employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a foreign private issuer and, as
a result, we are not subject to U.S. proxy rules and are subject to the Securities Exchange Act of 1934 reporting obligations that, to
some extent, are more lenient and less frequent than those applicable to a U.S. issuer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We report under the Securities
Exchange Act of 1934, as amended, or the Exchange Act as a foreign private issuer. Because we qualify as a foreign private issuer under
the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. public companies, including (i)
the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
under the Exchange Act; (ii) the liability for insiders who profit from trades made in a short period of time; and (iii) the rules under
the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified
information, or current reports on Form 8-K, upon the occurrence of specified significant events. We intend to furnish quarterly reports
to the SEC on Form 6-K for so long as we are subject to the reporting requirements of Section 13(g) or 15(d) of the Exchange Act, although
the information we furnish may not be the same as the information that is required in quarterly reports on Form 10-Q for U.S. domestic
issuers. In addition, while U.S. domestic issuers that are not large-accelerated filers or accelerated filers are required to file their
annual reports on Form 10-K within 90 days after the end of each fiscal year, foreign private issuers are not required to file their
annual report on Form 20-F until 120 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation
FD (Fair Disclosure), aimed at preventing issuers from making selective disclosures of material information. Although we intend to make
interim reports available to our shareholders in a timely manner, you may not have the same protections afforded to shareholders of companies
that are not foreign private issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are permitted,
to follow, and follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the listing
rules of the Nasdaq for domestic U.S. issuers. For instance, we follow home country practice in Israel with regard to, among other things,
director nomination procedures, the approval of compensation of officers and quorum requirements at general meetings of our shareholders.
In addition, we follow our home country law instead of the listing rules of the Nasdaq that require us to obtain shareholder approval
for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will
result in a change of control of the Company, certain transactions other than a public offering involving issuances of a 20% or greater
interest in the Company, and certain acquisitions of the stock or assets of another company. Following our home country governance practices
as opposed to the requirements that would otherwise apply to a United States company listed on Nasdaq may provide less protection to
you than what is accorded to investors under the listing rules of the Nasdaq Stock Market applicable to domestic U.S. issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we lose our status as a foreign private
issuer under the SEC&#8217;s rules, our compliance costs will increase.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We would lose our foreign
private issuer status if more than 50 percent of our outstanding voting securities are directly or indirectly held of record by residents
of the United States and if a majority of our directors or executive officers are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. Although we have elected to comply with certain U.S. regulatory
provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs for us
under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be
required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and
extensive than the forms available to a foreign private issuer. We would also be required to follow U.S. proxy disclosure requirements,
including the requirement to disclose more detailed information about the compensation of our senior executive officers on an individual
basis. We may also be required to modify certain of our policies to comply with corporate governance practices associated with U.S. domestic
issuers. Such conversion and modifications will involve additional costs. In addition, we may lose our ability to rely upon exemptions
from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exchange rate fluctuations between the
U.S. dollar and the NIS and the Euro and inflation may negatively affect our earnings and we may not be able to hedge our currency exchange
risks successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The dollar is our functional
and reporting currency. However, a significant portion of our operating expenses, including personnel and facilities related expenses,
are incurred in NIS. As a result, we are exposed to the risks that the NIS may appreciate relative to the U.S. dollar, or, if the NIS
instead depreciates relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of depreciation of the NIS, or
that the timing of such depreciation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel
would increase and our dollar- denominated results of operations would be adversely affected. In 2025, the NIS appreciated by approximately
12.5% relative to the U.S. dollar, compared to a depreciation of 0.80% in 2024, a depreciation of 3.07% in 2023, and a depreciation of
13.2% in 2022. The rate of inflation in Israel was 2.6% in 2025, compared to 3.2% in 2024, and 4.2% and 5.3% in 2023 and 2022, respectively.
Although we do not expect such appreciation and inflation to have a material adverse effect on our financial condition into fiscal 2026,
we cannot predict any future trends in the rate of inflation in Israel or whether the NIS will appreciate or depreciate against the U.S.
dollar. In addition, we may incur operating expenses denominated in Euros, and therefore, our operating results may also be subject to
fluctuations due to changes in the U.S. dollar/Euro exchange rate. We cannot predict any future trends in the rate of inflation in Israel
or the rate of devaluation (if any) of the NIS, the Euro and other foreign currencies against the U.S. dollar. Although we engage in
currency hedging arrangements from time to time, these measures may not adequately protect us from fluctuations in the exchange rates
of the NIS, the Euro and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies) and
involve costs and risk of their own.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never declared or paid a dividend
and currently do not intend to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of
our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared and
do not anticipate paying cash dividends on our ordinary shares in the foreseeable future. Our Board of Directors has discretion to declare
and pay dividends on our ordinary shares and will make any determination to do so based on a number of factors, such as our operating
results, financial condition, current and anticipated cash needs and other business and economic factors that our Board of Directors
may deem relevant. In addition, we are only permitted to pay dividends out of &#8220;profits&#8221; (as defined by the Israeli Companies
Law, 1999, or the Israeli Companies Law), provided that there is no reasonable concern that the dividend distribution will prevent us
from meeting our existing and foreseeable obligations, as they become due. If we do not pay dividends, our ordinary shares may be less
valuable because a return on your investment will only occur if the trading price of our securities appreciates. Further, you should
not rely on an investment in us if you require dividend income from your investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or reports about us or our business or publish unfavorable research about us or our business, the price of our securities
and their trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The trading market for our
securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. Management
is not aware of any research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our
securities, the price of our securities would likely decline. We do not have control over these analysts, and we do not have commitments
from them to continue to write research reports about us or our business. The price of our ordinary shares could decline if one or more
equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports
about us or our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our stock price has and may be subject
to fluctuation, and purchasers of our securities could incur substantial losses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our stock price has been
subject to considerable fluctuation since our initial public offering in February&#160;2015. The stock market in general has experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may not be able to sell their securities at or above the purchase price. The market price for our ordinary shares on Nasdaq
may fluctuate as a result of a number of factors, some of which are beyond our control, including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may
    not be able to complete the development of or redesign our products and technology, or redeploy our technology into other potentially
    viable products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to complete the Merger;</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to obtain the approvals necessary to commence further clinical trials and/or unsatisfactory results of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
    or delays in the regulatory review process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual
    property infringement actions in which we may become involved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    concerning our competitors or the medical device industry in general;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement
    of expected product sales and profitability or our failure to meet expectations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement
    of, or involvement in, litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major
    changes in our Board of Directors or management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation
    in the United States relating to the sale or pricing of medical device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    substantial sales of our ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trading
    volume of our ordinary shares; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes,
    emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including
    for example, the COVID-19 pandemic), boycotts, adoption or expansion of government trade restrictions, and other business restrictions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the stock market
in general, and Nasdaq in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our ordinary
shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly. See &#8220;<i>Risk Factors - Risks Related to Ownership of
our Ordinary Shares - We may be unable to maintain compliance with Nasdaq&#8217;s continued listing requirements, which could result in the delisting of our ordinary shares from the Nasdaq Capital Market.&#8221;</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The trading market for our ordinary shares
is not always active, liquid and orderly, which may inhibit the ability of our shareholders to sell ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our initial public
offering in February&#160;2015, the trading market for our ordinary shares has not always been active, liquid or orderly. The lack of
an active market at times may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider
reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our
ability to raise capital by selling shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have broad discretion in how we use
the net proceeds from our financings, and we may not use these proceeds effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management has broad
discretion as to the application of the net proceeds of our financings. Our shareholders may not agree with the manner in which our management
chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not
increase our market value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business, operating results and growth
rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect
to financial institutions and associated liquidity risk.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business depends on
the economic health of the global economies. If the conditions in the global economies remain uncertain or continue to be volatile, or
if they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and Ukraine, armed conflict
in Israel and Gaza, terrorism or other geopolitical events, our business, operating results and financial condition may be materially
adversely affected. See &#8220;<i>Risk Factors - Risks Related to Our Operations in Israel - Our principal offices, research and development
facilities our manufacturing sites and some of our suppliers are located in Israel and, therefore, our business, financial condition
and results of operation may be adversely affected by political, economic and military instability in Israel</i>.&#8221; Economic weakness,
inflation and increases in interest rates, limited availability of credit, liquidity shortages, trade restrictions and constrained capital
spending could negatively affect our financial condition, results of operations or cash flows. In addition, the military conflict may
affect the ability to purchase materials sourced in Russia. For example, one of our suppliers sources the enriched X-ray isotope substance
used in C-Scan from Russia. To the extent we continue to use such component in any redesigned or future products, we could experience
disruptions in our supply chain in the future if sanctions and export control restrictions on Russian entities and individuals are still
imposed, and we may not be able to find alternative sources for such key material in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Increases in inflation raise
our costs for commodities, labor, materials and services and other costs required to operate our business, and failure to secure these
on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, geopolitical developments and
global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest
rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately
respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, adverse developments
affecting the financial services industry, such as the closures of SVB and Signature Bank and their placement into receivership with
the Federal Deposit Insurance Corporation, other actual events or concerns involving liquidity and defaults or non-performance by financial
institutions or transactional counterparties, could have a material adverse effect on our business, financial condition, results of operations
and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is a risk that we could be treated
as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the transactions related to our acquisition of all
of the business operations and substantially all of the assets of Check-Cap LLC on May&#160;31, 2009, or the Reorganization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 7874(b) of the Internal
Revenue Code of 1986, as amended, or the Code, generally provides that a foreign corporation (i.e., a corporation created or organized
under the laws of a jurisdiction outside of the United States) would be treated as a domestic (U.S.) corporation for U.S. federal income
tax purposes if, pursuant to a plan or a series of related transactions, (1) the foreign corporation acquires, directly or indirectly,
substantially all of the assets of a domestic corporation (or substantially all of the properties constituting a trade or business of
a domestic partnership), (2) after the acquisition, the former shareholders of the acquired corporation by reason of holding shares of
the acquired corporation (or, in the case of an acquisition with respect to a domestic partnership, the former partners of the domestic
partnership by reason of holding a capital or profits interest in the domestic partnership) own at least 80% of the stock (by vote or
value) of the acquiring corporation, and (3) after the acquisition, the expanded affiliated group that includes the acquiring corporation
does not have substantial business activities in the foreign country in which, or under the laws of which, the acquiring corporation
is created or organized when compared to the total business activities of such expanded affiliated group. On the basis of analysis of
the relevant facts and circumstances and the relevant law (including the temporary regulations under Section 7874 applicable at the time
of the Reorganization), it was determined that the third condition described in the preceding sentence was not met with respect to the
Reorganization and, therefore, that the inversion tax rules of Section 7874(b) would not apply to treat us as a domestic corporation
for U.S. federal income tax purposes. However, since this determination was made on the basis of all of the relevant facts and circumstances,
and it is not clear which facts and circumstances the Internal Revenue Service, or the IRS, may consider more important than others,
this conclusion is not free from doubt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If Section 7874(b) were
to apply to the Reorganization (and we were to be treated as a domestic corporation for U.S. federal income tax purposes), then, among
other things, (i) we would be subject to U.S. federal income tax on our worldwide taxable income (if and when we have taxable income);
(ii) certain payments (e.g., interest and dividends) that we make (or have made) to our foreign investors may be (or may have been) subject
to U.S. withholding taxes; (iii) we may be subject to significant penalties for the failure to file certain tax returns and reports,
including reports with respect to our foreign bank accounts; and (iv) the U.S. unitholders of Check-Cap LLC would not have been subject
to U.S. federal income tax on royalties that are deemed to be paid to them under Section 367(d) of the Code as a result of the Reorganization.
As discussed under Item 5B &#8220;Operating and Financial Review and Prospects - Liquidity and Capital Resources - Application of Critical
Accounting Policies and Estimates - Royalties provision - Reimbursement liability to Check-Cap LLC unitholders,&#8221; as part of the
Reorganization, we committed to reimburse the unitholders of Check-Cap LLC for any tax burdens that may be imposed on them due to the
Reorganization, including royalties that are deemed to be paid to the U.S. unitholders under Section 367(d) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prospective investors are
urged to consult their own advisors on these issues. The balance of this discussion, including the discussion under Item 10E &#8220;Additional
Information - Taxation - U.S. Federal Income Taxation,&#8221; assumes that we will be and have been treated as a foreign corporation
for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be eligible for tax benefits from
government programs, which require us to meet certain conditions, including regarding the location of our property, plant and equipment
and manufacturing in Israel. We can provide no assurance that we would continue to be eligible for such benefits and/or that any such
benefits will not be terminated in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our manufacturing facilities
in Israel may qualify as a &#8220;Benefited Enterprise&#8221; under the Israeli Law for Encouragement of Capital Investments, 5719-1959,
which would entitle us to receive certain tax benefits. In order to be eligible for such benefits, we would be required to meet certain
conditions, including the making of a minimum capital investment in our productive assets and the carrying on of a required portion of
our manufacturing in Israel. The amount of the benefit will be determined in accordance with various conditions, including the location
of our property, plant and equipment and the location of certain of our sub-contractors. If we cease to meet the required conditions
for eligibility, the tax benefits could be cancelled and we could be required to pay increased taxes or to refund the amounts of the
benefits received with interest and penalties. We can provide no assurance as to the amount of future capital investment in our productive
assets, our future manufacturing location and the future location of our property, plant and equipment and certain of our sub-contractors,
and therefore, we cannot provide assurance that we will be eligible for such tax benefits or assurance as to the amount of such tax benefits.
Even if we continue to meet the relevant requirements, the tax benefits that Benefited Enterprises receive may not be continued in the
future at their current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we would be required
to pay would likely increase, as all of our operations would consequently be subject to corporate tax at the standard rate, which could
adversely affect our results of operations. See Item 10E &#8220;Additional Information-Taxation-Israeli Tax Considerations and Government
Programs-Law for the Encouragement of Capital Investments, 5719-1959&#8221; for additional information concerning these tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is a risk that we may be classified
as a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, we will be treated
as a passive foreign investment company, or a PFIC, for any taxable year in which either (1) at least 75% of our gross income (including
our pro rata share of the gross income of our 25% or more- owned corporate subsidiaries) is passive income or (2) at least 50% of the
average value of our assets (including our pro rata share of the assets of our 25% or more-owned corporate subsidiaries) is attributable
to assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, rents,
royalties, and gains from the disposition of passive assets. If we are determined to be a PFIC for any taxable year (or portion thereof)
that is included in the holding period of a U.S. Holder (as defined in Item 10E &#8220;Additional Information-Taxation-U.S. Federal Income
Taxation&#8221;) of our securities, the U.S. Holder may be subject to increased U.S. federal income tax liability upon a sale or other
disposition of our securities or the receipt of certain excess distributions from us and may be subject to additional reporting requirements.
Based on the past and projected composition and classification of our income and assets, we believe that we were a PFIC for the taxable
year ended December&#160;31, 2025 and may be a PFIC for the taxable year ending December&#160;31, 2026. Our actual PFIC status for our
current taxable year or any subsequent taxable year is uncertain and will not be determinable until after the end of such taxable year.
Accordingly, there can be no assurance with respect to our status as a PFIC for our taxable year ending December&#160;31, 2026 or any
subsequent taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. investors are urged
to consult their own tax advisors regarding the possible application of the PFIC rules. For more information, see Item 10E &#8220;Additional
Information-Taxation-U.S. Federal Income Taxation-U.S. Holders-Passive Foreign Investment Company Rules.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
4. Information On Our Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. History and Development of the Company
Our History</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our legal and commercial
name is Check-Cap Ltd. We were formed as a company in Israel on April&#160;5, 2009. On May&#160;31, 2009, we acquired all of the business
operations and substantially all of the assets of Check-Cap LLC, a Delaware limited liability company formed in December&#160;2004. On
May&#160;15, 2015, we formed our wholly-owned subsidiary Check-Cap US, Inc., a Delaware corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February&#160;24, 2015,
we successfully completed an initial public offering in the United States and the listing of our securities on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August&#160;16, 2023,
we entered into the Keystone BCA with Keystone, PubCo and other direct, wholly owned subsidiaries of PubCo. At our 2023 annual general
meeting of shareholders, such business combination transactions did not receive the requisite majority required for approval under Section
320 of the Israeli Companies Law 5759-1999. On December&#160;24, 2023, we received a notice on behalf of Keystone, terminating the Keystone
BCA in light of the results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 25, 2024, we
entered into the Apollo BCA. On September 4, 2025, we entered into the Parea APA to acquire certain assets relating to a Ghost
Kitchen area representative business. On September 12, 2025, we entered into the Merger Agreement, pursuant to which MBody AI will
become a wholly-owned subsidiary of the Company. Also on September 12, 2025, we entered into the BCA Termination Agreement, pursuant
to which the Apollo BCA will terminate upon the closing of the Merger. The Merger was approved by our shareholders on November 14,
2025, and closing is anticipated in the first half of 2026. Upon closing of the Merger, the Company expects to change its name to
&#8220;MBody AI Ltd.&#8221; or a similar name approved by the Israeli Registrar of Companies and continue as a publicly traded
company on Nasdaq, with MBody AI&#8217;s business comprising its principal operations. At the effective time of the closing of the
Merger, the Apollo BCA will be terminated by mutual consent of the parties such that no termination fee will be due to Apollo or the
Company, so long as the Company continues to be open to future integration with Apollo. Upon the closing of the Merger, the loans
made by the Company to Apollo that are currently outstanding will be converted into a 7.5% equity position in Apollo that will be
owned by the Company, and each of the related loan agreements between the Company and Apollo will be cancelled for no further
consideration</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See &#8220;&#8212; Evaluation
and Pursuit of Strategic Options&#8221; below for further details regarding the Apollo BCA, the Merger Agreement, the Parea APA and the
ARC ELOC Facility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the provisions
of the Israeli Companies Law. Our principal executive offices are located at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271,
Isfiya, 3009000, Israel. Our telephone number is +972-4-8303400 and our website is located at www.check-cap.com (the information contained
therein or linked thereto shall not be considered incorporated by reference in this Annual Report). Our U.S. agent is Puglisi &amp; Associates,
located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We use our website (http://www.check-cap.com)
as a channel of distribution of company information. The information we post through this channel may be deemed material. Accordingly,
investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
The contents of our website are not, however, a part of this Annual Report. Our filings with the U.S. Securities and Exchange Commission
(the &#8220;SEC&#8221;) are available to you on the SEC&#8217;s website at http://www.sec.gov, which contains reports, proxy and information
statements, and other information regarding us that we have filed electronically with the SEC. The information on our website is not part
of this annual report and is not incorporated by reference herein. Further, references to website URLs are intended to be inactive textual
references only.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principal Capital Expenditures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a discussion of our capital
expenditures, see Item 5 &#8220;Operating and Financial Review and Prospects-Liquidity and Capital Resources.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview of Our Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Historical Operations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical stage medical
diagnostics company aiming to redefine CRC screening through the introduction of C-Scan&#174;, a screening test designed to detect polyps
before they may transform into cancer to enable early intervention and cancer prevention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The disruptive capsule-based
screening technology aims to increase screening adherence worldwide and enable people to stay healthy. The system utilizes ultra-low-dose
X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. CRC is the third most commonly
diagnosed cancer, with more than 1.9 million new cases identified every year globally. It can take up to 10 years before a pre-cancerous
polyp develops into invasive cancer. As such, there is a crucial detection window for the prevention of colorectal cancer, through the
detection of these benign polyps. While routine screening is recommended by The American Cancer Society for healthy people aged 45 years
and older, screening adherence remains low. Currently, colonoscopy is the gold standard for the detection of colorectal polyps, but about
1 in 3 adults among the targeted screening population avoids having a colonoscopy in the U.S., and adherence in other regions of the world
such as Europe and Asia is even lower, due to the invasiveness of the procedure and bowel preparation. Most patient-friendly CRC screening
tests currently available, or poised to enter the market, such as fecal or liquid biopsy tests, are primarily designed to detect cancer
and demonstrate low sensitivity in detecting pre-cancerous polyps. As such, they do not necessarily provide patients with the time window
to pre-empt the disease. C-Scan is non-invasive and requires no bowel cleansing or sedation, allowing the patients to continue their daily
routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of
three main components: (1) C-Scan Cap, an ingestible X-ray scanning capsule; (2) C-Scan Track, three miniaturized patches worn on the
patient&#8217;s back for integrated positioning, control and data recording; and (3) C-Scan View, a proprietary software to process and
represent 2D and 3D maps of the inner surface of the colon. We believe that this solution has the potential to become an alternative for
both physicians and patients and to increase the number of people completing CRC screening.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our C-Scan Cap is swallowed
and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection
(currently, during clinical trials in the U.S., the C-Scan capsule is not intended to be disposed of in the sanitary sewer system, and
is therefore collected by the patient, and returned to the medical facility administering the device for further decay and disposal).
Unlike other existing CRC screening methods, this process should not disrupt a patient&#8217;s normal activities or require fasting. Our
C-Scan Cap employs ultra-low-dose X-rays, which allow the C-Scan system to scan the interior lining of the colon even when surrounded
by intestinal content. As such, we believe that patients using C-Scan will not be required to undergo any prior bowel cleansing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our C-Scan Cap is being designed
to transmit position, motility and the data it collects to the C-Scan Track that will be attached to the patient&#8217;s back. The external
data recorder is being designed to enable the download of the data to our C-Scan View application to allow physicians to analyze the data
collected by our C-Scan Cap. The C-Scan Track is being designed to provide the physician with localization data to yield a reconstructed
image intended to enable physicians to review the colon&#8217;s inner structural information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Colonic polyps are tissue
growths that occur on the lining of the colon. Polyps in the colon are common, and certain types of polyps may become cancerous over time.
In the event that polyps are identified by C-Scan, the patient may be advised to undergo a subsequent traditional colonoscopy procedure
to examine, remove and biopsy the polyps. For those patients who require a subsequent colonoscopy, concerns regarding pain, discomfort
and embarrassment may still remain. We do not, however, believe that these concerns will make the use of C-Scan any less attractive to
physicians and patients. Although patients who are initially screened utilizing a traditional colonoscopy could avoid the need for a second
colonoscopy if polyps are discovered, we believe that C-Scan will still be attractive option for physicians and patients who object to
or cannot undergo a colonoscopy in the first instance, as we believe a large number of these patients if screened will not require a subsequent
colonoscopy and those found with suspicious findings, will likely agree to undergo colonoscopy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We initiated our first clinical
studies in 2010, consisting of two single-center feasibility studies with non-scanning (no X-ray source) capsules for the purposes of
measuring gastrointestinal tract activity, colon contractions and associated capsule motility, and shortening capsule transit time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June&#160;6, 2023, we
announced that after further review of additional data and interaction with the FDA on a revised pivotal study protocol together with
the anticipated time and investment necessary to further develop the technology, we were reducing our workforce significantly to reduce
cash burn, concentrating our resources on essential research activities, discontinuing our calibration studies, and evaluating and pursuing
strategic options. We have discontinued development of our C-Scan technology and do not currently have any manufacturing capabilities.
Our current operations are focused on evaluating and pursuing strategic options and maintaining the inventory we manufactured prior to
our change in strategic priority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our formation, we have
not generated any significant revenue. We do not anticipate generating any significant revenue for the foreseeable future and we do not
yet have any specific launch dates for our product. We incurred net income of $4.1 million in 2025, and net losses of $25.1 million in
2024, and $17.6 million in 2023, respectively. We expect that we will continue to generate losses from our operations for the foreseeable
future. As of December 31, 2025, we had an accumulated deficit of $165.9 million and a total shareholders&#8217; equity of $3.4 million. We
have funded our operations to date primarily through equity financings, sales of ordinary shares and warrants, the exercise of warrants
and other funding transactions and through grants from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Evaluation and Pursuit of Strategic Options</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of our evaluation
and pursuit of strategic options, on August&#160;16, 2023, we entered into the Keystone BCA with Keystone, PubCo and other direct, wholly
owned subsidiaries of PubCo. At our 2023 annual general meeting of shareholders, such business combination transactions did not receive
the requisite majority required for approval under Section 320 of the Israeli Companies Law 5759-1999. On December&#160;24, 2023, we received
a notice on behalf of Keystone, terminating the Keystone BCA in light of the results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March&#160;25, 2024, we
entered into the Apollo BCA. In May&#160;2024, we reimbursed Apollo $3,808,815 pursuant to the provisions of the Apollo BCA. On September
8, 2024, our Board of Directors approved and ratified a Loan Agreement (the &#8220;September 2024 Loan Agreement&#8221;) with Apollo.
Pursuant to the September 2024 Loan Agreement, we agreed to provide Apollo a loan in the principal amount of US$6.0 million. The principal
outstanding under the loan will bear interest at 5% per annum, both before and after demand, default, and judgment, and will be payable
annually in arrears. The aggregate amount of the loan and any accrued and unpaid interest thereon will be due and be paid on the date
that is 30 days following the date the Apollo BCA is terminated, or the Check-Cap/Apollo Business Combination is consummated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, on September
8, 2024, our Board of Directors approved and ratified an amending letter (the &#8220;Amending Letter&#8221;)&#160;with Apollo. The Amending
Letter amends the Apollo BCA and obligates Check-Cap to deposit US$11.0 million into a designated, segregated and interest-bearing bank
account. Funds deposited into this account may be disbursed upon the mutual written agreement of the designated representatives of Apollo
and Check-Cap (being their respective board chairs) in order to fund the pursuit of accretive acquisition targets or other growth initiatives
of Apollo and for no other purpose. Any funds so disbursed will reduce the Net Cash Target (as defined in the Apollo BCA) on a dollar-for-dollar
basis. In the event that the Apollo BCA is terminated, then, subject to the payment of any termination fees triggered by Section 9.3(c)
of the Apollo BCA, funds remaining in the segregated account upon termination, together with interest earned thereon, will accrue to and
will be for the account and benefit of Check-Cap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 23, 2024, our&#160;Board
of Directors approved a Loan Agreement (the &#8220;December 2024 Loan Agreement&#8221;) with Apollo. Pursuant to the December 2024 Loan
Agreement, the Company agreed to provide Apollo a loan in the principal amount of US$6.0 million. The principal outstanding under the
loan will bear interest at 5% per annum, both before and after demand, default, and judgment, and will be payable annually in arrears.
The aggregate amount of the loan and any accrued and unpaid interest thereon will be due and be paid on the date that is 30 days following
the date the Apollo BCA is terminated, or the Check-Cap/Apollo Business Combination is consummated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The US$6.0 million loan will
be funded from the previously created designated, segregated and interest-bearing bank account. Funds deposited into the Segregated Account
may be disbursed upon the mutual written agreement of the designated representatives of Apollo and Check-Cap (being their respective board
chairs) in order to fund the pursuit of accretive acquisition targets or other growth initiatives of Apollo and for no other purpose.
Check-Cap and Apollo have identified acquisition targets and growth initiatives for which the proceeds of the US$6.0 million loan will
be used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2025,
US$2.1 million of the Segregated Account had been used for acquisition targets and growth initiatives, US$0.7 million had been used for
certain expenses incurred by the Company, and US$2.2 million remained in the Segregated Account. In July 2025, in connection with the
audit of the Company&#8217;s December 31, 2024 financial statements, the Company classified the $2.1 million used for acquisition targets
and growth initiatives as a $2.1 million loan to Apollo and entered into a loan agreement with Apollo on the same terms as the December
2024 Loan Agreement to document such classification. Also, in July 2025, in connection with the audit of the Company&#8217;s December
31, 2024 financial statements, the Company classified the $2.2 million remaining in the Segregated Account as of December 31, 2024 as
a $2.2 million loan to Apollo and entered into a loan agreement with Apollo on the same terms as the December 2024 Loan Agreement to document
such classification, given that the Segregated Account is in the name of an affiliate of Apollo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
the Company had provided total loan funding of approximately $16.3 million to Apollo under a series of loan agreements. Management recorded
a full allowance for credit losses against these loans under ASC 326, <i>Financial Instruments &#8211; Credit Losses</i>, as of December
31, 2024. During the six months ended June 30, 2025, management reversed the impairment and reinstated the loan receivable at $6,525,000,
reflecting the recoverable 7.5% interest based on the management-assessed equity value of Apollo at June 30, 2025. On November 14, 2025,
following the 98.01% shareholder vote in favor of the Merger at the 2025 Annual General Meeting, the Company recognized a noncash debt-for-equity
exchange: the loan receivable of $6,525,000 was derecognized and an equity investment in Apollo was recognized at cost of $6,525,000 with
no gain or loss recorded. See Note 14 to our audited consolidated financial statements presented elsewhere in this Annual Report. As of
December 31, 2025, a payable to Apollo of approximately $1,400,000 is presented as a standalone liability, representing amounts paid by
Apollo on behalf of the Company, net of settlements during the second half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 4, 2025, we
entered into the Parea APA with Parea to acquire certain assets relating to a Ghost Kitchen area representative business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 12, 2025, we
entered into the Merger Agreement, pursuant to which MBody AI will become a wholly-owned subsidiary of the Company. The Merger was approved
by our shareholders on November 14, 2025, and closing is anticipated in the first half of 2026. Upon closing of the Merger, the Company
expects to change its name to &#8220;MBody AI Ltd.&#8221; or a similar name approved by the Israeli Registrar of Companies and continue
as a publicly traded company on Nasdaq, with MBody AI&#8217;s business comprising its principal operations. Check-Cap&#8217;s legacy business
will continue its research and development activities. Check-Cap will continue to hold its legacy assets, consisting primarily of patents
and proprietary medical equipment. The Merger is also expected to complement and create potential synergies with Check-Cap&#8217;s Ghost
Kitchen franchise rights in New Jersey. At the effective time of the closing of the Merger, current MBody AI shareholders are expected
to hold approximately 90% and current Check-Cap shareholders are expected to hold approximately 10% of the outstanding ordinary shares
of the combined company on a fully diluted basis, subject to certain adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the effective time of
the closing of the Merger, the Apollo BCA will be terminated by mutual consent of the parties such that no termination fee will be due
to Apollo or the Company, so long as the Company continues to be open to future integration with Apollo. Upon the closing of the Merger,
the loans made by the Company to Apollo that are currently outstanding will be converted into a 7.5% equity position in Apollo that will
be owned by the Company, and each of the related loan agreements between the Company and Apollo will be cancelled for no further consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 17, 2025, we
entered into the Purchase Agreement with ARC, pursuant to which ARC has committed to purchase up to $30.0 million of the Company&#8217;s ordinary
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MBody AI </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Overview</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8221; is a Nevada
corporation incorporated on October 7, 2024 and headquartered in Las Vegas, Nevada. MBody AI is an artificial intelligence technology
company that designs, integrates, and manages AI-enabled robotic and software systems for large commercial environments, including hotels,
casinos, convention centers, and other high-traffic facilities. MBody AI&#8217;s core business combines its proprietary AI software platform,
the AI Orchestrator&#8482;, with robotic automation and data analytics to provide solutions for the hospitality, property management,
and commercial cleaning sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI provides turnkey
solutions to enterprise customers, including hardware procurement, deployment, financing, and ongoing operational management of autonomous
systems. MBody AI does not manufacture robots or autonomous hardware; rather, it procures third-party robotic equipment from suppliers
and integrates such equipment with its proprietary software platform to deliver coordinated autonomous solutions to its customers. MBody
AI&#8217;s customers include large-scale hospitality groups and other enterprises with complex operational environments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 12, 2025, the
Company entered into the Merger Agreement with MBody AI, pursuant to which MBody AI will become a wholly-owned subsidiary of the Company.
For additional information regarding MBody AI and the Merger, see the Company&#8217;s Report on Form 6-K filed with the SEC on September
12, 2025, which includes the proxy statement for the Company&#8217;s annual general meeting of shareholders. For MBody AI&#8217;s audited
financial statements as of December 31, 2024 and for the period from October 7, 2024 (date of formation) to December 31, 2024, and as
of June 30, 2025 and for the six months then ended, see the Company&#8217;s Report on Form 6-K filed with the SEC on January 30, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Technology and Products</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s AI Orchestrator
platform is a proprietary, hardware-agnostic software platform designed to integrate and coordinate diverse robotic and autonomous systems
within a single operating environment. The platform provides enterprise customers with a unified interface for managing heterogeneous
robot fleets, enabling coordination, monitoring, and optimization of autonomous hardware from multiple original equipment manufacturers.
The platform incorporates machine learning capabilities intended to enable the system to adapt and optimize its operations over time based
on data collected from customer deployments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The AI Orchestrator platform
is deployed through a phased rollout of features, with certain capabilities delivered incrementally to customers. Customer deployments
are typically customized to the specific requirements of each customer&#8217;s facilities and operating environments, and may involve
coordination with customer personnel and third-party vendors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI historically deployed
robotic equipment at customer sites under 36-month lease agreements, with customers making fixed monthly lease payments that bundled the
use of hardware together with maintenance, warranty, and service support. Beginning in 2025, MBody AI commenced a strategic transition
toward a software-as-a-service (&#8220;SaaS&#8221;) and AI-platform subscription model, which is intended to emphasize recurring, higher-margin
software revenues. Under this model, customers are provided continuous access to MBody AI&#8217;s proprietary software platform and AI-driven
analytics suite. MBody&#8217;s subscription agreements range from 24-60 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s revenue
is derived from the following sources:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AI Platform Subscription Revenue. Recurring monthly or annual
fees charged to customers for access to MBody AI&#8217;s cloud-based platform, including fleet management, task scheduling, AI analytics
dashboards, and model updates.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">AI-Enabled Services Revenue. Fees for integration services,
customization of AI models, data insights, and advanced analytics modules tailored to individual customer requirements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Deployment and Support Revenue. Fees for installation, on-site
setup, calibration, and initial operator training associated with new customer deployments.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Maintenance and Warranty Revenue. Fees for extended maintenance,
service, and warranty support, typically over a 36-month term.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Hardware Enablement Revenue. Revenue from the delivery of
robotic equipment procured from third-party vendors, which is provided to customers as part of MBody AI&#8217;s turnkey deployment model.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Market Opportunity</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI operates in the
markets for artificial intelligence, automation, and autonomous systems. The adoption of autonomous systems and robotics in enterprise
environments has been increasing across a number of industry verticals, including hospitality, gaming, healthcare, and data center operations.
MBody AI&#8217;s platform is designed to address the need of enterprise customers to coordinate and manage multiple autonomous systems
from different manufacturers within a single integrated environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">MBody AI&#8217;s target customers
include large enterprises with complex, high-traffic operational environments that may benefit from the deployment of autonomous systems
to improve operational efficiency. MBody AI has entered into arrangements with enterprise customers in the hospitality and gaming sectors
and seeks to expand the scope and number of its customer deployments over time. MBody AI&#8217;s customers operate in regulated industries,
and deployment of autonomous systems in certain jurisdictions may require regulatory approvals, licenses, or compliance with industry-specific
rules, including gaming and safety regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Competition</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The markets for artificial
intelligence, automation, and autonomous systems are rapidly evolving and highly competitive. MBody AI faces competition from companies
that develop and deploy robotics and autonomous systems, as well as other technology companies that offer solutions for enterprise automation.
New technologies, business models, and competitors may emerge that could reduce demand for MBody AI&#8217;s platform or render its offerings
less competitive. MBody AI&#8217;s ability to compete successfully depends on a number of factors, including the functionality and reliability
of its platform, the breadth of its hardware integrations, and its ability to continue to innovate and adapt to evolving market requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ghost Kitchens New Jersey</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 5, 2025, the
Company entered into the Parea APA, pursuant to which the Company acquired all right, title, and interest in a contract granting exclusive
Ghost Kitchen area representative rights across the state of New Jersey. As consideration for the acquired assets, the Company issued
1,169,596 ordinary shares to Parea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ghost Kitchen operations
involve commercial kitchen facilities that operate in non-retail environments and are designed exclusively for the preparation of food
for take-out and delivery. As the exclusive area representative for Ghost Kitchen in New Jersey, the Company has the right to drive franchise
sales, deliver training, and provide ongoing support to Ghost Kitchen franchisees throughout the state. Under the Ghost Kitchen Area Representative
Agreement, the Company is entitled to receive 50% of all initial franchise fees and 50% of all ongoing royalties paid by Ghost Kitchen
franchisees in New Jersey.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The acquisition of Ghost
Kitchen franchise rights in New Jersey represents a component of the Company&#8217;s strategy to pursue revenue-generating opportunities
while it evaluates and pursues strategic alternatives. The Company&#8217;s ability to generate revenue from the Ghost Kitchen area representative
rights is dependent on the successful sale of Ghost Kitchen franchises in New Jersey and the ongoing operations of those franchisees.
For additional information regarding the Parea APA, see the Company&#8217;s Report on Form 6-K filed with the SEC on September 5, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">CRC screening can reduce
the incidence of and mortality from the disease by enabling detection of precancerous polyps in the colon at an earlier, more treatable
stage. CRC is one of the few cancers that can be prevented through screening because pre-cancerous polyps, from which colon cancers often
develop, can be identified and removed. Today, there is a range of options for CRC screening in the average-risk population, with current
technology falling into two general categories: (i) structural exams that enable physicians to visualize the colon for abnormalities,
such as optical colonoscopy (which is currently regarded as the &#8220;gold standard&#8221; for CRC screening), sigmoidoscopy, CTC and
optical capsules-all of which require aggressive bowel preparation and are invasive exams; and (ii) stool and serum based tests, such
as FOBTs, FITs, stool DNA, and blood tests, which test for blood in stool and irregularities in blood and DNA. Notwithstanding the proven
clinical value of screening for CRC, the many CRC screening alternatives and the fact that screening is encouraged by clinicians and insurers,
a large portion of the population is still reluctant to perform CRC screening.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan is designed to enable
early detection of precancerous polyps while providing a patient friendly solution without requiring any colon cleansing. The purpose
of C-Scan is to detect colorectal polyps in subjects who, based on demographics and medical history factors, are considered average risk
for CRC. If polyps are detected, the patient is elevated to high risk for CRC and referred for a colonoscopy. Studies have shown the detection
of polyps through C-Scan, increases the likelihood of patients to agree (i.e., &#8220;adherence&#8221;) to undergo a colonoscopy procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although C-Scan utilizes
X-Ray technology (exposing the patient to approx. 0.05 mSv), we believe that the potential risks associated with such radiation exposure
are low compared to the potential risks associated with other procedures such as perforation, bleeding or sedation related effects (optical
colonoscopy and sigmoidoscopy) and dehydration and damage to kidneys. Unlike FOBTs, FITs and stool DNA tests, our capsule-based imaging
modality generates structural information on the colon, which could assist in the detection of pre-cancerous polyps. We therefore do not
believe that the ultra-low-dose radiation in our capsule will make C-Scan less attractive to physicians and patients than other less-effective
products that do not employ any radiation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our technology is based on
an ingestible capsule (C-Scan Cap), which is swallowed by the patient and propelled by natural motility through the gastrointestinal tract.
Our capsule transmits information to a receiving device (C-Scan Track) worn on the patient&#8217;s body that stores the information for
off-line analysis. Our C-Scan Cap consists of an X-ray source and several X- ray detectors. The X-ray source is contained in a rotating
radiation shield, enabling the generation of 360-degree angular scans. The collection of successive angular scans is intended to enable
the virtual reconstruction of a portion of the colon&#8217;s inner surface. During movement of our capsule longitudinally through the
colon, successive images of portions of the colon enable the three- dimensional reconstruction of the colon. C-Scan is also intended to
enable structural identification of polyps, and masses, which protrude inward into the colon, through the detection of irregularities
in the topography of the colon&#8217;s inner surface.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan is intended to be
prescribed to patients by physicians. Prior to capsule ingestion, patients will swallow 15ml of iodinated oral contrast medium, three
times a day, combined with oral fiber, and continue to do so in order to enhance the contrast of the colon surface. The capsule is propelled
by natural motility through the gastrointestinal tract. During transit, information is transmitted to the C-Scan Track, which stores the
information for off-line analysis. After our C-Scan Cap is expelled from a patient&#8217;s body, the C-Scan Track data will be downloaded
into our workstation (C-Scan View) and uploaded to a cloud-based server, through which an expert analyst will perform pre-analysis to
be followed by a physician&#8217;s final interpretation that includes a findings report and a determination of whether the patient is
considered average or elevated risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan consists of the following
three main subsystems that together enable the generation of high-resolution 3D imaging of the colon&#8217;s inner surface, further described
below: (i) an ultra- low-dose X-ray based colon scanning capsule (C-Scan Cap); (ii) C-Scan Track; and (iii) a client\server PC-based application
(C-Scan-View).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan system enables
a patient-friendly, preparation free and painless evaluation of colorectal abnormalities. Using the C-Scan system, suspicious findings
that may be colorectal polyps can be identified, thus assisting the physician in deciding whether to elevate the patient to high-risk
category and refer the patient to a colonoscopy procedure. Studies have shown that the adherence of an elevated-risk patient to undergo
a colonoscopy procedure is higher than that of an average risk patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan system provides
information for the physician, enabling him to make a &#8220;YES / NO&#8221; decision for suspected presence of polyps in the colon, based
on the premise that the presence of polyps in the colon is associated with the potential development of CRC. The C-Scan system is intended
to be used as a preliminary tool to assist in the detecting of subjects who are at elevated risk for polyps and thus potentially increase
the adherence of those subjects to undergo colonoscopy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan system is designed
to evaluate the presence of polyps, without the need for fasting and prior bowel cleansing, through identifying suspects in the human
colon supported by physiological data, such as measured transit time of the capsule through the GI tract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan system presented
in Figure 1 includes three main units, C-Scan Cap, C-Scan Track and C-Scan View. The C-Scan procedure steps are illustrated in Figure
2. The C-Scan Track is attached to the patient&#8217;s back, after which, the patient ingests the C-Scan capsule. The capsule starts moving
through the patient&#8217;s gastrointestinal system until it reaches the colon where it starts scanning the colon walls and transmitting
the acquired data to the C-Scan Track. Following the natural excretion of the capsule, the patient returns the C-Scan Track to enable
data loading and analysis using C-Scan View. The analysis report includes an indication of either &#8220;NO- Average Risk&#8221; in cases
where no suspicious findings were identified or &#8220;YES- Elevated Risk&#8221; in cases where suspicious findings were identified. An
operational block diagram is presented below in Figure 4.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 1: Illustration of C-Scan system units</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img1.jpg" style="height: 132px; width: 350px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 2: Illustration of C-Scan system procedure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" src="ea028762301_img2.jpg" style="height: 91px; width: 700px"/></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan Cap</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan Cap is an X-ray scanning
capsule, which enables detection of suspected polyps. C-Scan Cap is ingested by the patient and propelled by peristalsis, natural motility,
it passes through the gastrointestinal tract and is excreted naturally, with either no need for retrieval or required retrieval of the
capsule, depending on the local agency guidance (currently, during clinical trials in the U.S., the C-Scan capsule is not intended to
be disposed of in the sanitary sewer system, and is therefore collected by the patient, and returned to the medical facility administering
the device for further decay and disposal).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan Cap is designed to
measure, collect and transmit structural information, and is comprised of the following components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X-ray Source - Including radioactive material sealed in a cylindrical housing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collimator - Radiation shield around the source, which absorbs most of the radiation. Several radial holes enable emission of radiation in defined directions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X-ray Sensor - Comprised of several solid state X-ray detectors for measuring the scattered radiation intensity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tilt Sensor - Indication of capsule motion (3D acceleration).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rotation Motor - For rotating the collimator and X-ray Source.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compass sensor - Indication of true north (reference coordinate system).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pressure sensor - indicating the hydrostatic pressure inside the colon.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source Concealment Mechanism - Conceals the source inside the radiation shield.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R-T - Radio frequency transceiver device to communicate with the receiver.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Batteries - Electrical power supply for the capsule.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memory - Data storage. The capsule should be able to store up to an hour of measured data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C-Scan Track Coil - Transmits a continuous electromagnetic field utilized by an external localization system to track 3D position.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" src="ea028762301_img3.jpg" style="height: 146px; width: 260px"/></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 3: C-Scan Cap</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img4.jpg" style="height: 45px; width: 90px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan Track</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan Track is a small,
disposable system attached to the patient&#8217;s back via biocompatible adhesive skin patches. C-Scan Track communicates with the C-Scan
Cap and enables data download for analysis purposes. Both the C-Scan Track and C-Scan Capsule are equipped with an electromagnetic capability
allowing for capsule position and orientation estimations through the C-Scan Track. A dedicated scan control algorithm (SCA) identifies
the C-Scan Cap&#8217;s movements in the colon and, accordingly, commands the C-Scan Cap when to perform a scan. C-Scan Track also measures
the transit time from capsule ingestion to excretion through radio frequency communication to a non-volatile memory device, and enable
data retrieval, to an external processor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan Track is comprised
of the following components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sticker Housings - Biocompatible and water-resistant stickers and housing integrating all functional components, attached to the patient&#8217;s back, enabling approximately five days of continuous operation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recorder - Consists of receiver electronics embedded software and nonvolatile memory.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antennas - Radio frequency antennas are embedded into the sticker housings and used to communicate with the capsule.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation/Deactivation Circuit - Used to activate/deactivate the C-Scan Track through a specialized protocol.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UI Indicators - Provides user with vocal and vibration indication as required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCB - Electronics&#8217; printed circuit boards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microcontroller - Runs embedded software, logic that manages the C-Scan Track and SCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RF Transceivers - Several transceivers used to communicate with the capsule.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TILT/Compass Sensors - To determine the patient&#8217;s body movements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Batteries - Electrical power supply for the C-Scan Track.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memory - Non-volatile data storage to store data acquired by the system.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img5.jpg" style="height: 51px; width: 85px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan View</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan View software
is a client/server-based application that enables procedure data to be downloaded from the C-Scan Track, data analysis and report generation.
The C-Scan View&#8217;s main functions are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Load and display procedure information and data;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Image review, enabling the user to view structural information of the colon wall;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Produce procedure report; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Store procedure results on server.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The data from the C-Scan
Track is loaded and processed to create a reconstruction model of the colon wall, which is displayed in the C-Scan View as structural
information of the colon wall, as well as Whole-Gut-Transit-Time (WGTT) data. The data is analyzed by a team that includes expert analysts,
who review the structural information to identify suspicious findings that are protruding or bulging on the colon wall. The analysts consider
the capsule&#8217;s WGTT as part of the analysis process. The gastroenterology physician reviews the analysis in the C-Scan View and generates
the final report as to whether the patient is assessed to be at average or at elevated risk, determined through a combined analysis consisting
of both structural analysis and transit time analyses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 4: Conceptual block-diagram of the C-Scan
system</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img6.jpg" style="height: 104px; width: 280px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan System Non-Clinical and Clinical History</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have developed and validated
our capsule-based imaging modality for providing structural information on colonic polypoid lesions and masses for CRC screening. Below
is a summary of the validation tests carried out by us in the laboratory, in phantoms, animals and humans, which were designed to evaluate
this new imaging modality&#8217;s performance and potential clinical value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Clinical Testing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Imaging Performance Testing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan Cap transmits
data as it transits the colon. This data consists of imaged slices perpendicular to the capsule&#8217;s longitudinal axis; slices are
then reconstructed by the C-Scan View to produce 2D and 3D images of the inner surface of the colon. Following are performance measurements
of the capsule imaging.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modulation Transfer Function, or MTF. The capsule was moved along a longitudinal-edge phantom setup in 3mm steps. The figure below shows a typical raw signal after filtering for peak detection. The same test was carried out using an angular-edge phantom setup, which demonstrated similar results to those shown below. These tests do not take into account noise characteristics.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img7.jpg" style="height: 57px; width: 100px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For each position of the
capsule in the phantom, the mean signal intensity (peak) was measured, the result of which is shown in the right figure below. Resulting
line spread function, or LSF, which is the differential of the curve in the left figure below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Image for illustration purpose only</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img8.jpg" style="height: 64px; width: 115px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The graphs above demonstrate
that the existing design of C-Scan can detect objects of approximately 2-3mm when noise is not taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Resolution Limit: Estimation of the Smallest Visible Object Size. </i>In order to estimate the size of the smallest visible object, both spatial resolution and noise characteristics must be taken into account. The graph below presents the estimated MTF of C-Scan. Noise analysis indicates MTF 1/3 for minimum visibility, which demonstrates that the smallest visible object that can be detected with the existing design of C-Scan (in the conditions used, which included a colon diameter of 30mm) is of approximately 5-6 mm (see graph below).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Image for illustration purpose only</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img9.jpg" style="height: 113px; width: 200px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Image Reconstruction</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Two main characteristics of C-Scan contribute to the image
reconstruction performance:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of photons hitting the detector per time frame.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The angular spread of the photon beam coming out of the capsule collimator.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the laboratory tests
performed with a previous version of C-Scan, polyps of 6 mm and larger should be visible and 10 mm polyps and larger are expected to be
detected at higher sensitivity. To further enhance the visibility of 6 mm - 9 mm polyps, a new design of the collimator, which is expected
to enable 1.5 times the number of photons to be detected by the detectors, was successfully incorporated and tested in our advanced C-Scan
Cap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Animal Testing and Tissue Equivalent Phantom
Image Reconstruction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The physics of our imaging
modality was tested in the laboratory on phantoms with tissue equivalent material and in animals to ensure that laboratory conditions
mimic real life clinical scenarios.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the initial proof
of concept, we performed a series of studies in order to evaluate the feasibility and preliminary safety of our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The animal studies conducted
to date demonstrate that our technology provides sufficient resolution, in these studies, for the detection of 10 mm polyps which is the
size of clinically significant polyps. The animal studies also demonstrated that 5 mm polyps can be detected, though with lower resolution
than 10 mm polyps in the first animal capsule. Animal health was maintained throughout the studies. No adverse effects related to passage
of our capsule were noted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The capsules evaluated in
the animal studies were significantly larger than the capsules that we are using with humans. The differences in anatomy, physiology,
and capsules may have several effects on the data compared to use in the human population. Motility of the capsules through the digestive
C-Scan was slow due to the specific shape of the porcine gastrointestinal tract. In addition, because of the size of the capsule, it was
retained in the stomach for many hours and even days. Accordingly, the animal model required that normal ingestion be replaced by direct
insertion of the capsule into the small bowel. In order to simplify the development and animal testing, we used Tungsten radiation source
with long half-life (120 days).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the success of
the animal testing, a series of in-vitro tests were conducted to simulate different clinical scenarios in the laboratory using a miniaturized
human capsule. Polyps were created and reconstruction of the laboratory phantoms with a human capsule was generated to assess the ability
to detect polyps as the capsule advances in the colon. The in-vitro tests demonstrated the imaging capabilities of our imaging technology.
Below is the reconstruction of a laboratory phantom image.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028762301_img10.jpg" style="height: 86px; width: 154px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Polyp Detection Analysis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Laboratory tests were carried
out to estimate the capsule&#8217;s ability to detect polyps in phantoms and demonstrate sensitivity and specificity of such detection.
Below is an example of the reconstruction of a scan composed of three slices: XRF, CMT and a fused (combined) image.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="ea028762301_img11.jpg" style="height: 84px; width: 150px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Receiver Operating Characteristics</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Standard receiver operating
characteristics, or ROC, curves were generated from phantom data with 8 mm polyp in a 30 mm barrel phantom with 3% iodine concentration
mimicking the colon contents. CMT, XRF and fused (combined) data were analyzed based on 2D slices that were generated and standard deviation
indicator. There were a few cases where the noise in the phantoms was high enough to generate polyp false positive condition separately
for each data type, especially in CMT. However, fusion of CMT and XRF data contributed to noise reduction and enabled to demonstrate 100%
true positive and 0% false positive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Image for illustration purpose only</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="ea028762301_img12.jpg" style="height: 58px; width: 100px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We initiated our first clinical
study at University Hospital, Hamburg, Germany in 2010. The purpose of this study was to monitor and record the colon contractions and
the associated motility of the capsule in the colon. This study was conducted with a passive capsule that contained no X-ray source or
detectors. It included several electronic components of C-Scan and had similar dimensions to the current capsule. 63 healthy volunteers
were enrolled, and no adverse events were reported.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We completed a limited,
single-center, feasibility study at Rambam Medical Center, Haifa, Israel to assess the motility of a non-scanning capsule in healthy
subjects. The objective of the study was to optimize the daily routine of the subjects in order to shorten the transit time of our capsule.
15 subjects participated and swallowed a capsule with the same weight and dimensions as our current C-Scan capsule. No adverse events
were reported and all capsules were retrieved. A structured daily routine determined the timing of the following: capsule ingestion,
the subjects&#8217; daily meals, the contrast agent ingestion and one evening dose of 10 mg of Bisacodyl. All subjects continued their
regular active lifestyles (such as work and exercise). The average transit time of the capsule in the 15 subjects was approximately 38
&#177; 19 hours, which is comparable to the average transit time of our capsule in subjects participating in the multi-center feasibility
study, in which the participants do not ingest a daily dose of Bisacodyl, and participants are released to their homes and continue their
regular lifestyles during the study.&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A 10 subject clinical proof-of-concept
study, conducted at Tel Aviv Sourasky Medical Center in Israel using a prior version of C-Scan, did not identify any material safety or
feasibility issues. The study demonstrated the applicability of C-Scan to the human colon, generating images of the colon without any
prior bowel preparation. All subjects ingested the capsule easily with smooth passage within the designated transit time, on average,
within 48-72 hours. There were no reported device-related adverse events. Mild effects on bowel movements were noted, which were determined
to be related to the contrast agent and passed within one to two days after the capsule excretion. Estimated total radiation exposure
was calculated using standard established factors for calculating effective radiation exposure, such as the duration of the capsule inside
the body, and was based on the activity of the radiation source inside the C-Scan Cap and radiation energy, both of which were measured
for each case study. The average calculated exposure for the entire procedure in the 10-case study, from ingestion of the capsule to excretion,
was 0.03 mSv (STD 0.007 mSv). This level of radiation exposure is similar to a single chest X-ray (approximately 0.06mSv) and two orders
of magnitude less than a CTC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 10-subject study constituted
the initial phase of a multi-center, prospective clinical feasibility study to establish the safety, functionality and preliminary efficacy
of C-Scan in patients eligible for CRC screening, by comparing results from the clinical feasibility study with those from non-invasive,
low-sensitivity FITs, as well as from optical colonoscopies. The feasibility study has been designed to allow for the recruitment of 100
subjects. The study was conducted at multiple centers in Israel. The clinical feasibility study was used to evaluate the image resolution
generated by the capsule in a human colon without cathartic preparation, assess polyp imaging in various shapes and in different segments
of the colon, evaluate the safety of the device in terms of total and segmental transit time, and analyze the effects of the presence
of polyps and variable colon dimensions on these parameters. During the feasibility study we collected data regarding the overall imaging
of the colon&#8217;s internal surfaces during the passage of the capsule to support the development of a correlation map of polyps identified
through our imaging system with polyps imaged by optical colonoscopy and CTC. Additionally, the feasibility study allowed for the measurement
of total radiation exposure and the distribution of contrast material within the colon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Analysis conducted on the
first 66 capsules swallowed by participants enrolled in the multi-center, prospective clinical feasibility study showed that 65 of 66
capsules swallowed were naturally eliminated, without major or minor side effects, after 62&#177;40.7 hours. The average calculated
radiation exposure was 0.06 &#177; 0.04 mSv (similar to a single chest radiograph). Image reconstructions allowed 2D/3D views of the
colonic wall and lumen with the typical contour of different segments (hepatic flexure, triangular shape of the transverse colon). Both
pedunculated and sessile polyps were detected in several patients and validated later by colonoscopy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2017, we completed
a multi-center study of C-Scan in support of CE Mark submission. The objective of the study was to assess safety and the clinical performance
of C- Scan in detecting patients with polyps. The three-center trial enrolled 66 patients, with a mean age of 59 years. Following capsule
ingestion, subjects swallowed small doses of contrast agent and fiber supplements with each meal throughout capsule passage. Average capsule
transit time was 52&#177;32 hours, and the average total X-ray dose was 0.05 mSv (CT colonography effective dose is ~ 6.0 mSv). No bowel
preparation, sedation, or change in diet was required. Both confirmatory colonoscopy, performed by an independent investigator, and C-Scan
review, performed by a central review group, were blinded to results. The study demonstrated a 44% sensitivity in the 45 subjects included
in the analysis for polyps, with specificity (ability to correctly identify lack of polyps) of 89%. Sensitivity strongly correlated (R-squared
= 0.98) to the percentage of the colon scanned. Sensitivity was 78% (p&lt;0.05) and 100% (p&lt;0.05) for subjects where greater than 50%
and 70% of the colon was scanned, respectively. Specificity was consistent for all subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the fourth quarter of
2017, we initiated an interim clinical study for the purpose of introducing an advanced C-Scan version, Version 3, which incorporated
the then latest algorithms and system optimization and tailored scanning of the colon to the patient&#8217;s natural colonic movements
to maximize the amount of the colon that is tracked and imaged. In March&#160;2018, we announced results from the interim study. Evaluable
results of 21 patients showed average colon imaging coverage of 64%, a 40% improvement over 46% average colon imaging coverage in the
multi-center study. Sensitivity was 78% (p&lt;0.05) for subjects with greater than 50% colon imaging coverage and 100% (p&lt;0.05) for
subjects with greater than 70% colon imaging coverage. Specificity was consistent at around 89%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the first quarter
of 2018, we initiated a multi-center, open label, home monitoring, prospective study, designed to determine the performance characteristics
of C-Scan Version 3, for detecting pre-cancerous polyps compared with the fecal immunochemical test (FIT), in each case using colonoscopy
as the reference method, for the purpose of collecting additional evidence of clinical effectiveness and clinical utility to support market
adoption. The study included 90 evaluable patients who either had known polyps or were considered to be of average risk. Each patient
ingested a C-Scan capsule and also underwent a FIT and a comparative colonoscopy performed by independent gastroenterologists, who were
blinded to the corresponding test&#8217;s results. The C-Scan clinical evaluation was obtained using the evaluable patient population
implementing a gender-based motility analysis and the results of both C-Scan and FIT were compared to colonoscopy. The primary efficacy
endpoint of the study was sensitivity (ability to correctly identify patients with polyps) and specificity (ability to correctly identify
patients with lack of polyps) of the C-Scan system compared to FIT in detecting subjects with polyps &#8805;10 mm. In July&#160;2019, we
announced final results from our post-CE approval study. The results demonstrate that C-Scan achieved a sensitivity of 76% (p=0.0005)
in patients with polyps &#8805;10 mm, while FIT achieved a sensitivity of 29% (p=0.005) in patients with polyps &#8805;10 mm. C-Scan achieved
a specificity of 82% in all patients, while FIT achieved a specificity of 96% in all patients. In addition, C-Scan detected all 4 patients
(100%) with polyps &#8805;40 mm, while the FIT detected only 1 of the 4 patients (25%) with polyps &#8805;40mm. Overall, C-Scan achieved a sensitivity
of 66% (p=0.01) in all patients, including patients with polyps &lt;10mm, while FIT achieved a sensitivity of 23% (p&lt;0.0001) in all
patients, including patients with polyps &lt;10mm. In total, 142 patients enrolled in the study and after factoring in technical and physiological
dropouts and protocol violations, the number of evaluable patients was 90. No SAEs were reported, and the adverse events were mild in
severity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December&#160;2018, we
received from the FDA conditional approval of our IDE application to initiate a U.S. pilot study of the C-Scan Version 3 and received
final approval from the FDA in February&#160;2019. In April&#160;2019, we initiated the U.S. pilot study of C-Scan. The U.S. pilot study
(NCT03735407) was a prospective, multi-center, open label, single arm study designed to evaluate the safety, usability and subject compliance
of the C-Scan. The study included 28 evaluable patients, more than two thirds of whom were considered to be of average risk for colorectal
cancer. Each patient ingested a C-Scan capsule and also underwent a fecal immunochemical test (FIT) as well as a comparative colonoscopy,
which was performed by an independent gastroenterologist who was blinded to the corresponding test results. The study was performed at
two sites, the NYU Grossman School of Medicine and Mayo Clinic, Rochester. The primary endpoint of the study was to evaluate the incidence
of device or procedure related SAEs. Secondary endpoints included patient compliance, subject satisfaction and device and procedure related
performance. Due to sample size, the study was not designed to be powered for statistical significance. In December&#160;2019, we announced
the results of the study. No device or procedure related SAEs were reported and all device or procedure related adverse events were mild
in severity. In total, 45 patients enrolled in the study, of which 40 patients underwent the study procedure. 39 patients complied with
the procedure and completed a questionnaire following the procedure and reported higher satisfaction with C-Scan procedure compared to
colonoscopy. A total of 28 patients were evaluable after factoring in technical and physiological dropouts and protocol violations. Analysis
of the evaluable patient results revealed agreement between C-Scan and colonoscopy in detection of polyps was consistent with data from
the post-CE approval study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In preparation of the U.S.
pivotal study, we continued to optimize the functionality of our advanced version of C-Scan, which incorporates mainly advanced algorithms,
improved detection capability and reduced energy consumption, through additional clinical data collection in a study in Israel (initially
on average risk and high-risk patients and in May&#160;2022, shifted to enrollment of only average risk patients), for the purpose of
further calibration of the C-Scan system, which we have continued in parallel to conducting the first stage of the U.S. pivotal study
that was initiated in May&#160;2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In November&#160;2020, we
finalized our proposed U.S. pivotal study design and submitted our IDE application to the FDA and in March&#160;2021, our IDE application
was approved by the FDA. In January&#160;2022, we submitted a supplement to the FDA to amend the U.S. pivotal study design to add a first
part to the study that is designed to enable further device calibration of the C-Scan system and enhancement of C-Scan algorithms, specifically
for the average risk U.S. population. In February&#160;2022, we received the FDA&#8217;s approval for our IDE supplement. Following this
amended IDE, the U.S. pivotal study consists of two parts. The first part is designed to enable further calibration of the C-Scan system
for the average risk U.S. population, and is intended to include up to 200 patients in the U.S. The second part is a statistically powered,
randomized study which will compare the performance of C-Scan to traditional colonoscopy, and is intended to include up to 800 patients.
The goal of the pivotal study in the United States is to (i) demonstrate device safety as evidenced by a lack of device related SAEs;
and (ii) provide efficacy data concerning C- Scan&#8217;s performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May&#160;2022, we initiated
the first part of the U.S. pivotal study, which focuses on device calibration and enhancement of C-Scan algorithm among average risk population,
initially at Mayo Clinic Rochester, Minnesota and New York University (NYU) School of Medicine. In addition, we recently added a new site
as well as expanded the NYU site.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January&#160;2023, we
obtained approval from the FDA for our protocol amendment to lower the patient age enrollment criteria to 45-75 years (from 50-75 years
previously) in the U.S. pivotal study. Our NYU site has already obtained approval of this amendment from its Institutional Review Board
(IRB) and begun to implement it to recruit younger patients as part of the first part of our U.S. pivotal study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The initiation of the powered
portion of the U.S. pivotal study was dependent upon successful completion of the calibration portion of the U.S. pivotal study. On March&#160;21,
2023, we announced that following our internal assessment of the clinical data collected from the calibration studies until such date,
we had determined that the most recent efficacy results from our calibration studies did not meet the goal to proceed to the powered portion
of the U.S. pivotal study and, as such, the initiation of the second part of the U.S. pivotal study that was expected in mid-2023 was
also temporarily postponed. As a result, we adopted a plan of action that included conducting additional clinical data analysis and approaching
the FDA to make amendments to the U.S. pivotal study and a cost reduction plan in order to extend its cash runway to longer than initially
planned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June&#160;6, 2023, we
announced that after further review of additional data and interaction with the FDA on a revised pivotal study protocol together with
the anticipated time and investment necessary to further develop the technology, we were reducing our workforce significantly to reduce
cash burn, concentrating our resources on essential research activities, discontinuing our calibration studies, and evaluating and pursuing
strategic options. Currently, we do not have manufacturing capabilities, nor do we have any active studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
strategy has been centered on developing C-Scan. On June 6, 2023, we announced that after further review of additional data and interaction
with the FDA on a revised pivotal study protocol together with the anticipated time and investment necessary to further develop the technology,
we were reducing our workforce significantly to reduce cash burn, concentrating our resources on essential research activities, discontinuing
our calibration studies, and evaluating and pursuing strategic options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have received grants from
the Government of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of our research and development
expenditures and a portion of our expenditures relating to our transition to manufacturing pursuant to the Innovation Law and related
regulations and guidelines. As of December&#160;31, 2025, we had received funding from the IIA for research and development of our C-Scan
in the aggregate amount of approximately $5.6 million. As of December&#160;31, 2025, we had not paid any royalties to the IIA and had
a contingent liability to the IIA with respect to such funding in the amount of approximately $6.2 million. In addition, in January&#160;2021,
we received an IIA grant approval to support the funding of our transition from research and development to manufacturing. The final IIA
grant amounted to approximately $620,000 (NIS 2.25 million) (along with a co-investment by us of the same amount), which we are not required
to repay to the IIA, subject to the terms and conditions set forth in the grant approval, of which we received approximately $225,000
(NIS 816,075) in February&#160;2023 and $82,000 (NIS 297,414) in January&#160;2022. We may apply for additional IIA grants in the future;
however, there is no assurance that such applications will be approved in the amount requested or at all. We cannot predict whether we
will be entitled to any future grants, or the amounts of any such grants. See &#8220;<i>Risk Factors - Risks Related to Our Operations
in Israel - Pursuant to the terms of the Israeli government grants we received for research and development expenditures, we are obligated
to pay certain royalties on our revenues to the Israeli government. In addition, the terms of Israeli government grants we received require
us to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We incurred approximately
$0, $0 and $8.3 million in research and development expenses, net (after deducting participation by government grants) for the years ended
December&#160;31, 2025, 2024, and 2023, respectively. For additional information, see &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations- Financial Operations Overview-Research and Development Expenses, Net.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An important part of our
competitive strategy is to seek, when appropriate, protection for our products and proprietary technology through a combination of U.S.
and foreign patents, trademarks, trade secrets, non-disclosure and confidentiality, assignment of invention and other contractual arrangements
with our employees, consultants and suppliers. These measures, however, may not be adequate to protect our technology from unauthorized
disclosure, third-party infringement or misappropriation as these parties may breach these agreements, and we may not have adequate remedies
for any such breach. We intend to prosecute and defend our proprietary technology. The primary test for patent protection eligibility
includes patentability, novelty, non- obviousness, and utility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We submit applications under
the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a single
initial patent application to seek patent protection for an invention simultaneously in each of the member states. Although a PCT application
is not itself examined and cannot issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase
applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While our policy is to obtain
patents by application, to maintain trade secrets and to seek to operate without infringing on the intellectual property rights of third
parties, technologies related to our business have been rapidly developing in recent years. Additionally, patent applications that we
may file may not result in the issuance of patents, and our issued patents and any issued patents that we may receive in the future may
be challenged, invalidated or circumvented. For example, we cannot predict the extent of claims that may be allowed or enforced in our
patents nor be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and
file patent applications that also claim technology or therapeutics to which we have rights, we may have to partake in proceedings to
determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us. Moreover,
because of the extensive time required for clinical development and regulatory review of a product we may develop, it is possible that,
before C-Scan can be commercialized, related patents will have expired or will expire a short period following commercialization, thereby
reducing the advantage of such patent. Loss or invalidation of certain of our patents, or a finding of unenforceability or limited scope
of certain of our intellectual property, could have a material adverse effect on us. See Item 3D &#8220;Key Information-Risk Factors-Risks
Related to Our Legacy Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to patent protection,
we rely on trade secrets, including unpatented know-how, technology innovation, drawings, technical specifications and other proprietary.
We also rely on protection available under trademark laws, and hold the following registered trademarks in the United States and Hong
Kong: &#8220;CHECK CAP&#8221;, CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo) and the following registered trademarks in the
European Union: CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo), and the following trademark applications are pending in China:
&#8220;CHECK CAP&#8221;, CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March&#160;2021, we entered
into an exclusive license agreement with the University of Missouri with respect to certain patents held by the University of Missouri
that the University of Missouri claimed included background intellectual property in C-Scan. In consideration for the grant of an exclusive
license to those patents in the medical field, we agreed to pay royalties ranging from $0.30 to $5.00 per C-Scan unit depending on the
number of units sold up to $15,000,000 in the aggregate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C-Scan Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Competition for C-Scan comes
from traditional well-entrenched manufacturers of tests and equipment for CRC screening, such as colonoscopy, sigmoidoscopy, CTC, optical
capsule endoscopy, FOBTs and FITs. The principal manufacturers of equipment for optical colonoscopy and sigmoidoscopy include Olympus,
Pentax, Hoya and Fuji Film. The principal manufacturers of equipment for CTC include General Electric Healthcare Systems, Siemens Medical
Solutions, Philips Healthcare and Toshiba Corporation. The principal manufacturer of equipment for optical capsule endoscopy includes
Medtronic plc. All of these companies have substantially greater financial resources than we do, and they have established reputations
as well as worldwide distribution channels for providing medical instruments to physicians.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, several companies
have developed or are developing non-invasive technologies based on stool, serum (from blood and other bodily fluids), or molecular diagnostics
(MDx), tests that are used to indicate the presence of CRC and polyps in the colon. These companies include Exact Sciences, Polymedco,
Epigenomics AG, Gene News, EDP Biotech Corporation, Illumina, Inc., Quest Diagnostics, VolitionRx Nu.Q diagnostic, Freenome, Grail, Guardant,
Genoscopy and Universal DX. Exact Sciences commenced sales of its Cologuard &#174;, a non-invasive stool DNA screening test for colorectal
cancer in 2015, and is constantly seeking performance improvements through additional studies, alongside commercial expansion. During
the past years, there has been an extensive effort on the part of our competitors to utilize molecular biology and advanced computational
techniques to develop methods capable of identifying cell-free cancer biomarkers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Procedures for bowel cleansing
that are less onerous are constantly being developed, which could make our entry into the market more difficult. For instance, bowel cleansing
initiated by the ingestion of pills or food-substitute diet regimes rather than through drinking large amounts of distasteful liquids
may be viewed as an improvement to the cleansing process, but other screening methods may be even more palatable to patients.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not currently engaged
in any sales or marking activities. If we determine to resume the development of our C-Scan technology, we will need to rebuild and recommence
our sales and marking efforts. Any resumption of our sales and marketing efforts will be subject to certain challenges, including, among
others, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our technology has been tested on a limited basis and therefore we cannot assure the product&#8217;s clinical value;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we need to raise an amount of capital sufficient to complete the development of our technology, obtain the requisite regulatory approvals and commercialize our current and future products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">following the receipt of CE Mark of conformity to protection standards for sale of the C-Scan system in the European Union, we may need to obtain additional regulatory approvals in certain local jurisdictions in the European Union before we can commence marketing and sale of C-Scan and will need to obtain the requisite regulatory approvals in the United States, Japan and other markets where we plan to focus our commercialization efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we need to obtain reimbursement coverage from third-party payors for procedures using C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we need to scale-up our manufacturing capabilities of C-Scan in commercial quantities at an adequate quality and at an acceptable cost; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we need to establish and expand our user base while competing against other sellers of capsule endoscopy systems as well as other current and future CRC screening technologies and methods.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to operate our
business and achieve our goals and strategies is subject to numerous risks as described more fully in &#8220;Risk Factors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Suppliers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not currently have
any manufacturing capabilities. Prior to winding down our manufacturing capabilities, our manufacturing operations were conducted at our
facility located in Isfiya, Israel and in our own X-ray production line in Petach Tikva. On January&#160;26, 2021, we entered into a new
lease agreement, as amended (the &#8220;Amended Lease Agreement&#8221;), according to which, effective as of April&#160;1, 2021, we leased
a total of approximately 1,550 square meters at our facility located in Isfiya, Israel. The Amended Lease Agreement expired on December&#160;31,
2023. Monthly rental expenses under the lease agreement are $16,100. Prior to entering into the Amended Lease Agreement, we leased approximately
900 square meters at the same facility under a lease agreement, originally scheduled to expire on May&#160;31, 2022. Following the determination
of our Board of Directors on June&#160;6, 2023 to discontinue our clinical studies, we did not extend the Amended Lease Agreement that
expired on December&#160;31, 2023. However, on November&#160;11, 2023, we agreed with the lessor to lease part of the premises in Isfiya
(the &#8220;New Leased Premises&#8221;) until February&#160;29, 2024, for a monthly rental fee of $8,300. On April&#160;15, 2024, we and
the lessor agreed on extending the lease of the New Leased Premises for a two-year period commencing on March&#160;1, 2024, for a monthly
rental fee of $8,300. We may terminate such lease upon a 60 days prior notice to the lessor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December&#160;30, 2021,
we entered into a Sub-lease Agreement (the &#8220;Sub-lease Agreement&#8221;) with one of our suppliers, according to which we leased
approximately 70 square meters laboratory space for the production of certain components, at the supplier&#8217;s premises in Petach Tikva,
Israel. The Sub-lease Agreement entered into effect on September 21, 2022, after receipt of certain permits including a business license
from Petach Tikva municipality. The Sub-lease Agreement was due to expire on January&#160;31, 2025. We had the right to terminate the
Sub-lease Agreement at any time, upon at least 90 days prior written notice. The Sub Lease Agreement was part of an amended service agreement
with the supplier for certain additional services. Total monthly rental expenses under the Sub-lease Agreement and the payment for such
other services was $26,900. As the Sub-lease Agreement is part of a service agreement with the supplier, management was required to evaluate
the fair market amount attributed to the lease per month and based on its estimations, the amount allocated to the lease was approximately
$2,800 and the portion allocated to monthly services was $24,100. Following the determination of our Board of Directors on June&#160;6,
2023 to discontinue our clinical studies, on June&#160;8, 2023, we terminated the Sub-lease Agreement and such service agreement in Petach
Tikva, and the Sub-lease Agreement terminated on September 8, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March&#160;1, 2022, we
entered into a lease agreement of certain offices in Petach Tikva Israel, according to which, we leased approximately 140 square meters
offices. The lease agreement expired on February&#160;28, 2024, and we had an option to extend the lease period for two additional periods
of one year each. Total monthly rental expense under the lease agreement was approximately $1,700. In September 2023, the office lease
agreement in Petach Tikva was terminated by the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July&#160;2016, we entered
into an agreement with GE Healthcare to develop and demonstrate proof of principle of the process for high-volume manufacturing for the
production of the X- ray source and its assembly into our C-Scan capsule. The agreement was amended in November&#160;2017 in order to
further our manufacturing collaboration with GE Healthcare. The agreement involves GE&#8217;s final assembly, packaging and shipping of
C-Scan capsules. We supplied GE Healthcare with supporting calibration and final assembly methodology and equipment and in August&#160;2019,
we announced the completion of manufacturing line transfer implementation and qualification for C-Scan operated by GE Healthcare, primarily
to enable the availability of C-Scan for U.S. clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January&#160;2021, we
received an IIA grant approval to support the funding of our transition from research and development to manufacturing. The final IIA
grant amounted to $620,000 (NIS 2.25 million) including for the purpose of the establishment of our own X-Ray source manufacturing line
in Israel. We do not currently have any sales. During 2022 and 2023, we expanded our manufacturing capacity to support the expected larger
clinical volume and subsequent higher volumes expected in the early commercialization stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Environmental Health and Safety Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to environmental
health and safety laws and regulations in Israel, governing, among other things, the use of radioactive materials, including the Israeli
Radioactive Elements and their Products, Regulation, 1980, the Hazardous Substances Law, 5753-1993 and regulations thereunder, including
the Licensing of Business Regulations (Disposal of Hazardous Substances), 5750-1990, the Israeli Work Safety Regulations (Occupational
Safety and Health of Ionizing Radiation Practitioners) 1992-5753 and Women Employment Regulations (Work with Ionizing Radiation), 1979-5739.
Our current research and development activities, including our production activities, require (and our currently contemplated commercial
activities will require) permits from various governmental authorities including, Israel&#8217;s Ministry of Environmental Protection,
Israel&#8217;s Ministry of Health, local municipal authorities and the NRC and Agreement State regulators. Failure to obtain or maintain
any such permits or to comply with their conditions could have a material adverse effect on our business, financial condition and results
of operations. The Ministry of Environmental Protection and the Ministry of Health conduct from time to time periodic inspections in order
to review and ensure our compliance with the various regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These laws, regulations and
permits could potentially require expenditure by us for compliance or remediation. If we fail to comply with such laws, regulations or
permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses
necessary to continue our business activities and could be subject to work stoppages or delays. In addition, we may be required to pay
damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to radioactive
materials) or contribution claims. Some environmental, health and safety laws apply strict, joint and several liability. We may be identified
as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, laws and regulations
relating to environmental, health and safety matters are often subject to change. In the event of any changes or new laws or regulations,
we could be subject to new compliance measures or to liabilities for activities which were previously permitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan is a medical device
subject to extensive regulation by the FDA and other U.S. federal and state regulatory bodies. To ensure that medical products distributed
in the United States are safe and effective for their intended use, the FDA has promulgated regulations that govern, among other things,
the following activities that we or our partners perform and will continue to perform:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product design and development;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">validation and verifications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product manufacturing (good manufacturing practices);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product storage, shipping and handling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">premarket clearance or approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising and promotion;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product marketing, sales and distribution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market surveillance reporting death or serious injuries and medical device reporting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA&#8217;s Premarket Clearance and Approval
Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless an exemption applies,
before we can commercially distribute medical devices in the United States, we must obtain, depending on the type of device, either prior
premarket notification, or 510(k) clearance, de novo authorization or approval of a PMA from the FDA. The FDA classifies medical devices
into one of three classes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I devices, which are subject to only general controls (e.g., labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II devices, generally requiring 510(k) premarket clearance before they may be commercially marketed in the United States; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring the submission of a PMA approval supported by clinical trial data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>510(k) Clearance Pathway</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To obtain 510(k) clearance,
we must submit a premarket notification, or 510(k) notice, demonstrating that the proposed device is substantially equivalent to a previously
cleared 510(k) device or a device that was in commercial distribution before May&#160;28, 1976, for which the FDA has not yet called for
the submission of PMA applications. By regulation, a premarket notification must be submitted to the FDA at least 90 days before we intend
to market a device, and we must receive 510(k) clearance from the FDA before we actually market the device. The Medical Device User Fee
Amendments, or the MDUFA, performance goal for a traditional 510(k) clearance is 90 days. As a practical matter, however, the 510(k)clearance
pathway may take approximately between 6 to 9 months, but it can take significantly longer. FDA may require additional information, including
clinical data, to make a determination regarding substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are three types of
510(k)s: traditional, special, and abbreviated. Special 510(k)s are typically for devices that have certain technological, design or labelling
changes that require a new 510(k) but where the method(s) to evaluate the changes are well established and the results of change evaluation
can be sufficiently reviewed in a summary or risk analysis format. Abbreviated 510(k)s are for devices that conform to special controls
for the device type or to a recognized standard. The special and abbreviated 510(k)s are intended to streamline review, and the FDA intends
to process special 510(k)s within 30 days of receipt.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After a device receives 510(k)
clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change
in its intended use, will require a new 510(k) clearance or, depending on the modification, require PMA. The FDA requires each manufacturer
to determine whether the proposed change requires submission of a 510(k), or a PMA, but the FDA can review any such decision and can disagree
with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer
to cease marketing and/or recall the modified device until 510(k) clearance or PMA is obtained. If the FDA requires us to seek 510(k)
clearance or PMA for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device
until we obtain this clearance or approval. Also, in these circumstances, we may be subject to significant regulatory fines or penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>De Novo Reclassification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Medical device types that
the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk
they pose. To market low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate
device, a manufacturer may request a de novo down-classification. This procedure allows a manufacturer whose novel device is automatically
classified into Class III to request classification of its medical device into Class I or Class II on the basis that the device presents
low or moderate risk, rather than requiring the submission and approval of a PMA application. A medical device may be eligible for de
novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that
the device was not substantially equivalent or a manufacturer may request de novo classification directly without first submitting a 510(k)
premarket notification to the FDA and receiving a not substantially equivalent determination. The FDA is required to classify the device
within 120 calendar days following receipt of the de novo application, although in practice, the FDA&#8217;s review may take significantly
longer. During the pendency of the FDA&#8217;s review, the FDA may issue an additional information letter, which places the de novo request
on hold and stops the review clock pending receipt of the additional information requested. In the event the de novo requestor does not
provide the requested information within 180 calendar days, the FDA will consider the de novo request to be withdrawn. If the manufacturer
seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide
a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the de novo request for
classification if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device
is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.
In the event the FDA determines the data and information submitted demonstrate that general controls or general and special controls are
adequate to provide reasonable assurance of safety and effectiveness, the FDA will grant the de novo request for classification. When
the FDA grants a de novo request for classification, the device is granted marketing authorization and further can serve as a predicate
for future devices of that type, through a 510(k) premarket notification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alternatively, if a 510(k)
clearance is sought and the device is found not substantially equivalent, or NSE, a de novo petition must be filed within 30 days from
the receipt of the NSE determination. The request should include a description of the device, labeling for the device, reasons for the
recommended classification and information to support the recommendation. The de novo process following an NSE determination has a 60-day
review period, although it is typical for the review to take far longer. If the FDA classifies the device into class II, the company will
then receive an approval order to market the device. This device type can then be used as a predicate device for future 510(k) submissions.
However, if the FDA subsequently determines that the device will remain in the class III category, then the device may not be marketed
until the company has obtained an approved PMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Premarket Approval Pathway</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A PMA application must be
submitted if the device cannot be cleared through the 510(k) process or is found ineligible for de novo reclassification. PMAs are generally
required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health,
or which present a potential, unreasonable risk of illness or injury. The PMA application process is generally more costly and time consuming
than the 510(k) process. A PMA application must be supported by extensive data including, but not limited to, technical, preclinical,
clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device
for its intended use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After a PMA application is
submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive review and thus whether
the FDA will file the application for review. After a PMA application is sufficiently complete, the FDA will accept the application and
begin an in-depth review of the submitted information. By statute, the FDA has 180 days to review the &#8220;accepted application,&#8221;
although, generally, review of the application may take at least 12 to 18 months, but it may take significantly longer. During this review
period, the FDA may request additional information or clarification of information already provided. Also, during the review period, an
advisory panel of experts from outside FDA may be convened to review and evaluate the application and provide recommendations to the FDA
as to the approvability of the device. In addition, the FDA will conduct a preapproval inspection of the manufacturing facility to ensure
compliance with quality system regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon completion of the PMA
application review, the FDA may: (i) approve the PMA which authorizes commercial marketing with specific prescribing information for one
or more indications, which can be more limited than those originally sought; (ii) issue an approvable letter which indicates the FDA&#8217;s
belief that the PMA application is approvable and states what additional information the FDA requires, or the post-approval commitments
that must be agreed to prior to approval; (iii) issue a not approvable letter which outlines steps required for approval, but which are
typically more onerous than those in an approvable letter, and may require additional clinical trials that are often expensive and time
consuming and can delay approval for months or even years; or (iv) deny the application. If the FDA issues an approvable or not approvable
letter, the applicant has 180 days to respond, after which the FDA&#8217;s review clock is reset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">New PMA applications or PMA
application supplements are required for modifications that affect the safety or effectiveness of the device, including, for example,
certain types of modifications to the device&#8217;s indication for use, manufacturing process, labeling and design. PMA supplements often
require the submission of the same type of information as a PMA application, except that the supplement is limited to information needed
to support any changes from the device covered by the original PMA application and may not require as extensive clinical data or the convening
of an advisory panel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Breakthrough Device Program</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA has implemented a
Breakthrough Device Program that is intended to provide patients and providers with expedited access to breakthrough medical technologies
that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or
conditions by expediting their development, assessment and review while preserving the statutory standards for premarket approval. A device
also must meet one of the following criteria: (i) it represents breakthrough technology; (ii) there is no approved or cleared alternative;
(iii) it offers significant advantages over existing cleared or approved devices; or (iv) availability of the device is in the best interest
of patients. In February&#160;2021, the FDA granted us a Breakthrough Device designation for C-Scan. For further information, see &#8220;-<i>Regulatory
Pathway for C-Scan.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the program, we are
eligible to receive priority review and interactive communications from the FDA regarding device development and clinical trial protocols,
all the way through to commercialization decisions. In addition, the Centers for Medicare &amp; Medicaid Services (CMS) has created expedited
and special reimbursement pathways and programs based on FDA&#8217;s Breakthrough Device designation, for which we may be eligible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials are almost
always required to support a PMA application or de novo reclassification petition and are sometimes required for a 510(k) premarket notification.
If the device presents a &#8220;significant risk,&#8221; as defined by the FDA, to human health, the FDA requires the device sponsor to
file an IDE application with the FDA and obtain IDE approval prior to commencing the human clinical trials. During the trial, the sponsor
must comply with the FDA&#8217;s IDE requirements for investigator selection, trial monitoring, reporting, and recordkeeping. The investigators
must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of investigational
devices, and comply with all reporting and recordkeeping requirements. Clinical trials for significant risk devices may not begin until
the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical trial sites. An IRB
is an appropriately constituted group that has been formally designated to review and monitor medical research involving subjects and
which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety and welfare of human
research subjects. A nonsignificant risk device does not require FDA approval of an IDE; however, the clinical trial must still be conducted
in compliance with various requirements of the FDA&#8217;s IDE regulations and be approved by an IRB at the clinical trials sites. We,
the FDA, or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time for
various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements.
Even if a trial is completed, the results of clinical testing may not demonstrate the safety and effectiveness of the device, may be equivocal
or may otherwise not be sufficient to obtain approval or clearance of the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Similarly, in Europe the
clinical study must be approved by the local ethics committee and in some cases, including studies of high-risk devices, by the Ministry
of Health in the applicable country. For further information, see &#8220;- <i>Regulation in Europe, Israel, Japan and Other Countries.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sponsors of clinical trials
of devices are required to register with clinicaltrials.gov, a public database of clinical trial information. Information related to the
device, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is made public
as part of the registration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pervasive and Continuing FDA Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After a device is cleared
or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment registration and device listing with the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#8220;off-label&#8221; uses of cleared or approved products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements related to promotional activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the Federal Food, Drug, and Cosmetic Act that may present a risk to health;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Quality Systems Regulation Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our manufacturing processes
are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design,
manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing
of finished devices intended for human use. The QSR requires that each manufacturer establish a quality systems program by which the manufacturer
monitors the manufacturing process and maintains records that show compliance with FDA regulations and the manufacturer&#8217;s written
specifications and procedures relating to the devices. The QSR also requires, among other things, maintenance of records and certain documentation,
a device master file, device history file, and complaint files. QSR compliance is necessary to receive and maintain FDA clearance or approval
to market new and existing products. As a manufacturer, we are subject to periodic scheduled or unscheduled audits or inspections by the
FDA. Our failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, our manufacturing
operations and the recall or seizure of our products, which would have a material adverse effect on our business. The discovery of previously
unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency,
whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine,
could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA has broad regulatory
compliance and enforcement powers. As manufacturers, we and our third-party manufacturers are subject to announced and unannounced inspections
by the FDA to determine our compliance with quality system regulation and other regulations. We have not yet been inspected by the FDA.
If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement
actions, which may result in any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA untitled letters, FDA Form 483s, FDA warning letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated expenditures to address or defend such actions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall, detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions, partial suspension or total shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing or delaying our requests for regulatory approvals or clearances of new products or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing of 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to grant export approval for our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil or criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA can also publish
Safety Communications or Letters to Health Care Providers when the agency becomes aware of new issues involving a specific product or,
or more broadly, a product family. These communications are posted on the FDA&#8217;s website and describe the FDA&#8217;s analysis of
a current issue and provide specific regulatory approaches and clinical recommendations for patient management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FCC Clearance and Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because C-Scan includes a
wireless radio frequency transmitter and receiver, it is subject to equipment authorization requirements in the United States. The U.S.
Federal Communications Commission, or FCC, requires authorization of radio frequency devices before they can be sold or marketed in the
United States, subject to limited exceptions. The authorization requirements are intended to confirm that the proposed products comply
with FCC radio frequency emission, power level standards, and other technical requirements and will not cause interference. Our system
is using the same frequency band as other approved capsules. The current design of C-Scan complies with the FCC&#8217;s technical requirements
and received FCC authorization. We expect that our future advanced design will also comply with the FCC&#8217;s technical requirements,
so we expect that it will also be authorized by the FCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-Party Coverage and Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Coverage of and reimbursement
for C-Scan and related procedures, after approval, will be subject to the requirements of various third-party payors, including government-sponsored
healthcare payment systems and private third-party payors. Coverage policies and reimbursement methodologies vary significantly from program-to-program
and may be subject to federal and state regulations. For example, the Social Security Act requires all items and services to be &#8220;reasonable
and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member&#8221; in order
to be covered by Medicare. While Medicare might not provide separate reimbursement for a device, it may include payment for the device
in the payment to the facility or physician for the related procedure. Third-party payors&#8217; coverage and reimbursement policies,
including their interpretations of whether an item or service is &#8220;reasonable and necessary&#8221; or experimental and/or investigational,
and their payment methodologies, are subject to change pursuant to legislation, regulation, or, in the case of private payors, negotiations
with industry and providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fraud and Abuse Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, the
healthcare industry is subject to extensive federal, state, and local regulation. Both federal and state governmental agencies subject
the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. These laws constrain
the sales, marketing and other promotional activities of manufacturers of medical devices, by limiting the kinds of financial arrangements
(including sales programs) we may have with hospitals, physicians and other potential purchasers of the medical devices. The laws and
regulations that may affect our ability to operate include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly or willingly offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any health care items or service for which payment may be made, in whole or in part, by federal healthcare programs such as Medicare and Medicaid. This statute has been interpreted to apply to arrangements between medical device manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Further, PPACA, among other things, clarified that a person or entity needs not to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor may be subject to scrutiny;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. In addition, PPACA amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Many medical device manufacturers and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other benefits to physicians to induce them to use the company&#8217;s products. In addition, in recent years the government has pursued civil False Claims Act cases against a number of manufacturers for causing false claims to be submitted as a result of the marketing of their products for unapproved, and thus non-reimbursable, uses. Device manufacturers also are subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply regardless of the payor. Several states now require medical device manufacturers to report expenses relating to the marketing and promotion or require them to implement compliance programs or marketing codes. For example, California, Connecticut and Nevada mandate the implementation of corporate compliance programs, while Massachusetts and Vermont impose more detailed restrictions on device manufacturers&#8217; marketing practices and tracking and reporting of gifts, compensation and other remuneration to healthcare providers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the Department of Justice and the U.S. Securities and Exchange Commission. Violations of these laws can result in the imposition of substantial fines, interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires manufacturers of &#8220;covered products&#8221; (drugs, devices, biologics, or medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program) to track and publicly report payments and other transfers of value that they provide to U.S. physicians and teaching hospitals, as well as any ownership interests that U.S. physicians hold in applicable manufacturer. Applicable manufacturers must submit a report to the Centers for Medicare &amp; Medicaid Services, or CMS, by the 90th day of each calendar year disclosing payments and transfers of value made in the preceding calendar year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Violations of any of the
laws described above or any other governmental regulations that apply to us, may cause us to be subject to significant civil, criminal
and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, like Medicare and Medicaid, and the
curtailment or restructuring of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Privacy Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">HIPAA/HITECH and related
U.S. federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict
the use and disclosure of that protected information. In particular, the U.S. Department of Health and Human Services promulgated patient
privacy rules under HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These privacy rules protect
medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend
and seek accounting of their protected health information and limiting most use and disclosures of health information to the minimum degree
reasonably necessary to accomplish the intended purpose. Because, once approved, we intend to sell products to persons and entities subject
to HIPAA and are exposed to personally-identifiable health information in the course of our operations, we also may be subject to certain
elements of HIPAA, particularly as a business associate to covered entities, as well as similar state laws. HIPAA imposes civil and criminal
penalties for violations of its provisions, which could be substantial. State privacy laws have their own penalty provisions with which
we would also be expected to comply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>NRC Regulatory Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a manufacturer of a medical
device containing a sealed, radioactive source, we are subject to regulation by various governmental authorities that oversee the possession,
use, and disposal of radioactive material. These regulations govern, among other things, the design, development, testing, manufacturing,
packaging, labeling, distribution, import/export, sale, and marketing and disposal of our product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The C-Scan capsule contains
within the device a radioactive sealed source, which contains a small amount of radioactive material. This material aids in the imaging
and scanning capabilities of the device as it passes through the patient. The C-Scan capsule is ingested by the patient, and passes through
the patient&#8217;s gastrointestinal tract before exiting the human body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depending on where we manufacture
and distribute the device, various countries&#8217; nuclear regulatory laws and regulations may apply. Israeli nuclear regulatory laws
apply to the radioactive material in the device. We adhere to the Israeli regulations and guidance for the design, development, testing,
manufacturing and packaging, as well as the applicable nuclear regulations in the manufacturing phase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, the
C-Scan capsule is undergoing clinical trials. The U.S. Nuclear Regulatory Commission, or the NRC, and state nuclear regulatory agencies
oversee the use of radioactive materials in the United States. The NRC regulates the use of radioactive materials in medical devices under
several parts of its regulations, including 10 C.F.R. Part 20, &#8220;Standards for Protection Against Radiation,&#8221; 10 C.F.R. Part
30, &#8220;Rules of General Applicability to Domestic Licensing of Byproduct Material,&#8221; and 10 C.F.R. Part 35, &#8220;Medical Use
of Byproduct Material.&#8221; NRC Agreement States implement similar regulations under a nuclear regulatory framework developed by the
state pursuant to authority delegated by the NRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with applicable
NRC regulations, and relevant NRC Agreement State requirements, we comply with the radioactive materials safety and handling requirements
applicable for our development of our C-Scan technology applicable to clinical trials. The NRC also places conditions and limitations
on the disposal of radioactive material in the sanitary sewer. In 2022, after extensive engagement with the NRC, we submitted a petition
for rulemaking to the NRC, requesting that the agency amend the NRC regulations at 10 CFR 20.2003(b), which pertains to disposal of radioactive
material into the sanitary sewer system, to include the disposal of the C-Scan capsule. Under the NRC&#8217;s current interpretation of
the 10 CFR 20.2003(b) regulations, disposal of a device like the C-Scan capsule into the sanitary sewer system is not currently permitted.
The NRC&#8217;s review of the rulemaking request remains ongoing. Therefore, during the U.S. pivotal study, the C-Scan capsule is not
intended to be disposed of in the sanitary sewer system, and is instead intended to be collected by the patient and returned to the medical
facility administering the device for further storage, decay and disposal. For the collection and disposal phase of the U.S. pivotal study,
we have established, through a third party, a decay and disposal process of the C-Scan capsule that is in accordance with the NRC Agreement
State requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the U.S, engagement with
various sites to participate in the U.S. pivotal study has been progressing slower than expected, in part due to compliance with, and
the need for, the site-specific licensing and compliance with radioactive materials regulatory requirements associated with the X-ray
technology contained within our C-Scan capsule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The commercial sale of C-Scan
will also be subject to extensive nuclear regulations in various jurisdictions around the world where the C-Scan capsule will be used,
and we intend to comply with such regulations as they become applicable. We expect the commercial manufacture and distribution of C-Scan
will also require us, or a company affiliated with us, to obtain a number of licenses and certifications related to nuclear regulatory
compliance. We also expect that in commercialization, clinical centers/hospitals will need to obtain a number of licenses and certifications
related to nuclear regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Regulation in Europe, Israel, Japan and Other Countries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The European Union has adopted
numerous directives and standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical
devices. Each European Union member state has implemented legislation applying these directives and standards at the national level. Other
countries, such as Switzerland, have voluntarily adopted laws and regulations that mirror those of the European Union with respect to
medical devices. Devices that comply with the requirements of the laws of the relevant member state applying the applicable European Union
directive are entitled to bear CE conformity marking and, accordingly, can be commercially distributed throughout the member states of
the European Union and other countries that comply with or mirror these directives. The method of assessing conformity varies depending
on the type and class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment
by a &#8220;notified body,&#8221; an independent and neutral institution appointed to conduct conformity assessment. This third-party
assessment consists of an audit of the manufacturer&#8217;s quality system and clinical information, as well as technical review of the
manufacturer&#8217;s product. An assessment by a notified body in one country within the European Union is required in order for a manufacturer
to commercially distribute the product throughout the European Union. In addition, compliance with ISO 13845:2016 on quality systems issued
by the International Organization for Standards, among other standards, establishes the presumption of conformity with the essential requirements
for a CE marking. In addition, many countries apply requirements in their reimbursement, pricing or health care systems that affect companies&#8217;
ability to market products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&#160;9, 2018,
we obtained the CE mark of conformity for C-Scan. On December&#160;21, 2021, the European MDR issued a renewal of our CE mark according
to the EU Regulation 2017/745 on Medical Devices for the marketing and sale of C-Scan in the European Union, valid until December&#160;1,
2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">C-Scan and our operations
are also subject to regulation by AMAR, which is responsible for the registration of medical devices in Israel, issuance of import licenses
and monitoring of marketing of medical equipment. In September 2018, we received approval from AMAR for the marketing and sale of C-Scan
in Israel. Following the approval we received from our previous notified body according to the EU Regulation 2017/745, the AMAR approval
was renewed and is valid until December&#160;31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In Japan, manufacturing and
marketing medical devices are regulated by the Pharmaceutical Affairs Law, or PAL. In accordance with the PAL, manufacturers must obtain
a license for manufacturing medical devices from the Ministry of Health, Labour and Welfare, or MHLW. A license is required for each manufacturing
plant specified by an MHLW Ministerial Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A licensed manufacturer is
responsible only for manufacturing medical devices. In regard to the marketing of medical devices, the PAL specifies that a Marketing
Authorization Holder, or MAH, licensed by MHLW is responsible for putting medical devices into marketplace. Licenses for marketing medical
devices are divided into the following 3 types, which correspond to the classifications below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No. 1 type license for marketing - Specially controlled medical devices (Class III, IV)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No. 2 type license for marketing - Controlled medical devices (Class II)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No. 3 type license for marketing - General medical devices (Class I)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, the process for
obtaining marketing clearance for medical devices in Japan ranges from 12 months (for products with only very minor modifications from
previously cleared product versions) to a few years in the case of a completely new device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order for us to market
our products in countries other than the United States, Israel, the EU and Japan (which were described above), we must obtain regulatory
approvals and comply with extensive safety and quality regulations in those countries. These regulations, including the requirements for
approvals or clearance and the time required for regulatory review varies from country to country. It is customary that once a product
has been cleared for sales in the US and is CE marked in the EU, many other countries will follow. Failure to obtain regulatory approval
or clearance in any foreign country in which we plan to market our product may harm our ability to generate revenue and harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United Kingdom</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of January&#160;1, 2021,
the UK is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade Agreement) and EU law ceased to
apply directly in the UK. However, the UK has retained the EU regulatory regime with certain modifications as standalone UK legislation.
Therefore, the UK regulatory regime is currently similar to EU regulations, but under new legislation, the Medicines and Medical Devices
Act, the UK may adopt changed regulations that may diverge from the EU legislative regime for medicines and medical devices and their
research, development and commercialization. For a two-year period starting January&#160;1, 2021, the UK adopted transitional provisions,
which inter alia applied to the importation of medical devices into the UK and the acceptance of CE-certificates until the end of June&#160;2023,
subject to certain registrations with the UK Medicines and Healthcare Products Regulatory Agency. From July&#160;1, 2023, certification
under the new UK medical device legislation is required to place products on the market in the UK. Medical devices will need to be registered
with the MHRA before they are placed in the UK market. Medical device manufacturers based outside the UK that wish to place a device in
the UK market, will need to appoint a single UK Responsible Person, who will act on its behalf to carry out specified tasks, such as registration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Third-Party Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reimbursement in the United States</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, healthcare
providers that purchase and/or prescribe medical devices generally rely on third-party payors, such as Medicare, Medicaid, or private
health insurance plans, to reimburse all or a portion of the cost of the devices, as well as any related healthcare services utilizing
the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Coverage is not guaranteed
simply because a product has received FDA clearance or approval or has a CPT or HCPCS code that describes the product or service. For
example, Medicare&#8217;s general definition of a medically necessary service is one that is reasonable and necessary for the diagnosis
or treatment of an illness or injury, or that improves the functioning of a malformed body member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since the 1990s, Medicare
has covered a number of CRC screening tests from non-invasive fecal based tests to colonoscopy, providing a range of choices for patients
to choose the most individually suitable modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The cost-effectiveness of
a device (or the service in which a device is used) may be a key factor in obtaining third-party payer reimbursement for such device or
service, but is not commonly a factor for Medicare. Medicare covers certain CRC screening tests and procedures for Medicare beneficiaries
that meet certain eligibility criteria, as authorized by Sections 1861(s)(2)(R) and 1861(pp) of the Social Security Act and regulations
at 42 CFR 410.37. However, Medicare coverage of CRC screening tests as defined under Section 1861(pp)(1)(D) states &#8220;Such other tests
or procedures, and modifications to tests and procedures under this subsection, with such frequency and <i>payment limits</i>, as the
Secretary determines appropriate, in consultation with appropriate organizations.&#8221; (emphasis added).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A key factor affecting the
cost-effectiveness of CRC screening is patient adherence. Adherence is strongly affected by patients&#8217; willingness to use the device
(or service incorporating a device) as a screening tool for CRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Several models have been
designed to demonstrate the cost effectiveness of optical colonoscopy, CTC, fecal testing and capsule endoscopy. Today, several technologies
- FOBT / FIT, Flexible Sigmoidoscopy, Optical Colonoscopy, Barium Enema, and multi-target stool DNA - are covered for Medicare beneficiaries
meeting certain eligibility criteria for screening for colorectal cancer, while other technologies including CTC, capsule endoscopy, and
liquid biopsy are not currently covered by Medicare for CRC screening.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third-party payors in the
United States began issuing coverage policies for capsule endoscopy in early 2002, subsequent to FDA approval and availability of the
technology. Initially, reimbursement policies provided coverage for capsule endoscopy of the small bowel only for the diagnosis of obscure
gastrointestinal bleeding. Subsequently, reimbursement coverage has been expanded to include other diagnoses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Currently, there is no Medicare,
Medicaid, or commercial insurance reimbursement for capsule endoscopy of the colon in the United States for CRC screening, despite the
availability of CPT code 91113 Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), colon, with interpretation and
report, which became effective January&#160;1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the past CRC screening
NCDs, CMS has discussed appropriate test performance criteria such as point sensitivity and specificity compared to colonoscopy. The determination
of appropriateness is similar to the consideration of what is appropriate for the device to be, &#8220;at least as beneficial as an existing
and available medically appropriate alternative.&#8221; Through the evaluation of evidence from published studies, the clinical data for
the device must reach the threshold for being appropriate. The direct evidence suggests that there is clinical utility in using FOBT and
FIT for early detection of CRC because these tests reduce mortality of the disease. Conversely, there is no direct evidence on outcomes
such as mortality for blood-based biomarker tests used in screening for colorectal cancer. By comparing the test performance characteristics,
defined as sensitivity, specificity, and positive predictive value, of new screening tests to gFOBT or FIT, CMS can assess whether blood-based
tests might translate into similar reductions in disease mortality for Medicare beneficiaries. Thus, if the sensitivity and specificity
of the new screening tests are as good as or better than the sensitivity and specificity of gFOBT or FIT, then there is indirect evidence
suggesting that the new blood-based biomarker tests may reduce colorectal cancer mortality.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In January&#160;2021, CMS
updated National Coverage Determination 210.3, stating that, effective for dates of service on or after January&#160;19, 2021, a blood-based
biomarker test is covered as an appropriate CRC screening test once every 3 years for Medicare beneficiaries (i) when performed in a Clinical
Laboratory Improvement Act (CLIA)-certified laboratory, (ii) when ordered by a treating physician and (iii) when all of the following
requirements are met: The patient is: age 50-85 years; and, asymptomatic (no signs or symptoms of colorectal disease including but not
limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test); and, at
average risk of developing CRC (no personal history of adenomatous polyps, CRC, or inflammatory bowel disease, including Crohn&#8217;s
Disease and ulcerative colitis; no family history of CRC or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis
CRC). The blood-based biomarker screening test must have all of the following: FDA market authorization with an indication for CRC screening;
and, proven test performance characteristics for a blood-based screening test with both sensitivity greater than or equal to 74% and specificity
greater than or equal to 90% in the detection of CRC compared to the recognized standard (accepted as colonoscopy at this time), as minimal
threshold levels, based on the pivotal studies included in the FDA labeling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">CMS concluded that the published
evidence does not show that the available blood-based biomarker CRC screening test improves health outcomes for Medicare beneficiaries.
The indirect evidence (comparing a blood-based screening test to another test that has been shown to improve mortality such as screening
fecal immunochemical test) does not show that blood- based screening test is equivalent in the detection of large adenomas or early stage
cancer. The test performance of the Epi proColon&#174; test does not meet sensitivity and specificity levels established by prior evidence
at which the benefits of using the screening test outweigh harms to Medicare patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be no assurance
that coverage of the C-Scan by Medicare and/or commercial payors will be obtained in the near future or at all. Third-party payors may
deny coverage of the C-Scan if they determine that a procedure was not reasonable or necessary as determined by the payor, was experimental,
does not improve health outcomes, is not equivalent in the detection of large adenomas or early-stage cancers, and/or was used for an
unapproved indication (among other factors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Coverage Outside the United States</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In countries outside the
United States, coverage for CRC screening may be obtained from various sources, including governmental authorities, private health insurance
plans, and labor unions. In some countries, private insurance systems may also offer payments for some therapies. Although not as prevalent
as in the United States, health maintenance organizations are emerging in certain European countries. Coverage systems in international
markets vary significantly by country and, within some countries, by region. Coverage approvals must be obtained on a country-by- country
or region-by-region basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Organizational Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 9, 2025, we
formed CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Check-Cap. On May 15, 2015, we formed our wholly-owned
subsidiary Check-Cap US, Inc., a Delaware corporation. On April 9, 2024, we formed our wholly-owned subsidiary Check-Cap Canada, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Property, Plants and Equipment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our manufacturing operations
are conducted at our facility located in Isfiya, Israel and in our own X-ray production line in Petach Tikva. On January&#160;26, 2021,
we entered into the Amended Lease Agreement, according to which, effective as of April&#160;1, 2021, we leased a total of approximately
1,550 square meters at our facility located in Isfiya, Israel. The Amended Lease Agreement expired on December&#160;31, 2023. Monthly
rental expenses under the lease agreement are $16,100. Prior to entering into the Amended Lease Agreement, we leased approximately 900
square meters at the same facility under a lease agreement, originally scheduled to expire on May&#160;31, 2022. Following the determination
of our Board of Directors on June&#160;6, 2023 to discontinue our clinical studies, we did not extend the Amended Lease Agreement that
expired on December&#160;31, 2023. However, on November&#160;11, 2023, we agreed with the lessor to lease part of the premises in Isfiya
until February&#160;29, 2024, for a monthly rental fee of $8,300. On April&#160;15, 2024, we and the lessor agreed on extending the lease
of the New Leased Premises for a two-year period commencing on March&#160;1, 2024, for a monthly rental fee of $8,300. We may terminate
such lease upon a 60 days prior notice to the lessor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December&#160;30, 2021,
we entered into the Sub-lease Agreement with one of our suppliers, according to which we leased approximately 70 square meters laboratory
space for the production of certain components, at the supplier&#8217;s premises in Petach Tikva, Israel. The Sub-lease Agreement entered
into effect on September 21, 2022, after receipt of certain permits including a business license from Petach Tikva municipality. The Sub-lease
Agreement was due to expire on January&#160;31, 2025. We had the right to terminate the Sub-lease Agreement at any time, upon at least
90 days prior written notice. The Sub Lease Agreement was part of an amended service agreement with the supplier for certain additional
services. Total monthly rental expenses under the Sub-lease Agreement and the payment for such other services was $26,900. As the Sub-lease
Agreement is part of a service agreement with the supplier, management was required to evaluate the fair market amount attributed to the
lease per month and based on its estimations, the amount allocated to the lease was approximately $2,800 and the portion allocated to
monthly services was $24,100. Following the determination of our Board of Directors on June&#160;6, 2023 to discontinue our clinical studies,
on June&#160;8, 2023, we terminated the Sub-lease Agreement and such service agreement in Petach Tikva, and the Sub-lease Agreement terminated
on September 8, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March&#160;1, 2022, we
entered into a lease agreement of certain offices in Petach Tikva Israel, according to which, we leased approximately 140 square meters
offices. The lease agreement expired on February&#160;28, 2024, and we had an option to extend the lease period for two additional periods
of one year each. Total monthly rental expense under the lease agreement was approximately $1,700. In September 2023, the office lease
agreement in Petach Tikva was terminated by the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
4A. Unresolved Staff Comments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 5. Operating and Financial
Review and Prospects</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>You should read the following
discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements
and related notes included in this Annual Report beginning on page F-1. The following discussion and analysis contain forward-looking
statements about our expectations, beliefs or intentions regarding, among other things, our evaluation and pursuit of strategic options,
including the pending Merger with MBody AI, the Parea APA and the ARC ELOC Facility; our ability to consummate the Merger; the operations
of the combined company following the closing of the Merger; our financing activities and ability to raise capital; our ability to maintain
compliance with Nasdaq listing requirements; our results of operations; cash needs; financial condition, liquidity, prospects, growth
and strategies; the industry in which we operate; our ongoing and planned product development and clinical trials and lack thereof; the
timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates; our intellectual
property position; the degree of clinical utility of our products, particularly in specific patient populations; our ability to develop
commercial functions; and expectations regarding product launch and revenue. In addition, from time to time, we or our representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited
to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements made by
or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Our actual results and the timing of selected events could differ materially
from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Item 3D &#8220;Key
Information - Risk factors,&#8221; the section titled &#8220;Forward-Looking Statement&#8221; and elsewhere in this Annual Report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is a clinical stage medical diagnostics company that develops
C-Scan&#174;, a capsule-based screening technology for the detection of precancerous colorectal polyps. In June 2023, the Company announced
it was reducing its workforce significantly to reduce cash burn, concentrating its resources on essential research activities, discontinuing
its calibration studies, and evaluating and pursuing strategic options. For a more detailed description of the Company&#8217;s business
and strategic alternatives, see Item 4B &#8220;Information on Our Company &#8212; Business Overview.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Company&#8217;s evaluation and pursuit of strategic
options, the Company entered into the Keystone BCA in August 2023, which was terminated in December 2023 after the transaction did not
receive the requisite shareholder approval. In March 2024, the Company entered into the Apollo BCA. During the term of the Apollo BCA,
the Company provided loans to Apollo and deposited funds into a segregated account, as described elsewhere in this Annual Report on Form
20-F. In September 2025, the Company entered into the Parea APA, pursuant to which the Company acquired exclusive Ghost Kitchen area representative
rights in New Jersey in exchange for the issuance of 1,169,596 ordinary shares. On September 12, 2025, the Company entered into the Merger
Agreement, pursuant to which MBody AI will become a wholly-owned subsidiary of the Company. The Merger was approved by the Company&#8217;s
shareholders on November 14, 2025, and closing is anticipated in the first half of 2026. In December 2025, the Company entered into the
Purchase Agreement, pursuant to which ARC committed to purchase up to $30.0 million of the Company&#8217;s ordinary shares, subject to
certain limitations and conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since our formation, we have not generated any significant revenue.
We incurred net income of $4.1 million in 2025, and net losses of $25.1 million in 2024, and $17.6 million in 2023, respectively. As of
December 31, 2025, we had an accumulated deficit of approximately $165.9 million and total shareholders&#8217; equity of $3.4 million.
We expect that we will continue to incur losses from our operations for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have funded our operations to date primarily through equity financings,
sales of our ordinary shares and warrants, the exercise of warrants and other funding transactions and through grants from the IIA. In
December 2025, we entered into the Purchase Agreement with ARC, which provides for the purchase of up to $30.0 million of the Company&#8217;s
ordinary shares over a three-year period, subject to certain limitations and conditions. Our financing activities are described below
under &#8220;Liquidity and Capital Resources.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to continue as a going concern is dependent upon our ability
to consummate the Merger, raise additional capital, including through the ARC ELOC Facility, and generate positive cash flows from operations.
As further discussed in Note 2 to our consolidated financial statements in this Annual Report, substantial doubt is deemed to exist about
our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements. In the event
we are unable to consummate the Merger or raise additional capital, we may need to pursue a plan to license or sell our assets, seek to
be acquired by another entity, cease operations, and/or seek bankruptcy protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, management
fully impaired the Apollo Loans (as defined below) due to uncertainty surrounding their recoverability, recording a full allowance for
credit losses in accordance with ASC 326. During the six months ended June 30, 2025, based on new information regarding Apollo&#8217;s financial
condition, including a management valuation analysis in September 2025 estimating Apollo&#8217;s equity value at approximately $87 million as
of June 30, 2025, management determined that the original impairment indicators no longer existed and reversed the previously recorded
impairment, reinstating the loan receivable at $6,525,000 &#8212; being 7.5% of the management-assessed equity value of Apollo at that
date &#8212; in accordance with ASC 310-10-35-23.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2025, following the 98.01% vote
of Check-Cap shareholders in favour of the Merger at the 2025 Annual General Meeting, the Company recognized a noncash debt-for-equity
exchange under which the loan receivable of $6,525,000 was derecognized and an equity investment in Apollo was recognized at cost of $6,525,000,
with no gain or loss recorded on exchange. A payable to Apollo of approximately $1,400,000 is presented as a standalone liability as of
December 31, 2025, representing amounts paid by Apollo on behalf of the Company, net of settlements during the second half of 2025. For
further discussion of the Apollo loan receivable, the impairment history, and the debt-for-equity exchange, see Note 14 to the consolidated
financial statements and &#8220;Results of Operations&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed description of our business
and plans, see Item 4B &#8220;Information on Our Company &#8212; Business Overview.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Operations Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not generated any
significant revenue since our inception. To date, we have funded our operations primarily through equity financings, as well as from grants
that we received from the IIA. If our product development efforts result in clinical success, regulatory approval and the successful commercialization,
we expect to generate revenue from sales of C-Scan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Cost and Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operating costs and expenses
are classified into two categories: research and development expenses and general and administrative expenses. For each category, the
largest component is personnel costs, which consists of salaries, employee benefits and share-based compensation. Operating costs and
expenses also include allocated overhead costs for depreciation of equipment. Operating costs and expenses are generally recognized as
incurred. On March&#160;21, 2023, we announced that following our internal assessment of the clinical data collected from the calibration
studies until such date, we had determined that the most recent efficacy results from our calibration studies did not meet the goal to
proceed to the powered portion of the U.S. pivotal study and, as such, the initiation of the second part of the U.S. pivotal study that
was expected in mid-2023 was also temporarily postponed. On June&#160;6, 2023, we announced that after further review of additional data
and interaction with the FDA on a revised pivotal study protocol together with the anticipated time and investment necessary to further
develop the technology, we were reducing our workforce significantly to reduce cash burn, concentrating our resources on essential research
activities, discontinuing our calibration studies, and evaluating and pursuing strategic options. Despite these measures, we expect personnel
costs and operating costs to continue to constitute a significant portion of our expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, Net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
activities have been central to our business model. Our total research and development expenses, net of participations in the years ended
December&#160;31, 2025, 2024, and 2023 were approximately $0, $0, and $8.3 million, respectively. All research and development expenses
are expensed as incurred. In anticipation of the initiation of the strategic development plan, management terminated the majority of our
research and development activities. For additional information, see &#8220;<i>Information on Our Company - Business - Research and Development.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
expenses consist primarily of costs incurred for our development activities, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related expenses for research and development staff (including research and development, clinical, operations, production and Q&amp;A staff), including salaries, benefits and related expenses, share-based compensation and travel expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments associated with clinical activities including payments made to third-party CROs, investigative sites, patients, materials and consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments associated with the development activities of our advanced C-Scan system and non-clinical activities, including payments made to third-party subcontractors, providers and consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing development costs and manufacturing scale up costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with regulatory operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with obtaining and maintaining patents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
expenses, net, are net of grants for the research and development for C-Scan and for the transition from research and development to manufacturing
that we have received from the Government of Israel through the IIA. Under the terms of the Innovation Law as currently in effect, in
exchange for the research and development grants we received, we are required to pay the IIA royalties from our revenues up to an aggregate
of 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grant, plus interest at the rate of
12-month LIBOR. Pursuant to regulations under the Innovation Law, the rate of royalty repayment is 3% or 4% of revenues (which may be
increased under certain circumstances) from sales of products and services based on know-how funded by the IIA research and development
grants we have received. As of December&#160;31, 2025, we had received funding from the IIA for the research and development of C-Scan
in the aggregate amount of approximately $5.6 million. As of December&#160;31, 2025, we had not paid any royalties to the IIA and had
a contingent obligation to the IIA in respect of such research and development grants in the amount of approximately $6.2 million. In
addition, in January&#160;2021, we received an IIA grant approval to support the funding of our transition from research and development
to manufacturing. The final IIA grant amounted to $620,000 (NIS 2.25 million) (along with a co-investment by us of the same amount), which
we are not required to repay to the IIA, subject to the terms and conditions set forth in the grant approval, of which we received approximately
$0 (NIS 0) in 2025 and 2024, and $225,000 (NIS 816,075) in February&#160;2023. For additional information regarding the IIA grants, see
Item 10E &#8220;Additional Information - Taxation - Israeli Tax Considerations and Government Programs - The Encouragement of Research,
Development and Technological Innovation in the Industry Law 5744-1984 (formerly the Encouragement of Industrial Research and Development
Law, 5744-1984).&#8221; There can be no assurance that we will continue to receive grants from the IIA in amounts sufficient for our operations,
if at all. See also Item 3D &#8220;Key Information - Risk Factors- Risks Related to Our Operations in Israel-Pursuant to the terms of
the Israeli government grants we received for research and development expenditures, we are obligated to pay certain royalties on our
revenues to the Israeli government. In addition, the terms of the Israeli government grants we received require us to satisfy specified
conditions and to make additional payments in addition to repayment of the grants upon certain events.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our general and administrative
expenses consist primarily of salaries and other related costs, including share-based compensation expense, for persons serving as our
directors and executives, finance, legal, human resources and administrative personnel, professional service fees, directors&#8217; and
officers&#8217; liability insurance and other general corporate expenses, such as communication, office and travel expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Finance Income, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our finance income, net in
fiscal year 2025, 2024, and 2023consists primarily of interest earned on our cash equivalents and short-term bank deposits and changes
in provision for royalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency transactions
are translated into U.S. dollars using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured.
Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of year-end exchange rates
of monetary assets and liabilities denominated in foreign currencies are recognized to &#8220;finance income, net&#8221; in the consolidated
statement of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxes on Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The standard corporate tax
rate in Israel is 23% for the 2018 tax year and thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not generate taxable
income in Israel, as we have historically incurred operating losses resulting in net operating loss carryforwards totaling approximately
129.6 million as of December&#160;31, 2025. We anticipate that we will be able to carry forward these tax losses indefinitely to future
tax years. However, a tax loss that can be utilized in a certain tax year cannot be carried forward to future tax years. Accordingly,
we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Law for the Encouragement
of Capital Investments, 5719-1959 and other Israeli legislation, we may be entitled to certain additional tax benefits, including reduced
tax rates, accelerated depreciation and amortization rates for tax purposes on certain assets, deduction of public offering expenses in
three equal annual installments and amortization of other intangible property rights for tax purposes. See Item 10E &#8220;Additional
Information - Taxation- Israeli Tax Considerations and Government Programs&#8221; for additional information concerning these tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For convenience purposes,
the numbers set forth in the management&#8217;s discussion and analysis below are, where applicable, rounded up and presented in millions,
whereas the numbers in the tables below are presented in thousands. As result, the percentages set forth in the year-over-year comparisons
below are based on numbers that have (where applicable) been rounded up to millions, which may slightly differ than the percentages that
would result from the corresponding numbers set forth in the table that are presented in thousands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Apollo Loan Receivable
&#8212; Impairment, Reversal, and Debt-for-Equity Exchange</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2024, the Company
entered into a series of loan agreements with Apollo Technology Capital Corporation (&#8220;Apollo&#8221;, formerly known as Nobul AI Corp.)
in connection with the Apollo BCA (the &#8220;Apollo Loans&#8221;), including the September 2024 Loan Agreement, the December 2024 Loan
Agreement, the Third Apollo Loan, and the Fourth Apollo Loan. The aggregate principal of the Apollo Loans totaled approximately $16.3
million. The principal outstanding under each loan bore interest at 5% per annum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Initial Impairment (Year
Ended December 31, 2024)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, management determined that, due to uncertainty surrounding the recoverability of the Apollo Loans, the appropriate course was
to fully impair the outstanding loan balances. At that time, Apollo exhibited severe financial distress, recurring operating losses, and
negative working capital. In accordance with ASC 326, Financial Instruments &#8212; Credit Losses, management recorded a full allowance
for credit losses of $16.5 million, reducing the net carrying value of the Apollo Loans to zero. The impairment was recognized within
&#8220;Impairment of loans receivable&#8221; in the consolidated statement of operations for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Reversal of Impairment
(Six Months Ended June 30, 2025)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the six months ended
June 30, 2025, new information regarding Apollo&#8217;s financial condition became available, including a management valuation analysis in September
2025 which estimated Apollo&#8217;s equity value at approximately $87 million as of June 30, 2025. This represented a significant improvement
compared to the conditions that existed as of December 31, 2024. Management determined that the original impairment indicators no longer
existed and that the previously impaired receivable should be re-recognized in accordance with ASC 310-10-35-23. Accordingly, the Company
reversed the previously recorded impairment and reinstated the recoverable portion of the loan receivable at $6.5 million, representing
7.5% of the management-assessed equity value of Apollo at June 30, 2025. The reversal of impairment of $6.5 million was recognized as
a credit loss recovery in the consolidated statement of operations. The reinstated loan receivable was presented net of a payable owed
by the Company to Apollo of $2.2 million, giving a net carrying value of $4.3 million as reported in the Form 6-K filed December 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Debt-for-Equity Exchange
(November 14, 2025)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 30, 2025, the Company
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with Apollo under which the exchange indebtedness &#8212; comprising
the Apollo Loans and certain third-party notes held for the benefit of the Company, totaling approximately $16.3 million in aggregate
principal &#8212; would be exchanged for common shares of Apollo representing a 7.5% shareholding at the date of issuance. The Exchange
Agreement was conditional on the completion of the Merger .</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 14, 2025, Check-Cap
shareholders voted 98.01% in favor of the Merger at the 2025 Annual General Meeting, at which point the closing condition in the Exchange
Agreement ceased to be substantive. Accordingly, the Company recognized the debt-for-equity exchange for accounting purposes on November
14, 2025. The loan receivable of $6.5 million was derecognized and an equity investment in Apollo was recognized at cost of $6.5 million
&#8212; being the carrying value of the consideration surrendered &#8212; with no gain or loss recorded on exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity investment in
Apollo is carried at cost of $6.5 million under the ASC 321 measurement alternative. A payable to Apollo of approximately $1.4 million
is presented as a standalone liability as of December 31, 2025, representing amounts paid by Apollo on behalf of the Company, net of settlements
during the second half of 2025. The closing of the Merger remains subject to Nasdaq listing approval for the combined entity; no further
accounting impact is anticipated from the closing. For further information, see Note 14 to the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Year Ended December&#160;31, 2025 Compared
to Year Ended December&#160;31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands, <br/> except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,373</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">9,462</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,373</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,462</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of loans receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,487</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income on Debt Extinguishment and Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(25,149</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Operating Income (Loss)</i>.
Our operating loss for the year ended December&#160;31, 2025 was approximately $2.4 million, as compared with approximately $9.5 million
for the year ended December&#160;31, 2024, a decrease of approximately $7.1 million. The decrease was primarily attributable to lower
general and administrative expenses in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Finance Income, net</i>.
Our finance income, net for the year ended December&#160;31, 2025 was approximately $0.01 million, as compared to approximately $0.8 million
for the year ended December&#160;31, 2024, a decrease of approximately $0.8 million. The decrease was primarily attributable to higher
bank charges exceeding interest income in 2025, as well as lower interest income on short-term deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Net Income (Loss)</i>.
Our net income for the year ended December&#160;31, 2025 was approximately $4.1 million, as compared to a net loss of approximately $25.1
million for the year ended December&#160;31, 2024, an increase of approximately $29.3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><i>Research and
Development Expenses, net.</i> Research and development expenses, net for the years ended December&#160;31, 2025 and 2024 were $0.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(599</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office rent and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(161</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,373</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,089</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General and Administrative
Expenses</i>. Our general and administrative expenses for the year ended December&#160;31, 2025 were approximately $2.4 million, as compared
to approximately $9.5 million for the year ended December&#160;31, 2024, a decrease of approximately $7.1 million. The decrease was primarily
attributable to lower other general and administrative expenses, as well as decreases in salaries and related expenses and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year Ended December&#160;31, 2024 Compared to Year Ended December&#160;31,
2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands, <br/> except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,550</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Impairment of fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,462</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of loans receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,487</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,568</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Operating Loss</i>. Our
operating loss for the year ended December&#160;31, 2024 was approximately $9.5 million, as compared with approximately $19.3 million
for the year ended December&#160;31, 2023, a decrease of approximately $9.8 million. The decrease was primarily attributable to the absence
of research and development expenses in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Finance Income, net</i>.
Our finance income, net for the year ended December&#160;31, 2024 was approximately $0.8 million, as compared to approximately $1.7 million
for the year ended December&#160;31, 2023, a decrease of approximately $0.9 million. The decrease was primarily attributable to lower
interest income on short-term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Net loss</i>. Our net
loss for the year ended December&#160;31, 2024 was approximately $25.1 million, as compared to approximately $17.6 million for the year
ended December&#160;31, 2023, an increase of approximately $7.6 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,926</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,926</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,530</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Subcontractors and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(800</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost for registration of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(78</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(983</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,294</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less participation of the IIA (formerly the OCS)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total research and development expenses, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(8,311</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Research and Development
Expenses, net</i>. Research and development expenses, net for the year ended December&#160;31, 2024 were approximately $0, as compared
with approximately $8.3 million for the year ended December&#160;31, 2023, a decrease of $8.3 million or 100%. The decrease in research
and development expenses, net between 2024 and 2023 was primarily due to absence of research and development activities during the year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$ in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,256</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office rent and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(154</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,707</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,462</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(88</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General and Administrative
Expenses</i>. Our general and administrative expenses for the year ended December&#160;31, 2024 were approximately $9.5 million, as compared
to approximately $9.6 million for the year ended December&#160;31, 2023. While other general and administrative expenses increased by
$5.7 million, this was largely offset by lower professional services, office rent, and salaries and related expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sources of Liquidity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have funded our
operations primarily through equity financings consummated prior to our initial public offering, our initial public offering, private
placements, registered direct and underwritten public offerings, our warrant exercise transaction and grants that we received from the
IIA (formerly the OCS) and the BIRD Foundation. In addition, in December 2025 we entered into the Purchase Agreement to establish the
ARC ELOC Facility. As of December&#160;31, 2025, we had approximately $1,600 of cash and cash equivalents, including restricted cash,
and had invested most of our available cash in short term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first quarter of 2021, certain warrant holders exercised
warrants to purchase 1,210,235 ordinary shares at exercise prices ranging from $15 to $16 per share, for total gross proceeds of approximately
$19.2 million. On July 2, 2021, we consummated a registered direct offering of 1,296,297 ordinary shares and warrants to purchase up to
1,296,297 ordinary shares at a combined purchase price of $27 per share and accompanying warrant, for aggregate gross proceeds of approximately
$35.0 million, or the July 2021 Offering. On March 3, 2022, we consummated a registered direct offering of 1,000,000 ordinary shares and
warrants to purchase up to 750,000 ordinary shares at a combined purchase price of $10 per share and accompanying warrant, for aggregate
gross proceeds of $10.0 million, or the March 2022 Offering. In connection with the March 2022 Offering, certain warrants to purchase
up to 926,297 ordinary shares issued in the July 2021 Offering were amended to have a reduced exercise price of $13 per share and an extended
exercise period to January 2, 2025. As of December 31, 2025, warrants to purchase 84,996 ordinary shares remained outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception through
December&#160;31, 2025, we had received funding from the IIA for research and development of C-Scan in the aggregate amount of approximately
$5.6 million, of which $31,000 was received in the year ended December&#160;31, 2020. We did not receive IIA funding for research and
development for the years ended December&#160;31, 2025 and 2024. As of December&#160;31, 2025, we had not paid any royalties to the IIA
and had a contingent obligation to the IIA with respect to such funding in the amount of approximately $6.2 million. In addition, in January&#160;2021,
we received an IIA grant approval to support the funding of our transition from research and development to manufacturing. The final IIA
grant amounted to $620,000 (NIS 2.25 million) (along with a co-investment by us of the same amount), which we are not required to repay
to the IIA, subject to the terms and conditions set forth in the grant approval, of which we received approximately $0 (NIS 0) in 2025
and 2024, and $225,000 (NIS 816,075) in February&#160;2023. Royalties associated with the grant plan mentioned are not anticipated to
be payable in the foreseeable future and have been accounted for as a reduction in research and development expenses in the corresponding
years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July&#160;13, 2014, we
entered into a cooperation and project funding agreement with the BIRD Foundation and Synergy and during 2014-2017, we, together with
Synergy, had received funding from the BIRD Foundation in the aggregate amount of approximately $127,000. We do not anticipate to receive
additional funding from the BIRD Foundation for the project, which is no longer active. As of December&#160;31, 2025, the Company had
not paid any royalties to the BIRD Foundation and had a contingent obligation to the BIRD foundation in the amount of approximately $209,000.
Royalties associated with the grant plan mentioned are not anticipated to be payable in the foreseeable future and have been accounted
for as a reduction in research and development expenses in the corresponding years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical and development-stage
medical diagnostics company and have not yet generated revenues. We have historically incurred net losses since we commenced operations
in 2009. We incurred net income of $4.1 million in 2025, and net losses of $25.1 million and $17.6 million in 2024 and 2023, respectively.
As of December&#160;31, 2025, our accumulated deficit was $165.9 million. The extent of our future operating losses and the timing of
becoming profitable are uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As further discussed in Note
2 to our consolidated financial statements in this Annual Report, substantial doubt is deemed to exist about our ability to continue as
a going concern for the one-year period from the date of issuance of these financial statements. Our ability to continue as a going concern
is dependent upon our ability to consummate the Merger, raise additional capital, including through the ARC ELOC Facility, and generate
positive cash flows from operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, Management has
determined that, due to uncertainty surrounding the recoverability of the loans related to the September 2023 Loan Agreement, the December
2024 Loan Agreement, the First July 2025 Loan Agreement and the Second July 2025 Loan Agreement (collectively the &#8220;Apollo Loans&#8221;),
the appropriate and conservative course is to fully impair the Apollo Loans as of December 31, 2024. This assessment was made in accordance
with Accounting Standards Codification (&#8220;ASC&#8221;) 326 Financial Instruments &#8212; Credit Losses. During the six months ended
June 30, 2025, new information regarding Apollo&#8217;s financial condition became available, including a management valuation analysis in September
2025 which estimated Apollo&#8217;s equity value at approximately $87 million as of June 30, 2025. This represented a significant improvement
compared to the conditions that existed as of December 31, 2024. Management determined that the original impairment indicators no longer
existed and that the previously impaired receivable should be re-recognized in accordance with ASC 310-10-35-23. Accordingly, the Company
reversed the previously recorded impairment and reinstated the recoverable portion of the loan receivable at $6.5 million, representing
7.5% of the management-assessed equity value of Apollo at June 30, 2025. The reversal of impairment of $6.5 million was recognized as
a credit loss recovery in the consolidated statement of operations. The reinstated loan receivable was presented net of a payable owed
by the Company to Apollo of $2.2 million, giving a net carrying value of $4.3 million as reported in the Form 6-K filed December 30, 2025.
See &#8220;Results of Operations&#8221; for additional information on the Apollo Loans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As we continue to conserve
cash and evaluate strategic alternatives, including the Merger, we anticipate that we will need to raise substantial additional financing
in the future to fund our operations. In order to meet these additional cash requirements, we may incur debt, license certain intellectual
property, and seek to sell additional equity or convertible securities that may result in dilution to our shareholders. If we raise additional
funds through the issuance of equity or convertible securities, these securities could have rights or preferences senior to those of our
ordinary shares and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional
equity or debt financing on terms acceptable to us, if at all. Our future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>our ability to obtain funding from third parties, including any future collaborative partners; &#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to consummate the Merger and integrate the operations of MBody AI;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with the Merger and related transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital through the ARC ELOC Facility or other financing transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of operating the Ghost Kitchen area representative business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, defending and enforcing patents, patent applications, patent claims, trademarks and other intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to our product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenue, if any, received from commercial sales of our product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general and administrative expenses related to being a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of competition and market developments</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future clinical trial results, if any; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the political and security situation in Israel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Historical Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our statement of cash flows for the years ended December&#160;31, 2025, 2024, and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><b>US$ (in thousands)</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(46</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,004</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(16,954</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,356</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash used in operating
activities for the year ended December&#160;31, 2025 was $0.05 million, as compared to $8.0 million for the year ended December&#160;31,
2024. The decrease was primarily attributable to lower operating costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash flows from investing
activities for the year ended December 31, 2025 were approximately $0.05 million, as compared to net cash used in investing activities
of approximately $0.8 million for the year ended December 31, 2024. The increase was primarily attributable to lower investment in short-term
bank deposits in 2025.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Financing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There was no net cash provided
by financing activities for the years ended December&#160;31, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that our sources
of cash for the year ended December&#160;31, 2025 will include cash held in our bank accounts and may include proceeds from the exercise
of warrants.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Capital and Operating Expenditures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to incur losses
from operations for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our expected future expenditures
related to product, clinical and regulatory clearances include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of the clinical development of C-Scan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conducting clinical trials in the United States and other territories for purposes of regulatory approval and post-marketing validation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development of advanced version and future generations of C-Scan and future products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA and additional regulatory filing activities in countries we intend to commercialize our system;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing scale up costs; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital expenditures.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For additional information
on the capital expenditures related to our strategics transactions, see Item 3D &#8220;Key Information - Risk Factors-Risks Related to
Our Financial Position.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have operating lease obligations
consisting of payments pursuant to a lease agreement for office facilities in effect as of December&#160;31, 2025. See Note 5 to our audited
consolidated financial statements presented elsewhere in this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Royalties provision</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provision for royalties to an ASIC designer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December&#160;2007, we
entered into an agreement for the development of an ASIC component to be used as an amplifier for the capture of signals at low frequencies
from X-ray detectors contained in our product. The ASIC developer is entitled to receive royalties from us in the amount of &#8364;0.5
(approximately $0.53) for every ASIC component that we will sell, up to &#8364;200,000 (approximately $213,299). The net present value
of the royalty liability to the ASIC designer is dependent upon our management estimates and assumption as to future product shipments
and interest rates used to calculate the present value of the cash payments required to repay the royalties to the ASIC designer. In calculating
the present value of future royalty payments to the ASIC designer, we used a discount factor of 17.6%, commensurate with our risk at the
date of initial recognition of the liability. Any updates in the expected product shipments and the liability will be recorded to profit
and loss each period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As more information is gathered
to assist our management in making forecasts, the liability will be updated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Research and development, patents and licenses,
etc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of our
research and development programs and the amounts that we have incurred over the last three years pursuant to those programs, see Item
4B &#8220;Information on Our Company-Business Overview-Research and Development.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our results of operations
and financial condition may be affected by various trends and factors discussed in Item 3D &#8220;Key Information-Risk factors,&#8221;
Item 4 &#8220;Information on Our Company&#8221; and elsewhere in this Item 5 &#8220;Operating and Financial Review and Prospects.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our consolidated financial
statements are prepared in accordance with U.S. GAAP. The preparation of our financial statements requires us to make estimates, judgments
and assumptions that can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of expenses during the reporting periods. We base our estimates, judgments and
assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different
results can occur as circumstances change and additional information becomes known. See Note 2 to our audited consolidated financial statements
presented elsewhere in this Annual Report for a description of the significant accounting policies that we used to prepare our consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe the following
critical policies reflect the more significant judgments and estimates used in preparation of the Consolidated Financial Statements.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognize expense for
our share-based compensation based on the fair value of the awards granted. We estimate the fair value of equity-based payment awards
on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite
service periods in our consolidated statement of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognize compensation
expenses for the value of our awards granted based on the graded-vesting method over the requisite service period for each separately
vesting portion of the award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognize compensation
cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.
We reassess at each reporting period the probability of vesting for awards with performance conditions and adjust compensation cost based
on our probability assessment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We use the Black-Scholes-Merton
option-pricing model for our share-based awards. The option-pricing model requires a number of assumptions, of which the most significant
are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year
ended December&#160;31, 2024, 2023 and 2022, expected volatility was calculated based upon actual historical stock price movements over
the most recent periods ending on the grant date, equal to the expected term of the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The expected option term
represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the
simplified method in accordance with Staff Accounting Bulletin No.&#160;110, as adequate historical experience is not available to provide
a reasonable estimate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The risk-free interest rate
is based on the yield from U.S. treasury bonds with an equivalent term. We have historically not paid dividends and have no foreseeable
plans to pay dividends.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the years ended December&#160;31,
2023 and December&#160;31, 2022, we completed certain financing transactions in which we issued ordinary shares and warrants. The warrants
are immediately exercisable at a fixed exercise price per ordinary share, subject to certain adjustments and will expire on the expiring
date as determined in the applicable warrant. The warrants may be exercised on a cashless basis if at the time of exercise thereof, there
is no effective registration statement registering the ordinary shares underlying the warrants. We analyzed the terms of the warrants
and concluded that the terms of the warrants did not include features that would preclude equity classification. Therefore, we classified
the warrants as equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">In September 2025, we entered into the Parea APA,
pursuant to which we acquired exclusive Ghost Kitchen area representative rights in New Jersey in exchange for the issuance of 1,169,596
ordinary shares. In December 2025, we entered into the Purchase Agreement, pursuant to which ARC committed to purchase up to $30.0 million
of our ordinary shares, subject to certain limitations and conditions.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recent Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See Note 2 to our audited
consolidated financial statements presented elsewhere in this Annual Report for a description of the recent accounting policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 6. Directors, Senior
Management and Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Directors and senior management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth information for our executive officers and directors as of April 27, 2026. Unless otherwise stated, the address for our directors
and executive officers is c/o Check-Cap Ltd., 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 23%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name<sup>(1)</sup></b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 65%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Lontini</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer and Chairman of the Board of Directors</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Lewis</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlos Cheung&#160;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Hutton</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Kokiw</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive Officers and Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Alan Lewis </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alan Lewis has served as
our Chief Financial Officer since April 6, 2025. Mr. Lewis is a digital transformation leader and Co-Founder/Global Chief Strategy Officer
of The Aeon Group, Inc. He serves concurrently as Chief Financial Officer of INVENT Ventures, helping guide the technology startup incubator
back to &#8220;Pink Current&#8221; status on the OTC Markets. He leads fund administration services as Managing Member of AeonX. A U.S.
Army veteran and EdD candidate in Learning Technology at Pepperdine University, Mr. Lewis merges decades of entrepreneurial, financial,
and philanthropic expertise to drive transformative and socially responsible growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Lontini</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">David Lontini, who has served
on our Board of Directors since January&#160;25, 2024, is an experienced business owner / operator who has successfully completed M&amp;A
transactions. Mr. Lontini has held senior leadership positions at a variety of sports and media organizations such as Pointstreak Sports
Technologies, Maru/Matchbox and the Toronto Argonauts Football Club. Mr. Lontini holds a B.A. in Liberal Arts and Political Science from
York University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Carlos Cheung&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Carlos Cheung has served
on our Board of Directors since September 2024. Mr. Cheung is a seasoned technology entrepreneur and business leader with a strong background
in software development and strategic growth. Since September 2017, Mr. Cheung has been on the founding team of FOSSA, Inc. (&#8220;FOSSA&#8221;)
to build the company from the ground up in enterprise software and cyber security. Prior to FOSSA, Mr. Cheung helped lead other software
companies from inception to growth. Mr. Cheung has also played a key role in mergers and acquisitions, particularly in conducting software
due diligence, assessing technological assets, evaluating potential risks and opportunities, and guiding strategic decision-making in
complex business transactions. Mr. Cheung holds a Bachelor of Science degree in Business Administration (BSBA) from Georgetown University&#8217;s
McDonough School of Business. Mr. Cheung&#8217;s unique combination of entrepreneurial spirit, technical knowledge, and strategic business
acumen positions him as a valuable asset for public company boards, particularly those in the technology sector or companies undergoing
digital transformation. Mr. Cheung has been appointed to the Nominating Committee, the Compensation Committee, and the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Michael Hutton</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Michael Hutton, who has served
on our Board of Directors since January&#160;25, 2024, has spent the past 28 years at medical device technology companies and for the
last 15 years has held leadership positions at Phonak Canada, of Sonova Holding AG and WSAudiology. In these leadership roles, Mr Hutton
gained significant experience with M&amp;A and strategic business development. Mr. Hutton&#8217;s education includes studying at the Toronto
School of Business and the University of St. Gallen. Mr. Hutton has been appointed to the Nominating Committee, the Compensation Committee,
and the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Daniel Kokiw</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Daniel Kokiw, who has served
on our Board of Directors since January&#160;25, 2024, is an experienced business owner / operator who has successfully completed M&amp;A
transactions. For over 8 years, Mr Kokiw was in a senior operational role at Zodiac Recreational of North America, of Zodiac Nautic and
prior to that he ran the operations of Rokan Laminating. Currently, Mr Kokiw owns and operates a highly successful business in food retail.
Mr. Kokiw&#8217;s education includes studying Psychology at Carlton University. Mr. Kokiw has been appointed to the Nominating Committee,
the Compensation Committee, and the Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements Concerning Election of Directors;
Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not a party to, and
are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among our executive officers
and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Compensation of Directors and Executive
Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The aggregate compensation
paid and share-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended
December&#160;31, 2025 was $0.2 million. At our 2023 annual general meeting held on December&#160;18, 2023, our shareholders approved,
following the approval of our Compensation Committee and Board of Directors, the payment to each of our directors of the following fees:
(i) an annual fee of $25,000 for service on the Board of Directors and $2,500 for service on the Audit Committee; and (ii) a per meeting
fee of $850 for each meeting of the Board of Directors or any committee thereof attended in person or via telephone or any resolution
approved by written consent. In addition, our shareholders approved an annual fee of (i) $10,000 for service as Chairman of the Board
of Directors (other than an Active Chairman, who may be entitled to an increased fee in accordance with our Compensation Policy) and (ii)
$5,000 for service as Chairman of the Audit Committee. Our directors also benefit from directors&#8217; and officers&#8217; indemnification
and exculpation agreements as well as from our directors&#8217; and officers&#8217; liability insurance policy. The directors are also
entitled to reimbursement of expenses (including travel, stay and lodging), subject to the Israeli Companies Law and the regulations promulgated
thereunder, and in accordance with our company practices and our Compensation Policy for Executive Officers and Directors, or the Compensation
Policy. The foregoing fees are the same annual and per meeting fees that have been paid to our directors since our 2017 annual general
meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The directors are also entitled
to reimbursement of expenses (including travel, stay and lodging), subject to the Israeli Companies Law and the regulations promulgated
thereunder, and in accordance with our company practices and our Compensation Policy for Executive Officers and Directors, or the Compensation
Policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have any written
agreements with any current director providing for benefits upon the termination of such director&#8217;s relationship with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To our knowledge, there are
no agreements and arrangements between any director and any third party relating to compensation or other payment in connection with their
candidacy or service on our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements with Covered Executives</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into written
agreements with Alan Lewis relating to their employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with Mr. Lewis&#8217;
appointment as Chief Financial Officer, we entered into a Services Agreement by and between Check-Cap and Mr. Lewis (the &#8220;Services
Agreement&#8221;). Pursuant to the terms of the Services Agreement, we will pay Mr. Lewis a monthly fee in an amount equal to US$12,000
in consideration of his services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Board of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, the management of our business, including strategy and policies, is vested in our Board of Directors. Our Board of Directors may
exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers
are responsible for our day-to-day management and have individual responsibilities established by our Board of Directors. Our chief executive
officer is appointed by, and serves at the discretion of, our Board of Directors, subject to the employment agreement that we have entered
into with him. All other executive officers are appointed by our chief executive officer, and are subject to the terms of any applicable
employment agreements that we may enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended articles
of association, our Board of Directors must consist of at least four and not more than eleven directors, including the external directors
(if external directors serve on the Board of Directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors currently
consists of four members, each of whom satisfy the independence requirements of the Nasdaq Listing Rules, such that we comply with the
Nasdaq Listing Rule that requires that a majority of our Board of Directors be comprised of independent directors, within the meaning
of Nasdaq Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 18, 2025, we appointed
Mr. David Lontini to serve as the Interim Chief Executive Officer of the Company. In connection with such appointment, Mr. Lontini ceased
serving as a member of the Nominating Committee, the Compensation Committee and the Audit Committee of the Board but remains a director
of the Company and the chair of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors are elected
by the general meeting of our shareholders by the vote of a majority of the ordinary shares present, in person or by proxy, and voting
at that meeting. Each director will hold office until the first annual general meeting of shareholders following his or her appointment,
unless the tenure of such director expires earlier pursuant to the Israeli Companies Law or unless he or she is removed from office as
described below. In addition, our amended articles of association allow our Board of Directors to appoint directors (other than the external
directors) to fill vacancies on our Board of Directors, for a term of office equal to the remaining period of the term of office of the
director(s) whose office(s) have been vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors elected
to rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules and follow Israeli law and practice with
regard to the process of nominating directors, in accordance with which the board of directors (or a committee thereof) is authorized
to recommend to the shareholders director nominees for election (other than directors elected by the board of directors to fill a vacancy).
Our Board of Directors established a Nominating Committee, whose role is to select and recommend to the Board of Directors for selection,
director nominees, while considering the appropriate size and composition of the Board of Directors, the requirements of applicable law
regarding service as a member of our Board of Directors and the criteria for the selection of new members of the Board of Directors, and
determined that our Nominating Committee need not be composed solely of independent directors (within the meaning of Nasdaq Listing Rules).
However, our Nominating Committee currently consists solely of independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law and our amended articles of association, nominations for directors may also be added to the agenda of a future general meeting of
shareholders, at the request of any one or more shareholders holding at least 1% of our outstanding voting power. Any director nominated
by a shareholder is required to certify to us, as required by all director nominees, that he or she meets all the requirements of the
Israeli Companies Law for election as a director of a public company, and possesses the necessary qualifications and is able to dedicate
sufficient time, to fulfill his or her duties as a director of our company, taking into consideration our company&#8217;s size and special
needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, our Board of Directors must determine the minimum number of directors who are required to have accounting and financial expertise
(as defined in regulations promulgated under the Israeli Companies Law). In determining the number of directors required to have such
expertise, our Board of Directors must consider, among other things, the type and size of the company and the scope and complexity of
its operations. Our Board of Directors has determined that the minimum number of directors of our company who are required to have accounting
and financial expertise is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; must appoint at least two external
directors who meet the qualification requirements in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, pursuant to regulations
promulgated under the Israeli Companies Law, Israeli companies whose shares are listed on certain stock exchanges outside of Israel (including
the Nasdaq Capital Market) with no controlling shareholder (within the meaning of the Israeli Companies Law), such as ourselves, that
satisfy the requirements of the laws in the foreign jurisdiction where the company&#8217;s shares are listed, as they apply to companies
incorporated in such jurisdiction, with respect to the appointment of independent directors and the composition of the audit committee
and compensation committee, may elect to exempt themselves from the requirements of Israeli law with respect to (i) the requirement to
appoint outside directors and that one outside director serve on each committee of the board of directors authorized to exercise any of
the powers of the board of directors; (ii) certain limitations on the employment or service of an outside director or his or her spouse,
children or other relatives, following the cessation of the service as an outside director, by or for the company, its controlling shareholder
or an entity controlled by the controlling shareholder; (iii) the composition, meetings and quorum of the audit committee; and (iv) the
composition and meetings of the compensation committee. If a company has elected to avail itself from the requirement to appoint external
directors and at the time a director is appointed all members of the board of directors are of the same gender, a director of the other
gender must be appointed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following analysis of our
qualification to rely on the exemption, our Board of Directors determined to adopt the exemption, subject to and effective as of the approval
by our shareholders of a certain amendment to our articles of association, which was obtained at our 2017 annual general meeting held
on June&#160;22, 2017. If in the future we were to have a controlling shareholder, we would again be required to comply with the requirements
relating to external directors and the composition of the audit committee and compensation committee under Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee is currently
comprised of Michael Hutton, Daniel Kokiw, and Carlos Cheung. Michael Hutton serves as the Chairman of the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Composition of the Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with regulations
promulgated under the Companies Law described above, we elected to &#8220;opt out&#8221; from the Israeli Companies Law requirement to
appoint external directors and related rules concerning the composition of the audit committee and compensation committee. Under such
exemption, among other things, the composition of our audit committee must comply with the requirements of SEC and Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Nasdaq corporate
governance rules, we are required to maintain an audit committee consisting of at least three independent directors, within the meaning
of the Exchange Act and Nasdaq Listing Rules, each of whom must be able to read and understand fundamental financial statements, including
the company&#8217;s balance sheet, income statement and cash flow statement (and one of whom has past employment experience in finance
or accounting, requisite professional certification in accounting or other comparable experience or background that leads to financial
sophistication) and none of whom has participated in the preparation of our or any of our subsidiary&#8217;s financial statements at any
time during the prior three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All members of our audit
committee meet the requirements for financial literacy under the applicable rules and regulations of the U.S. Securities and Exchange
Commission and the Nasdaq Listing Rules. Our Board of Directors has determined that Michael Hutton is an audit committee financial expert
as defined by the U.S. Securities and Exchange Commission rules and has the requisite financial sophistication required by the Nasdaq
Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of the members of the
audit committee qualifies as an &#8220;independent director&#8221; within the meaning of Nasdaq Listing Rules and is &#8220;independent&#8221;
as such term is defined in Rule 10A- 3(b)(1) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which is different
from the general Nasdaq test for independence of board and committee members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee Role</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors adopted
an audit committee charter, which became effective upon the listing of our securities on the Nasdaq Capital Market, as subsequently amended,
which sets forth the responsibilities of the audit committee consistent with the rules of the U.S. Securities and Exchange Commission
and the Nasdaq Listing Rules, as well as the requirements for audit committees under the Israeli Companies Law, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the Board of Directors or shareholders for their approval, as applicable, in accordance with the requirements of the Israeli Companies Law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our Board of Directors or shareholders for their approval, as applicable, in accordance with the requirements of the Israeli Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee provides
assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee
also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that
the accountants are independent of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, our audit committee is responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors to improve such practices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest) and whether such transaction is extraordinary or material under Israeli Companies Law (see &#8220;- Approval of Related Party Transactions under Israeli Law&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether a competitive process must be implemented for the approval of certain transactions with controlling shareholders or its relative or in which a controlling shareholder has a personal interest (whether or not the transaction is an extraordinary transaction), under the supervision of the audit committee or other party determined by the audit committee and in accordance with standards to be determined by the audit committee, or whether a different process determined by the audit committee should be implemented for the approval of such transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the process for the approval of certain transactions with controlling shareholders or in which a controlling shareholder has a personal interest that the audit committee has determined are not extraordinary transactions but are not immaterial transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the Board of Directors approves the working plan of the internal auditor, to examine such working plan before its submission to the Board of Directors and proposing amendments thereto;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the compensation of our auditor; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee and Compensation
Policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our compensation committee
is currently comprised of Michael Hutton, Daniel Kokiw, and Carlos Cheung. Mr. Kokiw serves as the Chairman of the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Composition of the Compensation Committee</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with regulations
promulgated under the Companies Law described above, we elected to &#8220;opt out&#8221; from the Israeli Companies Law requirement to
appoint external directors and related rules concerning the composition of the audit committee and compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Nasdaq Listing
Rules, we are required to maintain a compensation committee consisting of at least two directors, each of whom is an independent director
within the meaning of the Nasdaq Listing Rules. Our compensation committee currently complies with the provisions of Nasdaq Listing Rules
relating to composition requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors adopted
a compensation committee charter, which became effective upon the listing of our shares on the Nasdaq Capital Market, as subsequently
amended, which sets forth the responsibilities of the compensation committee consistent with the Nasdaq Listing Rules and the requirements
for compensation committees under the Israeli Companies Law, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board of Directors for its approval (i) a compensation policy; (ii) whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years); and (iii) periodic updates to the compensation policy. See &#8220;- Compensation Committee and Compensation Policy.&#8221; In addition, the compensation committee is required to periodically examine the implementation of the compensation policy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of the terms of employment and service of office holders (including determining whether the compensation terms of a candidate for chief executive officer of the company need not be brought to approval of the shareholders); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving grants of options and other incentive awards to persons other than office holders to the extent such authority is delegated by our Board of Directors, subject to the limitations on such delegation as provided in the Israeli Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, the duties of the compensation committee include the recommendation to the company&#8217;s board of directors of a policy regarding
the terms of engagement of office holders, as such term is defined in the Israeli Companies Law, to which we refer to as a compensation
policy, and any extensions and updates thereto. The compensation policy must be approved at least once every three years, first, by our
Board of Directors, upon recommendation of our compensation committee, and second, by the shareholders by the Special Approval for Compensation
(as defined below under &#8220;- Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of an Office
Holder and Approval of Certain Transactions&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current Compensation
Policy for Executive Officers and Directors, which was approved by our shareholders at the 2023 annual general meeting held on December&#160;18,
2023, serves as the basis for decisions concerning the financial terms of employment or engagement of our office holders, including exculpation,
insurance, indemnification and any benefit, monetary payment or obligation of payment in respect of employment or engagement, including
and any severance payment or benefit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Compensation Policy must
be determined and later reevaluated according to certain factors, including: (i) the advancement of a company&#8217;s objectives, business
plan and its long- term strategy; (ii) the creation of appropriate incentives for executives, while considering (among other things) the
company&#8217;s risk management policy; (iii) the size and the nature of the company&#8217;s operations; and (iv) with respect to variable
compensation, the contribution of the office holder towards the achievement of the company&#8217;s long-term goals and the maximization
of its profits, all with a long-term objective and in accordance with the position of the office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with the Israeli
Companies law, our Compensation Policy refers to the following factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the knowledge, skills, expertise, professional experience and accomplishments of the relevant office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect to variable compensation - the possibility of reducing variable compensation at the discretion of the Board of Directors, and the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect to severance compensation, the period of employment or service of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during such period, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in according
with the Israeli Companies Law, our Compensation Policy includes the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation (e.g., bonuses) and long-term performance and measurable criteria (i.e., variable compensation must be determined based on long-term performance and measurable criteria). Only &#8220;non-material&#8221; portion of variable compensation may be determined based on criteria that is not measurable, taking into account office holders&#8217; contribution to the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ratio of variable to fixed compensation, and the ceiling for the value of variable compensation, which is determined at the time of payment, except that the ceiling for equity-based compensation is determined at the time of grant;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation, while taking into account long-term objectives; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors has
established a Nominating Committee, whose role is to select and recommend to the Board of Directors for selection, director nominees,
while considering the appropriate size and composition of the Board of Directors, the requirements of applicable law regarding service
as a member of our Board of Directors and the criteria for the selection of new members of the Board of Directors. While our Board of
Directors elected to rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules with respect to the process
of nominating directors and determined that our Nominating Committee need not be composed solely of independent directors (within the
meaning of Nasdaq Listing Rules), our Nominating Committee currently consists solely of independent directors. The Nominating Committee
is currently comprised of the following directors: Michael Hutton, Daniel Kokiw, and Carlos Cheung. Daniel Kokiw serves as the Chairman
of the Nominating Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approval of Related Party Transactions under Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Directors and Executive
Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Israeli Companies Law
codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#8220;Management-Executive
Officers and Directors&#8221; is an office holder under the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An office holder&#8217;s
fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of
care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes
a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to any such action.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The duty of loyalty requires
an office holder to act in good faith and in the best interests of the company, and includes, among other things, the duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity that is competitive with the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may approve an act specified
above which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided that the office holder acted in
good faith, the act or its approval does not harm the company and the office holder discloses his or her personal interest a sufficient
amount of time before the date for discussion of approval of such act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure of Personal Interests of an Office Holder and Approval
of Certain Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Israeli Companies Law
requires that an office holder promptly disclose to the company any &#8220;personal interest&#8221; that he or she may be aware of and
all related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#8217;s
disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is
considered. A personal interest includes an interest of any person in an act or transaction of a company, including a personal interest
of such person&#8217;s relative or of a corporate entity in which such person or a relative of such person holds 5% or more of the outstanding
shares or voting rights, is a director or general manager or in which he or she has the right to appoint at least one director or the
general manager, but excluding a personal interest arising from one&#8217;s ownership of shares in the company. A personal interest includes
the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect
to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest in the matter.
An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her
relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an extraordinary transaction
is defined as any of the following: a transaction other than in the ordinary course of business; a transaction that is not on market terms;
or a transaction that may have a material impact on a company&#8217;s profitability, assets or liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a person who has
a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee shall not be present
at such a meeting or vote on that matter unless, with respect to an office holder, the chairman of the audit committee or board of directors
(as applicable) determines that the office holder should be present during the discussions in order to present the transaction that is
subject to approval (provided that the office holder may not vote on the matter). If a majority of the members of the audit committee
or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate
in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof.
If a majority of the members of the board of directors has a personal interest in the approval of a transaction, shareholder approval
is also required for such transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Approval of Transactions with Officer Holders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If it is determined that
an office holder has a personal interest in a transaction that is not an extraordinary transaction, approval by the board of directors
is required for the transaction, unless the company&#8217;s articles of association provide for a different method of approval. Further,
so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an act by
the office holder that would otherwise be deemed a breach of his or her duty of loyalty, provided that the transaction is in the company&#8217;s
best interest and the office holder acted in good faith. An extraordinary transaction in which an office holder has a personal interest
requires approval first by the company&#8217;s audit committee and subsequently by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation of Officers Other than the Chief
Executive Officer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation of an office
holder (other than the chief executive officer) who is not a director generally requires approval first by the company&#8217;s compensation
committee, then by the company&#8217;s board of directors, according to the company&#8217;s compensation policy. In special circumstances
the compensation committee and board of directors may approve a compensation arrangement that is inconsistent with the company&#8217;s
compensation policy, provided that they have considered the same considerations and matters required for the approval of a compensation
policy in accordance with the Israeli Companies Law and such arrangement must be approved by a majority vote of the shares present and
voting at a shareholders meeting on the matter, provided that either: (i) such majority includes at least a majority of the shares held
by all shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation arrangement
present and voting on the matter, excluding abstentions; or (ii) the total number of shares of non-controlling shareholders and shareholders
who do not have a personal interest in the matter and who vote against the matter does not exceed 2% of the company&#8217;s aggregate
voting rights. We refer to this as the Special Approval for Compensation. However, if the shareholders of the company do not approve a
compensation arrangement with an executive officer that is inconsistent with the company&#8217;s compensation policy, the compensation
committee and board of directors may, in special circumstances, override the shareholders&#8217; decision if each of the compensation
committee and the board of directors discuss the arrangement again, analyze the shareholders&#8217; objection and provide detailed reasons
for their decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An amendment to an existing arrangement with an office holder (other
than the chief executive officer) who is not a director requires only the approval of the compensation committee, if the compensation
committee determines that the amendment is not material in comparison to the existing arrangement. However, according to regulations promulgated
under the Israeli Companies Law, an amendment to an existing arrangement with an office holder (who is not a director) who is subordinate
to the chief executive officer shall not require the approval of the compensation committee, if (i) the amendment is approved by the chief
executive officer and the company&#8217;s compensation policy determines that a non-material amendment to the terms of service of an office
holder (other than the chief executive officer) may be approved by the chief executive officer and (ii) the engagement terms are consistent
with the company&#8217;s compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation of Chief Executive Officer</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation of a public
company&#8217;s chief executive officer generally requires the approval of first, the company&#8217;s compensation committee; second,
the company&#8217;s board of directors and third (except for a number of exceptions), the company&#8217;s shareholders by the Special
Approval for Compensation. However, if the shareholders of the company do not approve a compensation arrangement with a chief executive
officer, the compensation committee and board of directors may, in special circumstances, override the shareholders&#8217; decision if
each of the compensation committee and the board of directors discuss the arrangement again, analyze the shareholders&#8217; objection
and provide detailed reasons for their decision. However, an amendment to an existing arrangement with a chief executive officer who is
not a director requires only the approval of the compensation committee, if the compensation committee determines that the amendment is
not material in comparison to the existing arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to regulations
promulgated under the Israeli Companies Law, the renewal or extension of an existing arrangement with a chief executive officer shall
not require shareholder approval if (i) the renewal or extension is not beneficial to the chief executive officer as compared to the prior
arrangement or there is no substantial change in the terms and other relevant circumstances; and (ii) the engagement terms are consistent
with the company&#8217;s compensation policy and the prior arrangement was approved by the shareholders by the Special Approval for Compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation of Directors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Arrangements regarding the
compensation of a director require the approval of the compensation committee, board of directors and (except for a number of exceptions)
shareholders by ordinary majority, in that order. The approval of the compensation committee and board of directors must be in accordance
with the compensation policy. In special circumstances, the compensation committee and board of directors may approve a compensation arrangement
that is inconsistent with the company&#8217;s compensation policy, provided that they have considered the same considerations and matters
required for the approval of a compensation policy in accordance with the Israeli Companies Law and that shareholder approval was obtained
by the Special Approval for Compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With respect to compensation
of an officer (including chief executive officer) or director who is also a controlling shareholder, see &#8220;- Disclosure of Personal
Interests of Controlling Shareholders and Approval of Certain Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure of Personal Interests of Controlling Shareholders and
Approval of Certain Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Israeli law,
the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a
shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights
in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private
placement in which a controlling shareholder has a personal interest, and the terms of engagement with a controlling shareholder or a
relative thereof, directly or indirectly (including through a corporation controlled by a controlling shareholder), for the provision
of services to the company and his or her terms of employment or service as an office holder or employment as other than an office holder,
require the approval of each of (i) the audit committee or the compensation committee with respect to the terms of service or employment
by the company as an office holder, an employee or service provider; (ii) the board of directors; and (iii) the shareholders, in that
order. The shareholder approval requires one of the following, which we refer to as a Special Majority:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting on the matter approves the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each shareholder voting on
the approval of an extraordinary transaction with a controlling shareholder must inform the company prior to voting whether or not he
or she has a personal interest in the approval of the transaction, otherwise, the shareholder is not eligible to vote on the proposal
and his or her vote will not be counted for purposes of the proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent that any such
transaction with a controlling shareholder is for a period of more than three years, approval is required once every three years, unless,
with respect to any such extraordinary transactions, the audit committee determines that the duration of the transaction is reasonable
given the related circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation committee
and board approval for arrangements regarding the terms of service or employment of a controlling shareholder must be in accordance with
the company&#8217;s compensation policy. In special circumstances, the compensation committee and board of directors may approve a compensation
arrangement that is inconsistent with the company&#8217;s compensation policy, provided that they have considered the same considerations
and matters required for the approval of a compensation policy in accordance with the Israeli Companies Law and that shareholder approval
was obtained by the Special Majority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to regulations promulgated
under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, relating
to terms of service or employment that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder
approval upon certain determinations of the audit committee and board of directors. In addition, disclosure of a personal interest in
a private placement of a public company (including disclosure of any material fact or document) is required by (i) a shareholder holding
5% or more of the company&#8217;s issued and outstanding capital or its voting rights whose holdings will increase as result of the private
placement and a shareholder who will hold 5% or more of the company&#8217;s issued and outstanding capital or its voting rights as a result
of the private placement, if 20% or more of the company&#8217;s outstanding share capital prior to the private placement is issued in
the private placement and the payment for which is not only in cash or listed securities or the transaction is not on market terms; and
(ii) a person or entity that will become a controlling shareholder as a result of the private placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholder Duties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Israeli Companies
Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain
from abusing his or her power in the company, including, among other things, in voting at a meeting of shareholder with respect to the
following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the company&#8217;s articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase of the company&#8217;s authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a shareholder
has a general duty to refrain from discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain shareholders have
a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that he or she
has the power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent the appointment
of an office holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the
duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exculpation, Insurance and Indemnification of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate
an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended articles
of association include such a provision, to the fullest extent permitted by law. The company may not exculpate in advance a director from
liability arising out of a prohibited dividend or other distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law and the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, a company may indemnify an office holder in respect of the
following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made
in advance of any such event or following an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law and the Israeli Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed
by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on the office holder in favor of a third party; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder or certain compensation payments to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, a company may not indemnify, exculpate or enter into an insurance contract for office holder liability, for any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed with intent to derive illegal personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, monetary sanction or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and
the board of directors and, with respect to the chief executive officer and a director or (under certain circumstances), also by the shareholders.
See &#8220;- Approval of Related Party Transactions under Israeli Law.&#8221; However, the insurance of office holders shall not require
shareholder approval and may be approved only by the compensation committee, if the engagement terms are determined in the company&#8217;s
compensation policy and that policy was approved by the shareholders by the Special Approval for Compensation, provided that the policy
is on market terms and is not likely to materially impact the company&#8217;s profitability, assets or obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended articles of association
permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Israeli Companies Law and the
Israeli Securities Law. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders
and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into indemnification
and exculpation agreements with each of our current officers and directors exculpating them from a breach of their duty of care to us
to the fullest extent permitted by the Israeli Companies Law and undertaking to indemnify them to the fullest extent permitted by the
Israeli Companies Law and the Israeli Securities Law, to the extent that these liabilities are not covered by insurance. This indemnification
is limited to events determined as foreseeable by our Board of Directors based on our activities and excludes expenses and liabilities
incurred by a breach of the duty of loyalty to the Company, willful neglect of the duty of care towards the Company, realization of personal
unlawful profits and other circumstances as set forth in the indemnification agreements. Under such indemnification agreements, the maximum
aggregate amount of indemnification that we may pay to any and all of our currently serving or future officers and directors together
may not exceed the higher of $5 million and 25% of our shareholders equity according to our most recent financial statements at the time
of payment. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities
Act of 1933, as amended, is against public policy and therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December&#160;31, 2025,
we had a limited number of employees and independent contractors. Under Israeli law, we and our employees are subject to protective labor
provisions, including the length of the workday, minimum wages for employees, annual leave, sick pay, determination of severance pay and
advance notice of termination of employment, as well as procedures for hiring and dismissing employees and equal opportunity and anti-discrimination
laws. While none of our employees are party to any collective bargaining agreements, orders issued by the Israeli Ministry of Economy
and Industry may make certain industry-wide collective bargaining agreements applicable to us. These agreements affect matters such as
the length of the workday and week, recuperation pay, travel expenses and pension rights. We have never experienced labor-related work
stoppages and believe that our relationships with our employees are a significant part of our operations and that we maintain a good and
positive relationship with our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli law generally requires
the payment of severance compensation by employers upon the retirement, death or dismissal of an employee. We fund our ongoing severance
obligations by making monthly payments to insurance policies. All of our current employees have agreed that upon termination of their
employment, they will be entitled to receive only the amounts accrued in the insurance policies with respect to severance pay. Furthermore,
Israeli employees and employers are required to pay predetermined sums to the National Insurance Institute, which is similar to the U.S.
Social Security Administration. These amounts also include payments for national health insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we have various
consulting arrangements with experts including in regulatory, research and clinical matters, including with physicians.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share Ownership of Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For information concerning
the beneficial ownership of our ordinary shares by our executive officers and directors, see the table in Item 7A. &#8220;Major Shareholders
and Related Party Transactions-Major shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Option and Incentive Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the transfer
of all of the business operations and substantially all of the assets of Check-Cap LLC to us in 2009, we assumed the Check-Cap LLC 2006
Unit Option Plan, or the 2006 Plan. On June&#160;23, 2015, our Board of Directors approved and adopted the Check-Cap Ltd. 2015 Equity
Incentive Plan, or the 2015 Israeli Plan, and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan,
or the 2015 U.S. Sub-Plan. The 2015 Israeli Plan and 2015 U.S. Sub-Plan are referred together as the 2015 Plan. As of such date, we ceased
to grant options under the 2006 Plan and all equity-based awards made after such date shall be made under the 2015 Plan. Our shareholders
approved the 2015 Plan at an extraordinary general meeting of shareholders held on August&#160;13, 2015.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary provisions of
the 2006 Plan and 2015 Plan are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2006 Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>General</i>. The 2006
Plan provided for the grant of options to purchase our ordinary shares to our employees, consultants and service providers. For the purpose
of the 2006 Plan: (i) an &#8220;employee&#8221; means any person, including officers, directors or affiliates who are employed by us or
by our affiliates; (ii) a &#8220;consultant&#8221; means any person who is engaged by us to render consulting or advisory services to
us or to any of our entities provided that such services are provided in good faith and are (a) not in connection with the offer or sale
of our securities in a capital raising transaction and (b) not directly or indirectly promoting or maintaining a market for our securities;
(iii) a &#8220;service provider&#8221; means an employee, director, supplier or officer holder as defined in the Israeli Companies Law;
and (iv) an &#8220;affiliate&#8221; means any entity which is directly or indirectly our parent or subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Administration of the
2006 Plan</i>. Our Board of Directors has had the authority to administer the 2006 Plan and to grant options under the 2006 Plan, including,
the authority to determine the persons to whom options would be granted, the number of shares subject to each option, the time or times
at which the options would be granted, restrictions on the transferability of the options, and the schedule and conditions on which such
options may be exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Awards under the 2006
Plan. </i>The 2006 Plan provided for the grant of options pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance New Version,
5721-1961, which we refer to as the Tax Ordinance. The 2006 Plan provides that Section 102 options may be granted only to employees who
are Israeli residents and who do not own interests possessing more than 10% of the total combined voting power of all classes of our equity
or the equity of our affiliates immediately before such option is granted. Options granted to optionees who are Israeli residents that
are not intended to qualify as Section 102 Options are granted under Section 3(i) of the Tax Ordinance, which does not provide for similar
tax benefits, and are referred to as Section 3(i) options. The 2006 Plan was submitted for the approval of the Israeli Tax Authority,
which we refer to as the ITA, as required by applicable law. Options granted to employees under the 2006 Plan were granted under Section
102(b)(2) of the Tax Ordinance, which permits the issuance to a trustee under the &#8220;capital gains track.&#8221; In order to comply
with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section 102 of the
Tax Ordinance, as well as the shares issued upon exercise of such options and other shares received subsequently following any realization
of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected
by the Board of Directors and held in trust for the benefit of the relevant employee, director or officer for a period of two years from
the date of the grant. However, under this track, we are not allowed to deduct an expense with respect to the issuance of the options
or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercise Price; Vesting.
</i>The exercise price of an option granted under the 2006 Plan has been determined by the Board of Directors or a committee appointed
by it. The first option grant to an employee generally vested over a period of three years and nine months commencing on the date of grant,
such that 8.33% vest on the first anniversary of the date of grant and an additional 8.33% vest on each subsequent three-month period
thereafter, for 33 months. Additional options granted to an employee generally vest over a period of three years commencing on the three
months anniversary of the date of grant, such that 8.33% is fully vested on the date of grant and an additional 8.33% vest on each subsequent
three-month period thereafter, for 33 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Options Term; Termination
of Employment or Service</i>. Options granted under the 2006 Plan generally expire within ten years of the grant date or upon the earlier
termination of employment of, or services provided by, the optionee, as applicable, subject to the extended period of exercisability upon
termination of employment or services, as applicable. Upon termination of the employment of or services rendered by an optionee, as applicable
(other than for cause, disability or death), generally vested options may be exercised within three months after the date of such termination
or within such shorter time period (not to be less than 30 days) or such longer time period (not to exceed five years) as our Board of
Directors or a committee appointed by it shall determine, but in any event no later than the expiration date of the options. If the employment
or services of the optionee are terminated because of death or disability (or if the optionee dies within three months after termination
of employment or services other than for cause), the optionee&#8217;s options may be exercised by the optionee or the optionee&#8217;s
legal representative or authorized assignee to the extent exercisable on the date of such termination or within 12 months thereafter or
as otherwise determined by the Board of Directors or a committee appointed by it. If the employment or services of the optionee are terminated
for cause, all outstanding options will, to the extent not previously exercised, be of no force and effect as of the date of termination,
unless otherwise determined by the Board of Directors or a committee appointed by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>M&amp;A Transaction</i>.
The 2006 Plan provides that in the event of a merger or consolidation of our company in which our company is not the surviving entity,
an acquisition of all or substantially all of the outstanding capital of our company or the sale of all or substantially all of our assets,
the optionee shall be provided the opportunity to (i) exercise his or her options in connection with the transaction and to receive in
the transaction such consideration as the holder of ordinary shares shall receive in the transaction; or (ii) retain his or her options
or receive a substitute option from the surviving company, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2015 Equity Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Awards under the 2015
Plan. </i>Awards under the 2015 Plan may be options granted pursuant to Section 102 of the Tax Ordinance, or Section 102 Options, or Section
3(i) of the Tax Ordinance, or Section 3(i) Options, &#8220;incentive stock options&#8221;, or ISOs, within the meaning of Section 422
of the U.S. Internal Revenue Code of 1986, as amended, and options not intended to qualify as ISOs, or Non-statutory Stock Options, stock
appreciation rights, or SARs, restricted stock awards, or RSAs, and restricted stock units, or RSUs, or any combination of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless the Administrator (as defined below) determines otherwise and
subject to applicable law, Section 102 Options may be granted only to Israeli employees, executives and directors (excluding controlling
shareholders) and Section 3(i) Options may be granted to consultants, controlling shareholders and non-Israeli employees, executives and
directors, in each case of our company or any subsidiary. The Section 102 Options may be granted either pursuant to Section 102(c) of
the Tax Ordinance, which are not required to be held in trust by a trustee, or pursuant to Section 102(b), which are required to be held
in trust for a specified period to qualify for certain tax benefits. Options granted pursuant to Section 102(b) shall be designated to
qualify for capital gain tax treatment in accordance with Section 102(b)(2) of the Tax Ordinance or ordinary income tax in accordance
with Section 102(b)(1) of the Tax Ordinance and thereafter, only such type of Section 102(b) options shall be granted until the Administrator
has determined otherwise in accordance with applicable law (which may not be prior to one year after the first grant of such type of Section
102(b) options).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless the Administrator
determines otherwise and subject to applicable law, ISOs may be granted only to non-Israeli employees and Non-statutory Stock Options
may be granted to non- Israeli employees and consultants, in each case of our company or any subsidiary. To the extent that the aggregate
fair market value of the ordinary shares with respect to which ISOs are exercisable for the first time by a participant during any calendar
year under all company plans exceeds $100,000, then unless the Administrator determines otherwise at any time and subject to applicable
law, such options shall be treated as Non-statutory Stock Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Administration of the
2015 Plan</i>. The Plan 2015 will be administered by the Board of Directors or, subject to applicable law, a committee appointed by the
Board of Directors, or Committee and the Administrator. Subject to the provisions of the 2015 Plan and, in the case of a Committee, the
specific duties delegated by the Board of Directors, and subject to the approval of any relevant authorities and compliance with all applicable
laws, the Administrator shall have the full power and authority at its sole discretion, from time to time and at any time, among other
things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine whether and to what extent awards are to be granted to participants under the 2015 Plan and to select the eligible recipients of awards under the 2015 Plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To approve forms of agreement for use under the 2015 Plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine the terms and conditions of any award under the 2015 Plan, including the exercise price, the time or times and the extent to which the awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any award or the ordinary shares relating thereto, based in each case on such factors as the Administrator, at its sole discretion, shall determine;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine the fair market value of the shares covered by each award;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To make an election as to the type of Section 102 Option;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To prescribe, amend and rescind rules and regulations relating to the 2015 Plan, including rules and regulations relating to sub-plans established for the purpose of qualifying for preferred tax treatment under foreign tax laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To authorize conversion or substitution under the 2015 Plan of any or all awards and to cancel or suspend awards, as necessary, provided the material interests of the participants are not harmed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To construe and interpret the terms of the 2015 Plan and awards granted pursuant to the 2015 Plan; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To alter, revise or otherwise adjust the terms of the 2015 Plan and the award agreement, as may be required pursuant to any applicable laws of local or foreign jurisdictions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Term of Awards. </i>The
term of each option shall be stated in the award agreement but in no event may it be more than ten years from the date of grant. Unless
the Administrator determines otherwise and subject to applicable law, no ISO may be granted under the 2015 Plan to a grantee who possess
more than 10% of the total combined voting power of our company or any of our affiliate (a &#8220;10% Shareholder&#8221;) unless the option
terminates on a date that is not later than the day preceding the fifth anniversary of the date of grant. Unless otherwise specified in
the applicable award agreement, the term of a SAR will be ten years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercise Price. </i>The
exercise price of any award under the 2015 Plan shall be determined by the Administrator, subject to applicable law. Unless the Administrator
determines otherwise and subject to applicable law, in the case of ISOs and Non-Statutory Stock Options, the exercise price per share
shall be no less than the fair market value per ordinary share on the date of grant and in the case of an ISO granted to a 10% Shareholder,
no less than 110% of the fair market value per ordinary share on the date of grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Non-Transferability of
Awards. </i>Unless the Administrator determines otherwise and subject to applicable law: (i) options and SARs may not be sold, pledged,
assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may
be exercised, during the lifetime of the participant, only by the participant. For as long as options or shares purchased upon the exercise
of options are held by a trustee on behalf of the participant, all rights of the participant with respect to such options and shares shall
be personal, and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution; (ii)
RSUs may not be sold, pledged, transferred, assigned or encumbered; and (iii) RSAs may not be sold, transferred, pledged, assigned or
otherwise disposed of during the restricted period, provided that the Administrator may provide for the lapse of such restrictions in
installments and may accelerate or waive such restrictions in whole or in part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Termination of Employment or Service.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Options and SARs</i>.
If a participant ceases to be an employee or consultant, in the absence of specified period in the award agreement and unless the Administrator
determines otherwise, such participant may exercise his/her options (to the extent vested on the date of such termination) or SARs within
three months following such termination (but in no event later than the expiration date of the option or SAR). If a participant retires,
he/she may continue to enjoy such rights with respect to awards under the 2015 Plan, on such terms and conditions as the Administrator
may determine. If the participant&#8217;s employment or service is terminated as a result if his/her death or permanent disability, the
participant (or, if the participant died, the participant&#8217;s estate or any person who acquired the right to exercise the option by
bequest or inheritance), may exercise his/her options (to the extent vested on the date of such termination) and/or SARs within such additional
period of time following such termination as specified in the award agreement (which may not be less than six months), or in the absence
of a specified period in the award agreement, until 12 months following such termination or any longer period determined by the Administrator,
but in no event later than the expiration date of the option or SAR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>RSAs</i>. If a participant&#8217;s
service of employment is terminated prior to the restricted period, subject to the terms of the award agreement or as otherwise determined
by the Administrator, the participant&#8217;s restricted stock and any associated dividends that remain subject to forfeiture will then
be forfeited automatically.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>RSUs</i>. If a participant&#8217;s
service of employment is terminated prior to the RSU vesting, subject to the terms of the award agreement or as otherwise determined by
the Administrator, the participant&#8217;s RSUs that remain subject to forfeiture will then be forfeited automatically.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>M&amp;A Transaction</i>.
In the event of a Transaction (as defined in the 2015 Plan, which generally includes (among other things) a sale of all or substantially
all of our assets or shares, a merger, consolidation or amalgamation with or into another company or a scheme of arrangement for effecting
any of the foregoing or such other transaction determined as such by the Administrator, all subject to the conditions and limitations
in the 2015 Plan), unless otherwise determined by the Administrator, in its sole discretion, any award granted under the 2015 shall be
assumed or substituted by us or the successor company, under terms determined by the Administrator or the terms of the 2015 Plan applied
by the successor company to such assumed or substituted awards, all in accordance with the terms of the 2015 Plan. Regardless of whether
or not the awards are assumed or substituted, the Administrator may, at its sole discretion, among other things, provide for the exercise
of any exercisable and vested awards, the cancellation of unexercised and unvested awards, the acceleration of unvested awards, or the
cancellation of awards for payment in cash, shares or other property of our company or the acquiring company or other party to the Transaction,
under such terms as the Administrator may determine, all in accordance with the terms of the 2015 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Term and Termination of
the 2015 Plan</i>. The 2015 Plan became effective upon its adoption by our Board of Directors and shall continue in effect for a term
of ten years. Our Board of Directors may at any time amend, alter, suspend or terminate the 2015 Plan. No amendment, alteration, suspension
or termination of the 2015 Plan shall impair the rights of any participant, unless mutually agreed otherwise in writing between the participant
and the Administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Disclosure of a registrant&#8217;s action
to recover erroneously awarded compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 7. Major Shareholders
and Related Party Transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Major shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth certain information regarding the beneficial ownership of our outstanding ordinary shares as of March 1, 2026, by each person who
we know beneficially owns 5.0% or more of the outstanding ordinary shares. Each of our shareholders has identical voting rights with respect
to its shares. All of the information with respect to beneficial ownership of the ordinary shares is given to the best of our knowledge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The percentage of beneficial
ownership of our ordinary shares is based on 7,020,502 ordinary shares, NIS 48.00 par value per share, outstanding as of January 31, 2026.
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting power or investment power with
respect to securities. All ordinary shares subject to options and warrants that are currently exercisable or exercisable within 60 days
of March 1, 2026, and underlying RSUs that are scheduled to vest within 60 days of March 1, 2026, are deemed to be outstanding and beneficially
owned by the shareholder holding such options, warrants or RSUs for the purpose of computing the number of shares beneficially owned by
such shareholder. Such shares are also deemed outstanding for purposes of computing the percentage ownership of the person holding the
option, warrant or RSU. They are not, however, deemed to be outstanding and beneficially owned for the purpose of computing the percentage
ownership of any other shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as indicated in footnotes
to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown
to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each shareholder&#8217;s
address is: c/o 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Mount Carmel, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<br/> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">5% or Greater Shareholders</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Vijay Ramanathan (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">360,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Symetryx Corporation (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">338,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EquityLine Alternate Assets GP Inc.(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">762,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Parea LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Alan Lewis</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Lontini</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Carlos Cheung</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael Hutton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Daniel Kokiw</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (5 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based solely upon, and qualified in its entirety with reference to, Schedule 13G filed with the SEC on December&#160;18, 2023. The address of the reporting person is 20 Adelaide St E, Suite 1105, Toronto, ON M5C 2T6, Canada.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based solely upon, and qualified in its entirety with reference to, Schedule 13D filed with the SEC on September 29, 2023, as amended on October 30, 2023 and November&#160;14, 2023. The address of the reporting person is 2828 Bathurst Street, Suite 400, Toronto, Canada M6B3A7.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based solely upon, and qualified in its entirety with reference to, Schedule 13D/A filed with the SEC on April&#160;1, 2024, as amended on April&#160;8, 2024. Sergiy Shchavyelyev, as the sole director of EquityLine Alternate Assets GP Inc., may be deemed to beneficially own the 762,724 Shares owned by EquityLine Alternate Assets GP Inc. The address of the reporting person is 550 Highway 7 East, 338 Richmond Hill, Ontario L4B 3Z4.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March&#160;1, 2026,
based on information provided to us by our transfer agent in the United States and other information reasonably available to us, we had
77 holders of record of our ordinary shares in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of our shareholders
have voting rights different from the voting rights of other shareholders. To the best of our knowledge, we are not owned or controlled,
directly or indirectly, by another corporation or by any government. We are not aware of any arrangement that may, at a subsequent date,
result in a change of control of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage
ownership held by any major shareholder since January&#160;1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than the executive
and director compensation, executive officer employment agreements, indemnification and exculpation arrangements and directors&#8217;
and officers&#8217; liability insurance policy discussed in &#8220;Management,&#8221; and the transactions described below, since January&#160;1,
2021, we have not been or are not a party to any related party transactions. The descriptions provided below are summaries of the terms
of such agreements, do not purport to be complete and are qualified in their entirety by the complete agreements. In addition, we note
that certain shareholders of Check-Cap are also shareholders of Apollo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pontifax Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 14, 2014, we issued
warrants to purchase an aggregate of 924 of our ordinary shares at an exercise price of NIS 48 per share, or the Pontifax Warrants, to
the Pontifax Funds in consideration of their commitment to provide to us, for no consideration, the following services, if and to the
extent requested by us: (i) business development services, in such scope and substance as shall be agreed between us and the Pontifax;
and (ii) a representative designated by Pontifax to serve as the Chairman of our Board of Directors. The Pontifax Funds subsequently agreed
that the exercise price of fifty-percent of their warrants will increase to equal the price at which our ordinary shares are sold to the
public in the initial public offering of our securities, or if units are sold in the initial public offering of our securities, the exercise
price per share will increase to be equal to the effective price per share of the ordinary shares underlying the units sold to the public
in the offering. The Pontifax Funds also agreed that such portion of their warrants would vest and become exercisable only upon the consummation
of the initial public offering of our securities prior to their expiration date. The remaining warrants with an NIS 48 exercise price
would vest on a quarterly basis in eight equal installments during a period of 24 months from issuance. In addition, the Pontifax Funds
agreed to reduce the term of their respective warrants such that these warrants will now expire after eight years (instead of ten years)
following their issuance, i.e., on October 14, 2022. Upon the closing of our initial public offering any unvested portion of the warrants
became fully vested and exercisable. In September 2018, Pontifax exercised 462 of the Pontifax Warrants, with an exercise price of 48
per share, into 376 ordinary shares on a cashless basis. On October 14, 2022, the remaining Pontifax Warrants to purchase 462 ordinary
shares, with an exercise price of $1,214.4 per share, expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transactions with Check-Cap LLC and the Members and Manager of Check-Cap
LLC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May&#160;31, 2009, we
entered into an asset transfer agreement with Check-Cap LLC pursuant to which Check-Cap LLC transferred all of its business operations
and substantially all of its assets to us. Our shareholders&#8217; holdings on the date of the asset transfer transaction reflected their
interests as members of Check-Cap LLC. In the framework of the asset transfer agreement and under the Shareholders Agreement, we undertook
to use commercially reasonable efforts to procure that distributions or advance funds are made to our shareholders holding (at the date
of the transaction) ordinary shares, Series A preferred shares and/or Series B preferred shares (i.e., the shareholders who are also members
of Check-Cap LLC), as would be necessary to eliminate the tax impact on such shareholders of the Reorganization and the transfer of all
of the business operations and substantially all of the assets from Check-Cap LLC to us. Notwithstanding the foregoing, we will not advance
payments to such shareholders to address the fact that they will no longer receive a &#8220;pass through&#8221; of losses generated by
us as they previously received while owning units of Check-Cap LLC. These advances, if and to the extent made, will be deducted from any
distributions such shareholders are entitled to receive from us. Since we do not expect to be profitable in year 2025, the liability based
on the discounted outflows is $0. As a result, as of December&#160;31, 2025, the balance of the reimbursement liability totaled $0 ($0
as of December&#160;31, 2024 and $0 as of December&#160;31, 2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with the asset
transfer agreement entered into in May&#160;2009, we assumed the former obligation of Check-Cap LLC to distribute any proceeds it collects
on the $1 million key man life insurance policy with respect to Yoav Kimchy, the Company&#8217;s chief technology officer and a former
director, to the former holders of the Series A preferred units in an amount equal to their respective capital contributed to Check-Cap
LLC, less any amounts previously distributed to them, plus any accrued and unpaid dividends due to them as of the date of distribution.
On November&#160;16, 2016, we cancelled the key man life insurance policy with respect to Yoav Kimchy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Interests of Experts and Counsel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 8. Financial Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Consolidated Statements and Other Financial
Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See Item 18 &#8220;Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, we may
be involved in litigation that arises through the normal course of business. The following legal proceedings were pending as of December
31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 7, 2024, a minority
shareholder of the Company filed an application in the Haifa District Court (the &#8220;Court&#8221;) seeking certification of a shareholders&#8217;
derivative lawsuit against the Company, certain present and former directors, and a third party. The claim seeks damages in excess of
NIS 2.5 million (approximately $784,000) and relates primarily to corporate governance matters, including the validity of certain board
decisions and the legality of certain corporate transactions. We filed a response with the Court requesting that certification of the
claim as a derivative action be denied. The parties are currently engaged in mediation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe the claims in
the derivative action are without merit and we intend to defend vigorously against this action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2024, two former senior
executives filed separate claims against the Company seeking an aggregate of approximately NIS 620,000 (approximately $195,000) in respect
of alleged unpaid compensation and contractual entitlements following the termination of their respective engagements. We have denied
both claims. Statements of Defense were filed in both matters and management believes it is probable the Company will be successful in
defending against both claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Also during 2024, a former
legal services provider filed a claim seeking approximately NIS 175,000 (approximately $55,000) for alleged unpaid legal fees. We have
denied the claim, a Statement of Defense has been filed, and the parties are engaged in concurrent mediation proceedings. Management believes
it is probable the Company will be successful in defending against this claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2024, we ceased
making rent payments in respect of our leased premises in Usfiyeh, Israel. The landlord commenced legal proceedings against us and an
eviction order was subsequently granted by the court. We have engaged legal counsel in connection with this matter. We have ceased active
business operations at the facility, and certain Company property and documentation remain on the premises pending resolution of access
and logistical matters. The landlord&#8217;s claim for unpaid rent and damages totals approximately NIS 207,000 (approximately $65,000).
For further information, see Note 8C to our audited consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For all of the above matters,
based on the information currently available and after consultation with legal counsel, management does not believe an unfavorable outcome
is probable and, accordingly, no provision has been recorded in these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid dividends on our ordinary shares and currently do not intend to pay cash dividends on our ordinary shares in the foreseeable future.
We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. See Item 3D &#8220;Key
Information - Risk factors - Risks Related to the Company.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to distribute
dividends also may be limited by future contractual obligations and by Israeli law. The Israeli Companies Law restricts our ability to
declare dividends. Unless otherwise approved by a court, we can distribute dividends only from &#8220;profits&#8221; (as defined by the
Israeli Companies Law), and only if there is no reasonable concern that the dividend distribution will prevent us from meeting our existing
and foreseeable obligations as they become due. Subject to the foregoing, payment of future dividends, if any, will be at the discretion
of our Board of Directors and will depend on various factors, such as our financial condition, operating results, current and anticipated
cash needs and other business and economic factors that our Board of Directors may deem relevant. See Exhibit 2.1 &#8220;Description of
Securities-Dividend and Liquidation Rights.&#8221; The payment of dividends may be subject to Israeli withholding taxes. See Item 10E.
&#8220;Additional Information-Taxation-Israeli Tax Considerations and Government Programs-Taxation of Our Shareholders-Taxation of Non-Israeli
Shareholders on Receipt of Dividends.&#8221; Furthermore, if we pay a dividend out of income attributed to our Benefited Enterprise that
was generated during the tax exemption period, we may be subject to tax on the grossed- up amount of such distributed income at the corporate
tax rate which would have been applied to our Benefited Enterprise&#8217;s income had we not enjoyed the exemption. See Item 10E. &#8220;Additional
Information-Taxation - Israeli Tax Considerations and Government Programs - Law for the Encouragement of Capital Investments, 5719-1959
- Tax Benefits Subsequent to the 2005 Amendment.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as disclosed elsewhere
in this Annual Report and in Note 17 to our audited consolidated financial statements, there have been no other significant changes since
December&#160;31, 2025, until the date of the filing of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 9. The Offer and Listing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Offer and Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our units were listed on
the Nasdaq Capital Market on February&#160;19, 2015 under the symbol &#8220;CHEKU.&#8221; Prior to that date, there was no public trading
market for our securities. Our initial public offering was priced at $1,440 per unit on February&#160;20, 2015. Each unit consisted of
one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable
Long Term Incentive Warrants. On March&#160;18, 2015, the units separated and ceased to exist. Since such date, our ordinary shares and
Series A Warrants were listed on the Nasdaq Capital Market under the symbols &#8220;CHEK&#8221; and &#8220;CHEKW&#8221;, respectively.
The Series A Warrants expired on February&#160;24, 2020 and ceased to be listed on the Nasdaq Capital Market since February&#160;20, 2020.
The Long Term Incentive Warrants expired on February&#160;24, 2022. Since May 1, 2023, our Series C Warrants are no longer listed on the
Nasdaq Capital Market. On April&#160;4, 2018, we effected a 1-for-12 reverse share split of our ordinary shares. On November&#160;23,
2022, we effected a 1-for-20 reverse share split of our ordinary shares. On December&#160;1, 2025, we changed our ticker symbol from &#8220;CHEK&#8221;
to &#8220;MBAI&#8221; effective at the opening of trading on December&#160;2, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Plan of Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Markets for Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See &#8220;-Offer and Listing
Details&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Selling Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Dilution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Expenses of the Issue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 10. Additional Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Share Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Memorandum and Articles of Association</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A copy of our amended and
restated articles of association is incorporated by reference attached as Exhibit 1.1 to this Annual Report. Other than as disclosed below,
the information called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into this Annual
Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Registration Number and Purposes of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our registration number with
the Israeli Registrar of Companies is 51-425981-1. Our purpose as set forth in our amended articles of association is to engage in any
lawful activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholder Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Israeli law, we are
required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after
the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in
our amended articles of association as special general meetings. Our Board of Directors may call special general meetings whenever it
sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Israeli Companies Law provides that
our Board of Directors is required to convene a special general meeting upon the written request of (i) any two of our directors or one-quarter
of the serving members of our Board of Directors; or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of
our outstanding shares and 1% of our outstanding voting power or (b) 5% or more of our outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, the Israeli
Companies Law requires that resolutions regarding the following matters be approved by our shareholders at a general meeting:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of certain related party transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions of our authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our Board of Director&#8217;s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is essential for our proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of the Israeli Companies Law and regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the Board of Directors, which, as a company listed on an exchange outside Israel,
may be between four and 40 days prior to the date of the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Israeli Companies Law
requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to
the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions
with office holders or interested or related parties, an approval of a merger or the approval of the compensation policy, notice must
be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, our shareholders are not permitted to take action via written consent in lieu of a meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Borrowing powers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Israeli Companies
Law and our amended articles of association, our Board of Directors may exercise all powers and take all actions that are not required
under law or under our amended articles of association to be exercised or taken by our shareholders, including the power to borrow money
for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For details regarding the
approvals required under the Israeli Companies Law for the approval of director compensation, see Item 6C &#8220;Directors, Senior Management
and Employees - Board Practices -Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of an Office
Holder and Approval of Certain Transactions-Compensation of Directors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Material Contracts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than as described below,
in Item 4. &#8220;Information on Our Company,&#8221; Item 7B &#8220;Major Shareholders and Related Party Transactions - Related Party
Transactions&#8221; or elsewhere in this Annual Report, we have not entered into any material contracts other than in the ordinary course
of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger Agreement with MBody AI</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 12, 2025, the Company, Merger Sub, and MBody AI entered
into the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub will merge with and into MBody AI, with MBody AI surviving the
Merger as a direct, wholly-owned subsidiary of the Company.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the effective time of the Merger, each share of MBody AI capital
stock outstanding immediately prior to the effective time (excluding treasury shares and certain excluded shares) will be converted solely
into the right to receive a number of Check-Cap ordinary shares such that, following the effective time, holders of MBody AI capital stock
will own ninety percent (90%) of the issued and outstanding Check-Cap ordinary shares on a fully diluted basis. No fractional Check-Cap
ordinary shares will be issued in connection with the Merger.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement contains customary representations, warranties,
and covenants made by the parties, including covenants relating to obtaining requisite shareholder approvals, indemnification of directors
and officers, and the conduct of each party&#8217;s business between the date of the Merger Agreement and the closing. The closing of
the Merger is subject to the satisfaction or waiver of certain conditions, including, among other things: (i) the absence of any order
or law preventing the consummation of the transactions; (ii) approval by both Check-Cap and MBody AI shareholders; (iii) the expiration
or termination of any applicable antitrust waiting periods; and (iv) the parties&#8217; commercially reasonable efforts to secure a private
financing on terms reasonably acceptable to each of the parties.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger Agreement may be terminated by either party if the Merger
has not been consummated by June 30, 2026, subject to certain exceptions. The Merger Agreement also provides for certain termination fees.
Under specified circumstances, the Company may be required to pay MBody AI an expense reimbursement fee of up to $1,500,000, and in certain
other circumstances, the Company may be required to pay MBody AI a termination fee of $2,500,000.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For U.S. federal income tax purposes, the Merger is intended to constitute
a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Merger was approved by the Company&#8217;s shareholders on November
14, 2025, and closing is anticipated in the first half of 2026. The Apollo BCA is expected to be terminated in connection with the closing
of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business Combination Agreement with Apollo</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 25, 2024, the Company entered into the Apollo BCA, pursuant
to which a wholly-owned subsidiary of Apollo was to merge with and into the Company, with the Company surviving as a direct, wholly-owned
subsidiary of Apollo. Under the exchange ratio formula in the Apollo BCA, Check-Cap security holders were expected to own approximately
15% and Apollo security holders were expected to own approximately 85% of the combined entity on a fully diluted basis, subject to certain
net cash adjustments. In May 2024, the Company reimbursed Apollo $3,808,815 pursuant to the provisions of the Apollo BCA.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Apollo BCA remains in effect as of the date of this Annual Report
and is expected to be terminated in connection with the closing of the Merger with MBody AI.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Apollo Loan Agreements and Segregated Account</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2024 and 2025, the Company entered into a series of loan agreements
with Apollo, including the September 2024 Loan Agreement ($6.0 million), the December 2024 Loan Agreement ($6.0 million), the First July
2025 Loan Agreement ($2.1 million), and the Second July 2025 Loan Agreement ($2.2 million). The principal outstanding under each loan
bears interest at 5% per annum and is payable 30 days following the termination of the Apollo BCA or the consummation of the business
combination contemplated thereunder.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, on September 8, 2024, the Company entered into the Amending
Letter with Apollo, which amended the Apollo BCA and obligated the Company to deposit $11.0 million into a designated, segregated and
interest-bearing bank account (the &#8220;Segregated Account&#8221;). Funds deposited into the Segregated Account may be disbursed upon
the mutual written agreement of the designated representatives of Apollo and the Company in order to fund the pursuit of accretive acquisition
targets or other growth initiatives of Apollo and for no other purpose. In the event that the Apollo BCA is terminated, then, subject
to the payment of any termination fees triggered by Section 9.3(c) of the Apollo BCA, funds remaining in the Segregated Account upon termination,
together with interest earned thereon, will accrue to and will be for the account and benefit of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2025, $2.1 million of the Segregated Account had
been used for acquisition targets and growth initiatives, $0.7 million had been used for certain expenses incurred by the Company, and
$2.2 million remained in the Segregated Account. In July 2025, in connection with the audit of the Company&#8217;s December 31, 2024 financial
statements, the Company classified the $2.1 million used for acquisition targets and growth initiatives and the $2.2 million remaining
in the Segregated Account as loans to Apollo and entered into loan agreements with Apollo on the same terms as the December 2024 Loan
Agreement to document such classifications, given that the Segregated Account is in the name of an affiliate of Apollo.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a discussion of the impairment and subsequent reversal of the Apollo
Loans, see Item 5A &#8220;Operating and Financial Review and Prospects &#8212; Results of Operations.&#8221;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Asset Purchase Agreement with Parea</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 5, 2025, the Company entered into the Parea APA, pursuant
to which the Company acquired all right, title, and interest in a contract granting exclusive Ghost Kitchen area representative rights
across the state of New Jersey. As consideration for the acquired assets, the Company issued 1,169,596 ordinary shares to Parea LLC. For
a description of the Ghost Kitchen area representative business, see Item 4B &#8220;Information on Our Company &#8212; Business Overview
&#8212; Parea.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Purchase Agreement with ARC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2025, the Company entered into the Purchase Agreement with
ARC, pursuant to which ARC committed to purchase up to $30.0 million of the Company&#8217;s ordinary shares over a period of three years
from the effective date of the registration statement filed in connection therewith. The Company may direct ARC to purchase ordinary shares
by delivering advance notices from time to time, subject to certain conditions and limitations. In consideration for ARC&#8217;s commitment
under the Purchase Agreement, the Company issued 267,857 ordinary shares as a commitment fee, having an aggregate value of $450,000.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purchase price for shares sold pursuant to the first advance notice
is 97% of the lowest daily volume weighted average price of the ordinary shares during three consecutive trading days commencing on the
date the advance notice is received by ARC. Any sale of ordinary shares pursuant to the Purchase Agreement is subject to certain limitations,
including that ARC and its affiliates may not own more than 9.99% of the then outstanding ordinary shares at any time. In addition, the
aggregate number of ordinary shares that the Company may issue to ARC under the Purchase Agreement may not exceed 19.99% of the ordinary
shares outstanding as of the date of the Purchase Agreement (the &#8220;Exchange Cap&#8221;), unless the Company obtains the requisite
shareholder approval or Nasdaq grants an exception; provided that because the Company as a foreign private issuer follows home country
practice, the Exchange Cap does not apply.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Purchase Agreement, the Company filed a Registration
Statement on Form F-1 with the SEC on January 30, 2026, as amended on February 2, 2026, which became effective on February 23, 2026, registering
the resale by ARC of up to 2,000,000 ordinary shares issuable under the Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Exchange controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or
other payments to non- residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of
war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_050"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to our ordinary shares, Series C Warrants and Series
D Warrants (sometimes referred to collectively or individually as our &#8220;securities&#8221;). You should consult your own tax advisor
concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state,
local, non-U.S. or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Israeli Tax Considerations and Government Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a brief
summary of the material Israeli tax laws applicable to us and certain Israeli Government programs that benefit us. This section also contains
a discussion of material Israeli tax consequences concerning the ownership and disposition of our securities purchased by investors who
are non-Israeli resident shareholders. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular
investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli
law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered
in this discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to judicial or administrative
interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion.
The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative
interpretations of Israeli law, which change could affect the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli resident companies
are generally subject to corporate tax, currently at the rate of 23% (effective as of January&#160;1, 2018) of a company&#8217;s taxable
income. However, the effective tax rate payable by a company that derives income from an Approved Enterprise, a Benefited Enterprise a
Preferred Enterprise or a Preferred Technological Enterprise (as discussed below) may be considerably less. Capital gains derived by an
Israeli resident company are subject to tax at the prevailing corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Law for the Encouragement
of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial
Companies.&#8221; The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as a company resident in Israel, of which
90% or more of its income in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221;
owned by it and located in Israel or in the &#8220;Area&#8221; (as such term is defined under Section 3A of the Israeli Income Tax Ordinance
(New Version), 5721-1961, referred to as the Ordinance). An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal
activity in a given tax year is industrial production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following corporate tax
benefits, among others, are available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization over an eight-year period, beginning from the year in which such rights were first used, of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under limited conditions, a Parent Company (as such term defined in the Industry Encouragement Law) may elect to file consolidated tax returns with related Israeli Industrial Companies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to a public offering are deductible in equal amounts over three years beginning from the year of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Eligibility for the benefits
under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. We believe that we may
qualify as an &#8220;Industrial Company&#8221; within the meaning of the Industry Encouragement Law; however, there can be no assurance
that we will qualify as an Industrial Company or that the benefits described above will be available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Capital Investments,
5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, was originally enacted in order to provide certain incentives
for capital investments in production facilities (or other eligible assets).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Investment Law has been
amended several times in recent years, primarily: Amendment 60, effective as of April&#160;1, 2005, referred to as the 2005 Amendment;
Amendment 68, effective as of January&#160;1, 2011, referred to as the 2011 Amendment; Amendment 71, effective as of January&#160;1, 2014,
referred to as the 2014 Amendment; Amendment 73, effective as of January&#160;1, 2017, referred to as the 2017 Amendment; and Amendment
74, effective as of August&#160;15, 2021, referred to as the 2021 Amendment. Pursuant to the foregoing amendments, generally tax benefits
that were granted in accordance with the provisions of the Investment Law prior to each such amendment remain in force; however, any benefits
granted subsequent to the respective amendment are subject to the provisions of the Investment Law as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits Prior to the 2005 Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the 2005 Amendment,
a capital investment in eligible production facilities (or other eligible assets) could, upon application to the Investment Center of
the Israeli Ministry of Economy (formerly named the Ministry of Industry, Trade and Labor), be designated as an &#8220;Approved Enterprise&#8221;
and accordingly, entitled to certain tax benefits under the Investment Law. Each certificate of approval for an Approved Enterprise relates
to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical
characteristics of the facility or the asset. We do not have any Approved Enterprises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits Subsequent to the 2005 Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the 2005 Amendment,
a company whose facilities meet certain criteria set forth in the 2005 Amendment may claim certain tax benefits offered by the Investment
Law (as further described below) directly in its tax returns, without the need to obtain prior approval. In order to receive the tax benefits,
a company must make an investment which meets all of the conditions, including exceeding a minimum entitling investment amount, set forth
in the Investment Law. Such investment allows a company to receive &#8220;Benefited Enterprise&#8221; status, and may be made over a period
of no more than three years ending at the end of the year in which the company chose to have the tax benefits apply to its Benefited Enterprise,
referred to as the &#8220;Year of Election.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The extent of the tax benefits
available under the 2005 Amendment to qualifying income of a Benefited Enterprise depends on, among other things, the geographic location
in Israel of the Benefited Enterprise. The location will also determine the period for which tax benefits are available. Under the &#8220;Exemption
Track&#8221; the tax benefits include an exemption from corporate tax on undistributed income generated by the Benefited Enterprise for
a period of two to ten years, depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax
rate of 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in the company in each year.
The benefits period is for a duration of seven or ten years, depending on the location of the Benefited Enterprise, from the later of
the first year in which the company generated taxable income from its Benefited Enterprise and the Year of Election, but in any event
not more than 12 or 14 years from the Year of Election, depending on the location of the Benefited Enterprise. A company qualifying for
tax benefits under the Exemption Track which pays a dividend (as well as a deemed dividend, such as investments in foreign resident subsidiaries,
granting loans to related parties, repurchases of shares, acquisitions of securities/shares, capital reductions and additional events
which reflect the transfer of funds out of the Benefitted Enterprise activity) out of income derived during the tax exemption period by
its Benefited Enterprise will be subject to corporate tax in respect of the amount of the dividend (grossed-up to reflect the pre-tax
income that it would have had to earn in order to distribute the dividend) at the corporate tax rate which would have otherwise been applicable.
Dividends paid out of income attributed to a Benefited Enterprise are generally subject to withholding tax at source at the rate of 20%
or such lower rate as may be provided in an applicable tax treaty. With respect to such dividends, the recently enacted 2021 Amendment
introduced a new dividend distribution ordering rule as well as a Temporary Order to incentivize the distribution thereof (see discussion
below under &#8220;<i>Tax Benefits under the 2021 Amendment&#8221;</i>)<i>. </i>Applying reduced tax rates in accordance with a certain
tax treaty is subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The benefits available to
a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. If a company
does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index,
plus interest, or other monetary penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have one Benefited
Enterprise program under the Investment Law, which, we believe, entitles us to certain tax benefits with respect to income to be derived
from our Benefited Enterprise. We chose 2010 as the Year of Election. We believe that we are located in the Zone A specified development
zone and therefore, believe we are entitled to a 10-year benefit period, during which taxable income from our Benefited Enterprise program
(once generated) will be tax exempt, commencing with the year we will first earn taxable income relating to such enterprise, subject to
a 14-year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Tax Benefits under the 2011
Amendment and the 2014 Amendment</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2011 Amendment canceled
the availability of the benefits granted to companies under the Investment Law prior to 2011 and, instead, introduced new benefits for
income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; or &#8220;Special Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) as of January&#160;1, 2011. The definition of a Preferred Company includes, among other
limitations detailed under the Investment Law, a company incorporated in Israel that is not wholly-owned by a governmental entity, and
that, among other things, owns a Preferred Enterprise or Special Preferred Enterprise and is controlled and managed from Israel. Under
the 2014 Amendment, effective as of January&#160;1, 2014, a Preferred Company is entitled to a reduced corporate tax rate of 16% with
respect to its income derived by its Preferred Enterprise in 2014 and thereafter, unless the Preferred Enterprise is located in a specified
development zone (referred to as &#8220;Zone A&#8221;), in which case the rate will be 9% for the tax years 2014-2016 and, pursuant to
the 2017 Amendment (as discussed below), 7.5% from 2017 and thereafter. We believe our facilities are located in the Zone A specified
development zone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends paid out of income
attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be
provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although,
if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower
rate as may be provided in an applicable tax treaty will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2011 Amendment also provided
transitional provisions to address companies already enjoying existing tax benefits under the Investment Law. These transitional provisions
provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011
with respect to income to be derived as of January&#160;1, 2011, a Benefited Enterprise can elect to continue to benefit from the benefits
provided to it before the 2011 Amendment came into effect, provided that certain conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently examining
whether we are eligible for the tax benefits under the 2011 Amendment and the possible effect, if any, of the provisions of the 2011 Amendment
on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits under the 2017 Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2017 Amendment was enacted
as part of the Economic Efficiency Law that was published on December&#160;29, 2016, and became effective as of January&#160;1, 2017.
The 2017 Amendment provides new tax benefits for two types of &#8220;Technological Enterprises&#8221;, as described below, and is in addition
to the other existing tax beneficial programs under the Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2017 Amendment provides
two new tax incentive tracks - the &#8220;Preferred Technological Enterprise&#8221; track and &#8220;Special Preferred Technological Enterprise&#8221;
track (as such terms are defined in the Investment Law). The benefits available to a Preferred Technological Enterprise or Special Preferred
Technological Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A Preferred Technological
Enterprise is entitled (among other things) to a reduced corporate tax rate of 12% with respect to its income which qualifies as &#8220;Preferred
Technology Income&#8221;, as defined in the Investment Law, unless the Preferred Technological Enterprise is located in a specified development
zone (referred to as &#8220;Zone A&#8221;), in which case the rate will be 7.5%. A Special Preferred Technological Enterprises is entitled
to a reduced corporate tax rate of 6% with respect to its Preferred Technology Income, regardless of the company&#8217;s enterprise geographic
location within Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently examining
whether we are eligible for the tax benefits under the 2017 Amendment and the possible effect, if any, of the provisions of the 2017 Amendment
on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits under the 2021 Amendment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2021 Amendment introduced
a new dividend distribution ordering rule to cause the distribution of earnings that were tax-exempt under the historical Approved or
Beneficial Enterprise regimes (Trapped Earnings), to be on a pro-rata basis from any dividend distribution, which is applicable to distributions
starting from August&#160;15, 2021 onwards. Accordingly, the corporate income tax claw-back will apply to any dividend distribution, as
long as the company has Trapped Earnings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The termination or substantial
reduction of any of the benefits available under the Investment Law could materially increase our future tax liabilities.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Encouragement of Research, Development
and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development
Law, 5744-1984)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Encouragement of
Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research
and Development Law, 5744-1984), referred to as the Innovation Law, research and development programs that meet specified criteria and
are approved by the IIA are eligible for grants. As of December&#160;31, 2025, we had received funding from the IIA for the financing
of a portion of our research and development expenditures for C-Scan in the aggregate amount of approximately $5.6 million. As of December&#160;31,
2025, we had not paid any royalties to the IIA and had a contingent liability to the IIA with respect to such funding in the amount of
approximately $6.2 million. In addition, in January&#160;2021, we received an IIA grant approval to support the funding of our transition
from research and development to manufacturing. The final IIA grant amounted to $620,000 (NIS 2.25 million) (along with a co-investment
by us of the same amount), subject to the terms and conditions set forth in the grant approval, which we are not required to repay to
the IIA, of which we received approximately $0 (NIS 0) in 2025 and 2024, and $225,000 (NIS 816,075) in February&#160;2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Innovation Law
as currently in effect, the research and development grants are typically up to 50% of the project&#8217;s approved expenditures. The
grantee is required to pay royalties to the State of Israel from the sale of products (and associated services) developed using IIA research
and development funding. Regulations under the Innovation Law, as currently in effect, generally provide for the payment of royalties
of 3% or 4% (and at an increased rate under certain circumstances) on sales of products and services based on technology and know-how
developed using such IIA research and development grants, until 100% (which may be increased under certain circumstances) of the grant,
linked to the U.S. dollar and bearing interest at the LIBOR rate, is repaid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The terms of IIA grants that
we have received (the research and development grants and the transition to manufacturing grants) require that products developed with
IIA funded be manufactured in Israel, unless the IIA approved grant program includes a pre-determined portion of manufacturing that may
be performed outside Israel (as certain of our IIA approved grants included). The approval of the IIA is required for the transferring
of manufacturing outside Israel in excess of such pre-determined portion (however, only a notice to the IIA, as opposed to approval, is
required for the transfer outside Israel of up to 10% of the cumulative manufacturing in excess of such pre-approved portion). If manufacturing
of IIA-funded products is transferred outside Israel (following IIA approval) in excess of the pre-determined percentage included in the
grant approval, then the royalty repayment rate is increased by 1% with respect to the additional approved percentage to be manufactured
outside Israel and the royalty repayment for the entire approved program may be increased to up to three times the amount of the grants
received, depending on the percentage manufactured outside Israel (plus accrued interest). We may explore from time to time whether certain
other components of C-Scan can be assembled outside of Israel. For example, we may in the future explore whether it would be possible
to assemble the capsule without the X-ray source in Israel, and have the X-ray source subsequently manufactured and assembled into C-Scan
at a certified radioisotope production facility or at a distribution center outside Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Over the years, we received
approval of grant applications (research and development grants and the transition to manufacturing grant) that included a certain predetermined
percentage of manufacturing of the X-ray source to be performed outside of Israel but additional examination of these approvals and consequent
manufacturing is required to determine liabilities to the IIA, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IIA prior approval is also
required for the transfer of IIA-funded know-how to a third party outside of Israel (including by way of license), which we may not receive
(and any such approval would be subject to payment of a redemption fee, calculated according to a formula under the Innovation Law, which
may be in the amount of up to six times the amount of the grants received, (less paid royalties, if any, and depreciation, but no less
than the total grants received), plus accrued interest). Even following the full repayment of any IIA grants, we must nevertheless continue
to comply with the requirements of the Innovation Law. If we fail to comply with any of the conditions and restrictions imposed by the
Innovation Law and regulations and guidelines thereunder, or by the specific terms under which we received the grants, we may be required
to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal
charges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Capital Gains Taxes Applicable
to Non-Israeli Resident Shareholders</i>. A non-Israeli resident who derives capital gains from the sale of securities of an Israeli resident
company will be exempt from Israeli tax so long as (i) the capital gains are not attributed to a permanent establishment that the non-resident
maintains in Israel, (ii) the securities were not received from a relative or in a tax free reorganization transaction and (iii) the securities
are not traded on the Tel Aviv Stock Exchange on the date of sale (provided, however, that other exemptions may apply if a an Israeli
resident company is listed for trading on the Tel Aviv Stock Exchange). However, non-Israeli corporations will not be entitled to the
foregoing exemption if Israeli residents: (i) have a controlling interest of 25% or more in such non-Israeli corporation; or (ii) are
the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or
indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, a sale of securities
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to
Taxes on Income, as amended, generally referred to as the United States-Israel Tax Treaty, the sale, exchange or other disposition of
shares by a shareholder who (i) is a U.S. resident (for purposes of the treaty); (ii) holds the shares as a capital asset; and (iii) is
entitled to claim the benefits afforded to such person by the treaty, is generally exempt from Israeli capital gains tax. Such exemption
will not apply if, among other things: (i) the capital gain arising from such sale, exchange or other disposition is treated as industrial
or commercial profits attributed to a permanent establishment in Israel, subject to certain conditions; (ii) the shareholder holds, directly
or indirectly, shares representing 10% or more of the voting capital of the corporation during any part of the 12-month period preceding
the disposition, subject to certain conditions; (iii) the capital gain arising from such sale, exchange or disposition is treated as royalties;
or (iv) such U.S. resident is an individual and was present in Israel for 183 days or more during the relevant taxable year. In such case,
the sale, exchange or disposition of our securities would be subject to Israeli tax, to the extent applicable; however, under the United
States-Israel Tax Treaty, the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed
with respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The United
States-Israel Tax Treaty does not relate to U.S. state or local taxes. The United States-Israel Tax Treaty is currently under review and
subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their securities, the payment of the consideration may be subject to the withholding
of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains and to obtain
an exemption from withholding tax certificate from the Israel Tax Authority in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Taxation of Non-Israeli
Shareholders on Receipt of Dividends</i>. Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends
paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country
of residence (subject to the receipt of a valid certificate from the Israeli Tax Authority allowing for a reduced tax rate). With respect
to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or at any time during the preceding 12
months, the applicable withholding tax rate is 30%, unless such &#8220;substantial shareholder&#8221; holds such shares through a nominee
company, in which case the rate is 25%. A &#8220;substantial shareholder&#8221; is generally a person who alone or together with such
person&#8217;s relative (as such term is defined in the Ordinance) or another person who collaborates with such person on a permanent
basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221;
generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or
order someone who holds any of the aforesaid rights how to act, regardless of the source of such right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, a distribution of
dividends to non-Israeli residents is subject to withholding tax at source at a rate of 15% if the dividend is distributed from income
attributed to an Approved Enterprise or a Benefited Enterprise and 20% if the dividend is distributed from income attributed to a Preferred
Enterprise or a Preferred Technological Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. The corporate
income tax claw-back may apply upon any dividend distribution, as long as the company has Trapped Earnings (see discussion above under
&#8220;<i>Tax Benefits under the 2021 Amendment&#8221;</i>). We cannot assure you that in the event we declare a dividend we will designate
the income out of which the dividend is paid in a manner that will reduce shareholders&#8217; tax liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the United States-Israel
Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident
(for purposes of the United States-Israel Tax Treaty) is 25%. With respect to dividends paid to a U.S. corporation that held 10% or more
of the capital of the paying corporation throughout the tax year in which the dividend is distributed and the preceding tax year and provided
that not more than 25% of the gross income of the paying corporation for such prior taxable year (if any) consists of certain interest
or dividends, the maximum rate of tax withheld at source is 12.5%; provided, however, that if the paying corporation is an Approved Enterprise,
the applicable withholding tax rate under such circumstances is reduced to 15% (rather than 12.5%). We believe that the reference in the
United States-Israel Tax Treaty to an Approved Enterprise under the Investment Law is deemed to include also a Benefitted Enterprise Preferred
Enterprise and Preferred Technological Enterprise under the Investment Law. The United States-Israel Tax Treaty is currently under review
and subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. residents who are subject
to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of
the taxes withheld, subject to detailed rules contained in U.S. tax legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercise or Lapse of Series
C Warrant or Series D Warrant. </i>A holder of a Series C Warrant or Series D Warrant generally will not recognize gain or loss upon the
exercise of a Series C Warrant or Series D Warrant for cash. An ordinary share acquired pursuant to the exercise of a Series C Warrant
or Series D Warrant for cash generally will have a tax basis equal to the holder&#8217;s tax basis in the Series C Warrant or Series D
Warrant (as the case may be), increased by the amount paid to exercise the Series C Warrant or Series D Warrant. The holding period of
such ordinary share generally would begin on the day after the date of exercise of the Series C Warrant or Series D Warrant. If a Series
C Warrant or Series D Warrant is allowed to lapse unexercised, the holder generally will recognize a capital loss equal to such holder&#8217;s
tax basis in the Series C Warrant or Series D Warrant (as the case may be).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is possible that a cashless
exercise would be treated as a taxable exchange in which gain or loss is recognized. In such event, a holder could be deemed to have surrendered
a number of Series C Warrants or Series D Warrants with a fair market value equal to the exercise price for the number of Series C Warrants
or Series D deemed exercised. For this purpose, the number of Series C Warrants or Series D Warrants deemed exercised would be equal to
the number of Series C Warrants or Series D Warrants, as applicable, that would entitle the holder to receive upon exercise the number
of ordinary shares issued pursuant to the cashless exercise of the Series C Warrants or Series D Warrants (as the case maybe). In this
situation, the holder would recognize capital gain or loss in an amount equal to the difference between the fair market value of the Series
C Warrants or Series D Warrants deemed surrendered to pay the exercise price and the holder&#8217;s tax basis in the Series C Warrants
or Series D Warrants deemed surrendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Adjustments with Respect
to Warrants. </i>The terms of the Series C Warrant and Series D Warrant provide for an adjustment to the number of ordinary shares for
which the warrant may be exercised or adjustment to the exercise price of the warrant in certain events. An adjustment of the exercise
price or an adjustment that has the effect of preventing dilution generally is not taxable. However, the holders of the Series C Warrants
and Series D Warrants may be treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant
holders&#8217; proportionate interest in our assets or earnings and profits (e.g., through a decrease in the exercise price of the Series
C Warrants or Series D Warrants) as a result of a distribution of cash to the holders of our ordinary shares, which is taxable to the
holders of such ordinary shares as described under &#8220;-Taxation of our Shareholders&#8221; above. Such constructive distribution would
be subject to tax as described under that section in the same manner as if the holders of the Series C Warrants or Series D Warrants received
a cash distribution from us equal to the fair market value of such increased interest. Holders of Series C Warrants and Series D Warrants
are urged to consult their own tax advisors on these issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Surtax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of an applicable tax treaty, individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual
income (including, but not limited to, dividends, interest and capital gain) exceeding NIS 721,560 for 2024, which amount is linked to
the annual change in the Israeli consumer price index.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli law presently does
not impose estate or gift taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">EACH HOLDER OF OUR SECURITIES
IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND
DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY ISRAELI TAX LAWS AND ANY APPLICABLE TAX TREATIES.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If a United States person is treated as
owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a United States person
is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our shares, such person may
be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group
(if any). A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable
income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S.
property by controlled foreign corporations, whether or not we make any distributions, and may be subject to tax reporting obligations.
An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain
tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. A failure to comply
with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations with respect
to your U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we
will assist any shareholder in determining whether such shareholder is treated as a United States shareholder with respect to any &#8220;controlled
foreign corporation&#8221; in our group (if any) or furnish to any United States shareholders information that may be necessary to comply
with the aforementioned reporting and tax paying obligations. A United States investor should consult its tax advisors regarding the potential
application of these rules to its investment in the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. Federal Income Taxation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following are certain
material U.S. federal income tax consequences of the acquisition, ownership and disposition of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The discussion below of the
U.S. federal income tax consequences to &#8220;U.S. Holders&#8221; will apply to a beneficial owner of our securities that is for U.S.
federal income tax purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual citizen or resident of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity treated as a corporation) that is created or organized (or treated as created or organized) in or under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income is includible in gross income for U.S. federal income tax purposes regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust if (i) a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust; or (ii) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A beneficial owner of our
securities that is described above is referred to herein as a &#8220;U.S. Holder.&#8221; If a beneficial owner of our securities is not
described as a U.S. Holder and is not an entity treated as a partnership or other pass-through entity for U.S. federal income tax purposes,
such owner will be considered a &#8220;Non-U.S. Holder.&#8221; Certain material U.S. federal income tax consequences of the acquisition,
ownership and disposition of our securities applicable specifically to Non-U.S. Holders are described below under the heading &#8220;Non-U.S.
Holders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This discussion is based
on the Code, its legislative history, U.S. Treasury regulations promulgated thereunder, the United States-Israel Tax Treaty, or the Treaty,
published rulings and court decisions, all as currently in effect. These authorities are subject to change or differing interpretations,
possibly on a retroactive basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This discussion does not
address all aspects of U.S. federal income taxation that may be relevant to any particular holder based on such holder&#8217;s individual
circumstances. In particular, this discussion considers only holders that own and hold our securities as capital assets within the meaning
of Section 1221 of the Code (generally, property held for investment), and does not address the potential application of the alternative
minimum tax or the U.S. federal income tax consequences to holders that are subject to special rules, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions or financial services entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that are subject to the mark-to-market accounting rules under Section 475 of the Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retirement plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">grantor trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expatriates or former long-term residents of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own 5% or more of our shares (by vote or value);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that acquired our securities pursuant to an exercise of employee options, in connection with employee incentive plans or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other integrated transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons whose functional currency is not the U.S. dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">passive foreign investment companies; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled foreign corporations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This discussion does not
address any aspect of U.S. federal non-income tax laws, such as gift or estate tax laws, or state, local or non-U.S. tax laws or, except
as discussed herein, any tax reporting obligations applicable to a holder of our securities. Additionally, this discussion does not consider
the tax treatment of partnerships or other pass-through entities or persons who hold our securities through such entities. If a partnership
(or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our securities, the U.S.
federal income tax treatment of a partner (or person or entity treated as a partner) in the partnership generally will depend on the status
of the partner and the activities of the partnership. This discussion also assumes that any distribution made (or deemed made) to a holder
in respect of our securities and any consideration received (or deemed received) by a holder in connection with the sale or other disposition
of our securities will be in U.S. dollars. In addition, as described in &#8220;Risk Factors - Risks Related to Taxation&#8221;, there
is a risk that we could be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the Reorganization;
this discussion also assumes that we will be and have been treated as a foreign corporation for U.S. federal income tax purposes. Moreover,
this discussion assumes that a holder owns a sufficient number of Series C Warrants and/or Series D Warrants, such that the holder will
not have a fractional warrant upon the exercise of a Series C Warrant and/or, Series D Warrant, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not sought, and will
not seek, a ruling from the IRS or an opinion of counsel as to any U.S. federal income tax consequence described herein. The IRS may disagree
with the description herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation,
regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">EACH HOLDER OF OUR SECURITIES
IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND
DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL
TAX LAWS AND ANY APPLICABLE TAX TREATIES.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation of Cash Distributions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As noted above, we currently
do not intend to pay cash dividends on our ordinary shares in the foreseeable future. Subject to the passive foreign investment company,
or PFIC, rules discussed below, a U.S. Holder generally will be required to include in gross income as ordinary income the amount of any
cash dividend paid in respect of our ordinary shares. A cash distribution on our ordinary shares generally will be treated as a dividend
for U.S. federal income tax purposes to the extent the distribution is paid out of our current or accumulated earnings and profits (as
determined for U.S. federal income tax purposes). Such dividend generally will not be eligible for the dividends-received deduction generally
allowed to U.S. corporations in respect of dividends received from other U.S. corporations. The portion of such cash distribution, if
any, in excess of such earnings and profits will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax
basis in the ordinary shares. Any remaining excess generally will be treated as gain from the sale or other taxable disposition of such
ordinary shares. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder
should expect that a distribution will be reported as a dividend even if that distribution would otherwise be treated as a non-taxable
return of capital or as capital gain under the rules described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With respect to non-corporate
U.S. Holders, any such cash dividends may be subject to U.S. federal income tax at the lower applicable regular long term capital gains
tax rate (see &#8220;- Taxation on the Disposition of Ordinary Shares or Series C Warrants or Series D Warrants&#8221; below) provided
that (a) our ordinary shares are readily tradable on an established securities market in the United States or we are eligible for the
benefits of the Treaty, (b) we are not a PFIC, as discussed below, for either the taxable year in which the dividend was paid or the preceding
taxable year, and (c) certain holding period requirements are met. Therefore, if our ordinary shares are not readily tradable on an established
securities market, and we are not eligible for the benefits of the Treaty, then cash dividends paid by us to non-corporate U.S. Holders
will not be subject to U.S. federal income tax at the lower regular long term capital gains tax rate. Under published IRS authority, shares
are considered for purposes of clause (a) above to be readily tradable on an established securities market in the United States only if
they are listed on certain exchanges, which presently include the Nasdaq Capital Market. Although our ordinary shares are currently listed
and traded on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax advisors regarding the availability of
the lower rate for any cash dividends paid with respect to our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends paid to a U.S.
Holder with respect to our ordinary shares generally will be foreign source income, which may be relevant in calculating such U.S. Holder&#8217;s
foreign tax credit limitations. Subject to certain conditions and limitations, non-refundable Israeli tax withheld on dividends may be
deducted from such U.S. Holder&#8217;s taxable income or credited against such U.S. Holder&#8217;s U.S. federal income tax liability.
The election to deduct, rather than credit, foreign taxes, is made on a year-by-year basis and applies to all foreign taxes paid by a
U.S. Holder or withheld from a U.S. Holder that year. The limitation on foreign taxes eligible for credit is calculated separately with
respect to specific classes of income. For this purpose, dividends that we distribute generally should constitute &#8220;passive category
income,&#8221; or, in the case of certain U.S. Holders, &#8220;general category income.&#8221; A foreign tax credit for foreign taxes
imposed on distributions may be denied if a U.S. Holder does not satisfy certain minimum holding period requirements. In addition, U.S.
Treasury regulations that apply to taxable years beginning on or after December&#160;28, 2021 may preclude a U.S. Holder from claiming
a foreign tax credit with respect to Israeli taxes on gain from dispositions of ordinary shares unless the U.S. Holder is eligible for
benefits under the Treaty and elects its application and other applicable requirements are satisfied. However, a recent notice from the
IRS indicates that the U.S. Department of the Treasury and the IRS are considering proposing amendments to such U.S. Treasury regulations
and allows, subject to certain conditions, taxpayers to defer the application of many aspects of such U.S. Treasury regulations for taxable
years beginning on or after December&#160;28, 2021 and ending before the date that a notice or other guidance withdrawing or modifying
the temporary relief is issued (or any later date specified in such notice or other guidance). The rules relating to the determination
of the foreign tax credit are complex, and U.S. Holders should consult their tax advisors to determine whether and to what extent they
will be entitled to this credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Adjustments with Respect to Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The terms of each Series
C Warrant and Series D Warrant provide for an adjustment to the number of ordinary shares for which the warrant may be exercised or to
the exercise price of the warrant in certain events. An adjustment that has the effect of preventing dilution generally is not taxable.
However, the U.S. Holders of the Series C Warrants and Series D Warrants would be treated as receiving a constructive distribution from
us if, for example, the adjustment increases the warrant holders&#8217; proportionate interest in our assets or earnings and profits (e.g.,
through a decrease in the exercise price of the Series C Warrants or Series D Warrants) as a result of a distribution of cash to the holders
of our ordinary shares, which is taxable to the U.S. Holders of such ordinary shares as described under &#8220;- Taxation of Cash Distributions,&#8221;
above. Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders
of the Series C Warrants and Series D Warrants received a cash distribution from us equal to the fair market value of such increased interest.
U.S. Holders of Series C Warrants and Series D Warrants are urged to consult their own tax advisors on these issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation on the Disposition of Ordinary Shares
or Series C Warrants or Series D Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon a sale or other taxable
disposition of our ordinary shares or the Series C Warrants or Series D Warrants, and subject to the PFIC rules discussed below, a U.S.
Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s
adjusted tax basis in the securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The regular U.S. federal
income tax rate on capital gains recognized by U.S. Holders generally is the same as the regular U.S. federal income tax rate on ordinary
income, except that long term capital gains recognized by non-corporate U.S. Holders generally are subject to U.S. federal income tax
at a maximum regular rate of 20%. Capital gain or loss will constitute long term capital gain or loss if the U.S. Holder&#8217;s holding
period for the securities exceeds one year. The deductibility of capital losses is subject to various limitations. Any such gain or loss
that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As discussed in &#8220;Israel
Tax Consideration and Government Programs &#8722; Taxation of our Shareholders&#8221; above. an Israeli capital gains tax may apply to
any gains from the disposition of our ordinary shares or the Series C Warrants or Series D Warrants by a U.S. Holder. If such Israeli
tax applies to any such gain, Treasury regulations that apply to taxable years beginning on or after December&#160;28, 2021 may preclude
a U.S. Holder from claiming a foreign tax credit for such tax unless the U.S. holder is eligible for benefits under the Treaty, if such
holder is considered a resident of the United States for purposes of the Treaty, and otherwise meets the requirements for claiming benefits
under the Treaty. However, a recent notice from the IRS indicates that the U.S. Department of the Treasury and the IRS are considering
proposing amendments to such Treasury regulations and allows, subject to certain conditions, taxpayers to defer the application of many
aspects of such Treasury regulations for taxable years beginning on or after December&#160;28, 2021 and ending before the date that a
notice or other guidance withdrawing or modifying the temporary relief is issued (or any later date specified in such notice or other
guidance). In lieu of claiming a credit, a U.S. Holder may be able to elect to deduct the Israeli taxes in computing taxable income, subject
to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid
or accrued in the relevant taxable year. U.S. Holders should consult their own tax advisors regarding the deduction or credit for any
such Israeli tax and their eligibility for the benefits of the Treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Taxes</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. Holders that are individuals,
estates or trusts and whose income exceeds certain thresholds generally may be subject to a 3.8% Medicare contribution tax on unearned
income, including, without limitation, dividends on, and gains from the sale or other taxable disposition of, our ordinary shares or the
Series C Warrants or Series D Warrants, subject to certain limitations and exceptions. U.S. Holders should consult their own tax advisors
regarding the effect, if any, of such tax on their ownership and disposition of our ordinary shares or the Series C Warrants or Series
D Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercise or Lapse of a Series C Warrant or
Series D Warrant</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the PFIC rules
discussed below, a U.S. Holder generally will not recognize gain or loss upon the exercise of a Series C Warrant or Series D Warrant for
cash. An ordinary share acquired pursuant to the exercise of a Series C Warrant or Series D Warrant for cash generally will have a tax
basis equal to the U.S. Holder&#8217;s tax basis in the Series C Warrant or Series D Warrant, as applicable, increased by the amount paid
to exercise the Series C Warrant or Series D Warrant. The holding period of such ordinary share generally would begin on the day after
the date of exercise of the Series C Warrant or Series D Warrant. If a Series C Warrant or Series D Warrant is allowed to lapse unexercised,
a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the Series C Warrant or Series D Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The tax consequences of a
cashless exercise of Series C Warrants and Series D Warrants are not clear under current tax law. A cashless exercise may be tax-free,
either because it is not a realization event (i.e., not a transaction in which gain or loss is realized) or because the transaction is
treated as a recapitalization for U.S. federal income tax purposes. In either tax-free situation, a U.S. Holder&#8217;s tax basis in the
ordinary shares received would equal the U.S. Holder&#8217;s basis in the Series C Warrants or Series D Warrants surrendered. If the cashless
exercise were treated as not being a realization event, the U.S. Holder&#8217;s holding period in the ordinary shares could be treated
as commencing on the date following the date of exercise of the Series C Warrants or Series D Warrants. If the cashless exercise were
treated as a recapitalization, the holding period of the ordinary shares received would include the holding period of the Series C Warrants
or Series D Warrants, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is also possible that
a cashless exercise could be treated as a taxable exchange in which gain or loss is recognized. In such event, a U.S. Holder could be
deemed to have surrendered a number of Series C Warrants or Series D Warrants, as applicable, with a fair market value equal to the exercise
price for the number of Series C Warrants or Series D Warrants deemed exercised. For this purpose, the number of Series C Warrants or
Series D Warrants deemed exercised would be equal to the amount needed to receive on exercise the number of ordinary shares issued pursuant
to the cashless exercise of the Series C Warrants or Series D Warrants. In this situation, the U.S. Holder would recognize capital gain
or loss in an amount equal to the difference between the fair market value of the Series C Warrants or Series D Warrants deemed surrendered
to pay the exercise price and the U.S. Holder&#8217;s tax basis in such Series C Warrants or Series D Warrants deemed surrendered. Such
gain or loss would be long-term or short-term depending on the U.S. Holder&#8217;s holding period in the Series C Warrants or Series D
Warrants, as applicable. In this case, a U.S. Holder&#8217;s tax basis in the ordinary shares received would equal the sum of the fair
market value of the Series C Warrants or Series D Warrants deemed surrendered to pay the exercise price and the U.S. Holder&#8217;s tax
basis in the Series C Warrants or Series D Warrants deemed exercised, and a U.S. Holder&#8217;s holding period for the ordinary shares
should commence on the date following the date of exercise of the Series C Warrants or Series D Warrants. There also may be alternative
characterizations of any such taxable exchange that would result in similar tax consequences, except that a U.S. Holder&#8217;s gain or
loss would be short-term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to the absence of authority
on the U.S. federal income tax treatment of a cashless exercise of Series C Warrants and Series D Warrants, it is unclear which, if any,
of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S.
Holders should consult their tax advisors regarding the tax consequences of a cashless exercise of Series C Warrants and Series D Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Passive Foreign Investment Company Rules</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A foreign (i.e., non-U.S.)
corporation will be a PFIC if either (a) at least 75% of its gross income in a taxable year of the foreign corporation, including its
pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the corporation by value, is passive
income, or (b) at least 50% of the average value of its assets in a taxable year of the foreign corporation, including its pro rata share
of the assets of any corporation in which it is considered to own at least 25% of the corporation by value, are held for the production
of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than certain rents or
royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that we were a
PFIC for the taxable year ended December&#160;31, 2025 and may be a PFIC for the taxable year ending December&#160;31, 2026. Our PFIC
status for our current taxable year or any subsequent taxable year is uncertain and will not be determinable until after the end of such
taxable year. Accordingly, there can be no assurance with respect to our status as a PFIC for our taxable year ending December&#160;31,
2026 or any subsequent taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are determined to be
a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of our ordinary shares or Series
C Warrants or Series D Warrants, and, in the case of our ordinary shares, the U.S. Holder did not make a timely qualified electing fund
or a QEF, election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) the ordinary shares, a purging
election, a QEF election along with a purging election, or a mark-to-market election, each as described below, such holder generally will
be subject to special rules for regular U.S. federal income tax purposes with respect to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares or Series C Warrants or Series D Warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder&#8217;s holding period for the ordinary shares).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under these rules,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. Holder&#8217;s gain or excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period for the ordinary shares or Series C Warrants or Series D Warrants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution or to the period in the U.S. Holder&#8217;s holding period before the first day of our first taxable year in which we qualified as a PFIC will be taxed as ordinary income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest ordinary tax rate in effect for that year and applicable to the U.S. Holder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such other taxable year of the U.S. Holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although a determination
as to our PFIC status is made annually, an initial determination that we are a PFIC generally will apply for subsequent years to a U.S.
Holder that held (or was deemed to hold) our ordinary shares or Series C Warrants or Series D Warrants while we were a PFIC, whether or
not we meet the test for PFIC status in those subsequent years. If we are determined to be a PFIC in any taxable year, and then cease
to meet the test for PFIC status in a subsequent taxable year, a U.S. Holder may be able to make a purging election to eliminate this
continuing PFIC status with respect to its ordinary shares in certain circumstances. A purging election generally creates a deemed sale
of such ordinary shares at their fair market value on the last day of our tax year during which we qualified as a PFIC (or, in the case
of a purging election made in connection with a QEF election, the first day of our taxable year in which qualify as a QEF with respect
to such U.S. Holder). Any gain recognized by the purging election generally will be treated as an excess distribution subject to the special
tax and interest charge rules described above. As a result of the purging election, the U.S. Holder generally will increase the adjusted
basis in its ordinary shares by the amount of gain recognized and will also have a new holding period in its ordinary shares for purposes
of the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, if we are determined
to be a PFIC, a U.S. Holder may avoid the PFIC tax consequences described above with respect to the ordinary shares by making a timely
QEF election (or a QEF election along with a purging election). Pursuant to the QEF election, a U.S. Holder generally will be required
to include in income its pro rata share of our net capital gains (as long term capital gain) and other earnings and profits (as ordinary
income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in which or with which our
taxable year ends if we are treated as a PFIC for that taxable year. However, a U.S. Holder may make a QEF election only if we agree to
provide certain tax information to such holder annually. At this time, we do not intend to provide U.S. Holders with such information
as may be required to make a QEF election effective. In any event, a QEF election may not be made with respect to warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alternatively, if a U.S.
Holder, at the close of its taxable year, owns ordinary shares in a PFIC that are treated as marketable stock, the U.S. Holder may make
a mark-to-market election with respect to such ordinary shares for such taxable year. If the U.S. Holder makes a valid mark-to-market
election for the first taxable year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) the ordinary shares and for
which we are determined to be a PFIC, such holder generally will not be subject to the PFIC rules described above with respect to its
ordinary shares as long as such shares continue to be treated as marketable stock. Instead, in general, the U.S. Holder will include as
ordinary income for each year that we are treated as a PFIC the excess, if any, of the fair market value of its ordinary shares at the
end of its taxable year over the adjusted tax basis in its ordinary shares. The U.S. Holder also will be allowed to take an ordinary loss
in respect of the excess, if any, of the adjusted tax basis of its ordinary shares over the fair market value of its ordinary shares at
the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market
election). The U.S. Holder&#8217;s adjusted tax basis in its ordinary shares will be adjusted to reflect any such income or loss amounts,
and any further gain recognized on a sale or other taxable disposition of the ordinary shares in a taxable year in which we are treated
as a PFIC generally will be treated as ordinary income. Special tax rules may also apply if a U.S. Holder makes a mark-to-market election
for a taxable year after the first taxable year in which the U.S. Holder holds (or is deemed to hold) our ordinary shares and for which
we are determined to be a PFIC. Currently, a mark-to-market election may not be made with respect to warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The mark-to-market election
is available only for stock that is regularly traded on a national securities exchange that is registered with the U.S. Securities and
Exchange Commission, including the Nasdaq Capital Market, or on a foreign exchange or market that is regulated or supervised by a governmental
authority of the country in which the exchange or market is located and which (A) meets certain requirements, that are enforced by law,
relating to trading volume, listing, financial disclosure, surveillance and other requirements that are designed to (i) prevent fraudulent
and manipulative acts and practices, (ii) remove impediments to and perfect the mechanism of a free and open, fair and orderly market
and (iii) protect investors and (B) has rules that effectively promote the active trading of listed stock. Although our ordinary shares
are currently listed and traded on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax advisors regarding
the availability and tax consequences of a mark-to-market election with respect to our ordinary shares under their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are a PFIC and, at
any time, have a foreign subsidiary that is classified as a PFIC, a U.S. Holder of our ordinary shares generally should be deemed to own
a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described
above if we receive a distribution from, or dispose of all or part of our interest in, or the U.S. Holder were otherwise deemed to have
disposed of an interest in, the lower-tier PFIC. A mark-to-market election generally would not be available with respect to such a lower-tier
PFIC. U.S. Holders are urged to consult their own tax advisors regarding the tax issues raised by lower-tier PFICs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A U.S. Holder that owns (or
is deemed to own) ordinary shares in a PFIC during any taxable year of the U.S. Holder generally is required to file an IRS Form 8621
(whether or not a mark-to-market election is or has been made) with such U.S. Holder&#8217;s U.S. federal income tax return and provide
such other information as may be required by the U.S. Treasury Department. Failure to file IRS Form 8621 for each applicable taxable year
may result in substantial penalties and the statute of limitations on the assessment and collection of U.S. federal income taxes of such
U.S. Holder for the related taxable year may not close until three years after the date on which the required information is filed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rules dealing with PFICs
and purging and mark-to-market elections are very complex and are affected by various factors in addition to those described above. Accordingly,
U.S. Holders of our securities should consult their own tax advisors concerning the application of the PFIC rules to our securities under
their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-U.S. Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cash dividends paid or deemed
paid to a Non-U.S. Holder with respect to our ordinary shares generally will not be subject to U.S. federal income tax unless such dividends
are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by
an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains or maintained
in the United States).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a Non-U.S. Holder
generally will not be subject to U.S. federal income tax on any gain attributable to a sale or other taxable disposition of our securities
unless such gain is effectively connected with its conduct of a trade or business in the United States (and, if required by an applicable
income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains or maintained in the United States)
or the Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of such sale or other
disposition and certain other conditions are met (in which case, such gain from U.S. sources generally is subject to U.S. federal income
tax at a 30% rate or a lower applicable tax treaty rate).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends and gains that
are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business in the United States (and, if required by an
applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains or maintained in
the United States) generally will be subject to regular U.S. federal income tax at the same regular U.S. federal income tax rates as applicable
to a comparable U.S. Holder and, in the case of a Non-U.S. Holder that is a corporation for U.S. federal income tax purposes, may also
be subject to an additional branch profits tax at a 30% rate or a lower applicable tax treaty rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Backup Withholding and Information Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, information reporting
for U.S. federal income tax purposes should apply to distributions made on our securities within the United States to a U.S. Holder (other
than an exempt recipient) and to the proceeds from sales and other dispositions of our securities by a U.S. Holder (other than an exempt
recipient) to or through a U.S. office of a broker. Payments made (and sales and other dispositions effected at an office) outside the
United States will be subject to information reporting in limited circumstances. In addition, certain information concerning a U.S. Holder&#8217;s
adjusted tax basis in its securities and adjustments to that tax basis and whether any gain or loss with respect to such securities is
long term or short term also may be required to be reported to the IRS, and certain holders may be required to file an IRS Form 8938 (Statement
of Specified Foreign Financial Assets) to report their interest in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, backup withholding
of U.S. federal income tax, currently at a rate of 24%, generally will apply to dividends paid on our securities to a U.S. Holder (other
than an exempt recipient) and the proceeds from sales and other dispositions of our securities by a U.S. Holder (other than an exempt
recipient), in each case who:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fails to provide an accurate taxpayer identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is notified by the IRS that backup withholding is required; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in certain circumstances, fails to comply with applicable certification requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A Non-U.S. Holder generally
may eliminate the requirement for information reporting and backup withholding by providing certification of its foreign status, under
penalties of perjury, on a duly executed applicable IRS Form W-8 or by otherwise establishing an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Backup withholding is not
an additional tax. Rather, the amount of any backup withholding will be allowed as a credit against a U.S. Holder&#8217;s or a Non-U.S.
Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that certain required information is
timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Holders are urged to consult
their own tax advisors regarding information reporting, the application of backup withholding, and the availability of and procedures
for obtaining an exemption from backup withholding in their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>THE DISCUSSION ABOVE IS
A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS
URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES,
SERIES C WARRANTS OR SERIES D WARRANTS, IN EACH CASE IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES, INCLUDING THE CONSEQUENCES OF
ANY PROPOSED CHANGE IN APPLICABLE LAWS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><div><a id="a_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Dividends and paying agents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Statement by experts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>H. Documents on display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the informational
requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K. As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the
rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the short swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange
Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements
and other information regarding registrants like us that file electronically with the SEC. You can also inspect this Annual Report on
such website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A copy of each document (or
a translation thereof to the extent not in English) concerning our company that is referred to in this Annual Report is available for
public view (subject to confidential treatment of certain agreements pursuant to applicable law) at our principal executive offices at
Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_054"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. Subsidiary Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>J. Annual Report to Security Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
11. Quantitative and Qualitative Disclosure About Market Risk</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Exchange Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some of our assets and liabilities
are affected by fluctuations in the exchange rate between the U.S. dollar and the NIS and between the U.S. dollar and the Euro. For example,
salaries and related expenses for Israeli employees are paid in NIS and some of our suppliers are located in Europe and require payment
in Euros.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December&#160;31,
2025, the exchange rate between the U.S. dollar and the NIS decreased by 12.5% and the exchange rate between the U.S. dollar and the Euro
decreased by 2.5%. During the year ended December&#160;31, 2024, the exchange rate between the U.S. dollar and the NIS increased by 1.09%
and the exchange rate between the U.S. dollar and the Euro increased by 5.25%. During the year ended December&#160;31, 2023, the exchange
rate between the U.S. dollar and the NIS increased by 3.07% and the exchange rate between the U.S. dollar and the Euro decreased by 4.26%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary objective of
our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing
risk. Currently, we have short-term bank deposits, which are held primarily in interest-bearing accounts..</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we invest and
intend to invest our cash balances, including certain of the net proceeds from our financings pending their ultimate use, primarily in
bank deposits, and fixed-income securities issued by corporations and securities issued by the U.S. and Israeli governments. We are exposed
to market risks resulting from changes in interest rates relating primarily to our financial investments in cash and deposits. We do not
use derivative financial instruments to limit exposure to interest rate risk. Our interest rates may decline in the future as a result
of changes in the financial markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
12. Description of Securities Other Than Equity Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span>&#160;</p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Part
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
13. Defaults, Dividend Arrearages and Delinquencies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
14. Material Modifications to The Rights of Security Holders and Use of Proceeds</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
15. Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>(a) <span style="text-transform: uppercase"><i>Disclosure
Controls and Procedures</i></span></b><i>. </i>Our management, including our Interim Chief Executive Officer and Chief Financial Officer
have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of
the Exchange Act) as of the end of the period covered by this Annual Report, or the Evaluation Date. Based on such evaluation, the Interim
Chief Executive Officer and the Chief Financial Officer have concluded that, as of the Evaluation Date, the company&#8217;s disclosure
controls and procedures are effective<span style="text-transform: uppercase">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>(b) <span style="text-transform: uppercase"><i>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</i>. </span></b><span style="text-transform: uppercase">O</span>ur management
is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a<span style="text-transform: uppercase">-</span>15(f)
and 15d<span style="text-transform: uppercase">-</span>15(f) of the Exchange Act<span style="text-transform: uppercase">. O</span>ur management
including our Interim Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal
control over financial reporting based on the framework and criteria established in internal Control<span style="text-transform: uppercase">-I</span>ntegrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as of the Evaluation Date<span style="text-transform: uppercase">.
B</span>ased on that evaluation, our management has concluded that our internal control over financial reporting was effective as of the
Evaluation Date<span style="text-transform: uppercase">. A</span>s all internal control systems, no matter how well designed, have inherent
limitations, our internal control over financial reporting may not prevent or detect misstatements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>(c) <span style="text-transform: uppercase"><i>Attestation
Report of Registered Public Accounting Firm</i></span></b><span style="text-transform: uppercase">. N</span>ot applicable (we are exempt
from this requirement due to our status under the Exchange Act as a non<span style="text-transform: uppercase">-</span>accelerated filer
as of the current time).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>(d) <span style="text-transform: uppercase"><i>Changes
in Internal Control Over Financial Reporting. </i></span></b><span style="text-transform: uppercase">B</span>ased on the evaluation conducted
by our Interim Chief Executive Officer and our Chief Financial Officer pursuant to Rules 13a<span style="text-transform: uppercase">-</span>15(d)
and 15d<span style="text-transform: uppercase">-</span>15(d) under the Exchange Act, our management has concluded that there was no change
in our internal control over financial reporting that occurred during the year ended December&#160;31, 2025 that materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16. [Reserved]</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16A. Audit Committee Financial Expert.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board of Directors has
determined that Michael Hutton, a member of our audit committee is an audit committee financial expert as defined by rules of the U.S.
Securities and Exchange Commission and is an independent director under Nasdaq Listing Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16B. Code of Ethics.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have adopted a Code of
Business Conduct and Ethics that applies to all of our directors and employees, including our interim Chief Executive Officer, Chief Financial
Officer, controller or principal accounting officer, or other persons performing similar functions, which complies with the &#8220;code
of ethics&#8221; contemplated by Item 16B of Form 20-F promulgated by the U.S. Securities and Exchange Commission. A copy of our Code
of Business Conduct and Ethics is available on our website at http://ir.check-cap.com/corporate-governance. Information contained on,
or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein.
If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision
of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and
regulations of the U.S. Securities and Exchange Commission. Under Item 16B of the U.S. Securities and Exchange Commission&#8217;s Form
20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial
officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form
20-F, we will disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16C. Principal Accountant Fees and Services.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 15, 2024, we received a notice of resignation from Brightman
Almagor Zohar &amp; Co., a firm in the Deloitte global network (&#8220;Brightman&#8221;), as our independent registered public accounting
firm. At the extraordinary general meeting of shareholders held on April 25, 2024, our shareholders appointed Fahn Kanne &amp; Co. as
our independent auditor for the year ended December 31, 2023, and until the close of the following year&#8217;s annual general meeting.
On April 6, 2025, we appointed RBSM LLP to replace Fahn Kanne &amp; Co. as our independent registered public accounting firm for the year
ended December 31, 2024. On December 19, 2025, we appointed BCRG Group as our independent registered public accounting firm for the year
ended December 31, 2025. We intend to ratify such appointment at our next annual general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table represents aggregate fees billed to us for professional
services rendered for the fiscal years ended December 31, 2025, 2024, and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Fahn Kanne &amp; Co.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit Fees (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">300,715</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Tax Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,943</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other Fees (3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 0.25in">Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">330,177</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">RBSM LLP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit Fees (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Tax Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other Fees (3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 0.25in">Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">150,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">&#8212;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">BCRG Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit Fees (1)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Tax Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other Fees (3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 0.25in">Subtotal</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">30,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">30,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">30,000</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">30,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">180,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">360,177</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">Audit fees represent fees for professional services rendered for the audit or re-audit of our consolidated financial statements, consents,
and in connection with certain of our filings with the U.S. Securities and Exchange Commission. BCRG Group was appointed on December 19,
2025 as our independent registered public accounting firm for the year ended December 31, 2025, and subsequently re-audited and issued
superseding unqualified opinions on our consolidated financial statements for the years ended December 31, 2024 and December 31, 2023.
BCRG Group fees attributed to 2024 and 2023 reflect re-audit services performed during 2025. RBSM LLP fees reflect their original audit
of fiscal year 2024. Fahn Kanne &amp; Co. fees reflect their original audit of fiscal year 2023.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">Tax fees for the year ended December 31, 2023 were for services rendered by Fahn Kanne &amp; Co. in connection with a tax audit and
tax study. No tax fees were incurred for the years ended December 31, 2025 and 2024.</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0in"/><td style="text-align: justify; width: 0.25in">(3)</td><td style="text-align: justify">Other fees for the year ended December 31, 2023 were for services rendered by Fahn Kanne &amp; Co. in connection with a benchmark
study. No other fees were incurred for the years ended December 31, 2025 and 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Audit Committee Pre-approval Policies and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee has adopted a pre-approval policy for the engagement
of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to this policy, which is
designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog
of specific audit and non-audit services in the categories of audit services, audit-related services and tax services that may be performed
by our independent registered public accounting firm. If a type of service, that is to be provided by our auditors, has not received such
general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent
registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee pre-approved all audit and non-audit services provided
to us during the periods listed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16D. Exemptions From The Listing Standards for Audit Committees.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16E. Purchases of Equity Securities By The Issuer and Affiliated Purchasers.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 16F. Change in Registrant&#8217;s
Certifying Accountant.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 19, 2025, the
Audit Committee of the Board of Directors (the "Audit Committee") approved the dismissal of RBSM LLP ("RBSM") as the
Company's independent registered public accounting firm, and the appointment of BCRG Group ("BCRG") as the Company's new independent
registered public accounting firm, effective as of such date. BCRG was engaged to review the Company's interim financial statements for
the six-month period ended June 30, 2025 and to serve as the Company's independent registered public accounting firm for all audit and
review services for subsequent periods. BCRG also re-audited the Company's consolidated financial statements for the years ended December
31, 2024 and December 31, 2023, issuing superseding unqualified opinions for both years. The re-audit was undertaken to enable BCRG to
serve as the Company's sole independent registered public accounting firm of record for current and prior periods, including for purposes
of providing opinions and consents in the Company's anticipated registration statements and other securities filings. The re-audit did
not result in any restatement, revision, or other change to the Company's previously issued consolidated financial statements for the
years ended December 31, 2024 or December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Audit Committee's decision
to dismiss RBSM was not the result of any disagreements with RBSM on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure. The audit report of RBSM on the Company's consolidated financial statements as of and for
the year ended December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to
uncertainty, audit scope, or accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the years ended December
31, 2024 and December 31, 2023 and the subsequent interim period through December 19, 2025, there were: (i) no disagreements with RBSM
on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which if not resolved
to RBSM's satisfaction would have caused it to make reference thereto in connection with its reports on the Company's financial statements;
and (ii) no reportable events of the type described in Item 16F(a)(1)(v) of Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the years ended December
31, 2024 and December 31, 2023 and the subsequent interim period prior to engaging BCRG, neither the Company nor anyone acting on its
behalf consulted with BCRG with respect to (i) the application of accounting principles to a specified transaction, either completed or
proposed, or the type of audit opinion that might be rendered with respect to the Company's consolidated financial statements, and no
written report or oral advice was provided to the Company that BCRG concluded was an important factor considered by the Company in reaching
a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of any disagreement of
the type described in Item 16F(a)(1)(iv) of Form 20-F or a reportable event of the type described in Item 16F(a)(1)(v) of Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The change from Grant Thornton
(the Company's predecessor auditor for the year ended December 31, 2023) to RBSM was previously reported (as that term is defined in
Exchange Act Rule 12b-2) under Item 16F of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and, accordingly,
is not repeated herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company provided
RBSM with a copy of the disclosures above on April 17, 2026 and requested that RBSM furnish the Company with a letter addressed to
the Securities and Exchange Commission stating whether it agrees with the statements made by the Company herein in response to Item
16F(a) of Form 20-F and, if not, stating the respects in which it does not agree. A copy of such letter, dated April 22, 2026, is
filed as Exhibit 15.6 to this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The re-audit was undertaken to enable BCRG to
serve as the Company's sole independent registered public accounting firm of record for current and prior periods, including for purposes
of providing opinions and consents in the Company's anticipated registration statements and other securities filings. The re-audit did
not result in any restatement, revision, or other change to the Company's previously issued consolidated financial statements for the
years ended December 31, 2024 or December 31, 2023.<span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16G. Corporate Governance.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Israeli Companies
Law, companies incorporated under the laws of the State of Israel whose shares are publicly traded, including companies with shares listed
on the Nasdaq Capital Market, are considered public companies under Israeli law and are required to comply with various corporate governance
requirements relating to such matters as external directors, the audit committee, the compensation committee and an internal auditor.
These requirements are in addition to the corporate governance requirements imposed by the Listing Rules of the Nasdaq Stock Market and
other applicable provisions of U.S. securities laws to which we became subject (as a foreign private issuer) upon the closing of our initial
public offering and the listing of our securities on the Nasdaq Capital Market. Under the Listing Rules of the Nasdaq Stock Market, a
foreign private issuer, such as us, may generally follow its home country rules of corporate governance in lieu of the comparable requirements
of the Listing Rules of the Nasdaq Stock Market, except for certain matters including (among others) the composition and responsibilities
of the audit committee and the independence of its members within the meaning of the rules and regulations of the U.S. Securities and
Exchange Commission. We currently rely on this &#8220;home country practice exemption&#8221; solely with respect to the following items:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination of our directors</i>. Israeli law and our amended articles of association do not require director nominations to be made by a nominating committee of our Board of Directors consisting solely of independent directors, as required under the Listing Rules of the Nasdaq Stock Market. Our Board of Directors elected to rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules and follow Israeli law and practice with regard to the process of nominating directors, in accordance with which directors are recommended by the board of directors for election by the shareholders (other than directors elected by the board of directors to fill a vacancy). Our Board of Directors established a Nominating Committee, whose role is to select and recommend to the Board of Directors for selection, director nominees, while considering the appropriate size and composition of the Board of Directors, the requirements of applicable law regarding service as a member of our Board of Directors and the criteria for the selection of new members of the Board of Directors, and determined that our Nominating Committee need not be composed solely of independent directors (within the meaning of Nasdaq Listing Rules). However, our Nominating Committee currently consists solely of independent directors (within the meaning of Nasdaq Listing Rules).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation of officers</i>. We follow Israeli law and practice with respect to the approval of officer compensation. While our compensation committee currently complies with the provisions of the Nasdaq Listing Rules relating to composition requirements and Israeli law generally requires that the compensation of the chief executive officer and all other executive officers be approved, or recommended to the board for approval, by the compensation committee (and in certain instances, shareholder approval is required), Israeli law includes relief from compensation committee approval in certain instances. For details regarding the approvals required under the Israeli Companies Law and regulation promulgated thereunder for the approval of compensation of the chief executive officer, all other executive officers and directors, see Item 6C &#8220;Directors, Senior Management and Employees- Board Practices - Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions&#8221;.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval. </i>We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Israeli Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq Listing Rule 5635. In particular, under the Nasdaq Listing Rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest (or such persons collectively have a 10% or greater interest) in the target company or the assets to be acquired or the consideration to be received and the present or potential issuance of ordinary shares, or securities convertible into or exercisable for ordinary shares, could result in an increase in outstanding common shares or voting power of 5% or more; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of a stock option or purchase plan or other equity compensation arrangements, pursuant to which stock may be acquired by officers, directors, employees or consultants (with certain limited exception); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. We will seek shareholder approval for all actions requiring such under the Israeli Companies Law. Under the Israeli Companies Law, the adoption of, and material changes to, equity-based compensation plans generally require the approval of the board of directors. For details regarding the approvals required under the Israeli Companies Law for the approval of compensation of the chief executive officer, all other executive officers and directors, see Item 6C &#8220;Directors, Senior Management and Employees - Board Practices -Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#8221; For details regarding the approvals required under the Israeli Companies Law for the approval of transactions with and compensation of controlling shareholders, see Item 6C &#8220;Directors, Senior Management and Employees - Board Practices - Approval of Related Party Transactions under Israeli Law - Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions.&#8221; For details regarding the approvals required under the Israeli Companies Law for certain acquisitions of our shares and mergers, see Exhibit 2.1. &#8220;Description of Securities - Acquisitions under Israeli Law.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum requirement. </i>Under our amended and restated articles of association and as permitted under the Israeli Companies Law, a quorum for any meeting of shareholders shall be the presence of at least two shareholders present in person, by proxy or by a written ballot, who hold at least 25% of the voting power of our shares (or if a higher percentage is required by law, such higher percentage) instead of 33 1/3% of the issued share capital required under the Nasdaq Listing Rules. If the meeting was adjourned for lack of a quorum, at the adjourned meeting, at least two shareholders present in person or by proxy shall constitute a quorum, unless the meeting of shareholders was convened at the demand of shareholders, in which case, the quorum shall be the presence of one or more shareholders holding at least 5% of our issued share capital and at least one percent of the voting power of our shares, or one or more shareholders with at least 5% of the voting power of our shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as stated above, we
currently intend to comply with the rules generally applicable to U.S. domestic companies listed on Nasdaq. We may in the future decide
to use the foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. Following our
home country governance practices, as opposed to the requirements that would otherwise apply to a company listed on Nasdaq, may provide
less protection than is accorded to investors under Nasdaq listing requirements applicable to domestic issuers. For more information,
see Item 3D &#8220;Key Information - Risk Factors Risks Related to the Company&#8221;- As a foreign private issuer, we are permitted,
and intend, to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which may
result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16H. Mine Safety Disclosure.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16I. Disclosure Regarding Foreign Jurisdictions
That Prevent Inspections.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16J. Insider Trading Policies.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-19812">adopted</ix:nonNumeric> insider trading
policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, executive officers, and employees.
They are designed to promote compliance with applicable insider trading laws, rules and regulations. A copy of our insider trading policies
and procedures is filed as Exhibit 11.1 to this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
16K. Cybersecurity.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-13018"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-19813">The Board of Directors is
responsible for overseeing our risk management program and cybersecurity is a critical element of this program</ix:nonNumeric>. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-19814">Management is responsible
for the day-to-day administration of our risk management program and our cybersecurity policies, processes, and practices.</ix:nonNumeric> Our cybersecurity
policies, standards, processes, and practices are based on recognized frameworks and other applicable industry standards are standalone
from our overall risk management system and processes. In general, we seek to address material cybersecurity threats through a company-wide
approach that addresses the confidentiality, integrity, and availability of our information systems or the information that the Company
collects and stores, by assessing, identifying and managing cybersecurity issues as they occur.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cybersecurity Risk Management and Strategy</i></b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our cybersecurity risk management
strategy focuses on several areas:</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification and Reporting</i>: We have implemented a comprehensive, cross-functional approach to assessing, identifying and managing material cybersecurity threats and incidents. Our program includes controls and procedures to properly identify, classify and escalate certain cybersecurity incidents to provide management visibility and obtain direction from management as to the public disclosure and reporting of material incidents in a timely manner.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Technical Safeguards</i>: We implements technical safeguards that are designed to protect the our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence, as well as outside audits and certifications.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incident Response and Recovery Planning</i>: We have established and maintains comprehensive incident response, business continuity, and disaster recovery plans designed to address our response to a cybersecurity incident. We conduct regular tabletop exercises to test these plans and ensure personnel are familiar with their roles in a response scenario.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third-Party Risk Management</i>: We maintain a comprehensive, risk-based approach to <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-19815">identifying and overseeing material cybersecurity threats presented by third parties</ix:nonNumeric>, including vendors, service providers, and other external users of our systems, as well as the systems of third parties that could adversely impact our business in the event of a material cybersecurity incident affecting those third-party systems, including any outside auditors or consultants who advise on our cybersecurity systems.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Education and Awareness</i>: We provide regular, mandatory training for all levels of employees regarding cybersecurity threats as a means to equip our employees with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes, and practices.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conduct periodic assessment
and testing of our policies, standards, processes, and practices in a manner intended to address cybersecurity threats and events. The
results of such assessments, audits, and reviews are evaluated by management and reported to the Audit Committee and the Board, and we
adjust our cybersecurity policies, standards, processes, and practices as necessary based on the information provided by these assessments,
audits, and reviews.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Governance</i></b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_11" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-13122"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-19816">The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-19817">The <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-19818">Board and the Audit
Committee</ix:nonNumeric> each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.</ix:nonNumeric></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_12" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-19819">Senior management works collaboratively
across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond
to any material cybersecurity incidents in accordance with our incident response and recovery plans. To facilitate the success of our
cybersecurity program, cross-functional teams throughout the Company address cybersecurity threats and respond to cybersecurity incidents.</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="ixv-19820">Through ongoing communications with these teams, <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="ixv-19821">our outsourced information technology team and senior management</ix:nonNumeric> are informed about and
monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and report such threats
and incidents to the Audit Committee when appropriate.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_13" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-13135"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material Effects of Cybersecurity Incidents</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_13"><ix:continuation id="_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-19822">not materially affected and are not reasonably likely to
materially affect</ix:nonNumeric> us, including our business strategy, results of operations, or financial condition.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Part
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
17. Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
18. Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Financial Statements
are hereby incorporated herein by reference. These Financial Statements are filed as part of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
19. Exhibits</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit Index</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>










</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 91%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b>&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891323001275/exhibit_1-1.htm">Amended and Restated Articles of Association of the Registrant (23)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891322001429/exhibit_2-1.htm">Description of Securities Registered under Section 12 (19)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000446/exhibit_4-1.htm">Form of Registrant&#8217;s Ordinary Share Warrant Certificate (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Warrant Agreement dated as of February&#160;24, 2015 between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (20)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm">Amendment No.1 dated as of June&#160;24, 2015, to Warrant Agreement dated as of February&#160;24, 2015 between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm">Form of Ordinary Shares Warrant Certificate issued pursuant to a certain Credit Line Agreement dated as of August&#160;20, 2014 (21)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm">Forms of Ordinary Shares Warrant Certificate issued to the Pontifax entities (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm">Form of Series C Warrant (5)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm">Form of Warrant Agent Agreement between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (5)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm">Form of February&#160;2019 Series D Warrant (7)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10 </span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm">Form of the February&#160;2019 Placement Agent Warrant (7)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-1.htm">2006 Unit Option Plan and Amendments thereto (1)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-4.htm">Form of Series C-1 preferred shares purchase warrant (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-5.htm">Forms of Series C-2 preferred shares purchase warrant (1)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-10.htm">Asset Transfer Agreement, dated as of May&#160;31, 2009 by and between Check-Cap Ltd. and Check-Cap LLC (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-11.htm">The Agreement for ASIC Design and Development dated November&#160;26, 2009 by and between Check-Cap Ltd. and Politechnico di Milano (1)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-12.htm">Form of Indemnification Agreement (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002199/exhibit_99-3.htm">2015 Equity Incentive Plan and 2015 United States Sub-Plan to 2015 Equity Incentive Plan (2)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1610590/000117891320002868/exhibit_99-1.htm">Compensation Policy for Executive Officers and Directors (15)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm">Underwriting Agreement, dated as of May&#160;4, 2018, by and between Check-Cap Ltd. and H.C.&#160;Wainwright &amp; Co., LLC (6)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of February&#160;4, 2019 by and between Check-Cap Ltd. and the Purchasers named therein (7)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320000745/exhibit_4-15.htm">Form of Securities Purchase Agreement dated as of December&#160;19, 2019 by and between Check-Cap Ltd. and the Purchasers named therein (8)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of April&#160;20, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto (9)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of April&#160;30, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto (10)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of May&#160;8, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto (11)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of June&#160;30, 2021 by and between Check-Cap Ltd. and the Purchasers signatory thereto (16)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-1.htm">Form of Warrant Exercise Agreement dated as of July&#160;23, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto (12)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of March&#160;1, 2022 by and between Check-Cap Ltd. and the Purchasers signatory thereto (17)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891322001429/exhibit_4-22.htm">Form of Warrant Amendment Agreement dated as of March&#160;1, 2022 by and between Check-Cap Ltd. and the Purchasers signatory thereto (19)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhiibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on April&#160;22, 2020 (9)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on May&#160;4, 2020 (10)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on May&#160;13, 2020 (11)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-3.htm">Form of Warrant issued by Check-Cap Ltd. on July&#160;27, 2020 (12)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on July&#160;2, 2021 (16)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on March&#160;3, 2022 (17)</a></span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top; background-color: rgb(204,238,255)"><td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif">4.25</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify; width: 91%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-5.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on April&#160;22, 2020 (13)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-6.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on May&#160;4, 2020 (13)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-7.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on May&#160;13, 2020 (13)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-2.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on July&#160;27, 2020 (12)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-3.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on July&#160;2, 2021 (16)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-3.htm"><span style="font-size: 10pt">Form
    of Placement Agent Warrant issued by Check-Cap Ltd. on March&#160;3, 2022 (17)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891321001100/exhibit_4-28.htm"><span style="font-size: 10pt">Exclusive
    License Agreement between the Company and the Curators of the University Of Missouri, dated February&#160;26, 2021 (18)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.32</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390024026835/ea020276201ex99-1_checkcap.htm"><span style="font-size: 10pt">Business
    Combination Agreement between Check-Cap Ltd. and Nobul AI Corp. dated March&#160;25, 2024 (24)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.33</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement, by and
    between Check-Cap Ltd. and Nobul AI Corp., dated September 8, 2024 (25)</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.34</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-34_check.htm">Loan
    Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated December 23, 2024 (25)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.35</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-35_check.htm">Loan
    Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated July 2, 2025 (25)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.36</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-36_check.htm">Loan
    Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated July 3, 2025 (25)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.37</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025087248/ea025717701ex99-2_check.htm#b_001"><span style="font-size: 10pt">Agreement
    and Plan of Merger, dated September&#160;12, 2025, by and among Check-Cap Ltd., CC Merger Sub Inc. and MBody AI. (26)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement, dated
    December&#160;17, 2025, between ARC Group International Ltd. and the Company (27)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.39*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex4-39.htm">Exchange Agreement, dated September 12, 2025 between Check-Cap Ltd. and Apollo Technology Capital Corporation.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">4.40*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex4-40.htm">BCA Termination
    Agreement, dated September 12, 2025 between Check-Cap Ltd. and Apollo Technology Capital Corporation.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316004712/exhibit_8-1.htm"><span style="font-size: 10pt">List
    of Subsidiaries (22)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex11-1_check.htm">Insider
    Trading Policies and Procedures (25)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex12-1.htm"><span style="font-size: 10pt">Certification
    of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a)</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex12-2.htm"><span style="font-size: 10pt">Certification
    of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a)</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex13-1.htm"><span style="font-size: 10pt">Certification
    of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C.&#160;&#160;Section 1350, as adopted pursuant to Section
    906 of the Sarbanes-Oxley Act of 2002</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028762301ex15-1.htm">Consent
    of BCRG Group, independent registered public accounting firm</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex15-4_check.htm">Nasdaq
    letter, dated April 9, 2025 (25)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/0001610590/000121390025080891/ea025346901ex15-5_check.htm">Nasdaq
    letter, dated August 5, 2025 (25)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex15-6_check.htm">Nasdaq
    letter, dated May 21, 2025 (25)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex15-7_check.htm">Letter
    from Fahn Kanne &amp; Co., independent registered public accounting firm (25)</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6* </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ea028762301ex15-6.htm"><span style="font-size: 10pt">Letter
    from RBSM LLP, independent registered public accounting firm</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1610590/000121390024043550/ea020589501ex97-1_check.htm"><span style="font-size: 10pt">Policy
    Relating to Recovery of Erroneously Awarded Compensation (Incorporated by reference to Exhibit 97.1 to the Form 20-F filed by the
    Registrant with the Securities and Exchange Commission on May 15, 2024)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            herewith.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Registration Statement on Form F-1 of the Registrant (File No. 333-201250).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to Annex B of Exhibit 99.3 to the Form 6-K filed by the Registrant with the Form 6-K filed by the Registrant with the Securities
    Exchange Commission on July&#160;6, 2015.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference
    to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on August&#160;12, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on June&#160;24, 2015.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registration Statement on Form F-1/A by the Registrant with the Securities and Exchange Commission on April&#160;25, 2018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on May&#160;4, 2018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on February&#160;6, 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on March&#160;6, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on April&#160;22, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on May&#160;4, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on May&#160;12, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on July&#160;24, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registration Statement on Form F-1 by the Registrant with the SEC on May&#160;20, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the Securities and Exchange Commission on March&#160;15, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit A to Exhibit 99.1 to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on October 21, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on July&#160;2, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on March&#160;3, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on March&#160;18, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on April&#160;6, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registration Statement on Form F-1/A by the Registrant with the Securities and Exchange Commission on February&#160;17, 2015.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on November&#160;22, 2017.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">

    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on March&#160;15, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on March&#160;31, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on March&#160;28, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on August 27, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on September&#160;12, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on December 22, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Signatures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 27, 2026</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHECK-CAP LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Lontini</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Lontini</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alan Lewis</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Lewis</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHECK-CAP LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER
31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB ID No. 7158)</a></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">F-2</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_002">Consolidated Balance Sheets</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_003">Consolidated statements of operations and comprehensive loss</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-5</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_004">Consolidated statements of changes in shareholders' (deficit) equity</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-6</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_005">Consolidated statements of cash flow</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-7 </td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><a href="#f_007">Notes to the Consolidated financial statements</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-9</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 47%"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="ea028762301_img13.jpg" style="width: 220px; height: 79px"/></span></td><td style="width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify; width: 33%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>200
                                            Spectrum Center Drive, Suite </b>1<b>300</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Irvine,
                                            CA 92618</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>(714)
                                            234-5980</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>www.bcrgcpas.com</b></span></p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 5.3pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and the Board of Directors
of Check-Cap Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-14232"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Check-Cap Ltd. (the &#8220;Company&#8221;) as of December 31, 2025, 2024 and 2023, and the related consolidated statements
of operations, stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2025,
and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity
with accounting principles generally accepted in the United States of America.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements,
the Company has incurred recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue
as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 148 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Critical Audit Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters communicated below
are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and
(2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter
our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below,
providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Investment in Apollo Technology Capital
Corporation / Conversion of Loan Receivable to Equity Investment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 14 to the consolidated financial
statements, during 2025 the Company converted loans receivable and accrued interest due from Apollo Technology Capital Corporation (&#8220;Apollo&#8221;)
into an equity investment representing approximately 7.5% of Apollo&#8217;s fully diluted equity, which the Company accounts for under
ASC 321 (Investments&#8212;Equity Securities). The Company recorded a full expected credit loss allowance on the loans receivable prior
to conversion. The initial carrying value of the equity investment was determined by reference to an independent third-party valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We identified this as a critical audit matter
due to the non-routine nature of the transaction and significant judgment required to evaluate (i) the transaction terms, (ii) classification
of the investment, (iii) timing of derecognition of the loan and recognition of the investment, and (iv) initial valuation and impairment
considerations. Limited observable market data increased audit complexity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit procedures included inspecting loan
agreements, amendments, approvals, and conversion documents; testing loan balances, interest accrual, and conversion calculations; assessing
valuation methodology and assumptions; evaluating impairment indicators at year-end; evaluating management&#8217;s accounting under ASC
321 (Investments&#8212;Equity Securities) and ASC 326 (Financial Instruments&#8212;Credit Losses) expected credit loss analysis; reviewing
Apollo&#8217;s available financial information and liquidity; assessing the adequacy of the related financial statement disclosures</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>/s/ BCRG Group</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-19823">BCRG Group</ix:nonNumeric> (PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-19824">7158</ix:nonNumeric>)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-19825">Irvine, CA</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 27, 2026</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 149 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 68%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: center">2(D)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19826">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Short-term Bank Deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2(E)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd" id="ixv-19827">217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd" id="ixv-19828">265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Total cash, cash equivalents, and short-term deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" unitRef="usd" id="ixv-19829">219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" unitRef="usd" id="ixv-19830">265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-19831">219</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-19832">265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Intangible Asset, net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-19833">726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Investments</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" unitRef="usd" id="ixv-19834">6,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right of Use Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">5</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-19835">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-19836">112</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-19837">7,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-19838">112</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-19839">7,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-19840">377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Liabilities and shareholders&#8217; (deficit) equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable and accruals</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Trade</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-19841">790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-19842">492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Other</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19843">2,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-19844">793</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19845">406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19846">406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other Accrued Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19847">640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#8211; current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">5</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-19848">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-19849">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19850">4,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19851">1,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Royalties provision</td><td>&#160;</td>
    <td style="text-align: center">8(A)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities - non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">5</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-19852">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-19853">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Share capital, Ordinary shares&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">48</ix:nonFraction></ix:nonFraction>&#160;NIS par value (<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">18,000,000</ix:nonFraction></ix:nonFraction>&#160;authorized shares as of December 31, 2025 and 2024;&#160;<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">7,020,502</ix:nonFraction></ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">5,850,906</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December 31, 2025 and 2024, respectively) (1)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">83,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">83,751</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-19864">85,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-19865">84,809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-19866">165,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-19867">170,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19868">3,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19869">1,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-19870">7,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-19871">377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes to the consolidated financial
statements are an integral part of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 150 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 56%; text-align: left">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: center">12</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19872">8,311</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19873">2,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19874">9,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19875">9,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Impairment of fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">4(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" unitRef="usd" id="ixv-19876">1,426</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19877">2,373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19878">9,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19879">19,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Impairment of loans receivable</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoansReceivable" scale="3" unitRef="usd" id="ixv-19880">16,487</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Income on Debt Extinguishment and Conversion</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-19881">6,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Finance income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">15</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-19882">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-19883">800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-19884">1,719</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-19885">4,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19886">25,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19887">17,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" unitRef="usd" id="ixv-19888">4,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-19889">25,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-19890">17,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Income (loss) per share:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net income (loss) per ordinary share - basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-19891"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-19892">0.66</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-19893"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-19894">4.30</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-19895"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-19896">3.00</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Weighted average number of ordinary shares outstanding - basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt">16</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-19897"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-19898">6,232,226</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-19899"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-19900">5,849,013</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-19901"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-19902">5,848,737</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes to the consolidated financial
statements are an integral part of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 151 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
DEFICIT </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 50%; font-weight: bold">Balance as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-19903">5,844,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19904">83,664</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19905">84,941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19906">127,293</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19907">41,312</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during 2022:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-19908">6,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-19909">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" sign="-" unitRef="usd" id="ixv-19910">82</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" sign="-" unitRef="usd" id="ixv-19911">57</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-19912">57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19913">17,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19914">17,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-19915">5,850,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19916">83,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19917">84,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19918">144,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19919">23,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during 2024:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-19920">351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-19921">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" sign="-" unitRef="usd" id="ixv-19922">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-19923">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-19924">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19925">25,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19926">25,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-19927">5,850,906</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19928">83,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19929">84,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19930">170,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19931">1,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during 2025:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of shares - Ghost Kitchens ARA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19932">1,169,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-19933">167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-19934">592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-19935">759</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" sign="-" unitRef="usd" id="ixv-19936">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" sign="-" unitRef="usd" id="ixv-19937">12</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-19938">4,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-19939">4,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance as of December 31, 2025</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-19940">7,020,502</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19941">83,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19942">85,389</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-19943">165,870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-19944">3,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes to the consolidated financial
statements are an integral part of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 152 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 56%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 7%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-19945">4,140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19946">25,149</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-19947">17,568</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-19948">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-19949">212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Impairment of loans receivable</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoansReceivable" scale="3" unitRef="usd" id="ixv-19950">16,487</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Impairment of fixed assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" unitRef="usd" id="ixv-19951">1,426</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" sign="-" unitRef="usd" id="ixv-19952">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-19953">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" sign="-" unitRef="usd" id="ixv-19954">57</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Financial expense (income), net</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-19955">305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes in assets and liabilities items:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operation leasing</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19956">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-19957">112</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19958">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease (increase) in prepaid and other current assets and non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-19959">6,491</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-19960">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-19961">480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in trade accounts payable, accruals and other current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-19962">2,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-19963">497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-19964">851</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Decrease in employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-19965">856</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Decrease in royalties provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" scale="3" sign="-" unitRef="usd" id="ixv-19966">94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19967">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19968">8,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19969">16,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19970">83</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of loans receivable</td><td>&#160;</td>
    <td style="text-align: center">1(A)8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="3" unitRef="usd" id="ixv-19971">16,487</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Changes (investment) in short-term bank and other deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19972">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19973">15,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19974">21,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided in (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-19975">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19976">840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-19977">21,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Issuance of ordinary shares in the registered direct offerings, net of issuance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-19978">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-19979">8,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-19980">4,402</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-19981">8,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-19982">4,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at the end of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-19983">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-19984">8,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Supplemental information for Cash Flow:&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Supplemental disclosure of non-cash flow information</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%; text-align: left">Purchase of property and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" unitRef="usd" id="ixv-19985">35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Assets acquired under operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Cash paid for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="3" unitRef="usd" id="ixv-19986">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Interest received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-19987">738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-19988">2,023</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes to the consolidated financial
statements are an integral part of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 153 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEET</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Cash and Cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19989">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19990">8,844</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Restricted cash included current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total cash, cash equivalents, and restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19991">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19992">8,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes to the consolidated financial
statements are an integral part of them.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 154 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CHECK CAP LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands, except share and per
share data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-16477"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; GENERAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(1)</td><td style="text-align: justify">Check Cap Ltd. (the &#8220;Company&#8221;) was incorporated
under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Avenue, Isfiya 3009000, Israel.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(2)</td><td style="text-align: justify">The Company has three wholly-owned subsidiaries: Check-Cap
US, Inc., incorporated under the laws of the State of Delaware on May 15, 2015; Check-Cap Canada Inc., incorporated on April 9, 2024,
and CC Merger Sub Inc., incorporated under the laws of the State of Nevada on September 9, 2025.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(3)</td><td style="text-align: justify">The Company was engaged in a clinical-stage medical diagnostics
company that aimed to redefine colorectal cancer (CRC) screening through the introduction of C-Scan&#174;, a screening test designed to
detect polyps before they may transform into colorectal cancer. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning,
control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is non-invasive
and requires no preparation or sedation.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(4)</td><td style="text-align: justify">On March 21, 2023, the Company announced that the most recent
efficacy results from its calibration studies did not meet the goal required to proceed to the powered portion of the U.S. pivotal study.
On June 6, 2023, the Company&#8217;s Board of Directors determined it was appropriate to pursue strategic options, approved a significant
reduction in workforce, discontinued the calibration studies, and concentrated resources on strategic alternatives.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(5)</td><td style="text-align: justify">On December 24, 2023, the Company received a notice terminating
the Keystone BCA pursuant to Section 10.1(e) thereof, in light of the failure by the Company&#8217;s shareholders to approve the transaction
at the December 18, 2023 Annual General Meeting. At the same meeting, the then-existing Board of Directors was replaced by five new board
members.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(6)</td><td style="text-align: justify">Since its inception, the Company has devoted substantially
all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets, and raising
capital. The Company has not yet generated revenues from operations.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(7)</td><td style="text-align: justify">On March 25, 2024, the Company entered into a business combination
agreement (the &#8220;Apollo BCA&#8221;) with Apollo Technology Capital Corporation (formerly known as Nobul AI Corp.) (&#8220;Apollo&#8221;),
a private Ontario corporation. Subsequently, the Company&#8217;s primary strategic focus shifted to a proposed business combination with
MBody AI Corp., a Nevada corporation (&#8220;MBody AI&#8221;) (the &#8220;Merger&#8221;). On November 17, 2025, the Company held a special
general meeting of shareholders at which approximately <ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="chek:VotesCastPercentage" scale="-2" unitRef="pure" id="ixv-19993">98</ix:nonFraction>% of votes cast were in favor of the Merger. The Merger is expected to transform
the Company into a Nasdaq-listed embodied-AI enterprise, subject to final regulatory and procedural conditions. See Note 19 &#8211; Subsequent
Events.</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"></p><div>

</div><!-- Field: Page; Sequence: 155 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(8)</td><td style="text-align: justify">During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo in connection with the Apollo BCA. On September 8, 2024, the Board approved the First
Apollo Loan ($<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="chek:AmountPayableForNonrefundableFee" scale="3" unitRef="usd" id="ixv-19994">6,000</ix:nonFraction>, <ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure" id="ixv-19995">5</ix:nonFraction>% per annum) and an amendment to the Apollo BCA requiring the Company to deposit $<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-19996">11,000</ix:nonFraction> into a segregated bank
account at the Royal Bank of Canada (the &#8220;Segregated Account&#8221;) for Apollo business activities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">On December 23, 2024, the Board approved
the Second Apollo Loan ($<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="3" unitRef="usd" id="ixv-19997">6,000</ix:nonFraction>). As of December 31, 2024, $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesSegregatedUnderOtherRegulations" scale="3" unitRef="usd" id="ixv-19998">2,100</ix:nonFraction> of the Segregated Account had been used by Apollo for acquisition targets
and growth initiatives; $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-19999">700</ix:nonFraction> had been used for certain Company expenses; and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesSegregatedUnderOtherRegulations" scale="3" unitRef="usd" id="ixv-20000">2,200</ix:nonFraction> remained in the Segregated Account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">In July 2025, in connection with the
audit of the Company&#8217;s December 31, 2024 financial statements, the Company reclassified the $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="chek:ReclassifiedAcquisitionTarget" scale="3" unitRef="usd" id="ixv-20001">2,100</ix:nonFraction> as the Third Apollo Loan and
the $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="3" unitRef="usd" id="ixv-20002">2,200</ix:nonFraction> as the Fourth Apollo Loan, each on the same terms as the First Apollo Loan. See Note 19 &#8211; Subsequent Events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">Also in July 2025, management evaluated
the recoverability of the Apollo Loans (First through Fourth) in accordance with ASC 326, Financial Instruments &#8211; Credit Losses,
and recorded a full allowance for credit losses on the Apollo Loans as of December 31, 2024. As of the date of issuance of these financial
statements, the Apollo Loans are contractually current and not in default. See Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(9)</td><td style="text-align: justify">The Company&#8217;s ordinary shares are listed on the Nasdaq
Capital Market under the symbol &#8220;MBAI&#8221; (formerly &#8220;CHEK&#8221;, prior to December 2, 2025). The Company has conducted
multiple registered direct offerings and warrant exercise transactions since its IPO on February 24, 2015. The Company&#8217;s Series
A Warrants expired on February 24, 2020 and Series C Warrants expired on May 8, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(10)</td><td style="text-align: justify">The consolidated financial statements include the accounts
of Check Cap Ltd., Check-Cap US, Inc., and Check-Cap Canada Inc. All intercompany transactions and balances have been eliminated.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(11)</td><td style="text-align: justify">Effective November 23, 2022, the Company effected a <ix:nonNumeric contextRef="c36" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-20003">1-for-20</ix:nonNumeric>
reverse share split. All share and per-share amounts in these financial statements have been retroactively adjusted.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.3in; text-align: left">(12)</td><td style="text-align: justify">Following the October 7, 2023 attacks in Israel, the country
has been involved in ongoing military conflicts. Although certain ceasefire agreements have been reached, the situation remains volatile
with potential for escalation. The Company continues to monitor developments and their potential impact on operations.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 156 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-16594"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING
CONCERN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="chek_GoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="chek:GoingConcernPolicyTextBlock" id="ixv-16598"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Going Concern</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation continuedAt="chek_GoingConcernPolicyTextBlock-c0_cont_2" id="chek_GoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The accompanying consolidated financial statements have been
prepared on a going concern basis. As of December 31, 2025, the Company had an accumulated deficit of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-20004">165,870</ix:nonFraction> and cash
and cash equivalents of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20005">2</ix:nonFraction>. The Company has not generated revenues from operations and has incurred substantial net losses
since inception.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="chek_GoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding net income of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-20006">4,140</ix:nonFraction> for the year ended December
31, 2025, which arose primarily from a non-cash credit loss recovery of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" unitRef="usd" id="ixv-20007">6,525</ix:nonFraction> recognized upon reinstatement of the Apollo loan receivable
during the first half of 2025 (see Note 14), the Company&#8217;s operating cash flows remain negative. These conditions raise substantial doubt about
the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans include consummating the pending merger with MBody
AI Corp. and utilizing the ARC Equity Line of Credit facility. There is no assurance these plans will be successfully executed.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-16613"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Basis of Presentation</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company&#8217;s consolidated financial statements have
been prepared in accordance with U.S. GAAP. The functional currency of the Company is the U.S. dollar.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-16626"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Consolidation</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The consolidated financial statements include the accounts
of Check Cap Ltd. and its wholly-owned subsidiaries, Check-Cap US, Inc. and Check-Cap Canada Inc. All intercompany transactions and balances
have been eliminated in consolidation.</p></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-16638"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Cash and Cash Equivalents</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company considers all short-term, highly liquid investments
with original maturities of three months or less to be cash equivalents.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="chek_ShortTermBankDepositPolicyTextBlock-c0_cont_1" escape="true" name="chek:ShortTermBankDepositPolicyTextBlock" id="ixv-16650"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Short-term Bank Deposit</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="chek_ShortTermBankDepositPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Bank deposits with original maturities of more than three
months but less than twelve months are included in short-term bank deposits and bear interest at market rates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-16662"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>F.</b></td><td style="text-align: justify"><b>Property and Equipment</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over estimated useful lives: laboratory equipment <ix:nonNumeric contextRef="c37" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-20008">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c38" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-20009">7</ix:nonNumeric> years;
office furniture and equipment <ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-20010">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c40" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-20011">7</ix:nonNumeric> years; computers and auxiliary equipment <ix:nonNumeric contextRef="c41" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-20012">3</ix:nonNumeric> years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ixv-16674"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>G.</b></td><td style="text-align: justify"><b>Intangible Assets</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Intangible assets are recorded at cost and amortized on a
straight-line basis over their estimated useful lives. The Ghost Kitchens ARA intangible asset, recorded at $<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-20013">759</ix:nonFraction> upon issuance of shares
on September 4, 2025, is amortized over its estimated useful life. Amortization expense for the year ended December 31, 2025 was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd" id="ixv-20014">34</ix:nonFraction>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-16686"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>H.</b></td><td style="text-align: justify"><b>Impairment of Long-Lived Assets</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company reviews long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying
amount exceeds the fair value of the asset.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"></p><div>

</div><!-- Field: Page; Sequence: 157 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-16713"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>I.</b></td><td style="text-align: justify"><b>Investments in Equity Securities</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for investments in equity securities
without a readily determinable fair value under ASC 321, using the measurement alternative (cost less impairment, adjusted for observable
price changes in orderly transactions for identical or similar investments of the same issuer). The Apollo equity investment of $<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20015">6,525</ix:nonFraction>
thousand, arising from the noncash debt-for-equity exchange recognized on November 14, 2025, is recorded at cost equal to the carrying
value of the loan receivable surrendered. No gain or loss was recognized on exchange. See Note 14.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-16725"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>J.</b></td><td style="text-align: justify"><b>Research and Development Expenses</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Research and development expenses are charged to operations
as incurred, net of participation from the Israeli Innovation Authority.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-16737"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>K.</b></td><td style="text-align: justify"><b>Share-Based Compensation</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company measures share-based compensation awards at grant-date
fair value using the Black-Scholes option-pricing model and recognizes compensation expense on a straight-line basis over the requisite
service period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-16749"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>L.</b></td><td style="text-align: justify"><b>Income Taxes</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company uses the asset and liability method for income
taxes. A full valuation allowance has been established against all deferred tax assets given the Company&#8217;s history of losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-16761"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>M.</b></td><td style="text-align: justify"><b>Loss (Earnings) Per Share</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Basic earnings (loss) per share is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share equals
basic in loss years as all potentially dilutive securities are anti-dilutive.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ixv-16773"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>N.</b></td><td style="text-align: justify"><b>Fair Value Measurements</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company applies ASC 820, using a three-level hierarchy:
Level 1 (quoted prices), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-16785"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>O.</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for leases in accordance with ASC 842.
As of December 31, 2025, the Company has one operating lease for office facilities in Isfiya, Israel.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-16797"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>P.</b></td><td style="text-align: justify"><b>Recent Accounting Pronouncements</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Tax
Disclosures) are effective for fiscal years beginning after December 15, 2023 and 2024, respectively. The Company is evaluating their
impact. No other recently issued but not yet effective pronouncements are expected to have a material impact.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PostemploymentBenefitPlansPolicy-c0_cont_1" escape="true" name="us-gaap:PostemploymentBenefitPlansPolicy" id="ixv-16809"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>Q.</b></td><td style="text-align: justify"><b>Severance Pay</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<ix:continuation id="_PostemploymentBenefitPlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">All Company employees are subject to Section 14 of the Israeli
Severance Pay Law. The Company&#8217;s monthly deposits release it from future severance obligations; accordingly, no related assets or
liabilities are presented on the balance sheet.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="chek_DeferredIncomeTaxesPolicyTextBlock-c0_cont_1" escape="true" name="chek:DeferredIncomeTaxesPolicyTextBlock" id="ixv-16821"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>R.</b></td><td style="text-align: justify"><b>Deferred Income Taxes</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:continuation id="chek_DeferredIncomeTaxesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Deferred tax assets and liabilities are recognized for temporary
differences between carrying amounts and tax bases. Given the Company&#8217;s history of losses, a full valuation allowance has been established
against all deferred tax assets, including net operating loss carryforwards.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 158 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-16845"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-16853"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government institutions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-16946"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 &#8211; PROPERTY AND EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-16953"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Office furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20016">827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20017">827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20018">1,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20019">1,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computers and auxiliary equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20020">571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20021">571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20022">3,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20023">3,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20024">3,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20025">3,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Impairment of fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Depreciation expenses amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-20026">0</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-20027">0</ix:nonFraction>, and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-20028">161</ix:nonFraction> for the
years ended December 31, 2025, 2024, and 2023, respectively.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Impairment of fixed assets: The Company recorded an impairment
loss of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" unitRef="usd" id="ixv-20029">1,426</ix:nonFraction> for the year ended December 31, 2023, following the decision to discontinue clinical studies. See Note 1(A)(4).</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-17065"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 &#8211; LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">The Company&#8217;s office lease in Isfiya, Israel (approximately
<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm" id="ixv-20030">1,550</ix:nonFraction> square meters, originally under the Amended Lease Agreement) expired <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-20031">December 31, 2023</ix:nonNumeric>. Following expiry, the Company agreed to
lease a portion of the premises at a monthly fee of $<ix:nonFraction contextRef="c0" decimals="-2" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-20032">8.3</ix:nonFraction>. On April 15, 2024, this lease was extended for <ix:nonNumeric contextRef="c51" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="ixv-20033">two years</ix:nonNumeric> commencing March 1,
2024, terminable upon 60 days&#8217; notice.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">The Petach Tikva sub-lease (laboratory space) was terminated
effective September 8, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">The Petach Tikva office lease was terminated by the parties
in September 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">As of December 31, 2025, operating lease right-of-use assets
and current lease liabilities were $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-20034">16</ix:nonFraction>. The Company uses its incremental borrowing rate as the discount rate.</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 159 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-17107"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 &#8211; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><span style="font-size: 8pt"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Composition:</b></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" id="ixv-17122"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term employee benefits:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Benefits for vacation and recreation pay</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" unitRef="usd" id="ixv-20035">142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" unitRef="usd" id="ixv-20036">142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Liability for payroll, bonuses and wages</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20037">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20038">264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20039">406</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20040">406</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Post-employment benefits</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All Company employees elected to be included under Section
14 of the Israeli Severance Pay Law. The Company&#8217;s monthly deposits at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="chek:DepositsRate" scale="-2" unitRef="pure" id="ixv-20041">8.33</ix:nonFraction>% of salary release it from future severance
obligations. Related assets and liabilities are not presented in the balance sheet. The Company did not make contributions to pension
funds in 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Short-term employee benefits</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Employees are entitled to paid vacation days in accordance
with the Yearly Vacation Law-1951. Accrued but unused vacation days are payable upon termination.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-17205"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; INCOME TAXES</b></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>The Company</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap Ltd. is taxed according to Israeli tax laws:</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b>Corporate tax rates in Israel</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Israeli corporate tax rate in years 2022, 2023, 2024,
2025 and onwards is <ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20042"><ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20043"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20044"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20045">23</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b>The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investments Law&#8221;)</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Under the Investments Law, including Amendment No. 60 as
published in April 2005, by virtue of the &#8220;Benefited Enterprise&#8221; status, the Company is entitled to various tax benefits as
follows:</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 18pt"><b>a)</b></td><td style="text-align: justify"><b>Reduced tax rates</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company has one Benefited Enterprise program under the
Investments Law, which entitles it to certain tax benefits with respect to income to be derived from its Benefited Enterprise. The Company
chose 2010 as the year of election (the &#8220;Year of Election&#8221;). Due to the location of the Company&#8217;s offices, the Company
believes it is entitled to a <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="chek:EntitledBenefitTerm" id="ixv-20046">10</ix:nonNumeric>-year benefit period, subject to a <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="chek:LimitationFromTheYearOfElectionTerm" id="ixv-20047">14</ix:nonNumeric>-year limitation from the Year of Election. The tax benefit period
ended in 2023.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 18pt"><b>b)</b></td><td style="text-align: justify"><b>Conditions for entitlement to the benefits</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The benefits available to a Benefited Enterprise are subject
to the fulfillment of conditions stipulated in the Investments Law and its regulations.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 18pt"><b>c)</b></td><td style="text-align: justify"><b>Amendment of the Investments Law</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Investments Law was amended as part of the Economic Policy
Law for the years 2011-2012, passed by the Israeli Knesset on December 29, 2010 (the &#8220;Capital Investments Law Amendment&#8221;).
The Capital Investments Law Amendment set alternative benefit tracks. Under the transitional provisions, the Company was entitled to elect
that the Capital Investments Law Amendment applies; however, the Company elected not to have the Capital Investments Law Amendment apply
to the Company.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On December 22, 2016, the Knesset approved amendment number
73 to the Investments Law introducing reduced corporate tax rate tracks of <ix:nonFraction contextRef="c54" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20048">7.5</ix:nonFraction>% for Preferred Technological Enterprises located in Development
Area A and <ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20049">12</ix:nonFraction>% for the rest of the country, and <ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="chek:ReductionInIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20050">6</ix:nonFraction>% for a Special Preferred Technological Enterprise.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In accordance with the Israeli Income Tax Ordinance [New
Version], 1961, as of December 31, 2025, all of the Company&#8217;s tax assessments through tax year 2017 are considered final. Tax years
2018 through 2025 remain open to examination by the Israeli Tax Authority.</p></ix:nonNumeric><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 160 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><b>B.</b></td><td style="text-align: justify"><b>Check-Cap US, Inc.</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap US, Inc. is taxed according to U.S. tax laws at
a federal rate of <ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20051">21</ix:nonFraction>%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap US, Inc. had <span style="-sec-ix-hidden: hidden-fact-119">no</span> net operating loss carryforwards
as of December 31, 2025 (December 31, 2024: $<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20052">177,107</ix:nonFraction>; December 31, 2023: $<ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20053">13</ix:nonFraction>).</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Utilization of any U.S. NOL carryforwards may be subject
to substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have
occurred or could occur in the future. The Company has not completed a detailed study to determine whether such ownership changes have
occurred.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><b>C.</b></td><td style="text-align: justify"><b>Deferred income taxes</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, Check-Cap Ltd. has accumulated
Israeli net operating loss carryforwards of approximately $<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20054">129,559</ix:nonFraction> (December 31, 2024: $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20055">127,162</ix:nonFraction>; December 31, 2023: $<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20056">118,512</ix:nonFraction>). Under the
Israeli Income Tax Ordinance, these losses may be carried forward indefinitely to offset future Israeli taxable income. No Israeli NOL
carryforwards are subject to expiry.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, Check-Cap US, Inc. has <span style="-sec-ix-hidden: hidden-fact-120">no</span> U.S.
federal or state net operating loss carryforwards.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In assessing the realizability of deferred tax assets,
the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will be realized. Based on
the Company&#8217;s history of losses, its cessation of operations in June 2023, the absence of revenue since that date, and the absence
of objectively verifiable projections of future taxable income, the Company has established a full valuation allowance against all net
operating loss carryforwards. The Company does not expect to pay taxes in Israel until it has taxable income sufficient to fully utilize
its carryforward tax losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-17333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Net deferred tax assets consist of the following components:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">NOL carryforwards &#8211; Israel (at <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20057"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20058"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20059">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" unitRef="usd" id="ixv-20060">29,799</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" unitRef="usd" id="ixv-20061">29,247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" unitRef="usd" id="ixv-20062">27,258</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">NOL carryforwards &#8211; U.S. (at <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-20063"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-20064"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-20065">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" unitRef="usd" id="ixv-20066">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total gross deferred tax asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-20067">29,799</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-20068">29,247</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-20069">27,261</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-20070">29,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-20071">29,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-20072">27,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Deferred Tax Asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>All amounts in USD thousands. The Israeli NOL DTA is
computed at the <ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20073">23</ix:nonFraction>% Israeli statutory corporate tax rate on accumulated Israeli tax losses of $<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20074">129,559</ix:nonFraction>, $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20075">127,162</ix:nonFraction> and $<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd" id="ixv-20076">118,512</ix:nonFraction> at December
31, 2025, 2024 and 2023 respectively. The U.S. DTA of $<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" unitRef="usd" id="ixv-20077">3</ix:nonFraction> at December 31, 2023 is computed at <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-20078">21</ix:nonFraction>% on $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20079">13</ix:nonFraction> of U.S. NOL and is immaterial.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="ixv-17443"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in accumulated Israeli net operating loss carryforwards:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Israeli NOL Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening accumulated Israeli NOL</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20080">127,162</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20081">118,512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Current year estimated tax loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" scale="3" unitRef="usd" id="ixv-20082">2,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" scale="3" unitRef="usd" id="ixv-20083">8,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20084">129,559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-20085">127,162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>The current year tax loss is estimated from the GAAP
net income/(loss) after the following adjustments applied consistently in both years: (i) the Apollo loan impairment charge of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoansReceivable" scale="3" unitRef="usd" id="ixv-20086">16,487</ix:nonFraction>
recorded in 2024 and the related reversal/conversion gain of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-20087">6,525</ix:nonFraction> recorded in 2025 are excluded from taxable income &#8212; tax recognition
is deferred until all closing conditions for the debt-for-equity exchange are met, which requires completion of the merger ; (ii) share-based
compensation is added back ($<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-20088">12</ix:nonFraction> charge in 2024; ($<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" sign="-" unitRef="usd" id="ixv-20089">12</ix:nonFraction>) credit in 2025); and (iii) IIA grants are excluded from taxable income ($<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="3" unitRef="usd" id="ixv-20090"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="3" unitRef="usd" id="ixv-20091">0</ix:nonFraction></ix:nonFraction> received
in both years). Depreciation timing differences are assumed <span style="-sec-ix-hidden: hidden-fact-118">nil</span> or immaterial.</i></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-17518"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in valuation allowance:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Valuation Allowance Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening valuation allowance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-20092">29,247</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-20093">27,258</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase &#8212; current year tax loss &#215; <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" scale="-2" unitRef="pure" id="ixv-20094"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" scale="-2" unitRef="pure" id="ixv-20095">23</ix:nonFraction></ix:nonFraction>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" sign="-" unitRef="usd" id="ixv-20096">551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" sign="-" unitRef="usd" id="ixv-20097">1,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-20098">29,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-20099">29,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has not recorded any liability for unrecognized
tax benefits under ASC 740 as of December 31, 2025 or 2024, and does not anticipate significant changes in uncertain tax positions within
the next <ix:nonNumeric contextRef="c4" format="ixt-sec:durmonth" name="chek:UncertainTaxPositions" id="ixv-20100">12</ix:nonNumeric> months. The Company&#8217;s policy is to record interest and penalties related to income tax matters in income tax expense;
<span style="-sec-ix-hidden: hidden-fact-121"><span style="-sec-ix-hidden: hidden-fact-122">no</span></span> such amounts were recognized in 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Current tax provision</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-17586"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The provision for income taxes consists of the following:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Federal (U.S.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total current tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Federal (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total deferred tax benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total provision (benefit) for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Reconciliation of theoretical to actual tax expense</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-17765"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table reconciles the statutory Israeli corporate
tax rate to the Company&#8217;s effective tax rate:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Statutory Israeli corporate tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20101">23</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-20102">23</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of full valuation allowance on NOL carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-20103">23</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-20104">23</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other permanent differences (immaterial)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Effective tax rate</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-20105">0</ix:nonFraction></td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-20106">0</ix:nonFraction></td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company generated no taxable income in Israel or the
United States in 2025 or 2024. No income taxes were paid in either jurisdiction in 2025 or 2024. The primary reconciling item between
the statutory rate and the effective rate is the full valuation allowance established against all net operating loss carryforwards, reflecting
management&#8217;s conclusion that it is more likely than not that these assets will not be realized given the Company&#8217;s history
of losses, absence of revenue since June 2023, and the uncertainty of future taxable income pending completion of the merger</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 162 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-17834"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Royalties provision</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Royalties to an ASIC designer: The Company had a liability to
pay royalties of <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="0" unitRef="eur" id="ixv-20107">50</ix:nonFraction> euro cents per ASIC component sold, capped at &#8364;<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="chek:RoyaltiesSoldComponent" scale="0" unitRef="eur" id="ixv-20108">200</ix:nonFraction> (~$<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="chek:RoyaltiesSoldComponent" scale="3" unitRef="usd" id="ixv-20109">213</ix:nonFraction>). <ix:nonNumeric contextRef="c0" continuedAt="_OtherCommitmentsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherCommitmentsTableTextBlock" id="ixv-20110">As no future sales are expected following the C-Scan
discontinuation, the provision was derecognized in 2023 as a reduction of R&amp;D expenses.</ix:nonNumeric></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_OtherCommitmentsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Royalties to an ASIC designer</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Reimbursement liability to Predecessor Entity&#8217;s unit holders:
The Company committed to reimburse unit holders of Check Cap LLC for tax burdens arising from the 2009 reorganization under Section 367(d)
of the Code. Since no profitability is expected, the liability based on discounted cash outflows is <span style="-sec-ix-hidden: hidden-fact-127">$0</span>.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Commitments</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Royalties &#8211; IIA and BIRD Foundation: Since inception through
December 31, 2023, the Company received IIA funding of approximately $<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="chek:FundReceivedInTotalAmount" scale="3" unitRef="usd" id="ixv-20111">5,600</ix:nonFraction> and BIRD Foundation funding of approximately $<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="chek:FundReceivedInTotalAmount" scale="3" unitRef="usd" id="ixv-20112">114</ix:nonFraction>. <span style="-sec-ix-hidden: hidden-fact-128"><span style="-sec-ix-hidden: hidden-fact-129">No</span></span> grants
were received in 2024 or 2025. Contingent royalty obligations to the IIA (~$<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="chek:ContingentLiability" scale="3" unitRef="usd" id="ixv-20113">6,199</ix:nonFraction>) and BIRD Foundation (~$<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="chek:ContingentLiability" scale="3" unitRef="usd" id="ixv-20114">209</ix:nonFraction>) as of December 31, 2023
remain; these are not anticipated to be payable in the foreseeable future.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Rental agreements: See Note 5.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Legal</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">From time to time, the Company is involved
in litigation arising in the ordinary course of business. The following legal proceedings were outstanding as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Derivative action. </b>On October
7, 2024, a minority shareholder of the Company filed an application in the Haifa District Court seeking certification of a shareholders&#8217;
derivative lawsuit against the Company, certain present and former directors, and a third party, seeking damages in excess of NIS <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="chek:DerivativeAmount" scale="0" unitRef="ils" id="ixv-20115">2,500</ix:nonFraction>
(approximately $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="chek:DerivativeAmount" scale="3" unitRef="usd" id="ixv-20116">784</ix:nonFraction>). The claims relate primarily to corporate governance matters and the legality of certain corporate decisions and
transactions. The Company filed a response requesting that certification be denied. The parties are currently engaged in mediation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Former executive compensation claims.
</b>During 2024, two former senior executives filed separate claims against the Company seeking an aggregate of approximately NIS <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="0" unitRef="ils" id="ixv-20117">620</ix:nonFraction>
(approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-20118">195</ix:nonFraction>) in respect of alleged unpaid compensation and contractual entitlements arising from the termination of their respective
engagements. The Company filed Statements of Defense rejecting all allegations in both matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Legal fee dispute. </b>During 2024,
a former legal services provider filed a claim against the Company seeking approximately NIS <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" unitRef="ils" id="ixv-20119">175</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLegalSettlements" scale="3" unitRef="usd" id="ixv-20120">55</ix:nonFraction>) for alleged unpaid
fees. The Company filed a Statement of Defense rejecting all allegations. The parties are engaged in mediation proceedings concurrent
with the court process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Lease and eviction proceedings. </b>In
September 2024, the Company ceased making rent payments in respect of its leased premises in Usfiyeh, Israel. The landlord subsequently
commenced legal proceedings and an eviction order was granted by the court. The Company has ceased active business operations at the facility.
Certain Company property and documentation remain on the premises pending resolution of access and logistical matters. The landlord&#8217;s
claim for unpaid rent and damages totals approximately NIS <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="chek:OutstandingAmountsOfLandlordClaim" scale="0" unitRef="ils" id="ixv-20121">207</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="chek:OutstandingAmountsOfLandlordClaim" scale="3" unitRef="usd" id="ixv-20122">65</ix:nonFraction>). No impairment has been recorded against the related
right-of-use asset as proceedings remain ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Management&#8217;s assessment. </b>For all of
the above matters, based on the information currently available and after consultation with legal counsel, management does not believe
an unfavorable outcome is probable for any of the above proceedings. Accordingly, no provision has been recorded in these consolidated
financial statements as of December 31, 2025. Management will reassess at each reporting date and will record a provision in the period
in which it becomes probable that a liability has been incurred and the amount can be reasonably estimated. </p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 163 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-17973"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820, the Company measures financial
instruments at fair value using a three-level hierarchy. As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden: hidden-fact-130"><span style="-sec-ix-hidden: hidden-fact-131">no</span></span> financial instruments measured
at fair value on a recurring basis through the income statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Equity Investment in Apollo Technology
Capital Corporation &#8212; ASC 321. The Company holds an equity investment in Apollo Technology Capital Corporation (&#8220;Apollo&#8221;),
representing approximately <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-20123">7.5</ix:nonFraction>% of Apollo&#8217;s issued and outstanding shares, arising from a debt-for-equity exchange recognized on
November 14, 2025 (see Note 14). Classification: The investment is classified as an equity security under ASC 321. The Company does not
have significant influence over Apollo: there is no board representation, no board nomination rights, no common directors or officers,
no shared management, and no governance, veto, or substantive participating rights. The equity method under ASC 323 does not apply. Measurement
alternative: Apollo&#8217;s shares are not publicly traded and do not have a readily determinable fair value. The Company applies the
measurement alternative under ASC 321-10-35-2: the investment is carried at cost of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" unitRef="usd" id="ixv-20124">6,525</ix:nonFraction> thousand, less any impairment, adjusted for
observable price changes in orderly transactions for identical or similar investments of the same issuer. No observable price changes
have occurred since initial recognition. Impairment assessment at December 31, 2025: Management performed a qualitative impairment assessment
supported by an independent external valuation (effective date December 31, 2025), which concluded a fair market value of CAD <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" unitRef="cad" id="ixv-20125">124.0</ix:nonFraction> million
for <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" scale="-2" unitRef="pure" id="ixv-20126">100</ix:nonFraction>% of Apollo&#8217;s equity. The implied value of the Company&#8217;s <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="chek:ImpliedInterestPercentage" scale="-2" unitRef="pure" id="ixv-20127">7.5</ix:nonFraction>% interest is approximately USD <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-20128">6.8</ix:nonFraction> million, exceeding
the carrying value of USD <ix:nonFraction contextRef="c75" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-20129">6.5</ix:nonFraction> million by USD <ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AlternativeInvestment" scale="3" unitRef="usd" id="ixv-20130">252,000</ix:nonFraction>. No impairment indicators were identified and <span style="-sec-ix-hidden: hidden-fact-132">no</span> impairment charge is required at
December 31, 2025. The carrying amounts of cash, short-term deposits, and current liabilities approximate fair value due to their short-term
nature.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>




</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-17986"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; SHAREHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Effective November 23, 2022, the Company effected a <ix:nonNumeric contextRef="c36" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-20131">1-for-20</ix:nonNumeric>
reverse share split. Share and per-share amounts prior to November 23, 2022 have been retroactively adjusted. See Note 1(A)(11).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Ordinary shares</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Ordinary shares confer upon their holders the right to receive
dividends, to participate in liquidation distributions, and <ix:nonNumeric contextRef="c0" name="us-gaap:CommonStockVotingRights" id="ixv-20132">one</ix:nonNumeric> vote per share at shareholder meetings.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Changes in ordinary share capital: The Company has conducted
multiple offerings from 2015 through 2022, including its IPO (February 2015), warrant exercises, and registered direct offerings. As
of December 31, 2024, <ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-20133"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20134">5,850,906</ix:nonFraction></ix:nonFraction> ordinary shares were issued and outstanding. On September 4, 2025, the Company issued <ix:nonFraction contextRef="c76" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20135">1,169,596</ix:nonFraction> ordinary
shares in connection with the Ghost Kitchens ARA arrangement, resulting in <ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-20136"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20137">7,020,502</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31,
2025.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">CLA Warrants to purchase <ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-20138">370</ix:nonFraction> ordinary
shares remain outstanding. Private Placement Warrants to purchase <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-20139">84,626</ix:nonFraction> ordinary shares remain outstanding.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-18025"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 &#8211; SHARE-BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company grants options and RSUs under the 2006 Plan and
the 2015 Equity Incentive Plan (including the 2015 U.S. Sub-Plan). No new options or RSUs were granted during 2025 or 2024. As of December
31, 2025, the same number of options and RSUs remain outstanding as at December 31, 2024, with no forfeitures or exercises occurring in
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Details of share-based grants</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The last options were granted on March 30, 2023 (<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-20140">903</ix:nonFraction> options
at $<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20141">2.82</ix:nonFraction> exercise price). The last RSUs were granted in 2022. No share-based grants were made in 2024 or 2025.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 164 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Options Fair Value &#8211; Black-Scholes parameters</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-18071"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The parameters used in applying the Black-Scholes model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-133">No grants</div></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-20142">117</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free rate</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-135">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-20143">3.6</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-137">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-20144">0</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term (years)</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-139">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20145">6.08</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-141">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-20146">1.43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-18171"><b>Effect of share-based compensation on statements of operations</b></ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-20147">144</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-20148">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-20149">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-20150">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-20151">12</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-20152">12</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-20153">57</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Option activity</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-18240"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2025:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life <br/>
(yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-20154">102,288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20155">47.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c95" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20156">7.34</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-20157">102,288</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20158">47.13</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20159">6.34</ix:nonNumeric></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-20160">55,286</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20161">66.01</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-20162">5.87</ix:nonNumeric></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2024:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life<br/> (yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-20163">102,288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20164">35.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20165">8.59</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-20166">102,288</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20167">47.13</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-20168">7.34</ix:nonNumeric></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-20169">55,286</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20170">66.01</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-20171">6.87</ix:nonNumeric></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Weighted average grant date fair values: 2023: $<ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20172">1.17</ix:nonFraction>; 2022:
$<ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20173">4.50</ix:nonFraction>; 2021: $<ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20174">15.70</ix:nonFraction>. <span style="-sec-ix-hidden: hidden-fact-170"><span style="-sec-ix-hidden: hidden-fact-171">No</span></span> options granted in 2025 or 2024.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">As of December 31, 2025, all outstanding options (<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-20175">102,288</ix:nonFraction> at
$<ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-20176">47.13</ix:nonFraction> average exercise price) are out of the money.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"></p><div>

</div><!-- Field: Page; Sequence: 165 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>F.</b></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-18574"><b>RSU activity</b></ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Unvested &#8211; beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20177">2,967</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20178">2,967</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20179">19,703</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8211;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-20180">6,092</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-20181">10,644</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Unvested &#8211; end of year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20182">2,967</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20183">2,967</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-20184">2,967</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">No RSUs were granted in 2025 or 2024. Weighted average grant
date fair value of RSUs awarded during 2022 was $<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-20185">9.20</ix:nonFraction>.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"/><td style="width: 0.25in; text-align: justify">(4)</td><td style="text-align: justify">As of December 31, 2025, unrecognized compensation cost related
to non-vested arrangements is approximately $&#8211; (all prior grants are fully vested or their remaining cost is immaterial).</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-18684"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 &#8211; RESEARCH AND DEVELOPMENT EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" id="ixv-18688"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-20186">4,926</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-20187">144</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SuppliesExpense" scale="3" unitRef="usd" id="ixv-20188">1,530</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Subcontractors and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="chek:SubcontractorsAndConsultantFees" scale="3" unitRef="usd" id="ixv-20189">800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-20190">121</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost for registration of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="chek:PaymentsExpensesForPatents" scale="3" unitRef="usd" id="ixv-20191">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-20192">983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-20193">8,294</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less participation of the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="chek:GrantedRevenue" scale="3" sign="-" unitRef="usd" id="ixv-20194">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total research and development expenses, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-20195">8,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="chek:GeneralAndAdministrativeExpensesTextBlock" id="ixv-18883"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 &#8211; GENERAL AND ADMINISTRATIVE EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" id="ixv-18887"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-20196">200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-20197">799</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-20198">2,055</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-20199">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-20200">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-20201">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitRef="usd">4,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office rent and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-20203">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-20204">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-20205">235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20206">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20207">88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="3" unitRef="usd" id="ixv-20208">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20209">2,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20210">8,409</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20211">2,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20212">2,373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20213">9,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20214">9,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">The 2024 &#8220;Others&#8221; line includes amounts arising
from the Apollo (Apollo) loan arrangements.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.3in"></p><div>

</div><!-- Field: Page; Sequence: 166 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-19057"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8211; IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT
EXTINGUISHMENT</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo (Apollo) totaling $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="3" unitRef="usd" id="ixv-20216">16,400</ix:nonFraction> (First through Fourth Apollo Loans). Management recorded
a full allowance for credit losses on all Apollo Loans as of December 31, 2024, in accordance with ASC 326. Notwithstanding the impairment,
the loans were contractually current and not in default. See Notes 1(A)(7) and 1(A)(8).</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the six months ended June 30, 2025, management reversed
the full impairment allowance and reinstated the loan receivable at $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="3" unitRef="usd" id="ixv-20217">6,525</ix:nonFraction> thousand (<ix:nonFraction contextRef="c108" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-20218">7.5</ix:nonFraction>% of the management-assessed equity value of Apollo
of $<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20219">87,000</ix:nonFraction> thousand at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during 2025. The reinstated receivable
was presented net of a payable owed by the Company to Apollo of $<ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="3" unitRef="usd" id="ixv-20220">2,247</ix:nonFraction> thousand pursuant to ASC 210-20-45, giving a net carrying value
of $<ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="chek:NetCarryingValue" scale="3" unitRef="usd" id="ixv-20221">4,278</ix:nonFraction> thousand as reported in the Form 6-K filed December 30, 2025. On November 14, 2025, following the <ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="chek:ShareholderVotingPercentage" scale="-2" unitRef="pure" id="ixv-20222">98.01</ix:nonFraction>% shareholder vote in
favor of the Merger at the Annual General Meeting, the closing condition in the Exchange Agreement ceased to be substantive and the exchange
was recognized for accounting purposes. The Company derecognized the gross loan receivable of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" unitRef="usd" id="ixv-20223">6,525</ix:nonFraction> thousand and recognized an equity
investment in Apollo at cost of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20224">6,525</ix:nonFraction> thousand, being the carrying value of the consideration surrendered in a noncash exchange. No gain
or loss was recognized on exchange; the estimated fair value of the equity received ($<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="3" sign="-" unitRef="usd" id="ixv-20225">6,596,000</ix:nonFraction>) exceeded the carrying value by $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="chek:ExceedingCarryingValue" scale="3" unitRef="usd" id="ixv-20226">71,000</ix:nonFraction>
(approximately <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-20227">1.1</ix:nonFraction>%), which is not material. The Apollo payable of $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="3" unitRef="usd" id="ixv-20228">2,247,000</ix:nonFraction>, previously netted against the loan receivable, was reclassified
as a standalone liability on November 14, 2025 and reduced to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesReduction" scale="3" unitRef="usd" id="ixv-20229">1,400,000</ix:nonFraction> through settlements and reallocations of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="chek:NotesReallocation" scale="3" unitRef="usd" id="ixv-20230">847,000</ix:nonFraction> during the
second half of 2025. The Apollo equity investment is carried at $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20231">6,525,000</ix:nonFraction> at December 31, 2025, accounted for under ASC 321 (Investments
in Equity Securities) using the measurement alternative. See Note 9 for classification, measurement, and impairment assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="ixv-19069"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Impairment of loans receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoansReceivable" scale="3" unitRef="usd" id="ixv-20232">16,487</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on debt extinguishment and conversion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-20233">6,525</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" scale="3" unitRef="usd" id="ixv-20234">6,525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" scale="3" sign="-" unitRef="usd" id="ixv-20235">16,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="ixv-19148"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 &#8211; FINANCE INCOME (EXPENSE), NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-19155"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income on short-term deposits and other</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-20236">172</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-20237">809</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-20238">1,770</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bank fees and interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="3" unitRef="usd" id="ixv-20239">185</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="3" unitRef="usd" id="ixv-20240">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="3" unitRef="usd" id="ixv-20241">13</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in provision for royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="chek:ChangesInLiabilityToPayRoyalties" scale="3" unitRef="usd" id="ixv-20242">94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-20243">188</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Changes in fair value of derivatives</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" unitRef="usd" id="ixv-20244">56</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total financing income, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-20245">12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-20246">800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-20247">1,719</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 167 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-19289"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 &#8211; EARNINGS (LOSS) PER SHARE</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Basic earnings (loss) per share is computed based on the
weighted average number of shares outstanding during each year. Diluted earnings (loss) per share equals basic in periods of net loss,
as all potentially dilutive securities are anti-dilutive. In periods of net income, diluted EPS reflects the dilutive effect of outstanding
options and warrants, to the extent dilutive.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All outstanding options and warrants were excluded from the
2024 and 2023 diluted loss per share calculations as their effect was anti-dilutive. For the year ended December 31, 2025, outstanding
options and warrants are out of the money and accordingly also excluded from diluted EPS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-19297"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Computation of basic and diluted earnings (loss) per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-20248">4,140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20249">25,149</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20250">17,568</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average ordinary shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20251"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20252">6,232,226</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20253"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20254">5,849,013</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20255"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20256">5,848,737</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Earnings (loss) per ordinary share &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-20257"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-20258">0.66</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-20259"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-20260">4.30</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-20261"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-20262">3.00</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Note: Weighted average shares for 2025 reflect the issuance
of <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-20263">1,169,596</ix:nonFraction> shares on September 4, 2025 (246 pre-issuance days at <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-20264">5,850,906</ix:nonFraction> shares + 119 post-issuance days at <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" unitRef="shares" id="ixv-20265">7,020,502</ix:nonFraction> shares, divided
by 365 days).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-19375"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-dilutive instruments excluded from diluted EPS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(number)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Warrants and share options</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-20266">2,631,603</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-20267">2,631,603</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-20268">2,631,603</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-19418"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 &#8211; RELATED PARTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><ix:nonNumeric contextRef="c120" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c120_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-19428"><b>Compensation to non-executive directors:</b></ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c120_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Fees, including reimbursement of expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20269">109</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20270">124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20271">448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20272">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20273">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20274">124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="chek:Compensationtothenon-executivedirectors" scale="3" unitRef="usd" id="ixv-20275">454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Transactions with related parties:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<ix:nonNumeric contextRef="c130" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-19513"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Sigalit Kimchy: No consulting fees were paid to Sigalit Kimchy
(wife of Yoav Kimchy, the Company&#8217;s Chief Technology Officer) during the year ended December 31, 2025. Ms. Kimchy had previously
served as marcom and user interface lead under an employment agreement dated April 4, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt">Consulting fees, including share-based compensation and reimbursement of expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20276">188</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20277">95</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20278">19</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20279">188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20280">95</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-20281">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 168 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock-c0_cont_1" escape="true" name="chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" id="ixv-19589"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 &#8211; APOLLO TECHNOLOGY CAPITAL CORPORATION &#8211; LOAN
RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">The Company holds an equity investment in Apollo Technology Capital
Corporation (&#8220;Apollo&#8221;, formerly Apollo AI Corp.), a technology-driven AI marketplace platform connecting homebuyers, real
estate agents, and mortgage providers across North American residential real estate markets. The investment arose from the conversion
of a series of loan receivables from Apollo (the &#8220;Exchange Indebtedness&#8221;) with aggregate principal of USD <ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-20282">16,648,253</ix:nonFraction>, pursuant
to the Exchange Agreement entered into on June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Initial Impairment &#8211; Year Ended December 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">During the year ended December 31, 2024, the Company fully impaired
its loan receivable from Apollo under ASC 310 and ASC 326, reducing the net carrying value to <span style="-sec-ix-hidden: hidden-fact-216">nil</span>, reflecting Apollo&#8217;s financial
distress, recurring operating losses, and negative working capital at that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Reversal of Impairment and Loan Reinstatement &#8211; Six Months
Ended June 30, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">During the six months ended June 30, 2025, management determined that
the impairment indicators no longer existed and reinstated the recoverable portion of the loan at USD <ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="chek:ReinstatedRecoverableLoan" scale="3" unitRef="usd" id="ixv-20283">6,525,000</ix:nonFraction> (<ix:nonFraction contextRef="c109" decimals="3" format="ixt:num-dot-decimal" name="chek:PercentageOfManagementAssessedEquity" scale="-2" unitRef="pure" id="ixv-20284">7.5</ix:nonFraction>% of USD <ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="chek:AmountOfManagementAssessedEquity" scale="3" unitRef="usd" id="ixv-20285">87,000,000</ix:nonFraction>,
being the management-assessed equity value of Apollo at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during
2025. The reinstated receivable was presented net of a payable owed by Check-Cap to Apollo of USD <ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="3" unitRef="usd" id="ixv-20286">2,247,000</ix:nonFraction>, resulting in a net carrying
value of USD <ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="chek:CarryingValueOfReinstatedReceivable" scale="3" unitRef="usd" id="ixv-20287">4,278,000</ix:nonFraction> as at June 30, 2025.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Debt-for-Equity Exchange &#8211; November 14, 2025</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On June 30, 2025, the (the &#8220;Exchange Agreement&#8221;) with Apollo
under which the Exchange Indebtedness would be exchanged for common shares of Apollo representing a <ix:nonFraction contextRef="c109" decimals="3" format="ixt:num-dot-decimal" name="chek:PercentageOfShareholding" scale="-2" unitRef="pure" id="ixv-20288">7.5</ix:nonFraction>% shareholding. The Exchange Agreement
was conditional on the completion of the Merger . At the Annual General Meeting held on November 14, 2025, Check-Cap shareholders voted
<ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="chek:ShareholderVotingPercentage" scale="-2" unitRef="pure" id="ixv-20289">98.01</ix:nonFraction>% in favor of the merger, at which point the closing condition ceased to be substantive and the exchange was recognized for accounting
purposes.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On November 14, 2025, the Company derecognized the loan receivable
of USD <ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-20290">6,525,000</ix:nonFraction> and recognized an equity investment in Apollo at cost of USD <ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" unitRef="usd" id="ixv-20291">6,525,000</ix:nonFraction>, being the carrying value of the consideration
surrendered. No gain or loss was recognized on exchange. Apollo&#8217;s shares do not have a readily determinable fair value; accordingly,
the investment is carried at cost under the measurement alternative provided by ASC 321-10-35-2. The Apollo payable of USD <ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLoans" scale="3" unitRef="usd" id="ixv-20292">2,247,000</ix:nonFraction>,
previously netted against the loan receivable, was reclassified as a standalone liability.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investment &#8211; Classification and Subsequent Measurement</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The equity investment is classified as an equity security under ASC
321. The Company holds <ix:nonFraction contextRef="c75" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-20293">7.5</ix:nonFraction>% of Apollo&#8217;s issued and outstanding shares and does not have significant influence, as evidenced by the
absence of board representation, shared management, governance rights, or substantive participating rights. The equity method under ASC
323 does not apply.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The investment is carried at cost of USD <ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" unitRef="usd" id="ixv-20294">6,525,000</ix:nonFraction> under the measurement
alternative (ASC 321-10-35-2), adjusted for observable price changes in orderly transactions for identical or similar investments. No
observable price changes have occurred since initial recognition.</p></ix:nonNumeric><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 169 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Impairment Assessment &#8211; December 31, 2025</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">At December 31, 2025, management performed a qualitative impairment
assessment supported by an independent external valuation report, effective date December 31, 2025. The valuation concluded a Fair Market
Value of CAD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="chek:ValuationOfFairValueMarket" scale="6" unitRef="cad" id="ixv-20295">124.0</ix:nonFraction> million for <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="chek:EquityPercentageOfWeightedAverage" scale="-2" unitRef="pure" id="ixv-20296">100</ix:nonFraction>% of Apollo equity using a weighted average of the Discounted Cash Flow method (<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="chek:PercentageOfDiscountedCashFlowMethod" scale="-2" unitRef="pure" id="ixv-20297">30</ix:nonFraction>% weight) and Comparable
Company Method (<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="chek:PercentageOfComparableCompanyMethod" scale="-2" unitRef="pure" id="ixv-20298">70</ix:nonFraction>% weight), with a cost of equity of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="chek:PercentageOfCostEquity" scale="-2" unitRef="pure" id="ixv-20299">13.53</ix:nonFraction>%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Check-Cap&#8217;s <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="chek:PercentageOfValuationInterest" scale="-2" unitRef="pure" id="ixv-20300">7.5</ix:nonFraction>% interest implied by the valuation is CAD <ix:nonFraction contextRef="c143" decimals="-5" format="ixt:num-dot-decimal" name="chek:InterestImpliedValuation" scale="6" unitRef="cad" id="ixv-20301">9.3</ix:nonFraction>
million (USD <ix:nonFraction contextRef="c143" decimals="-5" format="ixt:num-dot-decimal" name="chek:InterestImpliedValuation" scale="6" unitRef="usd" id="ixv-20302">6.8</ix:nonFraction> million approximately at the December 31, 2025 CAD/USD rate of <ix:nonFraction contextRef="c0" decimals="6" format="ixt:num-dot-decimal" name="chek:PercentageOfImpliedRate" scale="-2" unitRef="pure" id="ixv-20303">0.7287</ix:nonFraction>), which exceeds the carrying value of USD <ix:nonFraction contextRef="c144" decimals="-5" format="ixt:num-dot-decimal" name="chek:InterestImpliedValuation" scale="6" unitRef="usd" id="ixv-20304">6.5</ix:nonFraction> million
by USD <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="chek:InterestImpliedValuation" scale="3" unitRef="usd" id="ixv-20305">252,000</ix:nonFraction>. No impairment indicators were identified and no impairment charge is required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Carrying Value Summary (USD)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-19648"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loan receivable &#8211; gross principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableGrossCurrent" scale="3" unitRef="usd" id="ixv-20306">16,648,253</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" scale="3" unitRef="usd" id="ixv-20307">16,648,253</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loan receivable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity investment in Apollo (at cost)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" unitRef="usd" id="ixv-20308">6,525,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payable to Apollo</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="3" unitRef="usd" id="ixv-20309">1,399,579</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-19752"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span>The Company has evaluated subsequent
events through January 1, 2026 and the date on which these consolidated financial statements were issued, and has determined that there
are no subsequent events requiring recognition or disclosure in these consolidated financial statements.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 170; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>
</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="chek:RoyaltiesProvision" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-11" name="chek:RoyaltiesProvision" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-13" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-14" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-15" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-16" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-17" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-18" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-19" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-20" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-21" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-41" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-42" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-45" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-47" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-49" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-51" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-53" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-55" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:PaymentsToAcquireLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="us-gaap:PaymentsToAcquireLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-59" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-62" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-64" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-65" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-67" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-68" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-69" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-70" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-72" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-73" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-74" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-75" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-76" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-77" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-78" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-79" name="chek:PrepaidGovernmentInstitutions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-80" name="chek:PrepaidGovernmentInstitutions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-81" name="us-gaap:PrepaidExpenseCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-82" name="us-gaap:PrepaidExpenseCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-83" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-84" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-85" name="us-gaap:OtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-86" name="us-gaap:OtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-87" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-88" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-89" name="chek:AccumulatedImpairmentOnPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-90" name="chek:AccumulatedImpairmentOnPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-91" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-92" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-93" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-94" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-95" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-96" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-97" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-98" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-99" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-100" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-101" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-102" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-103" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-104" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-105" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-106" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-107" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-108" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-109" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-110" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-111" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-112" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-113" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-114" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-115" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-116" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-117" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-119" name="us-gaap:OperatingLossCarryforwards" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-120" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-121" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-122" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-123" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-124" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-125" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-126" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-127" name="chek:RoyaltiesProvision" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-128" name="us-gaap:GrantsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-129" name="us-gaap:GrantsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-130" name="us-gaap:FinancialInstrumentsOwnedAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-131" name="us-gaap:FinancialInstrumentsOwnedAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-132" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-133" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-134" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-136" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-139" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c4" id="hidden-fact-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-141" name="us-gaap:SharePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-142" name="us-gaap:SharePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-143" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-144" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-145" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-146" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-147" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-148" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-149" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-150" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-151" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-153" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-154" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-155" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-156" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-158" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-160" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-162" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-166" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-167" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-168" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-169" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-170" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-171" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-172" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-173" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-174" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-175" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-176" name="us-gaap:SuppliesExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-177" name="us-gaap:SuppliesExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-178" name="chek:SubcontractorsAndConsultantFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-179" name="chek:SubcontractorsAndConsultantFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-180" name="us-gaap:DepreciationNonproduction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-181" name="us-gaap:DepreciationNonproduction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-182" name="chek:PaymentsExpensesForPatents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-183" name="chek:PaymentsExpensesForPatents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-184" name="us-gaap:OtherExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-185" name="us-gaap:OtherExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-186" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-187" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-188" name="chek:GrantedRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-189" name="chek:GrantedRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-190" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-191" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-192" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-193" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-194" name="us-gaap:Depreciation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-195" name="us-gaap:AdjustmentForAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-196" name="us-gaap:AdjustmentForAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-197" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-198" name="chek:ImpairmentOfLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-199" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-200" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-201" name="chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-202" name="chek:ChangesInLiabilityToPayRoyalties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-203" name="chek:ChangesInLiabilityToPayRoyalties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-204" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-205" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-206" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-207" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c124" id="hidden-fact-208" name="chek:Compensationtothenon-executivedirectors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c125" id="hidden-fact-209" name="chek:Compensationtothenon-executivedirectors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-210" name="us-gaap:NotesAndLoansReceivableGrossCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-211" name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-212" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-213" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-214" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-215" name="us-gaap:LoansPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-216" name="chek:ReducingCarryingValueNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-20529">0001610590</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-20530">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-20531">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="chek-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-192 hidden-fact-193 ix_10_fact" toRefs="ix_1_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-17</xbrli:startDate>
    <xbrli:endDate>2025-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">chek:CheckCapMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-08</xbrli:startDate>
    <xbrli:endDate>2024-09-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">chek:CheckCapMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:FirstApolloLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:SecondApolloLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:SecondApolloLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:FourthApolloLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-23</xbrli:startDate>
    <xbrli:endDate>2022-11-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:ComputersAndAuxiliaryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GhostKitchensARAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:DevelopmentAreaAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-12-22</xbrli:startDate>
    <xbrli:endDate>2016-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:RestOfCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-12-22</xbrli:startDate>
    <xbrli:endDate>2016-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-12-22</xbrli:startDate>
    <xbrli:endDate>2016-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:DesignerRoyaltiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">chek:RoyaltiesToAnASICDesignerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">chek:RoyaltiesToAnASICDesignerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-09-04</xbrli:startDate>
    <xbrli:endDate>2025-09-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-30</xbrli:startDate>
    <xbrli:endDate>2023-03-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-30</xbrli:startDate>
    <xbrli:endDate>2025-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-14</xbrli:startDate>
    <xbrli:endDate>2025-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-09-04</xbrli:startDate>
    <xbrli:endDate>2025-09-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-09-04</xbrli:startDate>
    <xbrli:endDate>2025-09-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-09-04</xbrli:startDate>
    <xbrli:endDate>2025-09-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:NonExecutiveDirectorsCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:ExchangeIndebtednessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-14</xbrli:startDate>
    <xbrli:endDate>2025-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV7][8TKx/x5/wssKqoxe9Zn9AByOYrFTbC9FKlXetdhYTXfh8XOWm47RJkZ0vfld69Q/OFcqSpW4k6Wo4nCOk8NXUlGrRndwP2as05B7NOekCgmATzorOYgr7CvU1kSAyd6ZRvgtATNAhJDihUNy8oBB+2pCtDEqg8bNCMlHjlZ2kEVhEDF/Yw4efehyKizwY3HPqoxau2rP2n8g2zDRgBbOsyJk1a2qsWA1RJyhnN6LqeOIh5BQTh+Wqj3CPG9VPubsFmUvaJrUnuduSsHdsxqO9ZfIZEEBHpvTYZVIZk7mXd7ta0WGB1aqrWwoeB6sgcJsXUzpzMuraidBaThytw==] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.39
<SEQUENCE>2
<FILENAME>ea028762301ex4-39.htm
<DESCRIPTION>EXCHANGE AGREEMENT, DATED SEPTEMBER 12, 2025 BETWEEN CHECK-CAP LTD. AND APOLLO TECHNOLOGY CAPITAL CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 4.39</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXCHANGE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>by
and between</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APOLLO
TECHNOLOGY CAPITAL CORPORATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><I>and</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">CHECK-CAP LTD.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Dated as of September 12,
2025</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>EXCHANGE AGREEMENT </B>(this &ldquo;Agreement&rdquo;)
dated as of the 12<SUP>th</SUP> day of September, 2025, by and between Apollo Technology Capital Corporation (formerly known as Nobul
AI Corp.), an Ontario corporation (the &ldquo;Company&rdquo;), and Check-Cap Ltd., an Israeli company (the &ldquo;Holder&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>WHEREAS</B>, the Holder holds the
debt of the Company as set forth on Schedule I attached hereto, along with all incurred but unpaid interest (such securities, the &ldquo;<B>Exchange
Indebtedness</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>WHEREAS</B>, subject to the terms
and conditions set forth in this Agreement and pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), the Company and the Holder have agreed to extinguish the Exchange Indebtedness in exchange for the number of shares of
the Company&rsquo;s common stock (the &ldquo;<B>Common Stock</B>&rdquo;) set forth on Schedule I attached hereto (the &ldquo;<B>Exchange
Shares</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>NOW, THEREFORE</B>, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the premises and the mutual
agreements, representations and warranties, provisions and covenants contained herein, the parties hereto, intending to be legally bound
hereby, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Definitions.</B> In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth
in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&ldquo;Affiliate&rdquo;
</B>means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&ldquo;Apollo
Loans&rdquo; </B>means, collectively, (i) that certain Loan Agreement, dated as of July 28, 2024, by and between the Company and the Holder,
(ii) that certain Loan Agreement, dated as of December 23, 2024, by and between the Company and the Holder, (iii) that certain Loan Agreement,
dated as of July 2, 2025, by and between the Company and the Holder, and (iv) that certain Loan Agreement, dated as of July 3, 2025, by
and between the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&ldquo;Liens&rdquo;</B>
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><B>&ldquo;Loan Agreements&rdquo; </B>means the Apollo Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&ldquo;Rule
144&rdquo; </B>means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>&ldquo;Transaction
Documents&rdquo; </B>means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><B>2. Exchange. </B>On the
Closing Date (as defined below), subject to the terms and conditions of this Agreement, the Company agrees to issue to the Holder,
in exchange for the Exchange Indebtedness held by the Holder as of the date hereof and as set forth on Schedule I attached hereto, a
number of shares of Common Stock (the &ldquo;Shares&rdquo;) equal to the Holder&rsquo;s Exchange Shares. Subject to the conditions
set forth below, the Exchange shall take place virtually at the offices of Paul Hastings LLP (&ldquo;Paul Hastings&rdquo;), on the
BCA Termination Effective Date (as defined in the BCA Termination Agreement), or at such other time and place as the Company and the
Holder mutually agree (the &ldquo;Closing&rdquo; and the &ldquo;Closing Date&rdquo;). At the Closing, the following transactions
shall occur (such transactions in this Section 2, the &ldquo;Exchange&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>On the Closing Date, in exchange for the Exchange Indebtedness, the Company shall issue the Shares to the Holder. Upon receipt
of the certificate or other evidence of the issuance and delivery of the Shares to the Holder in accordance with this Section 2.1, all
of the Holder&rsquo;s rights with respect to the Exchange Indebtedness shall be extinguished and the Holder shall acknowledge the payment
of an amount equal to the Holder&rsquo;s Exchange Shares as repayment pursuant to the Loan Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></B>The Company and the Holder shall execute and/or deliver such other documents and agreements as are customary and reasonably
necessary to effectuate the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt">3.</TD><TD>Closing Conditions.</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conditions to Holder&rsquo;s Obligations.</B> The obligation of the Holder to consummate the Exchange is subject to the fulfilment,
prior to or at the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>Representations and Warranties. </B>The representations and warranties of the Company contained in this Agreement shall be true
and correct in all material respects on the date hereof and on and as of the Closing Date as if made on and as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Actions.</B> No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain substantial damages in
respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Proceedings and Documents. </B>All proceedings in connection with the transactions contemplated hereby and all
documents and instruments incident to such transactions shall be satisfactory in substance and form to the Holder, and the Holder
shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>Closing of the MBody AI Transactions. </B>The transactions contemplated by that certain Agreement and Plan of Merger by and among
CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Holder, the Holder and MBody AI Corp., a Nevada corporation
(the &ldquo;Transaction Agreement&rdquo;), shall have closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Conditions to the Company&rsquo;s Obligations. </B>The obligation of the Company to consummate the Exchange is subject to the fulfilment,
to the Company&rsquo;s reasonable satisfaction, prior to or at the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Representations and Warranties. </B>The representations and warranties of the Holder contained in this Agreement shall be true
and correct in all material respects on the date hereof and on and as of the Closing Date as if made on and as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Actions.</B> No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial damages in
respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Proceedings and Documents. </B>All proceedings in connection with the transactions contemplated hereby and all documents and instruments
incident to such transactions shall be satisfactory in substance and form to the Company and the Company shall have received all such
counterpart originals or certified or other copies of such documents as the Company may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Closing of the MBody AI Transactions. </B>The transactions contemplated by the Transaction Agreement shall have closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.05pt; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Representations and Warranties of the Company.
                                            </B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
                                            Company hereby represents and warrants to the Holder that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Authorization; Enforcement. </B>The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by this Agreement, including but not limited to the Exchange. The execution and delivery of this Agreement and
the Shares by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by
all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s
stockholders in connection herewith or therewith. The Transaction Documents have been duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.2 No Conflicts. </B>The
execution, delivery and performance by the Company of this Agreement and the consummation by it of the transactions contemplated
hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s
certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien
upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a
party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which
any property or asset of the Company or a Subsidiary is materially bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a material adverse effect on the business, operations or
financial condition of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Valid Issuance of the Securities.</B> The Shares are duly authorized and, when issued and paid for in accordance with this Agreement,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions
on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock a number of shares
of Common Stock for issuance of the Shares issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Acknowledgment Regarding Holder&rsquo;s Exchange of Exchange Securities for Shares. </B>The Company acknowledges and agrees that
the Holder is acting solely in the capacity of arm&rsquo;s length Holder with respect to this Agreement and the transactions contemplated
hereby and that the Holder is not (i) an officer or director of the Company, (ii) an &ldquo;affiliate&rdquo; of the Company (as defined
in Rule 144 promulgated under the Securities Act), or (iii) to the knowledge of the Company, a &ldquo;beneficial owner&rdquo; of more
than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended). The
Company further acknowledges that the Holder is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to this Agreement and the transactions contemplated hereby, and any advice given by the Holder or any of its representatives
or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental to the Holder&rsquo;s acceptance
of the Shares. The Company further represents to the Holder that the Company&rsquo;s decision to enter into this Agreement has been based
solely on the independent evaluation by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Commission Paid. </B>Neither the Company nor any of its Affiliates nor any person acting on behalf of or for the benefit of
any of the foregoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration for soliciting
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Compliance With Laws. </B>The Company has not violated any law or any governmental regulation or requirement which violation has
had or would reasonably be expected to have a material adverse effect on its business, and the Company has not received written notice
of any such violation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Consents; Waivers. </B>No consent, waiver, approval or authority of any nature, or other formal action, by any Person, not already
obtained, is required in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company
of the transactions provided for herein and therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36.05pt; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Representations and Warranties of the Holder.
                                            </B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
                                            Holder hereby represents, warrants and covenants that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Authorization. </B>The Holder has full power and authority to enter into this Agreement, to perform its obligations hereunder and
to consummate the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery of this
Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Validity; Enforcement; No Conflicts. </B>This Agreement to which the Holder is a party has been duly and validly authorized, executed
and delivered on behalf of the Holder and shall constitute the legal, valid and binding obligations of the Holder enforceable against
the Holder in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or
to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally,
the enforcement of applicable creditors&rsquo; rights and remedies. The execution, delivery and performance by the Holder of this Agreement
to which the Holder is a party and the consummation by the Holder of the transactions contemplated hereby will not (i) result in a violation
of the organizational documents of the Holder or (ii) conflict with, or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Holder is a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities or &ldquo;blue sky&rdquo; laws) applicable to the Holder, except in the case
of clause (ii) above, for such conflicts, defaults or rights which would not, individually or in the aggregate, reasonably be expected
to have a material adverse effect on the ability of the Holder to perform its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Commission Paid. </B>Neither the Holder nor any of its Affiliates nor any person acting on behalf of or for the benefit of any
of the foregoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the
meaning of Section 3(a)(9) of the Securities Act and the rules and regulations of the Commission promulgated thereunder) for soliciting
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt">6.</TD><TD>Additional Covenants.</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Blue Sky.</B> The Company shall make all filings and reports relating to the Exchange required under applicable securities or &ldquo;Blue
Sky&rdquo; laws of the states of the United States following the date hereof, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Fees and Expenses. </B>Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any,
and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Capital Changes. </B>From the date hereof until the Holder no longer holds any Exchange Shares, the Company shall not undertake
a reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.05pt">7.</TD><TD>Miscellaneous.</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Successors and Assigns. </B>Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Governing Law; Jurisdiction; Jury Trial. </B>All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of
any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state or
federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF
ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Titles and Subtitles. </B>The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notices. </B>Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement
must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party)
or by electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to the
party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">To the Company:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">c/o Apollo Technology Capital
Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">130 King Street West, Suite 1800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Toronto, ON MX 1E3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attention:
Regan McGee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">E-mail: rmcgee@apollocapital.ca</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">To the Holder:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Check-Cap Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">29 Abba Hushi Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">P.O. Box 1271</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Isfiya, 3009000, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attention: David Lontini, Chairman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">E-mail: david@londacorp.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">With a copy to:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Paul Hastings LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">2050 M Street, NW
Washington, DC 20036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">Attention: Sean Donahue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">E-mail: seandonahue@paulhastings.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Written confirmation
of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the sender&rsquo;s facsimile machine or e-mail containing the time, date, recipient facsimile number and an image of the first page
of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile
or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Finder&rsquo;s Fees.</B> Each party represents that it neither is nor will be obligated for any finders&rsquo; fee or commission
in connection with this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Amendments and Waivers. </B>Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the Holder. Any amendment or waiver effected in accordance with this paragraph shall be binding upon the Holder and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Severability. </B>If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and
shall be enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Entire Agreement. </B>This Agreement represents the entire agreement and understanding between the parties concerning the Exchange
and the other matters described herein and therein and supersedes and replaces any and all prior agreements and understandings solely
with respect to the subject matter hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: justify"><B>7.10
Interpretation. </B>Unless the context of this Agreement clearly requires otherwise,</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(a) references to the plural
include the singular, the singular the plural, the part the whole, (b) references to any gender include all genders, (c) &ldquo;including&rdquo;
has the inclusive meaning frequently identified with the phrase &ldquo;but not limited to&rdquo; and (d) references to &ldquo;hereunder&rdquo;
or &ldquo;herein&rdquo; relate to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Third Party Beneficiaries. </B>This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Survival. </B>The representations, warranties and covenants of the Company and the Holder contained herein shall survive the Closing
and delivery of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.13 Further Assurances.
</B>Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>7.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>No Strict Construction. </B>The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">[SIGNATURES ON THE FOLLOWING
PAGES]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">IN WITNESS WHEREOF, the parties have caused
this Exchange Agreement to be duly executed and delivered as of the date provided above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-top: 0pt; font-weight: bold">THE COMPANY</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-top: 0pt"><B>APOLLO TECHNOLOGY CAPITAL CORPORATION</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; width: 6%">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">By: <U></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; text-align: left">/s/ Regan McGee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">Name: </TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">Regan McGee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-top: 0pt; text-align: left">Title:</TD>
    <TD STYLE="padding-right: 0pt; padding-top: 0pt; text-align: left">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-right: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-right: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0pt; padding-right: 0pt; font-weight: bold">THE HOLDER CHECK-CAP LTD.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0pt; padding-right: 0pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">By: </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; text-align: left">/s/ David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">Name: </TD>
    <TD STYLE="padding-top: 0pt; padding-right: 0pt; text-align: left">David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-right: 0pt">Title:</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-right: 0pt">Chair, Board of Directors</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="text-decoration: underline solid">SCHEDULE
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">EXCHANGE INDEBTEDNESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">The Exchange Indebtedness consists of
all amounts outstanding under the following Loan Agreements, each by and between the Company and the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Loan Agreement, dated as of July 28, 2024 (the &ldquo;July
2024 Apollo Loan&rdquo;).</TD>
</TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Loan Agreement, dated as of December 23, 2024 (the &ldquo;December
2024 Apollo Loan&rdquo;).</TD>
</TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Loan Agreement, dated as of July 2, 2025 (the &ldquo;July
2, 2025 Apollo Loan&rdquo;).</TD>
</TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">Loan Agreement, dated as of July 3, 2025 (the &ldquo;July
3, 2025 Apollo Loan&rdquo;).</TD>
</TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Principal Amounts Outstanding in the Exchange Indebtedness:</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; font-weight: bold">Loan Agreement</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal Amount (USD)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-left: 0pt">July 2024 Apollo Loan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,000,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">December 2024 Apollo Loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,000,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">July 2, 2025 Apollo Loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,100,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">July 3, 2025 Apollo Loan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,248,253.29</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total Exchange Indebtedness</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,348,253.29</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>Accrued but unpaid interest under the Loan Agreements, if
any, is included within the Exchange Indebtedness.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><U>Exchange Shares:</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">The number of common shares equating to a
7.5% shareholding at the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.40
<SEQUENCE>3
<FILENAME>ea028762301ex4-40.htm
<DESCRIPTION>BCA TERMINATION AGREEMENT, DATED SEPTEMBER 12, 2025 BETWEEN CHECK-CAP LTD. AND APOLLO TECHNOLOGY CAPITAL CORPORATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.40</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BCA TERMINATION AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This TERMINATION AGREEMENT
(this &ldquo;<U>BCA Termination Agreement</U>&rdquo;) is entered into as of September 12, 2025, by and among Apollo Technology Capital
Corporation (formerly known as Nobul AI Corp.), an Ontario corporation (&ldquo;<U>Apollo</U>&rdquo;), and Check-Cap Ltd., an Israeli company
(&ldquo;<U>Check-Cap</U>&rdquo;). Apollo and Check-Cap are sometimes referred to individually as a &ldquo;<U>Party</U>&rdquo; and, collectively,
as &ldquo;<U>Parties</U>&rdquo;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms
in the BCA (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, reference
is made to that certain Exchange Agreement, dated as of September 12, 2025, by and between Apollo and Check-Cap (the &ldquo;<U>Exchange
Agreement</U>&rdquo;), pursuant to which Apollo and Check-Cap agreed to extinguish certain indebtedness of Apollo for shares of capital
stock of Apollo, subject to and conditioned upon the Closing (as defined herein) and effective as of the BCA Termination Effective Date
(as defined herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, reference
is made to that certain Business Combination Agreement, dated as of March 25, 2024 (as amended, the &ldquo;<U>BCA</U>&rdquo;), made by
and among Apollo and Check-Cap;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Section 9.1(a)
of the BCA provides that the BCA may be terminated and the transactions contemplated thereby may be abandoned at any time prior to the
Closing Date by the mutual written consent of Check-Cap and Apollo; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, subject to
and conditioned upon the Closing and effective as of the BCA Termination Effective Date, Check-Cap and Apollo have mutually consented
to the termination of the BCA and the resulting abandonment of the transactions contemplated thereby, as of the date of this BCA Termination
Agreement and desire to enter into this BCA Termination Agreement as their mutual written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the mutual agreements set forth herein and intending to be legally bound, Check-Cap and Apollo (for itself and Merger
Sub) hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination of the BCA</U>. Concurrently with the closing of the merger pursuant to that certain Agreement and Plan of Merger,
dated September&nbsp;12, 2025, by and among the Company, MBody AI Corp, a Nevada corporation, and CC Merger Sub Inc., a Nevada corporation
and a direct, wholly owned subsidiary of the Company (the &ldquo;<U>Closing</U>&rdquo;) and in accordance with Section 9.1(a) of the BCA
and the terms of this BCA Termination Agreement, the BCA shall be automatically terminated by mutual written consent of the Parties (the
&ldquo;<U>BCA Termination</U>&rdquo;) effective as of the Closing (the date of such termination, the &ldquo;<U>BCA Termination Effective
Date</U>&rdquo;). Except as set forth in Section 9.2 of the BCA, effective as of the BCA Termination Effective Date, the Parties&rsquo;
right, title, and interest in and rights, duties and obligations with respect to the BCA will terminate and be of no further legal force
or effect without any further action of any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Mutual Release; Waiver</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Effective as of the BCA Termination Effective Date, each of Check-Cap, Apollo and their respective partners,
members, shareholders, directors, officers, employees, Subsidiaries, Affiliates, agents or other Representatives (each, a &ldquo;<U>Releasing
Party</U>&rdquo;) represents and warrants that it (i) has no Claims (as defined below) and (ii) has not transferred or assigned, or purported
to transfer or assign, any Claims, and covenants that it will not transfer or assign, or purport to transfer or assign, any Claims, in
each case, against Check-Cap, on the one hand, or Apollo, on the other hand, or any current or former Affiliates of Check-Cap or Apollo,
which in each case includes, but is not limited to, Subsidiaries, officers, directors, employees, managers, partners, principals, advisors,
agents, stockholders, members, investors, equity holders or other representatives, successors, predecessors or assigns of such Party (collectively,
the &ldquo;<U>Released Parties</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Effective as of the BCA Termination Effective Date, each Releasing Party hereby fully, unconditionally,
irrevocably and forever releases, acquits and discharges the other Releasing Party&rsquo;s Released Parties from any and all claims, demands,
allegations, assertions, complaints, controversies, charges, duties, grievances, rights, causes of action, actions, suits, liabilities,
debts, obligations, indemnification rights, promises, commitments, agreements, guarantees, endorsements, duties, damages, punitive damages,
costs, losses, debts, interest and expenses (including attorneys&rsquo; fees and costs incurred) of any nature whatsoever, including without
limitation, notwithstanding anything to the contrary contained in the BCA (together with the other documents and transactions contemplated
thereby) relating to breach of contract, fraud or willful breach (whether direct or indirect, known or unknown, disclosed or undisclosed,
matured or unmatured, accrued or unaccrued, asserted or unasserted, absolute or contingent, determined or conditional, express or implied,
fixed or variable and whether vicarious, derivative, joint, several or secondary) in connection with or arising from the BCA (together
with the other documents and transactions contemplated thereby), including but not limited to their negotiation, execution, performance
or nonperformance (collectively, &ldquo;<U>Claims</U>&rdquo;), that such Releasing Party has or had or can, will or may now or hereafter
have, including any Claims arising under any applicable Law. Each Party acknowledges and understands that there is a risk that subsequent
to the execution of this BCA Termination Agreement, each Party may discover, incur or suffer Claims that were unknown or unanticipated
at the time of the execution of this BCA Termination Agreement, and which, if known on the date of the execution of this BCA Termination
Agreement, might have materially affected such Party&rsquo;s decision to enter into and execute this BCA Termination Agreement. Each Party
further agrees that by reason of the releases contained herein, each Party is assuming the risk of such unknown Claims and agrees that
this BCA Termination Agreement applies thereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this BCA Termination Agreement to the contrary, it is the express
intention of the Parties that the Claims described in paragraphs (a) and (b) of <U>Section 2</U> of this BCA Termination Agreement do
not include claims, if any, based upon a breach of this BCA Termination Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Each Party acknowledges and agrees that it is familiar with Section 1542 of the Civil Code of the State
of California (&ldquo;<U>Section 1542</U>&rdquo;), which provides as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS
THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT
IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective as of the BCA Termination Effective
Date, each Party hereby waives and relinquishes any rights and benefits that such Party may have under Section 1542 or any similar statute
or common law principle of any jurisdiction. Each Party acknowledges that it may hereafter discover facts in addition to or different
from those that such Party now knows or believes to be true with respect to the subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Conversion and Transfer of Outstanding Indebtedness</U>. Concurrently with the BCA Termination on the BCA Termination Effective
Date, the parties hereby agree that the following outstanding indebtedness of Apollo held by Check-Cap shall be converted as follows,
in accordance with the Exchange Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">$16,348,253.29 of indebtedness of Apollo
that is currently outstanding, pursuant to those certain loan agreements between Apollo and Check-Cap, shall be converted into a 7.5%
equity position in Apollo that will be owned by Check-Cap and each of the related loan agreements between Check-Cap and Apollo will be
cancelled for no further consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Compensation</U>. The Parties expressly state there are no amounts owed and due of any kind with respect to the BCA. Therefore,
the Parties are not entitled to seek any payment or different consideration of any kind, under or arising from the terms of the BCA. Apollo
hereby waives any further interest in or claim to the Nasdaq listing of Check-Cap, or any of Check-Cap&rsquo;s other assets, including,
but not limited to, intellectual property or carryforward losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Survival</U>. Effective as of the BCA Termination Effective Date, all Parties&rsquo; right, title, and interest in and rights,
duties and obligations with respect to the BCA will terminate and be of no further legal force or effect, except that, notwithstanding
anything to the contrary contained in the BCA (together with the other documents and transactions contemplated thereby), this BCA Termination
Agreement or the Confidentiality Agreement, the provisions set forth in Section 9.2 of the BCA and the Confidentiality Agreement shall
survive the BCA Termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Admission of Liability</U>. This BCA Termination Agreement and compliance with it shall not operate or be construed as an
admission by any Party of any liability, misconduct or wrongdoing whatsoever against any Party released herein, and shall not be construed
as an admission of a violation of the rights of any Party, or as a violation of any law, rule, regulation, or ordinance. Each Party expressly
denies and wrongdoing or liability to any Party. Each Party has freely entered into this BCA Termination Agreement, and neither Party
has relied upon any statements, promise, or representation from any other Party in entering this BCA Termination Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorities</U>. Each person signing this BCA Termination Agreement on behalf of a party represents and warrants that the execution
and performance of this BCA Termination Agreement has been duly authorized by all necessary laws, resolutions, and corporate action, and
this BCA Termination Agreement constitutes the valid, binding, and enforceable obligations of every Party in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any provision of this BCA Termination Agreement is held to be invalid, void or unenforceable, the balance
of the provisions will, nevertheless, remain in full force and effect and will in no way be affected, impaired, or invalidated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Counterparts; Electronic Delivery</U>. This BCA Termination Agreement may be executed and delivered (including by facsimile
or portable document format (.pdf) transmission) in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.
Delivery by email to counsel for the other party of a counterpart executed by a party shall be deemed to meet the requirements of the
previous sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. <U>Governing Law;
Jurisdiction</U>. This BCA Termination Agreement and any dispute arising hereunder shall be governed by, and construed in accordance
with, the laws of the State of New York, without regard to conflict of law principles. Any legal action shall be brought in the Borough
of Manhattan courts, subject to each Party&rsquo;s right to remove to federal court if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
each of Check-Cap and Apollo has executed and delivered to the other party this BCA Termination Agreement as of the date first written
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>CHECK-CAP LTD. </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name: </TD>
    <TD STYLE="width: 31%">David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: </P></TD>
    <TD>Interim Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>APOLLO TECHNOLOGY CAPITAL CORPORATION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(f/k/a NOBUL AI CORP.)</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Regan McGee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name: </TD>
    <TD STYLE="width: 31%">Regan McGee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: </TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Termination Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ea028762301ex12-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Rule 13a-14(a) of
the Exchange Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David Lontini, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="vertical-align: top; width: 0.25in">1.</TD>
    <TD STYLE="vertical-align: top">I have reviewed this annual report on Form 20-F of Check-Cap Ltd.;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD></TD>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD></TD>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD></TD>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(c)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(d)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 27, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%">/s/ David Lontini</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp; </TD>
    <TD>David Lontini</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD>Interim Chief Executive Officer<BR>
(Principal Executive Officer) </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>ea028762301ex12-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Rule 13a-14(a) of
the Exchange Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Alan Lewis, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">1.</TD>
    <TD STYLE="vertical-align: top">I have reviewed this annual report on Form 20-F of Check-Cap Ltd.;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(c)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(d)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in">5.</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">(b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 27, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%">/s/ Alan Lewis</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp; </TD>
    <TD>Alan Lewis</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD>Chief Financial Officer <BR>
(Principal Financial Officer and <BR>
Principal Accounting Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ea028762301ex13-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to 18 U.S.C. Section
1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of
Check-Cap Ltd. (the &ldquo;Company&rdquo;), does hereby certify, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Annual Report on Form 20-F for the year ended
December 31, 2025 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and
results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHECK-CAP LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">April 27, 2026</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%">/s/ David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp; </TD>
    <TD>David Lontini</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Interim Chief Executive Officer<BR>
(Principal Executive Officer)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>April 27, 2026</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Alan Lewis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: </TD>
    <TD>Alan Lewis</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer <BR>
(Principal Financial Officer and <BR>
Principal Accounting Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>ea028762301ex15-1.htm
<DESCRIPTION>CONSENT OF BCRG GROUP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 47%"><IMG SRC="ea028762301_ex15-1img1.jpg" ALT=""></TD><TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 33%"><B>200 Spectrum
                                            Center Drive, Suite <FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>300<BR>
                                            Irvine, CA 92618<BR>
<B>(714) 234-5980</B><BR>
www.bcrgcpas.com</B></TD>
</TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in Registration Statements on Form S-8 (No. 333-203384, 333-226490 and 333-259666) and in Registration Statement on Form F-1 (No.
333-293109), of our report dated April 27, 2026, relating to the consolidated financial statements of Check-Cap Ltd. (the
&ldquo;Company&rdquo;) appearing in this Annual Report on Form 20-F of the Company for the year ended December 31, 2025. Our report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>/s/ BCRG Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BCRG Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Irvine, CA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 27, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.6
<SEQUENCE>8
<FILENAME>ea028762301ex15-6.htm
<DESCRIPTION>LETTER FROM RBSM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 0px; text-align: right">April 22, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.W.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, DC 20549-7561</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs/Madams:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read Item 16F disclosure which will be
included in the Form 20F of Check-Cap Ltd. (the &ldquo;Company&rdquo;) dated April 17, 2026, and are in agreement with the statements
relating only to RBSM LLP contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no basis to agree or disagree with other
statements of the Company contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ <B>RBSM LLP</B></I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>chek-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:33 UTC 2026 -->
<xs:schema xmlns:chek="http://check-cap.com/20251231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://check-cap.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="chek-20251231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="chek-20251231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="chek-20251231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="chek-20251231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet" id="chek_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals" id="chek_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ConsolidatedIncomeStatement" id="chek_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareholdersEquityType2or3" id="chek_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ConsolidatedCashFlow" id="chek_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/GeneralInformation" id="chek_r_GeneralInformation">
        <link:definition>995306 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern" id="chek_r_SummaryofSignificantAccountingPoliciesandGoingConcern">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets" id="chek_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995308 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/PropertyandEquipmentNet" id="chek_r_PropertyandEquipmentNet">
        <link:definition>995309 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/Leases" id="chek_r_Leases">
        <link:definition>995310 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals" id="chek_r_EmployeeBenefitsandPayrollAccruals">
        <link:definition>995311 - Disclosure - Employee Benefits and Payroll Accruals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/IncomeTaxes" id="chek_r_IncomeTaxes">
        <link:definition>995312 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilities" id="chek_r_CommitmentsandContingentLiabilities">
        <link:definition>995313 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/FairValueMeasurements" id="chek_r_FairValueMeasurements">
        <link:definition>995314 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareholdersEquity" id="chek_r_ShareholdersEquity">
        <link:definition>995315 - Disclosure - Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareBasedCompensation" id="chek_r_ShareBasedCompensation">
        <link:definition>995316 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNet" id="chek_r_ResearchandDevelopmentExpensesNet">
        <link:definition>995317 - Disclosure - Research and Development Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/GeneralandAdministrativeExpenses" id="chek_r_GeneralandAdministrativeExpenses">
        <link:definition>995318 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment" id="chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishment">
        <link:definition>995319 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/FinanceIncomeExpenseNet" id="chek_r_FinanceIncomeExpenseNet">
        <link:definition>995320 - Disclosure - Finance Income (Expense), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EarningsLossPerShare" id="chek_r_EarningsLossPerShare">
        <link:definition>995321 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/RelatedParties" id="chek_r_RelatedParties">
        <link:definition>995322 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment" id="chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment">
        <link:definition>995323 - Disclosure - Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/SubsequentEvents" id="chek_r_SubsequentEvents">
        <link:definition>995324 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/AccountingPoliciesByPolicy" id="chek_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="chek_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996001 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/PropertyandEquipmentNetTables" id="chek_r_PropertyandEquipmentNetTables">
        <link:definition>996002 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables" id="chek_r_EmployeeBenefitsandPayrollAccrualsTables">
        <link:definition>996003 - Disclosure - Employee Benefits and Payroll Accruals (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/IncomeTaxesTables" id="chek_r_IncomeTaxesTables">
        <link:definition>996004 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables" id="chek_r_CommitmentsandContingentLiabilitiesTables">
        <link:definition>996005 - Disclosure - Commitments and Contingent Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareBasedCompensationTables" id="chek_r_ShareBasedCompensationTables">
        <link:definition>996006 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables" id="chek_r_ResearchandDevelopmentExpensesNetTables">
        <link:definition>996007 - Disclosure - Research and Development Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/GeneralandAdministrativeExpensesTables" id="chek_r_GeneralandAdministrativeExpensesTables">
        <link:definition>996008 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables" id="chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables">
        <link:definition>996009 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/FinanceIncomeExpenseNetTables" id="chek_r_FinanceIncomeExpenseNetTables">
        <link:definition>996010 - Disclosure - Finance Income (Expense), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EarningsLossPerShareTables" id="chek_r_EarningsLossPerShareTables">
        <link:definition>996011 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/RelatedPartiesTables" id="chek_r_RelatedPartiesTables">
        <link:definition>996012 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables" id="chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables">
        <link:definition>996013 - Disclosure - Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/GeneralInformationDetails" id="chek_r_GeneralInformationDetails">
        <link:definition>996014 - Disclosure - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails" id="chek_r_SummaryofSignificantAccountingPoliciesandGoingConcernDetails">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="chek_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996016 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/PropertyandEquipmentNetDetails" id="chek_r_PropertyandEquipmentNetDetails">
        <link:definition>996017 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable" id="chek_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996018 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/LeasesDetails" id="chek_r_LeasesDetails">
        <link:definition>996019 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails" id="chek_r_EmployeeBenefitsandPayrollAccrualsDetails">
        <link:definition>996020 - Disclosure - Employee Benefits and Payroll Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable" id="chek_r_ScheduleofEmployeeBenefitsandPayrollAccrualsTable">
        <link:definition>996021 - Disclosure - Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/IncomeTaxesDetails" id="chek_r_IncomeTaxesDetails">
        <link:definition>996022 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable" id="chek_r_ScheduleofNetDeferredTaxAssetsTable">
        <link:definition>996023 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals" id="chek_r_ScheduleofNetDeferredTaxAssetsTable_Parentheticals">
        <link:definition>996024 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable" id="chek_r_ScheduleofAccumulatedIsraeliNetOperatingLossTable">
        <link:definition>996025 - Disclosure - Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable" id="chek_r_ScheduleofMovementinValuationAllowanceTable">
        <link:definition>996026 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals" id="chek_r_ScheduleofMovementinValuationAllowanceTable_Parentheticals">
        <link:definition>996027 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable" id="chek_r_ScheduleofProvisionforIncomeTaxesTable">
        <link:definition>996028 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable" id="chek_r_ScheduleofStatutoryIsraeliCorporateTaxRateTable">
        <link:definition>996029 - Disclosure - Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails" id="chek_r_CommitmentsandContingentLiabilitiesDetails">
        <link:definition>996030 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofReductionofRDExpensesTable" id="chek_r_ScheduleofReductionofRDExpensesTable">
        <link:definition>996031 - Disclosure - Commitments and Contingent Liabilities - Schedule of Reduction of R&amp;D Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/FairValueMeasurementsDetails" id="chek_r_FairValueMeasurementsDetails">
        <link:definition>996032 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareholdersEquityDetails" id="chek_r_ShareholdersEquityDetails">
        <link:definition>996033 - Disclosure - Shareholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ShareBasedCompensationDetails" id="chek_r_ShareBasedCompensationDetails">
        <link:definition>996034 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable" id="chek_r_ScheduleofParametersUsedinApplyingtheModelTable">
        <link:definition>996035 - Disclosure - Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofShareBasedCompensationTable" id="chek_r_ScheduleofShareBasedCompensationTable">
        <link:definition>996036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofOptionActivityTable" id="chek_r_ScheduleofOptionActivityTable">
        <link:definition>996037 - Disclosure - Share-Based Compensation - Schedule of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofRSUsActivityTable" id="chek_r_ScheduleofRSUsActivityTable">
        <link:definition>996038 - Disclosure - Share-Based Compensation - Schedule of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable" id="chek_r_ScheduleofResearchandDevelopmentExpensesNetTable">
        <link:definition>996039 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="chek_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails" id="chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails">
        <link:definition>996041 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" id="chek_r_ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable">
        <link:definition>996042 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable" id="chek_r_ScheduleofFinanceIncomeExpenseNetTable">
        <link:definition>996043 - Disclosure - Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/EarningsLossPerShareDetails" id="chek_r_EarningsLossPerShareDetails">
        <link:definition>996044 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofEarningsLossPerShareTable" id="chek_r_ScheduleofEarningsLossPerShareTable">
        <link:definition>996045 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable" id="chek_r_ScheduleofAntiDilutiveSecuritiesTable">
        <link:definition>996046 - Disclosure - Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="chek_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>996047 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0" id="chek_r_ScheduleofTransactionswithRelatedPartiesTable0">
        <link:definition>996048 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails" id="chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails">
        <link:definition>996049 - Disclosure - Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable" id="chek_r_ScheduleofCarryingValueSummaryTable">
        <link:definition>996050 - Disclosure - Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://check-cap.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfReductionOfRDExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfReductionOfRDExpensesAbstract"/>
  <xs:element name="ScheduleOfShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRsusActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfRsusActivityAbstract"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfAntiDilutiveSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfAntiDilutiveSecuritiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfCarryingValueSummaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfCarryingValueSummaryAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_UnlabeledAbstract"/>
  <xs:element name="RoyaltiesProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_RoyaltiesProvision"/>
  <xs:element name="ImpairmentOfLoansReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_ImpairmentOfLoansReceivable"/>
  <xs:element name="GeneralAndAdministrativeExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_GeneralAndAdministrativeExpensesTextBlock"/>
  <xs:element name="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock"/>
  <xs:element name="GoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_GoingConcernPolicyTextBlock"/>
  <xs:element name="ShortTermBankDepositPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ShortTermBankDepositPolicyTextBlock"/>
  <xs:element name="DeferredIncomeTaxesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DeferredIncomeTaxesPolicyTextBlock"/>
  <xs:element name="ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
  <xs:element name="RelatedPartiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_RelatedPartiesTablesTable"/>
  <xs:element name="RelatedPartiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_RelatedPartiesTablesLineItems"/>
  <xs:element name="PrepaidGovernmentInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_PrepaidGovernmentInstitutions"/>
  <xs:element name="AccumulatedImpairmentOnPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance"/>
  <xs:element name="ShareBasedCompensationScheduleofOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationScheduleofRSUsActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable"/>
  <xs:element name="ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable"/>
  <xs:element name="SubcontractorsAndConsultantFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_SubcontractorsAndConsultantFees"/>
  <xs:element name="PaymentsExpensesForPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_PaymentsExpensesForPatents"/>
  <xs:element name="GrantedRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_GrantedRevenue"/>
  <xs:element name="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
  <xs:element name="ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment"/>
  <xs:element name="ChangesInLiabilityToPayRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_ChangesInLiabilityToPayRoyalties"/>
  <xs:element name="Compensationtothenon-executivedirectors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_Compensationtothenon-executivedirectors"/>
  <xs:element name="GeneralInformationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_GeneralInformationDetailsTable"/>
  <xs:element name="VotesCastPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_VotesCastPercentage"/>
  <xs:element name="AmountPayableForNonrefundableFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_AmountPayableForNonrefundableFee"/>
  <xs:element name="ReclassifiedAcquisitionTarget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_ReclassifiedAcquisitionTarget"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_LeasesDetailsTable"/>
  <xs:element name="EmployeeBenefitsandPayrollAccrualsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable"/>
  <xs:element name="DepositsRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DepositsRate"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_IncomeTaxesDetailsTable"/>
  <xs:element name="EntitledBenefitTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_EntitledBenefitTerm"/>
  <xs:element name="LimitationFromTheYearOfElectionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_LimitationFromTheYearOfElectionTerm"/>
  <xs:element name="ReductionInIncomeTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ReductionInIncomeTaxRate"/>
  <xs:element name="UncertainTaxPositions" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_UncertainTaxPositions"/>
  <xs:element name="CommitmentsandContingentLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_CommitmentsandContingentLiabilitiesDetailsTable"/>
  <xs:element name="RoyaltiesSoldComponent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_RoyaltiesSoldComponent"/>
  <xs:element name="FundReceivedInTotalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_FundReceivedInTotalAmount"/>
  <xs:element name="ContingentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_ContingentLiability"/>
  <xs:element name="DerivativeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_DerivativeAmount"/>
  <xs:element name="OutstandingAmountsOfLandlordClaim" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_OutstandingAmountsOfLandlordClaim"/>
  <xs:element name="FairValueMeasurementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_FairValueMeasurementsDetailsTable"/>
  <xs:element name="ImpliedInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_ImpliedInterestPercentage"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ShareBasedCompensationDetailsTable"/>
  <xs:element name="ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable"/>
  <xs:element name="NetCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_NetCarryingValue"/>
  <xs:element name="ShareholderVotingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ShareholderVotingPercentage"/>
  <xs:element name="ExceedingCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_ExceedingCarryingValue"/>
  <xs:element name="NotesReallocation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_NotesReallocation"/>
  <xs:element name="EarningsLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_EarningsLossPerShareDetailsTable"/>
  <xs:element name="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable"/>
  <xs:element name="ReducingCarryingValueNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_ReducingCarryingValueNet"/>
  <xs:element name="ReinstatedRecoverableLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_ReinstatedRecoverableLoan"/>
  <xs:element name="PercentageOfManagementAssessedEquity" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfManagementAssessedEquity"/>
  <xs:element name="AmountOfManagementAssessedEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="chek_AmountOfManagementAssessedEquity"/>
  <xs:element name="CarryingValueOfReinstatedReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_CarryingValueOfReinstatedReceivable"/>
  <xs:element name="PercentageOfShareholding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfShareholding"/>
  <xs:element name="ValuationOfFairValueMarket" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_ValuationOfFairValueMarket"/>
  <xs:element name="EquityPercentageOfWeightedAverage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_EquityPercentageOfWeightedAverage"/>
  <xs:element name="PercentageOfDiscountedCashFlowMethod" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfDiscountedCashFlowMethod"/>
  <xs:element name="PercentageOfComparableCompanyMethod" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfComparableCompanyMethod"/>
  <xs:element name="PercentageOfCostEquity" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfCostEquity"/>
  <xs:element name="PercentageOfValuationInterest" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfValuationInterest"/>
  <xs:element name="InterestImpliedValuation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="chek_InterestImpliedValuation"/>
  <xs:element name="PercentageOfImpliedRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_PercentageOfImpliedRate"/>
  <xs:element name="ApolloTechnologyCapitalCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ApolloTechnologyCapitalCorporationMember"/>
  <xs:element name="BinationalIndustrialResearchAndDevelopmentFoundationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember"/>
  <xs:element name="CheckCapMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_CheckCapMember"/>
  <xs:element name="CheckCapUsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_CheckCapUsIncMember"/>
  <xs:element name="ComputersAndAuxiliaryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ComputersAndAuxiliaryEquipmentMember"/>
  <xs:element name="ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember"/>
  <xs:element name="CreditLineAgreementWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_CreditLineAgreementWarrantsMember"/>
  <xs:element name="DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember"/>
  <xs:element name="DesignerRoyaltiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DesignerRoyaltiesMember"/>
  <xs:element name="DevelopmentAreaAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DevelopmentAreaAMember"/>
  <xs:element name="ExchangeIndebtednessMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ExchangeIndebtednessMember"/>
  <xs:element name="FeesAndReimbursementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_FeesAndReimbursementMember"/>
  <xs:element name="FirstApolloLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_FirstApolloLoanMember"/>
  <xs:element name="FourthApolloLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_FourthApolloLoanMember"/>
  <xs:element name="GeneralTransactionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_GeneralTransactionsMember"/>
  <xs:element name="GhostKitchensARAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_GhostKitchensARAMember"/>
  <xs:element name="IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_LaboratoryEquipmentMember"/>
  <xs:element name="NonExecutiveDirectorsCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_NonExecutiveDirectorsCompensationMember"/>
  <xs:element name="NonExecutiveDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_NonExecutiveDirectorsMember"/>
  <xs:element name="PrivatePlacementWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_PrivatePlacementWarrantsMember"/>
  <xs:element name="RestOfCountryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_RestOfCountryMember"/>
  <xs:element name="RoyaltiesToAnASICDesignerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_RoyaltiesToAnASICDesignerMember"/>
  <xs:element name="SecondApolloLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_SecondApolloLoanMember"/>
  <xs:element name="ShareBasedCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ShareBasedCompensationMember"/>
  <xs:element name="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
  <xs:element name="LoanReceivableExchangeAndEquityInvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_LoanReceivableExchangeAndEquityInvestmentLineItems"/>
<!-- [WMV7][2tDDGwNKobEwGZ6KQtBDhu839jm5XrWqD+K2TVkYCqR60B5GgBnMC1ldHuNRjm9yQp9NZnoSFNeZkNkX4eWwDbaybmVJomzylrNu1CGm4SEKPqrBABgG6JoL07lum5iOgkjWyHxTA+sElf5rx0GFurQ7b2LF3Jg+2U+dPkyXvzolPS2g432lA3XeifMbSISb96ZxnZtjwWwVN2IexG3p+OH4Kp9Q3U2bljoyPhtF9ncGaP0OKBCY1oxXZntkPQ2coHSZXsQDqlwypDn12kHCKol34S8JLNent0/R5snd1UQ4p1xKpGNZRbs1Vct3tQanfWy3CTKsvSp77Rlf] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="chek_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>chek-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:34 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedBalanceSheet" roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedIncomeStatement" roleURI="http://check-cap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedCashFlow" roleURI="http://check-cap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofEmployeeBenefitsandPayrollAccrualsTable" roleURI="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofProvisionforIncomeTaxesTable" roleURI="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofStatutoryIsraeliCorporateTaxRateTable" roleURI="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofResearchandDevelopmentExpensesNetTable" roleURI="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" roleURI="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofFinanceIncomeExpenseNetTable" roleURI="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofCarryingValueSummaryTable" roleURI="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"/>
  <calculationLink xlink:role="http://check-cap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="chek_RoyaltiesProvision" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_AssetImpairmentCharges" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="chek_ImpairmentOfLoansReceivable" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="chek_ImpairmentOfLoansReceivable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="chek_PrepaidGovernmentInstitutions" xlink:href="chek-20251231.xsd#chek_PrepaidGovernmentInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="chek_PrepaidGovernmentInstitutions" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:href="chek-20251231.xsd#chek_AccumulatedImpairmentOnPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_SuppliesExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_SubcontractorsAndConsultantFees" xlink:href="chek-20251231.xsd#chek_SubcontractorsAndConsultantFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="chek_SubcontractorsAndConsultantFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_DepreciationNonproduction" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_PaymentsExpensesForPatents" xlink:href="chek-20251231.xsd#chek_PaymentsExpensesForPatents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="chek_PaymentsExpensesForPatents" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherExpenses" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_GrantedRevenue" xlink:href="chek-20251231.xsd#chek_GrantedRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="chek_GrantedRevenue" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_CostMaintenance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_Depreciation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_AdjustmentForAmortization" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:to="chek_ImpairmentOfLoansReceivable" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="chek_ChangesInLiabilityToPayRoyalties" xlink:href="chek-20251231.xsd#chek_ChangesInLiabilityToPayRoyalties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="chek_ChangesInLiabilityToPayRoyalties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent"/>
<!-- [WMV7][Gm7ELz1HxJ6RRpQyDgrbpeB4dZfaQNZPEcVeBSdAtwNZsLNh4mIifG3udv+5YK35voIGCbEh9sOy81VEtqBwWgoQ1v6SsIFYaKpHL+M7hjlomo3TNRpobw9Y0NhgDD75GQ7ZQT+3KHaqWnRxFjang4yb+nV7XjaQ7rHtLXwbgheAHfKSj54edwrH2qpQCWK7tZKLkW1H77HDMi3hHwKaX3/WDCV6OY+ZW4gSORoTDblWI7vUWK93lCtAAt0UFQqfIH46azBSa0ZSbKb4o/u6JBP9hzoyWt78vWYYUKCrQbmhGQIZ6ihryjs0lSH1z/N15AxxYXn5/mAmP30=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>chek-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:34 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedBalanceSheet" roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedIncomeStatement" roleURI="http://check-cap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquityType2or3" roleURI="http://check-cap.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedCashFlow" roleURI="http://check-cap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralInformation" roleURI="http://check-cap.com/role/GeneralInformation"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SummaryofSignificantAccountingPoliciesandGoingConcern" roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNet" roleURI="http://check-cap.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_Leases" roleURI="http://check-cap.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccruals" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxes" roleURI="http://check-cap.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilities" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FairValueMeasurements" roleURI="http://check-cap.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquity" roleURI="http://check-cap.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensation" roleURI="http://check-cap.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ResearchandDevelopmentExpensesNet" roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralandAdministrativeExpenses" roleURI="http://check-cap.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishment" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FinanceIncomeExpenseNet" roleURI="http://check-cap.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShare" roleURI="http://check-cap.com/role/EarningsLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_RelatedParties" roleURI="http://check-cap.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SubsequentEvents" roleURI="http://check-cap.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_AccountingPoliciesByPolicy" roleURI="http://check-cap.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNetTables" roleURI="http://check-cap.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccrualsTables" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxesTables" roleURI="http://check-cap.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilitiesTables" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensationTables" roleURI="http://check-cap.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ResearchandDevelopmentExpensesNetTables" roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralandAdministrativeExpensesTables" roleURI="http://check-cap.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FinanceIncomeExpenseNetTables" roleURI="http://check-cap.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShareTables" roleURI="http://check-cap.com/role/EarningsLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_RelatedPartiesTables" roleURI="http://check-cap.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofEmployeeBenefitsandPayrollAccrualsTable" roleURI="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofNetDeferredTaxAssetsTable_Parentheticals" roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofAccumulatedIsraeliNetOperatingLossTable" roleURI="http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofMovementinValuationAllowanceTable" roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofMovementinValuationAllowanceTable_Parentheticals" roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofProvisionforIncomeTaxesTable" roleURI="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofStatutoryIsraeliCorporateTaxRateTable" roleURI="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofReductionofRDExpensesTable" roleURI="http://check-cap.com/role/ScheduleofReductionofRDExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofParametersUsedinApplyingtheModelTable" roleURI="http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofShareBasedCompensationTable" roleURI="http://check-cap.com/role/ScheduleofShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofOptionActivityTable" roleURI="http://check-cap.com/role/ScheduleofOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofRSUsActivityTable" roleURI="http://check-cap.com/role/ScheduleofRSUsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofResearchandDevelopmentExpensesNetTable" roleURI="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" roleURI="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofFinanceIncomeExpenseNetTable" roleURI="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofEarningsLossPerShareTable" roleURI="http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofAntiDilutiveSecuritiesTable" roleURI="http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofTransactionswithRelatedPartiesTable0" roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofCarryingValueSummaryTable" roleURI="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralInformationDetails" roleURI="http://check-cap.com/role/GeneralInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SummaryofSignificantAccountingPoliciesandGoingConcernDetails" roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNetDetails" roleURI="http://check-cap.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_LeasesDetails" roleURI="http://check-cap.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccrualsDetails" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxesDetails" roleURI="http://check-cap.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FairValueMeasurementsDetails" roleURI="http://check-cap.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquityDetails" roleURI="http://check-cap.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensationDetails" roleURI="http://check-cap.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShareDetails" roleURI="http://check-cap.com/role/EarningsLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#DocumentAndEntityInformation" roleURI="http://check-cap.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://check-cap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="chek_RoyaltiesProvision" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="chek_ImpairmentOfLoansReceivable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="chek_ImpairmentOfLoansReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/GeneralInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ResearchandDevelopmentExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:href="chek-20251231.xsd#chek_GeneralAndAdministrativeExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/FinanceIncomeExpenseNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EarningsLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_GoingConcernPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_GoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="chek_GoingConcernPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ShortTermBankDepositPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_ShortTermBankDepositPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="chek_ShortTermBankDepositPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DeferredIncomeTaxesPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_DeferredIncomeTaxesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="chek_DeferredIncomeTaxesPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/FinanceIncomeExpenseNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/RelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="chek_RelatedPartiesTablesLineItems" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_RelatedPartiesTablesTable" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="chek_RelatedPartiesTablesLineItems" xlink:to="chek_RelatedPartiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_RelatedPartiesTablesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_NonExecutiveDirectorsCompensationMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_NonExecutiveDirectorsCompensationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralTransactionsMember" xlink:href="chek-20251231.xsd#chek_GeneralTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_GeneralTransactionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_RelatedPartiesTablesLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_PrepaidGovernmentInstitutions" xlink:href="chek-20251231.xsd#chek_PrepaidGovernmentInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="chek_PrepaidGovernmentInstitutions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_TechnologyEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:href="chek-20251231.xsd#chek_AccumulatedImpairmentOnPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_AccruedVacationCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:href="chek-20251231.xsd#chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofReductionofRDExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesToAnASICDesignerMember" xlink:href="chek-20251231.xsd#chek_RoyaltiesToAnASICDesignerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="chek_RoyaltiesToAnASICDesignerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofRSUsActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:href="chek-20251231.xsd#chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SuppliesExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_SubcontractorsAndConsultantFees" xlink:href="chek-20251231.xsd#chek_SubcontractorsAndConsultantFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="chek_SubcontractorsAndConsultantFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_DepreciationNonproduction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PaymentsExpensesForPatents" xlink:href="chek-20251231.xsd#chek_PaymentsExpensesForPatents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="chek_PaymentsExpensesForPatents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_GrantedRevenue" xlink:href="chek-20251231.xsd#chek_GrantedRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="chek_GrantedRevenue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_CostMaintenance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Depreciation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="chek_ImpairmentOfLoansReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ChangesInLiabilityToPayRoyalties" xlink:href="chek-20251231.xsd#chek_ChangesInLiabilityToPayRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="chek_ChangesInLiabilityToPayRoyalties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofEarningsLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_FeesAndReimbursementMember" xlink:href="chek-20251231.xsd#chek_FeesAndReimbursementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_FeesAndReimbursementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationMember" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_ShareBasedCompensationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_NonExecutiveDirectorsMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chek_NonExecutiveDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_Compensationtothenon-executivedirectors" xlink:href="chek-20251231.xsd#chek_Compensationtothenon-executivedirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="chek_Compensationtothenon-executivedirectors" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" xlink:href="chek-20251231.xsd#chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralTransactionsMember" xlink:href="chek-20251231.xsd#chek_GeneralTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chek_GeneralTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_LoansPayable" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/GeneralInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralInformationDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralInformationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chek_GeneralInformationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_GeneralInformationDetailsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_GeneralInformationDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_FirstApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FirstApolloLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chek_FirstApolloLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_SecondApolloLoanMember" xlink:href="chek-20251231.xsd#chek_SecondApolloLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chek_SecondApolloLoanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_FourthApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FourthApolloLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chek_FourthApolloLoanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_CheckCapMember" xlink:href="chek-20251231.xsd#chek_CheckCapMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="chek_CheckCapMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_VotesCastPercentage" xlink:href="chek-20251231.xsd#chek_VotesCastPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chek_VotesCastPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_AmountPayableForNonrefundableFee" xlink:href="chek-20251231.xsd#chek_AmountPayableForNonrefundableFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chek_AmountPayableForNonrefundableFee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Deposits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LoansPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesSegregatedUnderOtherRegulations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuritiesSegregatedUnderOtherRegulations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SecuritiesSegregatedUnderOtherRegulations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ReclassifiedAcquisitionTarget" xlink:href="chek-20251231.xsd#chek_ReclassifiedAcquisitionTarget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chek_ReclassifiedAcquisitionTarget" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:href="chek-20251231.xsd#chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_LaboratoryEquipmentMember" xlink:href="chek-20251231.xsd#chek_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chek_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ComputersAndAuxiliaryEquipmentMember" xlink:href="chek-20251231.xsd#chek_ComputersAndAuxiliaryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chek_ComputersAndAuxiliaryEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_GhostKitchensARAMember" xlink:href="chek-20251231.xsd#chek_GhostKitchensARAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chek_GhostKitchensARAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LongTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LoansReceivableFairValueDisclosure" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_LeasesDetailsTable" xlink:href="chek-20251231.xsd#chek_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="chek_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_LeasesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfLand" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsForRent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable" xlink:href="chek-20251231.xsd#chek_EmployeeBenefitsandPayrollAccrualsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DepositsRate" xlink:href="chek-20251231.xsd#chek_DepositsRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="chek_DepositsRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_IncomeTaxesDetailsTable" xlink:href="chek-20251231.xsd#chek_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="dei_LegalEntityAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_CheckCapUsIncMember" xlink:href="chek-20251231.xsd#chek_CheckCapUsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="chek_CheckCapUsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DevelopmentAreaAMember" xlink:href="chek-20251231.xsd#chek_DevelopmentAreaAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="chek_DevelopmentAreaAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_RestOfCountryMember" xlink:href="chek-20251231.xsd#chek_RestOfCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="chek_RestOfCountryMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_EntitledBenefitTerm" xlink:href="chek-20251231.xsd#chek_EntitledBenefitTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_EntitledBenefitTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_LimitationFromTheYearOfElectionTerm" xlink:href="chek-20251231.xsd#chek_LimitationFromTheYearOfElectionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_LimitationFromTheYearOfElectionTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ReductionInIncomeTaxRate" xlink:href="chek-20251231.xsd#chek_ReductionInIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_ReductionInIncomeTaxRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_ImpairmentOfLoansReceivable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_UncertainTaxPositions" xlink:href="chek-20251231.xsd#chek_UncertainTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="chek_UncertainTaxPositions" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="chek-20251231.xsd#chek_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_CommitmentsandContingentLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DesignerRoyaltiesMember" xlink:href="chek-20251231.xsd#chek_DesignerRoyaltiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="chek_DesignerRoyaltiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:href="chek-20251231.xsd#chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:href="chek-20251231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesSoldComponent" xlink:href="chek-20251231.xsd#chek_RoyaltiesSoldComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_RoyaltiesSoldComponent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_RoyaltiesProvision" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_FundReceivedInTotalAmount" xlink:href="chek-20251231.xsd#chek_FundReceivedInTotalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_FundReceivedInTotalAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ContingentLiability" xlink:href="chek-20251231.xsd#chek_ContingentLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_ContingentLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DerivativeAmount" xlink:href="chek-20251231.xsd#chek_DerivativeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_DerivativeAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_OutstandingAmountsOfLandlordClaim" xlink:href="chek-20251231.xsd#chek_OutstandingAmountsOfLandlordClaim"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="chek_OutstandingAmountsOfLandlordClaim" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_FairValueMeasurementsDetailsTable" xlink:href="chek-20251231.xsd#chek_FairValueMeasurementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="chek_FairValueMeasurementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_FairValueMeasurementsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_LongTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ImpliedInterestPercentage" xlink:href="chek-20251231.xsd#chek_ImpliedInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="chek_ImpliedInterestPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_AlternativeInvestment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ShareholdersEquityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="chek_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PrivatePlacementWarrantsMember" xlink:href="chek-20251231.xsd#chek_PrivatePlacementWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chek_PrivatePlacementWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_CreditLineAgreementWarrantsMember" xlink:href="chek-20251231.xsd#chek_CreditLineAgreementWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="chek_CreditLineAgreementWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chek_ShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfLoansReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_NetCarryingValue" xlink:href="chek-20251231.xsd#chek_NetCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="chek_NetCarryingValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ShareholderVotingPercentage" xlink:href="chek-20251231.xsd#chek_ShareholderVotingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="chek_ShareholderVotingPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ExceedingCarryingValue" xlink:href="chek-20251231.xsd#chek_ExceedingCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="chek_ExceedingCarryingValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_NotesReduction" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_NotesReallocation" xlink:href="chek-20251231.xsd#chek_NotesReallocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="chek_NotesReallocation" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_EarningsLossPerShareDetailsTable" xlink:href="chek-20251231.xsd#chek_EarningsLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="chek_EarningsLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_EarningsLossPerShareDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:href="chek-20251231.xsd#chek_LoanReceivableExchangeAndEquityInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="chek_ApolloTechnologyCapitalCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ExchangeIndebtednessMember" xlink:href="chek-20251231.xsd#chek_ExchangeIndebtednessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chek_ExchangeIndebtednessMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" xlink:href="chek-20251231.xsd#chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ReducingCarryingValueNet" xlink:href="chek-20251231.xsd#chek_ReducingCarryingValueNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_ReducingCarryingValueNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ReinstatedRecoverableLoan" xlink:href="chek-20251231.xsd#chek_ReinstatedRecoverableLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_ReinstatedRecoverableLoan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfManagementAssessedEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfManagementAssessedEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_AmountOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_AmountOfManagementAssessedEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_AmountOfManagementAssessedEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_LoansPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_CarryingValueOfReinstatedReceivable" xlink:href="chek-20251231.xsd#chek_CarryingValueOfReinstatedReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_CarryingValueOfReinstatedReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfShareholding" xlink:href="chek-20251231.xsd#chek_PercentageOfShareholding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfShareholding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ShareholderVotingPercentage" xlink:href="chek-20251231.xsd#chek_ShareholderVotingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_ShareholderVotingPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_PaymentsForLoans" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_ValuationOfFairValueMarket" xlink:href="chek-20251231.xsd#chek_ValuationOfFairValueMarket"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_ValuationOfFairValueMarket" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_EquityPercentageOfWeightedAverage" xlink:href="chek-20251231.xsd#chek_EquityPercentageOfWeightedAverage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_EquityPercentageOfWeightedAverage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfDiscountedCashFlowMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfDiscountedCashFlowMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfDiscountedCashFlowMethod" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfComparableCompanyMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfComparableCompanyMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfComparableCompanyMethod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfCostEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfCostEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfCostEquity" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfValuationInterest" xlink:href="chek-20251231.xsd#chek_PercentageOfValuationInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfValuationInterest" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_InterestImpliedValuation" xlink:href="chek-20251231.xsd#chek_InterestImpliedValuation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_InterestImpliedValuation" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfImpliedRate" xlink:href="chek-20251231.xsd#chek_PercentageOfImpliedRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_PercentageOfImpliedRate" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://check-cap.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
<!-- [WMV7][N1GKpfiPysnRtWaTGiFgFp323gDRC/TJFPCK0swsdo2z07cxxtzGaAf1P2XpvX3WDzSGZAWW8bpFwVkzE5FBM50jD9xqcaL12VwvX2Cee5hNcrAIW+gwkErDSypHN5nMqS5RrRR/wPkz/oY1wyyRFbmih+z0K8h05CsU6fjIwhipnFWOijXKsk4Q7mVqEJyN4aBaFnv76XweNjqBb3NNbYhSEtFEWKHUCHyZZjao6X13bFou0DWybRxwtCS5cDl8ac3evAXWMgIs69EvQvZ2AmrcJXI8QhQHsO9WYAXMw4gedydraMa7ZcLm65svSg5vsgM1pYLR5H/AQdBc] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="40" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>chek-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:33 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents, and short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided in (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Going Concern [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl" xml:lang="en-US">Employee Benefits and Payroll Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee benefits and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US">Schedule of Accumulated Israeli Net Operating Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Opening accumulated Israeli NOL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Closing accumulated Israeli NOL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl1" xml:lang="en-US">Operating loss or NOL carry-forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US">Schedule of Movement in Valuation Allowance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Opening valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Closing accumulated Israeli NOL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total provision (benefit) for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Statutory Israeli Corporate Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingent Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Schedule of Parameters Used in Applying the Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Outstanding options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Wtd. Avg Exercise Price, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested &#8211; beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Unvested &#8211; end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Research and Development Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Reduction of R&amp;D expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract_lbl" xml:lang="en-US">Finance Income (Expense), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="us-gaap_InterestIncomeExpenseNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Schedule of Finance Income (Expense), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financing income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Finance income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Income (loss) per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Schedule of Earnings (Loss) Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract_lbl" xml:lang="en-US">Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term Bank Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_LongTermInvestments_lbl1" xml:lang="en-US">Investment cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_UnlabeledAbstract" xlink:href="chek-20251231.xsd#chek_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnlabeledAbstract" xlink:to="chek_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and shareholders&#8217; (deficit) equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_RoyaltiesProvision_lbl" xml:lang="en-US">Royalties provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesProvision" xlink:to="chek_RoyaltiesProvision_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities - non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Share capital, Ordinary shares 48 NIS par value (18,000,000 authorized shares as of December 31, 2025 and 2024; 7,020,502 and 5,850,906 shares issued and outstanding as of December 31, 2025 and 2024, respectively)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary share, par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl1" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Income on Debt Extinguishment and Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain on debt extinguishment and conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Reversal/conversion gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per ordinary share - basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings (loss) per ordinary share &#8211; basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net income (loss) per ordinary share - diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings (loss) per ordinary share &#8211; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding - basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average ordinary shares outstanding &#8211; basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding - diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average ordinary shares outstanding &#8211; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">RSU vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">RSU vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares - Ghost Kitchens ARA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares - Ghost Kitchens ARA (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ImpairmentOfLoansReceivable_lbl" xml:lang="en-US">Impairment of loans receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoansReceivable" xlink:to="chek_ImpairmentOfLoansReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chek_ImpairmentOfLoansReceivable_lbl0" xml:lang="en-US">Impairment of loans receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoansReceivable" xlink:to="chek_ImpairmentOfLoansReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_ImpairmentOfLoansReceivable_lbl1" xml:lang="en-US">Loan impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoansReceivable" xlink:to="chek_ImpairmentOfLoansReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operation leasing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in trade accounts payable, accruals and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Decrease in employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xml:lang="en-US">Decrease in royalties provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Issuance of ordinary shares in the registered direct offerings, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl" xml:lang="en-US">Assets acquired under operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash included current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Financial expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease (increase) in prepaid and other current assets and non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US">Issuance of loans receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Changes (investment) in short-term bank and other deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PrepaidGovernmentInstitutions" xlink:href="chek-20251231.xsd#chek_PrepaidGovernmentInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PrepaidGovernmentInstitutions_lbl" xml:lang="en-US">Government institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidGovernmentInstitutions" xlink:to="chek_PrepaidGovernmentInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:href="chek-20251231.xsd#chek_AccumulatedImpairmentOnPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl" xml:lang="en-US">Impairment of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:to="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee Benefits and Payroll Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Short-term employee benefits:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Benefits for vacation and recreation pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Liability for payroll, bonuses and wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">NOL carryforwards &#8211; Israel (at 23%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">NOL carryforwards, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Statutory Israeli corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">NOL carryforwards &#8211; U.S. (at 21%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0" xml:lang="en-US">Deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">NOL carryforwards, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">DTA percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">Schedule of Accumulated Israeli Net Operating Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_lbl" xml:lang="en-US">Current year estimated tax loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Movement in Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase &#8212; current year tax loss &#215; 23%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:href="chek-20251231.xsd#chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Increase &#8212; current year tax loss, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:to="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal (U.S.)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State (U.S.)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign &#8212; Israel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal (U.S.)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State (U.S.)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign &#8212; Israel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Statutory Israeli Corporate Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effect of full valuation allowance on NOL carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences (immaterial)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reduction of R&amp;D Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTableTextBlock" xlink:to="us-gaap_OtherCommitmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Parameters Used in Applying the Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Wtd. Avg. Remaining Life, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Wtd. Avg Exercise Price, Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Granted shares exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average of exercise Price, Options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Wtd. Avg Exercise Price, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Wtd. Avg Exercise Price, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Wtd. Avg. Remaining Life, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSUs Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SuppliesExpense_lbl" xml:lang="en-US">Materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuppliesExpense" xlink:to="us-gaap_SuppliesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_SubcontractorsAndConsultantFees" xlink:href="chek-20251231.xsd#chek_SubcontractorsAndConsultantFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_SubcontractorsAndConsultantFees_lbl" xml:lang="en-US">Subcontractors and consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SubcontractorsAndConsultantFees" xlink:to="chek_SubcontractorsAndConsultantFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PaymentsExpensesForPatents" xlink:href="chek-20251231.xsd#chek_PaymentsExpensesForPatents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PaymentsExpensesForPatents_lbl" xml:lang="en-US">Cost for registration of patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PaymentsExpensesForPatents" xlink:to="chek_PaymentsExpensesForPatents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:href="chek-20251231.xsd#chek_GeneralAndAdministrativeExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Share-based compensation, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Office rent and maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT EXTINGUISHMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSE), NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income on short-term deposits and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ChangesInLiabilityToPayRoyalties" xlink:href="chek-20251231.xsd#chek_ChangesInLiabilityToPayRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ChangesInLiabilityToPayRoyalties_lbl" xml:lang="en-US">Changes in provision for royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ChangesInLiabilityToPayRoyalties" xlink:to="chek_ChangesInLiabilityToPayRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Changes in fair value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Warrants and share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_Compensationtothenon-executivedirectors" xlink:href="chek-20251231.xsd#chek_Compensationtothenon-executivedirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_Compensationtothenon-executivedirectors_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_Compensationtothenon-executivedirectors" xlink:to="chek_Compensationtothenon-executivedirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Transactions with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl" xml:lang="en-US">APOLLO TECHNOLOGY CAPITAL CORPORATION &#8211; LOAN RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Carrying Value Summary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xml:lang="en-US">Loan receivable &#8211; gross principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Net loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0" xml:lang="en-US">Loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity investment in Apollo (at cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity investment cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Payable to Apollo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayable_lbl0" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_LoansPayable_lbl1" xml:lang="en-US">Loans payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl2" xml:lang="en-US">Net payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number, Options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number, Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GrantedRevenue" xlink:href="chek-20251231.xsd#chek_GrantedRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chek_GrantedRevenue_lbl" xml:lang="en-US">Less participation of the IIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:to="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Bank fees and interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xml:lang="en-US">Allowance for credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Furniture and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and auxiliary equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesToAnASICDesignerMember" xlink:href="chek-20251231.xsd#chek_RoyaltiesToAnASICDesignerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_RoyaltiesToAnASICDesignerMember_lbl" xml:lang="en-US">Royalties to an ASIC designer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesToAnASICDesignerMember" xlink:to="chek_RoyaltiesToAnASICDesignerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">RSU [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants and share options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_NonExecutiveDirectorsCompensationMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_NonExecutiveDirectorsCompensationMember_lbl" xml:lang="en-US">Compensation to non-executive directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsCompensationMember" xlink:to="chek_NonExecutiveDirectorsCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_FeesAndReimbursementMember" xlink:href="chek-20251231.xsd#chek_FeesAndReimbursementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_FeesAndReimbursementMember_lbl" xml:lang="en-US">Fees, including reimbursement of expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FeesAndReimbursementMember" xlink:to="chek_FeesAndReimbursementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationMember" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ShareBasedCompensationMember_lbl" xml:lang="en-US">Share-based compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationMember" xlink:to="chek_ShareBasedCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_NonExecutiveDirectorsMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_NonExecutiveDirectorsMember_lbl" xml:lang="en-US">Non-executive Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsMember" xlink:to="chek_NonExecutiveDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralTransactionsMember" xlink:href="chek-20251231.xsd#chek_GeneralTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_GeneralTransactionsMember_lbl" xml:lang="en-US">Transactions with Related Parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralTransactionsMember" xlink:to="chek_GeneralTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" xlink:href="chek-20251231.xsd#chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember_lbl" xml:lang="en-US">Consulting fees, including share-based compensation and reimbursement of expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" xlink:to="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ApolloTechnologyCapitalCorporationMember_lbl" xml:lang="en-US">Apollo Technology Capital Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationMember" xlink:to="chek_ApolloTechnologyCapitalCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_VotesCastPercentage" xlink:href="chek-20251231.xsd#chek_VotesCastPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_VotesCastPercentage_lbl" xml:lang="en-US">Votes cast percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_VotesCastPercentage" xlink:to="chek_VotesCastPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_AmountPayableForNonrefundableFee" xlink:href="chek-20251231.xsd#chek_AmountPayableForNonrefundableFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_AmountPayableForNonrefundableFee_lbl" xml:lang="en-US">First apollo loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountPayableForNonrefundableFee" xlink:to="chek_AmountPayableForNonrefundableFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Percentage of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposit in segregated bank account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesSegregatedUnderOtherRegulations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuritiesSegregatedUnderOtherRegulations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuritiesSegregatedUnderOtherRegulations_lbl" xml:lang="en-US">Segregated account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesSegregatedUnderOtherRegulations" xlink:to="us-gaap_SecuritiesSegregatedUnderOtherRegulations_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ReclassifiedAcquisitionTarget" xlink:href="chek-20251231.xsd#chek_ReclassifiedAcquisitionTarget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ReclassifiedAcquisitionTarget_lbl" xml:lang="en-US">Reclassified of third apollo loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReclassifiedAcquisitionTarget" xlink:to="chek_ReclassifiedAcquisitionTarget_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Reverse share split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableFairValueDisclosure_lbl" xml:lang="en-US">Loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableFairValueDisclosure" xlink:to="us-gaap_LoansReceivableFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of lease (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Lease monthly fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease extended</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DepositsRate" xlink:href="chek-20251231.xsd#chek_DepositsRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DepositsRate_lbl" xml:lang="en-US">Deposits rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DepositsRate" xlink:to="chek_DepositsRate_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_EntitledBenefitTerm" xlink:href="chek-20251231.xsd#chek_EntitledBenefitTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_EntitledBenefitTerm_lbl" xml:lang="en-US">Entitled benefit period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EntitledBenefitTerm" xlink:to="chek_EntitledBenefitTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_LimitationFromTheYearOfElectionTerm" xlink:href="chek-20251231.xsd#chek_LimitationFromTheYearOfElectionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_LimitationFromTheYearOfElectionTerm_lbl" xml:lang="en-US">Limitation from the year of election term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LimitationFromTheYearOfElectionTerm" xlink:to="chek_LimitationFromTheYearOfElectionTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ReductionInIncomeTaxRate" xlink:href="chek-20251231.xsd#chek_ReductionInIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ReductionInIncomeTaxRate_lbl" xml:lang="en-US">Reduction in income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReductionInIncomeTaxRate" xlink:to="chek_ReductionInIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated loss for tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred tax asset, NOLs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Excluded taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_UncertainTaxPositions" xlink:href="chek-20251231.xsd#chek_UncertainTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_UncertainTaxPositions_lbl" xml:lang="en-US">uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UncertainTaxPositions" xlink:to="chek_UncertainTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest and penalties related to income tax amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US">Royalties received (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RoyaltiesSoldComponent" xlink:href="chek-20251231.xsd#chek_RoyaltiesSoldComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_RoyaltiesSoldComponent_lbl" xml:lang="en-US">Royalties sold, component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesSoldComponent" xlink:to="chek_RoyaltiesSoldComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_FundReceivedInTotalAmount" xlink:href="chek-20251231.xsd#chek_FundReceivedInTotalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_FundReceivedInTotalAmount_lbl" xml:lang="en-US">Fund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FundReceivedInTotalAmount" xlink:to="chek_FundReceivedInTotalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants were received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ContingentLiability" xlink:href="chek-20251231.xsd#chek_ContingentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ContingentLiability_lbl" xml:lang="en-US">Contingent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ContingentLiability" xlink:to="chek_ContingentLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DerivativeAmount" xlink:href="chek-20251231.xsd#chek_DerivativeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DerivativeAmount_lbl" xml:lang="en-US">Derivative amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeAmount" xlink:to="chek_DerivativeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Unpaid compensation and contractual entitlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Unpaid fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_OutstandingAmountsOfLandlordClaim" xlink:href="chek-20251231.xsd#chek_OutstandingAmountsOfLandlordClaim"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_OutstandingAmountsOfLandlordClaim_lbl" xml:lang="en-US">Claims total outstanding amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OutstandingAmountsOfLandlordClaim" xlink:to="chek_OutstandingAmountsOfLandlordClaim_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US">Financial instrument fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Percentage of shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ImpliedInterestPercentage" xlink:href="chek-20251231.xsd#chek_ImpliedInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ImpliedInterestPercentage_lbl" xml:lang="en-US">Implied percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpliedInterestPercentage" xlink:to="chek_ImpliedInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Exceeding value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl0" xml:lang="en-US">Equity fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AlternativeInvestment_lbl" xml:lang="en-US">Carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestment" xlink:to="us-gaap_AlternativeInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of RSU</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollectionOfLoansReceivable_lbl" xml:lang="en-US">Loans receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfLoansReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod_lbl" xml:lang="en-US">Loans receivable rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Equity value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_NetCarryingValue" xlink:href="chek-20251231.xsd#chek_NetCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_NetCarryingValue_lbl" xml:lang="en-US">Net value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NetCarryingValue" xlink:to="chek_NetCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareholderVotingPercentage" xlink:href="chek-20251231.xsd#chek_ShareholderVotingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ShareholderVotingPercentage_lbl" xml:lang="en-US">Shareholder vote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareholderVotingPercentage" xlink:to="chek_ShareholderVotingPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_ShareholderVotingPercentage_lbl0" xml:lang="en-US">Voting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareholderVotingPercentage" xlink:to="chek_ShareholderVotingPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ExceedingCarryingValue" xlink:href="chek-20251231.xsd#chek_ExceedingCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ExceedingCarryingValue_lbl" xml:lang="en-US">Exceeding value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ExceedingCarryingValue" xlink:to="chek_ExceedingCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReduction_lbl" xml:lang="en-US">Reduction in notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReduction" xlink:to="us-gaap_NotesReduction_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_NotesReallocation" xlink:href="chek-20251231.xsd#chek_NotesReallocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_NotesReallocation_lbl" xml:lang="en-US">reallocations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NotesReallocation" xlink:to="chek_NotesReallocation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Weighted average shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ReducingCarryingValueNet" xlink:href="chek-20251231.xsd#chek_ReducingCarryingValueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ReducingCarryingValueNet_lbl" xml:lang="en-US">Carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReducingCarryingValueNet" xlink:to="chek_ReducingCarryingValueNet_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ReinstatedRecoverableLoan" xlink:href="chek-20251231.xsd#chek_ReinstatedRecoverableLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ReinstatedRecoverableLoan_lbl" xml:lang="en-US">Reinstated recoverable portion of the loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReinstatedRecoverableLoan" xlink:to="chek_ReinstatedRecoverableLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfManagementAssessedEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfManagementAssessedEquity_lbl" xml:lang="en-US">Percentage of management-assessed equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfManagementAssessedEquity" xlink:to="chek_PercentageOfManagementAssessedEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_AmountOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_AmountOfManagementAssessedEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_AmountOfManagementAssessedEquity_lbl" xml:lang="en-US">Value of management-assessed equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountOfManagementAssessedEquity" xlink:to="chek_AmountOfManagementAssessedEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_CarryingValueOfReinstatedReceivable" xlink:href="chek-20251231.xsd#chek_CarryingValueOfReinstatedReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_CarryingValueOfReinstatedReceivable_lbl" xml:lang="en-US">Carrying value of reinstated receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CarryingValueOfReinstatedReceivable" xlink:to="chek_CarryingValueOfReinstatedReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfShareholding" xlink:href="chek-20251231.xsd#chek_PercentageOfShareholding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfShareholding_lbl" xml:lang="en-US">Percentage of shareholding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfShareholding" xlink:to="chek_PercentageOfShareholding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLoans_lbl" xml:lang="en-US">Payable against the loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ValuationOfFairValueMarket" xlink:href="chek-20251231.xsd#chek_ValuationOfFairValueMarket"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ValuationOfFairValueMarket_lbl" xml:lang="en-US">Fair market value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ValuationOfFairValueMarket" xlink:to="chek_ValuationOfFairValueMarket_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_EquityPercentageOfWeightedAverage" xlink:href="chek-20251231.xsd#chek_EquityPercentageOfWeightedAverage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_EquityPercentageOfWeightedAverage_lbl" xml:lang="en-US">Percentage of fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EquityPercentageOfWeightedAverage" xlink:to="chek_EquityPercentageOfWeightedAverage_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfDiscountedCashFlowMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfDiscountedCashFlowMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfDiscountedCashFlowMethod_lbl" xml:lang="en-US">Discounted cash flow method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfDiscountedCashFlowMethod" xlink:to="chek_PercentageOfDiscountedCashFlowMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfComparableCompanyMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfComparableCompanyMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfComparableCompanyMethod_lbl" xml:lang="en-US">Percentage of comparable company method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfComparableCompanyMethod" xlink:to="chek_PercentageOfComparableCompanyMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfCostEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfCostEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfCostEquity_lbl" xml:lang="en-US">Percentage of cost of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfCostEquity" xlink:to="chek_PercentageOfCostEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfValuationInterest" xlink:href="chek-20251231.xsd#chek_PercentageOfValuationInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfValuationInterest_lbl" xml:lang="en-US">Valuation interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfValuationInterest" xlink:to="chek_PercentageOfValuationInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_InterestImpliedValuation" xlink:href="chek-20251231.xsd#chek_InterestImpliedValuation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_InterestImpliedValuation_lbl" xml:lang="en-US">Valuation interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_InterestImpliedValuation" xlink:to="chek_InterestImpliedValuation_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PercentageOfImpliedRate" xlink:href="chek-20251231.xsd#chek_PercentageOfImpliedRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PercentageOfImpliedRate_lbl" xml:lang="en-US">Implied rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfImpliedRate" xlink:to="chek_PercentageOfImpliedRate_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GoingConcernPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_GoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GoingConcernPolicyTextBlock" xlink:to="chek_GoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShortTermBankDepositPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_ShortTermBankDepositPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ShortTermBankDepositPolicyTextBlock_lbl" xml:lang="en-US">Short-term Bank Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShortTermBankDepositPolicyTextBlock" xlink:to="chek_ShortTermBankDepositPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments in Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss (Earnings) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DeferredIncomeTaxesPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_DeferredIncomeTaxesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DeferredIncomeTaxesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DeferredIncomeTaxesPolicyTextBlock" xlink:to="chek_DeferredIncomeTaxesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_CheckCapMember" xlink:href="chek-20251231.xsd#chek_CheckCapMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_CheckCapMember_lbl" xml:lang="en-US">Check Cap [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapMember" xlink:to="chek_CheckCapMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_FirstApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FirstApolloLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_FirstApolloLoanMember_lbl" xml:lang="en-US">First Apollo Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FirstApolloLoanMember" xlink:to="chek_FirstApolloLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_SecondApolloLoanMember" xlink:href="chek-20251231.xsd#chek_SecondApolloLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_SecondApolloLoanMember_lbl" xml:lang="en-US">Second Apollo Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SecondApolloLoanMember" xlink:to="chek_SecondApolloLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_FourthApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FourthApolloLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_FourthApolloLoanMember_lbl" xml:lang="en-US">Fourth Apollo Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FourthApolloLoanMember" xlink:to="chek_FourthApolloLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_LaboratoryEquipmentMember" xlink:href="chek-20251231.xsd#chek_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LaboratoryEquipmentMember" xlink:to="chek_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ComputersAndAuxiliaryEquipmentMember" xlink:href="chek-20251231.xsd#chek_ComputersAndAuxiliaryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ComputersAndAuxiliaryEquipmentMember_lbl" xml:lang="en-US">Computers and Auxiliary Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ComputersAndAuxiliaryEquipmentMember" xlink:to="chek_ComputersAndAuxiliaryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GhostKitchensARAMember" xlink:href="chek-20251231.xsd#chek_GhostKitchensARAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_GhostKitchensARAMember_lbl" xml:lang="en-US">Ghost Kitchens ARA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GhostKitchensARAMember" xlink:to="chek_GhostKitchensARAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DevelopmentAreaAMember" xlink:href="chek-20251231.xsd#chek_DevelopmentAreaAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DevelopmentAreaAMember_lbl" xml:lang="en-US">Development Area A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DevelopmentAreaAMember" xlink:to="chek_DevelopmentAreaAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RestOfCountryMember" xlink:href="chek-20251231.xsd#chek_RestOfCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_RestOfCountryMember_lbl" xml:lang="en-US">Rest of Country [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RestOfCountryMember" xlink:to="chek_RestOfCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_CheckCapUsIncMember" xlink:href="chek-20251231.xsd#chek_CheckCapUsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_CheckCapUsIncMember_lbl" xml:lang="en-US">Check-Cap US, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapUsIncMember" xlink:to="chek_CheckCapUsIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_CheckCapUsIncMember_lbl0" xml:lang="en-US">Check Cap Us Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapUsIncMember" xlink:to="chek_CheckCapUsIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl0" xml:lang="en-US">Israeli statutory corporate tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">U.S [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DesignerRoyaltiesMember" xlink:href="chek-20251231.xsd#chek_DesignerRoyaltiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DesignerRoyaltiesMember_lbl" xml:lang="en-US">ASIC designer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DesignerRoyaltiesMember" xlink:to="chek_DesignerRoyaltiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:href="chek-20251231.xsd#chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl" xml:lang="en-US">IIA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:to="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:href="chek-20251231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl" xml:lang="en-US">BIRD Foundation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_CreditLineAgreementWarrantsMember" xlink:href="chek-20251231.xsd#chek_CreditLineAgreementWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_CreditLineAgreementWarrantsMember_lbl" xml:lang="en-US">CLA Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CreditLineAgreementWarrantsMember" xlink:to="chek_CreditLineAgreementWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_PrivatePlacementWarrantsMember" xlink:href="chek-20251231.xsd#chek_PrivatePlacementWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrivatePlacementWarrantsMember" xlink:to="chek_PrivatePlacementWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ExchangeIndebtednessMember" xlink:href="chek-20251231.xsd#chek_ExchangeIndebtednessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ExchangeIndebtednessMember_lbl" xml:lang="en-US">Exchange Indebtedness [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ExchangeIndebtednessMember" xlink:to="chek_ExchangeIndebtednessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" xlink:href="chek-20251231.xsd#chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Debt-for-Equity Exchange &#8211; November 14, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" xlink:to="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RelatedPartiesTablesTable" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RelatedPartiesTablesTable_lbl" xml:lang="en-US">Related Parties (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RelatedPartiesTablesTable" xlink:to="chek_RelatedPartiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_RelatedPartiesTablesLineItems" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RelatedPartiesTablesLineItems_lbl" xml:lang="en-US">Related Parties (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RelatedPartiesTablesLineItems" xlink:to="chek_RelatedPartiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Schedule of Reduction of R&amp;D Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Schedule of Share-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation - Schedule of Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:to="chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US">Schedule of Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation - Schedule of RSUs Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:to="chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:href="chek-20251231.xsd#chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable_lbl" xml:lang="en-US">Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:to="chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Research and Development Expenses, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl" xml:lang="en-US">General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl" xml:lang="en-US">Schedule of Carrying Value Summary [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_GeneralInformationDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralInformationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralInformationDetailsTable_lbl" xml:lang="en-US">General Information (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralInformationDetailsTable" xlink:to="chek_GeneralInformationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">General Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:href="chek-20251231.xsd#chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Going Concern (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Going Concern [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_LeasesDetailsTable" xlink:href="chek-20251231.xsd#chek_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LeasesDetailsTable" xlink:to="chek_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable" xlink:href="chek-20251231.xsd#chek_EmployeeBenefitsandPayrollAccrualsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable_lbl" xml:lang="en-US">Employee Benefits and Payroll Accruals (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable" xlink:to="chek_EmployeeBenefitsandPayrollAccrualsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US">Employee Benefits and Payroll Accruals [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_IncomeTaxesDetailsTable" xlink:href="chek-20251231.xsd#chek_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_IncomeTaxesDetailsTable" xlink:to="chek_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="chek-20251231.xsd#chek_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CommitmentsandContingentLiabilitiesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="chek_CommitmentsandContingentLiabilitiesDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl0" xml:lang="en-US">Commitments and Contingent Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_FairValueMeasurementsDetailsTable" xlink:href="chek-20251231.xsd#chek_FairValueMeasurementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FairValueMeasurementsDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FairValueMeasurementsDetailsTable" xlink:to="chek_FairValueMeasurementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_lbl" xml:lang="en-US">Fair Value Measurements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareholdersEquityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareholdersEquityDetailsTable" xlink:to="chek_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Shareholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ShareBasedCompensationDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationDetailsTable" xlink:to="chek_ShareBasedCompensationDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Share-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable_lbl" xml:lang="en-US">Impairment of Loans Receivable and Gain on Debt Extinguishment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:to="chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl" xml:lang="en-US">Impairment of Loans Receivable and Gain on Debt Extinguishment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_EarningsLossPerShareDetailsTable" xlink:href="chek-20251231.xsd#chek_EarningsLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EarningsLossPerShareDetailsTable_lbl" xml:lang="en-US">Earnings (Loss) Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EarningsLossPerShareDetailsTable" xlink:to="chek_EarningsLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings (Loss) Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable_lbl" xml:lang="en-US">Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:href="chek-20251231.xsd#chek_LoanReceivableExchangeAndEquityInvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LoanReceivableExchangeAndEquityInvestmentLineItems_lbl" xml:lang="en-US">Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="chek_LoanReceivableExchangeAndEquityInvestmentLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated impairment on property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:to="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AmountOfManagementAssessedEquity_lbl0" xml:lang="en-US">Amount of management-assessed equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountOfManagementAssessedEquity" xlink:to="chek_AmountOfManagementAssessedEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AmountPayableForNonrefundableFee_lbl0" xml:lang="en-US">Represent the amount payable for nonrefundable fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountPayableForNonrefundableFee" xlink:to="chek_AmountPayableForNonrefundableFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl0" xml:lang="en-US">The entire disclosure for apollo technology capital corporation &#8211; loan receivable, exchange, and equity investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CarryingValueOfReinstatedReceivable_lbl0" xml:lang="en-US">Amount of carrying value of reinstated receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CarryingValueOfReinstatedReceivable" xlink:to="chek_CarryingValueOfReinstatedReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ChangesInLiabilityToPayRoyalties_lbl0" xml:lang="en-US">Represents value of changes in liability to pay royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ChangesInLiabilityToPayRoyalties" xlink:to="chek_ChangesInLiabilityToPayRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_Compensationtothenon-executivedirectors_lbl0" xml:lang="en-US">Amount of transactions with related party during the financial reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_Compensationtothenon-executivedirectors" xlink:to="chek_Compensationtothenon-executivedirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ContingentLiability_lbl0" xml:lang="en-US">Represents amount of contingent liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ContingentLiability" xlink:to="chek_ContingentLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DeferredIncomeTaxesPolicyTextBlock_lbl0" xml:lang="en-US">The entire policy disclosure of deferred income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DeferredIncomeTaxesPolicyTextBlock" xlink:to="chek_DeferredIncomeTaxesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DepositsRate_lbl0" xml:lang="en-US">Deposits monthly salary percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DepositsRate" xlink:to="chek_DepositsRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DerivativeAmount_lbl0" xml:lang="en-US">Represent the amount of derivative.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeAmount" xlink:to="chek_DerivativeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl0" xml:lang="en-US">The increase current year tax loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:to="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_EntitledBenefitTerm_lbl0" xml:lang="en-US">Represent the entitled benefit term in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EntitledBenefitTerm" xlink:to="chek_EntitledBenefitTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_EquityPercentageOfWeightedAverage_lbl0" xml:lang="en-US">Equity percentage of weighted average.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EquityPercentageOfWeightedAverage" xlink:to="chek_EquityPercentageOfWeightedAverage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ExceedingCarryingValue_lbl0" xml:lang="en-US">Amount of exceeding carrying value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ExceedingCarryingValue" xlink:to="chek_ExceedingCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FundReceivedInTotalAmount_lbl0" xml:lang="en-US">Fund received in total amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FundReceivedInTotalAmount" xlink:to="chek_FundReceivedInTotalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure for general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GoingConcernPolicyTextBlock" xlink:to="chek_GoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantedRevenue_lbl0" xml:lang="en-US">Revenue fron grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl0" xml:lang="en-US">Amount of net impairment of loan receivable and debt extinguishment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:to="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ImpairmentOfLoansReceivable_lbl2" xml:lang="en-US">The charge against impairment of loans receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoansReceivable" xlink:to="chek_ImpairmentOfLoansReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ImpliedInterestPercentage_lbl0" xml:lang="en-US">Implied interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpliedInterestPercentage" xlink:to="chek_ImpliedInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_InterestImpliedValuation_lbl0" xml:lang="en-US">The amount of interest implied valuation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_InterestImpliedValuation" xlink:to="chek_InterestImpliedValuation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_LimitationFromTheYearOfElectionTerm_lbl0" xml:lang="en-US">Represent the limitation from the year of election term in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LimitationFromTheYearOfElectionTerm" xlink:to="chek_LimitationFromTheYearOfElectionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NetCarryingValue_lbl0" xml:lang="en-US">Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NetCarryingValue" xlink:to="chek_NetCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NotesReallocation_lbl0" xml:lang="en-US">Notes reallocation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NotesReallocation" xlink:to="chek_NotesReallocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OutstandingAmountsOfLandlordClaim_lbl0" xml:lang="en-US">Outstanding amounts of landlord claims.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OutstandingAmountsOfLandlordClaim" xlink:to="chek_OutstandingAmountsOfLandlordClaim_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PaymentsExpensesForPatents_lbl0" xml:lang="en-US">Represents amount of payments /expenses for patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PaymentsExpensesForPatents" xlink:to="chek_PaymentsExpensesForPatents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfComparableCompanyMethod_lbl0" xml:lang="en-US">Percentage of comparable company method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfComparableCompanyMethod" xlink:to="chek_PercentageOfComparableCompanyMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfCostEquity_lbl0" xml:lang="en-US">The percentage of cost equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfCostEquity" xlink:to="chek_PercentageOfCostEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfDiscountedCashFlowMethod_lbl0" xml:lang="en-US">Percentage of discounted cash flow method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfDiscountedCashFlowMethod" xlink:to="chek_PercentageOfDiscountedCashFlowMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfImpliedRate_lbl0" xml:lang="en-US">The percentage of implied rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfImpliedRate" xlink:to="chek_PercentageOfImpliedRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfManagementAssessedEquity_lbl0" xml:lang="en-US">Percentage of management-assessed equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfManagementAssessedEquity" xlink:to="chek_PercentageOfManagementAssessedEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfShareholding_lbl0" xml:lang="en-US">Percentage of shareholding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfShareholding" xlink:to="chek_PercentageOfShareholding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PercentageOfValuationInterest_lbl0" xml:lang="en-US">Percentage of valuation interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfValuationInterest" xlink:to="chek_PercentageOfValuationInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PrepaidGovernmentInstitutions_lbl0" xml:lang="en-US">Represent the amount related to government institutions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidGovernmentInstitutions" xlink:to="chek_PrepaidGovernmentInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ReclassifiedAcquisitionTarget_lbl0" xml:lang="en-US">Reclassified acquisition target .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReclassifiedAcquisitionTarget" xlink:to="chek_ReclassifiedAcquisitionTarget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ReducingCarryingValueNet_lbl0" xml:lang="en-US">The amount of reducing carrying value net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReducingCarryingValueNet" xlink:to="chek_ReducingCarryingValueNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ReductionInIncomeTaxRate_lbl0" xml:lang="en-US">Reduction In Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReductionInIncomeTaxRate" xlink:to="chek_ReductionInIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ReinstatedRecoverableLoan_lbl0" xml:lang="en-US">Amount of reinstated recoverable loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReinstatedRecoverableLoan" xlink:to="chek_ReinstatedRecoverableLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesProvision_lbl0" xml:lang="en-US">Amount of the liability recorded to pay royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesProvision" xlink:to="chek_RoyaltiesProvision_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesSoldComponent_lbl0" xml:lang="en-US">Royalties sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesSoldComponent" xlink:to="chek_RoyaltiesSoldComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure for employee related liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of research and development expenses, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareholderVotingPercentage_lbl1" xml:lang="en-US">Shareholder voting percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareholderVotingPercentage" xlink:to="chek_ShareholderVotingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShortTermBankDepositPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policies short term bank deposit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShortTermBankDepositPolicyTextBlock" xlink:to="chek_ShortTermBankDepositPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SubcontractorsAndConsultantFees_lbl0" xml:lang="en-US">Fees for the services provided by subcontractors and consultants during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SubcontractorsAndConsultantFees" xlink:to="chek_SubcontractorsAndConsultantFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_UncertainTaxPositions_lbl0" xml:lang="en-US">Uncertain tax positions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UncertainTaxPositions" xlink:to="chek_UncertainTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ValuationOfFairValueMarket_lbl0" xml:lang="en-US">Amount of valuation of fair value market.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ValuationOfFairValueMarket" xlink:to="chek_ValuationOfFairValueMarket_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_VotesCastPercentage_lbl0" xml:lang="en-US">Votes cast percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_VotesCastPercentage" xlink:to="chek_VotesCastPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl0" xml:lang="en-US">Israel-United States Binational Industrial Research and Development Foundation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CheckCapUsIncMember_lbl1" xml:lang="en-US">This member stands for Check-Cap US, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapUsIncMember" xlink:to="chek_CheckCapUsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CreditLineAgreementWarrantsMember_lbl0" xml:lang="en-US">CLA Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CreditLineAgreementWarrantsMember" xlink:to="chek_CreditLineAgreementWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DesignerRoyaltiesMember_lbl0" xml:lang="en-US">Royalties to an ASIC designer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DesignerRoyaltiesMember" xlink:to="chek_DesignerRoyaltiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DevelopmentAreaAMember_lbl0" xml:lang="en-US">Development Area A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DevelopmentAreaAMember" xlink:to="chek_DevelopmentAreaAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FeesAndReimbursementMember_lbl0" xml:lang="en-US">Fees, including reimbursement of expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FeesAndReimbursementMember" xlink:to="chek_FeesAndReimbursementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralTransactionsMember_lbl0" xml:lang="en-US">General Transactions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralTransactionsMember" xlink:to="chek_GeneralTransactionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl0" xml:lang="en-US">This member stands for Israel Innovation Authority of the Ministry of Economy and Industry.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:to="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NonExecutiveDirectorsCompensationMember_lbl0" xml:lang="en-US">Non-Executive Directors Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsCompensationMember" xlink:to="chek_NonExecutiveDirectorsCompensationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NonExecutiveDirectorsMember_lbl0" xml:lang="en-US">Non-executive Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsMember" xlink:to="chek_NonExecutiveDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RestOfCountryMember_lbl0" xml:lang="en-US">Rest of the Country [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RestOfCountryMember" xlink:to="chek_RestOfCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareBasedCompensationMember_lbl0" xml:lang="en-US">Share-Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationMember" xlink:to="chek_ShareBasedCompensationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfImpliedRate_lbl1" xml:lang="en-US">Percentage Of Implied Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfImpliedRate" xlink:to="chek_PercentageOfImpliedRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTableTextBlock_lbl0" xml:lang="en-US">Other Commitments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTableTextBlock" xlink:to="us-gaap_OtherCommitmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl1" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfCostEquity_lbl1" xml:lang="en-US">Percentage Of Cost Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfCostEquity" xlink:to="chek_PercentageOfCostEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AmountPayableForNonrefundableFee_lbl1" xml:lang="en-US">Amount Payable For Nonrefundable Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountPayableForNonrefundableFee" xlink:to="chek_AmountPayableForNonrefundableFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl2" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DevelopmentAreaAMember_lbl1" xml:lang="en-US">Development Area AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DevelopmentAreaAMember" xlink:to="chek_DevelopmentAreaAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfShareBasedCompensationAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfShareBasedCompensationAbstract" xlink:to="chek_ScheduleOfShareBasedCompensationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl0" xml:lang="en-US">Proceeds from Royalties Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ExchangeIndebtednessMember_lbl0" xml:lang="en-US">Exchange Indebtedness Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ExchangeIndebtednessMember" xlink:to="chek_ExchangeIndebtednessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AmountOfManagementAssessedEquity_lbl1" xml:lang="en-US">Amount Of Management Assessed Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AmountOfManagementAssessedEquity" xlink:to="chek_AmountOfManagementAssessedEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl0" xml:lang="en-US">Accrued Vacation, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_lbl0" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract_lbl" xml:lang="en-US">Schedule Of Research And Development Expenses Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DepositsRate_lbl1" xml:lang="en-US">Deposits Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DepositsRate" xlink:to="chek_DepositsRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl0" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FeesAndReimbursementMember_lbl1" xml:lang="en-US">Fees And Reimbursement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FeesAndReimbursementMember" xlink:to="chek_FeesAndReimbursementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_lbl1" xml:lang="en-US">General And Administrative Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl0" xml:lang="en-US">Financial Instruments, Owned, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfDiscountedCashFlowMethod_lbl1" xml:lang="en-US">Percentage Of Discounted Cash Flow Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfDiscountedCashFlowMethod" xlink:to="chek_PercentageOfDiscountedCashFlowMethod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DesignerRoyaltiesMember_lbl1" xml:lang="en-US">Designer Royalties Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DesignerRoyaltiesMember" xlink:to="chek_DesignerRoyaltiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NetCarryingValue_lbl1" xml:lang="en-US">Net Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NetCarryingValue" xlink:to="chek_NetCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl2" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfValuationInterest_lbl1" xml:lang="en-US">Percentage Of Valuation Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfValuationInterest" xlink:to="chek_PercentageOfValuationInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ReinstatedRecoverableLoan_lbl1" xml:lang="en-US">Reinstated Recoverable Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReinstatedRecoverableLoan" xlink:to="chek_ReinstatedRecoverableLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod_lbl0" xml:lang="en-US">Loans Receivable, Basis Spread on Variable Rate, During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Employee Related Liabilities Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl2" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestment_lbl0" xml:lang="en-US">Alternative Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestment" xlink:to="us-gaap_AlternativeInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl0" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_UncertainTaxPositions_lbl1" xml:lang="en-US">Uncertain Tax Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UncertainTaxPositions" xlink:to="chek_UncertainTaxPositions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_InterestImpliedValuation_lbl1" xml:lang="en-US">Interest Implied Valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_InterestImpliedValuation" xlink:to="chek_InterestImpliedValuation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CheckCapUsIncMember_lbl2" xml:lang="en-US">Check Cap Us Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapUsIncMember" xlink:to="chek_CheckCapUsIncMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl1" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PrepaidGovernmentInstitutions_lbl1" xml:lang="en-US">Prepaid Government Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidGovernmentInstitutions" xlink:to="chek_PrepaidGovernmentInstitutions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl1" xml:lang="en-US">Apollo Technology Capital Corporation Loan Receivable Exchange And Equity Investment Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:to="chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LimitationFromTheYearOfElectionTerm_lbl1" xml:lang="en-US">Limitation From The Year Of Election Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LimitationFromTheYearOfElectionTerm" xlink:to="chek_LimitationFromTheYearOfElectionTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PaymentsExpensesForPatents_lbl1" xml:lang="en-US">Payments Expenses For Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PaymentsExpensesForPatents" xlink:to="chek_PaymentsExpensesForPatents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">Debtfor Equity Exchange November Fourteen Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" xlink:to="chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReduction_lbl0" xml:lang="en-US">Notes Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReduction" xlink:to="us-gaap_NotesReduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NotesReallocation_lbl1" xml:lang="en-US">Notes Reallocation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NotesReallocation" xlink:to="chek_NotesReallocation_lbl1"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfRsusActivityAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfRsusActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfRsusActivityAbstract_lbl" xml:lang="en-US">Schedule Of Rsus Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfRsusActivityAbstract" xlink:to="chek_ScheduleOfRsusActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CreditLineAgreementWarrantsMember_lbl1" xml:lang="en-US">Credit Line Agreement Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CreditLineAgreementWarrantsMember" xlink:to="chek_CreditLineAgreementWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FundReceivedInTotalAmount_lbl1" xml:lang="en-US">Fund Received In Total Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FundReceivedInTotalAmount" xlink:to="chek_FundReceivedInTotalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantedRevenue_lbl1" xml:lang="en-US">Granted Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollectionOfLoansReceivable_lbl0" xml:lang="en-US">Proceeds from Collection of Loans Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfLoansReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl1" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SuppliesExpense_lbl0" xml:lang="en-US">Supplies Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuppliesExpense" xlink:to="us-gaap_SuppliesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DerivativeAmount_lbl1" xml:lang="en-US">Derivative Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeAmount" xlink:to="chek_DerivativeAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnlabeledAbstract" xlink:to="chek_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Royalties Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl0" xml:lang="en-US">Payments for Legal Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfOptionActivityAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfOptionActivityAbstract" xlink:to="chek_ScheduleOfOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EntitledBenefitTerm_lbl1" xml:lang="en-US">Entitled Benefit Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EntitledBenefitTerm" xlink:to="chek_EntitledBenefitTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl0" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl0" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RestOfCountryMember_lbl1" xml:lang="en-US">Rest Of Country Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RestOfCountryMember" xlink:to="chek_RestOfCountryMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfManagementAssessedEquity_lbl1" xml:lang="en-US">Percentage Of Management Assessed Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfManagementAssessedEquity" xlink:to="chek_PercentageOfManagementAssessedEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareholderVotingPercentage_lbl2" xml:lang="en-US">Shareholder Voting Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareholderVotingPercentage" xlink:to="chek_ShareholderVotingPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesSegregatedUnderOtherRegulations_lbl0" xml:lang="en-US">Securities Segregated under Other Regulations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesSegregatedUnderOtherRegulations" xlink:to="us-gaap_SecuritiesSegregatedUnderOtherRegulations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl0" xml:lang="en-US">Payment for (Proceeds from) Other Investing Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfAntiDilutiveSecuritiesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfAntiDilutiveSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfAntiDilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Anti Dilutive Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfAntiDilutiveSecuritiesAbstract" xlink:to="chek_ScheduleOfAntiDilutiveSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NonExecutiveDirectorsCompensationMember_lbl1" xml:lang="en-US">Non Executive Directors Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsCompensationMember" xlink:to="chek_NonExecutiveDirectorsCompensationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl1" xml:lang="en-US">Israel Innovation Authority Ministry Of Economy And Industry Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:to="chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfReductionOfRDExpensesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfReductionOfRDExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfReductionOfRDExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Reduction Of RDExpenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfReductionOfRDExpensesAbstract" xlink:to="chek_ScheduleOfReductionOfRDExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CarryingValueOfReinstatedReceivable_lbl1" xml:lang="en-US">Carrying Value Of Reinstated Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CarryingValueOfReinstatedReceivable" xlink:to="chek_CarryingValueOfReinstatedReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ValuationOfFairValueMarket_lbl1" xml:lang="en-US">Valuation Of Fair Value Market</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ValuationOfFairValueMarket" xlink:to="chek_ValuationOfFairValueMarket_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change In Deferred Tax Asset Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:to="chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LaboratoryEquipmentMember" xlink:to="chek_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_VotesCastPercentage_lbl1" xml:lang="en-US">Votes Cast Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_VotesCastPercentage" xlink:to="chek_VotesCastPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Transactions With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="chek_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ContingentLiability_lbl1" xml:lang="en-US">Contingent Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ContingentLiability" xlink:to="chek_ContingentLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralTransactionsMember_lbl1" xml:lang="en-US">General Transactions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralTransactionsMember" xlink:to="chek_GeneralTransactionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_Compensationtothenon-executivedirectors_lbl1" xml:lang="en-US">Compensationtothenon-executivedirectors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_Compensationtothenon-executivedirectors" xlink:to="chek_Compensationtothenon-executivedirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl0" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl0" xml:lang="en-US">Payments to Acquire Loans Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableFairValueDisclosure_lbl0" xml:lang="en-US">Loans Receivable, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableFairValueDisclosure" xlink:to="us-gaap_LoansReceivableFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ReducingCarryingValueNet_lbl1" xml:lang="en-US">Reducing Carrying Value Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReducingCarryingValueNet" xlink:to="chek_ReducingCarryingValueNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfCarryingValueSummaryAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfCarryingValueSummaryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfCarryingValueSummaryAbstract_lbl" xml:lang="en-US">Schedule Of Carrying Value Summary Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfCarryingValueSummaryAbstract" xlink:to="chek_ScheduleOfCarryingValueSummaryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl0" xml:lang="en-US">Postemployment Benefit Plans, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl1" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GoingConcernPolicyTextBlock" xlink:to="chek_GoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesToAnASICDesignerMember_lbl0" xml:lang="en-US">Royalties To An ASICDesigner Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesToAnASICDesignerMember" xlink:to="chek_RoyaltiesToAnASICDesignerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl0" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Research And Development Expenses Net Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_OutstandingAmountsOfLandlordClaim_lbl1" xml:lang="en-US">Outstanding Amounts Of Landlord Claim</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OutstandingAmountsOfLandlordClaim" xlink:to="chek_OutstandingAmountsOfLandlordClaim_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FirstApolloLoanMember_lbl0" xml:lang="en-US">First Apollo Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FirstApolloLoanMember" xlink:to="chek_FirstApolloLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl1" xml:lang="en-US">Impairment Of Loan Receivable And Gain On Debt Extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:to="chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PrivatePlacementWarrantsMember_lbl0" xml:lang="en-US">Private Placement Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrivatePlacementWarrantsMember" xlink:to="chek_PrivatePlacementWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EquityPercentageOfWeightedAverage_lbl1" xml:lang="en-US">Equity Percentage Of Weighted Average</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EquityPercentageOfWeightedAverage" xlink:to="chek_EquityPercentageOfWeightedAverage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Employee-related Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesSoldComponent_lbl1" xml:lang="en-US">Royalties Sold Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesSoldComponent" xlink:to="chek_RoyaltiesSoldComponent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ReclassifiedAcquisitionTarget_lbl1" xml:lang="en-US">Reclassified Acquisition Target</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReclassifiedAcquisitionTarget" xlink:to="chek_ReclassifiedAcquisitionTarget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLoans_lbl0" xml:lang="en-US">Payments for Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl1" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Impairment On Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:to="chek_AccumulatedImpairmentOnPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ChangesInLiabilityToPayRoyalties_lbl1" xml:lang="en-US">Changes In Liability To Pay Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ChangesInLiabilityToPayRoyalties" xlink:to="chek_ChangesInLiabilityToPayRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationMember_lbl1" xml:lang="en-US">Share Based Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationMember" xlink:to="chek_ShareBasedCompensationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ImpairmentOfLoansReceivable_lbl3" xml:lang="en-US">Impairment Of Loans Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpairmentOfLoansReceivable" xlink:to="chek_ImpairmentOfLoansReceivable_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl1" xml:lang="en-US">Binational Industrial Research And Development Foundation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl1" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember_lbl0" xml:lang="en-US">Consulting Fees Including Sharebased Compensation And Reimbursement Of Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" xlink:to="chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FourthApolloLoanMember_lbl0" xml:lang="en-US">Fourth Apollo Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FourthApolloLoanMember" xlink:to="chek_FourthApolloLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl1" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfComparableCompanyMethod_lbl1" xml:lang="en-US">Percentage Of Comparable Company Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfComparableCompanyMethod" xlink:to="chek_PercentageOfComparableCompanyMethod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ExceedingCarryingValue_lbl1" xml:lang="en-US">Exceeding Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ExceedingCarryingValue" xlink:to="chek_ExceedingCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ReductionInIncomeTaxRate_lbl1" xml:lang="en-US">Reduction In Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReductionInIncomeTaxRate" xlink:to="chek_ReductionInIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SecondApolloLoanMember_lbl0" xml:lang="en-US">Second Apollo Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SecondApolloLoanMember" xlink:to="chek_SecondApolloLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SubcontractorsAndConsultantFees_lbl1" xml:lang="en-US">Subcontractors And Consultant Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SubcontractorsAndConsultantFees" xlink:to="chek_SubcontractorsAndConsultantFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of General And Administrative Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShortTermBankDepositPolicyTextBlock_lbl1" xml:lang="en-US">Short Term Bank Deposit Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShortTermBankDepositPolicyTextBlock" xlink:to="chek_ShortTermBankDepositPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl0" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ApolloTechnologyCapitalCorporationMember_lbl0" xml:lang="en-US">Apollo Technology Capital Corporation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ApolloTechnologyCapitalCorporationMember" xlink:to="chek_ApolloTechnologyCapitalCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GhostKitchensARAMember_lbl0" xml:lang="en-US">Ghost Kitchens ARAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GhostKitchensARAMember" xlink:to="chek_GhostKitchensARAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DeferredIncomeTaxesPolicyTextBlock_lbl1" xml:lang="en-US">Deferred Income Taxes Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DeferredIncomeTaxesPolicyTextBlock" xlink:to="chek_DeferredIncomeTaxesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities_lbl0" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Percent Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl2" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesProvision_lbl1" xml:lang="en-US">Royalties Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesProvision" xlink:to="chek_RoyaltiesProvision_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl0" xml:lang="en-US">Grants Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl0" xml:lang="en-US">Proceeds from Legal Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl2" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule Of General And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CheckCapMember_lbl0" xml:lang="en-US">Check Cap Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CheckCapMember" xlink:to="chek_CheckCapMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ComputersAndAuxiliaryEquipmentMember_lbl0" xml:lang="en-US">Computers And Auxiliary Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ComputersAndAuxiliaryEquipmentMember" xlink:to="chek_ComputersAndAuxiliaryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl0" xml:lang="en-US">Technology Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="chek_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="chek_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl0" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl0" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NonExecutiveDirectorsMember_lbl1" xml:lang="en-US">Non Executive Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsMember" xlink:to="chek_NonExecutiveDirectorsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PercentageOfShareholding_lbl1" xml:lang="en-US">Percentage Of Shareholding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PercentageOfShareholding" xlink:to="chek_PercentageOfShareholding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ImpliedInterestPercentage_lbl1" xml:lang="en-US">Implied Interest Percentage</label>
<!-- [WMV7][FL8IALemoxDzr6DJi58+flY2atYWeYeuX9uGcRS1CkNnE5JT0uWGrci63xgbpzs/kN6I5hQvdRkJgPVCbNpSUEZlvyfOerh3Tm17rb33cb8ZPlHYK91UPupXrl0dKKsJbRFkbsLyUGCARzYVCHJH6jOKOzoKsyzDF3Hhk9etBNK2kWKaFa46QQ79e3fjBOkE71DAIEu71chRy3EY54oinzJ9064N3pzx69jB8qiSTlq9mtKGpMvL4VWWe0NiwaIzVOWDx+C0pX2uyFoWROsuPyOzF/OBBwqm6C8ocnpjzEky8eoilKZeNzDZViCePySVL0tXjFtcqEVS9llEuQ==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ImpliedInterestPercentage" xlink:to="chek_ImpliedInterestPercentage_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>chek-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Mon Apr 27 14:12:33 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedBalanceSheet" roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedIncomeStatement" roleURI="http://check-cap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquityType2or3" roleURI="http://check-cap.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ConsolidatedCashFlow" roleURI="http://check-cap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralInformation" roleURI="http://check-cap.com/role/GeneralInformation"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SummaryofSignificantAccountingPoliciesandGoingConcern" roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNet" roleURI="http://check-cap.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_Leases" roleURI="http://check-cap.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccruals" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxes" roleURI="http://check-cap.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilities" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FairValueMeasurements" roleURI="http://check-cap.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquity" roleURI="http://check-cap.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensation" roleURI="http://check-cap.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ResearchandDevelopmentExpensesNet" roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralandAdministrativeExpenses" roleURI="http://check-cap.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishment" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FinanceIncomeExpenseNet" roleURI="http://check-cap.com/role/FinanceIncomeExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShare" roleURI="http://check-cap.com/role/EarningsLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_RelatedParties" roleURI="http://check-cap.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SubsequentEvents" roleURI="http://check-cap.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_AccountingPoliciesByPolicy" roleURI="http://check-cap.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNetTables" roleURI="http://check-cap.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccrualsTables" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxesTables" roleURI="http://check-cap.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilitiesTables" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensationTables" roleURI="http://check-cap.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ResearchandDevelopmentExpensesNetTables" roleURI="http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralandAdministrativeExpensesTables" roleURI="http://check-cap.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FinanceIncomeExpenseNetTables" roleURI="http://check-cap.com/role/FinanceIncomeExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShareTables" roleURI="http://check-cap.com/role/EarningsLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_RelatedPartiesTables" roleURI="http://check-cap.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofEmployeeBenefitsandPayrollAccrualsTable" roleURI="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofNetDeferredTaxAssetsTable_Parentheticals" roleURI="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofAccumulatedIsraeliNetOperatingLossTable" roleURI="http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofMovementinValuationAllowanceTable" roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofMovementinValuationAllowanceTable_Parentheticals" roleURI="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofProvisionforIncomeTaxesTable" roleURI="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofStatutoryIsraeliCorporateTaxRateTable" roleURI="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofReductionofRDExpensesTable" roleURI="http://check-cap.com/role/ScheduleofReductionofRDExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofParametersUsedinApplyingtheModelTable" roleURI="http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofShareBasedCompensationTable" roleURI="http://check-cap.com/role/ScheduleofShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofOptionActivityTable" roleURI="http://check-cap.com/role/ScheduleofOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofRSUsActivityTable" roleURI="http://check-cap.com/role/ScheduleofRSUsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofResearchandDevelopmentExpensesNetTable" roleURI="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" roleURI="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofFinanceIncomeExpenseNetTable" roleURI="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofEarningsLossPerShareTable" roleURI="http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofAntiDilutiveSecuritiesTable" roleURI="http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofTransactionswithRelatedPartiesTable0" roleURI="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ScheduleofCarryingValueSummaryTable" roleURI="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_GeneralInformationDetails" roleURI="http://check-cap.com/role/GeneralInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_SummaryofSignificantAccountingPoliciesandGoingConcernDetails" roleURI="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_PropertyandEquipmentNetDetails" roleURI="http://check-cap.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_LeasesDetails" roleURI="http://check-cap.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EmployeeBenefitsandPayrollAccrualsDetails" roleURI="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_IncomeTaxesDetails" roleURI="http://check-cap.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_FairValueMeasurementsDetails" roleURI="http://check-cap.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareholdersEquityDetails" roleURI="http://check-cap.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ShareBasedCompensationDetails" roleURI="http://check-cap.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails" roleURI="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_EarningsLossPerShareDetails" roleURI="http://check-cap.com/role/EarningsLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="chek-20251231.xsd#chek_r_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails" roleURI="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://check-cap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="RoyaltiesProvision" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="ImpairmentOfLoansReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLoansReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/GeneralInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ResearchandDevelopmentExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesTextBlock" xlink:href="chek-20251231.xsd#chek_GeneralAndAdministrativeExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/FinanceIncomeExpenseNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EarningsLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="GoingConcernPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_GoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GoingConcernPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermBankDepositPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_ShortTermBankDepositPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ShortTermBankDepositPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PostemploymentBenefitPlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxesPolicyTextBlock" xlink:href="chek-20251231.xsd#chek_DeferredIncomeTaxesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredIncomeTaxesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="chek-20251231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/FinanceIncomeExpenseNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/RelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTablesTable" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTablesLineItems" xlink:href="chek-20251231.xsd#chek_RelatedPartiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTablesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonExecutiveDirectorsCompensationMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NonExecutiveDirectorsCompensationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralTransactionsMember" xlink:href="chek-20251231.xsd#chek_GeneralTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GeneralTransactionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTablesTable" xlink:to="RelatedPartiesTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTablesLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidGovernmentInstitutions" xlink:href="chek-20251231.xsd#chek_PrepaidGovernmentInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidGovernmentInstitutions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TechnologyEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_TechnologyEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedImpairmentOnPropertyPlantAndEquipment" xlink:href="chek-20251231.xsd#chek_AccumulatedImpairmentOnPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedImpairmentOnPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedVacationCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:href="chek-20251231.xsd#chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofReductionofRDExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReductionOfRDExpensesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfReductionOfRDExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReductionOfRDExpensesAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesToAnASICDesignerMember" xlink:href="chek-20251231.xsd#chek_RoyaltiesToAnASICDesignerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="RoyaltiesToAnASICDesignerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedCompensationAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionActivityAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionActivityAbstract" xlink:to="ShareBasedCompensationScheduleofOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofOptionActivityDetailsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofRSUsActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsusActivityAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfRsusActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsusActivityAbstract" xlink:to="ShareBasedCompensationScheduleofRSUsActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofRSUsActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesNetAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:href="chek-20251231.xsd#chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentExpensesNetAbstract" xlink:to="ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SuppliesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SuppliesExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubcontractorsAndConsultantFees" xlink:href="chek-20251231.xsd#chek_SubcontractorsAndConsultantFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="SubcontractorsAndConsultantFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_DepreciationNonproduction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsExpensesForPatents" xlink:href="chek-20251231.xsd#chek_PaymentsExpensesForPatents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="PaymentsExpensesForPatents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedRevenue" xlink:href="chek-20251231.xsd#chek_GrantedRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="GrantedRevenue" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_CostMaintenance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Depreciation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="ImpairmentOfLoansReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureAbstract" xlink:to="ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInLiabilityToPayRoyalties" xlink:href="chek-20251231.xsd#chek_ChangesInLiabilityToPayRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="ChangesInLiabilityToPayRoyalties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofEarningsLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveSecuritiesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfAntiDilutiveSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FeesAndReimbursementMember" xlink:href="chek-20251231.xsd#chek_FeesAndReimbursementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FeesAndReimbursementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationMember" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ShareBasedCompensationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonExecutiveDirectorsMember" xlink:href="chek-20251231.xsd#chek_NonExecutiveDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NonExecutiveDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Compensationtothenon-executivedirectors" xlink:href="chek-20251231.xsd#chek_Compensationtothenon-executivedirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="Compensationtothenon-executivedirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" xlink:href="chek-20251231.xsd#chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GeneralTransactionsMember" xlink:href="chek-20251231.xsd#chek_GeneralTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GeneralTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ScheduleofCarryingValueSummaryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingValueSummaryAbstract" xlink:href="chek-20251231.xsd#chek_ScheduleOfCarryingValueSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingValueSummaryAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ApolloTechnologyCapitalCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_LoansPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/GeneralInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralInformationDetailsTable" xlink:href="chek-20251231.xsd#chek_GeneralInformationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GeneralInformationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationDetailsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CheckCapMember" xlink:href="chek-20251231.xsd#chek_CheckCapMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="CheckCapMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FirstApolloLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="FirstApolloLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondApolloLoanMember" xlink:href="chek-20251231.xsd#chek_SecondApolloLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondApolloLoanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FourthApolloLoanMember" xlink:href="chek-20251231.xsd#chek_FourthApolloLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="FourthApolloLoanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="VotesCastPercentage" xlink:href="chek-20251231.xsd#chek_VotesCastPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="VotesCastPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountPayableForNonrefundableFee" xlink:href="chek-20251231.xsd#chek_AmountPayableForNonrefundableFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AmountPayableForNonrefundableFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Deposits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LoansPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesSegregatedUnderOtherRegulations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuritiesSegregatedUnderOtherRegulations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SecuritiesSegregatedUnderOtherRegulations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifiedAcquisitionTarget" xlink:href="chek-20251231.xsd#chek_ReclassifiedAcquisitionTarget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReclassifiedAcquisitionTarget" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:href="chek-20251231.xsd#chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="chek-20251231.xsd#chek_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersAndAuxiliaryEquipmentMember" xlink:href="chek-20251231.xsd#chek_ComputersAndAuxiliaryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersAndAuxiliaryEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GhostKitchensARAMember" xlink:href="chek-20251231.xsd#chek_GhostKitchensARAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GhostKitchensARAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LongTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_LoansReceivableFairValueDisclosure" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="chek-20251231.xsd#chek_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfLand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsandPayrollAccrualsDetailsTable" xlink:href="chek-20251231.xsd#chek_EmployeeBenefitsandPayrollAccrualsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="EmployeeBenefitsandPayrollAccrualsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsandPayrollAccrualsDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DepositsRate" xlink:href="chek-20251231.xsd#chek_DepositsRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="DepositsRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="chek-20251231.xsd#chek_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentAreaAMember" xlink:href="chek-20251231.xsd#chek_DevelopmentAreaAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="DevelopmentAreaAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestOfCountryMember" xlink:href="chek-20251231.xsd#chek_RestOfCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="RestOfCountryMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="dei_LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CheckCapUsIncMember" xlink:href="chek-20251231.xsd#chek_CheckCapUsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="CheckCapUsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="EntitledBenefitTerm" xlink:href="chek-20251231.xsd#chek_EntitledBenefitTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="EntitledBenefitTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LimitationFromTheYearOfElectionTerm" xlink:href="chek-20251231.xsd#chek_LimitationFromTheYearOfElectionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="LimitationFromTheYearOfElectionTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReductionInIncomeTaxRate" xlink:href="chek-20251231.xsd#chek_ReductionInIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ReductionInIncomeTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLoansReceivable" xlink:href="chek-20251231.xsd#chek_ImpairmentOfLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ImpairmentOfLoansReceivable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UncertainTaxPositions" xlink:href="chek-20251231.xsd#chek_UncertainTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="UncertainTaxPositions" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingentLiabilitiesDetailsTable" xlink:href="chek-20251231.xsd#chek_CommitmentsandContingentLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingentLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DesignerRoyaltiesMember" xlink:href="chek-20251231.xsd#chek_DesignerRoyaltiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="DesignerRoyaltiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" xlink:href="chek-20251231.xsd#chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:href="chek-20251231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="BinationalIndustrialResearchAndDevelopmentFoundationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingentLiabilitiesDetailsTable" xlink:to="us-gaap_LossContingenciesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesSoldComponent" xlink:href="chek-20251231.xsd#chek_RoyaltiesSoldComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="RoyaltiesSoldComponent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesProvision" xlink:href="chek-20251231.xsd#chek_RoyaltiesProvision"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="RoyaltiesProvision" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundReceivedInTotalAmount" xlink:href="chek-20251231.xsd#chek_FundReceivedInTotalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="FundReceivedInTotalAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentLiability" xlink:href="chek-20251231.xsd#chek_ContingentLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ContingentLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeAmount" xlink:href="chek-20251231.xsd#chek_DerivativeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="DerivativeAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingAmountsOfLandlordClaim" xlink:href="chek-20251231.xsd#chek_OutstandingAmountsOfLandlordClaim"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="OutstandingAmountsOfLandlordClaim" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsTable" xlink:href="chek-20251231.xsd#chek_FairValueMeasurementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueMeasurementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ApolloTechnologyCapitalCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_LongTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpliedInterestPercentage" xlink:href="chek-20251231.xsd#chek_ImpliedInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="ImpliedInterestPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_AlternativeInvestment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementWarrantsMember" xlink:href="chek-20251231.xsd#chek_PrivatePlacementWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivatePlacementWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CreditLineAgreementWarrantsMember" xlink:href="chek-20251231.xsd#chek_CreditLineAgreementWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="CreditLineAgreementWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsTable" xlink:href="chek-20251231.xsd#chek_ShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ApolloTechnologyCapitalCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_ProceedsFromCollectionOfLoansReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetCarryingValue" xlink:href="chek-20251231.xsd#chek_NetCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="NetCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholderVotingPercentage" xlink:href="chek-20251231.xsd#chek_ShareholderVotingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="ShareholderVotingPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceedingCarryingValue" xlink:href="chek-20251231.xsd#chek_ExceedingCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="ExceedingCarryingValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansPayable" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_NotesReduction" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesReallocation" xlink:href="chek-20251231.xsd#chek_NotesReallocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="NotesReallocation" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="EarningsLossPerShareDetailsTable" xlink:href="chek-20251231.xsd#chek_EarningsLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="EarningsLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:href="chek-20251231.xsd#chek_LoanReceivableExchangeAndEquityInvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract" xlink:to="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ApolloTechnologyCapitalCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember_0" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ApolloTechnologyCapitalCorporationMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ApolloTechnologyCapitalCorporationMember_1" xlink:href="chek-20251231.xsd#chek_ApolloTechnologyCapitalCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ApolloTechnologyCapitalCorporationMember_1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExchangeIndebtednessMember" xlink:href="chek-20251231.xsd#chek_ExchangeIndebtednessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ExchangeIndebtednessMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" xlink:href="chek-20251231.xsd#chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable" xlink:to="LoanReceivableExchangeAndEquityInvestmentLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReducingCarryingValueNet" xlink:href="chek-20251231.xsd#chek_ReducingCarryingValueNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="ReducingCarryingValueNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReinstatedRecoverableLoan" xlink:href="chek-20251231.xsd#chek_ReinstatedRecoverableLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="ReinstatedRecoverableLoan" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfManagementAssessedEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfManagementAssessedEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfManagementAssessedEquity" xlink:href="chek-20251231.xsd#chek_AmountOfManagementAssessedEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="AmountOfManagementAssessedEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_LoansPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CarryingValueOfReinstatedReceivable" xlink:href="chek-20251231.xsd#chek_CarryingValueOfReinstatedReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="CarryingValueOfReinstatedReceivable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfShareholding" xlink:href="chek-20251231.xsd#chek_PercentageOfShareholding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfShareholding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholderVotingPercentage" xlink:href="chek-20251231.xsd#chek_ShareholderVotingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="ShareholderVotingPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_PaymentsForLoans" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationOfFairValueMarket" xlink:href="chek-20251231.xsd#chek_ValuationOfFairValueMarket"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="ValuationOfFairValueMarket" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityPercentageOfWeightedAverage" xlink:href="chek-20251231.xsd#chek_EquityPercentageOfWeightedAverage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="EquityPercentageOfWeightedAverage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDiscountedCashFlowMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfDiscountedCashFlowMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfDiscountedCashFlowMethod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfComparableCompanyMethod" xlink:href="chek-20251231.xsd#chek_PercentageOfComparableCompanyMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfComparableCompanyMethod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCostEquity" xlink:href="chek-20251231.xsd#chek_PercentageOfCostEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfCostEquity" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfValuationInterest" xlink:href="chek-20251231.xsd#chek_PercentageOfValuationInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfValuationInterest" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestImpliedValuation" xlink:href="chek-20251231.xsd#chek_InterestImpliedValuation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="InterestImpliedValuation" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfImpliedRate" xlink:href="chek-20251231.xsd#chek_PercentageOfImpliedRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanReceivableExchangeAndEquityInvestmentLineItems" xlink:to="PercentageOfImpliedRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
<!-- [WMV7][WdfGnSYw3OHDRbhtiw7LmA5EYlLI59gWs2+7t3LRIrMDmikeaZZarWw4egTpzNyhXwXrppk4T23v5nICoO8WrqYgWRX7mMk8ENBpeHTVFUaVd7SIuDtgyzrWAUfAhv5ZS6auWOiMh+5EGAxaGH92BcdRqzerD7na99Z1tgiySbBvrVth1ooxBISsEUipND5CbQkSrBzAB6Psot5sUOgeGrRIfKk/4QwvpwXPl2FNc1tMUYO3OtckHJ6SKtqs5kVpSXnFrfetHgO+ASpIMvzQeuz9S2VmcpAT3aTw6Aj9OvtwnypQsD3LoNhn1VSjXsAlrh4yXRYOFha+XVS7cw==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ea028762301_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !S 3$# 2(  A$! Q$!_\0
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MXR?NRFE9J\I))R2O;5I7:6]C^>*;_@X+_P""AL3A(/'G[-ERH'3_ (0(8_\
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MU9Y_X.2?^"B$7_,6_9QN?8>!G7U/&WQ,,],?_KX_M\'[*_[,6!G]G7X$]/\
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MN?35\,3^&_VG6N_LGB__ (2/3+'47'@+^W-&&N@D'YUD7G:05(VD89OXU?\
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M87"6^JOF=M;72;ZV3;LOF_,6'^M.SE\+UU^3TV?73\C[ZZ44=:*P.D*JS_\
M'K+_ ->Y_P#0&JU52[_X]9_^N!_DU"W7JOS$]GZ/\F>->*O&'ASP3X8U_P 8
M^*M5MM$\/^&-'.M:QJ__ #X:7UR<^XP,_3FOPO\ 'GQ!\1_%_P =ZQ\4_%4%
MUIMQJI-EX/\ ">23X2\!DDZ'HF6)QXB\6$_\)1XV[!<    #Q3_@K#_P4 \8
MZ!\==*_9N^&>E^&M2\'_  G_ +*\3_%^S\5V>MC2_%GCK7!_;VA>"ROA]RI\
M/^$_#Q;Q0754+>,=B,&\M37QUX5_X*'>%KS_ )'_ .&7B3PW<<_;+OPG>?\
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M^%_]M?V]H6B^G_%6?\C0"/\ F3!X8!(Z5]4:#CQY\<_$'BK_ (^='^%VC_\
M"%^&^H_XJC73_P 3W\_KUKS>;]M[X ZEX7U"Q\'>,M.T3QQ]CTO1?#?PR\;Z
M/K/@GQ-_:FN_\2'0O^)'K_;W\)GKGZ#AOVD/BTO[%_[+]O!93C4_B_\ $8CP
MQX#M+3!U+Q;X]\<-_P 3W6M#XQE6UOC/(9?#'H<>MAWA<+A&U;FN[7EK=W]7
MIIWT^XYSP[XZ7VJ_MQ_M0Z=^S)X<OKK_ (4#\'L^)?V@O$6D:J]@NN$(S_\
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MM-TJXG^,/P=\?^&[BULQ>WFK?"?_ (NUX9O_ /N!_P#%(^)__+/Y/OS7P?\
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M $%KD_%W_(F>*_\ L7=6_P#31)765R7C/_D3?&/_ &+VL_\ IGDKCW7;]/\
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MVTM1_P""B%EJEA?? ?2=,U'P_IE[]NO?#WV/^TO[?TP_\P8^_;//Z&OV1HH
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M'5=$^!OB]M#DGMI]3;3='N[RV 9['3=<U@)K4JGC&Z)F4\;L';P"<_@KXP^
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MI?[1^#_[,?B'PS\0/B*VEZNWAK^WOB=H9.MZ)X.37,@-_P (IA_$A)#*/G
M<!D9)_6Y^U-\6S\?_BP/"VB3-<?"#X)>)/L9NK8+_9WQ)^*&A\Z]JYV97_A'
M?"&=O!8?\)HO5OO'S"SA@Z]\?Y]_R_$#FOA_X8_MI? '4K#1]#UR?4OA+<6O
M^A6=IXLL_P#BF>.__"<>'_\ BF/_  K.^<^WVQH.I:5K%A;ZKI5_INIZ?=?\
M>>K:3>?VEIE^3^'I^=&^^H&QY'O^O_UJX_7O ?@[Q5=6]]KFAVW_  D%K>?Z
M'XATG_BFO$UAJF?^8'KGA_\ XJ?CM_*NP_Y:_P"?[U?*_P"V-^U%X _9+^"/
MC'XM^/Y[FYT_0++[#9^'M)_Y&;QYXHUW_B0Z'\,=#_ZF+Q9^'_%%GQ/XZ]J+
MVVT]- /VD_X)]_&;5?BII?Q)\#>)/&4_C_Q+\"/&_AS1F\0:RC-XD/ACQSHJ
M:]H/]OR [->\089@WB9E+/NW(P6-PWZF5_+O_P &_P!I7Q'^&&G?$!?CS:F3
MXY_M>:P/C_\ $BZ+LC>$O$.C:5#H/@SX:*JEE.A>$/AI'H?AR($,Q=!&K*'8
MG^HBM*C=U?\ 4 KF?%W_ "*7BG_L7]8_]-<U=-7(^-I!%X0\8R_W/#/B$\^J
MZ1(?R^6LP/\ '7_8D_:)\2_LP_M??M+?$7P]X3\)>-+G5+GXG?#_ %?P[XWL
MO[1\-:AI/B#QGOUIFXYRNBA@2,[2N#V'^D?_ ,$??V[]<_:F_8ZTSXH^,8O"
MFH?%'4/BE\0-#\=>'_"&M:2!X1U236?^*'.O>'R__"0:&WBOP\L3QF:&41,C
M%1ER1_"AX\_X(T_%J]^(WC[Q5\'_ -IC1?!7A;XB>(]3\3-I.JZ3K0\3V2ZX
M3KPT36SH.\:\=NN[00I4 +E"=V['L_\ @BY^V%9S3FP_;0\.:;-D?Z3;-\2]
M.STR"0J8ST'MWSR>CZK=?#^'_P!J8?6L)O=7[V=_\_Q/]-O7OVI/#6@ZSK&A
MWVAZY]HTJ\^QC[':?V@+W@C"[<8'7.22><FN2_X:T\ 6=]]A@\'>+?\ 2O\
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MM4:SSI7[4-MIOVK'_'W\5/C[_+'MUK0@_P"#=W]LO4HKB"?]KSP3J5O=V?\
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MFGT5K^G6*\OD?VO4445Z%EV7W([>>/?\&%%%%,H**** "BBB@ HHHH ****
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M\0?\7._X2+_J51X/SWK#ZOAO^82]_-O?YOOH>^N(\1B?^1SE4<X7>T8I+O\
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ML$Z5\<O%OBB#_A=/Q(TW1_\ A&]+&L?\)99CXM:G8:5H7C3Q]X"_L30_''B
M>$?$_P#R+FA_\)1_Q5G_  F/_(?Y-?VA^-?V8O!GC)[AKR#1(!=_\?>W28SN
M'M\X!.?4CWKQ;5/V%K9Y&N=&\??8YKG/VMKWP]#J*N?]DM(#Z_>V^E%K=+?*
MWZ"4EM&2OVC)7^Z,K_@?D;\!_@%\*_V;OASH_P )/A)X<_L3P_I?_'Y>7?\
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M=![GI7HVD:/I>A:?#I>D6=O9V-LNU+6W7Y4_#J22,G=].@H UJ*** "BBB@
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M_AJ1L^M^U]'U[[QU^V1\3=.\-> [/P!!XATGP]X9M?%'@GXT?&KQ7\$?B?\
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3! /4 _6BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ea028762301_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 G # 2(  A$! Q$!_\0
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M3&B4?\/$_P!KK_HK2_\ A,:)7QC>0SZ9=7%C?0?9M0M;S[%>6EW_ ,N&J?\
M0%X'X_\ U^EC3=(U77KK[#H=C<ZEJ%K9ZI>_9+2S_M+4_P"R]"_Y#NM#CN?J
M:U_U+X#^J?6_]6.%;7_FC;\[?,Y7QKQU>W]K<4>FM_N/LC_AXE^UY_T5/_RV
MM%_PH_X>)?M>?]%3_P#+:T7_  KXWATW59M4_L3^RM2_M@?Z%_9/V/.I]\G^
MPQ^7^16?Y_M^G_UZE<&<"RMR\+\+-NVSB]_1ON'^NO'*U>;<4)=W=+[S[9_X
M>)_M??\ 15#_ .$UHO\ A1_P\3_:^_Z*H?\ PFM%_P *^)J*Z_\ B'O"._\
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M.J_)A]JN=ZJI&&Y7#<U_0MR0,(,GG ///.>IX[],GK7\HW_!/W_D[GX3=_\
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MSZK\6[;1;>ZUC5?#%F=5^''C'3=3OO$^A?V__;A_L3/_ "+N/ ^N-X(\4_\
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M:+_A7Q-11_Q#_A#_ *)+A7_R7_(/]=>+O^BJXG^]GVS_ ,/$_P!K[_HJA_\
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M_P!=>+O^BJXG^]GVS_P\3_:^_P"BJ'_PFM%_PH_X>)_M??\ 15#_ .$UHO\
MA7Q-11_Q#[A#_HDN%ON7^0?ZZ\6_]%5Q/_X$_P#,^V?^'B?[7W_15#_X36B_
MX4?\/$_VOO\ HJA_\)K1?\*^)J*7_$/^$-_]4N%;=_=M]]@_UUXN_P"BJXG_
M / F?;/_  \3_:^_Z*H?_":T7_"C_AXG^UZ>OQ4/_A-:+_A7Q-11_P 0_P"$
M/^B3X6UZI1OZK35K=>=@?&O%UO\ DJN)_G)V^?EW\KGVK_P\-_:XZ?\ "STY
M_P"I7T/O_P !K]7O^";'[0/Q1^.FA?%:[^*/B8>(IM"\2Z;::/<I8:7IJV.G
M/I/FN72#J6?+LS @$LQ^\QK^<ROW1_X([Y_X1WXXX^]_PD'AG!]/^)*V3_WS
MFOR/QCX.X:R?@?,\=@,GI4I\].//&G3C:+J14H*481E:2]U:]C]&\*>)N(LV
MXKRW"8_-93BHS;3;ES+EENFVFWU\[H\B_P""P'_)7OA7_P!D]U?_ -/@K\BZ
M_73_ (+ ?\E>^%?_ &3W5_\ T^"OR+K[KP<=O#GA9ZZ.HW;?251_?IIYV/F/
M%E7X[S5=[K[[+]0HK[7^'OPW^ 6I?!?1[?QSXJT73?B?KMYI?Q-O!:7@_P"$
MET+X8'QI_8.NZ-_;G_(L_P#(N?VYXG_X1;/_  F>>W7'8:!^RQ\ ;T>,-*US
MX[D:_P"#M8\+Z->7?A[5_!HTP:IKNB_V]KNM:(#SK_AW_F5\'!']@>)\CJ!Z
M=?Q%RG#2S2.+I\4.TW"+C3E)/EFJ;<>6F[1YDTMG97U34GX='@_-,4LK>$J4
MTN5R:=2%U=-ZWFMEKKZ'Y\45][Z/^S)\'/%^C:??>%?B-K=MK&I_'?2_AEH_
MA^[\2>#?$GB6^\+#QI_8&O:U_8GA_I_T-'X9^MWXO_LJ?!?X??#OX@^(;#QK
MXVTWQMX6LA?:/X,\6WW@O^T=1).B*VKJ 2_B#0/%)UG6O^$+\4,J)C0QM=F5
MU7F7B=PX\9'!<G%+E)I)>SES:\J>GLT[)O5VY%UE=6*? >;?598SGCHVW[\=
MDW_?WTT5K];'Y]T5]K^"/A-\"-8TO0-$O_%.I#6/$_ASX.>)_$>J_P!K^#O]
M U/QSK6O_P!NZ+X'Z'P__P (G_8?_%;_ /"6>W/:E_:)^%?PD\'Z7\+[CP/X
MC\-^)-0TR\\+^"_&%IX>\2:/J6F6&E'6=?\ ^)UKG]@?\C!XB\6#'_%4'!SX
M?SBN]>(&3O-%E<<IXH:<')-P:5ES6>L+:RCI=IZIVU2,/]5,5]5^MN<=TFW.
M.E[7NN?97U79,^)Z*_2;7/A9^RO\4_'_ ,1M#\+ZYI_PXT_X8>&_$PO=7TK5
M]&\-Z;XMU0ZSKXT(Z+H6O>(O%@U__A$_#NA\^*=JCQF23A5R*SX/@=^SKXIU
M/1]*LO%-MX!\/Z\WAC6K*[NO%_@[Q%XFUY?^%,G7=<T70]<9L^']OB$\GQ8<
M-XURZJ,A1PQ\4,G=OK>3\4II*5G3DW%-*4>91I]I)^ZGHI7LU8]'_4/&-7PF
M;\,]-Y:O35:RWZ;K4_.FBOT-M?@#^S#H_BS0=*O/'_B+Q'#_ &OX8.K6MYXO
M\'^'M+O]-\<ZSX^T%=%*#:V@CPF=#T3Q05#*3_;PQR>/@+6++['K6L6,$%S;
M6]KK&J67V2[O-&U+4[#/3_B>>'\?\)!Z?H*]_)>+,+GV,<<+2JT[1YG[6E*F
MK7E&RYXQ;DN771*UFFT]/%S'A[%94KXNI"6_PSC);;IJ3T?37LK'T!^R!_R=
M+\"?^Q\TK^>OU_79'R1GG]V/_017\B?['_\ R=+\"?\ L?-*_GK]?UUP]1_N
M'^5?R_\ 2(?_ !EF5:_\TY3>_7G>N^_F?TOX#?\ )/9EV56.C_[>[^A97^#_
M (%7CWQU_P"2*?&'_LF7CG_U'-:KV%?X/^!5X]\=?^2*?&'_ +)EXY_]1S6J
M_!\O=L?E3WMB*#LM],1AW9>;MIYV/V/,K_V=FMM/W%6U]OX-75^7?R/Y<_@1
M\9?!OPW^'_Q \.^(_#G_  DNLZ]=Z9K7@_[7X;T;Q)X:T_Q1H?@O7]"T/6M;
MT3Q 1@?\)'K8S^'-=;X7^.G@#POXS^->H:7HEYHG@CX@ZUX$UWPUI.C^%/"5
M]J.A-X&\8:'K1T61%8+HRX?72$\,AT5]DP ECC88'P.G^".C_!GXC>(OBUX;
MTWQ)K_\ PD6F^&?#MK]D&H^)LZYX-US T3/B+PE_PCY/B(Z-_P 53N\7\#H<
MY3W"]_9V_9U\(,MC+XR'C37[GPEX$\3VV[QSX/;3=$U'_A9>@Z%XZ"$,HUT_
M\(^5\4GPPP92$>,(#(LB_P!H9IBN&\/F>:+-\HXK2SA48<T%)1<XTL+4YX<C
MY4HOD]]VT3BG*W*OXZP>'S;$9=ESP>;<+*7M*KM)QYK>TJI1E=WN[6?KTW*&
MF_M*_L]:EK'C?Q%XW^#VG:CK_B?1]3LO[6_X0/1O[,./&GC[7@3HA/(_X1S6
M]$SXI[_V#R<CGS#X;_&7X5^"? F@:5<:'J5MXHM='\=Z-XC&D^#]&U+^W=4\
M<_V__86M?\)Q_P C-QX=US_A&/\ A%^O/3@&O6;S]F_]FV'PE<^.+[XM:EJ-
MQ_Q7FM7GA[PIK'@W3<_V%_;_ /87@O0_^$@_Y%[Q%_Q(]# Z=/3&?*_B;\)_
M@QH(^&6D^#]=N-234_B[XD\ >.O&MUXK\(:BP\,_VYH@T36_[)+%-#SX;UI<
M>)41?!T6TLY82QA<,!_J17_V/#1XN47*SYE54$HPFK2Y[)12IRTL]>65G=2+
MQZXLPW^UXF7"LK)+W7!O=)-<K=V[W_X8[R\_:0^!\^J>?!\.?LT%KK&J:U9Z
MM:>#]&_X27^U/^$T\??\QO/_ $+FN:'X7Z_G7BOQ(^(_PS\2:#<V7@[0_P#A
M'/M7A'PQHUEX?_X5QX.TT:#J>AC0!KG_ !6^?^$G\0 #^W/$_P#PE&?^$RSK
M_P#PA& 3Q[QX:_9J_9M\5:%J&M_\+HUOPW]D^(^I^&+32M6UCP;_ &E_9FAZ
MT= _XG9Y_P"1KP3X)\48Z%?4BET#]G#X$6>@^'O%6J_$8_VQ_P +(_L76/!&
MK>(_!WB/3-"TO^VAH/\ 8NN:YX?[_P#,T?\ "4>%,>#.#D=*>'S#@G+<;'ZK
M'BYRA.22E&LTYKE4KJ46G9I*][)W46[ZK$T.*\5A'A.;A9)I.Z<4[6OH[[Z]
M]['Y\45][^"?V:OV>O$FM>'X+WXT7>FZ?XH\(ZI\0-(M?[8T8:EI^E!?#^A?
M\(9KF3SXA_X2/_A-URN<^#= P> 2,Z?X#_ KPWXV\#Z3>>*M1\:Z1XQ\"?$Z
M].[QWX.\.:E_PG>A:./[$ QC_A'SXM7(!\6$A6()! (/VW_$1LHY7A8T^*9<
MJ=DJ4W=I/W5>FDW[K3][H];V3^8_U-S5OZVZD%?1VJ0Y5?1M>^W;732]K'PS
M17Z.S? W]F[X@^,?"_\ Q7W_  @,!\.Z78^)-)M=9\&C3=>U/0_@UH&N_P#$
MDP#_ ,(\%\0G7/\ A-_7QGX?YP:\@\-^ _!&FZ7\;;'PK8_#CXG^*/#'Q(_X
M1G2!\3/$H\.'3_A@-%U['C+1,^(_"0/B'_A(R02,>H/<&'\0,KQ.$M_8N(4U
MR73IU(R]^HX)\\H*FY)QYFN9M:.RYHW,1P9BL+K_ &O!WOISQ?2[6DF_)'R#
M17V=\,OAO\'M9^%GB^QU7Q7X!&H76K^&+T_&'Q"O]FC0=,_XD/\ ;O@S1/!'
MB#Q'X3\3^'O$?'_"4+XH'A'Q?X+\: DL#D8[FT_98^"UY8>)[[5?B;=>$[C2
M_'GA?PQH^DW?Q(^&GB/4[_2]=UG0=!UW6O\ BG^F/#FM_P#"3\^O/&<%?Q&R
MG#8MX7%T>*DE)15J4I*3?*ERJ-*3LY2Y4G9V5W9-,6'X-S3%87ZWA*D-;WO4
MC?K=V=1/HWHC\^**^SO"WP]^!]G\8]'T,>,&M_AQXH^$'CN]O/$'C?\ L7Q)
MJ?A+5,Z]H)/_ !("!_PD(_L/_A*/!1'.-P )PM3^./A9\&M!^%'BV?3X5N?B
M+X8\-^&;W2A:^./![,VF#XF^/=!UO6M:<.%\>!?#FAZ)N_X19&+?V^  I^:C
M_7_!_6U@UD_%+4G!1E[.35ZD_9IM\D4HQDTYOFT5W9Z7Q_U4Q*PC;S>":NVG
M)?93;6[=W:RTWZK<H_\ !/S_ ).Y^$O_ %^^*?\ TRBOZMB2&)!P=AY'UK^4
MG_@GY_R=S\)?^OWQ3_Z917]6S=3_ +A_G7\S>/SOQQ0>MI</T'KOK)O7SUU\
MTS^E/ ]6X0FM[<05X_<K?=IMMKL6AT'T%(_W&_W6_D:5>@^@_E2/]QO]UOY&
MOQ)-::KIU7EYG[54^&?^&?\ Z3,_C"^-'_)9?BM_V4GQ1_Z>Q7FU>D_&O_DL
MOQ9_[*3XI_\ 3W7EWFP^OZG_ !K_ $CR+%TXY+DO/*G"].G\<H133IP7VI1N
MK7VO=7M<_P ]L^C)YUG#4)2_>S^&,G_R\EHFHM7Z+SL>C_#+P5JOQ-\;:/X
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M-;:+;9;W-?3OV4?BY=Z-XXOM5\-W.B:OX7O-,T72/"GVS1=2U/Q9XG'C+0?
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MJ9Z[@1@@\C!&/SKT@?'?XB_\)%_PD?G^'.N?^$4M/"&CGX:?VIU_MH^"2?\
MA&3XA]/%)/!-?T?GN%XG>,;R1QC#V+Y;Q3M6YDU*7-&TH<FEDTD^9R4O<M^
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MOX7\*Z'_ ,)9I]K=BTTCQ!]LT;3=,UTG61H1&/\ A).H\1G7"<?EG%<AXI^
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MSY_PFT6OSZI?:UHMN/#>J:S\++3_ (1#_BIOBSI6A#G_ (0?0]?\2'GPF/\
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MQ-T3P]<7FC:M?Z9XKTM= UV/^VQMB*Z I !\OQ2( A!*DJ?+'ZH$-TX(]#T
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M^V9X<^UW'D> -2N;?5+S3++6-6\1?\(;_P )-XM\+_\ %>_\277/^*<_X1<
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M^$W\+\GP8!\W/)^"?'@\*_\ "9>)[?P/8W.F^$+76-4LO#=I=ZQ_PD8_LO\
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MOQ+9'5_& \-Z7X5&A:PNB;UPQ_X2!?%?B-O^$F\$DX(\'*1@KM8\!\<?"OP
MA\+ZQXI\ >,-%U+QA_PL?2[*SM-)UG_C_P# @T8?\3K1/!'A[PWG0,@G!QVY
M/(S]'P]Q;E.#AEN083*.*G#W_?E&HXN2=2_/*4=N:#4FW;2][6;\[,N&\UQ3
M_M?&9KPLF]XQ<5+5=$GN[Z:;M:+I\?UL:#-Y/B/P_/<?\NOB3PO[?\QK]?SZ
M5^COC#X>_LL?$WXD:]>Z5XDMK:ZN]'\3_$S5[OP3XO\ ^$E\-#PQX&_L!=<W
M#_A'!_8'B+Q7X<.MAO"^X'P8<XY) _./09X)O%/A^>W@^S6W_"8:7]CM,<V
M_MK\/Y5[F5\2X7/\FSR$LIJ4Y1HS<E-2BXJ4*ZBI-J/O>Y)NR^S?1OE7E5,F
MQ.69ADMI0DG5@TXRC)/]Y!WT;TZKU2/ZX[+]I7X,16EK_P 55J&/LB_\R?XS
M/&!Z>&^2#TZ@CU!&+/\ PTO\&/\ H:=1_P#")\:__,Q7MUD@-E:G_IU5N_\
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M0X.=?P=<QD\'D^H&SK'[%'Q T&QT_6]<\8>"M%T>Z_X2?[9JMV=8U+3+'2_
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M'Q8=$['KQ['Y?_X6=X^&J>)];L?&/B/3=0\8ZN-9\2?V3K&L:;_;VI].!VX
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MAW6_PS^O JL1E7B&I+_C*>&+>ZFO]7(W2OJ^91OSM:-MN/VDKZLP^:<$6?\
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MC)?^BGZU_P""?1:/^'1DO_13]:_\$^BT?\1J\/?^AH_Q'_Q![CG_ *%B_P#
MO_MC\6:*_:;_ (=&2_\ 13]:_P#!/HM'_#HR7_HI^M?^"?1:/^(U>'B=UFC3
M[I6?WI)_B#\'N.6K/++KLY77W<UOP/Q9HK]IO^'1DO\ T4_6O_!/HM'_  Z,
ME_Z*?K7_ ()]%H_XC3X>7O\ VH[][:_?:_XA_P 0?XZ:L\M;79S;7W<UOP/Q
M9HK]IO\ AT9+_P!%/UK_ ,$^BT?\.C)?^BGZU_X)]%I_\1K\/?\ H:R_$7_$
M'>./^A6OO7^9^+-%?M/_ ,.BYO\ HIVM_P#@FT;_  H_X=%S?]%.UO\ \$VC
M?X4_^(Y>'M_^1K?RY7KY;==A/P<XXL_^$Q+1ZW6FCUWZ'P]_P3^X_:X^$Y]+
MSQ5_Z9/:OZO5.=I/1ASGIGO@>Y]?4U^0/[/W_!."[^"GQ<\(_$R'QSJ6MKX9
MNM4!TJZTC1]--^K\ Y4[AGLRD8ZAAC(_8 %55<<@<#_)^E?S%XL\295Q5Q+]
M?RA_NE2Y7JW>2GS?<X.W:_0_HGPIX;S;A7AWZCF[]]SYDNVZN_._S\V/IK_<
M;_=;^1IU(PR"#P""#^5?F:W/T^2O&26[C)+U<6E^+1_&#\:/^2R_%;_LI/BC
M_P!/8KS:OW,\=_\ !*B3Q5XV\8>*X?B?K(/BCQ)JFLG_ (E.BX4ZYK&]@<X(
MPO)S@[>3BN9_X=&2$X'Q/UHGT_L?1<_E7]K9%XP<#X/)LIP6-S1IPC!25FFF
MH15GIH[KKH?QSFGA%QKC<YS?'1RV+C.4W!J4;24IR::M+71K9/0_%FBOVF_X
M=&2_]%/UK_P3Z+_A1_PZ,E_Z*?K7_@GT7_"O2?C5X>ZK^U9-:JVNJU_/]3SO
M^(.\<;_V9&_1W6_1WO\ ,_-#X8_'WQ'\,?">L>#]*\.^'-:T[5+SQ1>V=WJW
M]L_VGH.J:YX,_P"$$UTG_A'_ !'C'_".?]#7CKZCCV'2/VS-5FEU"#QCX(\-
MZEI]U9_$_P#Y!-YK)U/^U/'.BZ_H1T4?\5)_Q3_A[_B>8SX3Y],'FOL__AT7
M-_T4[6__  3:-_A2?\.C)1U^)^M#_N#Z+_A7QV8\9^#.:8R6-Q:FG+63BYJ[
MZOW6FM=?=M=MNS;N?09?P5XLX/"?5,*EI_,EMLM7Y;>A\(S?MF?$V\NI[ZXT
M/PB=8-YQJ]K=^,M--AX8_P"$ST#QW_PA?_(R<'_A(]#'_%5?\CIC//-=/J7[
M>OQ;U&VT^Q_X1SP1IUOI?B33-:L[72;/6M-TW_D-<Z+KG4^(!Q_R-(&,C/U^
MR/\ AT7-_P!%.UO_ ,$VC?X4?\.BYO\ HIVM_P#@FT;_  K'_6SP.O=7YDTT
M_P#A=O=*R=[VNEHKMI+161O_ *I>,>WNOI;W/NVZGY+_ !-^(]]\3O$]OXCO
M=*TW1/LOAOPQX9L])TF[UC4M,L-+T/1O["T//]O@>)\Y//&>I))R:X"OVF_X
M=&2_]%/UK_P3Z+2_\.C)3T^)^MG_ +@^C?X5]=EGB]X<Y3@OJ."S)**5DN71
M1[:J_P!^N]]3Y_$^%'B%C,8\9B\LBVUK:47ZZ)_H?BQ17[3?\.C)?^BGZU_X
M)]%_PH_X=&2_]%/UK_P3Z+_A72O&OP^Z9K*_;5*_;2W70P_X@[QQ_P!"Q)/>
MSZ??T3)_^"/7_(3^-(]3X8&?3C7_ ,^_'Y=*_=&!?E*YZ9Y_+_&OS]_8U_9!
ME_9=OO&,Q\27/B2W\9?V5@7=E_9YL#H@*KE1G.X\ ' XZU^A))(8=, ?XFOY
M+\1L[PG$'%V:YQ@O>IU''E?32*3?G?3;8_J?@+)<5P_PGE648W^)&+OW5W>S
M^:]=",QDH5R>HYZG@GD?G^0K\=/^"PPV_#'X1)DG;XZU <^^BN?Z_6OV-5B!
MZ\GKZ 9./\XKXK_;-_9A;]J+PQX1\/CQ)<^&?^$8\17VL[K>R%^;\OI+Q1QE
M"!MPX*JO5BY"@DBO/X+S3"Y'Q=D^<8MVA1KWF];64)QTWM;FO\F;<:99B<VX
M5S;*\'K4J4N5+J_>3M;K?;KYG\J%%?M-_P .C)?^BGZU_P""?1?\*/\ AT9+
M_P!%/UK_ ,$^BU_8:\:O#ZROFLKV5]][:_C<_E+_ (@[QQTRQ>3NOD]_0_%F
MBOVF_P"'1DO_ $4_6O\ P3Z+1_PZ,E_Z*?K7_@GT6G_Q&OP]_P"AK+\0_P"(
M.\<?]"Q?>O\ ,_%FBOVF_P"'1DO_ $4_6O\ P3Z+1_PZ,E_Z*?K7_@GT6C_B
M-7A[_P!#67XA_P 0<XX_Z%<?O7^9^+-%?M-_PZ,E_P"BGZU_X)]%H_X=&2_]
M%/UK_P $^BTO^(U>'NW]JNW;6WW;?@'_ !!WCC_H5K[U_F?BS17[3?\ #HR7
M_HI^M?\ @GT6C_AT9+_T4_6O_!/HM/\ XC5X>MK_ (5&]5O=]5W#_B#O'%_^
M16OO5_S/Q9K8\-_\C)X7_P"QD\+_ /IX%?L?_P .C)3T^)^MG_N#Z-_A5C3?
M^"3$MGJFG7I^)VM9TR\TR] _LC1>2.N!ZCIZCIUKES3QHX'G@,X@LT;<Z<XI
M)/5RA**V7>2V.O!>$'&T,?2F\LBHPJ4Y-N2248S@W9\RZ)]NQ^XVG?\ 'I:_
M]>B_^A&M.L^RA\FU@&?N@'],#KW_ ,^M:%?Q'-J4YR6TIRDO24I-?@T?V733
MC3IQ>\:<(OUC3@G^,65)SF"7/41G'TZ'/Y_Y[_Q:_$7_ )*%\0?^Q]\4?^GK
M7Z_M*DQ)&W'W@0>F,] <?7K_ (U^(/B7_@E!+K/B7Q!K?_"SM:!U76M4UC']
MCZ-R==U@OM^NWYO0CGI7[#X.<5Y#PEF6;XW.FE"5*E&"OKSQG4Y_6R<'K?1'
MY%XL\)YMQ7@\KIY0DY4YS<EI]I)I>6B\C\0**_:;_AT9+_T4_6O_  3Z+_A1
M_P .C)?^BGZU_P""?1:_H7_B-?A[O_:LE]_W'X-_Q!WCC_H6+[U_F?BS17[3
M?\.C)?\ HI^M?^"?1:/^'1DO_13]:_\ !/HM'_$:O#W_ *&LOQ#_ (@[QQ_T
M*U]Z_P S\6:*_:;_ (=&2_\ 13]:_P#!/HM'_#HR7_HI^M?^"?1:/^(U>'O_
M $-9?B'_ !!WCC_H5K[U_F?BS17[3?\ #HR7_HI^M?\ @GT6C_AT9+_T4_6O
M_!/HM+_B-7A[_P!#5_B'_$'../\ H5Q^]?YGXLT5^TW_  Z,E_Z*?K7_ ()]
M%H_X=&2_]%/UK_P3Z+_A37C5X>W5LU>ZMOWT#_B#O''_ $*U]Z_S/Q9K]TO^
M"._'AWXXD=1XA\,XZ=3HK#O[9KDQ_P $C)3T^)^M'Z:/HI_I7W?^QK^RB_[+
MMCXTTU_$MUXEM_%M]IE\+BYLOL'V/^QXY(E79U.[S"1V..2!DU^>^+7B;PEQ
M9PAF>39/F7-G'-3E9K1J,HROM9\ME)6O\-MS[_PP\.>*N'^*WG&<9<H1Y6DT
MX^ZK-*VMD]MON/NO_EE_G^[4D??\/ZT45_)T_P"-1]%^1_3<OXE3_%^A)111
M5B"BBB@ HHHH **** "BBB@!%Z#Z#^5-3H?K_0445I+XX?,E_#4_[='TQ^@^
MO]#116T?B7K_ )BE\'R7Z#Z***Y2PHHHH **** "BBB@ HHHH **** "BBBN
M=;KU7YH"O_RU_P _WJL445V_;?\ A0I_!\G^:"BBBK&%%%%83VI^OZ, HHHI
M 0-U/U/\ZGHHH ****OI\OT ****@ HHHH ;_'_P'^M.HHK7K/T7Y,72'HO_
M $F0B]!]!_*D_C_X#_6BBB7Q1]6)[3_KI$=1116104444 %%%% !1110 444
M4 %5Y^WX?UHHIU/AJ?(N'Q?)DL?W%^E/HHK9;+T7Y(S>S]'^3&)T_ ?S:GT4
M4GO5]7^1DOAI>B_0****Q-@HHHH **** "BBB@ HHHH C'W4_P!X?S-./WE_
.X%_*BBE'^+5]/T __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ea028762301_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "' / # 2(  A$! Q$!_\0
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M_:<?9_M/^B>NSO[]?\]:YP+E%8FCG4HK"WAGBG^T+:C)NF'#K@ ,1T/(&#G
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MI8,^F+$R:0)74Z&C;8]T:%"VT@'S6B"^G44 %%%% !1110 5Y7\7-1^(VD>
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MZQ\(/BP?$?Q.\2?"[1_&7CS2]%L_%GA[PWXR\;:G8?\ $Z_M[0M%T+0_A_\
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MO>?C9X;\<']O#XG_ -N?\));7^J?&S5+W1[3Q#>:S_R*^N_\@+^P^G_%._\
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M1?\ @Y^&?_S24[_AU!_P4 _Z-2\1?^#KX8__ #1T_P#B%WAC9_\ &W.G_/\
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M</VM+/XX?$+6?A_^R#^SG\=_ 'BWX?6NC^%]%_X1/X>_$C6M-_M[QYXZUO\
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MGE9W(2@=C6/HG@K]K;3WO7E^-_P]URUO;R_U<V]WX%F+:>-5UU@=(TIMY?\
ML"TT5&@\*M(3<6TN?MH\7Q9DK[-HJ /C>#P-^UO8V4.FV/QD\ 7W_$PU2\N=
M7\0>"3>7UOIFKR:Y)%I$8CN%B<>'&?0U1G5?M$:-%-F$!#J3^#OVL.8+;XR_
M#HP3B9AJMS\. -0L\L/[)']C^8L#%9"0ZR2!D<,>H)KZTHH \Z^'>G?$#3/#
M<=G\1?$.C^*_%$%YJ!_MS0])_P"$?L+G3BQ.E*VD)+,JND997VRNF]24=N2W
MHM%% !1110 4444 %%%% !1110 4444 %5ZL55C^ZW^>ZUS8C;Y?HP$Z=6!_
M4^IYSD<_R'?BFF5%XS[#_/\ DU^'/_!:[X]_M_\ P!^&7PG\7?L6?#_Q?XR\
M)2:YX[_X7UK_ ,,?!X\<?$WP?I,>@1CP)/H>@;W0Z"?$LK2>,)U572TTB-05
M\Z0/_-]IO_!8;_@I[!-;,/ 7[;NZY.K-=G5OAHNI:9I[.7+L#_PI'.?"IET<
ML1RWF2$D[FS]KD7 N*X@P2QN&S3ARDW?W*M11J))M+W>;1NUXIMNS7>QY&8Y
MPL&[<LFEORI__(OI>Y_H%DR<9Q@]/O=__K4A8CMQZY_GD<?CQ7\_7_!/O]JS
M]OY?V;=%\??M*_#[Q]^T-X_\7ZMXKUA/^$=\&IX(.G:3HNL#P]X)T30-$_X1
MGPD8SXNCW>)"WBDHP1F4,"01^U7P8\9^-/B#X*MO%/COX>ZG\+]5U*ZO?LGA
M#Q#<!_$&GZ8CCRVU@(%2.9LC*Q\ !&\M!L8_/9UP_B\IQ<L)B<RC-QDOX,Z<
ME+:]N5W5KVM*SMJMTCHR[,,-F>%6+PJMT:DI1::O?=+SV6AZ[Y_M^G_UZ*L4
M5YAWE?S_ &_3_P"O1Y_M^G_UZL44 5Z*L44>P7?\?^ !7H\_V_3_ .O7@6C_
M !#\=7LMF]U\/[B]TZXG\3/KD6F_VEIE_P"$X]'_ +(&BZ7-'K:Q?\)'K]UO
MF#CPQF!G@+Q1*R.STY_C+XS/AG^VK3X*^.KC4#HVA:S_ ,(^H2/4<ZOXW70]
M>T3:!@>(/#?AX?\ "2S1@[7B8QH$)R2_G^/_  0/HFBO&=:\>>(M/\40Z7%X
M4U/^R1X>U36;F^FT;5=0DUK4=(54&AZ&VB&54=MQ8OXE%OO#*$CR &I^%/BS
MJ?BK5)],;X=^+M'N+3P=I/B>^75[-5CLM6UK2_.3PBP _P!>K*"S@JKN"2B
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M&ZX#D?NL( #Z4H\_V_3_ .O7BUC\5]1N%'V[X;^-M/;[)X>O,)I2Z@V-;?Q
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M%%9^SC_5O\@#R/?]?_K4>1[_ *__ %J**T **** "CR/?]?_ *U%% !Y'O\
MK_\ 6H\CW_7_ .M116?LX_U;_( \CW_7_P"M1Y'O^O\ ]:BBCV<?ZM_D >1[
<_K_]:CR/?]?_ *U%%'LX_P!6_P @"BBBM /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ea028762301_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  K $P# 2(  A$! Q$!_\0
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MYI2;U22O[S=]KG:G]JCX$7GQ!T?X5P?%OPE<^.-4O/L7]DZ3>?\ "2?V"/\
MJ.?\(^._M7[C^%[#1]/\-:!8^'\#1+32+&#2@.?]!CA40'M@E,9'(SG!KX\^
M!/\ P3F_9*_9\@LI_!?PKT.ZUFT'R^(=>M%U+5<]1RX* _4,!UYR!7W+#%';
MQB*"%8XUZ(N% ]>.?S->/^/GW/1_#R.>\21:K/I\\.E?\?!'&?\ ]=?B/^VS
M\-_C]XDM=8M]#OM2MOM7_'G]D_\ K9Y[?_JK]X*SKO3=/U* )?V5M=J5SB>%
M'Z?49'X4 ?Q,> _&W[5_[,>J:AI6N>%=;^*/@^ZO/MUGI/VS^S?$V@ZIQ_R
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.\#T'Y"EHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ea028762301_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M $L# 2(  A$! Q$!_\0
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MX T#(TGPGX*T*/1]+A!2*1W8+(LFLZLY7+Z]=O-<R *KL=C ^V'D'Z&EHK[
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MJ O+<<?V=+YJ1[8/]L9/;::\ :TC\4?"OPJUS'::=:P:A]H\,Z?H^GV%A9Z
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?SMOVT^X>=?[2OK6S22MYI)7[=.Q_4/1117W!X!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ea028762301_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !D 0P# 2(  A$! Q$!_\0
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M_P""72/_ (W4WA'_ )%+PM_V+^C_ /IKAKIJ .4_X0SP?_T*?AS_ ,$NE_\
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MU_8?!WV_&<9_L?KNS_#YN<<[<5Y_\8_CY\//V?='NOB3\7+Z^TKP_=>+]/\
M VEWND:+J_B)[ R:%+KI_MF+0UE:%I9]'UQVE9)<JN@(X#LI;PS7/^"FO[(/
MA]='N]5\;^*M/L=>%^O]I/\ "WXEI'INI_V+H.O:+H>K;/#*M%KOBS0=:AG\
M()EQ<JACP"H# 'VAI_A[P'JL9EL_"GAK-MFTGMV\/Z.+^S8 _(Y"'RN,$ ;]
MV,KD@XUO^$,\'_\ 0I^'/_!+I?\ \:KR3X9_%WP+\8=*\%?%+X::Q-K7A+QS
M?:KX<CO;K3-:T 7K:)#KS.T>CZ[!;RKY<NCRQAA&LCQ -_&8U^AJ .1_X0;P
M7_T)OAW_ ,$FD_\ QJO)_&NE:'I>KQ6UEI.CV5NUA;S+!'I*1*I=YE)*(J*"
M=@!PHQC:?F!KZ&KQ#XA?\A]?^O"V_P#1D] 'I/A'_D4O"W_8OZ/_ .FN&NFK
MF?"/_(I>%O\ L7]'_P#37#734 %%%% !1110 4444 %<_KFF2:C9E;*9;6^M
MK@7=E<<;5OE# ;@<Y!!(8'.>F.":Z"B@#Q75=,^%_B>_M1X^\'^"6\2VJK91
M6_C72=%U+4I"5P$T;6->@QK,0 78T)8=2X7@.NDV7PT\.W]S_P *V\'>!X_$
M=Y9)9*?"GAW1-/(T_<#$VM:QHD'RZ$)-A4,64.%41ER2.RFUG^UPMOIN@7&K
MV9G_ ./JX(L=/^7[S*9$+2;<G&8^2<D9.*+77O[/6.UU/1KC0( -MM<^8+[3
MP<9"F2+:4)'3*Y/7('- &IH6EG2=-M[*6=;BY/\ I=]=DY:]U)RW]J2E>.'?
M. >?F.1E371T52N)K>TBFN)95@AMP;FZ8] ""<L?0[>PR<"@"[17FEYXWN;=
M8%L?#'B;6+F9#/;6-I'HK7DN8E*A]^O1_P!BH#)DMXB, ),D+,&C8*Z?QIJ>
MG*GVSP'XPM(&&XW;+X1U"QLE!V_.-(\2O*%YQA@#GHV#R >DT5R$6M:G/&LU
MOX8U6X@G'#+JFA'@^A;7RH^B8-8^H>-KK2V^S?\ "(^(]1O=F_\ LO2[K0K_
M %$+C.YB?$2%5 Y); QW H ]'HKS2;QIJMHJM>^ _%UK;L,F\,_A&_LK(*=H
MW_V1XFDEVCI\P##C# =>ATO7H=3E: I/;7 MENT%R"HO].*E5U32RI;=&[.N
M1M4_,HP3AB =51110 4444 %%%% !163J>IZ7I,'VG5+^TTZWZ&XN[M;%2?3
M<2F2.."1]*HQ^)/#LMU;6<.LZ<US=9-I;+>+NN\CG:O);V W$]P0<$ PGFM_
M#&I7UY<6Z+HFNW/VN[O([7_CPU%@NY]6(.1&WRA6(!4@ \]>D_MC18K,W_\
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M]?\ #?Q#^+K>)/!?B_5=7TE=%EUKQEH7]@6ZZ[XA$:1FVN1,GDW"K+M;:B,
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M#4+T@ G:&\1A-ON@Q].E8MSJ/Q263S;70?"MQ8$9$$^JZK8:EQVWO%+$#[$
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M9FF<CH.""6 .2"5/R#JW[9/Q!F$]MX!_82_;,\?:@HQ;K=^&_@W\*=+<$?\
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M(XPA*GIDY&0#Z HKPS^R?CQ_T,OA3_P,B_\ G>5FW$?QJ@BN;B;Q9X,@M[4
MW9N;Z-19<9QD_#M<\=G '7% 'T+7,:_I<FI6D$EG(D&J:=<&ZTFXNPI07P#
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M%$+^+5/F( ?L=HUD-'T?2M*$N?[.M-.LSGN4"Q8YYY X]A^(IW'_ ".>G_\
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MH/\ T#K7]7G/H<=:]_KYN^*/_(RQ?]@JR_\ 0[B@#V;PC_R*'A7_ +%[1_\
MTU)75UQOA#_D4?"W_8NZ3_Z:5KJJ +%<7?>#O"6JZYIWBS4_#>@:AXJTRPU+
M2M(\07FE:5=^(-.T[5OFU;2-*U=T%S;P3-%MFBC=8W5'619!)*QZRB@#R6'X
M)?!J.?3Y[;X4_#"UFTFV6VT:>V\"^$Q)IMB%G_=Z.PT1C!"/[7U8&.W58V;6
M+D,'-T0-'7OA9\-/%,.G1^*?A[X'\2PZ&=331[3Q#X2T754L)-<=O[=32AK,
M<D<!\0D[96C*1RXVSO*!@>DT4 <3X2^''@+X?G63X)\'>'O"A\3:NVN>)?\
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MM\0/!&L>!]1O-8.BP:\D>CZ3X@CAEDC;P_K.A>(/,"9:#6X1+&27-?6%5Z*
M+%>$_$/_ )#Z_P#8/M?_ $*:O;J^=/B?_P C)'_V"K'^<] &#IGQ/U_3-%TV
MSMK+1C!8Z8L< EMKR1@H4*-Q^WJ"0  .!]*AF^.?BU6"_P!G>'\'(/[G6 >N
M.JZV*** (/\ A>WB[_H'>'_^_6M__+VB+XZ^+2/^0=X?Z$_ZK6CWQWUPT44
M3_\ "\_%O[G_ (E_A_Y@<_N=9[''_0;Y_P"!9IL7QR\6'/\ Q+O#XZ](M:/I
MZZX:** (I?CKXM _Y!WA_H#_ *K6AW([:X*/^%[>+O\ H'>'_P#OUK?_ ,O:
M** )O^%Z>+?^@?X?_P"_.L__ "[I/^%Y^+/^@?H'_?K6O_EY110!<U7XGZS/
M)]EO-'\,7]MC/DWVD-<Q],_<DNBOZ5'I/Q-UBVW_ &'1_#&F_:L&;^S](-KO
MZ#YMES\_7_EIO]>N:** *7_"]?%O[_\ XEWA_P"4#'[K6OI_T'./PQ^51?\
M"^?%W_0,\.?^ ^L__+RBB@"7_A>WBWR\_P!G>'_IY6M?W<]?[=S^OZT?\+V\
M6^9C^SO#_P!?*UK^]CI_;N/T_2BB@";_ (7IXM_Z!_A__OSK/_R[JI_POGQ=
M_P! SPY_X#ZS_P#+RBB@!_\ PO3Q9_T#?#__ 'ZUO_Y>T[_A>WB[_H'>'_\
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IZUO_ .7M6=>\2W^JW_VJ[BLS*(8XOW<#*NQ-Q7@R-S\Q[^G%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ea028762301_img7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U %T# 2(  A$! Q$!_\0
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.'3)[X]Z** %HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ea028762301_img8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ &L# 2(  A$! Q$!_\0
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A?4-4*_;+E>&O",,-_P QYR <8Y]".1N444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ea028762301_img9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L , # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_/SH_-\K
M</,QG;CG&-W7TQ3MX]#^G^-)Y8\SS.^,?ICUJG]C@\WS_(&<8ZC/\_N_Y]Z
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M(L?M'^NV#/\ X]CWZ9S[5KQ[M@\SKSG./7C/:@;W?J_S/D26+]M2W^W^1>_
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ea028762301_img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 )(# 2(  A$! Q$!_\0
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M+Y?\$Y/!3-;^,OB;XI\*7..+/5O"4\.J\Y_YABO+(!R>0A//2N7D_P"#B/\
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M]D/?\?\ ZWM7M'_!.N&#_A:O]E7'V8?VIX;U3_1,8_Y 6M?V][^O./Z5[_\
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M>B:G\0?CO^U3XPTS3KC7_AN?#'P9^$%E<V:8\+:GKNAMKOCKQCHI96(\0?\
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M%_Q8_P""<G[!/QJLKNW^)7['/[.'BQ[@ W5U)\)_!MAJKD\8_MW0=!MM?)]
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M?QC;F,JY"%5Q79?MF^#I[#X^?$/41>_:+>?7T6[!Z !0 N?;'/6OZ;B"\D;
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M=,<?\5'Z=L#IU\W^*GBJ^_X:O_9?_L.Q_P")/X-^)'POO=9'_,,_M3QU\3]
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MBCX[\?Q_%0:=8^--=35FT-_"?]I1V#*BH529M?C+Y &6")G@E%X _3L@!@H
MZ\9' S]/KU/7IBH3(F\@.P<'!RIQUQU&>_?/<UX>=\/97Q#A%@\UI^T@O>2N
M]+-J-K6NN2\;Z;[:(^HX3XWXCX#Q>/QO#6:RR>MFE&.'J5(4Z<W.FIJMR?O(
M3C%.JE/17OL]3\LM:_X)J66LQ$3?$@"X3_CVN1X<?<I(SR/[? /^>W-9;?\
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)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ea028762301_img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 )(# 2(  A$! Q$!_\0
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M_"T^&_B5I.[2Y]-7Q4WC/7-=_MC0-"_X1R3PS'X@_P"$;;0O"Z^(U"+]YTC
MW.?TL_X1Z]_Z&KQ+_P!]Z'_\SM<+)K.M/XTT?PO]LU?[!=:3J5W=:M;G1U4O
MI#A "RH[(7=P"=IY/S>M:^W6GP:>7;Y]]0/A-?!W_!5><ZI'-\7?V>[>WNKW
M5CI+6_A.9M0L-**:V=$_M?S/#IC_ +<VC0"PA_<!]ZM\XEQJ^,/AI_P4'G\;
M7&J> _BYX2TKP]JFC^ CXDM=;E;4EU#Q1X:\)>'X]7/@;1O^$8:/P#X?\6^*
M%UF3Q8I<RLK))$G-?HK_ &/<_P#0P:[_ -_]-_\ D:F_V)<_]!_Q'_X%:;_\
MC4>V7:'W?\$#\\=,\#_\%)9=6T::^^,'PT@BNK33K'Q(QT;1Y-.L&_L,;]8T
M71CX:)W'Q!@;6;<R*0JE$('WO\-K?QQ;^!?"\/Q+N--NO'D&CQKXKN-( &EW
M6J ,KO%P!L*;".HR&(.#BJ::E>KXHT_P\+R_,#:3J-X;MK15R0RA<L03E?X1
MR2V N":[?^SI_P#H)WO_ 'TO^%9 :M?/?[/_ /Q[_%__ +. ^*G_ *>UKV_^
MSI_^@G>_]]+_ (5\;_!74];NO'/Q/\+P^*5TVRNOBI\8;L:3;6NC_P!I%FUQ
M576"^QF(+MP2I^8Y(&30!]NT5Q'_  CNN_\ 0Z:S_P" FD__ !JC_A'==_Z'
M36?_  $TG_XU0!ROQR\.?$#QC\(?B/X<^%?B4>"OB/KGA+5;+P/XK$^1H/B9
MHV&AZJ" <8F"NS9/RC8V>37PW<_"S_@HM>>%?!MZWQM\ :?X_P#"&L^*)7MK
M:SCU'PMXXTG4]&\":)HFF^(4E\/(X%O+%XS\2/*D;/'-);;L*"\?VQI>L:E?
M^,(/#$_B"_R?#J:P3:[5SO=5&YMI/&X$#OP.]>D?V)=?]#+XA_[YT;_Y0T ?
M%W[-VC_MI:'\3/$VE_'KQ'X3UOX0Z3X>U;2_"%[HEOI,>I:[JL&N:)_8FL2R
M1@^(U5M /B".2.<JK%M (!=)*^]JYK^Q+K_H9?$/_?.C?_*&O,-*U/5-:\:7
M'AV;Q#J%L+;PEI.LD6F%#-+(%+'CJ2^XGDL<CJ<T >Z8'I17&_\ ",7_ /T-
MWB;_ +ZT/_YGZ)/#E\8SGQ?XE'O]KT0#\QX<)/X#/O0!V5%8-I/>?9;;/7[/
M#GZ^6N>WK10!XS%-!_PNJV@$TQG U$[;+E<#1@2-9Z<@#,?3YMO3K7T)7SHU
MXJ?'"PLC?"UFG&J'[*;08OE71 =Q9CV SGVKZ+H *\37R/\ A:>@8^U?:/[)
M\39Q_P @[[XZ=\XS^.?>O;*\-:\A_P"%L>'[$7A@N3I'B:\-F+3'VX%@&8'U
M09; Y.W Y- 'N5%%% 'F:RPGQSI8^U7,<YT75P+=,C3KP'6/O G/S*=S+QC@
M<9'/IE>6QS ^/["W-]:X/AK5+S^R#C^TN=:VC6"",8;.W&._ / KU*@ KXC^
M!1\GXK_$"+S8#]I^*GQV;:H^8[=<\/,!C...XSR,U]N5\,_ R3?\6O'T7GVA
M%M\5OCE=?91SJ/[W7XXR1SRN7[GICW-7':7H!]S4445 'S]X6O#-\5((!< 0
M77@(WHM.V?[9]/;J1CIGK7T#7S]X7\G_ (6G! MQ:YM? 1Q:M_R$0?[9X+>P
M_BQCC/3FOH&@ KP7P9*3\1M0'G?>\!Z9=FU_N_\ $X;YLXZ=OJ:]ZKP3P9-
M?B?J%O\ ;;=I[?P'IBFU7 *@ZPQW<^XP,9.6! /(H ][JG.1%;33>EL1^(4X
M/ZCCOBKE4[L9MKB'_IV;GGI@J?Y4 0:9.O\ 9NG_ /7C:>O_ #PC]J*ETO\
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MXWL-3@\0^'=*/]H7?AO2P?M.DZWJ&FC/'#+A@>A!4@\@Y'%5IO'7QN,4$_\
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JHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ea028762301_img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U %L# 2(  A$! Q$!_\0
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MFZY\$(K35K1M42_B_P"&@O%6M!YVUG4)&NAJ5Y:O=7 O0ZWH69B]N+@6O A
M'Z JAZGUZ8!R*-X7("@ $].._)Z=SR?>L:F 52O4K7NI[)OSWL[VOUMON>_0
MS3%4</"A'E2B[W2E!MVMJX.#EZMNVWHU>OX'^1KR'XPF-?"-P9[Z:U)+H<:D
MVF_:C]DYV&.*7=\Q5MBX 96 ..:]=4@')Z $GZ8.:\C\1Z&\6@MIUSJ^J:S%
MJFORWDLEWJ-G:M#8:F<QZ?$;B$_\2^(';':0[;O;]T[2,>F>75^!_/\ ([[P
MO;^1X>T*)I$F9-,L TR*JB4_9XSN^4=\\GJ>YKHF "G  ^@ [BJ&G01VMI:6
M\6/)A@C1.F JH H'8#T'; '%:#_=/X?S%-Z:=DOR,J"5EHMNR_N^0NU1G"J,
M]>!S]:,#T'Y"EHI/7?7UU_,Z++LON7^0F!Z#\A6??VOVE HEG@V'<&@52<CD
M'Y@1D=O?MZ:-%*R[+[E_D%EV7W+_ ".#USP+HOBK2'T77FO=2TZ5S(\;R)$Z
MR'AB'B575CDY(P03G)[;.EZ5;Z2\5G;^:T,5K!;Q*TP86MM:86WC88R6=5 +
M#[W4G/-='@#H.O)]SZU2P/MI.!DQC/'7 XSZX[9Z4679?<O\@LNR^Y?Y%VBB
MBF,0 #H!7$^-+1Y]/MKA"Q^QZI8WN%%FVTHP0.!=*RJR[LAUQ( ?E:MU=6T]
M'$4VHV<3YBS#+=PP3Q&8J+.VFMIG%Q'/,&QL=0[.I7D_+5J\TZQU&!X+NWAN
M()2K8=5D7*<J0&!'RD$KC(!SC!H FMVC%M$01CR%; Q]W:.<#T/ Y]N,U&+F
M(N\?FQ&18%F:,.#<*K'J\ Y5#T#>O0 @&IHH$@B6%1N5%*AFP2!S@'J3C_(K
M.32-.CU*76DMXEU*>V2V>]+N=Z#^#RBVP?D#QC'7(%EV-*218U#O+'%'V9R%
M'KU8@8_I]::9EDB+JXV8)$L1$BD#D[6'&>@Y[^W-0WUI:7T+V-TJ212J0\6\
MI(PQ_P L]K*X'4'8P.,@'KG"F\/0+)ILMCJ>J:5:Z>@C2PL9XHH+A<@'[4EX
MD[2#'WLYD*YPVX@T ;YN(QOC\X;XTCD91*C3@,1GS(<Y0'NQ &,XZ5*]Q"D;
M2O-$L05F+LP50@!+,S%N%4 ECP  3Q65'HNFQZC=:O':K'J%]!':W5UOSN@B
MSY9\LN57S ,$J S _,2>MR[T^TU"TFL;J -;3PR02"-]NZ.5#'( R%6 968'
M% $\<T3*DB/&?.4-$Z2>9')'PP9&SM((R0W3OFH%F4WWEM<1I(8R19-)$9F7
M./.5<ER@!SP<<#OD46EE9:=:VUE#%%%;6<(M[:(LSE(0 @7+Y8Y7[V<Y)[55
M;1-+EU:+6VM8VU2&#[/%<AY %MR>0%'R9V\8(.1[= #;HHHH _/7QU_P3=_9
M5^(_QOD_:#\5^'/'%S\2=5U+2/%%Y<V'Q1\>:7X??5/#D2BQ8>%[+6X]%6)M
MY,L:VP5B 0!7W)X;T2RT'2;/3=/>_>U@!V/J>HWNKWAR2/GOM0GGN'.0/O/@
M#@ $DT45TR;Y-]GY=/:)=%_*ONZ@=-2'@$@#(!YQ[?Y[T45S 8-WH]A?SQZC
M<QS-<VRO$ABNKB%"&^5CL1PO1CC@X]2>:C3POI43!XS?JR\Y&I7HW8[-^^Y!
MZ$=""0:** )9=&T^4^84NE8J-QCOKM"ZKR$<B7YD[;3QCC&*OVMA;6FYH1-\
HY *R7$\R#G'RK+(X7\![444 7L#.<#.,9QSCTSUQ2T44 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ea028762301_img13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_img13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !V 4H# 2(  A$! Q$!_\0
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MS1110 4444 ?GS=_\%I_A%9W<]N_@WQJ7B=HR5M[/!(./^?BH?\ A]A\(/\
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M^1JEA#J$*LD 94D7(5OWF,CO@D4O_#PKP5_T+FO?]\P?_'*^ M%_Y)_\/_\
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M\4?3Y?F\,7+V55<LOP9[Y1117S1]$%%%% '\LNN_\AO4?^OB3_T(U1J]KO\
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MP]:Q?9I;-I&4H"N=P<9SC/2NTN_^"=WB)-OV7QCIDO\ >\ZTD3'TP6S7MG[
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M@WL^Q<YQEB2>OK6K7YK/EYGR;=#]%CS<JYM^H4445!1_++KO_(;U'_KXD_\
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M9_++KO\ R&]1_P"OB3_T(U1J]KO_ "&]1_Z^)/\ T(U1H ^D/^"=#M'^V?\
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M76EXB_:J^%GA3Q_=>"-2\5I%XKMFB672H;*YGF7S$WH?W<; KCJP. 2H)!8
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M0_M.?&'Q&US8_8-<\#66EV\8D?S4E2,J6<;,!<]P2?:OGZ__ &5/%GAWX1?
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B[YNYYK=KB&-K>(@-^Z4L,MDD]:** /LFBBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ea028762301_ex15-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028762301_ex15-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ , # 2(  A$! Q$!_\0
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ME:0]AXF-X%Q#>J'!_P!L###^1_&K4(4ZWNZ<R_(ERE4I:ZV?YG)VC!;VW8G
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M$5M^$?$,GAS7(KC>1:2D)<IV*Y^]]1_CZUZN(A*=-\C_ .">7AYQA-<R_P"
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*K9'KE%%%2!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Check-Cap Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">29 Abba Hushi Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O. Box 1271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Isfiya<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3009000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value NIS 48.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBAI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">7,020,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">David Lontini<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">david@londacorp.com<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">29 Abba Hushi Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O. Box 1271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Isfiya<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3009000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+1 (647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">892-9516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BCRG Group<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">7158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Check-Cap Ltd. (the &#8220;Company&#8221;) as of December 31, 2025, 2024 and 2023, and the related consolidated statements
of operations, stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2025,
and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity
with accounting principles generally accepted in the United States of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Bank Deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents, and short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Asset, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">726<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,525<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of Use Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,267<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">790<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">406<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital, Ordinary shares 48 NIS par value (18,000,000 authorized shares as of December 31, 2025 and 2024; 7,020,502 and 5,850,906 shares issued and outstanding as of December 31, 2025 and 2024, respectively)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83,918<span></span>
</td>
<td class="nump">83,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,389<span></span>
</td>
<td class="nump">84,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(165,870)<span></span>
</td>
<td class="num">(170,010)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,437<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,486<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liability recorded to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value (in New Shekels per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8362; 48<span></span>
</td>
<td class="nump">&#8362; 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,373<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(2,373)<span></span>
</td>
<td class="num">(9,462)<span></span>
</td>
<td class="num">(19,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpairmentOfLoansReceivable', window );">Impairment of loans receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,487)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Income on Debt Extinguishment and Conversion</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Finance income, net</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,140<span></span>
</td>
<td class="num">(25,149)<span></span>
</td>
<td class="num">(17,568)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (17,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per ordinary share - basic (in Dollars per share)</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per ordinary share - diluted (in Dollars per share)</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares outstanding - basic (in Shares)</a></td>
<td class="nump">6,232,226<span></span>
</td>
<td class="nump">5,849,013<span></span>
</td>
<td class="nump">5,848,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares outstanding - diluted (in Shares)</a></td>
<td class="nump">6,232,226<span></span>
</td>
<td class="nump">5,849,013<span></span>
</td>
<td class="nump">5,848,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpairmentOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against impairment of loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpairmentOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 83,664<span></span>
</td>
<td class="nump">$ 84,941<span></span>
</td>
<td class="num">$ (127,293)<span></span>
</td>
<td class="nump">$ 41,312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">5,844,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">RSU vesting</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">RSU vesting (in Shares)</a></td>
<td class="nump">6,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,568)<span></span>
</td>
<td class="num">(17,568)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 83,746<span></span>
</td>
<td class="nump">84,802<span></span>
</td>
<td class="num">(144,861)<span></span>
</td>
<td class="nump">23,687<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">5,850,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">RSU vesting</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">RSU vesting (in Shares)</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,149)<span></span>
</td>
<td class="num">(25,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 83,751<span></span>
</td>
<td class="nump">84,809<span></span>
</td>
<td class="num">(170,010)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">5,850,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares - Ghost Kitchens ARA</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares - Ghost Kitchens ARA (in Shares)</a></td>
<td class="nump">1,169,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">RSU vesting</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 83,918<span></span>
</td>
<td class="nump">$ 85,389<span></span>
</td>
<td class="num">$ (165,870)<span></span>
</td>
<td class="nump">$ 3,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2025</a></td>
<td class="nump">7,020,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (17,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpairmentOfLoansReceivable', window );">Impairment of loans receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,487<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Financial expense (income), net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operation leasing</a></td>
<td class="nump">95<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in prepaid and other current assets and non-current assets</a></td>
<td class="num">(6,491)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade accounts payable, accruals and other current liabilities</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Decrease in employees and payroll accruals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Decrease in royalties provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(8,004)<span></span>
</td>
<td class="num">(16,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Issuance of loans receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,487)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Changes (investment) in short-term bank and other deposits</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">15,647<span></span>
</td>
<td class="nump">21,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided in (used in) investing activities</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="nump">21,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in the registered direct offerings, net of issuance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(8,844)<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,844<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1', window );">Assets acquired under operating lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest received</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and Cash equivalents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpairmentOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against impairment of loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpairmentOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, classified as other, acquired in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; GENERAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(1)</td><td style="text-align: justify">Check Cap Ltd. (the &#8220;Company&#8221;) was incorporated
under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Avenue, Isfiya 3009000, Israel.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(2)</td><td style="text-align: justify">The Company has three wholly-owned subsidiaries: Check-Cap
US, Inc., incorporated under the laws of the State of Delaware on May 15, 2015; Check-Cap Canada Inc., incorporated on April 9, 2024,
and CC Merger Sub Inc., incorporated under the laws of the State of Nevada on September 9, 2025.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(3)</td><td style="text-align: justify">The Company was engaged in a clinical-stage medical diagnostics
company that aimed to redefine colorectal cancer (CRC) screening through the introduction of C-Scan&#174;, a screening test designed to
detect polyps before they may transform into colorectal cancer. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning,
control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is non-invasive
and requires no preparation or sedation.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(4)</td><td style="text-align: justify">On March 21, 2023, the Company announced that the most recent
efficacy results from its calibration studies did not meet the goal required to proceed to the powered portion of the U.S. pivotal study.
On June 6, 2023, the Company&#8217;s Board of Directors determined it was appropriate to pursue strategic options, approved a significant
reduction in workforce, discontinued the calibration studies, and concentrated resources on strategic alternatives.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(5)</td><td style="text-align: justify">On December 24, 2023, the Company received a notice terminating
the Keystone BCA pursuant to Section 10.1(e) thereof, in light of the failure by the Company&#8217;s shareholders to approve the transaction
at the December 18, 2023 Annual General Meeting. At the same meeting, the then-existing Board of Directors was replaced by five new board
members.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(6)</td><td style="text-align: justify">Since its inception, the Company has devoted substantially
all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets, and raising
capital. The Company has not yet generated revenues from operations.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(7)</td><td style="text-align: justify">On March 25, 2024, the Company entered into a business combination
agreement (the &#8220;Apollo BCA&#8221;) with Apollo Technology Capital Corporation (formerly known as Nobul AI Corp.) (&#8220;Apollo&#8221;),
a private Ontario corporation. Subsequently, the Company&#8217;s primary strategic focus shifted to a proposed business combination with
MBody AI Corp., a Nevada corporation (&#8220;MBody AI&#8221;) (the &#8220;Merger&#8221;). On November 17, 2025, the Company held a special
general meeting of shareholders at which approximately 98% of votes cast were in favor of the Merger. The Merger is expected to transform
the Company into a Nasdaq-listed embodied-AI enterprise, subject to final regulatory and procedural conditions. See Note 19 &#8211; Subsequent
Events.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(8)</td><td style="text-align: justify">During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo in connection with the Apollo BCA. On September 8, 2024, the Board approved the First
Apollo Loan ($6,000, 5% per annum) and an amendment to the Apollo BCA requiring the Company to deposit $11,000 into a segregated bank
account at the Royal Bank of Canada (the &#8220;Segregated Account&#8221;) for Apollo business activities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">On December 23, 2024, the Board approved
the Second Apollo Loan ($6,000). As of December 31, 2024, $2,100 of the Segregated Account had been used by Apollo for acquisition targets
and growth initiatives; $700 had been used for certain Company expenses; and $2,200 remained in the Segregated Account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">In July 2025, in connection with the
audit of the Company&#8217;s December 31, 2024 financial statements, the Company reclassified the $2,100 as the Third Apollo Loan and
the $2,200 as the Fourth Apollo Loan, each on the same terms as the First Apollo Loan. See Note 19 &#8211; Subsequent Events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in">Also in July 2025, management evaluated
the recoverability of the Apollo Loans (First through Fourth) in accordance with ASC 326, Financial Instruments &#8211; Credit Losses,
and recorded a full allowance for credit losses on the Apollo Loans as of December 31, 2024. As of the date of issuance of these financial
statements, the Apollo Loans are contractually current and not in default. See Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(9)</td><td style="text-align: justify">The Company&#8217;s ordinary shares are listed on the Nasdaq
Capital Market under the symbol &#8220;MBAI&#8221; (formerly &#8220;CHEK&#8221;, prior to December 2, 2025). The Company has conducted
multiple registered direct offerings and warrant exercise transactions since its IPO on February 24, 2015. The Company&#8217;s Series
A Warrants expired on February 24, 2020 and Series C Warrants expired on May 8, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(10)</td><td style="text-align: justify">The consolidated financial statements include the accounts
of Check Cap Ltd., Check-Cap US, Inc., and Check-Cap Canada Inc. All intercompany transactions and balances have been eliminated.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(11)</td><td style="text-align: justify">Effective November 23, 2022, the Company effected a 1-for-20
reverse share split. All share and per-share amounts in these financial statements have been retroactively adjusted.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left">(12)</td><td style="text-align: justify">Following the October 7, 2023 attacks in Israel, the country
has been involved in ongoing military conflicts. Although certain ceasefire agreements have been reached, the situation remains volatile
with potential for escalation. The Company continues to monitor developments and their potential impact on operations.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING
CONCERN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Going Concern</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The accompanying consolidated financial statements have been
prepared on a going concern basis. As of December 31, 2025, the Company had an accumulated deficit of approximately $165,870 and cash
and cash equivalents of approximately $2. The Company has not generated revenues from operations and has incurred substantial net losses
since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding net income of $4,140 for the year ended December
31, 2025, which arose primarily from a non-cash credit loss recovery of $6,525 recognized upon reinstatement of the Apollo loan receivable
during the first half of 2025 (see Note 14), the Company&#8217;s operating cash flows remain negative. These conditions raise substantial doubt about
the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans include consummating the pending merger with MBody
AI Corp. and utilizing the ARC Equity Line of Credit facility. There is no assurance these plans will be successfully executed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Basis of Presentation</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company&#8217;s consolidated financial statements have
been prepared in accordance with U.S. GAAP. The functional currency of the Company is the U.S. dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Consolidation</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The consolidated financial statements include the accounts
of Check Cap Ltd. and its wholly-owned subsidiaries, Check-Cap US, Inc. and Check-Cap Canada Inc. All intercompany transactions and balances
have been eliminated in consolidation.</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Cash and Cash Equivalents</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company considers all short-term, highly liquid investments
with original maturities of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Short-term Bank Deposit</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Bank deposits with original maturities of more than three
months but less than twelve months are included in short-term bank deposits and bear interest at market rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>F.</b></td><td style="text-align: justify"><b>Property and Equipment</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over estimated useful lives: laboratory equipment 5&#8211;7 years;
office furniture and equipment 5&#8211;7 years; computers and auxiliary equipment 3 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>G.</b></td><td style="text-align: justify"><b>Intangible Assets</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Intangible assets are recorded at cost and amortized on a
straight-line basis over their estimated useful lives. The Ghost Kitchens ARA intangible asset, recorded at $759 upon issuance of shares
on September 4, 2025, is amortized over its estimated useful life. Amortization expense for the year ended December 31, 2025 was $34.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>H.</b></td><td style="text-align: justify"><b>Impairment of Long-Lived Assets</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company reviews long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying
amount exceeds the fair value of the asset.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>I.</b></td><td style="text-align: justify"><b>Investments in Equity Securities</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for investments in equity securities
without a readily determinable fair value under ASC 321, using the measurement alternative (cost less impairment, adjusted for observable
price changes in orderly transactions for identical or similar investments of the same issuer). The Apollo equity investment of $6,525
thousand, arising from the noncash debt-for-equity exchange recognized on November 14, 2025, is recorded at cost equal to the carrying
value of the loan receivable surrendered. No gain or loss was recognized on exchange. See Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>J.</b></td><td style="text-align: justify"><b>Research and Development Expenses</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Research and development expenses are charged to operations
as incurred, net of participation from the Israeli Innovation Authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>K.</b></td><td style="text-align: justify"><b>Share-Based Compensation</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company measures share-based compensation awards at grant-date
fair value using the Black-Scholes option-pricing model and recognizes compensation expense on a straight-line basis over the requisite
service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>L.</b></td><td style="text-align: justify"><b>Income Taxes</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company uses the asset and liability method for income
taxes. A full valuation allowance has been established against all deferred tax assets given the Company&#8217;s history of losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>M.</b></td><td style="text-align: justify"><b>Loss (Earnings) Per Share</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Basic earnings (loss) per share is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share equals
basic in loss years as all potentially dilutive securities are anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>N.</b></td><td style="text-align: justify"><b>Fair Value Measurements</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company applies ASC 820, using a three-level hierarchy:
Level 1 (quoted prices), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>O.</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for leases in accordance with ASC 842.
As of December 31, 2025, the Company has one operating lease for office facilities in Isfiya, Israel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>P.</b></td><td style="text-align: justify"><b>Recent Accounting Pronouncements</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Tax
Disclosures) are effective for fiscal years beginning after December 15, 2023 and 2024, respectively. The Company is evaluating their
impact. No other recently issued but not yet effective pronouncements are expected to have a material impact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>Q.</b></td><td style="text-align: justify"><b>Severance Pay</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">All Company employees are subject to Section 14 of the Israeli
Severance Pay Law. The Company&#8217;s monthly deposits release it from future severance obligations; accordingly, no related assets or
liabilities are presented on the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>R.</b></td><td style="text-align: justify"><b>Deferred Income Taxes</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Deferred tax assets and liabilities are recognized for temporary
differences between carrying amounts and tax bases. Given the Company&#8217;s history of losses, a full valuation allowance has been established
against all deferred tax assets, including net operating loss carryforwards.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government institutions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4 &#8211; PROPERTY AND EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Office furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">827</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computers and auxiliary equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Impairment of fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Depreciation expenses amounted to $0, $0, and $161 for the
years ended December 31, 2025, 2024, and 2023, respectively.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Impairment of fixed assets: The Company recorded an impairment
loss of $1,426 for the year ended December 31, 2023, following the decision to discontinue clinical studies. See Note 1(A)(4).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 &#8211; LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">The Company&#8217;s office lease in Isfiya, Israel (approximately
1,550 square meters, originally under the Amended Lease Agreement) expired December 31, 2023. Following expiry, the Company agreed to
lease a portion of the premises at a monthly fee of $8.3. On April 15, 2024, this lease was extended for two years commencing March 1,
2024, terminable upon 60 days&#8217; notice.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">The Petach Tikva sub-lease (laboratory space) was terminated
effective September 8, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">The Petach Tikva office lease was terminated by the parties
in September 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">As of December 31, 2025, operating lease right-of-use assets
and current lease liabilities were $16. The Company uses its incremental borrowing rate as the discount rate.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits and Payroll Accruals<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefits and Payroll Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 &#8211; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><span style="font-size: 8pt"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Composition:</b></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term employee benefits:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Benefits for vacation and recreation pay</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Liability for payroll, bonuses and wages</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Post-employment benefits</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All Company employees elected to be included under Section
14 of the Israeli Severance Pay Law. The Company&#8217;s monthly deposits at a rate of 8.33% of salary release it from future severance
obligations. Related assets and liabilities are not presented in the balance sheet. The Company did not make contributions to pension
funds in 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Short-term employee benefits</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Employees are entitled to paid vacation days in accordance
with the Yearly Vacation Law-1951. Accrued but unused vacation days are payable upon termination.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; INCOME TAXES</b></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>The Company</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap Ltd. is taxed according to Israeli tax laws:</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b>Corporate tax rates in Israel</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Israeli corporate tax rate in years 2022, 2023, 2024,
2025 and onwards is 23%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b>The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investments Law&#8221;)</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Under the Investments Law, including Amendment No. 60 as
published in April 2005, by virtue of the &#8220;Benefited Enterprise&#8221; status, the Company is entitled to various tax benefits as
follows:</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 18pt"><b>a)</b></td><td style="text-align: justify"><b>Reduced tax rates</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company has one Benefited Enterprise program under the
Investments Law, which entitles it to certain tax benefits with respect to income to be derived from its Benefited Enterprise. The Company
chose 2010 as the year of election (the &#8220;Year of Election&#8221;). Due to the location of the Company&#8217;s offices, the Company
believes it is entitled to a 10-year benefit period, subject to a 14-year limitation from the Year of Election. The tax benefit period
ended in 2023.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 18pt"><b>b)</b></td><td style="text-align: justify"><b>Conditions for entitlement to the benefits</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The benefits available to a Benefited Enterprise are subject
to the fulfillment of conditions stipulated in the Investments Law and its regulations.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 18pt"><b>c)</b></td><td style="text-align: justify"><b>Amendment of the Investments Law</b></td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Investments Law was amended as part of the Economic Policy
Law for the years 2011-2012, passed by the Israeli Knesset on December 29, 2010 (the &#8220;Capital Investments Law Amendment&#8221;).
The Capital Investments Law Amendment set alternative benefit tracks. Under the transitional provisions, the Company was entitled to elect
that the Capital Investments Law Amendment applies; however, the Company elected not to have the Capital Investments Law Amendment apply
to the Company.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On December 22, 2016, the Knesset approved amendment number
73 to the Investments Law introducing reduced corporate tax rate tracks of 7.5% for Preferred Technological Enterprises located in Development
Area A and 12% for the rest of the country, and 6% for a Special Preferred Technological Enterprise.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-size: 8pt">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In accordance with the Israeli Income Tax Ordinance [New
Version], 1961, as of December 31, 2025, all of the Company&#8217;s tax assessments through tax year 2017 are considered final. Tax years
2018 through 2025 remain open to examination by the Israeli Tax Authority.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><b>B.</b></td><td style="text-align: justify"><b>Check-Cap US, Inc.</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap US, Inc. is taxed according to U.S. tax laws at
a federal rate of 21%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Check-Cap US, Inc. had <span style="-sec-ix-hidden: hidden-fact-119">no</span> net operating loss carryforwards
as of December 31, 2025 (December 31, 2024: $177,107; December 31, 2023: $13).</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Utilization of any U.S. NOL carryforwards may be subject
to substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have
occurred or could occur in the future. The Company has not completed a detailed study to determine whether such ownership changes have
occurred.</p>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify"><b>C.</b></td><td style="text-align: justify"><b>Deferred income taxes</b></td>
</tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, Check-Cap Ltd. has accumulated
Israeli net operating loss carryforwards of approximately $129,559 (December 31, 2024: $127,162; December 31, 2023: $118,512). Under the
Israeli Income Tax Ordinance, these losses may be carried forward indefinitely to offset future Israeli taxable income. No Israeli NOL
carryforwards are subject to expiry.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, Check-Cap US, Inc. has <span style="-sec-ix-hidden: hidden-fact-120">no</span> U.S.
federal or state net operating loss carryforwards.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In assessing the realizability of deferred tax assets,
the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will be realized. Based on
the Company&#8217;s history of losses, its cessation of operations in June 2023, the absence of revenue since that date, and the absence
of objectively verifiable projections of future taxable income, the Company has established a full valuation allowance against all net
operating loss carryforwards. The Company does not expect to pay taxes in Israel until it has taxable income sufficient to fully utilize
its carryforward tax losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Net deferred tax assets consist of the following components:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">NOL carryforwards &#8211; Israel (at 23%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,258</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">NOL carryforwards &#8211; U.S. (at 21%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total gross deferred tax asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">29,799</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">29,247</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">27,261</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,799</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,261</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Deferred Tax Asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>All amounts in USD thousands. The Israeli NOL DTA is
computed at the 23% Israeli statutory corporate tax rate on accumulated Israeli tax losses of $129,559, $127,162 and $118,512 at December
31, 2025, 2024 and 2023 respectively. The U.S. DTA of $3 at December 31, 2023 is computed at 21% on $13 of U.S. NOL and is immaterial.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in accumulated Israeli net operating loss carryforwards:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Israeli NOL Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening accumulated Israeli NOL</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118,512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Current year estimated tax loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">129,559</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">127,162</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>The current year tax loss is estimated from the GAAP
net income/(loss) after the following adjustments applied consistently in both years: (i) the Apollo loan impairment charge of $16,487
recorded in 2024 and the related reversal/conversion gain of $6,525 recorded in 2025 are excluded from taxable income &#8212; tax recognition
is deferred until all closing conditions for the debt-for-equity exchange are met, which requires completion of the merger ; (ii) share-based
compensation is added back ($12 charge in 2024; ($12) credit in 2025); and (iii) IIA grants are excluded from taxable income ($0 received
in both years). Depreciation timing differences are assumed <span style="-sec-ix-hidden: hidden-fact-118">nil</span> or immaterial.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in valuation allowance:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Valuation Allowance Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening valuation allowance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(29,247</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(27,258</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase &#8212; current year tax loss &#215; 23%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,799</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has not recorded any liability for unrecognized
tax benefits under ASC 740 as of December 31, 2025 or 2024, and does not anticipate significant changes in uncertain tax positions within
the next 12 months. The Company&#8217;s policy is to record interest and penalties related to income tax matters in income tax expense;
<span style="-sec-ix-hidden: hidden-fact-121"><span style="-sec-ix-hidden: hidden-fact-122">no</span></span> such amounts were recognized in 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Current tax provision</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The provision for income taxes consists of the following:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Federal (U.S.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total current tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Federal (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total deferred tax benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total provision (benefit) for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Reconciliation of theoretical to actual tax expense</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table reconciles the statutory Israeli corporate
tax rate to the Company&#8217;s effective tax rate:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Statutory Israeli corporate tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of full valuation allowance on NOL carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other permanent differences (immaterial)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Effective tax rate</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company generated no taxable income in Israel or the
United States in 2025 or 2024. No income taxes were paid in either jurisdiction in 2025 or 2024. The primary reconciling item between
the statutory rate and the effective rate is the full valuation allowance established against all net operating loss carryforwards, reflecting
management&#8217;s conclusion that it is more likely than not that these assets will not be realized given the Company&#8217;s history
of losses, absence of revenue since June 2023, and the uncertainty of future taxable income pending completion of the merger</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; COMMITMENTS AND CONTINGENT LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Royalties provision</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Royalties to an ASIC designer: The Company had a liability to
pay royalties of 50 euro cents per ASIC component sold, capped at &#8364;200 (~$213). As no future sales are expected following the C-Scan
discontinuation, the provision was derecognized in 2023 as a reduction of R&amp;D expenses.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Royalties to an ASIC designer</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Reimbursement liability to Predecessor Entity&#8217;s unit holders:
The Company committed to reimburse unit holders of Check Cap LLC for tax burdens arising from the 2009 reorganization under Section 367(d)
of the Code. Since no profitability is expected, the liability based on discounted cash outflows is <span style="-sec-ix-hidden: hidden-fact-127">$0</span>.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Commitments</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Royalties &#8211; IIA and BIRD Foundation: Since inception through
December 31, 2023, the Company received IIA funding of approximately $5,600 and BIRD Foundation funding of approximately $114. <span style="-sec-ix-hidden: hidden-fact-128"><span style="-sec-ix-hidden: hidden-fact-129">No</span></span> grants
were received in 2024 or 2025. Contingent royalty obligations to the IIA (~$6,199) and BIRD Foundation (~$209) as of December 31, 2023
remain; these are not anticipated to be payable in the foreseeable future.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Rental agreements: See Note 5.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Legal</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">From time to time, the Company is involved
in litigation arising in the ordinary course of business. The following legal proceedings were outstanding as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Derivative action. </b>On October
7, 2024, a minority shareholder of the Company filed an application in the Haifa District Court seeking certification of a shareholders&#8217;
derivative lawsuit against the Company, certain present and former directors, and a third party, seeking damages in excess of NIS 2,500
(approximately $784). The claims relate primarily to corporate governance matters and the legality of certain corporate decisions and
transactions. The Company filed a response requesting that certification be denied. The parties are currently engaged in mediation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Former executive compensation claims.
</b>During 2024, two former senior executives filed separate claims against the Company seeking an aggregate of approximately NIS 620
(approximately $195) in respect of alleged unpaid compensation and contractual entitlements arising from the termination of their respective
engagements. The Company filed Statements of Defense rejecting all allegations in both matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Legal fee dispute. </b>During 2024,
a former legal services provider filed a claim against the Company seeking approximately NIS 175 (approximately $55) for alleged unpaid
fees. The Company filed a Statement of Defense rejecting all allegations. The parties are engaged in mediation proceedings concurrent
with the court process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Lease and eviction proceedings. </b>In
September 2024, the Company ceased making rent payments in respect of its leased premises in Usfiyeh, Israel. The landlord subsequently
commenced legal proceedings and an eviction order was granted by the court. The Company has ceased active business operations at the facility.
Certain Company property and documentation remain on the premises pending resolution of access and logistical matters. The landlord&#8217;s
claim for unpaid rent and damages totals approximately NIS 207 (approximately $65). No impairment has been recorded against the related
right-of-use asset as proceedings remain ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Management&#8217;s assessment. </b>For all of
the above matters, based on the information currently available and after consultation with legal counsel, management does not believe
an unfavorable outcome is probable for any of the above proceedings. Accordingly, no provision has been recorded in these consolidated
financial statements as of December 31, 2025. Management will reassess at each reporting date and will record a provision in the period
in which it becomes probable that a liability has been incurred and the amount can be reasonably estimated. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820, the Company measures financial
instruments at fair value using a three-level hierarchy. As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden: hidden-fact-130"><span style="-sec-ix-hidden: hidden-fact-131">no</span></span> financial instruments measured
at fair value on a recurring basis through the income statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Equity Investment in Apollo Technology
Capital Corporation &#8212; ASC 321. The Company holds an equity investment in Apollo Technology Capital Corporation (&#8220;Apollo&#8221;),
representing approximately 7.5% of Apollo&#8217;s issued and outstanding shares, arising from a debt-for-equity exchange recognized on
November 14, 2025 (see Note 14). Classification: The investment is classified as an equity security under ASC 321. The Company does not
have significant influence over Apollo: there is no board representation, no board nomination rights, no common directors or officers,
no shared management, and no governance, veto, or substantive participating rights. The equity method under ASC 323 does not apply. Measurement
alternative: Apollo&#8217;s shares are not publicly traded and do not have a readily determinable fair value. The Company applies the
measurement alternative under ASC 321-10-35-2: the investment is carried at cost of $6,525 thousand, less any impairment, adjusted for
observable price changes in orderly transactions for identical or similar investments of the same issuer. No observable price changes
have occurred since initial recognition. Impairment assessment at December 31, 2025: Management performed a qualitative impairment assessment
supported by an independent external valuation (effective date December 31, 2025), which concluded a fair market value of CAD 124.0 million
for 100% of Apollo&#8217;s equity. The implied value of the Company&#8217;s 7.5% interest is approximately USD 6.8 million, exceeding
the carrying value of USD 6.5 million by USD 252,000. No impairment indicators were identified and <span style="-sec-ix-hidden: hidden-fact-132">no</span> impairment charge is required at
December 31, 2025. The carrying amounts of cash, short-term deposits, and current liabilities approximate fair value due to their short-term
nature.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; SHAREHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Effective November 23, 2022, the Company effected a 1-for-20
reverse share split. Share and per-share amounts prior to November 23, 2022 have been retroactively adjusted. See Note 1(A)(11).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Ordinary shares</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Ordinary shares confer upon their holders the right to receive
dividends, to participate in liquidation distributions, and one vote per share at shareholder meetings.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Changes in ordinary share capital: The Company has conducted
multiple offerings from 2015 through 2022, including its IPO (February 2015), warrant exercises, and registered direct offerings. As
of December 31, 2024, 5,850,906 ordinary shares were issued and outstanding. On September 4, 2025, the Company issued 1,169,596 ordinary
shares in connection with the Ghost Kitchens ARA arrangement, resulting in 7,020,502 shares issued and outstanding as of December 31,
2025.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">CLA Warrants to purchase 370 ordinary
shares remain outstanding. Private Placement Warrants to purchase 84,626 ordinary shares remain outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 &#8211; SHARE-BASED COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>General</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company grants options and RSUs under the 2006 Plan and
the 2015 Equity Incentive Plan (including the 2015 U.S. Sub-Plan). No new options or RSUs were granted during 2025 or 2024. As of December
31, 2025, the same number of options and RSUs remain outstanding as at December 31, 2024, with no forfeitures or exercises occurring in
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Details of share-based grants</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The last options were granted on March 30, 2023 (903 options
at $2.82 exercise price). The last RSUs were granted in 2022. No share-based grants were made in 2024 or 2025.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Options Fair Value &#8211; Black-Scholes parameters</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The parameters used in applying the Black-Scholes model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-133">No grants</div></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">117</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free rate</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-135">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-137">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term (years)</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-139">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.08</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-141">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Effect of share-based compensation on statements of operations</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(144</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(12</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">12</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(57</td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Option activity</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2025:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life <br/>
(yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">102,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">102,288</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">47.13</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6.34</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">55,286</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">66.01</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5.87</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2024:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life<br/> (yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">102,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">102,288</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">47.13</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7.34</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">55,286</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">66.01</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6.87</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Weighted average grant date fair values: 2023: $1.17; 2022:
$4.50; 2021: $15.70. <span style="-sec-ix-hidden: hidden-fact-170"><span style="-sec-ix-hidden: hidden-fact-171">No</span></span> options granted in 2025 or 2024.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">As of December 31, 2025, all outstanding options (102,288 at
$47.13 average exercise price) are out of the money.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>F.</b></td><td style="text-align: justify"><b>RSU activity</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Unvested &#8211; beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,967</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,967</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,703</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8211;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,092</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,644</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Unvested &#8211; end of year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">No RSUs were granted in 2025 or 2024. Weighted average grant
date fair value of RSUs awarded during 2022 was $9.20.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0in"></td><td style="width: 0.25in; text-align: justify">(4)</td><td style="text-align: justify">As of December 31, 2025, unrecognized compensation cost related
to non-vested arrangements is approximately $&#8211; (all prior grants are fully vested or their remaining cost is immaterial).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 &#8211; RESEARCH AND DEVELOPMENT EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,926</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Subcontractors and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost for registration of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,294</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less participation of the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total research and development expenses, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 &#8211; GENERAL AND ADMINISTRATIVE EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,055</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office rent and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">The 2024 &#8220;Others&#8221; line includes amounts arising
from the Apollo (Apollo) loan arrangements.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT EXTINGUISHMENT</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 &#8211; IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT
EXTINGUISHMENT</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo (Apollo) totaling $16,400 (First through Fourth Apollo Loans). Management recorded
a full allowance for credit losses on all Apollo Loans as of December 31, 2024, in accordance with ASC 326. Notwithstanding the impairment,
the loans were contractually current and not in default. See Notes 1(A)(7) and 1(A)(8).</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the six months ended June 30, 2025, management reversed
the full impairment allowance and reinstated the loan receivable at $6,525 thousand (7.5% of the management-assessed equity value of Apollo
of $87,000 thousand at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during 2025. The reinstated receivable
was presented net of a payable owed by the Company to Apollo of $2,247 thousand pursuant to ASC 210-20-45, giving a net carrying value
of $4,278 thousand as reported in the Form 6-K filed December 30, 2025. On November 14, 2025, following the 98.01% shareholder vote in
favor of the Merger at the Annual General Meeting, the closing condition in the Exchange Agreement ceased to be substantive and the exchange
was recognized for accounting purposes. The Company derecognized the gross loan receivable of $6,525 thousand and recognized an equity
investment in Apollo at cost of $6,525 thousand, being the carrying value of the consideration surrendered in a noncash exchange. No gain
or loss was recognized on exchange; the estimated fair value of the equity received ($6,596,000) exceeded the carrying value by $71,000
(approximately 1.1%), which is not material. The Apollo payable of $2,247,000, previously netted against the loan receivable, was reclassified
as a standalone liability on November 14, 2025 and reduced to $1,400,000 through settlements and reallocations of $847,000 during the
second half of 2025. The Apollo equity investment is carried at $6,525,000 at December 31, 2025, accounted for under ASC 321 (Investments
in Equity Securities) using the measurement alternative. See Note 9 for classification, measurement, and impairment assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Impairment of loans receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,487</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on debt extinguishment and conversion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,525</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCE INCOME (EXPENSE), NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 &#8211; FINANCE INCOME (EXPENSE), NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income on short-term deposits and other</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">809</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bank fees and interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in provision for royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(188</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Changes in fair value of derivatives</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total financing income, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/720/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 &#8211; EARNINGS (LOSS) PER SHARE</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Basic earnings (loss) per share is computed based on the
weighted average number of shares outstanding during each year. Diluted earnings (loss) per share equals basic in periods of net loss,
as all potentially dilutive securities are anti-dilutive. In periods of net income, diluted EPS reflects the dilutive effect of outstanding
options and warrants, to the extent dilutive.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All outstanding options and warrants were excluded from the
2024 and 2023 diluted loss per share calculations as their effect was anti-dilutive. For the year ended December 31, 2025, outstanding
options and warrants are out of the money and accordingly also excluded from diluted EPS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Computation of basic and diluted earnings (loss) per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(25,149</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,568</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average ordinary shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,232,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,849,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,848,737</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Earnings (loss) per ordinary share &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Note: Weighted average shares for 2025 reflect the issuance
of 1,169,596 shares on September 4, 2025 (246 pre-issuance days at 5,850,906 shares + 119 post-issuance days at 7,020,502 shares, divided
by 365 days).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-dilutive instruments excluded from diluted EPS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(number)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Warrants and share options</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 &#8211; RELATED PARTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Compensation to non-executive directors:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Fees, including reimbursement of expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Transactions with related parties:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Sigalit Kimchy: No consulting fees were paid to Sigalit Kimchy
(wife of Yoav Kimchy, the Company&#8217;s Chief Technology Officer) during the year ended December 31, 2025. Ms. Kimchy had previously
served as marcom and user interface lead under an employment agreement dated April 4, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt">Consulting fees, including share-based compensation and reimbursement of expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract', window );"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock', window );">APOLLO TECHNOLOGY CAPITAL CORPORATION &#8211; LOAN RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 &#8211; APOLLO TECHNOLOGY CAPITAL CORPORATION &#8211; LOAN
RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">The Company holds an equity investment in Apollo Technology Capital
Corporation (&#8220;Apollo&#8221;, formerly Apollo AI Corp.), a technology-driven AI marketplace platform connecting homebuyers, real
estate agents, and mortgage providers across North American residential real estate markets. The investment arose from the conversion
of a series of loan receivables from Apollo (the &#8220;Exchange Indebtedness&#8221;) with aggregate principal of USD 16,648,253, pursuant
to the Exchange Agreement entered into on June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Initial Impairment &#8211; Year Ended December 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">During the year ended December 31, 2024, the Company fully impaired
its loan receivable from Apollo under ASC 310 and ASC 326, reducing the net carrying value to <span style="-sec-ix-hidden: hidden-fact-216">nil</span>, reflecting Apollo&#8217;s financial
distress, recurring operating losses, and negative working capital at that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Reversal of Impairment and Loan Reinstatement &#8211; Six Months
Ended June 30, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">During the six months ended June 30, 2025, management determined that
the impairment indicators no longer existed and reinstated the recoverable portion of the loan at USD 6,525,000 (7.5% of USD 87,000,000,
being the management-assessed equity value of Apollo at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during
2025. The reinstated receivable was presented net of a payable owed by Check-Cap to Apollo of USD 2,247,000, resulting in a net carrying
value of USD 4,278,000 as at June 30, 2025.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Debt-for-Equity Exchange &#8211; November 14, 2025</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On June 30, 2025, the (the &#8220;Exchange Agreement&#8221;) with Apollo
under which the Exchange Indebtedness would be exchanged for common shares of Apollo representing a 7.5% shareholding. The Exchange Agreement
was conditional on the completion of the Merger . At the Annual General Meeting held on November 14, 2025, Check-Cap shareholders voted
98.01% in favor of the merger, at which point the closing condition ceased to be substantive and the exchange was recognized for accounting
purposes.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On November 14, 2025, the Company derecognized the loan receivable
of USD 6,525,000 and recognized an equity investment in Apollo at cost of USD 6,525,000, being the carrying value of the consideration
surrendered. No gain or loss was recognized on exchange. Apollo&#8217;s shares do not have a readily determinable fair value; accordingly,
the investment is carried at cost under the measurement alternative provided by ASC 321-10-35-2. The Apollo payable of USD 2,247,000,
previously netted against the loan receivable, was reclassified as a standalone liability.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investment &#8211; Classification and Subsequent Measurement</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The equity investment is classified as an equity security under ASC
321. The Company holds 7.5% of Apollo&#8217;s issued and outstanding shares and does not have significant influence, as evidenced by the
absence of board representation, shared management, governance rights, or substantive participating rights. The equity method under ASC
323 does not apply.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The investment is carried at cost of USD 6,525,000 under the measurement
alternative (ASC 321-10-35-2), adjusted for observable price changes in orderly transactions for identical or similar investments. No
observable price changes have occurred since initial recognition.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Impairment Assessment &#8211; December 31, 2025</b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">At December 31, 2025, management performed a qualitative impairment
assessment supported by an independent external valuation report, effective date December 31, 2025. The valuation concluded a Fair Market
Value of CAD 124.0 million for 100% of Apollo equity using a weighted average of the Discounted Cash Flow method (30% weight) and Comparable
Company Method (70% weight), with a cost of equity of 13.53%.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Check-Cap&#8217;s 7.5% interest implied by the valuation is CAD 9.3
million (USD 6.8 million approximately at the December 31, 2025 CAD/USD rate of 0.7287), which exceeds the carrying value of USD 6.5 million
by USD 252,000. No impairment indicators were identified and no impairment charge is required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Carrying Value Summary (USD)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loan receivable &#8211; gross principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,648,253</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,648,253</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loan receivable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity investment in Apollo (at cost)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,525,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payable to Apollo</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,399,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for apollo technology capital corporation &#8211; loan receivable, exchange, and equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span>The Company has evaluated subsequent
events through January 1, 2026 and the date on which these consolidated financial statements were issued, and has determined that there
are no subsequent events requiring recognition or disclosure in these consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (17,568)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Board of Directors is
responsible for overseeing our risk management program and cybersecurity is a critical element of this program<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board of Directors is
responsible for overseeing our risk management program and cybersecurity is a critical element of this program. Management is responsible
for the day-to-day administration of our risk management program and our cybersecurity policies, processes, and practices. Our cybersecurity
policies, standards, processes, and practices are based on recognized frameworks and other applicable industry standards are standalone
from our overall risk management system and processes. In general, we seek to address material cybersecurity threats through a company-wide
approach that addresses the confidentiality, integrity, and availability of our information systems or the information that the Company
collects and stores, by assessing, identifying and managing cybersecurity issues as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cybersecurity Risk Management and Strategy</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our cybersecurity risk management
strategy focuses on several areas:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification and Reporting</i>: We have implemented a comprehensive, cross-functional approach to assessing, identifying and managing material cybersecurity threats and incidents. Our program includes controls and procedures to properly identify, classify and escalate certain cybersecurity incidents to provide management visibility and obtain direction from management as to the public disclosure and reporting of material incidents in a timely manner.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Technical Safeguards</i>: We implements technical safeguards that are designed to protect the our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence, as well as outside audits and certifications.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incident Response and Recovery Planning</i>: We have established and maintains comprehensive incident response, business continuity, and disaster recovery plans designed to address our response to a cybersecurity incident. We conduct regular tabletop exercises to test these plans and ensure personnel are familiar with their roles in a response scenario.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third-Party Risk Management</i>: We maintain a comprehensive, risk-based approach to identifying and overseeing material cybersecurity threats presented by third parties, including vendors, service providers, and other external users of our systems, as well as the systems of third parties that could adversely impact our business in the event of a material cybersecurity incident affecting those third-party systems, including any outside auditors or consultants who advise on our cybersecurity systems.</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Education and Awareness</i>: We provide regular, mandatory training for all levels of employees regarding cybersecurity threats as a means to equip our employees with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes, and practices.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We conduct periodic assessment
and testing of our policies, standards, processes, and practices in a manner intended to address cybersecurity threats and events. The
results of such assessments, audits, and reviews are evaluated by management and reported to the Audit Committee and the Board, and we
adjust our cybersecurity policies, standards, processes, and practices as necessary based on the information provided by these assessments,
audits, and reviews.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Governance</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats. The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Senior management works collaboratively
across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond
to any material cybersecurity incidents in accordance with our incident response and recovery plans. To facilitate the success of our
cybersecurity program, cross-functional teams throughout the Company address cybersecurity threats and respond to cybersecurity incidents.
Through ongoing communications with these teams, our outsourced information technology team and senior management are informed about and
monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and report such threats
and incidents to the Audit Committee when appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material Effects of Cybersecurity Incidents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have not materially affected and are not reasonably likely to
materially affect us, including our business strategy, results of operations, or financial condition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Management is responsible
for the day-to-day administration of our risk management program and our cybersecurity policies, processes, and practices.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats. The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Senior management works collaboratively
across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond
to any material cybersecurity incidents in accordance with our incident response and recovery plans. To facilitate the success of our
cybersecurity program, cross-functional teams throughout the Company address cybersecurity threats and respond to cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Through ongoing communications with these teams, our outsourced information technology team and senior management are informed about and
monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and report such threats
and incidents to the Audit Committee when appropriate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material Effects of Cybersecurity Incidents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have not materially affected and are not reasonably likely to
materially affect us, including our business strategy, results of operations, or financial condition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Going Concern</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The accompanying consolidated financial statements have been
prepared on a going concern basis. As of December 31, 2025, the Company had an accumulated deficit of approximately $165,870 and cash
and cash equivalents of approximately $2. The Company has not generated revenues from operations and has incurred substantial net losses
since inception.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding net income of $4,140 for the year ended December
31, 2025, which arose primarily from a non-cash credit loss recovery of $6,525 recognized upon reinstatement of the Apollo loan receivable
during the first half of 2025 (see Note 14), the Company&#8217;s operating cash flows remain negative. These conditions raise substantial doubt about
the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans include consummating the pending merger with MBody
AI Corp. and utilizing the ARC Equity Line of Credit facility. There is no assurance these plans will be successfully executed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Basis of Presentation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company&#8217;s consolidated financial statements have
been prepared in accordance with U.S. GAAP. The functional currency of the Company is the U.S. dollar.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Consolidation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The consolidated financial statements include the accounts
of Check Cap Ltd. and its wholly-owned subsidiaries, Check-Cap US, Inc. and Check-Cap Canada Inc. All intercompany transactions and balances
have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Cash and Cash Equivalents</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company considers all short-term, highly liquid investments
with original maturities of three months or less to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ShortTermBankDepositPolicyTextBlock', window );">Short-term Bank Deposit</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>E.</b></td><td style="text-align: justify"><b>Short-term Bank Deposit</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Bank deposits with original maturities of more than three
months but less than twelve months are included in short-term bank deposits and bear interest at market rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>F.</b></td><td style="text-align: justify"><b>Property and Equipment</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over estimated useful lives: laboratory equipment 5&#8211;7 years;
office furniture and equipment 5&#8211;7 years; computers and auxiliary equipment 3 years.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>G.</b></td><td style="text-align: justify"><b>Intangible Assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Intangible assets are recorded at cost and amortized on a
straight-line basis over their estimated useful lives. The Ghost Kitchens ARA intangible asset, recorded at $759 upon issuance of shares
on September 4, 2025, is amortized over its estimated useful life. Amortization expense for the year ended December 31, 2025 was $34.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>H.</b></td><td style="text-align: justify"><b>Impairment of Long-Lived Assets</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company reviews long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying
amount exceeds the fair value of the asset.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>I.</b></td><td style="text-align: justify"><b>Investments in Equity Securities</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for investments in equity securities
without a readily determinable fair value under ASC 321, using the measurement alternative (cost less impairment, adjusted for observable
price changes in orderly transactions for identical or similar investments of the same issuer). The Apollo equity investment of $6,525
thousand, arising from the noncash debt-for-equity exchange recognized on November 14, 2025, is recorded at cost equal to the carrying
value of the loan receivable surrendered. No gain or loss was recognized on exchange. See Note 14.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>J.</b></td><td style="text-align: justify"><b>Research and Development Expenses</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Research and development expenses are charged to operations
as incurred, net of participation from the Israeli Innovation Authority.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>K.</b></td><td style="text-align: justify"><b>Share-Based Compensation</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company measures share-based compensation awards at grant-date
fair value using the Black-Scholes option-pricing model and recognizes compensation expense on a straight-line basis over the requisite
service period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>L.</b></td><td style="text-align: justify"><b>Income Taxes</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company uses the asset and liability method for income
taxes. A full valuation allowance has been established against all deferred tax assets given the Company&#8217;s history of losses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss (Earnings) Per Share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>M.</b></td><td style="text-align: justify"><b>Loss (Earnings) Per Share</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Basic earnings (loss) per share is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share equals
basic in loss years as all potentially dilutive securities are anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>N.</b></td><td style="text-align: justify"><b>Fair Value Measurements</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company applies ASC 820, using a three-level hierarchy:
Level 1 (quoted prices), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>O.</b></td><td style="text-align: justify"><b>Leases</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company accounts for leases in accordance with ASC 842.
As of December 31, 2025, the Company has one operating lease for office facilities in Isfiya, Israel.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>P.</b></td><td style="text-align: justify"><b>Recent Accounting Pronouncements</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Tax
Disclosures) are effective for fiscal years beginning after December 15, 2023 and 2024, respectively. The Company is evaluating their
impact. No other recently issued but not yet effective pronouncements are expected to have a material impact.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>Q.</b></td><td style="text-align: justify"><b>Severance Pay</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">All Company employees are subject to Section 14 of the Israeli
Severance Pay Law. The Company&#8217;s monthly deposits release it from future severance obligations; accordingly, no related assets or
liabilities are presented on the balance sheet.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_DeferredIncomeTaxesPolicyTextBlock', window );">Deferred Income Taxes</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>R.</b></td><td style="text-align: justify"><b>Deferred Income Taxes</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Deferred tax assets and liabilities are recognized for temporary
differences between carrying amounts and tax bases. Given the Company&#8217;s history of losses, a full valuation allowance has been established
against all deferred tax assets, including net operating loss carryforwards.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DeferredIncomeTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire policy disclosure of deferred income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DeferredIncomeTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ShortTermBankDepositPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies short term bank deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ShortTermBankDepositPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Government institutions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Office furniture and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">827</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Computers and auxiliary equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Impairment of fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits and Payroll Accruals (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>Employee Benefits and Payroll Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock', window );">Schedule of Employee Benefits and Payroll Accruals</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term employee benefits:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Benefits for vacation and recreation pay</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Liability for payroll, bonuses and wages</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">406</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for employee related liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Net deferred tax assets consist of the following components:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">NOL carryforwards &#8211; Israel (at 23%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,258</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">NOL carryforwards &#8211; U.S. (at 21%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total gross deferred tax asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">29,799</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">29,247</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">27,261</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,799</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,261</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Deferred Tax Asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Accumulated Israeli Net Operating Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in accumulated Israeli net operating loss carryforwards:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Israeli NOL Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening accumulated Israeli NOL</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118,512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Current year estimated tax loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">129,559</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">127,162</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Movement in Valuation Allowance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Movement in valuation allowance:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Valuation Allowance Rollforward (USD thousands)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Opening valuation allowance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(29,247</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(27,258</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase &#8212; current year tax loss &#215; 23%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Closing accumulated Israeli NOL</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,799</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,247</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The provision for income taxes consists of the following:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Federal (U.S.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total current tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Federal (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">State (U.S.)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign &#8212; Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total deferred tax benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total provision (benefit) for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory Israeli Corporate Tax Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table reconciles the statutory Israeli corporate
tax rate to the Company&#8217;s effective tax rate:</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Statutory Israeli corporate tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of full valuation allowance on NOL carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other permanent differences (immaterial)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Effective tax rate</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Schedule of Reduction of R&amp;D Expenses</a></td>
<td class="text">As no future sales are expected following the C-Scan
discontinuation, the provision was derecognized in 2023 as a reduction of R&amp;D expenses.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Royalties to an ASIC designer</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Parameters Used in Applying the Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The parameters used in applying the Black-Scholes model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/>
year ended<br/> December 31, <br/>
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-133">No grants</div></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">117</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free rate</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-135">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-137">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected term (years)</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-139">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.08</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-141">No grants</div></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation</a></td>
<td class="text"><b>Effect of share-based compensation on statements of operations</b><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(144</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(12</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">12</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(57</td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2025:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life <br/>
(yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">102,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">102,288</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">47.13</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6.34</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">55,286</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">66.01</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5.87</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended December 31, 2024:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Exercise<br/> Price <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Wtd. Avg.<br/> Remaining<br/> Life<br/> (yrs)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value <br/>
($000s)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Options outstanding &#8211; beginning of year</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">102,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8211;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options forfeited</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Options outstanding &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">102,288</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">47.13</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7.34</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">Options exercisable &#8211; end of year</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">55,286</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">66.01</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6.87</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">&#8211;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs Activity</a></td>
<td class="text"><b>RSU activity</b><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Unvested &#8211; beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,967</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,967</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,703</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">&#8211;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,092</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">&#8211;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,644</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Unvested &#8211; end of year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,967</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock', window );">Schedule of Research and Development Expenses, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,926</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Subcontractors and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cost for registration of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,294</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less participation of the IIA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total research and development expenses, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salaries and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,055</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office rent and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">The 2024 &#8220;Others&#8221; line includes amounts arising
from the Apollo (Apollo) loan arrangements.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Impairment of loans receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,487</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on debt extinguishment and conversion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,525</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,525</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Finance Income (Expense), Net</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income on short-term deposits and other</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">809</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bank fees and interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in provision for royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exchange rate differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(188</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Changes in fair value of derivatives</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-206">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-207">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total financing income, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Computation of basic and diluted earnings (loss) per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(25,149</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(17,568</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average ordinary shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,232,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,849,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,848,737</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Earnings (loss) per ordinary share &#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.66</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-dilutive instruments excluded from diluted EPS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(number)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Warrants and share options</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,631,603</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember', window );">Compensation to non-executive directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_RelatedPartiesTablesLineItems', window );"><strong>Related Parties (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><b>Compensation to non-executive directors:</b><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Fees, including reimbursement of expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-208">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-209">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember', window );">Transactions with Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_RelatedPartiesTablesLineItems', window );"><strong>Related Parties (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Sigalit Kimchy: No consulting fees were paid to Sigalit Kimchy
(wife of Yoav Kimchy, the Company&#8217;s Chief Technology Officer) during the year ended December 31, 2025. Ms. Kimchy had previously
served as marcom and user interface lead under an employment agreement dated April 4, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt">Consulting fees, including share-based compensation and reimbursement of expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">188</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RelatedPartiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RelatedPartiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract', window );"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Carrying Value Summary</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loan receivable &#8211; gross principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-210">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,648,253</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,648,253</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loan receivable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity investment in Apollo (at cost)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,525,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payable to Apollo</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,399,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2025</div></th>
<th class="th"><div>Sep. 08, 2024</div></th>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_VotesCastPercentage', window );">Votes cast percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesSegregatedUnderOtherRegulations', window );">Segregated account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ReclassifiedAcquisitionTarget', window );">Reclassified of third apollo loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chek_FirstApolloLoanMember', window );">First Apollo Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit in segregated bank account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chek_SecondApolloLoanMember', window );">Second Apollo Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesSegregatedUnderOtherRegulations', window );">Segregated account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chek_FourthApolloLoanMember', window );">Fourth Apollo Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=chek_CheckCapMember', window );">Check Cap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>General Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_AmountPayableForNonrefundableFee', window );">First apollo loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Percentage of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_AmountPayableForNonrefundableFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount payable for nonrefundable fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_AmountPayableForNonrefundableFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ReclassifiedAcquisitionTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassified acquisition target .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ReclassifiedAcquisitionTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_VotesCastPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Votes cast percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_VotesCastPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesSegregatedUnderOtherRegulations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of securities deposited in a special reserve account for the exclusive benefit of customers pursuant to regulations other than SEC Regulations and the Commodity Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesSegregatedUnderOtherRegulations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chek_FirstApolloLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chek_FirstApolloLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chek_SecondApolloLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chek_SecondApolloLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chek_FourthApolloLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chek_FourthApolloLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=chek_CheckCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=chek_CheckCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Going Concern (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 14, 2025</div></th>
<th class="th"><div>Sep. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (165,870)<span></span>
</td>
<td class="num">$ (170,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4,140<span></span>
</td>
<td class="num">(25,149)<span></span>
</td>
<td class="num">$ (17,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Loan receivable</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Issuance of shares</a></td>
<td class="nump">726<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_GhostKitchensARAMember', window );">Ghost Kitchens ARA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chek_ComputersAndAuxiliaryEquipmentMember', window );">Computers and Auxiliary Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_GhostKitchensARAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_GhostKitchensARAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chek_ComputersAndAuxiliaryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chek_ComputersAndAuxiliaryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chek_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chek_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PrepaidGovernmentInstitutions', window );">Government institutions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PrepaidGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount related to government institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PrepaidGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 3,336<span></span>
</td>
<td class="nump">$ 3,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">3,336<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_AccumulatedImpairmentOnPropertyPlantAndEquipment', window );">Impairment of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and auxiliary equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_AccumulatedImpairmentOnPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated impairment on property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_AccumulatedImpairmentOnPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Lease monthly fee</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease extended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of lease (in Square Meters) | m&#178;</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits and Payroll Accruals (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Benefits and Payroll Accruals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_DepositsRate', window );">Deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DepositsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits monthly salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DepositsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract', window );"><strong>Short-term employee benefits:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Benefits for vacation and recreation pay</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Liability for payroll, bonuses and wages</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee benefits and payroll accruals</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_EntitledBenefitTerm', window );">Entitled benefit period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LimitationFromTheYearOfElectionTerm', window );">Limitation from the year of election term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss or NOL carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,559<span></span>
</td>
<td class="nump">$ 127,162<span></span>
</td>
<td class="nump">$ 118,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">DTA percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpairmentOfLoansReceivable', window );">Loan impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,487<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Reversal/conversion gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Excluded taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_UncertainTaxPositions', window );">uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to income tax amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=chek_CheckCapUsIncMember', window );">Check Cap Us Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss or NOL carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax asset, NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ReductionInIncomeTaxRate', window );">Reduction in income tax rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember', window );">Development Area A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=chek_RestOfCountryMember', window );">Rest of Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss or NOL carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Check Cap Us Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss or NOL carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Check Cap Us Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss or NOL carry-forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israeli statutory corporate tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated loss for tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,559<span></span>
</td>
<td class="nump">$ 127,162<span></span>
</td>
<td class="nump">$ 118,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_EntitledBenefitTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the entitled benefit term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_EntitledBenefitTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpairmentOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against impairment of loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpairmentOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_LimitationFromTheYearOfElectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the limitation from the year of election term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_LimitationFromTheYearOfElectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ReductionInIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction In Income Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ReductionInIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_UncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_UncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=chek_CheckCapUsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=chek_CheckCapUsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=chek_RestOfCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=chek_RestOfCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">NOL carryforwards &#8211; Israel (at 23%)</a></td>
<td class="nump">$ 29,799<span></span>
</td>
<td class="nump">$ 29,247<span></span>
</td>
<td class="nump">$ 27,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">NOL carryforwards &#8211; U.S. (at 21%)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax asset</a></td>
<td class="nump">29,799<span></span>
</td>
<td class="nump">29,247<span></span>
</td>
<td class="nump">27,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(29,799)<span></span>
</td>
<td class="num">(29,247)<span></span>
</td>
<td class="num">(27,261)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net Deferred Tax Asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Schedule of Net Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">NOL carryforwards, Percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">NOL carryforwards, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Schedule of Accumulated Israeli Net Operating Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Opening accumulated Israeli NOL</a></td>
<td class="nump">$ 127,162<span></span>
</td>
<td class="nump">$ 118,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Current year estimated tax loss</a></td>
<td class="nump">2,397<span></span>
</td>
<td class="nump">8,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Closing accumulated Israeli NOL</a></td>
<td class="nump">$ 129,559<span></span>
</td>
<td class="nump">$ 127,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Movement in Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Schedule of Movement in Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Opening valuation allowance</a></td>
<td class="num">$ (29,247)<span></span>
</td>
<td class="num">$ (27,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase &#8212; current year tax loss &#215; 23%</a></td>
<td class="num">(551)<span></span>
</td>
<td class="num">(1,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Closing accumulated Israeli NOL</a></td>
<td class="num">$ (29,799)<span></span>
</td>
<td class="num">$ (29,247)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Schedule of Movement in Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance', window );">Increase &#8212; current year tax loss, Percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase current year tax loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal (U.S.)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State (U.S.)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign &#8212; Israel</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal (U.S.)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State (U.S.)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign &#8212; Israel</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of Statutory Israeli Corporate Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Israeli corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effect of full valuation allowance on NOL carryforwards</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other permanent differences (immaterial)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Oct. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 07, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants were received</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Unpaid compensation and contractual entitlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">&#8362; 620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Unpaid fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">&#8362; 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_OutstandingAmountsOfLandlordClaim', window );">Claims total outstanding amounts</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember', window );">ASIC designer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Royalties received (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_RoyaltiesSoldComponent', window );">Royalties sold, component</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_FundReceivedInTotalAmount', window );">Fund received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ContingentLiability', window );">Contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember', window );">BIRD Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_FundReceivedInTotalAmount', window );">Fund received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ContingentLiability', window );">Contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingent Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_DerivativeAmount', window );">Derivative amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">&#8362; 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of contingent liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DerivativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DerivativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_FundReceivedInTotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund received in total amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_FundReceivedInTotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_OutstandingAmountsOfLandlordClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding amounts of landlord claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_OutstandingAmountsOfLandlordClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liability recorded to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesSoldComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesSoldComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities - Schedule of Reduction of R&amp;D Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Schedule of Reduction of R&amp;D Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Reduction of R&amp;D expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=chek_RoyaltiesToAnASICDesignerMember', window );">Royalties to an ASIC designer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Schedule of Reduction of R&amp;D Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Reduction of R&amp;D expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=chek_RoyaltiesToAnASICDesignerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=chek_RoyaltiesToAnASICDesignerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Nov. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Financial instrument fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investment cost</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities', window );">Fair market value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpliedInterestPercentage', window );">Implied percent</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Exceeding value</a></td>
<td class="nump">$ 6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Carrying value</a></td>
<td class="nump">252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Exceeding value</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpliedInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Implied interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpliedInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482134/820-10-35-54B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the total value of investments that are equity securities for a given category of investments for which net asset value per share is calculated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 04, 2025</div></th>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse share split ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting right</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember', window );">CLA Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chek_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020,502<span></span>
</td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,169,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chek_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chek_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares granted (in Shares)</a></td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted shares exercise price</a></td>
<td class="nump">$ 2.82<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Parameters Used in Applying the Model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Options outstanding</a></td>
<td class="nump">102,288<span></span>
</td>
<td class="nump">102,288<span></span>
</td>
<td class="nump">102,288<span></span>
</td>
<td class="nump">102,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Wtd. Avg Exercise Price, Options outstanding</a></td>
<td class="nump">$ 47.13<span></span>
</td>
<td class="nump">$ 35.35<span></span>
</td>
<td class="nump">$ 47.13<span></span>
</td>
<td class="nump">$ 47.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Wtd. Avg. Remaining Life, Options outstanding</a></td>
<td class="text">7 years 4 months 2 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">7 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number, Options exercisable</a></td>
<td class="nump">55,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,286<span></span>
</td>
<td class="nump">55,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Wtd. Avg Exercise Price, Options exercisable</a></td>
<td class="nump">$ 66.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.01<span></span>
</td>
<td class="nump">$ 66.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Wtd. Avg. Remaining Life, Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
<td class="text">6 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Wtd. Avg Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average of exercise Price, Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number, Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Wtd. Avg Exercise Price, Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of RSUs Activity (Details) - RSUs [Member] - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested &#8211; beginning of year</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">19,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested &#8211; end of year</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details) - Research and Development Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfIncomeCaptionsLineItems', window );"><strong>Schedule of Research and Development Expenses, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Materials</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_SubcontractorsAndConsultantFees', window );">Subcontractors and consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PaymentsExpensesForPatents', window );">Cost for registration of patents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Others</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_GrantedRevenue', window );">Less participation of the IIA</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GrantedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue fron grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GrantedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PaymentsExpensesForPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of payments /expenses for patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PaymentsExpensesForPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_SubcontractorsAndConsultantFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees for the services provided by subcontractors and consultants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_SubcontractorsAndConsultantFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfIncomeCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfIncomeCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - General and Administrative Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Professional services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Office rent and maintenance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">8,409<span></span>
</td>
<td class="nump">2,702<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 9,462<span></span>
</td>
<td class="nump">$ 9,550<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2024 &#8220;Others&#8221; line includes amounts arising
from the Apollo (Apollo) loan arrangements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2025</div></th>
<th class="th"><div>Nov. 14, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLoansReceivable', window );">Loans receivable</a></td>
<td class="nump">$ 2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod', window );">Loans receivable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="num">$ (6,596,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_NetCarryingValue', window );">Net value</a></td>
<td class="nump">$ 4,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ShareholderVotingPercentage', window );">Shareholder vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ExceedingCarryingValue', window );">Exceeding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Reduction in notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_NotesReallocation', window );">reallocations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,247,000<span></span>
</td>
<td class="nump">$ 2,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ExceedingCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exceeding carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ExceedingCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_NetCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_NetCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_NotesReallocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes reallocation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_NotesReallocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ShareholderVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholder voting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ShareholderVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage points added to the reference rate or index during the adjustment period to compute the variable [fully indexed] rate on the loans receivable realized during the reporting period. This may be an effective margin for the period depending on the specific terms of the underlying loan agreement (for example, an annual disclosure for a loan with a quarterly adjustment period).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureAbstract', window );"><strong>Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpairmentOfLoansReceivable', window );">Impairment of loans receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,487<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment and conversion</a></td>
<td class="num">(6,525)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment', window );">Net</a></td>
<td class="num">$ (6,525)<span></span>
</td>
<td class="nump">$ 16,487<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net impairment of loan receivable and debt extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ImpairmentOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against impairment of loans receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ImpairmentOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Schedule of Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income on short-term deposits and other</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 1,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Bank fees and interest expenses</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ChangesInLiabilityToPayRoyalties', window );">Changes in provision for royalties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange rate differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Changes in fair value of derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financing income, net</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ChangesInLiabilityToPayRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents value of changes in liability to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ChangesInLiabilityToPayRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 04, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings (Loss) Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average shares</a></td>
<td class="nump">1,169,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings (Loss) Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average shares</a></td>
<td class="nump">5,850,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings (Loss) Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average shares</a></td>
<td class="nump">7,020,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Schedule of Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (17,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding &#8211; basic</a></td>
<td class="nump">6,232,226<span></span>
</td>
<td class="nump">5,849,013<span></span>
</td>
<td class="nump">5,848,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding &#8211; diluted</a></td>
<td class="nump">6,232,226<span></span>
</td>
<td class="nump">5,849,013<span></span>
</td>
<td class="nump">5,848,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per ordinary share &#8211; basic</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per ordinary share &#8211; diluted</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants and share options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Warrants and share options</a></td>
<td class="nump">2,631,603<span></span>
</td>
<td class="nump">2,631,603<span></span>
</td>
<td class="nump">2,631,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Schedule of Transactions with Related Parties (Details) - Non-executive Directors [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_Compensationtothenon-executivedirectors', window );">Total</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_FeesAndReimbursementMember', window );">Fees, including reimbursement of expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_Compensationtothenon-executivedirectors', window );">Total</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_ShareBasedCompensationMember', window );">Share-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_Compensationtothenon-executivedirectors', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_Compensationtothenon-executivedirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_Compensationtothenon-executivedirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_FeesAndReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_FeesAndReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Schedule of Transactions with Related Parties (Details) - Transactions with Related Parties [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember', window );">Consulting fees, including share-based compensation and reimbursement of expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_GeneralTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_GeneralTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ReinstatedRecoverableLoan', window );">Reinstated recoverable portion of the loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfManagementAssessedEquity', window );">Percentage of management-assessed equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_AmountOfManagementAssessedEquity', window );">Value of management-assessed equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_CarryingValueOfReinstatedReceivable', window );">Carrying value of reinstated receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfShareholding', window );">Percentage of shareholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ShareholderVotingPercentage', window );">Voting percentage</a></td>
<td class="nump">98.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ValuationOfFairValueMarket', window );">Fair market value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_EquityPercentageOfWeightedAverage', window );">Percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfDiscountedCashFlowMethod', window );">Discounted cash flow method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfComparableCompanyMethod', window );">Percentage of comparable company method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfCostEquity', window );">Percentage of cost of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.53%<span></span>
</td>
<td class="nump">13.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfValuationInterest', window );">Valuation interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_InterestImpliedValuation', window );">Valuation interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_PercentageOfImpliedRate', window );">Implied rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7287%<span></span>
</td>
<td class="nump">0.7287%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chek_ExchangeIndebtednessMember', window );">Exchange Indebtedness [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,648,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember', window );">Debt-for-Equity Exchange &#8211; November 14, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment cost</a></td>
<td class="nump">$ 6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Payable against the loan receivable</a></td>
<td class="nump">2,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Net payable</a></td>
<td class="nump">2,247,000<span></span>
</td>
<td class="nump">$ 2,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment cost</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_ReducingCarryingValueNet', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="nump">$ 6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_InterestImpliedValuation', window );">Valuation interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_InterestImpliedValuation', window );">Valuation interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems', window );"><strong>Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Net payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of shares issued and outstanding</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_AmountOfManagementAssessedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of management-assessed equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_AmountOfManagementAssessedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_CarryingValueOfReinstatedReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of carrying value of reinstated receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_CarryingValueOfReinstatedReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_EquityPercentageOfWeightedAverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity percentage of weighted average.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_EquityPercentageOfWeightedAverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_InterestImpliedValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest implied valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_InterestImpliedValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_LoanReceivableExchangeAndEquityInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_LoanReceivableExchangeAndEquityInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfComparableCompanyMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of comparable company method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfComparableCompanyMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfCostEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of cost equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfCostEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfDiscountedCashFlowMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discounted cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfDiscountedCashFlowMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfImpliedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of implied rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfImpliedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfManagementAssessedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of management-assessed equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfManagementAssessedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfShareholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shareholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfShareholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PercentageOfValuationInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PercentageOfValuationInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ReducingCarryingValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reducing carrying value net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ReducingCarryingValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ReinstatedRecoverableLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reinstated recoverable loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ReinstatedRecoverableLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ShareholderVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholder voting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ShareholderVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ValuationOfFairValueMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation of fair value market.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ValuationOfFairValueMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chek_ExchangeIndebtednessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chek_ExchangeIndebtednessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Apollo Technology Capital Corporation &#8211; Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Schedule of Carrying Value Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan receivable &#8211; gross principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,648,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent', window );">Allowance for credit losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,648,253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Net loan receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember', window );">Apollo Technology Capital Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Schedule of Carrying Value Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment in Apollo (at cost)</a></td>
<td class="nump">6,525,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Payable to Apollo</a></td>
<td class="nump">$ 1,399,579<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForNotesAndLoansReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph c<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 948<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477011/948-310-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=chek_ApolloTechnologyCapitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>146</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Shareholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/GeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Summary of Significant Accounting Policies and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern</Role>
      <ShortName>Summary of Significant Accounting Policies and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Employee Benefits and Payroll Accruals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals</Role>
      <ShortName>Employee Benefits and Payroll Accruals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Research and Development Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ResearchandDevelopmentExpensesNet</Role>
      <ShortName>Research and Development Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment</Role>
      <ShortName>Impairment of Loans Receivable and Gain on Debt Extinguishment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Finance Income (Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/FinanceIncomeExpenseNet</Role>
      <ShortName>Finance Income (Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment</Role>
      <ShortName>Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Employee Benefits and Payroll Accruals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables</Role>
      <ShortName>Employee Benefits and Payroll Accruals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Commitments and Contingent Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables</Role>
      <ShortName>Commitments and Contingent Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/ShareBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Research and Development Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables</Role>
      <ShortName>Research and Development Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/ResearchandDevelopmentExpensesNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables</Role>
      <ShortName>Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Finance Income (Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/FinanceIncomeExpenseNetTables</Role>
      <ShortName>Finance Income (Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/FinanceIncomeExpenseNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/EarningsLossPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/RelatedParties</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables</Role>
      <ShortName>Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/GeneralInformationDetails</Role>
      <ShortName>General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/GeneralInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/Leases</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Employee Benefits and Payroll Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails</Role>
      <ShortName>Employee Benefits and Payroll Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable</Role>
      <ShortName>Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable</Role>
      <ShortName>Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable</Role>
      <ShortName>Income Taxes - Schedule of Movement in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals</Role>
      <ShortName>Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable</Role>
      <ShortName>Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Commitments and Contingent Liabilities - Schedule of Reduction of R&amp;D Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofReductionofRDExpensesTable</Role>
      <ShortName>Commitments and Contingent Liabilities - Schedule of Reduction of R&amp;D Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/FairValueMeasurements</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Shareholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/ShareholdersEquity</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofShareBasedCompensationTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Share-Based Compensation - Schedule of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofOptionActivityTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Share-Based Compensation - Schedule of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofRSUsActivityTable</Role>
      <ShortName>Share-Based Compensation - Schedule of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable</Role>
      <ShortName>Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails</Role>
      <ShortName>Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable</Role>
      <ShortName>Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable</Role>
      <ShortName>Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/FinanceIncomeExpenseNetTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofEarningsLossPerShareTable</Role>
      <ShortName>Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable</Role>
      <ShortName>Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0</Role>
      <ShortName>Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails</Role>
      <ShortName>Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0287623-20f_checkcap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ScheduleofCarryingValueSummaryTable</Role>
      <ShortName>Apollo Technology Capital Corporation ??? Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chek-20251231.xsd</File>
    <File>chek-20251231_cal.xml</File>
    <File>chek-20251231_def.xml</File>
    <File>chek-20251231_lab.xml</File>
    <File>chek-20251231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0287623-20f_checkcap.htm">ea0287623-20f_checkcap.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ea028762301_img1.jpg</File>
    <File>ea028762301_img10.jpg</File>
    <File>ea028762301_img11.jpg</File>
    <File>ea028762301_img12.jpg</File>
    <File>ea028762301_img13.jpg</File>
    <File>ea028762301_img2.jpg</File>
    <File>ea028762301_img3.jpg</File>
    <File>ea028762301_img4.jpg</File>
    <File>ea028762301_img5.jpg</File>
    <File>ea028762301_img6.jpg</File>
    <File>ea028762301_img7.jpg</File>
    <File>ea028762301_img8.jpg</File>
    <File>ea028762301_img9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="665">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0287623-20f_checkcap.htm": {
   "nsprefix": "chek",
   "nsuri": "http://check-cap.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "chek-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "chek-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "chek-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "chek-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chek-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0287623-20f_checkcap.htm"
     ]
    }
   },
   "keyStandard": 289,
   "keyCustom": 51,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 21,
   "memberCustom": 25,
   "hidden": {
    "total": 220,
    "http://fasb.org/us-gaap/2025": 192,
    "http://check-cap.com/20251231": 25,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 146,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 749,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 665,
    "http://xbrl.sec.gov/dei/2025": 46,
    "http://xbrl.sec.gov/cyd/2025": 13,
    "http://xbrl.sec.gov/ecd/2025": 1,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://check-cap.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://check-cap.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://check-cap.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Deficit",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://check-cap.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherNoncashIncomeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://check-cap.com/role/GeneralInformation",
     "longName": "995306 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern",
     "longName": "995307 - Disclosure - Summary of Significant Accounting Policies and Going Concern",
     "shortName": "Summary of Significant Accounting Policies and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995308 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://check-cap.com/role/PropertyandEquipmentNet",
     "longName": "995309 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://check-cap.com/role/Leases",
     "longName": "995310 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals",
     "longName": "995311 - Disclosure - Employee Benefits and Payroll Accruals",
     "shortName": "Employee Benefits and Payroll Accruals",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://check-cap.com/role/IncomeTaxes",
     "longName": "995312 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://check-cap.com/role/CommitmentsandContingentLiabilities",
     "longName": "995313 - Disclosure - Commitments and Contingent Liabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://check-cap.com/role/FairValueMeasurements",
     "longName": "995314 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://check-cap.com/role/ShareholdersEquity",
     "longName": "995315 - Disclosure - Shareholders\u2019 Equity",
     "shortName": "Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://check-cap.com/role/ShareBasedCompensation",
     "longName": "995316 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://check-cap.com/role/ResearchandDevelopmentExpensesNet",
     "longName": "995317 - Disclosure - Research and Development Expenses, Net",
     "shortName": "Research and Development Expenses, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://check-cap.com/role/GeneralandAdministrativeExpenses",
     "longName": "995318 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment",
     "longName": "995319 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment",
     "shortName": "Impairment of Loans Receivable and Gain on Debt Extinguishment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://check-cap.com/role/FinanceIncomeExpenseNet",
     "longName": "995320 - Disclosure - Finance Income (Expense), Net",
     "shortName": "Finance Income (Expense), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://check-cap.com/role/EarningsLossPerShare",
     "longName": "995321 - Disclosure - Earnings (Loss) Per Share",
     "shortName": "Earnings (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://check-cap.com/role/RelatedParties",
     "longName": "995322 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment",
     "longName": "995323 - Disclosure - Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment",
     "shortName": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://check-cap.com/role/SubsequentEvents",
     "longName": "995324 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://check-cap.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:GoingConcernPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:GoingConcernPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996001 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://check-cap.com/role/PropertyandEquipmentNetTables",
     "longName": "996002 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables",
     "longName": "996003 - Disclosure - Employee Benefits and Payroll Accruals (Tables)",
     "shortName": "Employee Benefits and Payroll Accruals (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://check-cap.com/role/IncomeTaxesTables",
     "longName": "996004 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables",
     "longName": "996005 - Disclosure - Commitments and Contingent Liabilities (Tables)",
     "shortName": "Commitments and Contingent Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://check-cap.com/role/ShareBasedCompensationTables",
     "longName": "996006 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables",
     "longName": "996007 - Disclosure - Research and Development Expenses, Net (Tables)",
     "shortName": "Research and Development Expenses, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://check-cap.com/role/GeneralandAdministrativeExpensesTables",
     "longName": "996008 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "chek:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "chek:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables",
     "longName": "996009 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)",
     "shortName": "Impairment of Loans Receivable and Gain on Debt Extinguishment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://check-cap.com/role/FinanceIncomeExpenseNetTables",
     "longName": "996010 - Disclosure - Finance Income (Expense), Net (Tables)",
     "shortName": "Finance Income (Expense), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://check-cap.com/role/EarningsLossPerShareTables",
     "longName": "996011 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://check-cap.com/role/RelatedPartiesTables",
     "longName": "996012 - Disclosure - Related Parties (Tables)",
     "shortName": "Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c120",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c120",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables",
     "longName": "996013 - Disclosure - Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment (Tables)",
     "shortName": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://check-cap.com/role/GeneralInformationDetails",
     "longName": "996014 - Disclosure - General Information (Details)",
     "shortName": "General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c29",
      "name": "chek:VotesCastPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c29",
      "name": "chek:VotesCastPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies and Going Concern (Details)",
     "shortName": "Summary of Significant Accounting Policies and Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996016 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://check-cap.com/role/PropertyandEquipmentNetDetails",
     "longName": "996017 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996018 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://check-cap.com/role/LeasesDetails",
     "longName": "996019 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseExpirationDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails",
     "longName": "996020 - Disclosure - Employee Benefits and Payroll Accruals (Details)",
     "shortName": "Employee Benefits and Payroll Accruals (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:DepositsRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:DepositsRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable",
     "longName": "996021 - Disclosure - Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details)",
     "shortName": "Employee Benefits and Payroll Accruals - Schedule of Employee Benefits and Payroll Accruals (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccruedVacationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccruedVacationCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://check-cap.com/role/IncomeTaxesDetails",
     "longName": "996022 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:EntitledBenefitTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable",
     "longName": "996023 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals",
     "longName": "996024 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable",
     "longName": "996025 - Disclosure - Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details)",
     "shortName": "Income Taxes - Schedule of Accumulated Israeli Net Operating Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable",
     "longName": "996026 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Movement in Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c16",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals",
     "longName": "996027 - Disclosure - Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)",
     "shortName": "Income Taxes - Schedule of Movement in Valuation Allowance (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable",
     "longName": "996028 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable",
     "longName": "996029 - Disclosure - Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Statutory Israeli Corporate Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails",
     "longName": "996030 - Disclosure - Commitments and Contingent Liabilities (Details)",
     "shortName": "Commitments and Contingent Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable",
     "longName": "996031 - Disclosure - Commitments and Contingent Liabilities - Schedule of Reduction of R&D Expenses (Details)",
     "shortName": "Commitments and Contingent Liabilities - Schedule of Reduction of R&D Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://check-cap.com/role/FairValueMeasurementsDetails",
     "longName": "996032 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://check-cap.com/role/ShareholdersEquityDetails",
     "longName": "996033 - Disclosure - Shareholders\u2019 Equity (Details)",
     "shortName": "Shareholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://check-cap.com/role/ShareBasedCompensationDetails",
     "longName": "996034 - Disclosure - Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable",
     "longName": "996035 - Disclosure - Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details)",
     "shortName": "Share-Based Compensation - Schedule of Parameters Used in Applying the Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://check-cap.com/role/ScheduleofShareBasedCompensationTable",
     "longName": "996036 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://check-cap.com/role/ScheduleofOptionActivityTable",
     "longName": "996037 - Disclosure - Share-Based Compensation - Schedule of Option Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c94",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://check-cap.com/role/ScheduleofRSUsActivityTable",
     "longName": "996038 - Disclosure - Share-Based Compensation - Schedule of RSUs Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c101",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable",
     "longName": "996039 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details)",
     "shortName": "Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c90",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c90",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "shortName": "General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "chek:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "chek:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
     "longName": "996041 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)",
     "shortName": "Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c110",
      "name": "us-gaap:ProceedsFromCollectionOfLoansReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c110",
      "name": "us-gaap:ProceedsFromCollectionOfLoansReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable",
     "longName": "996042 - Disclosure - Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)",
     "shortName": "Impairment of Loans Receivable and Gain on Debt Extinguishment - Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "chek:ImpairmentOfLoansReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable",
     "longName": "996043 - Disclosure - Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details)",
     "shortName": "Finance Income (Expense), Net - Schedule of Finance Income (Expense), Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://check-cap.com/role/EarningsLossPerShareDetails",
     "longName": "996044 - Disclosure - Earnings (Loss) Per Share (Details)",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c114",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c114",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable",
     "longName": "996045 - Disclosure - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)",
     "shortName": "Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable",
     "longName": "996046 - Disclosure - Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "shortName": "Earnings (Loss) Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c117",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "996047 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "chek:Compensationtothenon-executivedirectors",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "chek:Compensationtothenon-executivedirectors",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0",
     "longName": "996048 - Disclosure - Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c134",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c134",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
     "longName": "996049 - Disclosure - Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment (Details)",
     "shortName": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c108",
      "name": "chek:ReinstatedRecoverableLoan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c108",
      "name": "chek:ReinstatedRecoverableLoan",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable",
     "longName": "996050 - Disclosure - Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details)",
     "shortName": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment - Schedule of Carrying Value Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:NotesAndLoansReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:NotesAndLoansReceivableGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0287623-20f_checkcap.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies and Going Concern [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accruals",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r35"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits for vacation and recreation pay",
        "label": "Accrued Vacation, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r37"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r132",
      "r538"
     ]
    },
    "chek_AccumulatedImpairmentOnPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "AccumulatedImpairmentOnPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of fixed assets",
        "documentation": "Accumulated impairment on property plant and equipment.",
        "label": "Accumulated Impairment On Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated loss for tax",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r52",
      "r138",
      "r533",
      "r555",
      "r556",
      "r1019"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r726",
      "r1084"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r927",
      "r928",
      "r929",
      "r930",
      "r1020",
      "r1087"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r808",
      "r843"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r811",
      "r846"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r838",
      "r847",
      "r851",
      "r859"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable",
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation",
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r347",
      "r356"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, net",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForNotesAndLoansReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable": {
       "parentTag": "us-gaap_NotesAndLoansReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for credit losses",
        "label": "Financing Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on financing receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r219",
      "r227"
     ]
    },
    "us-gaap_AlternativeInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AlternativeInvestment",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value",
        "label": "Alternative Investment",
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439",
      "r444",
      "r445",
      "r446",
      "r718",
      "r720",
      "r721",
      "r1021",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r155",
      "r237",
      "r238",
      "r680",
      "r684",
      "r685",
      "r687",
      "r689"
     ]
    },
    "chek_AmountOfManagementAssessedEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "AmountOfManagementAssessedEquity",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of management-assessed equity",
        "documentation": "Amount of management-assessed equity.",
        "label": "Amount Of Management Assessed Equity"
       }
      }
     },
     "auth_ref": []
    },
    "chek_AmountPayableForNonrefundableFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "AmountPayableForNonrefundableFee",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First apollo loan amount",
        "documentation": "Represent the amount payable for nonrefundable fee.",
        "label": "Amount Payable For Nonrefundable Fee"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and share options",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-Dilutive Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APOLLO TECHNOLOGY CAPITAL CORPORATION \u2013 LOAN RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT",
        "documentation": "The entire disclosure for apollo technology capital corporation \u2013 loan receivable, exchange, and equity investment.",
        "label": "Apollo Technology Capital Corporation Loan Receivable Exchange And Equity Investment Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Technology Capital Corporation \u2013 Loan Receivable, Exchange, and Equity Investment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ApolloTechnologyCapitalCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ApolloTechnologyCapitalCorporationMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apollo Technology Capital Corporation [Member]",
        "label": "Apollo Technology Capital Corporation Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of lease (in Square Meters)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow",
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of fixed assets",
        "verboseLabel": "Impairment loss",
        "netLabel": "Impairment charge",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r735",
      "r736"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r86",
      "r133",
      "r165",
      "r167",
      "r168",
      "r203",
      "r208",
      "r213",
      "r214",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r405",
      "r408",
      "r447",
      "r523",
      "r524",
      "r530",
      "r601",
      "r695",
      "r696",
      "r704",
      "r726",
      "r739",
      "r740",
      "r751",
      "r959",
      "r960",
      "r1040"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r142",
      "r165",
      "r167",
      "r168",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r405",
      "r408",
      "r447",
      "r726",
      "r959",
      "r960",
      "r1040"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r168",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r405",
      "r408",
      "r447",
      "r959",
      "r960",
      "r1040"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable",
      "http://check-cap.com/role/ScheduleofRSUsActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "chek_BinationalIndustrialResearchAndDevelopmentFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "BinationalIndustrialResearchAndDevelopmentFoundationMember",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BIRD Foundation [Member]",
        "documentation": "Israel-United States Binational Industrial Research and Development Foundation [Member]",
        "label": "Binational Industrial Research And Development Foundation Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r788"
     ]
    },
    "chek_CarryingValueOfReinstatedReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "CarryingValueOfReinstatedReceivable",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value of reinstated receivable",
        "documentation": "Amount of carrying value of reinstated receivable.",
        "label": "Carrying Value Of Reinstated Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r129",
      "r681"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents, and short-term deposits",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r162"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r58"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r1052"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash flow information",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies and Going Concern [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r523",
      "r525"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "chek_ChangesInLiabilityToPayRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ChangesInLiabilityToPayRoyalties",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in provision for royalties",
        "documentation": "Represents value of changes in liability to pay royalties.",
        "label": "Changes In Liability To Pay Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "chek_CheckCapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "CheckCapMember",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Check Cap [Member]",
        "label": "Check Cap Member"
       }
      }
     },
     "auth_ref": []
    },
    "chek_CheckCapUsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "CheckCapUsIncMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Check-Cap US, Inc [Member]",
        "verboseLabel": "Check Cap Us Inc [Member]",
        "documentation": "This member stands for Check-Cap US, Inc.",
        "label": "Check Cap Us Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r205",
      "r281",
      "r287",
      "r288",
      "r289",
      "r291",
      "r294",
      "r299",
      "r301",
      "r414",
      "r566",
      "r567",
      "r568",
      "r569",
      "r705",
      "r891",
      "r918",
      "r920"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r243",
      "r244",
      "r663",
      "r950",
      "r955"
     ]
    },
    "chek_CommitmentsandContingentLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "CommitmentsandContingentLiabilitiesDetailsTable",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails",
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r927",
      "r928",
      "r930",
      "r1020",
      "r1082",
      "r1087"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share, par value (in New Shekels per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r589"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued (in Shares)",
        "verboseLabel": "Ordinary shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding (in Shares)",
        "verboseLabel": "Ordinary shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r589",
      "r607",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital, Ordinary shares 48 NIS par value (18,000,000 authorized shares as of December 31, 2025 and 2024; 7,020,502 and 5,850,906 shares issued and outstanding as of December 31, 2025 and 2024, respectively)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r279",
      "r284",
      "r532",
      "r726"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting right",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://check-cap.com/role/EmployeeBenefitsandPayrollAccruals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFITS AND PAYROLL ACCRUALS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "chek_Compensationtothenon-executivedirectors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "Compensationtothenon-executivedirectors",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Compensationtothenon-executivedirectors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Provision for Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r144",
      "r146",
      "r151",
      "r521",
      "r542",
      "r543"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and auxiliary equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "chek_ComputersAndAuxiliaryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ComputersAndAuxiliaryEquipmentMember",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and Auxiliary Equipment [Member]",
        "label": "Computers And Auxiliary Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r166",
      "r172",
      "r527",
      "r895"
     ]
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r166",
      "r172",
      "r527",
      "r895"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r166",
      "r172",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r478",
      "r527",
      "r668",
      "r901",
      "r902",
      "r903",
      "r958",
      "r961",
      "r962"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r108",
      "r166",
      "r172",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r478",
      "r527",
      "r668",
      "r901",
      "r902",
      "r903",
      "r958",
      "r961",
      "r962"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r691"
     ]
    },
    "chek_ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting fees, including share-based compensation and reimbursement of expenses [Member]",
        "label": "Consulting Fees Including Sharebased Compensation And Reimbursement Of Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "chek_ContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ContingentLiability",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liability",
        "documentation": "Represents amount of contingent liability.",
        "label": "Contingent Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office rent and maintenance",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "chek_CreditLineAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "CreditLineAgreementWarrantsMember",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CLA Warrants [Member]",
        "documentation": "CLA Warrants [Member]",
        "label": "Credit Line Agreement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal (U.S.)",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r918",
      "r924",
      "r1011"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign \u2014 Israel",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r918",
      "r924"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r918",
      "r924"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State (U.S.)",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r918",
      "r924",
      "r1011"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r870"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r870"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r872"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r870"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r865"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r864"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r864"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r864"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r867"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r867"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r871"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r869"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r866"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r36",
      "r37",
      "r78",
      "r79",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r725",
      "r918",
      "r919",
      "r921",
      "r926",
      "r951",
      "r952",
      "r953",
      "r1033",
      "r1034",
      "r1050"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r725",
      "r918",
      "r919",
      "r921",
      "r926",
      "r951",
      "r952",
      "r953",
      "r1033",
      "r1034",
      "r1050"
     ]
    },
    "chek_DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt-for-Equity Exchange \u2013 November 14, 2025 [Member]",
        "label": "Debtfor Equity Exchange November Fourteen Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Option Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal (U.S.)",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r924",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign \u2014 Israel",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r924",
      "r1010"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r91",
      "r918",
      "r924"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_DeferredIncomeTaxesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DeferredIncomeTaxesPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income Taxes",
        "documentation": "The entire policy disclosure of deferred income taxes.",
        "label": "Deferred Income Taxes Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State (U.S.)",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r924",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Deferred Tax Asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset, NOLs",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accumulated Israeli Net Operating Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards \u2013 Israel (at 23%)",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards \u2013 U.S. (at 21%)",
        "verboseLabel": "Deferred tax asset",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening valuation allowance",
        "periodEndLabel": "Closing accumulated Israeli NOL",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r815"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit in segregated bank account",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "chek_DepositsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DepositsRate",
     "presentation": [
      "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits rate",
        "documentation": "Deposits monthly salary percentage.",
        "label": "Deposits Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26",
      "r154",
      "r684",
      "r685",
      "r687",
      "r689"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow",
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r156",
      "r203",
      "r210",
      "r214",
      "r684",
      "r695",
      "r696"
     ]
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "chek_DerivativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DerivativeAmount",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative amount",
        "documentation": "Represent the amount of derivative.",
        "label": "Derivative Amount"
       }
      }
     },
     "auth_ref": []
    },
    "chek_DesignerRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DesignerRoyaltiesMember",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASIC designer [Member]",
        "documentation": "Royalties to an ASIC designer [Member]",
        "label": "Designer Royalties Member"
       }
      }
     },
     "auth_ref": []
    },
    "chek_DevelopmentAreaAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "DevelopmentAreaAMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Area A [Member]",
        "documentation": "Development Area A [Member]",
        "label": "Development Area AMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r938",
      "r1083"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r312",
      "r343",
      "r344",
      "r345",
      "r709"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r815"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788",
      "r839"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788",
      "r839"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "chek_EarningsLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "EarningsLossPerShareDetailsTable",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share [Abstract]",
        "terseLabel": "Income (loss) per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per ordinary share - basic (in Dollars per share)",
        "verboseLabel": "Earnings (loss) per ordinary share \u2013 basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r152",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r190",
      "r192",
      "r195",
      "r196",
      "r197",
      "r202",
      "r277",
      "r346",
      "r400",
      "r403",
      "r427",
      "r428",
      "r522",
      "r544",
      "r692"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings (Loss) Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r195",
      "r197"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per ordinary share - diluted (in Dollars per share)",
        "verboseLabel": "Earnings (loss) per ordinary share \u2013 diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r152",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r192",
      "r195",
      "r196",
      "r197",
      "r202",
      "r277",
      "r346",
      "r400",
      "r403",
      "r427",
      "r428",
      "r522",
      "r544",
      "r692"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss (Earnings) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r199"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r198",
      "r200",
      "r201"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r711"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statutory Israeli Corporate Tax Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals",
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards, Percent",
        "verboseLabel": "Statutory Israeli corporate tax rate",
        "netLabel": "Income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r365",
      "r390",
      "r711"
     ]
    },
    "chek_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance",
     "presentation": [
      "http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase \u2014 current year tax loss, Percent",
        "documentation": "The increase current year tax loss.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Asset Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of full valuation allowance on NOL carryforwards",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r711",
      "r918",
      "r925",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofNetDeferredTaxAssetsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards, Percent",
        "verboseLabel": "DTA percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r368",
      "r711",
      "r918",
      "r925",
      "r1000"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofStatutoryIsraeliCorporateTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences (immaterial)",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r918",
      "r925",
      "r1000",
      "r1001"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Payroll Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_EmployeeBenefitsandPayrollAccrualsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "EmployeeBenefitsandPayrollAccrualsDetailsTable",
     "presentation": [
      "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Payroll Accruals (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee benefits and payroll accruals",
        "terseLabel": "Employees and payroll accruals",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term employee benefits:",
        "label": "Employee-related Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Payment Arrangement, Option [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "presentation": [
      "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Payroll Accruals [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "chek_EntitledBenefitTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "EntitledBenefitTerm",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entitled benefit period",
        "documentation": "Represent the entitled benefit term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Entitled Benefit Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails",
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r120",
      "r121",
      "r122",
      "r148",
      "r149",
      "r150",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r188",
      "r204",
      "r225",
      "r226",
      "r239",
      "r276",
      "r302",
      "r346",
      "r388",
      "r389",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r464",
      "r470",
      "r541",
      "r551",
      "r552",
      "r553",
      "r575",
      "r631"
     ]
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity value",
        "label": "Equity, Fair Value Disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1022",
      "r1026"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r396",
      "r447",
      "r892",
      "r893",
      "r894",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity percentage",
        "verboseLabel": "Percentage of shares issued and outstanding",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r447"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment in Apollo (at cost)",
        "verboseLabel": "Equity investment",
        "netLabel": "Equity investment cost",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r212",
      "r214",
      "r220",
      "r906",
      "r943"
     ]
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeding value",
        "verboseLabel": "Equity fair value",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investments accounted under the equity method."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r678",
      "r724",
      "r907",
      "r1021",
      "r1022",
      "r1026"
     ]
    },
    "chek_EquityPercentageOfWeightedAverage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "EquityPercentageOfWeightedAverage",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fair market value",
        "documentation": "Equity percentage of weighted average.",
        "label": "Equity Percentage Of Weighted Average"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r808",
      "r843"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r805",
      "r840"
     ]
    },
    "chek_ExceedingCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ExceedingCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeding value",
        "documentation": "Amount of exceeding carrying value.",
        "label": "Exceeding Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "chek_ExchangeIndebtednessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ExchangeIndebtednessMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Indebtedness [Member]",
        "label": "Exchange Indebtedness Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r433",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r519",
      "r718",
      "r721"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Percent Equity Securities",
        "documentation": "The percentage of the total value of investments that are equity securities for a given category of investments for which net asset value per share is calculated."
       }
      }
     },
     "auth_ref": []
    },
    "chek_FairValueMeasurementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "FairValueMeasurementsDetailsTable",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "chek_FeesAndReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "FeesAndReimbursementMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees, including reimbursement of expenses [Member]",
        "documentation": "Fees, including reimbursement of expenses [Member]",
        "label": "Fees And Reimbursement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instrument fair value",
        "label": "Financial Instruments, Owned, at Fair Value",
        "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableAllowanceForCreditLossesLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Value Summary [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "chek_FirstApolloLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "FirstApolloLoanMember",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Apollo Loan [Member]",
        "label": "First Apollo Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction [Member]",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r451",
      "r452",
      "r453",
      "r454",
      "r628"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r847"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r799"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "chek_FourthApolloLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "FourthApolloLoanMember",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fourth Apollo Loan [Member]",
        "label": "Fourth Apollo Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "chek_FundReceivedInTotalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "FundReceivedInTotalAmount",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund received",
        "documentation": "Fund received in total amount.",
        "label": "Fund Received In Total Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable": {
       "parentTag": "chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment",
       "weight": 1.0,
       "order": 1.0
      },
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income on Debt Extinguishment and Conversion",
        "negatedLabel": "Gain on debt extinguishment and conversion",
        "verboseLabel": "Reversal/conversion gain",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total general and administrative expenses",
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r610"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative, net [Member]",
        "verboseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "chek_GeneralAndAdministrativeExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesTextBlock",
     "presentation": [
      "http://check-cap.com/role/GeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "Disclosure for general and administrative expenses.",
        "label": "General And Administrative Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "chek_GeneralInformationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GeneralInformationDetailsTable",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Information (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_GeneralTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GeneralTransactionsMember",
     "presentation": [
      "http://check-cap.com/role/RelatedPartiesTables",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with Related Parties [Member]",
        "documentation": "General Transactions [Member]",
        "label": "General Transactions Member"
       }
      }
     },
     "auth_ref": []
    },
    "chek_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_GhostKitchensARAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GhostKitchensARAMember",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ghost Kitchens ARA [Member]",
        "label": "Ghost Kitchens ARAMember"
       }
      }
     },
     "auth_ref": []
    },
    "chek_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern",
        "documentation": "Disclosure of accounting policy for going concern.",
        "label": "Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947"
     ]
    },
    "chek_GrantedRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "GrantedRevenue",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less participation of the IIA",
        "documentation": "Revenue fron grant.",
        "label": "Granted Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants were received",
        "label": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "IL",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r788"
     ]
    },
    "chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net",
        "documentation": "Amount of net impairment of loan receivable and debt extinguishment.",
        "label": "Impairment Of Loan Receivable And Gain On Debt Extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ImpairmentOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ImpairmentOfLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable": {
       "parentTag": "chek_ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment",
       "weight": -1.0,
       "order": 2.0
      },
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow",
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofImpairmentofLoansReceivableandGainonDebtExtinguishmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of loans receivable",
        "negatedLabel": "Impairment of loans receivable",
        "verboseLabel": "Loan impairment charge",
        "documentation": "The charge against impairment of loans receivable.",
        "label": "Impairment Of Loans Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r67"
     ]
    },
    "chek_ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Loans Receivable and Gain on Debt Extinguishment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ImpliedInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ImpliedInterestPercentage",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Implied percent",
        "documentation": "Implied interest percentage.",
        "label": "Implied Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable",
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable",
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r410",
      "r411",
      "r412",
      "r413",
      "r432",
      "r434",
      "r438",
      "r448",
      "r449",
      "r450",
      "r548",
      "r550",
      "r615",
      "r677",
      "r678",
      "r712",
      "r713",
      "r716",
      "r717",
      "r719",
      "r724",
      "r1016",
      "r1017",
      "r1054"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable",
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r410",
      "r411",
      "r412",
      "r413",
      "r432",
      "r434",
      "r438",
      "r448",
      "r449",
      "r450",
      "r548",
      "r550",
      "r615",
      "r677",
      "r678",
      "r712",
      "r713",
      "r716",
      "r717",
      "r719",
      "r724",
      "r1016",
      "r1017",
      "r1054"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r365",
      "r366",
      "r376",
      "r384",
      "r711",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r365",
      "r366",
      "r376",
      "r384",
      "r711",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r361",
      "r365",
      "r372",
      "r373",
      "r374",
      "r377",
      "r383",
      "r391",
      "r393",
      "r394",
      "r395",
      "r529",
      "r558",
      "r571",
      "r711"
     ]
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year estimated tax loss",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "documentation": "Estimated amount of loss resulting from an adverse tax position."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofProvisionforIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision (benefit) for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r92",
      "r165",
      "r187",
      "r188",
      "r203",
      "r211",
      "r214",
      "r364",
      "r365",
      "r392",
      "r546",
      "r686",
      "r688",
      "r690",
      "r711"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r362",
      "r363",
      "r377",
      "r378",
      "r382",
      "r386",
      "r565"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excluded taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r1000"
     ]
    },
    "chek_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r62",
      "r915",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade accounts payable, accruals and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in employees and payroll accruals",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities items:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operation leasing",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r914"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in prepaid and other current assets and non-current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in royalties provision",
        "label": "Increase (Decrease) in Royalties Payable",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r838",
      "r847",
      "r851",
      "r859"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r863"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r863"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r863"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, net",
        "verboseLabel": "Issuance of shares",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r948",
      "r949"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank fees and interest expenses",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "chek_InterestImpliedValuation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "InterestImpliedValuation",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation interest",
        "documentation": "The amount of interest implied valuation.",
        "label": "Interest Implied Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r159",
      "r160"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income on short-term deposits and other",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r209",
      "r214",
      "r695",
      "r912"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of interest",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r644",
      "r645",
      "r647",
      "r648",
      "r652",
      "r653",
      "r743",
      "r941",
      "r942"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Equity Securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r561",
      "r562",
      "r563",
      "r564",
      "r642",
      "r643"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1022",
      "r1026",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "chek_IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IIA [Member]",
        "documentation": "This member stands for Israel Innovation Authority of the Ministry of Economy and Industry.",
        "label": "Israel Innovation Authority Ministry Of Economy And Industry Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel Tax Authority [Member]",
        "verboseLabel": "Israeli statutory corporate tax [Member]",
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": []
    },
    "chek_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease extended",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r1035"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://check-cap.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r80",
      "r535",
      "r726",
      "r739",
      "r740",
      "r918",
      "r923",
      "r944",
      "r1032"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r128",
      "r165",
      "r167",
      "r168",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r406",
      "r408",
      "r409",
      "r447",
      "r726",
      "r959",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r39",
      "r40",
      "r41",
      "r42",
      "r165",
      "r167",
      "r168",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r406",
      "r408",
      "r409",
      "r447",
      "r959",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_LimitationFromTheYearOfElectionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "LimitationFromTheYearOfElectionTerm",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limitation from the year of election term",
        "documentation": "Represent the limitation from the year of election term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Limitation From The Year Of Election Term"
       }
      }
     },
     "auth_ref": []
    },
    "chek_LoanReceivableExchangeAndEquityInvestmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "LoanReceivableExchangeAndEquityInvestmentLineItems",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Technology Capital Corporation - Loan Receivable, Exchange, And Equity Investment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansAndLeasesReceivableDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansAndLeasesReceivableDisclosureLineItems",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Loans Receivable and Gain on Debt Extinguishment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT EXTINGUISHMENT",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r937"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/GeneralInformationDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to Apollo",
        "verboseLabel": "Loan amount",
        "netLabel": "Loans payable",
        "label": "Net payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r1051"
     ]
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansReceivableBasisSpreadOnVariableRateDuringPeriod",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans receivable rate",
        "label": "Loans Receivable, Basis Spread on Variable Rate, During Period",
        "documentation": "The percentage points added to the reference rate or index during the adjustment period to compute the variable [fully indexed] rate on the loans receivable realized during the reporting period. This may be an effective margin for the period depending on the specific terms of the underlying loan agreement (for example, an annual disclosure for a loan with a quarterly adjustment period)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansReceivableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansReceivableFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan receivable",
        "label": "Loans Receivable, Fair Value Disclosure",
        "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r724",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "verboseLabel": "Loan receivable",
        "netLabel": "Investment cost",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reduction of R&amp;D Expenses [Line Items]",
        "terseLabel": "Commitments and Contingent Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r245",
      "r246",
      "r247",
      "r250",
      "r357",
      "r698",
      "r956",
      "r957"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/EarningsLossPerShareDetails",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r99",
      "r100",
      "r102",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r207",
      "r246",
      "r247",
      "r248",
      "r249",
      "r307",
      "r338",
      "r339",
      "r340",
      "r357",
      "r431",
      "r483",
      "r547",
      "r549",
      "r557",
      "r581",
      "r582",
      "r639",
      "r644",
      "r648",
      "r649",
      "r652",
      "r658",
      "r659",
      "r661",
      "r662",
      "r674",
      "r675",
      "r697",
      "r705",
      "r708",
      "r712",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r737",
      "r963",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/EarningsLossPerShareDetails",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r99",
      "r100",
      "r102",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r207",
      "r246",
      "r247",
      "r248",
      "r249",
      "r307",
      "r338",
      "r339",
      "r340",
      "r357",
      "r431",
      "r483",
      "r547",
      "r549",
      "r557",
      "r581",
      "r582",
      "r639",
      "r644",
      "r648",
      "r649",
      "r652",
      "r658",
      "r659",
      "r661",
      "r662",
      "r674",
      "r675",
      "r697",
      "r705",
      "r708",
      "r712",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r737",
      "r963",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "chek_NetCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "NetCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net value",
        "documentation": "Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts.",
        "label": "Net Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided in (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r63"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow",
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable",
      "http://check-cap.com/role/ShareholdersEquityType2or3",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r63",
      "r84",
      "r122",
      "r126",
      "r143",
      "r145",
      "r150",
      "r165",
      "r167",
      "r168",
      "r171",
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r194",
      "r224",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r277",
      "r280",
      "r282",
      "r285",
      "r346",
      "r400",
      "r403",
      "r428",
      "r447",
      "r540",
      "r608",
      "r629",
      "r630",
      "r686",
      "r688",
      "r690",
      "r749",
      "r959"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "chek_NonExecutiveDirectorsCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "NonExecutiveDirectorsCompensationMember",
     "presentation": [
      "http://check-cap.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation to non-executive directors [Member]",
        "documentation": "Non-Executive Directors Compensation [Member]",
        "label": "Non Executive Directors Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "chek_NonExecutiveDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "NonExecutiveDirectorsMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-executive Directors [Member]",
        "documentation": "Non-executive Directors [Member]",
        "label": "Non Executive Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r796",
      "r812",
      "r838",
      "r847"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired under operating lease",
        "label": "Noncash or Part Noncash Acquisition, Other Assets Acquired",
        "documentation": "Amount of assets, classified as other, acquired in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financing income, net",
        "terseLabel": "Finance income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable": {
       "parentTag": "us-gaap_NotesAndLoansReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan receivable \u2013 gross principal",
        "label": "Financing Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r657",
      "r682",
      "r945"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loan receivable",
        "terseLabel": "Loan receivable",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r939"
     ]
    },
    "chek_NotesReallocation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "NotesReallocation",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "reallocations",
        "documentation": "Notes reallocation.",
        "label": "Notes Reallocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in notes",
        "label": "Notes Reduction",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "verboseLabel": "Office Furniture and Equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r686",
      "r690",
      "r694",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities \u2013 current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of Use Assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/ScheduleofAccumulatedIsraeliNetOperatingLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening accumulated Israeli NOL",
        "periodEndLabel": "Closing accumulated Israeli NOL",
        "terseLabel": "Operating loss or NOL carry-forwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL INFORMATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r123",
      "r124",
      "r125",
      "r559",
      "r560"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Accrued Liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r726"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reduction of R&amp;D Expenses",
        "label": "Other Commitments [Table Text Block]",
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://check-cap.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofEmployeeBenefitsandPayrollAccrualsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for payroll, bonuses and wages",
        "label": "Other Employee-related Liabilities, Current",
        "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails",
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "verboseLabel": "Other expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r739",
      "r740"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r1086"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/FinanceIncomeExpenseNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCE INCOME (EXPENSE), NET",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r998"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financial expense (income), net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable",
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Reduction of R&amp;D expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794",
      "r810",
      "r845"
     ]
    },
    "chek_OutstandingAmountsOfLandlordClaim": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "OutstandingAmountsOfLandlordClaim",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims total outstanding amounts",
        "documentation": "Outstanding amounts of landlord claims.",
        "label": "Outstanding Amounts Of Landlord Claim"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r813",
      "r848"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r797",
      "r813",
      "r848"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "chek_PaymentsExpensesForPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PaymentsExpensesForPatents",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost for registration of patents",
        "documentation": "Represents amount of payments /expenses for patents.",
        "label": "Payments Expenses For Patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid compensation and contractual entitlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLoans",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable against the loan receivable",
        "label": "Payments for Loans",
        "documentation": "Cash payments for and related to principal collection on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes (investment) in short-term bank and other deposits",
        "label": "Payment for (Proceeds from) Other Investing Activity",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r913"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease monthly fee",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquireLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLoansReceivable",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of loans receivable",
        "label": "Payments to Acquire Loans Receivable",
        "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "chek_PercentageOfComparableCompanyMethod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfComparableCompanyMethod",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of comparable company method",
        "documentation": "Percentage of comparable company method.",
        "label": "Percentage Of Comparable Company Method"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfCostEquity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfCostEquity",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cost of equity",
        "documentation": "The percentage of cost equity.",
        "label": "Percentage Of Cost Equity"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfDiscountedCashFlowMethod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfDiscountedCashFlowMethod",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow method",
        "documentation": "Percentage of discounted cash flow method.",
        "label": "Percentage Of Discounted Cash Flow Method"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfImpliedRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfImpliedRate",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Implied rate",
        "documentation": "The percentage of implied rate.",
        "label": "Percentage Of Implied Rate"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfManagementAssessedEquity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfManagementAssessedEquity",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of management-assessed equity",
        "documentation": "Percentage of management-assessed equity.",
        "label": "Percentage Of Management Assessed Equity"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfShareholding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfShareholding",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shareholding",
        "documentation": "Percentage of shareholding.",
        "label": "Percentage Of Shareholding"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PercentageOfValuationInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PercentageOfValuationInterest",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation interest",
        "documentation": "Percentage of valuation interest.",
        "label": "Percentage Of Valuation Interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r234",
      "r235",
      "r683"
     ]
    },
    "chek_PrepaidGovernmentInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PrepaidGovernmentInstitutions",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government institutions",
        "documentation": "Represent the amount related to government institutions.",
        "label": "Prepaid Government Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "chek_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "label": "Private Placement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollectionOfLoansReceivable",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans receivable",
        "label": "Proceeds from Collection of Loans Receivable",
        "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares in the registered direct offerings, net of issuance expenses",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid fees",
        "label": "Proceeds from Legal Settlements",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties received (in Euro)",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r468"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r131",
      "r539"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r468",
      "r528",
      "r539",
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r88",
      "r89",
      "r537"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://check-cap.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r468"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/EarningsLossPerShareDetails",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r99",
      "r100",
      "r102",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r207",
      "r246",
      "r247",
      "r248",
      "r249",
      "r304",
      "r307",
      "r338",
      "r339",
      "r340",
      "r345",
      "r357",
      "r431",
      "r481",
      "r482",
      "r483",
      "r547",
      "r549",
      "r557",
      "r581",
      "r582",
      "r639",
      "r644",
      "r648",
      "r649",
      "r652",
      "r658",
      "r659",
      "r661",
      "r662",
      "r674",
      "r675",
      "r697",
      "r705",
      "r708",
      "r712",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r737",
      "r743",
      "r954",
      "r963",
      "r1024",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/EarningsLossPerShareDetails",
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r99",
      "r100",
      "r102",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r207",
      "r246",
      "r247",
      "r248",
      "r249",
      "r304",
      "r307",
      "r338",
      "r339",
      "r340",
      "r345",
      "r357",
      "r431",
      "r481",
      "r482",
      "r483",
      "r547",
      "r549",
      "r557",
      "r581",
      "r582",
      "r639",
      "r644",
      "r648",
      "r649",
      "r652",
      "r658",
      "r659",
      "r661",
      "r662",
      "r674",
      "r675",
      "r697",
      "r705",
      "r708",
      "r712",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r737",
      "r743",
      "r954",
      "r963",
      "r1024",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Loans Receivable and Gain on Debt Extinguishment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ReclassifiedAcquisitionTarget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ReclassifiedAcquisitionTarget",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified of third apollo loan",
        "documentation": "Reclassified acquisition target .",
        "label": "Reclassified Acquisition Target"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r805",
      "r840"
     ]
    },
    "chek_ReducingCarryingValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ReducingCarryingValueNet",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value",
        "documentation": "The amount of reducing carrying value net.",
        "label": "Reducing Carrying Value Net"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ReductionInIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ReductionInIncomeTaxRate",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in income tax rate",
        "documentation": "Reduction In Income Tax Rate",
        "label": "Reduction In Income Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "chek_ReinstatedRecoverableLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ReinstatedRecoverableLoan",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinstated recoverable portion of the loan",
        "documentation": "Amount of reinstated recoverable loan.",
        "label": "Reinstated Recoverable Loan"
       }
      }
     },
     "auth_ref": []
    },
    "chek_RelatedPartiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RelatedPartiesTablesLineItems",
     "presentation": [
      "http://check-cap.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_RelatedPartiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RelatedPartiesTablesTable",
     "presentation": [
      "http://check-cap.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r217",
      "r305",
      "r306",
      "r474",
      "r475",
      "r531",
      "r536",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r606",
      "r638",
      "r1085"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with related parties",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
      "http://check-cap.com/role/RelatedPartiesTables",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r474",
      "r475",
      "r1039"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r1039"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r217",
      "r474",
      "r475",
      "r476",
      "r611",
      "r612",
      "r615"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r217",
      "r305",
      "r306",
      "r474",
      "r475",
      "r531",
      "r536",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r606",
      "r638",
      "r1039",
      "r1085"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r475",
      "r477",
      "r572",
      "r573",
      "r574",
      "r613",
      "r614",
      "r615",
      "r635",
      "r637"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total research and development expenses, net",
        "terseLabel": "Research and development expenses, net",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r677",
      "r686",
      "r687",
      "r695",
      "r1048"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable",
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, net [Member]",
        "verboseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/ResearchandDevelopmentExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES, NET",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r676"
     ]
    },
    "chek_ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ResearchandDevelopmentExpensesNetScheduleofResearchandDevelopmentExpensesNetDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses, Net - Schedule of Research and Development Expenses, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_RestOfCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RestOfCountryMember",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of Country [Member]",
        "documentation": "Rest of the Country [Member]",
        "label": "Rest Of Country Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r790",
      "r806",
      "r841"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r791",
      "r807",
      "r842"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r798",
      "r814",
      "r849"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r129",
      "r162"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash included current assets",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r916"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "verboseLabel": "RSU [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r70",
      "r534",
      "r554",
      "r556",
      "r570",
      "r590",
      "r726"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r188",
      "r225",
      "r226",
      "r239",
      "r276",
      "r346",
      "r388",
      "r389",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r415",
      "r417",
      "r418",
      "r420",
      "r426",
      "r462",
      "r464",
      "r551",
      "r553",
      "r575",
      "r1087"
     ]
    },
    "chek_RoyaltiesProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RoyaltiesProvision",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails",
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties provision",
        "documentation": "Amount of the liability recorded to pay royalties.",
        "label": "Royalties Provision"
       }
      }
     },
     "auth_ref": []
    },
    "chek_RoyaltiesSoldComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RoyaltiesSoldComponent",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties sold, component",
        "documentation": "Royalties sold.",
        "label": "Royalties Sold Component"
       }
      }
     },
     "auth_ref": []
    },
    "chek_RoyaltiesToAnASICDesignerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "RoyaltiesToAnASICDesignerMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofReductionofRDExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties to an ASIC designer [Member]",
        "label": "Royalties To An ASICDesigner Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and related expenses",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r51",
      "r218",
      "r940"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value Summary",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r51"
     ]
    },
    "chek_ScheduleOfAntiDilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfAntiDilutiveSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Anti Dilutive Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "chek_ScheduleOfCarryingValueSummaryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfCarryingValueSummaryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Value Summary Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impairment of Loans Receivable and Gain on Debt Extinguishment",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r919",
      "r926",
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings (Loss) Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Statutory Israeli Corporate Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r711",
      "r1000"
     ]
    },
    "chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/EmployeeBenefitsandPayrollAccrualsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Benefits and Payroll Accruals",
        "documentation": "Tabular disclosure for employee related liabilities.",
        "label": "Schedule Of Employee Related Liabilities Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/FairValueMeasurementsDetails",
      "http://check-cap.com/role/ScheduleofCarryingValueSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r396",
      "r447",
      "r892",
      "r893",
      "r894",
      "r1012",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "chek_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/FinanceIncomeExpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Income (Expense), Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r468"
     ]
    },
    "chek_ScheduleOfReductionOfRDExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfReductionOfRDExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reduction Of RDExpenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable",
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r474",
      "r475",
      "r476",
      "r611",
      "r612",
      "r615"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037"
     ]
    },
    "chek_ScheduleOfResearchAndDevelopmentExpensesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ResearchandDevelopmentExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses, Net",
        "documentation": "Tabular disclosure of research and development expenses, net.",
        "label": "Schedule Of Research And Development Expenses Net Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfRsusActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfRsusActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsus Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ScheduleOfShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Parameters Used in Applying the Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "chek_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Transactions With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "chek_SecondApolloLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "SecondApolloLoanMember",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Apollo Loan [Member]",
        "label": "Second Apollo Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuritiesSegregatedUnderOtherRegulations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuritiesSegregatedUnderOtherRegulations",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segregated account",
        "label": "Securities Segregated under Other Regulations",
        "documentation": "Fair value of securities deposited in a special reserve account for the exclusive benefit of customers pursuant to regulations other than SEC Regulations and the Commodity Exchange Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r115",
      "r116",
      "r117",
      "r206",
      "r215",
      "r216",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r524",
      "r525",
      "r526",
      "r578",
      "r579",
      "r580",
      "r641",
      "r646",
      "r650",
      "r654",
      "r658",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r679",
      "r693",
      "r706",
      "r707",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r738",
      "r743",
      "r1053",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow",
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of RSU",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested \u2013 beginning of year",
        "periodEndLabel": "Unvested \u2013 end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Parameters Used in Applying the Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r311",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg Exercise Price, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number, Options forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number, Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number, Options outstanding",
        "terseLabel": "Outstanding options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Wtd. Avg Exercise Price, Options outstanding",
        "terseLabel": "Options outstanding exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg Exercise Price, Options exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average of exercise Price, Options forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable",
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg Exercise Price, Options granted",
        "verboseLabel": "Granted shares exercise price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "chek_ShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareBasedCompensationDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ShareBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareBasedCompensationMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation [Member]",
        "documentation": "Share-Based Compensation [Member]",
        "label": "Share Based Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r316",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355"
     ]
    },
    "chek_ShareBasedCompensationScheduleofOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareBasedCompensationScheduleofOptionActivityDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation - Schedule of Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ShareBasedCompensationScheduleofRSUsActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareBasedCompensationScheduleofRSUsActivityDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ScheduleofRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation - Schedule of RSUs Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://check-cap.com/role/ScheduleofParametersUsedinApplyingtheModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Remaining Life, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wtd. Avg. Remaining Life, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "chek_ShareholderVotingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareholderVotingPercentage",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails",
      "http://check-cap.com/role/ImpairmentofLoansReceivableandGainonDebtExtinguishmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholder vote",
        "verboseLabel": "Voting percentage",
        "documentation": "Shareholder voting percentage.",
        "label": "Shareholder Voting Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "chek_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "chek_ShortTermBankDepositPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ShortTermBankDepositPolicyTextBlock",
     "presentation": [
      "http://check-cap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Bank Deposit",
        "documentation": "Disclosure of accounting policies short term bank deposit.",
        "label": "Short Term Bank Deposit Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Bank Deposit",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r909"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails",
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r48",
      "r49",
      "r120",
      "r121",
      "r122",
      "r148",
      "r149",
      "r150",
      "r173",
      "r174",
      "r175",
      "r177",
      "r184",
      "r186",
      "r188",
      "r204",
      "r225",
      "r226",
      "r239",
      "r276",
      "r302",
      "r346",
      "r388",
      "r389",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r464",
      "r470",
      "r541",
      "r551",
      "r552",
      "r553",
      "r575",
      "r631"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails",
      "http://check-cap.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r115",
      "r116",
      "r117",
      "r206",
      "r215",
      "r216",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r524",
      "r525",
      "r526",
      "r578",
      "r579",
      "r580",
      "r641",
      "r646",
      "r650",
      "r654",
      "r658",
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r679",
      "r693",
      "r706",
      "r707",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r738",
      "r743",
      "r1053",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r204",
      "r278",
      "r279",
      "r281",
      "r283",
      "r464",
      "r484",
      "r561",
      "r576",
      "r577",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r631",
      "r688",
      "r690",
      "r744",
      "r1085"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r204",
      "r217",
      "r278",
      "r279",
      "r281",
      "r283",
      "r464",
      "r484",
      "r561",
      "r576",
      "r577",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r631",
      "r688",
      "r690",
      "r744",
      "r1085"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r809",
      "r844"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails",
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares - Ghost Kitchens ARA (in Shares)",
        "verboseLabel": "Issuance of ordinary shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r70",
      "r566",
      "r631",
      "r655"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU vesting (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r70"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://check-cap.com/role/ScheduleofOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number, Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r70",
      "r322"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares - Ghost Kitchens ARA",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r70",
      "r575",
      "r631",
      "r655",
      "r750"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r70"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://check-cap.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r1018"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet",
      "http://check-cap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r48",
      "r49",
      "r64",
      "r591",
      "r607",
      "r632",
      "r633",
      "r726",
      "r751",
      "r918",
      "r922",
      "r923",
      "r944",
      "r1032",
      "r1087"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r286",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r302",
      "r414",
      "r425",
      "r634",
      "r636",
      "r656"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails",
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse share split",
        "verboseLabel": "Reverse share split ratio",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "chek_SubcontractorsAndConsultantFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "SubcontractorsAndConsultantFees",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractors and consultants",
        "documentation": "Fees for the services provided by subcontractors and consultants during the period.",
        "label": "Subcontractors And Consultant Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://check-cap.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://check-cap.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Israeli Net Operating Loss",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement in Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "chek_SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "SummaryofSignificantAccountingPoliciesandGoingConcernDetailsTable",
     "presentation": [
      "http://check-cap.com/role/SummaryofSignificantAccountingPoliciesandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies and Going Concern (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SuppliesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SuppliesExpense",
     "crdr": "debit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable": {
       "parentTag": "us-gaap_OtherResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofResearchandDevelopmentExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials",
        "label": "Supplies Expense",
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_TechnologyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TechnologyEquipmentMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment [Member]",
        "label": "Technology Equipment [Member]",
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1038"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://check-cap.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "chek_UncertainTaxPositions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "UncertainTaxPositions",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "uncertain tax positions",
        "documentation": "Uncertain tax positions.",
        "label": "Uncertain Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://check-cap.com/role/ScheduleofFinanceIncomeExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of derivatives",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r624",
      "r625",
      "r626",
      "r627",
      "r651"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and penalties related to income tax amount",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r710"
     ]
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movement in Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://check-cap.com/role/ScheduleofMovementinValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase \u2014 current year tax loss \u00d7 23%",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "chek_ValuationOfFairValueMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "ValuationOfFairValueMarket",
     "crdr": "debit",
     "presentation": [
      "http://check-cap.com/role/ApolloTechnologyCapitalCorporationLoanReceivableExchangeandEquityInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value (in Dollars)",
        "documentation": "Amount of valuation of fair value market.",
        "label": "Valuation Of Fair Value Market"
       }
      }
     },
     "auth_ref": []
    },
    "chek_VotesCastPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://check-cap.com/20251231",
     "localname": "VotesCastPercentage",
     "presentation": [
      "http://check-cap.com/role/GeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Votes cast percentage",
        "documentation": "Votes cast percentage.",
        "label": "Votes Cast Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://check-cap.com/role/ScheduleofAntiDilutiveSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and share options [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r745",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://check-cap.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding - diluted (in Shares)",
        "verboseLabel": "Weighted average ordinary shares outstanding \u2013 diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r197"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://check-cap.com/role/ConsolidatedIncomeStatement",
      "http://check-cap.com/role/ScheduleofEarningsLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding - basic (in Shares)",
        "verboseLabel": "Weighted average ordinary shares outstanding \u2013 basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r197"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477011/948-310-45-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001213900-26-048090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-048090-xbrl.zip
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MF]'+I*@=D'+UV(LFEX(+L=?8;366;<++.!6-XO@T@+Z%=G[_"0 ./O1]',"
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M"4U4?'S)G#&G)27O1OSC1]$G/7[_Z;]02P,$%     @ "8J;7$WDT?!*#P
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M-KK6Z]MCB1U\C0Q'% ^88FP,=^QAAK5Z]^@5?M4N$&FK.?_1#'@:O%>VP$%
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M(OR.S:(G59<3>Y=KKD=G4\]J*.S%G#7%O-6)E02?B7DU\I;B<]FCB#ZF*=5
MKSZ)K)%&%M+,,I7:()-H3=.ZG4R35]2\M<ZF@R6#VX2C%D"U:PW>9MMD^XE0
M90"6@$-FIGT0$U[:*-8T7&23G,#L-:E K,-?F82&;D2)D#S#A_?<\;89W#("
M\/>09CITN']HZ<UY'ILAVZYE3 53DES&3>"#5_H\95\&FBNE1MP!D55QFRF1
M2=LMA ];R>[0XV)&="&\RAS6=IWU254\F6P^K7,/:E!(VD_;QK(3Z,0T+ &[
MUQS6H-?+Z>[*7D-8KOZK'J:6[]CJYB\?S@+[#3,M;\0&%X0"":$;WHFG1ES3
M:W1YLVU<G,TE=WC4,2,Y?TNV@+35R3!:,=]G]\1=!,QG\TT2(CQF?,6X,I3)
M,]ON@);F"TE";J--G'0*ZKJ@;E%-=1H5=2J?>9J+*8;<!K=M0#7L+N8H@EN?
MI]A#:'O9Q^&IY3=:#R'Y8RU-?8_0 0#[;6/Y1W5B&GI&]YI#\X1JY73G^:PA
M+.?SU,/4[O95>-MUME%_ G7X#^\E86R-S#RLC$&Q--16?-_S9X#U_<>HE';F
MA#2<S/94W%1B?_"8,13:<\)L(<0H3IY[9(U+6J6H@5!5#1=&>;7RM!;(3!G)
M' IE9@!"5F)3*_'=@G%QR.7+,R?X<DY6+*11DQW)I)V>4V&.!T;Y->V#1=Q)
M9"RVY^39PXA1J>T#8]X3]:6;^2J(Q)62RNI#ZB4V+HT6@@="I V4**7:=A5*
M^3D-Q4+@^+)6:3"_IH]IJDY<4ANI,!!ZF\&+4Z(MM?4@LZF5,Q3*]$!A5%*K
M#'S+6Q+:B(!,) Z$*R/P,(JEE8<&3U;)0]PK<>4/9-R5>H*+PF(3#0;":B-P
M4:JK;5^@8J^9&C$#(4P/$TJ5M'T_/BXY==(&PE$M:"@ET+9O\C(Y J\"H>5Z
MN;OX Q-F)G,@M!D"B%(/+4[3$F=GP9UC59(&0E0E6$@5S9XR*G(6B#^Z)#,L
M<#FS%C\0(NUAQ:EPQL*(J/=H4G0VHPO*HEDK;B#LU<,&6L1,&5/3%(?9B@L-
M;,L&S?2<!&,T3$J/M9OU]%X%_T/Z[$^Y3QM+17N8?*@ZQY1%]7!N^I!J%7[>
M'GW"U=9];#V8/[#)5?N;JA)^.AQ[PLK8'2[^ZZU]<<E.Q24!\YG\;@I:RV@!
M^V8[SWW1*!]E8Q"[2DD)/T^&G)ARQUQZ*!"M)\7[ M,Y<+A'HZ$60TEGV1AE
MC$C1I#C*9+;+PLS"4)5GFC'^Y' /,?+<0O1@R+7"$R-X=*N!-!?'*[7OLR?Y
ME!R=R2J1@V.P$C^,J-+=PB#W619(4^-DME4_L5LD&W-+2["])H/A^1"T(0-3
MBPK%]<_I(]EJ(ZNB3XG+ E?L#6I0ML1_ U6&-P":X&T0%-MJVFGXD^RQ)Y^.
MC;\[0:@SJD;8<)-+UZ'8@TRC>,:0KSW?Z&X)+62N',FSKLI(&P=LA;OC5!BN
ME_&_M;2)@2C7N44&-!LI-',H=]."(:D: E\U)T,$9W+OG@?*C4$X9;%SHX73
M$K">QSKFP/E$N4B73)&L?MDI,I+'1QIM6E_0+!4ZU@'5G"'<BWRY7KOZZ$K#
M3X&TL\M5MQ?#R%:[KVM,67-G8"IH,6TW_%GX6))W[_FN*D5LD6SJ![1M?3CY
MN ^%L5?)N.%GR]&EY-Y179MS^I )8]GXX!)V-X=Q /F[,3:=_F?Q#GF4<S*(
MW@;R,.&$BTN?/=U%XE"R1<?JL"=:SG1!_&VG?D.A?<W7W13#/B3JQH@M.89T
MW3L^E>WXA@4L]97G)+5T";)28E )O)L"W7DF;P2#_2#S>6<,9GL-R^QDKCQ3
M4W\=R0"B=IS!5EH,(A=X8XAQ#=ZC(**>%"P.?G?$77/EX[UX=OVUF .7HKMQ
M9:/$/-I6XG<$!0<V2N"(,3!98Z6:AUM?U=VEK'&A&[D29[,P/P(U][SJ%AK<
M2LL:5/]MK$[\-<YH=7P_/T;-8=U>("MZ7%RJF#A-/$<7OCH[BU,VF2=YTP'3
MV90FFA\]TQ!X3:J2A$/70GS)W?4#>27^51R@Z*Z8:0U]N2%HD)<_A@LEI8E&
MXKE:.-NA*)&%M .DU+SR<ETRJJ&0':8&-*6@89P)*D7^]N:XF"(S9^U'^%1)
MW"!=QFK"B_O5Q;,X$LBCP3GEQ!6_%V9=1Q]SIY'*'<BTK;X5'\DO']O-R1@:
MR!F4+828K75B08/^ZX$ 7]%]W) )7:&9EFZJAN*[J0EB?+!K#NM02_< WTR^
MW@(^)3?7.'5'7/52^6Z$M"275##?Z=*"[<!:DZ.LW0-"4;OAU8FF;&:<2@72
MB)L7FD],D4K&RLU@+KG!(25I_@-[)#R0PT5F=J/16BWM1@M.=0L=IENP9FQ[
M=*D!!>.NE5<W41!U**4RAL90#6(89\ND.D&8TPV8G'(90R5'@QA&Q&M1,6!F
M2@0,E98RK##>DQJHV?XV.5C6C-!L]5%H]C2FSXD%>P#3)$+2>'OP4DDU=0X5
MS]SZY$Y%=Q'@':A&;$M^)GMBRR\N=2!VX8'2ZG2VN1>?(WBB3"1VY)%J.NZ-
MTJ!E 47Q5>EU%1^C>*Q,)';IM[(8W&:9[#) XMRL:@6#^[)ZP6&51PN/1&C_
MUO;H.IM1EVP%EGE2#C_IE\KH7\;(XMJ3.^27(X4QMW8&2EQB]'*&1DX%8CCE
M7&5$&.&X].BD#(T<+5H8=@NMCA\X"UL['\;"^D=4Y>F_#CJ,I6[DNNOE6KE
MS\F*$S?.S23^[!,%6."-EHQ'],^X%K!.16!BP=0:V!" HP,\&">C6J;VHNF(
MT+EU;1L=")\-$6MU0;XAK25<EZ(&PIP9;*VF(-B9)0W3E$-:*(\]2WEFY174
M>;\X<8(<''.^1DCG^3X:I2:O0P[CN*)<!/HDZ(B>LGJAPV;1%%F,ZUS;A!X[
ME^8T5ITT,#8PL7D64K2#;UG9[,/%A/!HZ54-9!Y6ZVG;GCX3^CE;DC"B+G#O
MFFC090)6<_K+ZC99X8RQRUDH<LDXH7-H9TT#!8Z:[BW*.&%8>WI@6,HT0HZ
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M\6N@KXZV[UNV#NT"16*?>YI!-35WP3\#*[6JE<%8'N&"]#@,2*M3B%4/0JR
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M8MPVQ,"XL4[24)LM+-O[ACDR&-</M9++Q*7Y7+\?N-CZXQ1FT(]B3"1V=MV
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ML);V%B.H]Y)Q0N<!YLI1*J+7%%2#@Q&8>S&;$5?6Y=FJ)\.VIK+&LBOS%RJ
MHDLB)#N^-/^N9>K/W"\#LP:A4?<DUX4H@>(/OJ&HTX5/O"2ZLAA>KPL[+?FN
M_USHNPR?0I@N::1(O12ZWB_(/XG#)[,+GZA\Q\9 F[0S$."-( '/F3HEWEJU
M?Q54+&;:K5WS\4 @UW<>]^T'"T.5F6_&^)/#/;RD 05!_2?&!"V,Y%^9I)>J
MO*7,8<R)S*V[W92D)C=$' M%-X ILY4^'!ZM<<7("W9.9H1SXLE3IWIOU-I<
MM)$\'%*M\,1('&:A0'*'Z([75(&CI'>++D9Y69-+0:) [C?.J?B0$]%9!SIA
M(XA*PQD), P8E*2U?,2S32XUF>WEOS,ZN%9]WW]RZB%( /\!<C)^$/J'<OZ3
M<!)</$L-US1<Q!J<DP?HY\OU\OK/E 5V*$]Z[A8.)V?RF;4\=HDS%T9.08V0
MX;"C0PFETN-NF<PMHN(?+I[)<I6D#(?VUIL)'0YEIBBB5(O+IIX4?_9)NWD[
MM2*'0Y\9@J !N6K3_"3+$<IB%T+76_DX6\@)C4X,Y5_V'_&J;H.&&*::?0H$
MLVP>T#_5_2'-2[!5^)8$CA]1(FM#7061."2&T<6S7'6A%[U#-.D_L2!XIR.@
MRM@"EY5 [*Y+&M=?< )OV\'HFCH/8@672B)D*U!7UBV8%"])2H6@)I$YQF"9
MYR^P;;/EO ;U3&4KS-FATW;JUWOI1)-I]#WZ2+TUV*O \G:[#'!O.%#3"#<-
M4."Y8 MR/M-HH<KLR<UP05?WS#!"OC%5-1*[>E%8.52U--7!!QWW::D R,O#
MWC&H>X^(02'6"\74"Y0N&@CO$TM%#'2-K(8-Q42Q+PKEQ:)&2)?O%:M&9A45
MF&\5RV6!OU3LBHVJ=XJ'T8&1[N&<BKN6^!'8XX.]!CMY?=#P8)3N*ON8( 1U
MAW0>$#YEF_@B:Q757?YM=\E/*Y?63%"WIL_@Z,:OH*Z"@#W&,9;;QU "F##B
MF\GL0ER5V'*C[ ?>.K2+_CZD_;ZS=!!VX"&59S106CA^(HHZ_I2$1/1;UH;-
MO!.X9.O 4[]K0>0!S?>=QT.0PW@2<,N92X@7RCC0[0H0NW<)=-&!:EF=,6=F
M"C($#'S1W,JX8[[R&;*@D U?%S);_FG/@:[L-?Q+HU20X/619J]49M#N/AL4
MK)G>@H=Y7XIU*YT05\$]BQQ_M)2O:HR0U7\]!( K^HX1YOV!.V*KT04D'1X6
ML]]\SRG0PP(9Q9U86?;M*AM#MTCQNYZCJN\O9/AT<A?A5)YO'XG%BE'X: AX
M%GN*$;J<*16CTJ[<D2B*G5#09M J23WGPP@LC)#C[%$2FYXJ44/AIQ(N\+C?
MR3H*(R>0A>3C*1K&I<=\(6GL.]3LT6!]*SU'WQ0+@S!@N.B.;>'QC\21E3'B
M&S=\/$=)@7/U2$'<U+?;X V+$BV\4;3]H( EU/MZ (V:G.DK #>/":EOI>4H
M$$!^=U> >JA:KPTL%//6TO(N:VK+Y%/1@HG[R2,)E;&J^*^$V-3*J$NJ>XCX
M+EVIQJ-^FX+W(*#!XU!TXL#"3FH$=):W&F"\IY3680@=>U(M#R34I&O6M)FN
M6Z,-/+&D7"U&*^;[[)ZXBX#Y;+X9.RL:.?Z8\17CMBX0X\8Z\>.:+2S;+=$<
M&8RPADL:..)\*STNH6A&+>*RREIV.X<^I9F([.S@#WSJL<,9@^'RY6)724]L
M]>+OSAP\;9*QW&/CV@)QC+B^:Q;,99*:G6CX /NBA&,CL11%#"=S1D!)5X"9
MJQ%V;"3688OA=MH*R@A7<5N4A/<+)QH[OJO2L-R([LD^JE\6BX)Z_9HL#O$2
M<D?<-5<?8AE*0'4\MM&#Q"2XN^UJN?(IV3XJT^WH^A0,FJ^/A<\ZD# 2'96?
M 5I8X2T$'PN_33#'<"B.?#&V B?.TI**!Z:W7,:Q,:E!$L//J-3=Y7 9BZ5[
M#K[?:H0<'6T:+ W<CW#N+[7Y+I@O1(;QBH#@^QK[3AA.9JHH/98WJUQ&@_.!
M%A%SYU1-$RU[IBK1W^[X==WNHNSZMEYAK- V>!/C\5VUK"Y=1V8#,I<9J!HW
ME)Q->Z)0'M^5R^CR[9W1""V>N@HPX9DR]T2!/\'KB).J%W@PI& ])+Y;/X34
MHP[?W#G20:7698P%32MG8(N9'B^49\09*=(/-9G=<R<('95P&V55,Q#8Z1)7
M-UYS9!F A['6U<L%7_CZ0%OE*@C+&]9RF)Q./SM<1MI/^)3.%Q'"<JB7,ZSE
ML (OE*R!I?)0UL$J25TN@+4CM)8>S)6O0B#XDM<I0U5K'11%*,$\M^IY!KGU
M'5>=2A/!-@D!:IKHS#)F?E;:VAGJT$"9(VRY9(%2$Z526;']SABIO(;G9D$1
M$_ 'QV-./!I)F]-HSDG3P5_?2F=H&VR.NV=O]6"@G(PEP[D3QI0\BC\3]8.[
ME4^AG2XF$KMF3&\,M<(->;'ZA<D7-6I0@1^'-5+Z3XP6'Y3;R4Z8.JJ'5V&X
M!L]FH9,R*#+R^&#$?A6$9=Z283.2%35 6G)(8<1Q*5DQ^>=K+L3<$DZ9%TN_
M(4_J1_ ^&R.A_>?+%#V,"G*E9QC$F54GKO]LU2-F$",%[,(OU %!<..7"QI)
M%.;J/'NVV?U*\@1^),MM%=!$+>%BI5#3  $=WI9! M7-M!PH ,=O/JJ@!JLN
M(@N4VO?B%Q$LS?FV.[<N&XW47%Q2'IL6*SQEAEJH&VL[[0+OUG<"NT>HD(M+
M$Q6[M&.7COGZ@E*'DH)BU$#0%-Y!.,@!5&5F[V0$H<5AR'/>9*5[3 MS.<FU
MWYV9'G&U+5QC\I!BS/XID<E.W8AX2N G@64XO?N$PF*UK*-GM 9JE'G9]!1Z
MLY9*B0N<NC6/'L4A1QYQ+AE72?SZ<O>H4[._8\KJ^(]/9[\.%O&R%\;Y(J^"
MV(#SF4C3 /%&CX0[<W+Q+ [M-"2W8DI!OV1J4_.O;8A"DMZK)3/1/V.[BF==
M7]9*K7Y?VPBT)Q## 0.H9I]61B"M3V.R&=DH[JBFRL>N_FS:&5F,X7[A!"9K
MO?KAN1,1K&Q _>G7:;1C#1@#)Q^<\VCW_I3-KID39%*=B[G[09 A#<8/T<6S
M#+58TW A?Q>EWJT0+E_4$H%P1HO=FULL+Y*-Y&;Y)IHC;.Y. A#3LKNI >/9
M_!0'@]J%WTD5*),+"(\VF5A9!"]4E:0N?5)PTR%OIZK %<6#I9&(XHJJEM6E
M3\E@/!O0A.DJJA0)[O/IF*DJYPTD5:>DIX>?8XT6D)[D/<W62Q@+18A2=;*_
M@ -/)E.I'98]:'2"L485@](](>)>0\.[%2>.-PE^<3B5_S@5 S0;CXAQ\+95
M8:AD-\,;PUH<WUC;RJW6JU1J!W)8@1QXZ;L;$HT=SC=B,)08DC2[7N&CH2&M
MZ3JDB7#_W77\B,0R#635]X/$O!(0C+!S3?I!E#6H*&5H'-6B=LK*>11$HF??
M5)/]XEF>.\4DM]]A-)\.C89*&# 29RH];YT-PC4IU_30B"C'![("7RKAAD52
M+V^M;EG '.PU/E06]C$RJ,1G>:J-!3B^^IT"#[IC;>&KH0&LZ[R):1K.V7?A
M\$ L<Z$LUY@F7D=PY:5B4A'RKNL68($Z*U0+:[([ZE$R=\?5-M*RL\V,D]W6
M6(M!VX4'I](1#U1%<-=6EYXPTW&6UB'+( !>WD^U;1Y ;X(OKGV]MG!?8;SD
M8,0PEN\U#E)?KU4D=<7T3*"$]@C)YC^*;B[72[!AF6^ODVIW)?,L!7.OM] C
M\Z/S# MFKKW>@9GO+889?2^2*XZ[/:?^6CZ6V4^Z,?)^7Z-4N&BJ17<)RHP/
M(@<#;3"%X,[6]0Y:>77871@NGMV%'+]"[32$,+4" 1[)U4&C7/"H*%AS1M<<
M<1LTBQ(58(NK^2$>2W9+9_\#R;>(/6A(P:EX^3"*ER//P5/)\U/)\U/)\Z^W
MY/EQFG=:6C1+K$*PI)RL0B>K4%^L0C6QL^'9)ON3]EY5E D^\K6G"14H!2JR
M8M!?7_3WR47%V-?1U=:SBQ;>6O3X@45C8EI>/+^B-VC=+X_Y]1#TZ?OI8=KI
M85KOF!KJP[14J'R1NGOCC[!4E@CX2E;(,FA3"D$CSO."T/+&:L5TN1SJQZ^>
M"NPDKCIIX&M?=XQ4+7N'47)Z@3OT%[B==K=7KXQ/L3ZG6)^V8WU:5=[,D]CQ
M+$R?Q*ASW%7@B8V'> $);4KU57S>V;)7=^S+/@?2]AT<:*G5C/%X9*22;]BC
MDG?)UEP,D>#^B=TOV#H4I^K[)Z'\YI(^EOIC-'0<+*3_I!V.(_YU,2[L=,MI
MX-*5XYLLR(U/M_NR6F<0(.C($$7P.:D>/NT_![PAD=%<TWX\1 9JX "_>$P)
M%3S+TZG0F<DX3Z&T[((A]+JO!XR]%A#P3!.[E_Z3V4<G<.)\EZ,P%/L?270V
MXL&HH<%28@83>*:*T9*M@^A 9FH;&2PK]?!@)*\XVM?<@+MWZ8MND/P4<3GM
M[*XTF>46S-)T9+KJX@;M#)$&<Y# TTMD5\IM7IE")5&#323W\6!)T,,!F6CB
M^-(:0>%ODMH(/M.$S!&03_DFTUJM.8=_ U8O;XC<6: )F:;B*\U/!4A878XJ
MV#S,22[^\))Q-4* "2HT/V1FBEB!AHQ7#X#)4T!XN* KW9Z$-)G*Y Z91 MT
M0>-M51?D0=*)L]1N4Y5]=/@70R-9Q>=#I*06$M  O]A)H?3*'BGWGD>;^6EJ
M6QDL'08 @487%8[X,A.4M$D0;^R$BTN?/<5SU?KVHVUHL-R8P932 V<KR,J5
MY7T<94Y5?PHV#=G1M7,4Y&A!2KG!,1:,61@UM#=G/CT2!G90I*##V0FRDK;[
MUY68C%PH:8U]L86CH* $F)0)$'.!$IBV?;5<^91X6YE&)&@_'BS^>CA2Z.%R
M46:Y3N3)!/S6PS_[[6"!UX*1NAO;R:)SSMPX'%;H'D1*]QGCR]R4."0?CD?H
M;ZF,3-,%7$INI"%Q_S)GCZ*K-+Z,BC_L[J"U#=L-4$US):EK#M>QU9PTI@3(
M@5D-0IO)8Z0F\7@<>1Z7[L4P^<.]^*KF.4@]*35-=_00Q&0,IC35@0-J^I,"
M,Q)J7W'4$U!LK8O'&N:C+(6]! 7(J*A2$97/,WH)==DK# "LH9]@2"%GZY#*
MN-.Q6,L<-ZJ-X*['N[S%UL\IE7,VA5C3>^@A'?,^%LL:=WP9[?O\,]D +.#[
M+78"LLWFJ@$"&N]4)4D\R.%%-=1[=//=AEXITM:G9$[#*'X6<"=C.VJ2C)JC
M7-[R8&#7  ,9/ID5-PJ"M>-/R8IQ&/AS#0X&]3P,D-&04DKB\;^DH>OX_R0.
MOPB\\\*=W1)P;:.]!UT/!V308U:KN"XA!.KE+?8><@T0D.&-63$[:B_%O\"8
M)_;;' SF!3 @(Q=S.[9\#*R0 %S/"XT.!O<B')"!BUE)=POB^XG+"1#ZDF8'
M WX9))!!B[M[P"7UD^3J '>A3&.]A[K8?<B PIV$]$0:/V@$ 'FOP8$ O0\#
MN&TP]1RXNP?3Z@(PEO$&?#-F'@3XU>T/A(L:D$## PLFM^1_4L6W</;S7*L#
MH:$4$-#HO2I9[U# ?S=<\-\!1^X59(W%'R?\GCT=YK;0M3DLX+-@@(;F%23=
MLC!R_'_1%= 64-KLL,#?@P0T]J[(=+RW ([YI,%A8;Z% 32:3AF$8L?)+>$A
M"P+B'WS.+&VP]VB7PP :1J?$2$HY<0Y>37(-]1_=7+=!0^)D\]?B)_[M@@40
ME]%"8[U'M]A]T,BWLNEQ(93WD[4)=+7(-=Q[Y*MA,8F#LV+ACKAK+J;2VW</
M]S0Z,*RKT%COT2YV/T48[+)YSQWYSOINLWQ@55F7ZN'-M]1[;/<ZG@(+=I%,
MN=OFVSKTF%':8.]A+H<A11OXYCAFRZ4TT3#W2Z'H)<"!NK+YWC-A E'*"_#5
M\C/Q_9\#<7F](X[8-XBG\I1!F-!U+0^$#2TP*1' =\Q?F"^N50Y7AGP.$9"[
MW^) @"\ D0(.=LU,IEL<?1 [I>1V$SG1@2[JRH8' K\.EI0%L.MG:L&/")>)
MJQ_)N1,Y]1E&S/T;I0T/A 4=+"D+"+Y3/G8B,F<@]JU\>P/!? ^$%&I@+^K%
MDO"YF%<?.'N*%HEG' #R\G8' KT&E#3^#NS2>N7.^&CM4?'34101F4Q,*'?I
M.X>=02N:[3T!59"D^(-'_5Y2<<Y=1A><,SYF8FUS07@P:+[W?)A E/("'P7L
MJJ0&\;8?> [W0/@H:78P/)1!DN(/?$?.QDH![ BYYGJ/=QD$*<Y@=]YDH9NL
M! 8LN"?/T9GXY2\'@:UKL_>(:\%(80>[X2:2#K:S9=L9"KPYJ]HW8'?8I/5+
MRI=7ARW2^9:& FO:\118L&MITK[T8Q43632#=MO64,#==3Z%%^R^.1*J>.I\
M<^AA+]]2_Z'-=SP%%NQVF7]E$+_O@'YTD6U5:/BW?W_UZL7_?/[XRW?_^S\W
M;S_\O)K1VTT83*//SOT'>CF_7'WS[IOY^73\^OZ_+V_'/[\)GT*/O?OSS7?N
M\W/TYP=G-'M[^^[7U>.OWWP^__/NP[]&GS]__["Z?/KERY\7[R_//KY_\_OY
M#\]_N,[UVW>_/#W^^FY,R/O%C<M'5Y__8_[TY8*?WVU6?[]Y'WS\X^[]E$^G
MKY]NO_SYFOWS[=-F,[U\6-+%?_SYYN?O%V_>C\-/W\Y^OWI:T%5P^7E"?__U
MY_#+7__QW?*7/R[^>W/S5^?,N0P>O_OVUR=R\_L?9P_?W-P\_'-Q=Q%=7GS^
M^>^?QG_?_.M?OSOLVU_??O-PR=9OSC]O'J;/3]'X[KU[[G_ON-^0Q]&OGS_.
MK\)O?[AX_,?CO]Z-EMS][U^OOO_'XA]_#R<_?/[GZ->/3W^=$V_C<>>C\]V_
MW.OEM^_#Q[OY^\=P_O'MZI_7T_=_?SWZAW?F_N^+\=WTU:N^C^J*49>^X;++
MO/*WU[+]!R<D__EO_Q]02P,$%     @ "8J;7)64TJV:H0  P X( !4   !C
M:&5K+3(P,C4Q,C,Q7VQA8BYX;6SLO7USXSB2)_S_?0H\/?%,5$78W5TU.[LS
MT[MWH;+E&NW9EE>6NW>B8Z.#%B$;VQ2I)2F7U9_^D !?10 $01*@:R9B7LHV
M@4QD_@ D$HG,?_T_K[L O> X(5'X;]]\^/;[;Q .-Y%/PJ=_^^;A_GQV?[%8
M?/-__O?_^M?_[_P<?<8ACKT4^^CQB#[%D>?'Q'_":!U[8;*-XAUZE^[>HW/T
MG*;[OWSWW9<O7[Y]+#[[=A/MT/EYUM=%C*&GOZ";*$2S?8P^_@OZ\$]_^?#Q
M+W_X WI87Z"/WW_\9_YY0,)?'[T$(\ILF/S;-Y7>7Q_CX-LH?OKNX_??_^&[
M_,-O^)=_>85?U+[_\@?V]8<___G/W[&_%I\F1/0A[?;#=_]Y<WV_><8[[YR$
M2>J%&R"0D+\D[)?7T<9+F?A:^4+2+^"G\_RS<_C5^8>/YW_X\.UKXG_SO_\7
M0O\:1P%>X2UB7/\E/>[QOWV3D-T^ &;8[YYCO!4S$<3Q=]#^NQ _@="!P)^!
MP(=_!@*_RWY][3WBX!L$7SZL%M+Q_+G6%V_TG2T>UU'J!4:,5EH.RFW:Y#3M
MRF!:Y2N ?U]3^AD7\(T"7*R+#,J5D>#7%(<^YNB!7J--[>\!P#:*\T:,Z+]]
M<TC.GSQO_\N%ESS#?^?_<R O7H##-)F%_OUS%*=K'.\6X0M.TAW\NBFKA++)
M6-QZR2/C,^N5\OOQC]_A($WRWYS#;YC0# A_EX\,6*^-+<9)=(@WA1YU))A6
M@-53)+\$CP%;5V@7L([B\/SA_IO_S0"(-K2+,_:_")<]G2$O]%$"G9VGM#?D
MXWV4D#3YU^\8&]6ASN*Z)KUXD[-,_]DRUNR+[S817<;VZ7E0'?$VCG9],)!&
MQN+ZS@BFLR3!:7)QB&/:T<!(K/=M&6PUXFH\\6^0QUHXA(M0%U5$-,?41^FW
ME*,1]5[IWHGJ2_I*[8=1>#XQ!#05TP3!R>CZX& 4[;O1N5+3$]&N7*<]-'E-
MO$<2D)3@D=9R 0'+&FYRH+6J!V4SAZJ7ZZ<* \D0>T-BM)5>3,,=, S6_,GA
M0[WZRP=KAI+[--K\^AP%/HX3,#33X\ 0$1"PC(\F!TIP),]>C+//?_^[/WW\
M\"\_L'-&>G2(#[F:JN"0C'18>>]Q3"+_/O7BM+O4OQ>(_9,7@$?HC4KW^U'$
M.P_][L+]\-4)]T/_O0^.S&.O<:WDW.V(0GZ4ZU]E0\Q<*A-<#W45+-DZY5(Q
MP]MR#UY]$CXMPDVTP]=1,O2I2D3!,JH$+$B 5'R)"/L4O0OHQ^\=XD6AH"I$
M9$,T0\4M3D?#0[UORTBH$9=@@'XS&>T+%5'5>W- PTKT!<>/48([R51D*KUM
MH7YO.(\NHMV>;D$X3,@+YEW2OI?;M?<Z]-V)@I+MRQ(Y*Y(95VLQ&9AH**]V
MZ=$R;,-3+M@PR?*0PN4S7,T/?<AM]._FS'7*A@0IV:$ O2,AXFU<(D2JG-KY
M0#@T%T<O$2.*8^V;%[+IJDW1FF*XGN36-4SL*&27F*]D:&M(36M8E 0J<*CX
MD$Q&_BDJOT4_P]?_Y?3(KJ&Z^NF];=S&%C3<@-_%T0OQL?_I^)!@?Q$69OIL
MDY(7=J(;WKS6)6S?]M;D3&&8L^") VU(S004%:<UKVCKUJ[LJ/,3H[.+> :%
M)8_(< !+$>%IP%+ 61LL]UD7 ,UW&4;?T_]F'4T:I H$:(!4)JQ!07I%0FJ6
M. "IB/ T0"K@3!NDCT>TS9M/&IH*O6M 4R8BPP-],[)M19$?DTV*??C#+/3K
MOZA\><>L='HTC+&7X$O,_W_^N@D.8++2?SQ3E>$5M4CFVRW>#'WG;9EY]S&:
M(XY.[3MDK=$[/^L'-@%)\">[J(@+MMC?IQ7W:0'?+;&C8ZO1P5(PI9GMQN/3
MBV69'U%[BB$O1>DS1H_XB80A[(#1EOWBB+WXK<Z_P:>3*T]5;Z9%7JWNX,#T
M3_^ A4S"AO?-\9,7DM_8JZF+*$RB@/CL!TKPCNJ!]L]^7&XSP\T+"A=-,GND
M''F#VT7#\&3/5S<(OY(EE#_S"] BA#=]K!OT<][&I6=O4.#4;LX'DZ9A*/MF
M$QU".#S?4=(;B/$8!^8*0O:P*V=" LC[PV[GQ4=8B._)4TBV9..%*2K[07E'
M;"G_',&O+@!/\420VZ[@6D"]6D!F&+O$6QS'="&/DC2Y\/:$GJ7(;QCPO?>(
M3Y&^I+M<S(/Y+TFR":+D$..1@-B7&WMH[<FI!-)9:S1_W>,PR8#+.D)9\#SB
M/4X#OP.!IPKR(>1J-A,R"IGHZX0RX8^$^BZ4[2&\ U>R!7KSC/U#@&&%?F/(
M-@!#%<5=93<:8NTCU;9S3X,E96CP/@,FK@(S8L"<S!/*#HKNB,(1SO$ICM51
M@9ILB4[J=W_WRC(]7=_%<"6>'N^H/%/:.QS:][LQ][0V>C9WLA9>I-88;\=0
M5C0Z0^#*G\@NI:G4.M!TI#$PRCX=U[3Y"%%2.A0G@+22&PG6KJ/PZ?R:O& ?
MK>GOR2,UF]CD=Q\YU4&I6C@[D<7 2*.3TQ;$@)1U:T?.B\XJALM5+,3I%$%5
MT9\6FO*!6S=BU/R(K9>_!TV86BC7<"$[EH?SI'-[.T*=L&SQ9Q]-PZ80JZ'V
MYK Y)#.-SW?[(#IB_ F'>$NR3%!>C#_1_GV(MZ66,/>WCP.*[O3MX:8S;[)(
M[*P?E'?$%I\[[T@Y",!7'A^\8"+0,\9#%9UF@NL'X!4.6-+#L1/6M-.S;(ZT
M,M2&RL<J*O<9*KT,E1. 8JMF1=!32\.RH:+%E,A:R1O^'>G&U'3A;_K6WNOH
M%V0J2O8V)P47D@G/6]"C[>M4[!P-G57QTS9D\U? _%'1<IO??%$:W.LW$H3T
M:-H#DQ8_&C=,X)7+VP/0)G6?U$G1IV^']:33[_Z_Z/-S/'QB!PD1R\:*F OE
MY= 3?('\'%4I116[7YC G;M88:*K=,%X!\)*\0(-LB%<>'%\W$;Q%R_VD\IK
MR7$C1<QXL1\G8L2GQJI'3W"'W8'9-&B1Q!X."%L)RW0U0&<:B^ @^%$BO+-P
M>Z9&:I 9&.4*0DY"\^7\R+,FA?P5F0"FR^LI9$^2ZE"81$D\< >1\&J.A&'N
MU&S]^G4Q=.["U@.VFAU1_L)R;89$-BB*0?QH TW/\[9?B39,DQW^Z 4'[J4+
M@N@+Y!P9R8Y0$+)G),B9T+  ;J(7%G$.+PF+CE#1TS2V_G9]5C'5(H^AK%<(
ML!G=+&5$G&S68EY:-NJ7 D%>+OM)68Q5G:E-P6*P#C9G.3=O:V,>0OY],N3E
MGH_"^Y:%QV67.Q<1/(<X4-EENU 4VO":F7#CQI]FP*E6+'?T0J V'*);/9J>
M:W<@Y,C<<*9"-9P&_'I"0G1HE*N)V<[;H.1&JU(&>.SV.5Q=0E)+BS7$M0^^
MGQUD!U%MU!SY@$TP57,#9Q?7$]B;.V!*9_0];T!'!=-$0&0"GF(10N\RZ+QG
MNV>6TC:%W7,*MZ'M(!H>/#SA2I$;EW8-:5A$^VGVIQ6&(9& C!H=-A!7%F/&
MAN%8PP*$9^X'JM!C<4ZYB.)]!%6 V=4K=#X-6W!@;-5"2@84]]@3Q]G<L!Z1
MILV9+#0M[X!M\X#H-X'>?@#M%\*R([QDZRST>>=/.(3T!*-'0W6C;?4(KL^7
M//-]W@<+P"MZ25$E>&T:BZP1!DZ.UQT%UL=,+9*TY$7:1WB7IJ)D.U!/R(5L
ME\^_A6T^<^WDS<Y0GO_=^9LT#44V;5:Y',S0=.61&*XJ<(G1L=R/2E+V\*1B
M0P(H:,+NI3"ZP1ZTV&4)X2>P<.EHL(JCUO$/5;#R-DK'VC1;B-DL+*!B1+8^
M"2JW9=4&)H$H/56JJP0VQ-#O=<H]CE_(!DM>P3P]Q?B)KHOCKV']^;'__,J8
M5Q5\SUE/J-K5-, [&&)$+R_ZB;)'C:0FL3B&7+_\+7KYR9UW9&D0('BE6.AG
M27+8[?EE3NC?X/0Y\J,@>CJ.M3I;X-CB$C_^:'3N*[W8VV$(Y$(/67V0V7X?
M'.'.'5*XWD0^E<,D9J!%P#:*)%G0D^59O.0,58H_W1YVCX,'_0S/GZL:8$,.
M0I8'G_WQ#&7-4%2V>XOSK@UB@\PRI8@MA[N.,@A15%3E0Q1E8)E0W;DW"1;C
MNG?#,?,3)D_/*?9G+SCVGO#\%<<;DN"[F)1 G=ZZK.3Z;:_6JJ%)UO"?4O];
M-'MY0OG'B'W]%2_J.J@=:?:VZN?M;@!M0Q-N"TV((9S#< \M_X&XT=7B?!=9
MA&E,PH1LV.%CNOO&"9]O>Z>H#T:R-Q2>'%1\SMW_7_'N($;C2+-3H 7+TY%[
MJ1<A/=@?V&4.B_5?/WMAQNUMQ*H^8G]:Q^W.?+LK>&YC>)()_)!]A-CURH<?
MZI6P')<[LH[902:QD6;>TEYA,D"1<=? 7E9HZQ^HLZ84L[UDA1.JH@T4![O$
M+SB(6$;0/)GY.%<E>C3M779H\2-9=/.V+-2KTKJHES&AK..==%U%LKZ #--R
M +Z51 9&H 9!R^&O[1RI7BFX3#J@K;M:\@&]X=K."*'%E6C_6V'_L&'Q '33
M6_W>V^U_N"R*77REVAEER[&YU=B>X\;3&ZJ9EKN,7]EE<+'+N,U%WAEBDYO[
MAM/^[TXOIK,^JT)*^YWY.Q(2,!K@B<.XIJ8N57O&IB9'+;5< 6_U]F6!MDG8
MFAW5785@%PF-@D6[&+2]"[6PHTZK68&?5X??!(P=3;5VP)J+C4B#)=%6]/GO
M4#7F%N@&DQ?O,1@M9%I$P:9#HT%=EMY[M_=(G#\;NHZ\,$%E:UY^V2/T5!.B
M2_P(7@UXX'4@R3-K,XFM1J'-NF4C%HIAT1L0%<4FKZE2]CWZT\D.A"T6R]%F
M2B/J]VO 9'=XU KU=!.GZ9-*NA7A)$M4DZVJMWBLNI*MY&P^KE2S(GL01T+V
MAC)[7/DN:_A^0AY>79W6GUAJ2*.'7Y?W"_7&,C-D)("U$+,'+S4C&@O@&P":
MGF8;/D6U5,Q =AN%49[*MH;A@?$EIV/Y "=E1'ETVS)003  SUSDVC/5JK8J
M>-1#MGQ 4S(C.IKE\_EK$[SI\6ONQ1"5DMSAF%V C_5L54;&XFM4"0NR%#;9
MY^@=Y.1^CV@S_FIB&HM^F]YJCT=5([==24W!BVB^YOMNP)1 X8\2:/:7KT#T
M0TW93UY"-I;F;9V6N\E;XT/#C'MCLUFH4A6NFO(PP]8L3(E/@@,X]^[QYA"S
M!$GSUTUP\+%_19F&^*E#RL*GEML&&T=Q!R/D!AJ34WNX'G$4LM#R2@-4MG"?
MC<@"]*HS:&S)FWK#6>;Z.R].C^O8"Q-O,V9"]E9R-OWD:E:D,7\\U3^TFTPJ
M-UTMUEWB&N,?%%0C+,HJ2LZAI%@4JR@ZHDH;]\NBAO(T8#32LO3I6/V+/4")
M"#O'EX"I%KC!]0D]U<>--6R:F%.H6V<EDXBG&R*I3?_K+[-]% 31&F^>0Y8>
MY<+;D]0+\O3)E!C<VI1W-717?X9 ?W!V9O'\$+//@OR%&RM086#\\/$/'Q@@
M1Z,[/FS'8EUF8#)*J"2%,EJH0JQXFP)4*S>*9R@G?,9F1Y:5KB3N=H,?&WTP
MC4955[?)EL3I+_DIFIK K&.>E:CLOOE;C&^]'=;=#"B-RD9 ?RHW@=[DQY];
M?5F45GK/&Y\A^-3=EC 4! #9@PC+\)GNX3'!_W,  B]XO(+*4C(6L\5)6) Y
MR8K/$?]^&B>H-GW5WO:I1FSH!A.6E!_*<U7OW+(#7E#T7K"'LX]<.H.$"JCY
M;YKCZ*/KK%+4J"H_I>%$\R=,R!+G9Z6_O&D 0:*=)AY$HS,LR> E\/ "_@_V
MI!<O8&M+RJKSDO!IC)PI>C0MPT:+*1F,:"-FQV_@'[AL[K+.0A?%UNHK: O"
M-)5(%*=K'.]*:VAH=XJ0A/745TT>I(F>Z:?GM,<=^N2%OZ)+O(\2I_7B5#JJ
MYQN0#++/'G5+^;.P30G(.-FIFGS(LJ%&X?EF6AN67%7-/4LR3N-(8BH:\AC@
MK'.<\CLMND!]CB+_"PF"@5&C1=(R@G1XDIZ]\Z:(M74=(]9%HR>QQ'HB&%8U
M+SA^C(91CC >*$D.+( OVO)((+<%'\=5C6F$T'44/HUK2(@H6)[B A9:O6DN
MP:)02OV]B7A8UF>IA!'1I&1._+AP1K]9(7\_E)3_S*5,-PX#"7]00AAMHL3E
M=M1/PA],7Z_D@<_L&=8*4JLNMP\)7S\'7MO4M&RGP5$Q([M>AJ]@@Z3?(>>N
M/"W5U5ZGM [9^EK8RI(XR7+6" 70"L70[#S:GA_H#\[/*<.KI:NUPBXZ'T+V
M$_8[7<0W6UF:EF+JDGGHZH):*M/B>ED\ D-CLRRD.@O]9B&VL=Y>ZY*U;99J
M\B7!3+4L+3A.$T&IOG<^WI(-2=\SCVIZ=&D-=%1^S43H(JG>V!SW@D=!R!W^
MNEWU!&7#:0!*X]*G9;"&SM;-)CI0>_7..\)I!I*>;#;Q ?M-:D/[7SM0MNV2
MU6=-=J><]8#VO N>'0<Z\0*G#MONZJ[Y<#L*9A!,KF//QU8P6*/D%G-55F3/
MJ^&3Z6!)I"8%=AH#' 0K[+&_%:S4*+G%2I45"5;8)]/!BDA-"JPT!M@C*XBM
M[:V%F(L$PUTW,=8(9:W0]21,)CT=-O)_C+%-U7T$>=?'D>"D)N;447?*C0Q.
M)RZBB@U>1,AG=\.3<17)M"KW%0F%T?M -WHTA)J6NV.=45S$Y$YW>A$2[<,V
M\#FNHJ,70)=W<?1"$A*%6DY'03.;7L<F>9G[/_\0[?,O77DBY9(N7)&280VZ
M_Y30L;,%5>A-8Q<J&3+8B,Y16"XDT]N&FLK5V(E.!&(8L&G+UST=[W9G?_:]
MP'_MW&O=S4\]BF?Z(MKMHI!U/4HD^6GWMH/&3^BKT($V_''C&5K&/@F]^)A%
M=J%_^A.Z7=RCO1>C%^@%O?OPI[/OO_\>_HN\0_H<Q>0W[.>?>PE<>E_B#89*
M7.@/'\X0"(8Y&ND__ND']"]GWW_\_NR/WW]DO_OCV9_^^/W9G[__Y[P#DB2'
M[%EVM3)N6[]G4!-DCS>0"20XNBRJ+D-5+8Q=I)K>(+[SXF5\G\+S;M9KGB=E
M/%Q+*;J#NHPEV:9;@_M9%><D1+?X"[JG%A(.DC+OV43 U:9M"=Z4\ND-0=95
M,BN6A?&@UZ#D#G*GK&A!+3DKELQR$07,\=XF C*9/B7@$DIB(% MV,8P-J R
M*J[!Q-GH"*1LZYPHB.KZ4P*H,GKK868*9H0!9B?F$M?!FY>[:=1[H\M*O>^Q
MIVZ5E.OY6^&EXR2N&KT3G<D"G2IA=2H,]W/ZA".=B5W1RU>D"]-Y/O-] AEP
MO.#.(_XBS'+C#'VW+:%B^UY;S(8LQJ;XFAXFB'].YW!VN'9YT:W65^V26S%:
MT\QUJ4="[.?Y.V>;S6%W8&G(+GD4Y<"XT2!HO9IF&T?RB*W\0Y2%G#I-2J>K
MR7HR.JW!]WB6799(NJ"KW!,>/-&QF(B+)]D-+K0JF6W)*SC57#]X4"NK\2Q;
M/%;KYH.<%^'KV%+PD##_C4O;\G,\.2/"%WFEJ#?LRS<N;-.7>=*J)"/=A;73
MFTH)FI:;,1Y*1K+Z%EE=T/<N"UMHJU*K*LT0M8'IUIU P09Z=@CKI0676Z@W
M.#"VVNG9KC_;QI#TQ3M#E:0J(]Q;740AW7T<Q89TUF^M%JV63(;>.9[ 8NRM
M*F&QX*Q^I@^:PDU-;;YN30VVR>O;5%I\B?;\%09->,%WI4[0$^WLJU2,J4$@
M+$TS\$(MIN&XE!5C0A:*B=-BJR]+644U/Q\Z1X_0!7.]7D9!X,43N?E5JK2U
M+)&;@Y.4%=$:7):'DBHG#\=F*GK3NABJ[M@E%+\9_%941L7QY,[8Z#>]?=[)
M]"?XB6I5L*H*QODDKS#3<YIGJGKS.C&=[#]A2/"!_1G5@O>$;P\0^K;<-BYR
MQMC=N]&VO#!T8DZR7.1]((]W@D+6"SA+(_G57\T^<'\U:X20*FJ[2]+Z^M*9
M1=&JT]"V2L=3,3/L:W?@E2I; \>.!.E*?1JKE8R]H=>KJL$SV16K#2D:J%;*
M<RJKEHK)P=8M]W:3&RV;KEXL/(;'OET>8MH9M>%(Q,.C5SA)8[(!DO#5[(L7
M^Y]C:KD.O(:9\>#BY5%7)F4O).\?$*2E=!M/U4OUC0=*1J(9%+-\7C@&;1L3
MTT!M"Y?ML)W(CMH/"1H8UA&4:13A?Q^RQ+3K2!)WQJA32QS[4 L:APFKO+>"
M]XL)2?$]CE_(!G-.5W@3/86LES$>](W.KO6XQG''HWIP>,[Z1)M*IT[#(^T
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M*H$>,Z2ZK#756='5);*;4(Q/Y% UY4=OPV/W1KGVD!"Q?UH6<"%[790O<Y"
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MJ+H*Q0R/#V&,O0#*9>6]+L-+'-.S'?BAAHX";*-F&7<M[+0O=%MZ,$8OD,,
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MBEIIU9O+=I.G:.;RPK9],$H31S)T2TI884+/I5"A>H4W$3RP8R'G7BA30-D
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MNN (BZP0$11]' ,TT1!54#4LLN:.ZH+W]RT$.+[%1=N(W]"0!PUWC'IER*/
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M[@U9']S62!4!6DRK. N?ZMI1CG>CEO5$NIS7*20HV6720GP\M! 0AUSCC*6
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MGQ)$'DR!4H4-6:=9K52!#%^RSYU^P;,5.#\E>:^].@1I@F0;A>,XKAO!(LC
MF'4*'3K%B@QH-B[+JFN1AG?7)(<V@&25.2A#-! *-KW<+PLE-'T8;>2YQ:6
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MU\^?!]^XC1_+8.=V?%;TX^:?RP5I2#Z9;Z&#.[(:_N__^O]02P,$%     @
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MO6P92#G7R9"E_8[\:;_7R5*SW"114IU9,S%C.C6J"IW'7Y[5].8P\LJLSU5
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M^$L0/@(UD!&SE?I\'?IZ#9)!MX$2O2- 7T"H/?("53LB%]PUFP:ZK[,\*D<
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M+-+P"BYT[Z4B%-U#5DB.%DK@[A.Z$S(O6L")%I)/8K)WG#_Z81J0"7Y *'B
M8:@9:"&2[B$M)DGUO$L-BWJR1CC)2U),%X<,Z\Z8:2?F'L!=TK-0(;:2 +YO
M0W;A0<Q,M'HO+IV9]>T$W0-81(KZ,C3U)N05YXQ7.F+(#F0@Y8Y[HAG*O.NF
MI_QN" ,?%B5YRJM;\PS:*(TQ8-"4H28D-9M]A.DF?+G>D#5+IT!V +S4_KJ
M0\0U#'FR4K_.UVT3O;O;%?!B$!O8S+*!#>U<!X-+Y@&4IRR>^-OPF6*\F^B5
M1X].-F*0&3FUXU-7X+N=F,4%UJP@+$VA :#ALSUW)>,^ +3$WF8%?2_4E)3+
M']L"(/SU4*38M8C" BY@><B*ML)K_+$M93UV*N$.(KY4E..3S,3'VZ^75RVB
MW17'S7XY+Y";_:%4)'<_U)@E69ZQJR'(]N4L>@C92:2<8.!-%U?DJJ7;OMP/
M;+-PJ=#)7S$H2P*Q> =@_)X_;B#.:@N1I?3&A$EW2,(IK)J%9#&2=^-M6<#C
M N$9^:]N[\'!Z$YA51.-Q6<#5[0A)*C.80;HV5W\B0:PM"\W(:).@2HJ2(NI
MEP?,T4YHT\6G./-T&[WZ'=)R"MD.L>FLRZ+7O7*^WH1H"\ )B, ")C3SBVP]
MY)_"B>_CU M-N%X.B4ZB8+XBJ)Q0:=/L9!#%&=YFO#/R].46D[!0Q9T[DD.J
M+?Z"""M#,'V(R&:R@AOJ8#R?3V_VL1!CSB %!BQN$\IJ3'<.61W1Y<<84$YJ
MRZ"\K:HHY+ .GZ*.6KW$(&<A5SX8@?+*KW4*4'7:^BY^>@^W+!7NUGLT$D#8
MC;X7EJ'SJHV2G+K6)2)^!/&^5<T^RD<[12Q,#R)_:^I8::=E<1$*J!!=;5S4
MAMWK:EQ/TF2%:.\L6L;>P'.L%D(60.M8.]6$,+Z$QH29D>=4K:3&L-BX:ML-
M8>^0Q6[X&'L@+ ]OY%DQEXP[.' %I3-GX6E6/Q+8T9IK&@T4=7FN::18T^BY
MOL[P-8V>ZT@-&IQX4ADP@AMU=QK,0$_WG]-@;*3!?)IK2X,A0XU9DN496^TT
M<FC)#G()'O$NU"49.T4 ZMP,=/$=XZ57_,*K[;)+!@)Q OW3;-D:N>DVTW!"
M\ASQ6-C8SL ]"%'VB@ #3Z;@"^?340/ FZX%<W9&-&"Z:%D@W#8*]>]&+?/&
MB5I,>+E &,!E9')K:B0Q:I#:A6/AS7H X-<KL/3"<]JENLO,*FQ=\E6&#_EA
M#TO36..TIAIGK?Z,7,6$HBQDU#M-IFZI5P:R(/(6+2K$79UK[X[PGV("LT);
M^/)WXQ-4X^PTN^/'M1(%H];J=0#Z7&_.%PO@TUXT.^YH6L:,]FWV:7%/)L+D
M @2T R^]7Z>TPF[EEW7G<6G@: P'9%MN0B5/20<""EDT[S/EB4"B<JBRQ1V"
M(,_/JB=Q\W(1&[YS :W&^5JX95W!-<PD=$$F<KL"_P >GB[.0\ J4@KC(#*.
M"[@(R</*G2Q(&0>74<MFR;V8<3YV 1'^S$?Q- '%,2M'N$#XP<.!N2?I-4(N
M@"<B+XMEQTJU0UDG2YHHC0$MK[L[/RG#UR"9+LAL-6,K2]TEP*4E:[$3[%E.
MC7HAV/.:P5:W#&67T)>2J,6"91)\YNXG>PI0,'"D>K"3KWII,PVE"44N3SFG
ME=\X@^1#*C[HZ:Y3J84EEY1&#P;J+6M[J-&^FM5T<5#&3\A0;_O>!0A;YY\C
M\M[*PO[@P2BFFPZ(I]'Y(YU%"N-5QNH9N-/]3*:;G@MX2DBO\%TH/+S2 &_S
M6T?-F'*(N 0D3TX%>E8SEZI;//F+\T>PWN1%Y$WEQ[03=0E;43D66-LHWU&N
MVTE^#L&P94^Y)%W"64R&!<I#>L<^T0X]M#L+F<T-?9-+>QH)&3[-7[J "F?.
MA?AM>+4^140_T#*"W]G-JWCROIO2#8B\,*$]X*/@,B+D0)R</]+30/<NVX<3
M%\#7(O%"532XOO0^62<FPAIF;4"\*-C)(KF"WATY7>A\##QE+U&=E*C25F#&
M'[?+T99,PQ"6IO@S>-DQ5<OZQW%%%K6UH*V</Y>0S3+^*@J9]S:50WSX^K"W
M- A-NT@$\!X&J;872\WC6@!1<=453V0X\AD!4%]@LF+-(JF]L8*;6R28&J<,
M80=%2V]T6C68"V.7]'H]>3V#Q!H@_Z3M_>7!@&.6].'<;;9*S^..N\U;_WNH
M1A)N[7+MTK)3V?B0%R,OI#A$;)9Z;%'8-JAZ;UIG((;+". 9VF;7%*FW-LW?
MCEB.W.E:V*RRDB*7483N,Q'M*HO "!*3<CM=G/LH0NLMNSH&:2SW)J?/^".&
ML)?8+*3OG<"(\>F%.3/0"V=$JD0BM,-MZ?'7!4JC@/VN!,H]AA\QR'V$IC4W
MT*V3O.VZ;C%E\@8C'X @IGFUNYTWBP\#W1T,VFG9[./3Z4HYZ-K:)C(+/0YV
M7,Q1R$*(* *'Q?)Y2<C-GXX>#-Z4+1@+.U:(8MS#N!8KZY+\_C-WI%Z:JH5S
M^X*<*\6"NXQN:2/RR9J^0!42//_KT<N_9>(6SY /V",'(R^IJG_2SN'PHX>)
M+Q@+6?5U:V4K&,6H?S=ZR3=.UD(2^QG D-Z![H'$QE3[:/3BKD_38MIXJ2$.
M>YD\!TD2LD)1NAV,;91&CYF0N/1ULNYU(S&-8QLI=X!L%9AZQK4RDM,TB1-R
M3R;L9]M"G/5_"PDOIZ$'Q=ZN=H\R>H0$!*&>?FTVRV37W_XC\&@D/7-IZ\\K
MV=$I]9,PE$;22DKR M(B'?$\D>Y1% L6U2?*WOE,HF!G%5VC)*<:3)+=!S4M
M-B=Z:8XLKG81)677LVZUL-!LF.A:D-(8,>W_3HNC)RM$;H_W(&8>S?K? B#3
MK:&K$&L?\A8P%U[:NWJMO>0[O#[P^-&6HM)!P%;56 W+H("\2X3*(=_)!H4A
MN@7^*D(A6FY/O0U,O/ 4X0W"LN$GX<$<1T1<:*[VPY;:D[1: 78R32Y@Y!&K
MFD88R2&;LNG2!F1E)G5;*"(DQV6"J-IT%241DK3%MMW-6\.^&QW /D5BJ;T^
MF3#=XU,*"9E;3"2\0M&2%G[:<Z@_\;U.X?C0;I2CPK[?K]+<_I'/CHN&^6H&
MN(/8\6'=)5V;598+?DH\LNQO".+;E9><>J'/*A==$RE04;!?)GL1>SR=[TG9
MSC4'?HK9AZ;<&%IY/#XU,X2EA>#IY7H30K!['<@S-_B%0SA?'P_F+1*R6#RL
MV809X$B1('P\.J B=8N!XDE(AHB\K)A1P:5F/6BF<7R0<V1I,7[,9K4O>71*
MCI2E=DN 0^0(\>5(4R&LW'A!T!NU9/;#"H6$MSC;C R$+.<)\K]5B!"YFGK[
MWD%,;HEPQ2,>L^P80FW)GH9>'$\7;*ZF0I#--"PN6#$UHFNQ"S8[_<)W;?@R
MEG8YV"9>=+;3L@"BV$JJU/AJ%Y<=# ]X,?*BLYF&U84GH+AUL[8FI=Y-[^BK
M(A2Q?<!(5ZGZ^"Y)O4$Z5OJY[R:0WL4P@![>SCT:M&2<F=CKN'3<V.?X8K(3
M3"RQ0:/'T\4M]J+88\T+C&QX @1MKL,N-:Z *2 [Y6WPAN6.@YO0\]G&\,7#
M[+V$1(I#QQ!C%W.7!"Q&UW)S.>=HBF=PN4H,['9\.D[L=BUB&K:?>BM#1K:Y
M-DHVZX)U*6XG?/U;^Q&@84(OF9,E!JI[6_<H8Y>R@!Q<S<A2WBD.?1QVVIW7
M?0\S<$\%ROYAO@FA>3]6G:)]?6[V0%6O\0*24\^7TG!/*=V;/B/Z0(6M3>WG
M-H>*"QAR)633WMKSQ/:6^#*.4^T5.'A4'$.M*B'U:Z7>U99Q57KS91J\,BDG
M$:S(2MU>UN'<H4QE"G668L+/#< 0!1F;U^"!_9-^K[8041>@%96?NKFC8ZTV
M&:T&UVL7.1> [9:9OBP? ['@6E,5 _'@\_4F1%L Y@#?0Q\TTYTLR15HR?IA
MF7[GVI\?A:@R3]"2D>7V871V(9I0A5ZR2^G)=O\K>56$">U^5UL81CL623%D
M<>O0INZ[T':'[M@)C3*!WY)?-.#TK(YMRWTAM&0KN4!5D=A*.R!'UG3#>PNI
MQRBKC&]QK34J8<WNJDK#XF.M&:#E0/T$!(RO3Q%,XMG\DQ&<VFF-&;,.*6D.
M<H]^5]%Q/%NH0=B;_>N4XDUL<'9'FMP3(5$172#,RL:-Q>;H8M-FC%6;8:=%
M'SL!M;@S=TXJYLTJ.USBK)3A993=Z[\ >@T$P81L.=X2G#\"[,,8W)!M3?>#
MBB$Y?WJZK!-VN]E9JO++)UIR:63K>"S[+Y>_IZ>L\A"Z:!?49S.FW583U\_*
MJPJWQ2?:RG/, N7E$B.TQ\3MRHM$CAGVCV=> DS5?AG/O)Z7A3F5T?=Z7&^<
M8O^X#BVND!>5ZH63_>"#!R-ZA[Y+SA]IJD(*XQ7]70-QC#U=4Y&))@K2[_'5
MA24>B]! 1K6H#2%&GVP"LB!*5/=N=%-!"1G*%K>I%B7-JQ'TU@\[?FW6]Y+N
M@3C9EK+L#40?VBA90%;?DJXZ65O$.2J$C21GM].RNGX[U5P QN="FX;D?ORU
M-,UL-U+GMIUW<.4V :<$9< 48'HH!,T;D2A5J[7\I6TN7ON%5KE:=/\?\$)N
M6S">$QZ\8!I]]C"D?SFCV1JEW#T3]J4L"^YJA9K$+2:@9Q?NH0IDC:P>5D^P
M6V1GP0-]#9)3#^,MT:L&;QG'AJE]Y!X:]7E;\)66'H9E;TLD2P:V?>\>)*W2
ML%#.L;I@:X7JC&QU=2KNX=@I-_4D< VQW^=BCQ8PUUS4L8<:G#]2^YML+O*G
M'N=3]\#BR<!B'48VDQMO:^!261G:/;":):2KHJ(T4+3L'&$^2-G%53-4!X.[
M"]:AE/0U[A,W[#,6O)#]<PTKGF5?^\H]$!IF7ER5-;A3],9SSST<D0TXIBTB
MBY+F)EZ=Y60*$J8>D_'(2)[1?*&(1V4[!U$T'P^F2'TU?DT-#<GS@)C-=UT=
M"L7,C$X8A^]G-Z.I))J:%>['L@"$Z!HINM"5)FY)ZN(/>T3D;K<;74V-*F)N
M>%PE+[./,(+K=*U-:M7QQB:W@]E:<&TS+KQ'O3*OC#<ZF5=GJ]7Y/-*=4/04
MMQ-T/<A+S/+2SV"8TM=_AS50)L&_4B/-*%2Y&)$UTFR4E15 6=3ZXK)Z+Q+=
MN1CT-K6_0YT_^BNZ,9 9%MFSA;=.X_U#E:M)G:OF*XMRDHT\7=TY0[)XB%]]
M3-&6DX"PA#FW)\[D%(:UL#,95'RQS"M%[7KN.#_RCO.&]Y7G/O7/?>J?^]2/
M !%+N;5/T),VT(Y:=\ -=+M\=L ].^">'7"CE+E!!YR6UT;QR;;\+\,]+VLB
M?)Q'@PH"=IJ%E/DP_@QMM&_/6I8$#\[!#.BO/SIO0O>3OHR@++Z>>+*O=^WO
MIY4-=. ^*L]/>MU[TOOUS;%OJ<I[Z!NK>RA]=;LO^&)@ZVP@<-P[9I-$U5]J
M]-DHJYS(N7&5$;;KS.U6:SY46IRTA>)<1@$9' 01B&7ZS[5\/EIIMDW9PLY&
MF5T@G"W;@K=K=,\XND I3@"(;A_0[0JE,5G?MP]D3ML+>-_HV./@U)O(:-'L
M+SY7$Z &."-48OGJS[OTG1U9DZ$;#",?;KS0Z %R2,N")JBG7/!/EYH(+52F
M8"]I#M^K70.Q7"#NQ\X!Q!>#A>-J!B#1$7JC(!-"-(V.S(C.3Q 4WM<.HL(5
MA 6/_O[-_'3QT8N\K'#F)(Z)<0/R"0DA)#20<V")B<="*8C)&J51TA.SSD&<
MPZM;+!8+0QSQHV4]ED3CF^6!G F50W*ZJ.S2C=7+>)W5!<9Q#B AX:@;\%I.
MKUTYF%JS38$3J_*Q<_#PQ6"A1,.1%2GJAXQ(C2*9H@SZZMJP5^_TL7RUEARM
M<Y5BK/^94#<]Y\"5$*6%@@Y/MAR5'E"[JE%)U8;04TLE;V$07R#,5$TSA+7A
MG<6N+J@"-'O%+P\U:?H0D8%7<,,['@TMR2:ZS@(M(=I" Q2<*SU.6VHP>UG)
MWEU-LX\>_B;HBVSYW#G,VD11@#.D!R5CNFPZ'SSR%0MD=H[B'% "@BGP&M*+
M4F:(5G2BCAX0G'KQZB)$#]D>('WOXP[D'&IBXBF 4W"J: &.-FKRF,>;_11M
M%7'CC>,T;%SA%*C9<JV<HCA1# 64/G4<F[T("CB&]*J4>=F=I)=DB1-ABMD2
M[2,X#4Z#0 J,%)PKRA@5U"_7FQ""8,>5$#S<CYU#AB^& I0AW2!E/<DYHJT1
MI)=,^5OG(.$*H8@XVZU/PT:/@?_#$MV_#@#," 3(9QDEKT]IE/QE1;IJY67(
MT%\G04 XBF_)KW5FB9998A=N\L/^GMT\FF%93-( )I?1 N%U96_I*Y;S*"%J
ME$\'Q*5Y=>1*=\NH8VBYY<R$3F6 <$.!&UGTR@-96-2\R= E*P)*V16I(,8A
M5L+P A73Y$+$#4)0SHFFXYVD,:2)P:>(S-A/.E\F=PNV>43"V5___=6K%__S
MY>/G7__W?[X$BP_1_!\/[Z9_.YO=K1+X\.O5>O+S^3_"J\N?WR^_Q&__]&OR
M[FIVB3^>K>$WX/WSGQ[^\O 36-YNOE]O5[\__(XWFV\_W;Y]=_]S='F*IG_^
M@O_XQ_++[/=?UQ^__?G\^F0#_G;[^>*3]SGX=7Z9GB7+[7?\9?)I,5G=__S/
M^2]>^F4*/Z[^]//YA\FC]^%O[]^>^,'LC^\ G_T:>>_?__--LH3;^=W)/?Z<
MK-X@]'AR.8_//\'-]=G/IW=__S;')]\G)[_<Q"CY.?XTI7UV9Y>+__[V^J>_
M/]QO'GZ_"=]>7/MODH^?_C%]-TW\;W_[KU_F_YW\$?_\[?-F_GMT@1<@^=MR
M^J?)?'/Y\?[[WT'Z_?W\[>>UOYG<OO-N'WZ9_.O]]#YYB+:;O\=G[Z[0]2IZ
M\WG^K]_C28A7/VU_G_UC>K'R_O3[Y_FO_L-OO_WOB]/Y[-4K%[28HW7ZTOR:
M#K2_OJ8\W'DQ^(]_^_]02P,$%     @ "8J;7(E>+<<6Z0, &Y\= !H   !E
M83 R.#<V,C,M,C!F7V-H96-K8V%P+FAT;>R]>W?;2)8G^#\^!=;=->T\"\F2
M_+:S/$O+<I8J;<LKR5U=.V?.G" 0)*,, DP\)+,__=Y'O ""$NVD1$I&GYE*
MBP2!0,1]W]^]]]?_^6V:AA>R*%6>_?4_]G?W_B.469PG*AO_]3\&9X?'Q__Q
M/]\$O_Y?.SOA;S*3A:AD$@[GX=LB%TFADK$,SPN1E:.\F(8/J^DOX4XXJ:K9
MJT>/+B\O=X?VLMTXGX8[._I>AX7$.[T*/^99.)@5X<'S</_)J_V#5X^?A%_.
M#\.#O8-G?/FD@A7"*K/R53R17__Z0-\>_HB_[L1BAG=^!-<_W3]XO/_ 7)I/
M9V6LW-7\=R'+O"YB6>*/W+5U5A5S>^VW89'NEC+>'><7C_27] #[@WFRY.)Y
MTK@PD:K[0OBB>6%5V MQW^CBO!@_@B\>5?.9Q*N?[.SM[[A7E/&25< 7C9NK
M,G]RL/^\^P$'>WN/'^DK[ ^^+;MV'Z[-4I7)_WI[^L%=7G5?[RY]5!DB$150
M&BYO;V?O8&?_P+O)#KQ XT;FA:ZZS_[3G;T7WJ[ E5^O>%/\>BA*:2XO"[?V
MD2B'="5\V-C NMP9"S%;O%!_T;X8#ZSLO)J^:5Z^[.1AN2\?P;?F0OPB:9&3
MON[9(_[2OU1===Q968DLMIOP+;WBXO_Z %OFKFQO[^5CNG3_Y<N7C^A;>VG9
M=1W<<O_1?WW\< ;L.Q4["RLIU??_:OEZ4'8\0!DB1?(F"/'_?JU4E<HWX:^/
M^!]!\.M45B*,\ZR2&1!#);]5C^B'),AVY!^UNOCK@T/^?N<<3O#!([CG([[I
MK\,\F;_Y-5$785G-4_G7!R.X\E6XOS>KPG,UE67X25Z&I_E49!%_$(5GLE"C
M!_0K7, C_.^O,W,#7,&.2-4X>Q7&\$Q9O Y7O>GK<"J*L<IVJGSV*H3+[0?#
MO*KR*7T&3WXT:ST=I?)[)5.0R:=U*G<^"Q#M((#]-[M4237!5>S]Y<'"*^^4
MZK\E?(F/'.9%(@M>P]M4Q%_# UAXF:<JL5^:]?#W^^;[!V_^Q[_M/]M[K9>U
ML+A'"ZOKV,'5=ZMKKU?;P:%=Z+!C.V]Y*5\^'9\?O0O/S@?G1V>_#@L@T+.C
MPR^GQ^?'1V?AX-.[\.B_#O\V^/3;47AX\O'C\=G9\<DGONX?HIR MJ]R6-"[
MW<-=4+U/G[Q<VUOQ@FFEX5[72[H#OYVGP6Z]/SG]&/ZJOKW*\NQ3/86?QLS_
MWZI3.?KK@WCO09B)*3P9]/2K=WD,UV05<7ZH0.FJ;Q<[^R^?/W_QX VHL?>_
M/FK<ZLUM[MWZR7"5AUZ]=:R><9M(I;\:YGDZ%&F:5\/\6]?.GLJQ*D&SHTH_
MJ\ PQ ^;6_T2R>3E\R=/7K=W.X0M.#WZ[?CL_'1P#E3-3/#QZ--Y^/G+Z=F7
M ?SC_ 39@;[=/W@X_"4\.0T?CN$_[\/SOQV%'JM8-AD<GN/7^R\?/[GWYWER
M>D]9?<UT.LBR6J2G<I873?)\L:?)\UDG>0X^??HR^!">'GT^.6U096BI\G$
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M^\]?EVP>T55AK$4!G (X0],<A5P."EZ4YK=QFI?2_#$C;!!<>D%<,YS3IX)
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ML>$XS/,?.JVM8;*5C+:U1M? HI[!ELRC\',J#&;LZ(]:S3:?Y_BQP]RXZMU
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M@^-/X?&G]R>G'P?GQR>?;H/YME^3?<E2]*HI['.IT*_ !'D"OCJ(29"S>5V
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MA7&!XF^FN^6V^UYR[Z$2A)SG<U=YQ3A8_@G+OF%G#PXL$*;?_/OCO=T]6XQ
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M<&(1E9EB+'#>>$\#:<-DD-^FRZU5ZUDRN%8."36:+^,V<H=N8U/9>"*W-<J
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MK$0([_>%>.EI/9DV9=22;C>+$,!8H4S=7T8"/0L2Z&Y3_,1>=Y#=7K<FAN(
MY)7T<'SXZ(%NEN=]5_@K7%QE[.-OBNOL\2>/GYP]?/+D"9U=49/](S,3,@Y$
M,@VPTD QN45Y6=1K/%SG)<]"2";RGV-=^!I^@XY'.7C,F?DX5[GVT?07\[,6
M)*2(?"3$2L_QP'U\5%=6&V^^V'>2,/C+A_FG#S[-/WWXF&W#2,=2XJ9GS,Q8
MVY/&^JK<#CQ)'\UDDURQE%4)6&J_)P:1!9"@KLC^ZQ*G[W]7PQ+H(6\C14SX
M<-8A)(+3[WSX:"Z%-;'5L>;M[Y5._OV+,W<J1WYX*D=.RY$?GLJ1]]*X#Y1F
M?BS%MQ%?1[2?2<CYB,MN+NK;1J%R',Y&B"PPN(J.XFP4""2RCA*IFW5%;CMU
MQM@4ZS6Q2)/#P:VY_JLW?)HQWBL M- 0Y_]^?EC44?%C*4I=\&#0E(+1:1PT
MF@FCY,6,Q-X11N^D;7A6V!HIANLM]"S>0N=^1?WMBFZ_QY]K92#RIV& ,9GR
MDGU'_/"%ROQE9]DW%/1J//Q,0OJ789QGV2MULM;QP^=2;;@/I<+[L#.^]0<0
M<HPA]]"7Y6N;*]$TS B)&/ ^,XA#!%V@5U1\,;?/$X#)*EY*6I&-=5,6\$N?
MK\GY( SD:! ]M7+V[-+**"SP<=_NE!+9CXR.8ZOC&:"+WAKV%,-?@T;[LMJ&
M5&P48_7;I1;NFI7Y$N(^HA!>LCG>]:C:CMT@H![E !#G53UK;M1"TRN5J<C9
MTI>3R$UPG:, :?*6F((=-UAQL-CW5603(U=9'Y4S?P"UF T!F"8Z.O,#XS9_
M!- E-5[H45/[,*@R"Z.KX1B.S3TYJ$1)C%UU'')6FA)G;7>:',R2P5Q:>Y"N
M8G^$8 $NBC%VU#:F[6BP!"5U158S#JW0F4JSZY2+8(<2S87F6UJ)306J2OXK
M?SZXSI8,)"H&)0W(L1B66]0S0N:(H@5L+XY*>F8.V;O,L&ZYV^\G>B%G@+X&
M_&^BI;#99_.3ZH2+D=B;0M0EZ1K)!<D[F?->)MW%2>=/*HU&8)12*Z'"*ME(
MX#;<->OBJNVX)0!WTGT'=_P.8WA%,XUEG^E_H+-I!8)X#K)GZG_H>6\8PX.-
M"NC,JMA#0GQ5[).D@Q& #8";F"A!OR85Z83@/TIHN5^?HX^]0+/=';.-0608
MG"1"GL</<E'T5>^(LT LRK:6X.-):\G3Y9+.P L<<5R8'<Q0I4XQ;CW,K1XN
MFD3  ,SGL;#5^ ?X8-_/!#ZAR?N:4]0"X(V5>:TZT"LF:?^#[8PD#<&7S43
M)!59=A/$E#W>@IZ@;4E]^QVI;Q5T9XD*[+T\OBP3X@\7DH^21:#XPH06*-7"
M ]',5,W7VU5+=D59WW'N"_]^=EDN7Y]YYY8)G37A,HM H=N'4L)!FI$W5/+0
MFY_#8R]_+KLEKJ7T)6I6K9#&="$F(O="CQN7THF;S+V $?O=9I-DJ05 <S_
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MP#3V,R)H01"[Y^Y'OB*QVR4Z7I50.J/X$8>)?+6?I=ROVZ9D=;,F3.TQDXA
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MOV;\/3Z8O&V-+$:6PH4.@QR7@EB,4B^:UI[$ ,#0I[H@?+SPB1>0788)ZS!
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M<+OQIT)NHM3F1+^"- C$5PD[# U0EG1*ZJ%,PR8_YA2I5DIE0N7;2?94+8@
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M7YO[L>JO*FR_[_WM"3ESUC(7_AW( $25=60#4"$H&P$3]_ZY?FWQKVY3QHB
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MKFJMJN!;OBZJ=9%]47&VV"^//\&S][]4W/<7)5QX6.8'8$2NBVH3<)=Q@-1
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M$^[^]ZSS!S\W"K(SX*_ &GG>L3D0:R!!ZCJY' AV)Z*1?13FL>X6KE1AH[7
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M.B-S'9!)*7 2:3J"/?OI,F$50GW_8'\*FZDX0Z\[\G%P^:_:VA_5W-%&7[(
M0I,2O4V094PZ+JQ\41%%R,1HF6P]Z(V/Q<Z(-*O/S;P0N@_U#IVUD&-.II5=
MS)XJW53.BI4K/=P$5#1:MJ3X))7UZRGA @N[-BN7G'J&/>-VY!AWO;EH6RA4
M5HYGQLVX95WTO7%RP&TO;[J C<:^<<U&(J[SR__P008V;Z+]9I6>H>RL85>]
M6A?*6]QM74GU=*XGQRF4!YK$:-R)0\EI.\ >R2E6; "/3MT@/[;0':1?/#&\
MWJB+S6T[OM^<]@*M2@9JE-IYE18%J=P1\K0)Y!:RNH#UF'*#/JR(OI"*F8]K
MC7@O/XC6I&Z+7E\!^TSN8=VR3=.B=9L"H(,7+X\D$$&RE-JLAT09W?2P<_IB
M_'BP1&9E0](X''9)7[@P-?@782Z-=I(PY;<SEH)$:]GP=% :6@+Y=PRY^/P8
M@(.O(R9%DKP%/*^"[R41719=;KZT!!51KW=,[@P+9P\YNR[DUJ.G]NEC&>(4
MGSM^JO:<I2X@X:3IBJ KP19W3'.H)-0)MZ_I=+_7.P%G%;&^-C4MB5T.%#Q.
M/J.A2KQFP-VFM% TUR9588O4ON)L>YI@-Z=CKG55)!;D9%0;L">Y)N"HA"=!
M[8":E7#9][ONJO1_1X4,&$WKCVF)-\4IQ-(K6(_9(,;WK!3^>V(]!,I-*TOC
M/N8C)FGJC2XE2H^?LIIO+!3)><*PH?H W1>2C-"C>C)"!N+CNDA7P1TX&$9K
ME;(GC!T&O4"B2U+AM-CP)<?H07T2]%*E-$BN%9UXY)+&$V]U],3#3_ 4L_*<
M@S#G*'MZ=?4:]^C,43W_!4Z^@-V:Y*Q6CYA?XOU1;B2]'#X(M=L.FA6:(U+H
M;)2E+\5#U.LW6+9C[TD]NZ1&B2+FNBLV4@N/+0YW\P9.>T+VA.21O_WBI9ZB
MKFFO)5Q,:R=<455.XA2TOAYMF3Z[JBXJ.EFYHZT/R6RKB5HLEZW R=OL:3><
M9Y]^B+%09])XGPG+@#W-[0DN_5K$V$;TM;0G&)\EW6+"T-11BIBWP: *H11X
M1( ;=PN%CK%ASTJ]_'8YA8 LU'6!W+#% FOS?Z2TDY&=@TNLY%Q VY@0OQ>T
ML!F(CS J"@?Y?=W<^\K.X8R&0#;TWMIMI5N$%5Z (WSUCY=YR%%@%;7:+1V'
M(:B:MG;A>6WC*,?:#XR2Q_,8=WW)O$R+,GG2"'R5HBA&UM,8:V%@PA)$FX.Y
M_F ,P?B<*9$E4Z)#7THSVCBS3"C\H2N;"_^;YO=SZ&][#-RF%O_)J18_K<5_
M<JK%WU/"WJ=ZQ,,WYOZ>T(KFJ/_&GX'>^_"WS*YYW2 )> 09:=):*9IRMG,#
M1^/LS]?I7SO2*Q<VWE!*&F?Q=%ATG!["%QR ;JG0-PZD_R<7Q"N^KPR?6>[2
MOCTEIT'U5!*&^0CZV:3\/&G.-84X6I!HVK?2CT&CN8N)*G[B2E]*$F"%?3_Q
M@HNJRS,ECR<P@G<@5W*G](.F*D?.]77B7R?<9&6.Q"2CPWJB5FJ;$=JU37!I
MQ]HD\@@0+*M?5$+MIQ ]R4U?;93VG7*[D#@@][RK-MQW7?K_34"-4JHVL5E(
M>_HU)/Y9=4#AF%HW-$?OA_2GV8R;GQITEL?&>O)[Z=H3M1V]K#>@R>URGK-B
M:9ET1?HDB,VE&5OM$9M)S)GR)26\.SI+KU/XO+M3!3..0J=&/ \"F+Y[M<Q0
M<B3Z!(/215?ISSYVN:JZ5DLXE(BG6A6LJ>KYM+ ,RTE5FYU=3CNSPR1MG+U,
M.ZTV7$UOX$W;1#3J*6T5FX>82)SDI:47)::NI@K3YI2U"1QB?N$4MLBIBXLL
M:D=M+54Y?]"OM)\R0$YKWIWK'2-U%*T2=>@NBU^*;@4#"-J_Y)PS'DEI]N:_
M?X2@A?6I-276EZOI4<:,HXNZN X@I7AWQ1?GJIOFL'9]F0?)X#R\JO^9/[/A
M^=#T&F@.YP*,G+&DU(C<.VAFVG17-.% J^R?,#=,"UFA*F&(++T7PL\S2.Q;
MS001 W.P%@N#<&TN=\ /4?$O-X@P=1TB@T4A#;YE@)<P%[%_)<7 L%X,+C&]
M?X3SMA^D,H5K-=PT^EM Q=-%1I$,,[^%DRN%6W19I?W%EC/M&"GM72M_[@>-
MMZEPZJ<UMAUWFN%29\0:@6FQ+VNZB@=AOD,">2GQ(CD==2FU>T(@F8VC$SZS
M;_BBNV$-HC!26(UH\^NV,[DMD:>@-0E3(OEEWN9.V3W"#(Q%,L/:VH7AQ51V
M^Q$ (#+5V+S)%CW@/&!* Y)JTT^[U06YIHXJG'0-\]ZKNM49\AG[0#U@A]42
MP6;LVF!1()+@H+5[/WX8VIV]%MG,,H0U_2#)2@+;Q=\80!B<6$P7Q9BR@0<F
M&W5"J%#^7''6/_T8G0_Z8'^$L*Z'@_/97)!JJ9UY;U8TG1>4.NEL$T>\6N7&
M)4>'B(NYGR9LV5%7$)\Y4A-OC8B >/X.E/]L>=;GSQ6O-RX?"'^ 7D71SA7F
M/%J"< 134EFNH TU @5X2^-V36#+%.<S*KO*EFN7XCDFY,/32T>SP#9F"JLC
M[:0SB]1V+LG/_PM'4+2D(V?<.U;J58@K76P &(,5XZI8ZOU&G!6AZ\SQDJR3
M[K.*42^S/J>=?W[6ST2_Q;$.GT=T76F,%02 3PYI@KW[FOV/H#*8O2"\">L>
M80:1;$'8+E"RIWRF/WSRY&-.67.7=F1%MF!9BAK($UI ])A@1RL!:%4#Z5F$
MID7O8-()6-=<&L7&Z;.OG[]X^C1W%AW(IK(;*/TR V.G"Y"0 %&Q)3GL>!_;
M)CA.L_"%)4'PK@].Y+*F.P?N%V!W_MC9^9M&$^Q;AFN7(9XRE3I.:],[!//O
M=G49Z=4R$5VAY!60[-HM)^HK(<O##U^BLSD>?2:*PW&*<PM^SJZ7HT\&S\5I
M,WA+)7)P\$#24?>"3D=\(&8#>$/I0XCJ%/$KR/?J([X<1V+P('"E!'1XP.NE
M4Z149T.8P:!73[_/,YDSIW/&E8@2LEUUU2-_XK<^Y3 8_+>]W/>4)2)3+9>7
MPBODW>Z+'?$H,]!W8!! &=2Y8$(D5\C%&:%ASJQ()HR#E#@ZXE0\-J\!#<83
M$7M!=!9)"-/_)[/J2%VG O'Q95&OS[,?+ZN:<EP"V$(6K[QBCAHM<A598E%[
MF67>3@@T [PO@J4"(V%JBM8]HK\_SUY18V7RATFRR5%R'M/5&B2T.BI,!B6]
MT++_D:]J_;)1#9</\; N@0!K9BYCM[-4=?UAU?6*MW168#=4'#<QX2GY+JKG
M6;[RT>X7W4K[Q>29;>C.@3LO2JE-QMI4-I<+"F\GI%>43Z/=P>_Z>X+N[_%%
ME$0<;*GQ;G+/S;3_@&W;UNT%T[8'2242^=&&.+G3Y*IZ].#!$_)XOW[^PY?/
MO@XFYP]50&=9+!39\&O2>3)EUW^<OSKWLU!M=O6N=]MB^1I^;87^G47G+7//
M<\=?H$;J_Y9VB3EC^53CWA<]PNS]PV#/:RY]L@!-O;<Y S\\N2=T-[FPFWJ]
M*52FUVY=AB3)]L7),N@7)(CN!-@P,M]1N;Y/^0+/W8\A0%QA4Z\X8S$:;MS\
M9K0]PJ/Q*72>/8T9#QM^ZFO,/=Y-'C_O!,:HZ<A+FGF?7[I=/9J#[%L?XV$Z
M<\<V%FOA0NL3RQJZ\?V5?'".>O,64I''@;T@&2VN--%HX';%&Q>ZD'19K2F]
MX&9.2_9MJFY\.:2 63[6^IG9D@#=WSM]>]^.K=O4N3\]U;FG=>Y/3W7N>UKG
M-M=B<+[ +]8/3JXFXJV@ ,OO5?(WA:-P[+MRU,0LAN+A:LE0F5S9KY<D:OC;
M4%I-(@.I5NRGXU!]0=3)NTAO32$(?D5Y36DI'56>B%/8_U%ATX-Z!$<O/8]'
M<5! X0B1"'3"+^6X9,C0<MHKK=H^\15"ZAW^@5P[U)5!BFPAAX=I;$Q<DH)M
MM7-C"Q]W&[WZ;"T9D90+2.H0!7=,2==WBCA.[M^-!JC>8'@LTBV2N OD;_[^
M?9WWV,7\8=2TJ\R>S@ B>#E##84,0U<-F-9@(T*+8)*'G+LM.IK_N2(1]P%H
M-S[+/EZ'/A 7,X]"*7= K"])XB?I8LUE^[D@>V^&\^PK\7"X%6WLYW ,2,AT
MW4<NDO'J02(;,!?G@KH)R_6@;-\:"Z'S9QD/AW0K8B^I_\8#";Z%W>OLL6W:
MI@1*Q*5E*61TX#".6,]G010VG*#(35V]3:A;C!N'$AD?,_W.L&^(]&+J+:DV
M(QR]Z,6>-MP/C 52*H-V'>HZ#L:1&] N,=^RM?&O4@2#A.J'=A4E,TR?_ ^T
M13B-* LK;?BAL,2N,8TC2)_\@^BE*"B*9_9_B;SK%_BD(6:( "O\YSG^^M&#
MAQ__]>-/GNC]L2B7WM.RQ[+_\+>%QHR/H0#[\%-B=Z9O^N+%2QX[_BOXX);,
M([TXXK9!.U5()[ L5OE:$UB]]-B:S"6G794ZRBZ*U+]SR>6-.@X4Z#L&]YI'
MY^EU"W0S'BOU(\I*QL3'%!S,14L=C+&>D2"$23,":#Y1J*$S30\?KEJGWI!B
MU=0@\'UF]BD0ER5P8GZ<MQ60-27MUKPLR4.0F-:G^Z')&])-\M7!F'H"?!_"
M0$)2G7 $3B<H&T]0K)^4TRE)$8 $?S,W89HF'8$! I0KB-9G/Y9.BC*$G!A$
MGI!O)<@!HI3 ZM$I)=UA!,7H,*@"G")51R%R5WIST>6MR\Z9CHY-630"> E;
MZEVJN:5=,6,CL^Z,>^JWPME_5\O7"T2LL!.EB=(R"WL[;("HWRLCE/C(\^7S
M<!O3IJ/K/+6G\F?A_6>^8AD.1$9VQ*H7RQRP[HNNV/19"F'XEN*1CH?&_ZA6
M\<-I77$T=OU4;F7DG32!A +V\<;TH^PII\JB(+1CAX[NQE?(;=7NE1[+3]%T
MB7[,MJ'2D#]-99L+IED][UE3S4,%C3\,E+?V8**8 (!;"U9.'"W[#2$OD)%9
M"I\CRP(ORVH;,,2X[03VM&MD3?.8CB4LCOZ+!'*617\I"E:O*P@34"L:TSSB
MZ=>H7?#IC9<C?!KEB^B_:L9TY&Z[ZWP,HB6[HO-7RX6@?P2H05VK3=@!\1GI
MG\H3_3L  URR:HO@)9#8WL,+R;G.T=8B8D<G;^Z\OZ,;*X^[2IKRA*E8UF.Z
M1<^S%R^>/GOJ/7^_F!?R<9S*%\1>7G3<LR-MBWQ?<@<TQ1.04B7=#A<ZLKA(
M@D6MR]5%8$TY:A+TMDJK1S2=C$!D#)Z?D?/LJ1\XP2>9,H4+9='!ZNE!D. M
M?T;L;JK% 0Y.@AO^5ER P4,I9NVPLLFX])K&E2A% K9[<Z;0JFLY %%%H/UU
M5-(%K-GO'$6U)0-J+//4:.3)</&^P+@WWM'J.C^WTEJ\10!#1D)+)&7%=35D
M_3]W_H_JO=ZRP![J%]!\Q\?/@#_[9>='W.S9LSJ^>-[Y)B4AUGI#L+?T)VM(
M-)'7-_0N-OZQI7#]LVRRG8]Z_0:NA<EF3?08A"* *70^6I543( &$1T/JCYI
M,#\*'S?292!ALN:YG.:YR)W1.W/.'J8G%ZV+U#ZL3]1)MHFF@!L,FYN?YU)E
M(#T6 YT;:QSC:)H<"5U9;18HEVH1/FS\Z!TJ=D>N5YQ)6!PTMQ#62\3@\"62
M/*BEIYUFC,D0X27S*7R>_4_ I]UN5Z?.JP5UJ+.1BZ?1CGU99[(, 5X9W=_4
M%Q$7%-T[DH\\?."=XGM_Q4=B)\OT$^OM/>.FT]E3H+K<7/3?P=B0%XMJE;;_
M*)BLM^/#R^)/@H:HCHI..S,-\-V-@_OC=C?UA;%+B7Y' 1=IDE7Z2>?"GOFO
M<C=]U=?M-?;9,3FP*(\]C [?!#A,D^@C7TT2^/DHR<F(:%&7G$;Y&"&<:FH$
MH#@?+3N##4_9H+#G0R4<?46<,3S61N3F=2_NXJ./SO"*S32Y9(E0(*#UU4DP
M:^4.W.:PQLE:Y3'=PN4S.MPH]1AG..50N-4;F;SP//(TI1<,6-73^717.O(G
MI]+PM#3\Y%0:GJ,C?^?WU@\A?$I"0Q?!WK'<3#[HK"P2'V/EN$=%[TIVZKXJ
M:G\H/F,54LH9\/40PO_9J-/9=+=&FI6*^$BR &4'].-!2N.":W@%0V>5>H)^
M2>#F;$WCH%[N8K?:47*)6DL('"/>+0[GB*MRR&G1U\<OW!2OZ<L"1#?]RHUW
M_(4WV'PKLP6&$B1]4[@WD# 9%P#0GH,R&J:9FH+BH-+A0(?3NU$REOAS@0%!
M#1X)V>*JK58T[E6IS2A2] Q_?_,@=&'C8"1Q$*2^8IXHLWDBJV$>J$S-*Y&)
M]7W9#9ICX)6)=D6QCTMC'VV\$EVG<$_/AB53/P"7O3<JHI.[T3Q8'+S7'JWC
M)F[P9#/X-VR<)!_#7\U?QKY(>.]D;R#VT>^5R,D9'YH&SOX$/3":&J=%-#M
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M3*T#70YQ2=&T:)H='81-*9Q@YNOXT!I_QB;?"6NVM"G9/E=@@YZR-!V-/D6
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MKR(5-XX$=TK<88]_AC,H$BL*,!C,FU@0Z)@#&AR&ZE)*Y[J])F)H$-OWBO3
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M08T[WG&:NC)LD"+(<UVF,:F-W8KT4U/CE5Y,$,1R!J*=6(4$K.\ [SUKZC)
M3Q)J%P&[QE/&_(NJ"S4*F(NRXQU/7 &-IYJVZ$3 DN[$YW/= J8-1]2.TX$Q
M.L?Q\ULIC++X!\]'HZJV2;YS)F#-8>G.Q*1CR)I60&-XS+*E@?S/DGIMK(+J
M<Z-<>P&7U=^+U8JRRU)QLMO:FA=3<GV1A9'4AP$(ZRJM1[%VG>D4;CD0U%NN
M+TY01=/R[85T;E<P.L1PMF QZ>((?*BY(2@ETY9FQ T27E6):Q^&M[<J$[JX
M+6&A375;FSK(Q(P:-R0-;. ("*'^]'(Z];XVK+3\[;L6>5]=E"F XJDM.AIC
M>575<IN6M.N+JKO1HDCZ(\ICXJ!H9J=/'WV5)R3NC !$JG]13<4^<XRWX"_G
M:1E(;Z.DP\2HR^KZ9M*T'+L+O'&!'D^^3G>8&.T,Z:35>4,^].^O-ZL^S_[L
M5ZU W![8(3\1CH>_P2O_MTON:>_5B8M<&$4=>(MIDNN:[ [I#_(V;$L$ZG(?
M;31*-RFO\3,O42MOB-!JG)V<G&@5-3CU&'W$^2%O:)H+4B(,+T+Y#43/;E#;
M3# A9R=G%V0J!RO?#__%M&_HR4]R^OB<,'^+Z6O4K_VI6)+1I^,S^CL8?!T1
M 'IC0,(VN9,UG97314$+>E>TX;+GYT%OJ51XH36[@)6R[JB5/ME\[ 2>E&=_
M*O\UH6:W&Y*7N(Y-Z]>M^A=7VTZ*CI_U0SDI:CHEKS;>,,8PGK=T;"?>M#!2
MC!L<2T9VP)M49 KVRN84!QV1.EFQIGEM>GIDA=WI"9;X0F6C(D!.CC@6O!QP
M!RHC>&SK6_[$0%-TG+VHLV?EI%W3^IQ]A6<_3IG PZ'BW.DL*ZK6D;G[NHR)
M6%H$DMVPUCT14(K91Y5X7L??5"MSE.L\\+&+QT;/" \<O+XR+H@8IS]6L]FB
M=-]3N5S8][N*2NC]"?%3NPS>RDST ^S/BK'?YKQ*EW5-QMK+DNI$:*&?$>'=
MV<G1LSQ.1L\4!G1#-#=\KX9%A5_*!.ME.KZ,QI<'D\[?NFLMO PGBFV]:_IK
M6RY!I"XDX@KV@621XL)*^:(>77DO0_)1IIRI:@#H-1.J'G]5%*CKY-?P!8VS
M\%DT?+T%E[B!@ "?);I+P7AR*'R8MWX?VS4 UVVI*_R,6.U#?AXH$R&Z/V?=
MINLIXQ8=9"XYH/)%B4<$LPLYI*H623:%+ $<L9RYH/2@%/U.OT9%RG'V)TU&
M ]\8E9:L.(=9#$5)&[QV+(5,1W:0MI202)(AF55=NU[Q(VVCQ MV5J/_KDHJ
M +$#4Q>)(X5\1]J0O"Z@WFAVB:)'7"4Q0,QRN!K,!;B,9VWK(S,"^-C^N!15
MO0N#AL>&.A(>7RB'XM&EXQB:%X-+F>]#<P?0 %6U&5<X NGB]9WH!EB[/6MS
MJBN!F/)M$VI8D"\B.TTB&A1^&0X H,.2</;+<U_2"MK1CHS^DX+ZP@,:UH\3
MGEQ'SG>-Z]9:O*T3X7Q;T& R9JGRXN6EI*1,!4O<\AS6#ZZ,^56 Q#YAO?9<
MP)QQ 5D[V1EC(T:[* A7E9U15=*1)&$?->@GS6;:]#T:H9@S.1*1<#FC1L-B
M$5VXQ :F.KQ#?+@U#H6*"J&U6Z$> :]<0_BQ$@YBP:B#0*0PD!%G3KS0<3=5
M$B[E&__VSM2+1B?DTI\42A!?XS-=!8[B=/U2*R,[_V@.5 2C)*!G1O,F1I9-
MHGG1-6Y43\=!_"35%5BSNQNOD!55O+$EBT+GX2T=J+*^]4NTH/]2RYIC !R.
MA#:X(3?''\]R)FX%5J3$6@P<1#9&Q-,3\A%_7NG.B.9-ZM[%(H'5K@G$)LZE
M%/%+4:PS#4CFL:$'40/@L:Y#^B)9;N77$61]6?7\!FR+_WN3H.URZP#*1QLN
MA/##^T?I=:-+HYP<_0N_&WK17K%92S%,)XS_'91:-$9,.2*'@EN"G\61(@\?
M=2Q\[,UO1)2YK,< SX::9(XM<W8R&RF9IH^;-B#ABPF#F]8-:RS\(;XM36T%
MW:0!S/;3XD7Y+8(0/-J72FR72CS:ETI\HB $0PX/XQ^X>.L)7!,Y$3%O:+O;
M"1G/*PG"%UY8I1X\=.F )@-[,0Q=4B OHO*$6HF&@]PQMJ,AS5<F'A[?FEYH
MDW+\EBDXG!#&1<'Y]I8*.3A.'<W^[+MR#J#T9W3'H/=?6%5$@U<4\RK%W!%>
M*7F"=S8V[%[%Y4R K]*51#,G%Y[#PVTY*J!!WC?^]H9YQ7=("X_W=> _*17&
M+>FMD$SFC -*PWW@"E.0H,2?R+AD'LW8Z$,#5+!X'!7/4X7EP*RC\@3)Q9IF
MC2JM4MF>&M-Q)V%MJKH@JV<EL*X[1"MW0(W@.XOV 2>&,KF%,$AZ.Z"]]@N]
MR1G^QW (2\?&+]NS9.%=C&C;TH.0+-L:=F)BWG/M)LO^Z[<0?,)^U>4NT\ZI
M5;\5C1?&AV@U#])7)@(HC@C"G7I<&@ Y>&=[$=(>2&V/IRR<((7@2S#SO<U=
MP^)#2ZHYD<U=W:_;V%06G#S"BQA#RI\'S^6>XEBCXX4$'*0=)C>I?!Z,TR_,
M#; >);NQ$WD";:^4V9I^<MP_OS;&CPDIN4%U!7P:L=A#Z%A6?(+8IQ4+QK3O
MHK\8,C7_6!,%/'D1B&MJ>4;LA!2L>(ZPNSX%>^;*-DG,("I$2E0&%5CHD68@
MG]H&38GF!>"YC=>KE1"*K#O<Z9R19G=NL0D=9IT$TUV1<;4TK(AP OU>50%0
MGPEI!.&:I&X#=X[[T;GTA^=B9!@.%#UEYF]\G*V8,%*K(V+KY X9(G)[0ZPU
M\%KJF>(%>D/GM^-H(K<>PL45(" !"@2PG-DH6H&P._/66\AT0V9#V _MZAGL
M:]#[97U;M4W-9S1&N367Q75-,T3Y_-_Q$S]^LILI+L* XH*HP/\0B",H 'U+
MS/WF(9\YD]#G=*.Y#TL/!#T*0Y BB?VB:3BY.*5[M<\DP%/0[8MR!VJ5E"9O
MI$A;QD^(+XOOH,%(_((#2M1R(&TF7"ZD8U@6T[8)&I(]]!"FLH)AXCG;2LP&
M?A?%!&C.]$HG21U J7.1T>AM05_S0K>0,(U_?R.1JYZA"8H^;2^<BZU+IBPG
M-K$N=>?5BM9-A5B$>W" -1^W#W9W) X"!6U1=;;SP]\(JXH0J0C<**!],*%1
M%@F-/J>"GY],)(J[ROUB:!YS.WG@KEN N*%G:UI6I&7G*$8<+Q#BWFF__J2<
M ]UJZM90M9TR_H"C"I9,O75QC]\](X'#,(>1Y ?&GPP_[18BZ*MN[DU;LL-Q
M"\1Z$KYYJ&7H==)/%!BXJI2]H2T-LA8-3!8/;H!.F7-.^ZJBI*IH9[V9UQ--
MJ'S&M<VJ@+NH887FX2:9K]G7#:T&SY]?ALS=M\]??N?]XC5HJ"C^_/=2RU!%
M,&2WPJ__&$_!CJ(@?;&^ZX +8A?L;KVX>G48>2!8@W&50!(./:@.1?0?<*1@
M_!Y4_B?),U"08'XBOFI:G4>1^SP)16/<==W<<GS]A^(N 6+PWL-Z86R/ZW5%
MH5BOJ8\=%T)\Y]>.7$>6H_-3K2-!0^G,J(QWV)F =]'T@<D7B[9"U<N2.;:_
MN#A^[)9D,LA5\,7)\>EI)G_)%8\1!HJ6;;QEM.CV+RH.,D3-I.LD(Z9O%F+O
M7D,V0DS)?G4("HG(OBZ#AEQVS>WQ\9G.9*#N_"__[#?5.^,\"3^!4YJ "TM-
MU>;/+T7OX;FWQ8)' +PJED892!-Z4&N)!F&'=HHBE*&1*<8A(-E>T%N=O!7S
M8FW_Q>.SDYQJPP[^^OQ5=N;/O,[L,#LHJ*2 EXJ6](C-.[R)L[0BVE2V+4\]
MS%.&2.ZYE8X(U<$N;D1N,1#C92$^BRKZKNSII/IQR-:DRY='&F9[DPQV3>9X
M<D@/(<G"8?7_\8@MOR_.O+"%I?CJ]'%^\N0"7]9JJ;"GYP&"HD U!6)ET:P)
M&QR<;(;;,_ !II++#2JY.,ED(34T_<[SC3BK(J"TOGY?V$-2$L@M-Y%DJC,L
MDC3F.%!'14F*>,T!S<EZ=EWN++BT[1_L(%0Q]VP;MN<\D.'7>$6PCE*-( $S
MI^1P=['NP (KT.D7]$(>>J[Q$UZ.3L$VL([\E<\B;/ +LTL7^^S2=G;I8I]=
M^D2S2W^3#/[0-0IFDH.9U)FR*K+JX<_F,44MMZ:2,)(BU$N7Z][CE874M5ZJ
M-FV4*\=ZL#]4/T/K4.V _X^EQ%0H]4 Z[LA0.!D3,;4%0UT<H3MP=J*,X2-1
MP0<T2W%;Q%+8'D4G\*3E[)"M@6!SZ,KYGU1=G+%:Q# ZYF7;BB$RX)I/AT)+
M_&8JH2$HWG2F3F=Z$&[ IJ8 "1D(E#RR%H&?%J.(L+X/E_Q]HQP.R ]CO:*?
MGYY\J3.=KI>PEV]+ETYF?/1A'67LA^@5&RS#G(9\1*)3SJ)T^9&&Y1O9M] N
MZ^)^%8O#=!P,%I.*2]F2ZJ/3K9NZRR"B:FM.,0C-='1^43NB-VL(CSEOT9U^
MN647XUZ-EDU<DSB4D2,RF'!H;ML:BVXC7?!M-'#"T5&4CA#$HY[-%0^LI<98
M:)G46#>>O9J">3;,M-H)W#-T=[!:4$/'=-JN!4*-(G"'P?[SSM^"$JOL.5$G
M'XV-_E_-F'!"I0]QN6IJ[:BY.GH%7%^F7R6\L^5D48[$B8]=TJ<<RE*-*16&
MHB^FRDS--?K3U%725ZJOX3-1K+KUH@R$L/2W_SYJ_<,E@)[T@7'3[]9W"*I4
MT0O3U12^2YD6:M5ESF2G8FTXJD-IJZ;JFIXR"G*.X.]P2=-&3=N4>I(-@<&>
M?1;&WEMB-K=R1VZ\G]CEUBMR5O\'K1%]#2[J5>U21*!=OYVCFFC[[FK&;ZWH
M.W":*)4AOZ-6T3 J=6$"*%V\NB(?!$O=8 #VGD"Z2X8=2-YCV,#APF%8OV-<
MA2OP,H5%HJ8:BNG?<_$D5P#16Q_Y.PX'+;-H4-O+<! +^PCTN]@PON242D2L
M'ZW%ZK*%_M[72@OQ%'FH?-C[S4I )28)OX )?5*)_:Q<<IYY7A)^0;$@O"EJ
M-BBTN8]G0'OH/PF%D\. 5&[0MR?E=N2$E757O7FHJ@;XL4.<)\1X(O B!SR\
M+$Z5R)7DAF"FV0XK;&QJ\&2_I*/*_#C[_I8"ETEW&Y6?N"1@3 L>_676P?X0
M9C69,_XG"T$.#1U7I.K]-H0Z:!&AI2K_AT?WW""ZQU$=K^NO&RERCJ@8_ CS
M)LLH@4L#B%=;;1^E%%&9QA92W  6A> Z<WY;IOWH-<G:QN.0A#F'(4Y3&C$T
M-&AYM6J@288Q=AD.@QLIET@,<@@["2H(;IH%M:0Q"#K&RQE&4Z<[:E%:O67&
MA8HI/>WWN!,'"H)19"@6:BU(N!G&H9XA#90(H8M&-10G8N">4+;#6,_[R^\;
M1@*9$RAL>@J=X<<99)&2(^1/2*/=-+\T J^4/ B/<NYJRAZK8U6Z':Z,RM"B
M1:7!4Q(J2(7H-L((H99CX.7H<YIK":!5")A*/APU#V4M&M4QJGG,>TVKUOM'
M@=A!WFX):EJJ\:"D[0WU>7XZ:',?X^7_9T#+)U4B53 G<+Z-FD%7%N<Y69)B
M_C_<F50NB(H%+F ,27C1BB;5==^;R66UZLW_&XVTL:MFG\L,;9_WKZ7F$<U2
MHK:-["'45](Z<P6IW5I<I4N4)66 [ESPMFB_H*; 4BD(S4[WC.?#2(A_'"2$
MJZ"UGX3[-Y];^-%\(-.P@@9M6QL4FQ5<[4SW^!0]/]=-0PPN2!VA+(I<"?2$
M%&@JJ6N>5_F&.D4!6$K("V8:XD#H)Z8TW#'Q62>*G$<1:W?L7'.M$?"JLR4U
MAP4K)NOPQA7X-P(?"1YFRJ!RNG\I:H!'4R'7-7?1W#8] X3[B0GVOK_?&5)M
MZTA2PVG? PI,C0&2EZ52%VP#8NV0HUC/)';,X'>N8" )PN+BLDDIL<G%^!"*
MD:F_5#IS_X6"#[G8V&4QUHFZ5("1B7.+W@??:EH/P@BZ27.45-JAB"QYQ+A4
M<?6Y^=K=30-O[(YFI:VG*_21=N)8\%Y:EP]^ID'O3Q\)(%HV9OT\O"W=<ZF=
M,KZ4^N?H.7$#;@,C;JO4?"!&##_7L>PX#$Y)^[I4W,P1HM(Z;Y_7S.X+@C_S
M52@-3APJ=-N4:F<)H3FQ>HDGCND(*VE&!#\1\/3\X[QGO6[+@(C ;Y8JY*6)
M!@37._;!J=XRG7'!^3,H>XV84=:IMV<8(!'&'_=GY"UJE\O<)*<<W5RUU@A/
M;?P>-/KM<[@"?V$>\/$^#[B=!WR\SP-^FH"\ST-Z+&FZ4:#"@@JCK[4VK%!-
M0.B.%D%PD#U+.H94TW>J&/6&8IC%#CCJDG_9 I6)47/^\18O7F WP<A,,3+Z
MW2.S4!)QX;XR4.9TC'_ZH/%+^J53A,B]1Y @\0KRK+95V[Y =TF-X #F>DM_
MF5GM4/5DH--(?@8BP%1OEN5MT(,MX3>+WZ8AJ:W'B5W  'U1^/V-*W =5NH3
M?ONNE(;'A,W1/(*]!**W(#,$9>AZ;V^L$:"S)'E6P,^!7 ^(<P";61DZP&W>
M3/-].=I(5 XA6[VMV7.<?DLI4/@3 ">-%K5KOR*UAL2CE"S%^(#$4L2Y=2/G
MUAQ;+S+7"):H]:Q](0,0/CN);@ \>U,2F T_-.P"0"^$@?FV:@0$2FV=H1YI
M-#G<H/@+%I1F[!F-ASX&]38,^54+JB3FVPQ0 9308<,?S@N/:&#>D\GLJOG6
MSC!:0C><3T[&.S L0G+&#*YB>[;FFD_,C/Y UG]D+)&8IPYF'K[G*@IZKVLM
MWHB_";'BO@QUG?JX\!8$]2=LWQ)Z!UGF%,$F]YWU)P76:G@=H=-2$KB<^05O
M]A+>(=)4':5%1=2.LRO1V>H1JAC.R"!'6E[;HW>$CQ(?H._]V"<5AYJ#*Q O
M#D8(FLW:Z"7IBV=E-VVK"2F'B7\3JG M^A**EO4<;8;H1W(>!\K"T*";,ADZ
M?WZSW0 ^7S0 E)'"  D'%Q:[@L\MES>S6:/EB(_\YQ1^_"E1L\-#8N)/;E?\
MB<_:@E@" JZTY;_Q7E3)1+R<HZ MEIO"1@O\8W/<(?0(JC10[D,IQ6(-X6QV
MA>Y#T]Q#F-MAU-9AVQLE,8,1-*A"O3 /)9(-9><DE)-K<H"P-FL.I<Q+Q>JW
M(1X-2'5\U$TW#971=+0#]FG2]&[R[?.F3:-!L0$Z6#YYM(@&/<>)7\XA2IF*
MQ-54)=FRM[9<E+?2",% Z=Y5ZZ01.@PD!?!W!>,&V.7@U6" VR)V?:;A-B'/
MUAY-"97HHI%Z1[D:\_WY-^$>EVKI*5:MU01,YQBZ :TKW$MJXK0F.A&(GY]>
MA!(U&4<2N@OE4[9RHT@,4T2Y:+*EQDEF#;2M8 VQ66- _4,3AUFH4,X8!_95
MK)T;+-C(*B$NA^<1TZ--T<)T3,.RML^4HD2([M5$;RH<#02%,9V6*R2D=!3)
MOAZ8ZLNP"?Y8K=:!,@5$D.8WS)R0!@&ET99>U<6%#)8G<3=@Y8NJH\@[ M2'
ML&3!W0VZ=-1[<9LOE3HLO8JXZ085!2(X8JYM+WY@!=@RH>:BAM-!L!.YZ*4L
M(\V :Y6*T0+#>*PC>,$U8SRQSD^,<S)AEEC'H51<G/C;>B,]7ZL";<M!OAEV
MM0X4]MRW+ "FP])3?J^[\S;6O%K(K5]0^27"SZ%R0I?C)<C;V@(QXZN 7@=/
M2D=W_O#1Q2%D?@@NU#9JVG8038PC^ZQLC[]K*AHQ=)L09F_'U)>08(.HH>ZB
M&%(D^IJL6/6[&%L,MX@DSZ146VR\A+)B)_&<H< =P8U(&%/WEL5(];R>*2:Z
M[AQJN2Z>G#TY.GWZ^$GHJ9&/N=3+[!QP"JI;+5.))#,S+6 W1-D4'Z-<2)D0
M6'$ARS7;^UX%T-UR=O*UB(F++\,'IU]G2FO9W-7QE"HK3<[P.=#N6F\1X; 5
M-<7\HK2X0&UV784*H/"%K:&(^B<83#9N3\\?J3(S*\5AD9G>Q=4<>-U;@XG+
MU@IX4GQU^0; Z<+W))Y:I[U1T/UW]!E#  AT0<U_,[4MR70&#+5MN5S7]L(P
MV[1]5J6DG"PQI^8:[D!T3YL2TL'&>*>;XC%^1\2M*TS[]Y'DUY"&-GH#-F+H
M\&0 Q[XT5 #>TXD5B8F,BMQ>Z6\,_FZ*$1;!)V>:,+NNU3]9Z$VOI6GCY-F4
MBNU!V94*/-LO5M8!R]V%SE_5>):]*P;?R(*%560A[?OQ'N)1.J1\.+N[HN+"
M;1J6PEG(#+=:84?V_AZB2[X% L?EI'03=%TGP0#"[=BMY(FO26S)1"BK>L2L
MN><^01A("V.=CHQB)3 O# -S@"5>;!59K1"$,Z.0&L+[QC\'- TR^^G@G%U$
MJ@BS1*MRAPFI$ \WO>\BB,LH2<:_-RW0NZ4OG^S3E]OIRR?[].5X^O(38;FZ
MJYDC0Y7Y"REY<*_@4G]N;%=_+Q5IOYYM,YCP1Q87D4+KW9 T(()_XX,TX#.:
MV,E#/-*PLFTUD:!8R*;KI-O+P;&O!*HZ()GMG8X(GCBR#W=DWSB3KT+TB! .
M9SOVZ.[=A"-;^+MSD5-DA^KG(0^A1) )^21MZEX5[:3P%^K1BS>+<I-=3B%'
M9R<G9^A%O:/6"*(K7"_*)'RIQ>(+2$QT29"O>&6FYG_R_1L&;F/#M LH=/3]
MOQ;=K/AG[J1@2EFDTGZ1.EW!*C498W$>3.^$,8OSJ,#_TE@:9T+)))Q5W731
MP*2C[P4@+R?5>D+I80Y&7,4(E*N<[LGY,&T^VA>)'.N.\Y)=";*=;#\2QFY\
MT=D8 L[E8%&D"RH&"@S8'+2%&/@"F47QV9D,K6J3)0_UN30"-QR!8JN^+I')
MI+[+F'-6M-W ^R@DO# E)UQN+UG $-0./"5V6T-L7>*N3&@I47;YF\G&FV?@
MD(PV$7"H,W29@%9AP]6$VE<GK!] C<.Q,KN*571Q(NCQ$5:57K%@3(>+/HV;
MEA305TL/$ADW$'H[%C8NH_= "=!9]@5O_Z?W@#BIH5G\4#(CZ&7?-E1.24A#
M)F<1_A[<3*9,Z49*/4;@2OQW'=&X+9EK-G:WM1$4,X&\@Q0FO#)8Q1E7KMJF
M,;@%B4A^3L9 VL839"RJ+N0RZJBJ&%XT0A&V*,5"#3>*@ULI^ABK+=U)3+F_
MQA,@.%WSS*ZY&UGS+/![W'D7@JLEAJA.'#\0?<V@?].F;26T!A3#I3]C1402
M-+=50'S2%[E1.IBW[3Q.]!#Q(]R?\>X$6Y8ID1E="'-]AH4XSIYY$5XSMW!\
M,,=W])(--5ES^2X4I/U&1O%6&_^Z%XV9;T47EZN32*O2ET5$3S\E[B491_%D
M+,D13/ TFQ3M@]C!@,I\30N\9;T&@L-,S?/-VX2G+@-$B]:XS!1H?OA&M_.-
M6@BQG89FP-* R3MOVHAW.\RGD9$K(6RBR:9K=E%R02%%G]I<PMA.>CC][;+T
M1S#DIM)2.@TP/SIY=# Y#"!<VY:JM?S0N1]9#UJDRT!/*F92-(;]F:62#0E4
M([WHYTXI082Y S4BS$E5N8K]^^#-/"9,/S&_K##*%KWZ_LHQ-V.GK *H"J'$
M9/?V%=6\ .V4&@PW!6[29*<XAELL-O]2]/$1@7:)^1N/12A#Q!M&V\$RR8_"
M(N&;27'RF.W,P#@3;@+2)CLEV[VS9.\^2\2OEJC,>\^I#2D_Z&*-2OZ7Z=[/
MR9P):=1L76LE5+A9HDOD8/FQ1QBV*!)_>MW?1W^O%$SR\10I)PST%SL,GZ!^
M^)79%=><N!\!4/VQK9]?=:=VF#VR,"![CM>O.G .53#HZ-*:B^W=XL8S)4SS
M)X.?"2;>2-%\;O!.(X:EWT+F520GK:3[:6O/?N#7N/_-#I#V;GU74K$"#C:!
M;,T!D[^.0 )(C) GDPA@9@10GYR])(B@BXN+$W\7'9P&;))0,,8^F8HS 8I[
MSWZY7M+,OSC++TX88[1*6[34@:6G]-S:%J8HH)&@P)R%(1.XZZ,+@BLI:=%1
MZ:&=]LI'?:9LR0Z%8Q/OTU'X:5$(!O1U,3+? >*567,Q1:H8E^(APG#DQTO%
M$K\C\C:'D1R[%P$6-COG/SYF\&WO2:[KZ6"&/$;)B6[O2E +NLB[U]3JB:]=
M@%[C?),)PW3Q_@$:^Q =9$1122UZ4S,&R:3H*NU"T'+H;9+J.])O@F6Z6P>.
M3O9^'3A$%67GD<PLUH!:!*2AMGM\0/_]ZTH!4I5.12;K5^_(O^8(5E2I,/ZC
M 4N8A[">;@-&O\'$I>F;*$H1=06]B<U1+NGOF^EK@H7C\*$?TS_7C9AIF@&=
M-^V8<@]%]A-0!=!2>3<A"5,AY AD,(<<IBUY4E08#HT-5VM\SC\V;=E QJK[
M=P"X/6'R"#"A/<+I.NR8TX[@L+#0^E5\77)*E]91]P?R!"-M47F9F3'-!$=?
MM6D&I?T5TF,F.>P0@&(C)O)'9  :BK^869W^RJZAY1D6@;]G3;'W NL4EP1R
MX%)1^R=!A%>,C<14F(ROI+0)P?1*O.Q!UCLV#/-BT51Y@8+<\UN3U@ 7@G?"
M,H&]WH63,+[Y;XW'H+<!6\D,082I0G2LP9YQ]]DS<GO=1\DQ4' BB1$%/HA?
M).[R O/[X ZC^]X1C7&&HK=Z3A<%X9AMHN.!W0A5 I]:\_%#LNI?[;/JVUGU
MK_99]4^S*5A">47H%/(ZYA;1.BJK1^:0 C5.55EN;V13V8J+E[#C-R;I1]\;
M8-6;'%_([TGV\/3I^2/KB!MB2U+(5,#G@.D2"OC:4C1P65>:9\.=-6\%Y5#@
M[9JN'/3!28L4SW(?L;;-O1+)BL6"<<_<V)[E 9R%0JSBT25?Y(; 40$[SKXM
MF>3NKI1TU.:^[_.PW/ 502QMB##B< X[;I/1!9",5$)8HN])(!]4A]RE42KK
MULC#-0&J];U@9!=;E-L8W^"Q0.9$UMJ?.0&DT71Y'7RMU"N.P4I3V6G?_C7S
MJL #"QE/CO.A0K!##XD?P[S2J"J5$Y --BL9+*>[(5D0&E/)2W-9L7^T/)L/
M_/C&#-+L'+HT1/??7]%3_<:W/5AF6/A@USTC?M'3DZ/_#4?&;R2<\;KPJ\_Q
M3 VN&1PC;=)R50TR=&'4C:6(P^=_=?07J<=%'\M4Z-5@9<66+ULD(6Q'V=\Y
MH\&Y<.]\UY2CV)J(\G9@HO+.QT=_X?+')@-;"&?61Y1E5(9#(,Q83'UP?4CS
M.[TXF!V.26!.#2\HYL7>F'5!KE#&;8SND)$NN!;:_H+CY:;,AW/(]^T=311'
M:>95M]<\4\<'>9@,N -%8O)-.?(#&)L%0>EM1[;YY&S_=9BHF@L38]4Z(>T8
M&?9?M#7IJ;3&%'-M&BI13L"=+?.J(]XY0@S.=^BK;I329=<@PAC.3HZ>991V
M6'@SYJ%C0&/?SC' J!]F4%Z&^@SW[+OLX!G!G'X7PM^'7G@J0NS@BGJ4Y2IO
M9"N.P[)XC8:V<K%5'M-Q^%P V(P<F0+S.WN**%_@$$JOEF%;'H),6L%-9XBT
MT#N=A6Z^(-)>U?6JK0OBX9KQ?@S[EH*^=XGH[=CBSRHH?[G[;@Z7\(KP"2C&
MAX B]_1Q](#_.]S,-PUZ_[V@MQO3NLO=#HAKK9 @FI8,!U$6$/S8@VVN;/%@
M1\+\CD$B0A\468A1$MA&K !R' 0B)L+X9A6;-C$0@IHREN2^AG%0P[A#4MQ0
M4K(@*/]3X6!K/XI(T+O11M* ".^J7)HB/W1?C>\LVJ;!,8IR,;H]><#)0'5,
M!E!"PN77 *9K1N$10TMX1GTF N(>,"ZXDRCI!4UZ?^A(6&2=?ZZ!1I(8#5Z-
M#3 7 VI< BG@TELY3)*^F$R403/,LI<QS#RRKE"D*5&E1)#&L!$16E5!F%4+
MKBECTRL/B)#;A9M-&V$BL4Q*4<FQ?87O-&M'&0B4,V.?3=R] IIY"%QE&DV>
MQQSR7/NF&)(P%"C:KG_=9DKWJCN!]F5F45$8;7TYM[G[^_]+FLLUFJ5:-^Q!
M#Z^T0)1#^ +<>@B%-P$9"<"1D58#\(C/0L_UUAZ/G367<LVPG6H$C5</<<14
M3V_$[TX @K2X64*>(2B,"UQ++;8T=N.DF4K:]]ZBO=\FFZ^P2IR_?:"2_WPN
M?,X++1KAH;>5)@/E[JR+KEY/R$9AX;EXU.2MI+:3$A%:=KR_0FTTAD]26'Y9
M<C>(BLBN5',.B.%D7)PHYTA(&1@$"@;CS0;M!'P-+39<R!S^=5,NH.3]/_TA
MHX!]@&I39(9M(+)J"+E!0T@@ L> X5IQ J=^4/\JF<L\XL))C78H<2U+2X'B
M$D54EX0>18D.TCNW385E3)C81U<Q]4Z8;'Z!RM9AM;%J7@Q8(CU-NW$QX,3R
M_J#7RDZC9DH(M0Q:+#')^D=SQC^^2@JA!L>):[XE*#2*<H;C.^9L:_+31#QH
M_T$4;W/$2,C>YP=(TMIMN;T<2Z)>6G7PN$\ ,!6<HR49"CT<HZ,D5[)+PDA:
M8!&"PC,J<5\P0HU#R+CCAEXA/.%'I C .X.4X2 JT%@R+;:03 C<5) E_HBS
M&"[)9[AK^%?#\=L 3#%1QJDM Y!T<UE7X\>*D_%THOV%2FW/4GR@E*PCLUKZ
M39IOAGB9Z'T0,J#D*-QOGP^1T'9$A%YQE45-F4=M]\$X4EY7Z?'>ZA$8AI1X
M<D%WFN1E2_$"A/TX(H(JPB1H/#JA87_12+F!B58ELO6 V,&O;$P\)+GY=)_<
MW$YN/MTG-S_-Y&:(@^,<SQ=K*BH6&)V(;N)$&2VH]RHT&#Y_%?[[^W7;""7#
M?!&Q <>1!LJBK>%<FW:R03G+33F[+@U PG03M(=KT?#L[W^R70B8;;,WAQ,N
M$MDGPETA<WA=3\7V8S-"$R:ZLL?9G[2$KTC2. /DX-@"K8VN-M47VS81Q&2"
MQ0HM(MR9'G[D!!IYW4IZQ M24@MD,I6I#XV-Q]VA\B=DZ<S<5O*[8,(TL6>6
MEX-27+FBZ_F?.@W,!.(W'>NNWX<71QEON6E'HUA,W3FE(GONLA-R<\LM%_SJ
MYZ]H2"X\-?;UX;?);W!'%]?^A-Q4R2&SJ+^FS M1(&EN8F&8&I@84WT4?N_8
M=E,',_2N\\^/_' DZE9J,?B@TR&R@HZTN]'@N HY*(ZP:0S?LT*:ES(ABXT[
M/3N^^/+^S4!01'M/MQ;XY/BKDR]I<OZEE'S?^L+Y\<D3_<*YHF8/ON1.SX_/
M]$MGXE;(CH[L *&]96?'C_47%^D@S;,>\0L?T5_H/RZ.S\-8\ =Z7ZX9;:C/
M8V<=KED#?4DGBI"GE:^QM+1 <82D3AFP,22:M*M"L*NE-'>L4PODJI) 0X&Q
MN]OJ546+&;/%]EZCS$(YY7VKU;2!4E9E@F&*XVFF,',XG 'W1T7!L2B,&[3<
M KNML1(Y]H.A>ZO;JMI,M9V*N_4"8A;:)7>F]!M-TZ9S([F_QTU9VEMWK/WW
MERRID[J2J'5NO1W*7SI@JLO#1/LD%S='/ ,8,M\-B'D,UCW3=;<26=;7S!_M
MPGU-5S@3G[<T5:&-'!(:YU+UN?1:9ZWUTO"<9]Y(A#K0L":%Q/'[9,5E79(5
M#1&7=YBFTA3)B1G,%NRH5*>) <3%5VV]_<!#.-7JA@FF"-V__A*+8%[-7?U9
M14K_+M$BT)NB!!?Z$6"/%70P>=]>X!GDG"M2J+R\D9X2S8,3GM:TZ&["#V*Q
MOM^*KBQA26KA/K7+M:7_;W12Q$8Z#>4HZY%L/)T;.D*.(P8:%]J;F3;J.K:/
M)/*R551)/JU6I(O\7@F.O-TNN71V5.*/[>*+4; %]%!17*@M]?#*>"!#)"AO
M?6D ?T%H$<CQPB 0%(*?%JG^0)B0U6OT5X%92RK6->F6W!^2(1OOA,Y#U15#
M->J:S7BUJ%^S,WI+&ZP99%(1]^3];*".(U(X1FHOEP$ >_O>! @FX5$G&>?!
M^JUA14K_+)?%!23- ]J(<EX9'$W% PVPNHP(>OKTZ=-0![GU'8)</,PUM34+
MAC>S$]04FBH(>)ID0[JHHW&N8TTHW7ES%:)^+7&L0*P' A9)?G$)1A0^4V.;
M2T(UP-;ZVUX#OB+UR6KE]X%"@) :%S2]92(5GH514QONF@VZ"G/ !J$&3WT9
M;:I(.A]LSB(85%W S^8"H.Z&3';'E5>+38B AC<2R1LR)O1M34R'!29V&[\(
M6,K!6#^[])]9;TX+^6\@]5 L-G3SLW@X)+<[- :61>N5!3(W$N-'W'J-!U@P
M!5R.\KMU'3D/PC-V_7"D(28.TXG)6\5N-&^IK)<*9:G=,?LKST96T@8F;>>Q
M@&,XI R60,>'>F6U:3UN6 C#B,Y^F_3H]N_:Z>/LQ]"![X2"AQDM&T8N#:\.
M*$Q>/W<IEMC6:Z':FKH,P%-B5(=A464T'HA6W9FW9:^Y-CI=DWOE4).WW)85
M>K+^'C0JS(P$,H =!AU% *5*OT^@2]!$3@LYEYR/B>!N=WX$9E?>=@XY '!O
M?UER=-"_%E?/A=[9( 5!-\C"C3ZS$47?F#ES9D1L JL3:-Y^TO1S% =1)$>$
MASU9+KC>.<7/Z)2_*Q3LQ<D^K[.5UWETLL_K?)IYG1>H0Z*L*VLL< $+YDR,
M7Z'V.$936)>NUEX]><T1.7.-NIYJF'@ X+< 9?+>7$APS88;,"G+VEFN"X4A
MAY<;]R'SZGA:"FI.Q2R.6V61V;-RTA+X \_V[.3T@J\H?FOL[-::5F"-Q.YR
M)\W[@P[TGLFEYWU98[S^?FDCMC Z@$)D5,C4%?\S4KS'[H 1_C=OH,17YBY6
M(M[?UF[-%:YB!>D4; N16%YJ7@69/R_^KK;_4$L)_UAWH!R"_XX[^T+^'6MJ
M)N6FD;2)&"R[*-^[/[Q_X>3_A?0]1$Z/WG98>K8H_ :L*$Q07__G[TY^]^YC
MO*MF_0U]]>3+<.4115^QZKS&U_\*'W6K@CKE:4YOOOX=:>[_Z%M]J[?^>N+G
MUIGY*^)WHMS[F7Y)7CB<7C^[_YM?9S2GHZ[Z5\D3HY\^??SDZ?AO1Q=XZPG_
MX:=3VS4[FA?+:K'YP]M6;>M)G-? *+;X#IDZC*,? RH'<B^]14ZA:90FM<UL
MK?!C?3F]J9M%<[W)]8N$*8 OQL\X R30O ;"@D9R6V$0^E2_4C3?;[!@_G]:
M;-_O(4@B7'M9W\OZ6V7=JV@N0\- AB+^([BU$ED3^VXO<'N!>S\")VTWMJ-H
M4"S-GO:T#)ABY//3\F4]9=@#KLL:]:<=6PT;6SHQ^,%>>>YE^7W(LH*_<?"+
M!H.FA%@-'SKD./LRCSC"(O55#WL@\)TMB@DQ>S.-)G=.4;JV!Y[(JED%]'K
M)O04#"P94("K('@0+1,%QT*&.*2VO*W*.^6RWA^$_4%X/P<AY5?#> +'6E7/
MR8\6\HE /RS>W%W"3JE\:7O)W$OFAU'1DL769#0:5_I*>\!(71)D/1D+WL'C
MSFE)UL3XSEXZ]]+Y7J1S>E.5MYQ+%/.!"TT)\)T]_:PK%+^,2T"T;4C";,:F
M0/LA_YZMA+V8[L7T?8BIZ$DX8496<\Z@X\*6&I;<T#KOI6\O?>_+N$3?-E_?
ML=Q[O/R.^:RT1&,OA'LA?!]"N*".<($FHZ&,@5A+43MU4S<"\K5 30HEQJ3?
M*+4M]]*YE\[W(9U<M8U1V$(!-AW'"ZCVHK<7O?<A>C;P2,A6VF^LC(J"F,+F
MXTRBE\.*2"TOO >&'L6/TL HW]^+\%Z$WX<(F\I^3K5S<?8.O>G_L)>[O=R]
M![FK"W]K2[!\5G5%URMB(L':8%72YB.@/7+XQ\(!W!54(^5_W#9MU2US\W,J
M*.OZ/,F%*@;A(D#/^G<0^W.78RC>;VJO%72ZR/QL9Z5_>QY9%OTBE]VJI8[^
MFY+PG,-O2)T?-&TD7-0J\HQ9:B1T)9V<1,$B/[03PBCF0 XJJ!B!B]JO7OS7
M\^^.3I^& 1WF7L VTZ9'8?JL62G=9?G&?Z63EE&&RV%,(Q1^TX)X>UR[C+;[
MO>P7CC_:4?^MU5PF'6W]H!32Q5 Y+[$@&TJ7!A<NYL,J2:4XDD)"%DNHXJ0+
M60HG@2<U4CG)C(F4?&)(#4("?%LU9;<LP$8?"BF_;9MBIG6-2<>&-@".0Z[T
MPVK(P27BE->)\5<70L<)."BAF!P;HVDF*[+.VSXD_['Y0=HX0\LCCT"AS'A9
M=-Q<..E,X22FPBUQ 7Y51A^I>[*V6%6S!2.\K6N-4B\VQUZ22FU2_(_JFY?4
M<_U,7G:4O02.R,M8U?KBSHM%=U.MM.?WA=ZOK]C8.U(4L+<1+?X"DK$/0;0H
M0)W'TIG)5=FK?W?EP.T.[]S8<;IO[-AN[#C=-W9\FHT=N]L0A\HA= (N[L"-
M "B97+G88&20G"XVN>$\K^H;;Q'QI5%$TVB+5$!K\[?)=_<-(#R&5SMZ.-S]
M/1QYTM1]_P[#6#%;#*MCL,]-J]LL5*BDC/PU5^@W@T71,]D?BX&W.JJ6V[H-
M)B2V?!.$H;,L@6@2OP,+?>S;6 IS8*&7-]E)]$5M?7&QES\97[8UO@"_TY:S
M];34XK5 EZF@'79\A/SAEWG'@V22U*UJ<2^9G5TN4D2%%F#D^3SII6'43F!Z
M&I -< _<49V4-]' FE/#O&RF0*R 66(@I0B_?XCV1[8=M_*&GP5*^#VDWZ"3
M+"8/N9&,]L.9_2@ZS>\(-KN%FDNV1I1YW!C&5>G&^$6+Z[8L(X0PD\?$*KDF
M&9B;WC1-Q["WWG-IIFBD\GO>H1E^.!#+ZIH^"*\7Z1B(%;QX!9U=K=L5OY"4
MBHS9!00[?FA4#9_5P7V1X$!L8YG1OERWS5U_XP"8I<[--G8?:4#%J"'\*P8E
MLTWG(13$_:58\0!P(RR'@C=GVI.ZA"(;C:C!5Z28$I'4QM]';.3 M0LDK;V:
M2-1$B!<Q @4U.$(YARV2T)@HANM%,_'++9^6C/C R-EA^\03'7[5;QRYOQG5
M,0KZ=9N@*TQ"8RF*P1VCU0BP4H43;..%Q;!+M,3US(1^2[J<"U#<U'.OW?J4
MW^2N: -8[<MUUU4%A.9OKULB/"<2S"4H3?BW+F(0TK?^6/RK,('*&%"\+IL8
MLU1:E>8!YVH,1E&.EP(P+C9N#"7S':,6%*@8@?+TWWV!7C^_NM4*7#@$<8X
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M!0I,S,"<_L.ZX*MIV?02:Q33CWYU7?C+JZ%D%6$=^V_A$CAV+\Q]@2;6985
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MY&U]_. 7!AF.)N+W@#4$=_\,-1R!CC I+I:3,.Q0NH[]J>.N8[LMQR328Q!
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M)W\\I$WLQX*J.I2S.0,,P*C7!]T_!Y3_)?]%Z_SD\;X%+6F","FA?<<V*6<
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MZBU&4+(N"GD4F]EH'H00J,\V6'1;)S"Y?7GH1.&:6(P\TXC_>+%#!^3V)[D
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M2UM)^2#]EHG!ZC#ZF^8 0#2KK-/(F,+U@P*+X\GA)]/#5[(VDZ5"4-<R).;
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M+LN>P:J)<-RK"</P%ND;A+)HAGH80Q:^V'\RFS"W?35IBXJC%;11-D'.:Q7
M-C(% &H):>*QA[P(Z%L'KH)@$>3PV'FGX-MN :2.#"B?RI"^%]*@6D) 8@(F
MS@3TJ"%T6_(!HE6CS>W9[H1IRWVPNZ_PXUYY#5QVO1VKORADQ7/8C;X&336B
M.4WL^X)'H;GGSMF']D70XBN_ K=D^B13QJ=/5_2SVOH:3QQ#UQ7]%.DM[K-L
MW2?;(A;I$3R*14S0?(&1/4;SC:.Y@8> 9Q;O<NA2<@$,<ZM WUTPEG^*6VZO
MX?AA#/P;4^.R/Q-$D85;'X8+>XK1)_-N24+X6HS.D^]<>Y*%R![I=LW)C#Y0
M#475?_YUD$_O'$6/JDD[%8SY-Z<T;$OC( ;F4:-?AJ_Y,R6^HVI-?V#[.1W2
M!2Y<A%\WE2KV#WQ%[HZ3QA;4)\2-Q:"Q3_?6;Q![LQB%ED.\:IO+-E]_PJ%\
MQLKE3>"MN*;G<$F2.Z9.=D09>-M!WA1M8%T'7/UEJW!4G&5+WC3P?3I6#1?A
M>RS5[M'[A1[_#.X7,T$#+N%+^3SV;6R +^_7"LI9EOEEW2A27JIC49= ADIM
MY;$MPC\MVNLAD<'6?"Z\1&4'2"AW;0SZD'+PA#]%O96R#7M^9-RVONM<>WH]
MVNC<JQ1IU5X[_!0[CMB4!JJ7@?J<:H BM7 'V0F-6$3KHN@]&4O88(?,3&[Y
M)\9K";UA(*]XTMUD;]5D[+GD@5$"/I_"+IT$_7*?U?PJ49,+T;(5%CJ$K9*^
M0=DQ]^.B":9)TZ)G>Y(SMARJ-K!1\NN\K"9]*Y$]0;,5C!6A 3$&9^7DC_VO
MY\5%.VX:'Z79.5)$NG]*VN6D\4>4M'LZ3)]SJDR2Z%$U45<XW_Z E,]K!]I-
M-/8</@;Z1YW]60U]7)KJX9RFVDU3/9S35%_\-OBI7OJ2$YRT7!H U].E3]B;
M$D@ ^[_0C4%HBS6A]J*'"XTFWFJ&1^A67\>X-&47M$.'5QFS,M!X^F;15%V6
M6#D$])D[0IH@^&%@(ZMM&7<!QLUGO!_DI!/ .ITX_TG^Q%?Z8[G$;$J*9^_L
MY?D^FR@+/K>7WI!(0DQ76Y3KBZ'MQ$37^E)GB& ^.Z"?<>[4D>OY'NT?5AW?
M[$"6/YT9_9MD4L],$-YP>&).G[KNCZ.X#9<E5.N&S)"\8L$+@=3.&=QQ[>[(
MAWH@%T/KP6+6K(N>/RB.6+T'B9>\B,PG9P?F9J]$Q49 _*MI B=S6:P87>-Y
M:;@^.DJ-[H3UPM=Q[VH.U26<VZ';7CQ]%DV":VKO.F)*395>)V$M%_"3R/S"
M3&@9R2B.%H'"^5<R2!U,PM9SV*]]'(_"JT/J-9[HDAQJ$HI+F'5D[U42K\]4
M2ZZ;NJ0_<(1DQ!:'=$*[?%L4Z$<A.>#P65T2,$.:#:O692%UE.Q8M.5ETTK)
MCECZ/&S_) DI@NU'X[&#9%E8>6<16I=\FPVY13X]$STC<3Q!TO/=SU/.:"YC
M%]KYMFC.#M/Q+F'T]DC87"[?0[Z0AF.P%Z<&Q]+B L\Q6Y+!)T-8=*D%J#(Q
M>E)>-'"S./+\XO4W^,9>86G1H4>3@V:KIS6N FK:HJ'R;,XP6GWKDOR)9MBD
MZJR"!:*HI3:;N4+U--G)1:G(.,\7.S-O.2Q_W537RC0 7#D?9(F<0G@!?ZDD
M'R0GI%/B"U_C,%PI%""H$-5$AGN7>-*]A0-)R*[ $1'DWF^*:J4H"MYMB;O7
M1@?OM$;%P.3:NO($-SA>L+!8B#?[5S%GQ&A!A.>D1PI-LGO(HDF+VW$F[#H7
M(N%H!T^4A,@N]UUL\;&&K%?QRGG]IV6D,R'YN<@2IQTU_*9W<:4Q+L,/FDT8
M?UD)@>&@IS!Q%!+NL_J*45G5Z.9<8HP,#T&A@?]V!MD&@5NZ=YS4$= ^5^5#
M5SAA:X;^IB@5VG-1U'0(])T4.:W(+^?>PTVD&+"BLJ-B'9 \0P*"L<_N8RTU
MKVGED!O!?9LTIG1*(8;Z?R@R)'/F&A#3#3V8<VST.VY.?%-R95X?DR\P2:BH
MX@!T&];VKLQ*AP3.28JOS\MU6>4M@]SK]-E .I)7R<.#1+Q<%F^DOBNL3%KT
MM#LZS?WU1:$N3<27ZF493RPEX7!%@GH0'B69/?@EO9Z$9HO0T'?29EXC1WJ@
M,/5B0V<-H%D?%-I)?6Q'JIGT>[/T1=?F!1VS?\DW>@#_R(\ZX^=+J?8<]?%"
M(Z;8:-NS6DT"6L0HF<6GYR4M*?*(T#IVHUI]E\TU$SD-%[2XG R!Q[?[AAC
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MIFR+"GG#-E^6C8>+I3W-:,=LJJW5< &6V'+VG1OF.O@.4"S: $)[6N9*B!F
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M1 (B*2V7EIF +&6B;<]4RN/6:17J)E.RC0?'(&:"-C5?I/E*.82]A/I!KT:
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M4,:0$VO4\4.I?U*YM")E2@G;=]?),_UR^[/E_ZY#P7@3W[MN]9<4[1Z!-[U
M@<RF__W3_D\W'^-5,E[.\*/[/YN,.1JC\:)4OX3Z7^9/R&I&S8CV%U^?_X2)
MW_]:%OJME]AS"RYX/;-EOOA)<L/+L?Z0O+ ^O>5X_2<Y'KM7@FW.$ZM5[=-?
MN;'3+]?-N?&D__R/L].G9\]-C7[+8#IQ2W<T).U&[>F*="/H$RY :]=5)1&E
M[-B$:=<G(^. 1!Y:Q2&JPV_\?_\9SQ?/S_FYNVXFUGI\GJ-7'V[4Z?IQ#*:
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M YG;DKO"8! E:-"Y=$Y %LK!:S*$IE!>UX]%O-+#"XM\%:<4Z3' (T%1EE*
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MR=/' B?&01"5 -WE^A+^D>H8.\8 =K:"CTG 9+3RV L)MDZ_2(70%>Y[)^0
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M#M!7S->FFWAN1>/P;>EA+IS7C=9C@7+[D6 GL$+JV8B+-=8]2:1QJFS29]N
M4%OT%Q)_P-MY1]N8AJ\:C$+*NW"^&\$[Y+3^G@^K%%M>X;<'NP'W/L]4C8S(
MMCH+=_!G[_',,BXOV?6[6BB?3/N8I<OI-(4?<7NT\">"VB<^8QV>2VIN"6A?
MY\A@Y/Z-D2,6W;. A4?7.ZUQW;Z5]FRP>'7$!38A&AP%!BCS>>8]IEI2U >G
MR( JXD&C_1KFU*+-HL%.?L:+G9R+^0-?MUMT&HC>)"':)ZM7PIW_ 5LL>-5.
M>;^[%:/>E@5<WR<@:.L34.=XBS;H E#K =!V@OB$TO%98$]KM%"K MM9QV5
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MM:=6[1Z_S:Y:]M$F),R=X&@56SW4D9NSIM "&N6HULSYW;A!5Y^IPDUOV[Q
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MLWRIO\V#US.J32)P)^&&,LKU[=$$^GJ\H1F-PUG$":KL55CDJS@ES*L8\#!
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M-U*XX^;T52+#P)Y@;4,QE-TT%!-O)=R/'/FVKQ'&B6C"5LB&I<)\!*,-L7W
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M\PNA.@BVA: MU,[NWJ1* S*=5H$*_'DOV>>BL5X3 VC9$-=7)SDN"V9N/?R
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M.\YLP+8)YU_(J$L?1,27<+^2+FPK)8HF%$^C/@'[5MFUJ!J84*@.S%"Y(-:
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MJB;:@[_PUL??\%;?C^HT_8"=E*#&QH&CJ =I-_IL[+^S:TK%Y\E-O<X 9)5
MQDT/,'8H'$[>XRG$CK'#5<7L2#=76<60))*M69YD2QR9=3V3I36Q*5_Y<495
M&092GD>34^?X[]EYJ,J/F3W2H!+FF\=/3H#7#?N^,N8)TZR 7<HQ9"HH[I21
MV^AWVMNMC8M8!F!'EZCDM5W->4;=J.2[+@!08&=CEM4N%HIQ,=@,K6O]NT+
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MMT[L,0N*M<KVFFQY 3X$CL>^"61FO8);OIG&IX?8:BP6JDH>G:%]_%M&T/Y
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M<Q1(/5L_##5J+1>&FJFQ%_]17@)]VJSBKS.@VY]ZT98]-T^AN0C<!C 6I\6
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M3Y^Z"86 7A#F[\A[0T$]N]9=WE?CQ=TCZSM6J'CM6H7@+L,H@QWZMLWI/@*
MCV#M!L.7=QG1C>I+^C*1O6_04>27DCA_D:PD?@R=K/.4[7?Y" )HUZQ5&:)M
M^B#:$*3E;IN7W)=3P3B?*?X%F*B+=):LZS1T6$#G@-%D]Z8 =VD&*TZH /7L
M$N1Y;;V5C5EQ%2=I-OU-T;Q,"7X*<.,_6:'+J_YPWFTG IV.2:0YZ\T[=WA"
MIU;K $7?'TS],]^]? %_^&=20 =7!>GUB$?=XC4ZDK^3X0!2L-2'>'#ML5Q,
MQSF>KX8$$=4.Z2&/NCU"P*W]_\[>!"'"_-RV+;BKO3P>JEGX=Q._A3 <4(Y-
MPAU/3874[Q'&X(LF!UWM^)3IE[.-S!K(9V,/9R;DQ)"T-8T1ZTUE*Z ((?M3
M%GUM?F/0E7 *B/6(H>;<Z78Y!#SQB_TW \LY285!$6B8#6.!EU$04MC.22U[
M2\7AF*Y*_$P^E_$>4K99ZHD:8G@UEN%"SB*F )($?,Q-PFDI>MF.[JK3AVH(
M_-+Z%<G'9.R!HTF?/#Q"Q>G !H83NQ^?SYQT>8J\>$F^J3/B5\AS1/NCC4N1
MFE:)6=\&>Y=VFH@CM A^:[[SO]VKK;W1X$SHK@= P2E]UVD?XIY>8T42&&3V
MG6QI,5:0RY<H3__?Y=J.I%SG<T)]Y$VTP6'>%/@MUO;.:KNE9] JHBH<C*3]
MF?;S\3[B#%SG=N=9\VQ-26(8QTT*">":3-OVW=1NPIJ=204T+?YHS).;6K+<
MN*UCDY>S)(]1HV"YA4O(VZ?"\'ZUWUC/2>7];GNA"+F'W:] *N$];I*.OT-$
MHD!;Z&U56AMW.1Z//3L:JC*B"[N1%@;Q3+[JW/$SR$2#2**PJ9I N[O684FT
M7*WF?\7S+[X$X1;66"N&7:G(],4:,:EJ->T$8>]P@AW2VG^ 2:[JJXPJ(>W#
M$&?#3T-R(;?774P O>6LN+:'=$D'K"&JH^) 7BLG=' 4RY?P##IWAC^!U!ZX
MZ9QQ=(>[FU6_O[&:+$^OV1U/E+XP,C3B#(-"<OLD>#,<\6!/"*D-74AUPKIX
M+:**]QJKKC8KTDK^@Y6'+]Q\4/Y.#PHX=:"E$EB@"2AY? KFR/VCF&"OSZ+!
M050)VC#V0]0ZM"R:8!QVGL"S6/+40H4RT3H0EM=+RR3ZEMU5F+G:H7V5/,$[
M+G"]H5^5W6*X"N"W$!,LK8;41&Y2KHM4P_IU;?5G1GYT,E]F!3MAURFAPU95
MVK!FOP$Z]P*]VQK9A^PIX.,/Z)!;]QDC.7":$!4\3H?#&JZKIG;X(+ %X=>0
MLD*X<@74P?.H9R8,;';UW<@JTP[EH ^AP:-S!B"!1TCF:4BGQ#1?=&,M,2.E
M%>X\.<%.H*9-Z&DZOP8.W80PW+UG:HLPYW=5X67-C3&?U\GG30_'?-YN5GC]
MG5E:7T@W2#2]WC75>M:LB02*MO+OI,#K <;0,1IFCK@1CB#FO<TW@3YVTVNU
M7:QB&'Q@5!PW/CI^%.WY6!P%ECFT1]^.4+_IDWUB%IVU,GCVZ:"L#=5@3Z)_
ME#> LHI;B3H\=^&5 II'AGRA6,1CS.H<!/AQ-3=&00#/+_7#+TGG6[?%NCGV
M<$;[+_A]E)BWSF-3OT:@F/_+^W1V591Y>0DM$O1U>XD[]N0HV!=CRF7C@#H"
M(N83:9$<76*PG(:/IE]2F($EV[3M$CRK&R[$LM9:EA-OBEH\G+>'.Y(>5.!%
M*6@^R)<%6"I,Y8@G>S&W5UN#>,]JBK3>C\WIXZ.G!].G9T]'':']L<%9-'VS
M&+E9C)4*T1$/QK>Z.\.50>YB1\91PZYG YM],V+H<$@J? @@A1T-J&"C, D_
M_!:[M18 L0)MT'F:AA3 HX)&!F[WN4,E!H%"Z] \/0P:"\)X6?50NU?\%$ >
MQ"&CH-=.=EQ("I(3@#3S2D"45W>X7MWPB W5V8+'2(!5"+MPG:!W=!C_R\\[
MM\:)?# H+:+U2JLEC6&!2'"RMAUUQ;FCK6#5](J^!$[?-Q@JL_:1V0/)_"_K
M4E&IE161*8C(-.X3#'?;/N2%[_*Q>GP))0N]^K5N6ZTJM(STV:58,\.D>4T(
M$^U>9,60FV']0?D</STT$YPE1K9FP# %/T&N XX?B<=T=IC=KV,?Q[$9TU?N
MXVBU=2-</006LRH$0E@'J!4(.!;;$\B*&,;P7#*-M$;!H0'4F(1@ID)^ NA
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MY&@)D$(K!96)\#S'#A&SEIY1L88DA,) -92_88@,J5N@\- MKEL':C@Z)V!
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M:YKNWRD\>/2HF^+SX4&*MA&:"@WM;MC:"\6&R=5"];9%2@="B(-2-AA0[.8
M/T] $>)^ "N[^[:M]:J8.RS 6?_\][Q)IA>;!"75'&?. ;U#?E*?"U1H2Z.
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MV/<=WJ>?TMJ>38!W_$YY!F"%A8;[JZ(HKTE?M D88<.?/CXY.9@^?7*B>!&
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MA9X)Q-(V* 4$IZ,ZWG$?8$&I=CH8,Z.3=66Q_+*NRUF&T<LZK:ZS65KOR\<
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M8@\KW#!AMA.\Q-B'ZY>-_0/L"]>GXE +0@RU,!N/)%>X9PQE1 #Q0Y@O@BF
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M]-,$<8P1(GML%43J3(N3L/'273$H,4TR6^\PI47AZN:*B2SH+P50R.5C&''
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M/<?I(BLI\M6=#A^%U6C,=#/W,8*.+8JNVPBV,O0/]QMU;ROG_Y_-RR,*S:,
M["#Z&BK&VX:?VV6-S>QG%HXG:2RC%^@]]XQD$=,O[_"8FV5=J@N,[FY3];_
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MC$B+U;>*&EU8:2AMR-$EE+RQ;K9'DS);")*CEA=>\5D2B0Y##=Y(]")Z_6C
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MF6E%"5?XR]XOU@(1;^(VQ90@L?\!/A$)M@<V9<H'/"*.F-%%Y7H[V ?*RPV
MU&BN\C/RY6T9IA\#>PK':N%2Q/#.L(M"K*TG_RB-NT ZT"FW44!B2)-*XC1B
M\D!"N!5T4'H3*?LI2*=BITA=,'S., AQD@ZE., @"4FMM!MEQ//ZE.V8^T27
M,I+-Q  4^;#TC!S!R62,\EN&4H:8@I _IA%8360R[JDS_HTS$O-4(*,O8= 3
M^E@@LPQ(,,=CL+/I7:1!!*"![?I(GB-9=QD 'T$_"__-YT0+J@+W1X,@UMD+
M(=>26](^2%,<3*2$C@PH&?9C\*<%<(HZ0T0<$2*_8LK[4,IN7Z1\PA8&R!VV
M+(3+032D@D5V?\,TMG_S.27[?EOM3C;CDLRZ$UO:8SZ' BH.$JB(G=GFW13
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MJX&JVY@MX&QIECG%F>C!9_:C#Q2ZWS$H1F"KGF-G(S=1MB:WL#>")&M$DKO
MTIXN(S>2I>V_+\+:!<(Z:AQJ\ZFV4]_3I)4M25LBR^L*8]+]X(>/V1BD?;\N
M5>K@?1'!(=G0%G?9M=D+#@ZS.E9GO[7WMJ[]X;L_\;U9VG-HJ2G/JX,\G:I>
M@&:.WA?-',&_F[7F;!TDI[76ZD>2;YQHOG'PMOA&O>:_=RIHVE2 \M]!"5>#
MH,L<A*_Z"@AB[<>]^\[<K$[MD$^[4:OM^]]BL!@NV=F*4(-2"K M3,4_:0@J
MX4\H?QMXZ7??FW?5004SU,.=.J8)@\Q/9:_W3'4&]!_DC7]%IL#N>_.J.LXZ
M;PZJPVX\[V%OY-5_9QY/EP"H"9]GEH5CK>0K"Z%B.8V^!D():-;18U0[HOY:
M(";FV!'&K\Z/7QF[>&=^21=]" T!80.TV8AX;*WVV;%_0M6^=,XG&C1!T,Q%
M<D]5\D)OW%^89+#IK>@ID/B]R/\:@3KR]A2/TCE9;]B:!R;)#6/=K$=3W.OB
M&^_,XTB1M".=OW%T),U("G2=_L]$U#:B _D^U-8%_1GMCK#'F;R9WYYT=NCO
M8&G,>7NK\;9XP:OU6&9/2_F!?S8.]P]-DA&2!GV*89PQ Z#VYU.2-Z>JF?BE
M:";.8D?UT=VJOR)_X^Y[\S>BCWIWOU',[/N&Z5L/F-85WSZJ=W+L_+"R@!+Q
M1_6XRB_]&40Q#'![-Q;.Z^.D6F%M=/]M<9%Z[7T15=Y]J3U:VI>A4@:OI#6[
M2)8&$]HBRBI%2,6G@0MAY7./?651_-K\H>_+(8I"J':PNS<G;K8X^9R$7</8
MJ1^MB'X.WQB#>E_.U@;]<[^^$@;5&J71P$S8:=26)R\TUP6XNG3G/SU9^B4(
MZ'UY<(F 0%%>-0$U5TE ]3>5!PLT]K[<PD1CN\W5T)C2U ]726"OROE3?U]>
MXT8=3/E&[6@EY*/SJP6'JJ^&@-Z:G?>^7,?D+:H=SE.C9 +*J>@C.).^!C*-
MI;E*!O5T;^1+4,_[<D]C>6$-_G=%\@W^+&P\(J#&:@CH3272 8F]6G_V:BI8
M=W<:C1D9N*JX:+T$]KJLO/?E'+?<!))%S: ?49H!-)&C PR7&AZ"AA!O/V'>
M;R1G:;PO%[?+ ? $RK #*$@6/V&TO\2IOS_/=-XD_YE3KS?5L;^Q')K&^W,H
MYRVAYO*$89A!!XHR7I4-TWAG?F"'D^4)#,$X=^%=>7.ND<8[<]XZC-LG20IE
M=32%U3'7)I4]:&W(Z)\'LIL%5#D7C+I9@E$[P*B;)1CU$@2V @S&S<%:7 7C
M+L(9_@2B(C'FN6$1 S+QR6,4(0L78.<FRN)/C+TBG7]OK^DHUBG.RA0BR.=I
MH<#K9]5E+NTUJ"->GMC(GU4*5RO?G:&/-1/-QA'*_CH(Q>%$^&DJ64:'7"T=
M.8,@[YV.#M9*1X9;8F/9C3.0\=[().]R:*R#3&8Z*5XIPW'&--X5)3F<&,TU
M4Y+E]MA$AM-TQC?>%9DX7!IK(9.93I#7R7":SIC)NZ*D.OZS5C/#\H>+4-+I
MC^Y@DL$ M,+SJ!O&5D:(#,5;[7Q%'/YXD@94CR;0<[[%$784QQK&R[[_%0@P
MF:21K&_*8>OL*_YTN*G\R1EP>1]4U:@WCT"$[=8:^X?-O8]A #I)XV"_4:N'
M/[" \:\N\I1N,%J$QCZ++H*T7""B3A0'N:+G.1D?%TEG,O!;9_!F.JH*8C(8
M6&./* DA/7=?+P=S!GE>"ZTYEG2>!+%9X\B9/32)A<]:<HYV.!I3Q9%_J(YZ
M;WN3.(4S$O.*3V\%K&.O=E@#R42L8Z^YNW^$K&-WI[G+K(/Y!E()+:U *<M3
MB2Q+\T6^JZ22U\8)G,[CDI9<M+3W7+2$9I3/%M3>3Y'1<Q')JW8-KY=(]I^5
M2)HK()*7XS7OV#.LJ>:@L7O(5'-0/S@0&FY#4\V_=?Z"YQ]3<A5!T9()VPG1
M6S#/.4QOP[2@S C'L. RB@R#81+?YHBPXA\?B\\@:@PBQ#!A?OV<]*9 F%6@
MOXUU\[QJO[)C2<6Z"7&V-(]<=?R!.E[!7EK7Q_[O<-E'<(KC,&5+*!C8&>[2
MTMYJ'#Q)SWTYCG+TOU_S:1LL!1G"(5B\32%&CEB G/Z LX]OBX=O6"GR3L_%
M'!\E@T'BWR#V&YS0[=2'/T=C((1CT1<6R*+Z<E>9,"-K;_0P=P44Y.?C%IQ
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M)O->,Z2M9!1R/FPF>DD-1VEXA[W P&@<)-DJ-FQOD\AC=^YV<*9CAIVTLKL
M=@*&"M/L?_E;O1 4\FB\[:.3=SQ=P;;LORXZVIN_<4%VY_<'R<,*-N; WR2"
M.0!3.!D#38@PJ;4)?66PZ>U8P0X<S3'X-E_Y_N#0I^9:C >_^9<C8D*_XA#M
ML$L9^B]D/,;8<&_PO#;DEYTG69&;9D-NJ/6XHDC3IO48W#UX>I #7HR&MWXP
M&/_] VQ%VOW[!VS%?GBPWVC6ZG_!W^K-ZG^/;C_DQFPT< W^G>"D!T>C']CG
MT-V!4+Y3^Z7(;5?7.<8>TQF7E &:YB]%TGV.-H-@<S1J-2+_1?^O/0(NETZ&
M_C'Q#?\D!8T+/@C*1>BC\5*'CS9KM5QH?JDQ%OF_-6W/67H?Q6%EJ>D?M_RC
MQG[]\(ULP=9!?7=[J<DWFKL[>T>';X4&'AX>JIUN>ML=!5D5+(U\ULG"_4*?
MYN1EG6\64T^9P>U5FS/]OK,5)9<>L%(YLU)E[>F>[WEJW?5D$.Z8DMY)4PN(
MT0_6VV:DQ-#GZ&NLS#6TB\BM[&E53VXBS;VHIQ26\#+;O$ VF? 1_5PVV=/I
MH//I^O3J\OH&W<=G%R>G5Z?PGXL;__KT][/VS>GUZ8E_]>WS^=FQWSH^OOQV
M<7-V\;OWY>SZZSJ<K864X#4-=\/V8=OP&XALK]#_G 1I#^WDDR@%N9^DF8<N
MZ+NP^WWG.!CYY^/>NK*V9N]+]./7.(DO)D/X5)?:BL/;UV@(=T%][E*"Q23L
MM4"%_*LUZ46PC,M1%(.I=@,/?AXDL)AN[2]\\*_Z!S_,NL$(F6,Z"3_X,=@R
M?__0"Z-?9[SZ@0@[^G&_4]]M-!M/"^HMLGR@7C$VILT53'H=@VT;)KT@VX_6
M'KWX<8DS(0<>;=\"Y_)L\_PS].^"^] /< HB?3'HHD<QB*?HGNX:V^QUA%LV
M([>L7[@-_A:^_^__=@@6R&_'_!'ZJ?[;MA_0"RK_7 2N]CA\19<.R]LJZOJE
MX8#.MNMV8'F6([0"?X$M$U<8QZP?_";<?MH/R!]7;B].^ R#[IW,!AW?I6'H
M3\,@)7<B_@J&B)*>CZ[\GF/V7GZZ,?F=MC#>@RZ1^W @TO93S@:%;3 VJ?N8
M8TIN7]4_ ]*?I+!FHI(*?<4Z'=?K_B@-,XQ!](,H'4PKN"K,?AT&F'($C\*?
MT:C)^'OZ$Z,DBXA"Q<Z(TWS\%+W\*6:3 =,*)KOF7-?XJY4>!SX&FX*9TW#R
M'E4_!#K8,DHC6-YH "=T&\8PE0&<#OP="V5Z<HAO,5T%XB0T\18QCJ"JN(EY
MA=^D6 1V^[?HT^\)[ADPVFZ8QK#P3V]:$YC'^9Q7TR/.V0G#&&_9*, +'F39
M9(AO4[JX>7$>(KAV4A[C-0K\VT2,@_M;]5N9WXNR[B3+F!;1@^TWI O[T>E4
M/',X3%,'6I\0VTD1'"+%P3 Z)" BXO VH#1#\P*FR="\H[2*-(@RX/F3#HP%
MTX=!>\FD,_:#3C(9TQ4..M$ &2U,5:[0<ZWP:Q"#HHZS%1P:^!-(%+K<*4PG
M[8G5PGC H<:DC:6P6X,L\7N@FZ11Q]R;JG^SR,YXO039,N['8-*#SR$?Z^')
M,X^D50[1EA3LBO<!MQ-6""01,D.*,G^"*QD'43R>OKSN]ZR7_W.01<R1A5[R
M#AA M@ Q$4$":7@H.>'A2-"^+2<5?0\5R5?]2Q#?N;<B"E&%/U!,X[64XEUK
MN?;GW-/SC.EU F0?"2L+I-9E51_4/+I'_HCS#PR1V,?\@U1G**B"09&J(!F*
MD;)P>4_E+7!=V$3:8HGIL<3<]K>$<D-)#5K_PT*95%7<T%7OA'YD)$K0V$(C
MT:$['A\5%YA"VB,-5,WR6[5=]?MA#V6YGRD0'&\0/&A++AB-8"D48$@G \'_
M8,V3@>!SXO 6 -&1GZ2UO5D6\"==A-ZDBV2F"6G&(2#YQ3V@!+61O#O G1.4
M'.JOXNB9X3Z$Q/QI1T'BH,K&A\5#P?$G'>2T\%:0)3&='HK7E,9FX?-P%\(K
MZ8*Z,%)?'S5*F*52@/%@Y2,5]<'>A$IL06L'!HA582E,B\6-(LB,A(I)SJ@0
M5# 6"8N#L1Y"+XQOX?K3'\4:437F-4J=.$(O3ARP=I F S^!^V7PGI22BN#B
MD8H >@:]J4^E@EN9OUEB[V LKD;#,X!/H-6T\'A^![88UXA2@)3O23K"$X6/
M"):%3Q6Y5MCOL^T3(U=S<T9OF643S<$_T8*!Q4I^&2>@EJ"YP,._V>MX:=Y
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M>'P+(6K#7X!'$4,C%]A8U15]J"I:P<)X.$V]8(0GG:FPX*M)GFJ36MS#VU,
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M9_>&S5GEO'MQ7JE<7/J/$TYF>Z>RG5<N ?)I=?<7SCTK+UM^SH#CO[Y</4\
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M:9<P-[3()NKK! P4385SX+UV35@1OC1,]95J9L&XDNG>0B'!/G!3.,L$L[\
M\1:%+E_XB@\LVR8/N7<&" ^TX+'R1I;\[!)JB+!.@',TRCGG6.8<_5B<8^!2
MLJB:DD#/*-_8@=B.PCD(E+*Z3M9@KN$#4]&%3M$%1RA(CO RMR5+H#_]Y-J;
MRRT4:@,@1S*!'N$Q(RJ)\[Y+6@@Z!%5GEKMBX]$P<11=SAGG+'\\FNA(LQ>/
M&H:%]1%*"DKFV%$SB;I>@,4TJSF+668Q-[%8C -VHD<7YAGE,+L0W5%83 "J
MW-DD,0>RCD9XV8?8Y$\3A:QN"*\ #,+$!BHBB^K:]Q/Z1M"@F5-35\OQZV++
M&,Q)*FGHU9UR>V*,&,8%X+K9%)C#I_EXKH$:](9=;#7E!5O!8(,0;V\;LR1;
M@8@!3M3Y-)J;&,^(?(V_TQ;NU#$/1@G:OB)JAZYDLL?&+;7WMR6L3ES>$@5O
MK,\%T0N:C>>FKMISF<,9$8J=O6VY4MX-BO7R_K9460]%AXQ-(0:5^2]54Y7(
MY%BO[&_7(%!JX;O.N#S^:A@C#,[ (6]U6]%?5>#876JQMJ-$CKYB0";CB--<
M)@=E\M=8,MF#-NO*89[9%,<[T=Q1!+(/I*+M(,EBK[A02F/B1E/LA/NG3!<J
M!,7KBX@_O8FZ+G6=C!7ACJ\37//OJ@V6D6ZQ[E,7E?W /HJ!/6RIT4\2Q5_&
MSSVW^[_03(%;XJ Q4E@?8YBM1F<UJ$^1?'\-I:B6*P0:R]>=; > H@_0"$_J
M/KD*S3&_9%WQI* \V0%@4U:%F[]%S4WWER7BW]?#>!G$T< )W+*V.LHNX\+F
M=CI35!/EZ(-YK5I@TBK:PQ@S1>ZPP6XBL;/+V@$!U,ZC8RL"Z/=X LA% =YC
M!'V)8)]Q<920*H_NQC;YF\I_6DQ#@&NB4[405LCK5 \I/T&>8&59@;^)/$R3
M#2?85HRJAH:J">8DIBG1T!H=IS[8W&LN/Y0ID[+@C"8L8++CBZ_H7T.NJ_N_
M21EGJN7/W5+'@?4*<CV<:<9'EM,.VV385\"IJA<G6L/>#M):<HGS[>\;,5M+
MMO+:H)7:H$I>&Q23@$,98^QRH'C51EYFZ*XB?]T"?KG>RK/G5N7Z;4S#THU_
MHJ"0V:!>JZO,"O8(!'9TZ>WDMPAA'80T%Y"V7$A3^-F8@\6)];8CS/1VIJ00
M@?ODIN@B(CKH@%GC.7ZG7,&.K\*S[(TJ8>>>8]F3WT6W0)SV9[Q8W!0)U3,3
M'9H^_8$(75M*FJ%#X<FIES^.'U*GJJ8$3RI%//5F0DN0F[)/B<SEEF#P7MF>
MN5Y/W(#PR<T=OP%84)V(URXWFHW66)?)7G!&N0)X39I@(!+V$0KP'"4+C/B+
M3?T!Y.E!/2)8^S4IP]]<W6\CKW@H8!&<NV $-:^ AK64,<\L2K4<81N82_@,
M>U4(R4*C$],__!MQ]K?:J2B[]NB3'%71U4?77EFY[$DH>$94611AJ8!4JC9R
MJ;0LE?XKEE1Z\L\9\<&<.3TELRJ6XE'=4034TYH9+FX?3=&\;((M"&D@@5?9
M5O 5M16I\ KXRTQ!<E)G @HNKQ.-*E1VJ^O&F_A;=PZ\T<2JDFRSC@%Z*;\H
M%A^A( >8"&_>3+9>OZ4Q82!6,8)DQ6,E.RP=8"VU5LY:EEG+WV,F4 $&2H0"
MYL=!5CE*,F(\N@HL-5(YYJST0G ?^D["</KMB&:_O&*?MQ+FCA?\RJZKW9+C
MHC083@P-D[$(!"745:GPS1AQ;T@GZ2Y6\$-.E(!*OC?%<$0#=DN%?:!*C+HP
ML$#5R'HQFRA/?59^[6QSA[\?X$#U3LZ!ECG074R3FXJ5 <[9U6,BD-+160M-
M]G7]QW3U-=6IL)5)3\+PQK,4;(3W)>N*IK&BL2WQ'[=]K-M'"TQ10(-J3=#*
M0ML(X\#PTHB/.17TPUJ.'_X5>*\>6E4\42U*J (=213\9YQ].-TC'KE)0F='
M+K)EF0 S:;[K232[,9-OL9@)-B-@YP[,+]@C#GU'L&>5LT2GLB-E@EMP4;C<
M)#O'FWM!\UM$1T9_PN7+@HW4-]7I0E&072CD.W+<ZT^.:@8R$HRBO7*FS\FG
M UQAN8FP,;?=KA:CX+"A2W:M:O31]5LC/Y!5>*$3X!!:) W*4Z,> \"_W$9Z
MZ%O$]= WZ'D@F6A ::LEYX\9YUBN]\XW <O71#R>:19IL0#W:N71AQ7N=1^+
M>R',&0&=??-<UYG5BN+2V]%5)&4VT_!B8ZB@72T[H0)%%*^4-/3^@)X"C,D<
M3A:?"G?TBPH[__><9@)3(,"Z*#+QARH[]Z($P&* #0+7PNDGHNY%OGXA&C*+
MGVKL?*ZOO'61<<YRQT%AXW?8%G77I*4-2P2X2#OW%J]PD8=X.A#!.*M,(QHI
M'9]5^&.5&NUVW=B.=KUZ68C8'@]'<'!?@R5:6<0;9=F$Z#2D<MG>>*PNE*+T
M'F><2<"G?+D3IJ'#/X?<)PIVY!QQUPVPDT[N(5YA)X\Q@T_H4F4>"E@0!UEE
M- G(\2C<ISOXCBRC5BJWV/F OU(0ZHG/,(%:?Q63,KUG.NS<<YP5O' ]F$!D
M_+A3 )"WC%6,X4OCYX7#-G72>\8VL"J79U4:3G]U^)(8' CKS;CLGQ_L_XA3
MNJ732-AEJED0[<@I@BZT()-(1UN(5(<1E05C'N6"V[X=S@*X$=OW#0"G_B,*
MUAT#G-VFYQGGA8^&9?/I3#,6>*@O7.=CU=XA0+9M'3^O:Y=S7_0*K_OO>-$P
MS!DFZ?ZH+ [.V.)PBPB5P-%)\#C\3M.\622T3RY]+M;\Y5\XB@DN_T".-JS4
MG=P=&4@O!%#%[I2?X:.6J.D Y8[)K@(F%SH7=G7$X/QX3D6JEKN<\0);%P'^
MSU+? WK6%D5L^0AOB^)DX>TVS(+C8W<<1C/1=L^;?"4;*3%KPM>F=6>$;5%_
MBFOIU7=C'K%-/NJ%LGV9 .^JYJ[O%=[U%(MW.0!G)Q!0BT]H1V%1UR$!+G]<
MS;GSOO1 JKD#=F:8BKDHC%2<)L>IS.2%VS\QFK947"(GN\ ',!G NF1?HT?0
MBL[,QZCAN\*6\%U1=F9Q&DG[#%7TGM/6X824HK"I0B7XFWVD^.\F*^-,HFGG
MU28KU2;5O-HDA4DTFQ1^&I[=$\-113E>N+RL-U)@B6?N^)B:.S[F\:G_V+V]
M9OW_?>S?#^20F(?GW_M/K/?]Z:F/HV0&@_[S(,59,>'-95-9%7FH(:9(?TIU
M[1@ZUB9\.R*F!]JZ):>CHB!YQ)[!ZJBKCX@B!"EX9GXX4312C,!)OC7$#L,S
M"VZK\Z](JA-<Q W:D[C:9_*Z>JJ-W+!W]9%->J .ZD%XE)(()^.*VN@SV_[^
M\A>W<>?/+.0SJ\K:T@X!5  /_6]GC;/4/B38.^ 75P[ 8*Q,56WQ:1M"Z5D+
M:$O@7^J,GK]:W Y<?47E#(7K-CB@OOFQR2!MU&- (2)J(JX8ON$PK2(;8-Z\
M[S0!74\'T&E<BZ73;@)P5)+T/[<TKG']@V$+9F@S40$+(@OHXM4$XVN$XLTP
MX;.O+^?5<KU8K;6+U4;C8I4G29G7:OX6AN"OF"NMD\<>S2O5GI/_:/D CN#\
M;>,M<9^*SF+D*YVE5R0T_1HXM@(KJ;]*$W4$%M(G)OX+,F1HEUJ=LZN2U&#7
M[3SVGK)ZV'8Y^6&CD]PJ0:VN+%4^M_!HSW<L,J J:P%U).X0>>?5'7>^'U9R
M)9O]9@:QM9-%;'WOB-U^8=<J0&2P28=:)"TBH<Z4GAZ:!"6-M2C9R7KX""!K
MI@NR_2I D<G_V; 53<P\\@DS\G*+K  QV,C^<#>DE=^0N"!K[^>&K(F"[;>Y
MUCZ\Q6N;]V[Q%';JS53=QW6?^_CAL?_T_$]R&_?_^_OMX[?^_7.1W?>?]^=^
M_1">XK6X#L?P=E]P5 ]O;)]Q(E_P7MQ\KD.V>;9AP3"_U_;P7="'NIO3*&47
M4<I JZ8/M"2NS/UX@O=\VIW]B8E) R-+GS8:;KZC;[#S$KY]3/?<P\:1!%EQ
M7&UL\E5/T.1KK>3X:D:=W5T!?:%=;:VT]SIA/^%&<#>.#.Y6RN!.UU-Y%S(>
M9=^NH8WH:AX976"G5(J=6GLKPH[E6-L(O=:1H==)!WH9\7_TMDUN.7WS?2,U
MM8]+354<]-.J;*6E#^=SV8BTSI&15MDCTI+(OEBI*.^+)I+,4DF#)'#.5+%6
M:^8W.0[6DC0#3@-KM;UB+2,BONM-(V3^:83OF[22, 0?Q/P#&^'?&I>M&_VC
M@M928C0BK.>LX\"LX[#X;62$R21@(<$!0F/UEUM4>/I$%C6ZMS[=[,/=RX@@
MZZQ/6CME>1H^#)A::G\<U*Y/L\MOPQJ0K<_OVT=Z0/K!X/=:[QR[V/F\<K')
MU^=^+##LVTLMHD):T2UD?Z,L_=]>4F>B:2W-LZORBL92W#;=Y9@[;H7O&+GT
MYETG"9\DWC4ZXYNKOB1G'&I!M,%9,P^U*#O?R!XXM:4>.()=_M5?2[_/VOF<
M03@,HAJ-0:Q7JS\%VA=Y4X/\(QP+5.6^=>)2$NJF0DYOESV:*Q+1MT)QDGIU
MU>R),ND7*'F,(Z9^.GUT<8,6G@VXYDBUG$8@;*BI.HVPLNSY2,6.!-Z4H_/N
MQ7G](NP6G%[NG&A$^.!T.! ="<-RJ5KE9KK%U@TW6^ZNWQWTTZRD_G"<9)?6
M*E&UC;!^0K)-H^PAM-RAD9TKLYEI_*(1W=JBL)F-!+21<CPV8G+E87P'4LIE
M'64?Z[#^/0VPCEH964>CL2K-F?7O.;8PF>)L/<"S 3JXJE-+;#%6#UE%=RIX
M"MT1UGTU.?5JNT 53,4.(ENNH?]@.,^D1%V9\$2ED;(H(=<J<7WU@L+7^O@%
MX4N"%RO!4U6"V7?$YI89T26[<=D>;7<1[,FIX&E0=2P(G"J,.NX!LF3#*=!&
MIBJIF3B+T.DG->9\NZ (JIO5>,YXA?IV63>&^135,58#@ZA]65M!\B5[T%EW
M9JJ:T^2OCD!0+4G'..(.-BV0C+)D$SX;E< YT$#[-)J;/^&>6V%(7.6R3WRJ
MJ+KSTS,WEXBU=G9E_S1$N\)E=&*[>8 +S;CY1G.[*L6"/) W''(^ U0TRPRH
MRY)7%QL/PLW--;@C\MV(2ASRW4=N*X#<9_7'FX(-X4J"4L\U+_4(C\8OB'@E
MZL$&+'A])0=\9@O>T!:L(<?]$7%?VQ'W 8$;Q+4S4X)&[G&K .+8PWF.\",C
MO!X-X6L;9R\WR2;G8,D8E^:6G'%D%=!*=\K)Q%/^UFP_.2@VFR5TDICFDE##
M[3V,OUN<3+QH\KJ.KHH0<;TRUTFE*<E#,1 ";#- N"ET&M@"@D.8=&C&S0$6
M^,LL66DIV$XK:VYLWM;)F[>M-&^KY<W;]NQ2\(^DQ*BV[&KK[[T;ZF"HE%NI
M.AB:KH.A_^WQ[N&?_3[[TK_OW]P^BW9NC]U_/CW<W;%NK_?TO7NW!P<$M:%=
M;54EVD^U9?<I?\<WV7<J%Z.K;6"[L=K KI8Q;E2! D!:!=$6)#H8]&,O_O6A
M?L$#^/_17.,/8^?:/(E>RW>>1'_&[8??($P7S,L=\W+'S!8 YN6.!R&-M8<Y
MNQI,#-,NH?GH]IMG+T(T6Q^\0%)J*&+:T9LRE+VDQ?1H4/OHQQF.1,A^[5["
M-%602Z-_2 C(/KS1;+D&V'+UZD>ID$R8++HSE)LI0_D@R9YW[AQFO%]PCTQ0
M/8JPLCYW6N/\!"/G':1^[LW7@IV#UBN&L4@(;*UJLY[GAA_JNJ>)N_8><;=?
M ;R\I7KT.K+E1R,1#KS$1L8<#**$=+-NH7U?^90HIG-V52_'KQ2H)KOMIXNR
M)#<]'935RWM$V2%R?&.[3'*'5\#A]266PPOGG)6\06>N21?!^95"_"\VKF<;
MSA/'^;1F*,ZZN6I<<P<JOG YY0=^%#D^<LI:867*&MMURAKERE!H"A:,GB-3
MC\1NY'PQ\:DG^(C+5C#'QN4KL[G)@XRE0NDQJ_DQO^$N+47#-@W;YL,5?//A
M+ME3<!Y<V' H''CI#853PX;"!>)](W5$[TR5'YQ 9:HOHITX(@_C"XBJ,6".
M1@2C:XD9%.^N7Q[:B9\SLZW,K!=O .4&'U76&=I^!GJ=7?4#PR'A&JFV)C@9
M=9AUW568[!6<T5V@&=UXW_[)%1/XD^-R0$Y6JG0:E4LFG1$TFW:.]OCRBC34
M45EX>65. @H\X<U VUM0?2MX_'/-T@RXQZ*#.!'4X*1<=_I?2,O2J%-R-ZWA
MCQ)5R^DF<K?<..OM?>_A6Y\]=_\W/)T[_3!;SF83!$E]\C8"5]V#ID:'S""O
M[4TX7+N>,F-W]N@2IWS;"M70.'-PD>TZRB'.C=24GQ@\B:#:GO85"*5Z<3'^
M=H878]L5"%)[*(1<.E^Y 9L?E\3T<E6)F2E@XIA2T-$1D?@/2U0T(':]A4[H
M5NQA2RW:TK//)!JN@ VA)HH*00FO.M56E)1>(/6<>M_K-#45K]3FJI" SRQ>
MS4#?R7UV!2):1T\</C#$+G24EV3?<*!D11O8BCW'1.K PU%-J>H6-U*C=A+'
MJ&UKC'82IZAO.47Y)$X!NEEUU3;?X1>_K=C!>V,,N<Q**K.JL14WL-W<@M<^
M$-K<5%ZY4_(K1ZBR6_V-6S954!496'H==H[/H[Y>+7_V_167H]]6/E_D0L]/
MV]_=^K\E</FGA%-I( '_WKC$DBO%*LSF<MPX"D91=@;WNU'$>HTWU;3GW'$S
M2G3(]!-XH8\Y1O"&Q25.X)3 4ZQ@S9YJ!=P ;XJI&G-+#%%W,EE@'Z+>.:)Z
MFG.#-+E!*Q8[J#@9P<I%'&;PQ$?SH9Q?3^KK4>YOUJYOQ5%8G=LR42S0/CD+
MNV5L9AJOIC+UBGT+*Y?]YT0=3IP+AZ4H>.>&0!\*.K/]=X[<;;)?!CZDDAH@
M8PZP/J@1(^%5QZ?#]A-PA1>&$P.V6"U7RDZ%"S4X .9!X0S4<_Q<_9_RCWWY
M1X>M7[+K.>T"G]4,Z=R3+"B\P#O(< HOH/CS-W'X)>:CQ"A^=FIE\12!8$9?
M+BA!LE(2B^-Z*N5E1R,53CO09S/XG3$J8K'DOR3\4]G;G3H%B8H@NP', 7H0
MS ]C!\BK>VUABE;X7C5W+4$&CFO6CS5! CZZDB<KB/)D$?*H[5_%J^0</06.
M_A*+H_<,?:2*6!=J>/*>D7HAK^]*,.1PK'XW@C@ H_=TGC=%U8@ Z?*',GP,
M9T@649 P'<^UL:IIC@H]])  NYS)/K<R<+DD'<BU@9\V^2L^2%'1++H#=RSQ
MV/T>'O_J#6-=/4^1=U( @IC.=2O_E5N^!EB8KL@N*?!/K$AWX-B'^V1,0?@^
M&IHZ7!3\YJOC-:Q40')6JD5XT;*\PG;'Y?AW';MHP(JZ5RA=[12%9N37@$*L
M7]J>BUQ7)2J0GK7M<89?531@'ACO?'-9#;--9?C#NF2>C0B_T479&4W_--ZH
MN=22X4:-1GS*$ZEQ!7NBV.*QK?M19C/0Q*S/;&+\Q(R,X/).D@NF3\#J$P5V
M''W=A<,/Y7*'\")EDL ?_&1&_NQ*4P#:(43J<H3*O.)"4)_C\X56S9'4R\!6
M==LTP&"CHG5IN87XT@5E;4T;:@0\LS'3% _GTVR?7;4N&R$)1\@!'DT^YB;V
M3WKFPXEN:,8K-5[SI+4ES!4A?J^!X#6#6N,6L/\3ZY+TW0RFQDFX?K&SW6I1
MQV\NGP2;TN6GU.$ NSAM/WPS_N')Y"'' JYWJ^]RG 9H+ZOIJ^(T"AO,L+NE
M%@'['Y8!W?J3>)B;Q..(0X$3!DAA#QB4IJ?^'_A(X1_<1*GS_Z++MUDIHB@.
M;RZB:-HZ!P!R(I3"EB5XESTQC?GKA'Y/1BRPPQ:IT4!LE@K4CTX-[)EV25LB
MF5Z A]KNJQ0$-*GK%;8UH9:+_)?B9!$MBWM<I3NW)X:IVHLX*4:'4+33_72L
MKA[-<M[58Z6K1_U]=O78C9XVM/2066>**R9BIJ!5!8N/FJ^VI1G!"29H18CG
M1<W:\MN=\9+]O?RD[X,B"H++8^9OI3J$/$9NEG/V-?E9WR\'EVYR%E/L@L+&
M0DN+EI+?:)V"TMB 2U9=;?-]D.!_1M _44 #]DOO3=,2*CAG4S>D*,?9&OX6
M:]CX>JB8Y@)P38E*A36Z$SM?_E7]T[9^V4FF"WI=UF"+/?\.(Q63-:I@6K1:
MQ4IY=9KNY]4FV=N.TDPR02#I46IGV,1K^107[Y7@O]O ,/YT@W7HX"'.=O]P
M%R156'>!$4:?6QO^:=D*"'G@>8H.8E_SQYX"54^LUJYZ/D]R=6GL"6QM;(;>
M,T;$+RN==I/,">GD*[*1""D:/W6P.2;JC TGBO[*T5Y0;'(]%8PA]28<87D.
M6*T:_ -_X[C21651L/@'8[7HO0)VB).SD+,#O=F*B@XS;,B^H';M7-0@@&TT
MX5A=#><=3D+V$MA&2G[Y=]WQ<D]*3KPBH&O',>#$ST'$1ZG^2=\8;UVV UT+
M#G/QU[8$7<I.Q\NB>(/G"H[]O$VT$3?Q]VG?QO0KZ4S&HT8(>---/L$R/D=)
M0G%PS^V',2A T20!]@VM=HJ-1F>UH7M\^=Q,:;)C>N?#7CI5$-K-5:?@+D([
MI<F&Z9T/TSDJ[6(CQ.EYX0NJ%#9YO,@CCQUO#716.3(0"5T57=R1UH&%C/A8
MA8T@F:.\&H_1@2^K6GV5',3(!<,!$>L5>8"T+01OCR^"+!Q9V%3_ /D8F65&
M/GW<BJ&/XZ1R3Q]'U:;@F&F&27F/?"LK>[=@1Q<P.6&=<34F5U ;E'V4 "4C
M1THZ#EO;*A;\T4#'/6NY6I+(WIH:)O:)_D$W A0E$2Y$K8V\P@!ZO&M+4R!"
MO@9Z 3S_XFP-%"SV1<'HK:$7PAS+$]6BOO6PHKBS1<J<&,(A7257XAIS+T!+
M_*^YSF4U"2ZHO%CDVX/G3*F? GB&7&P>!VN(H(COV0*N25>5YE>Q-\2%2G<=
MY-^_A 9,%"XY0I 3!,.K2-[<0KU#9/<JF#FBL3=%DVXU!?-MR1NOO"JJ;@F(
M @T7-M)PL/S=X$(%QO%N@L/,@+61#N25)P%O!>L $8J;"FX:F!/F\*DR:PCW
MN&!S,B9X@2#N^[KPDQ Z4JV>#[\VN[<6]MJC.MHA" /J-&YU]6@]4FLX6&/_
M-Q<D8>AMH>OHA?&\851HZQ@ZQEI6,K53-$8^8OO72CG]YI[_#!\QEK>"S5O!
M[K45[(F<MI;!QK?7J]PX _UN3Z!;;K,>VC]TU0'IMH%PIL#9,9H>93; TGH/
MQ;&-]K9*Y9,X16?'XMC?5J;PI-!-^#\RTJYY115>'V&Y!I"#@CJ,Y)]I@F99
M[11;G57W6C;:.:>)@"3.L;TAH$((J-97@W;O#P&59A8Q .*WV@+QV#ZQ7MOK
MA3,%#X\MFF\,$W2S8%KIM0HO8GM4%=>,) ^:1VY<D=8QMG6NV+-P3NL8C=!4
ME%VD\^FU#??E$FYR=W> 8DLR'>^C=UJ/"K)Z#K(L"5#)+:+)S^;959B^GOD^
M]:O??C:P=@K6L:P0Q^Y6[\Q&LMKB>EFC;&UYZ^!FQU>$332R:$6V+"*!)J*'
M+)LX2-7RB(&#=F3CXOWC(%W>&0,)'6%?-,/4IH1(.(B=\0\WZMEUHI['D;(K
M5+&3@#T_'+=T(><"+A+%M*([92*+U2.IWX= 6:K,=5>417?CY"A+FQ?OBK-J
M9,8<%V?[55PCB(E59DYS>C!CP8V14?%EF&)[@!$_T8ALVW2?J-9E([)UF;UA
M2(>%5#.'5$1(M=*%U"&F-1TVK_&O*@WH4:;8Q8 2VKX/KID],>:6HCNY<+[<
M6W;]W&6J5< DJ3G5@XA6*9L3GD\B,MNJA<8T?W./;SFKA_4),71_[G^P)[W(
MB#;&IY;7W]J0UU\\M23^UH8D?DI3/;&D_=:&I'V\E4XV7,%+$<?L)SHJ)@8Y
MC3$I$5?<<XI(X07?2JI9='&V6F$N3C\HW H-3+OV<[!W$/-IM</+CY$Q;:'L
MQO%J2%N=T!I2)$"WMI):^H%HFF)QE D0N83G4YY $E)/FB W>@Y;-1</X_7
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MGBUJ/ PTUMOS&5$:#FOJ9<.ANU>_>5P2J:SW6KSOQAY9@?]ZU\NAO>\)3=#
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MM"BM"8@,8?@RUS@5B!NK&LU$0QU+@QOGI.?B,[\KZEAAUZIEF^K0AE?FILU
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M[E1DHG?!?Q-<6GLUX.>TF-?&CJ<'8UC?5FM9$0:6A;\2_.I&"!>X2%2(J[R
M1>=<GJ(7M,:_J;J@!*(8UYI2WA15(X\C\90QO$A#@N>:O,PD)00'PKBWQ;4B
M\XILO<GJ+UQ3.2B'"L;?Q\H;&(JXJC&W1?4RH>U%>+UQT_K"\7J(30=8<7<X
M))_4J[8HRC"]+!A8I1OA%[$X;1MS78ARQBK:M2JJ4)XZNLXSQ3Q(BX)?DPM
M(QODRG "OP#+UQ8N#5GA+!^D^>J*;X?23P/,437([_9SHL(**H((0>$#!)G
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M57H8Q-P F8\4=T(H#@2[AQ>CRKXF'#TD^!\F^P3_%!P*2$Q#9N+B.*P=6'2
MQ7#4W8HOWZ(-"M"*+^U;ZZ2]*I=$9AE49;X/LD7 *URS#5SSLKV6?(N4?T+N
M)7*440,Y%(\N^K:>L-5(<,1PC6WWXW;PN"$B0AX7&5Q,E,63;EU/_GK'B23?
MT(RJ-JK%<LB=6W82 X-&C0_U(\HR$_))Z'AZ+-NMZK/&_%\ 066^DB:'F2DJ
M>=SLE7S_ALRI<8A&..-('&(-4!&4() K)=1G *0SPU)MF1?EC(5W7'P4I_-N
MEM_>&\V=V1[P*V_! D!9Y @?QKD7P[67@@]F8!O#'S([3=P1U/FW-&7KM)NI
M^F,J9=<A,_B]^]3__>'NNO\TD%R<]?_[^^WS/U/TR="7'7"ZJ^9YOPG:L'VE
MQJG[S_S=IU/$WR?:-8BQU@@X4#7HN1*:*>F;FRY?K;G]OCUQ0*_%Z0\#4"SL
M(+>N@'9$!KR70^6VW37%J\($9!:^?,E()2/>-T.B$C])?@G& =9S&JO'$\:A
M#.S8IB$BTQB?DD;-I9=O7SGO7IQ7*A?I9RKDF?CIU4D^.#GEPD&0UTJ>0%/$
M)9PA,QG#)9W/1 @9]!*G4)N"].A9$L7<5-)6 %T -33LR R_]=Q05/JDJ<!N
M9/77B++77R@'1"I*6W2(U7ZNADXLZQ\&>KF>R,D5Y%R@\ADZ7V9:[ U9"#8\
ME*S)#B3B3SFW*02=TVK&VQ/T OXL']EBTTKTWB\W\21RQGZ"?%28SC5;G6%Z
M LX?H402<E@#W33<&(L0NRJY=D3;<XO=/CZP\QO^8L[Q>_@X.H' +E#(AP2F
MN"J:?NOH$L9T)HXVA?#S>E_#2%4A)%)5+VXQV<J[)VGZ+@W):.N6//FAJ4GB
M_@?O4VW+"()4]^9+1HJ\P3I6,K<;Y6*GW P9/[!L*AM+S$Y8F*'1C4OVH#,O
M+U#&*):+K>C-S2Z$0,_1V_N;6$ B\ BDB93A1THQ$0 #ED!_"L^W#0,7NOR*
ME6:GV.BL@LN%3D%"A\H_=%WVU'!31[].T)'^=]4>3K ]1_>IR^@R.#$+>!6O
MFB@UVTP^"9KD)B7MYC;23G-ONY V>NR*Y6JYV"A7(Y"V@[/P4-UJ%E1!UN?M
M5^1)9J^2P]U50_=B3;76QYA[=UWV/X)A4TW];&X.)Y@8O/GFMI+<7(I>/HSE
M9Q],4E=VH8/VV56M%>*D7[ZM3E:DGX4]4I$99X^:,A31DQW T$YP$=("0N?L
MJETO-JL;N!9;#X<L)LE%<J,%.T![+K*'<<]7ZO,D,F=[P)8MXC=?, ?4J4&*
MW2(ZX6=\7KMVN9K&F&6?UZX2]-J5OG0'?9RC\.VQ?S_H/M\^W.]I>D+NO<N]
M=SM-=Q+<UIC93NDL>QI\MV0"@^QFUD0&K8NZ6OH-6"1N7A0&^M ]2(^<>Z:)
M^^3WR\$E&\Q?2OB$2+K7X2#.)PU3?)%T7:=49.36G_EF/P4SZ0I.(*3HQ?^!
MW;^(TO65 ZVR7<K)68WF@R9-JJ1.U:ICKMJ4"2C*584M)=,'A I9V$\C@8]B
MC!_"[W?-;475B'I(")=$$8*@_?=ZPT&UL=UK$+A<H$%]P^145BN+MD%L\XS:
M5F=W#<L3Q'Y1W?7LL2^+%5G=Q1%J]W25'\;"0.DZ)2$WAOD5CQ%5,ZN#=.Z4
M5Z=;.)#!!-?-"5?M!+,EMY[>6G?\![&]_[^]9VUNU%KRNW\%Z[JIFMFU/0*]
M)UE7R;8\4>*1?&W/3)*MK1061Q8["#2 ;"N_?KO/ 03B2( $"&15W<H=VQ+T
MZ7?WZ0<]J]7365C]C4X9!V\+9$Y^(EU'']UB?1,7(3-+N<7ZRS!:L*_KK!4.
MW#PEQZJFWKO=;L!+82W-QH5)5*6'!8M]=B(K)#17+#>'=TF1)FD J1T:0$(-
M(*U# TC<!I# II9LXB2)B72*<5=J.V+VQ<](-NG+4=H"EE )M(;*"P>IW)_>
M#\<&[BC"*2<3K#7.T/L(+P_:M!YF.";*3"..+0Z9*II'=(Z^6"MO6;,)^]VJ
M%4X0?C?%%,+O6-[0 N/"S&*FBQ:5NY%*D#X30R$:K1^7+6?0F/5Q)S- ULIC
MW$U,B7<[+4EAG%TEG#TE?D0EWAN38(^U:_FB3>TU6U,L_/)H?C@_FA,9@CH(
M=!7Z<S 29!_A+=;9_#C>]B?I.-NC"=%'$[99<9/JAJ!\41.3ZM5T4(,Z/:V%
M-)QM)(T:9QG-\7G777_W;( '0-NX5V[]6"ET[B?$GWAX3["I 6]IP7]TH^VU
M.T@BH>&>-W*YRC:+)O .E[T@_-_HE2J)=]/DB(%U46\]PZ!W5<SK59[[G >7
ME;]ZG'P'/FW,KH(:';4=GEZ2B%X_)9/DH)R&'W>G6M]/1R9A"^AY6[16?3^Y
MX-57"EZ<]R7<V!4?K-6;6Z)>GP78L:4@63="JE* 3',-/./VUR21 ="^U3->
M\4D4ZA,R?E(3%G[AE5.K)\PQ;,]6-)K%%(U6.46C  ;"99XDH@&6/5RXD+I@
M1+&]YZW17IUWZ)]:[[/E_G8AN1]S]87C?F[&)-AHAX?ZJ,Q,I!R7UQ^C>?TQ
M":]C#[<89.4Z-M]56J&D>N(%FFFJ^G/6>$%O$C)E:+S.*")#2SDP]+^VU>1B
M8TM5OLG]$W8XG]7"]W*;,*Q_99^_%^BPL2_C[/A5@NQXDD*R1<:Y.YEJQIR0
M>S9S>(7GH&D&&\(R&-UY,US8E2F]_$A<8I89 /[LMTBSWX].A]UR<4)@5K:!
M+<7^"=:+J:B, ARMG]_NON7;+GHIE0<-(ZZK\DJ/;[7,>ZO4J;>\-<OTZ3;+
MY;-9)9_Q:8N1%L_KM"EFNC-?OKXBWWU'+$(+FNAD)QS 9TQ9KX=.['B9UC7K
MOG/.-V/"QKDUSCB[7* SUPIYYI!KO?ZXZZOHVINL#US,-J'FD2A\ZXF!H6X1
M_[ 3G!@'KUDS]:36!!^\%M[6DPCW[Y-*?UBVPP]U:J_9^&=EHNK8FTL'NP0D
M>AU=-XN3(BBXR3:E3"F(:UAXS5=1,10WO90."M=C<+OY/DDQN!IQ[0T1MSI(
MSP-[U6)@KPYA<2OZ5BTZ=,_.7^ X*W1/;Z1GMM981+A=*\@<\:U8JJ=HMJ,N
MQA*@6 @+;3LM#E$R6^V3IC1*Z9$B9OA24"&I%TU(P).O1^O))$+B:DU_RM.?
M>\F@</20\PSD/+L;5 2SI4:T"JN4U;Y^2?!7^W:<8ZVN\)7P3B^=!ML_O;H]
MS@#>5"?AE;< =]UE&E^W;UZ>N5G"*>4U2-Y-X7+[<W;O88UIWGL2X[/PY;+?
M;.5,Z#P_G;'Z6+?+C/U$[_J<,MEW_PJY;OM90+R$D3O:2@PPL1]OU)&'D;FO
M=&._<=)Q=^\R)/1TVU1U2QVR'UGSB\LFE4HE+;1D7%!=E[A9+K>QQ]\][G;V
M/!)0&L@->"^')2#Q$I&[*^UMU[::^+1I\9:#0]]T%:9)XW;RUFLX%%TZD5KA
MD=J9I8NS2A4G(%!.M75A\J37;5RO'Y_7FF=B=+E'J2KGN>YU.X?:L$A:>1;J
MTO 6;&/1F!0D2P.'[E=K445C)2%*[,NF>EJ736E5@+KFQ>FK+T3I6B,"2;NH
MR(P-?+-XP$=_L," Y-<#X(J",WJG(,+0*AX_Q0>^73S@WX0PQ&5U=^)*(5B]
M7BD>M\0'7BP>\&^"U9/J_5A7'NN";NP26Q%NKT\@)(8B=DXF<92WU?C6W87A
MS?AA>&9WCH6X_PT2<!_"]%;<,+TXA$U!//EA?*,\83Q=O!8=QN\)T6([ U*$
M,Y 8U,T<OT2VSO$%Z9WCP=:EI"R["Z0FLW4-<(;K=3!UT>WSQ1&N?3-U/NJE
M9^H:$"DT&F<5L42$W0-3MYJ6JTQ=L,VY 3J]?K:H/3V8.F;JHEI&-C1UF94G
M95T05#L4!!T*@@X%08>"H)T5!+%_'>J!#O5 Q:\':I4R$=FHOIEZH-:>)1H;
MM>/S:OVL6B\@X5*O!VJ7)I'8J!^?M\[J[3=6#U1/K?E\C^N!ZE%%4X6^%RY@
M,=/A7KB\]4#U M:7Q0>^@,5,;T(8RED/5,#JL=C -PI8S/0F6/U0#_1FVG(:
MC4,]T)ZV[32:AWH@;TANI5*>.+X5KZ]G3Z@6VQN(J@X^% 2]$6.W>4%0^U 0
MM'-;ETE!4+-R* C:A:W;MB((9V@W#A5!(5N74?'KRE'[AZE3'N[63IU*/'+J
MG1BZ*>>^S)4>06;BPRX/!$6VB3#"?;3/> 5O?:0+WS]&[3P7]W#G>1,'Y9UQ
MUL']3+>8?SR*P(FTCSBI0HAW5@]O0:(X$2/YI+J/.*D!G]3/FF&DG F_8/U,
M+ V,#D6"3],%-K]\P"^<._\G&,%K0-Q9C,/.!,.D-8YG5"^LGB07T'UAS7=0
MN"L4KA1/X7;H(H[0*+H30=:T0([2)>/ZX96MP!:>2CF2?\WZZN2?(-M1&G7;
MQ4-%2Y@U&ZL29IY5=B]WV%*L]W3'.# +LA*N*)X8.IGS!#L\Z1-]011<YMZE
MM-RE&ESNDMT[PD__C]-3X1H7/WX4;@%3/\,C?LR(/B3PID9=.#UU/D_'S;*O
M^+QAO]X1)8[B:>#ODI<CZ\B26JRS\NHF8ZC#X_/K4__AW6/_+#S,IW#XCBD_
MJL.?A3[P/T--WT!LB&W_MSZX7Z.(HG7(+HI6H>S1)/+WTT<"4@</GE*<^^%M
M<.!%U/J1Y*/O\;K7^B'%(RS(F2<#<Q<57:G64#.LF4D&([\NN2,:S@.FRX="
MJH2SCDB*6D=48B.ZX:S<Z\SW@_'-P!VQ;'@*3G/&:;5?0'%;5/GS!]8FWPJ6
MRFO]<W+KZ'0"QN[NORP-"R[R9J^TL1\A0(=]7H=]7IN<]K#/JV3[O+[HSZ!#
M(.+=LJ<B^P57:_>J5L2=7')U?\Q R?9TT,(SZJL,(+(P'\:R[L0^?</!;\)@
MKPG\==)N1&\T*-&&LO4$E/:+@*TW1\#J?A$0UU:U3YJ5% ?I;K*Y[?S3ZL:$
MZ#U8&=1Y1O6_)RFOW,D!HEI0"G^ [=I#LG$VSK]2&2L,CM+L0MG) =)L>TCQ
M .L3ZV*E44PCP+C3O;^*:P-:6*AR4FEOL?9Q(Y5_O:X!9R?<F&8?RTX.D&9K
MQ4&</ 9-+%&XR[!RTHBQ"C<%D4IEFV6LH'GC,M&-7I]9J:A8V<WPN*R<^)84
M-PHKULK&# F\7WF25O5 X+W.H[1JF1'XL-]SAX4_U7B%/WU#N+O_8@DOQ"0K
M:[,$?CWFT5(])AIH^C 9&18^K<Q,3'-C0:+P(EM1]7>[F,L9*59K"_/H'Z\
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M=GA!9JI;$](H7>CHMNI6>RSV2G2=(@RVW,XK+ A7.G"K&JK->EI5#1U_-8J
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MOA958GZH6N"!/*&LLM\YOU7@[:]331VJ]F<R>837*2I\"!-*?D754100' A
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MVTIRWI8_$BLN/HO\-K"CLNR==55L^]_*WT8#V:?JF?\0\L* +!D&GSX]:U8
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M>0TWB6GT&=]D2D&+KC9(C$5EUB:HX$Q%ES6!EZPM=&]AHC6E23KW5)*T5GJ
MV8!V13TDPC7+,#I"W ;XS(J^)]=?IUT<0:MF-(UG+)=Z(N[YQ?C6NS5GB?!6
M7?-)=0P&(]^,<@,!_ N[:1RG$\SLK^9EI?,*'>O1S\@P)35$$8W=?#/L:S?L
M)BB\!I#]O!0->0L[J00T86JB0R&GC00Z=^MKRLU$G!A@)'M(K0:M8AF&EQYO
M;7&=/; ;-D#UP.J*QS),%3V^50-Q*X+M]([D.](<\R-T!Y.N#3!)O;AGZO?$
M2\!\/.&CSU(O,$\:.\#^/C'5,SN+78YTD>3K_J )&ADJ-19!+[&+Z>4!;,AN
MG@BK0)'!4^P9LV&A97,*/>#Z:_9U<2"^CSW%"A#,BC\4R0=]KCM /0&&-K!B
ML_:(Z"DAI$D"=H*FU6M,=2B(H$N(D[KJPB(AB<AAK.4,XL#C;"[#XPMK) VW
MAG 9E^2EC4J!+4,##;@-9DRE"<MBY+,$B)PSCA_"RS QSFCSC6V)N3W%/L>9
M$8@$]A":]A7'H/*75"QTT:8R%@4KM(.Z/=UH-JA4IUZF&1.RH][B)RLB?I4H
MQ?!T/X@4X"W K)4,\V5"ACE/CS:<?R+!"0!8CZ7 \F5M)/)J'<5[0%PB;%Q(
M2:O'K8TM17/)AK=PU4DK_,)P=P'^/^@C@D=\$4/L(IWR=)1CIY7'H@>G"?MO
M+_6@H"N$?/A6;$7HA;@)JER9@]]#^X(369:6];)^G(1(TG)I;;9?'4/D GSL
M7(4:U#V4O]=;NO9J*EO?$K&;='?*,/1,'.\F';53I-@E.O3:#.U4=9@M[*L9
M(@^$CRCG\B(.M]8/[>LI(VI'T!V[J!9@>\L2OG2$H0I<#F")_NAD\>V9X@7P
ML9#QC,?RQR8Z2M21=C'H=L*,D"C#J-P%6R.GC/:$&*M!"ZU*:.># ;8"#9<^
MB/U'>J-NG&Z%#N_:.[O>]T53MP)" =>\S#E)2E!CG27I,JL2-V6;3_LW2[NN
M"IT+>3 <OU7ZK.9(SF7FWU6\5>BR6G4IZ52,2"'1G*'XZ](9\DJ&*F7@YMA!
MX#BZIHG*Z% ?=A1$K*B(Y]$5QX?/EW87$OB>R<:'99A[:HG9 NWP,;-9PJ00
M3*\??LN<_(2RM6I(.QDZ:G0%G3MO*D54.PS'F$WK!N0 3>G[49T1C:@0H/L0
MJ5Z7JR @K8>$XH>02!30-*0K2GF,NN&A-2 ]YE=+.?J69E[21_5_=5GS[>^G
ME0L" PZ*C.^(H3NS]#60\S\I<CY1#K%-]DI4+^, T\* W *7P;R>KMQ*SW6X
M7-(:&/?:B_03IP9'*,"NNMO1HHBWR2="!V%4O.[14;=M?357;R#T,I*$P#?3
M1X;K%:6*C7T]/[,(4#:U#@/JWL^-##$4]_WCE]'C=S!J7V&A<>P#&48QH/[V
M\F4'DG%BN+ML<"<?2"(H4 %>=:+'WO!;!50#&2:QG/=$AI&@M=NLQP?@TD4\
MS$%Q DLS<I(<H1Z"2B5A 6_/#?C),,I7T1PY(ZUH"5*/7)0^$3S!QLLP,W)X
M4XZU<A ?P**&:IM9(V,I$X6T#=< G@IXT?K$UO-3\X[Z7/?QS*6(0;E)*>YG
M! /MH0-RC!AQ9&C_K"ILKLM^Z9^EUX/?-.35/^)?R<V[0ZBL"0XV^G";QQ/A
M//&;-#ZBV5#0TV .7/+*?[7_ UP*LXY!B:B_]K%H(,41E& L 08F;@*!(@,I
M 7KAV<>J+.^"H"099JE@:N8Z_>7&'Y><S]ZR]_TU]XL[]7.#.6HQ#@6DB4+A
M^"Q431:'NL@P/7\^['/=*B LJE)_?X\L1F<@[Y8A/61@3H:)M<3.7$25W5XL
M:H"L)'_B%BEX+>A3#V'.4I[^ZN/$T]"?1X \$JQ:1H<N =CV'XL$T5G*J+AY
MQ'* EW(B+&KEOJ#4O:0?#FCDB6!1H0 +;<=-$7B#6 ^.M<7+RUE8J$WA;ME3
M&<;?[ZSH.6KJQK+VO5=(L>,QW&48E#X,/M,3YW#]B?55^GO]N3W^8:T)NT("
M75UJ^TP'B2=[5Y8T";4\&GT/:.PZJ!#I2'VAL[Z1]VB]Z-^TP#Q>Z,:KS-._
MYOJG0U\?0$KCESB]6@N!!;.5(:.#Y5/90I86X>*P,O6<R"5=8!4/VY/?N%'"
M2,JJ%T6XEBRM'G7'AUP[^\ZR';B#J0<[_IVQ=OBQ?M6*TBR6"W1=M$W@'$5:
M#?O5@(P[@=3MIDJX!AP8.YZEITDK(.?M?JQ;@6SI0TV;IL".=_%,QFDWC[A+
ML_H^DV)FH>%!SJ.^=<=NO5>KM'P(_649Z+S\+#MP<8QUH*!",Y^[=VVKNO;W
M:WOL6=>7D'.<E39H:KS5%%6VI58:/3GQ::+4B^B9-K-FTUISK8V[+FFY.?+[
M?BZ$#M;53E?:?@ZD&@D2C17]W%T*!2M%^7=-!W(#/9I#P^S2>=]99S811/J=
M"@\UEM,'6QQ&BHT8#]]" <TFEQE79TR)Z*QS?I2F6J$%8CEN9NCX%<85?'6\
ML43-,[+K:_O5,7W*XL7UB"(MZ?6;7/NVSYLV;5[F@#?*]@JX3^$V-+2>>_>^
MJZPF^5('N(Q0CJ)OO%JBM,(.71FD?.NIV,;<Z*6\C'#.P)G>NJ+V"-+CSN[0
MJA._?DW8A%?GA_Z8G[6)#=1=PLZW< =ZM%. #LL%4\#[<NF?P'7A,#./P.ZK
M;B\\UM+]JZ$M"+E_LSG0%3/ZLKZ>K7W]1"JP6_))Y4+$@WOVSWQ:>[3#1L*<
M+PZTY]5E7V1FB;N16B1TOP30AFRN9 3QC39YN U=#C/[_K'J\*.,BKNG RS=
M+F'B*K\Z;C^ D8_%GS4/H>,HA(/=!GWEA<")GN#P<.>;2^7?GEQ1,ZF_,9)Z
M%*/S_I,"9HR9"!\2&2&9_ BMALXA=/6;A@B--P38-^%$6WO>!AL%'$03L"UD
MQH[J$O+OM?#U^PN-%628JT/N*#$.I$U4/<H6LS>X13 =4'GQ#TG,@8^R_IA@
M;^Q^N^35-C!96)G_\T;-X1^4JQ5APU_F6&MA!] B,8]5"8[%S]6Z"!S4XDY7
MECTH+I[5NK'ZT)F67_9M9W<K;&%]=D16,0@HIBD<H1[S3E-J;28,7$M*R3&F
M'UVZ@<KQ><X2WHU[V1F^T.5^:UJ&*9U"U"X_JE0;>=7C<09E7M8A+4X*J7WM
M2CG\66%D ZL#BZQZ)<,8VE./HMHI7X(RA;%NWWJ6)P$[8Z@LPS#?R3!$S>W/
M[W>Z,#IFZ&ET K@P/]7#G&6V @..J*2(NNMV^9'ZL-Q<IHDSB#P.%PN'L:A2
M<90 QPFS*_'24O9X@-@N 8/<HJ[.1[BX]7.0]0'>\-=99&-@[?-RZ=1P<HWW
M"RBH$0#3 FQ_]#5 %#61\K[]?YTX*J^?)%7BX:!M%DUDS0$/XRDSB2,T? I<
M9'/K5.%U>CS6[:=RU8B!^XA!$U>&T5M>O65,7W=>LN.(;D3XO&1!D101$8(/
MA\PD^^#ED%S.D1RJ'N3# U:;KH.YA0_O &#J4%2<PFG.]_CYB<<+U';]?Q,P
MB_@93N<=^2_R\_^U4YS)77Q4*2_I^]S:>W9) CP]T[9=?A%U>E'O:"THP^I+
M<ZFVHN%CH$62M3W8V&IIE_9&Z+4+=(DO_"G?X%X1G[TML6B\SIR,_:X/?M7<
M(SJ0UH2L3]TC$0S7:AOSA^$_\,&NJN-A/YZ\BG@ ?'6<Q"UH@T@$ZP>Q]82A
MA"\MG-=Q_1/2XHL[1[.X$4YE@[J_9KZN#->Q.->W+.#D*X'6\TNG6B9U:I8%
M088";"1A;4VX40VR%U2(G:].)$&SU=6ER.<ODWLGBB@ LA-XJ=TW,;BR=19U
M=*N8">6)D@AE[)J?7OI?=K/*C9WRXUC\G+DQW)APJ(9T5L1JH6^ #X,6D\4@
MH75H%SC6A$UT9\-Z*]N/B?[X4L9:1CFGC5KBL%^Q.13?1AD&3*!<4QE)7:77
MXANEK$230 /(ZFEPK 4W(R^BTV'5:[O*'8TAN*LF, ]H6D!:L&S&INLD M)*
M*&%-SH.^?&P3'0<?$)UAHT7Q&FBN*Q5A$\V2M4Z*S)#T[&4AJ-3JK"$P('N4
MJW>)<+/3D0'R+[ QS7QF0GW_@%U6I?NPDV0.WPD1P/0/,LPRO#J$&YENS#24
M6-4C\N!0^O-^\9?I)1]WCDDTJDO5$PG,RW,)8_ 9?@&P9@+@EGX=/"<M. O6
M)?I>(A,$,LQI3@AS4D=Q29+ 0[1@]VY$'_#SJ,\]-YZNZ9F5'B[#X#+,<_-(
M$V&_RIGC>A+L.1"QAS]4S2&OA2](VUAVYP7;8>?4"+*&4=BO=(^L^Z_\WU[>
M&Q%WIKCB2QG2EW[3YV0/84F&29]A,LP"/4: 28GD!*T%T**2R2%DLD(K28EJ
M7-)M1MH0D)ZE^9:@=AI2.-P7%QW"6@\T'% !&7?G/V.;EYU%*,@,=<2U*\@)
M'1%N;*)>2C!V1_Q8J*9)KHJ;,I$$HGE@Q>0B71!!LA>*:R2LPV^I2"^HC&55
MUAGX71"&&42GG?N(JME5>;BF._?:\-<PUS0T#.;?2TY1/0@X9!=6T2_-K+4!
M&^6E+]&HJE"49HH,^+%Q';4%F8])D#WUC\P:-1R88>PB:?UW%R^:20480+M(
M/@,">/2I7%#AY-NN.9L;$8X\HV;FTL;,_,1=,@S_L8 %&^CB4"&*:I(U'8OL
MR@%-Y=S< #6UI:*'0-[/L @.?.L_=M$?/:81>1.+775+MXM'PQ&6]+)@?EH.
MLFIV=5G@_H@+1"=S1>'8$NYN, /*JW'R?NV+_!TV%H<^(U]0.5/4B*!"@S'M
MVB;#5%A,'1G!]AN/T)-H1A 2_B23<+!$HL2(*V,L:M2@7B<4T;?$->I@D3QC
M-1I.=(2A"@FYB0.!-J;RXC1D]8+HR1GH5>YON(ZWODB@PXZ@7@NBW?6D2;/-
MA'(/\FFUW!G Q8KAR$E.S:'8OX>V7=PEJ=1;D=Q(RW.=01%Y)<KU)!5DD__P
M.G7!YU=I L;4K3=8U+"LWYU88G&GQO:%_U_C^+60W^O<!^->ZR!_W3C>Q]MK
MFSOMWF1_9?S<4O9RL%>&^6O-#ZJG#+,E/0&8)/41YCAFP;T?(>XA]3O6/L8+
MUB9\5?;KB?6X]N]OT'6@ WQ-$\>+C"<;)21:][ *U89'6$WI'CO]'LH$91A7
M<#IYDE5&-7OIC]\LRI+Z/TFY4;7][Z,=W>]LXI;0M5:/ ZY*@\1YTI0R=@)^
M;V)#1ERSCBT_O4D)V^J%2J+RG-L\G9-.OLCV(":%RD(5D1:%V=BNVG(IUEE5
M;Z/&#7LP6\"&](C-!<-WA_ B5U2"<WV.@*XQ=5LH]%,B$W_+HK1"K&K_[G<G
M:DR=KHQ;M=3<%%8?6G,:\_YPZ-565+9$[:9]=0DZ<840B%7V+[T Y Q8--5:
MV>Q;O>8?]J&I8>LL^NM!*@&=\,O>\V^V+;A.^P*S,'%N@,.Z3%3RL^PHSA[V
M"QOCFA:PB^G%7,!/<6A5PU2+PKG1U%N?BAP1S9X/:J'#WM'U0T8RS#%T0;(F
M@=9A'1GF$W/6/PY9U2HA?T;RQ4+4&8-!(BM1QR;?? [#N:4"9>+E'M**XRR6
M])WI0!;J&#9!GS@3[&.SK-+B4);)]%ND\@YR$4*M*O*X@J1NBM6$UJ,*F.7[
MOJ?LB56E1_6EQ?*_35U<KYF>F@W<5?"P0[FWX^8KW4.%U C(!I2<J^H,>0^[
M9O_4]+-L3N^OT1+8G#K&*5&N(A2',+!04/.3N(7T:]_D-'0"8"AX&-K"G$))
MV7BXO+PB]_H :K*3'J,*7VYJJJ^VD4>'582"A1BJO7?A,-4?'$YFE<@PY5A8
M;V@7=%^T@*ADVN+FM+MLE.UU+*]_*'H8V[*;P?EF7#@B80I_ -=N#E<:1_VR
M#O+V?^67$<&\71CL?2N47^PO2C\I,L_D7TN(/D+_, SF- 1<7I9$R3!6U[]\
MXXR<#^-8#^$*.49SBI%@5G K1()3A"Q[&MW92; ;DV+1[*4#UL7G4"*/*Q<M
ML>.?@65'J ;2!U."Z%(@^JOQTQDJ6BS1+X&1.ZQRN]*.AY*_!OQ9EUOA"/@T
M)(&+I_K*-J/70X$KM<<,[QI(F=:JKSP&^V68UCS4A]"YZ6* I5,*B?HJ*8'F
M$P.%M0KS-08A4O]OTFW5:%7-(%^SK* >$8Y'BL-KT.JK&#$UAJ)P";;1ZP\H
M4_2^QHJ7"31PQ>5,P#L@;-L[(GS:'E%YBP?6_"+7SE*;LEH%OK#:K/@7M)6?
M3/B Z$$.$KF?KNJNC*]]OO4X3?CB*W^&: N4B2(K[AD*=*&<?-CY C26OQ'B
MO0+J2X$*Z>B+24(%J=[&?!BIJ=L7 8Q[&,!2I=]TNK(:&>QL68NK5*@WO/HT
M@L[W(JRED(739ZW-]_(TG5ZYY<QW5>=,C4XB?_*]L,'ST_F"0!LB-Q\-; 09
MZ!LR%5U]/JP(_'W*HG$ZSO$EZ=L0U1M*Y9Y!4E=6%M58JI6UM4O?;P<7UV<K
MA#[A]=PCT<>&$25(A(ZV"0?MKVCEFQ?D<R>6Z"FCTOR:P A?7QEFL\3F5*ON
M:M'*VC<Q"O+RDAL'B?*['X^;+U7"AT62&T#7#*R*(H9]$QNY5# O1-4JND)V
MB\8F#24W)@CEY%865[&!M(E*]N<Q-T 6'ZI<HX(C;GZ>G \,.N0D[]EG-N7C
MN;/H%6\$T4C62[Z(#VB9<9S9.%ORK=*\?ECB:H+T5U%?Z;\_55V1,/33_V;7
M0F@C]FZ#44;$1N9$GV'[*!#PQ?E(F)IG^K>4(<H"O,GYR(:V_SR(\#]MSWRA
MNJ-H6WK$\P"71TNQF:_<GW@,6-W3N."BL#G)5\/JMO;HLOWZKBU>>Z1)<U;U
M8KK"STI+7PWS=&HD/@<[BH^JFW@>25!B^1%NH["-:,,FHHZ"P-QOGM*TH^;F
MZ6$'ELL7HB*EH^2HS2'.'OOS>ZX%T6/-<,LAG%=7F72GI#%C6V4^:NB_5H0"
M*//%9\9)6VV >U(@CYC P):Q$G!*M,U4L]Y+YGUX&S NOL8X/'C9XT!USZZK
MILZO=HZN"^PC[C477%MQ0^X\X2XC/L, WA JQKSKA6U$TPU#^M##YQ-5+2^I
M6J+U[ 9-BR;Z,M@)Q/ZV("F5 D8<H@_2FZ;OZ&X&7VJX0$R4.U-+> \>_DW$
M&WB(0R7E4Z/!WM?/UN@:"BD6EZK\R>\E=5=_#L[A^7WX36RSF.:4.('.U0%B
ME0SS>V.7V/Q85!D;AI9,(F.=#--,?.9+F-O?AX_VY1/B6'[OHGD&L;^")<S)
M:L-VUIT%1C]+9-C)^FG/$<DPC[*L9A,@UH@, V_TX)'HQE/P 0$]CK >KTYY
M,97AE2CVJ-6&!HZS>LT& R0*AY%&CC5!AME(T&6!<936V1&I=[CD;]KG>Y!>
ML^[^:/YPU-5@0+%?<+;,D@V?'N9F L4 3T&D )^;AHZR?I[1Q;+#&G]"Y,4[
MM?# \ _)>+CPKF@38U'[NW.'>KC=CMTHO-]-;RA?8!##7Z&CJF!/Y8X,]T^+
M::+6I"N^!/ IX"--;*2M$BG3WTQ4,>"MFM-P)*O2E+ .X*&X>][E=@9,EF8
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M:$099I=17?K-B'?3TUG2VKT>Z@S0D310U<&16H:3R25HC?J'!<U/S+,+@1O
MWV]E&(8?8?K^Z=S.N7C1F)O'^@@KJ1QLF/TCE%7-NA?A=A,F2$[-$)#5/)%
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MEX;DG^2(U$HFM!Z>A7M=OM,?SST[P-Z$L,:6. \3EBI-EO(2AVJGX+:^WHE
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MR>+X_M/G@V==7M25P )9M0-W(?/_FP!02P,$%     @ "8J;7+X_>JW3'@
M-"   !4   !E83 R.#<V,C,P,5]I;6<Q,"YJ<&>EEW=4$VNX[@=!4!0B342$
MH(@H*%@HTA+=" @*V8(4I41E(TU >H20<8N 2A,04 0CHB(@1*5)C73+QM!#
M$1(2BC23((2!)).3?>Z]Y]X_[A]WW3-9L[*R9M8W\WQYW^?YO<)A(1W886=M
M:PV(B8D!5T0?0#@&6/[[Z[]U_+O(?W<-,>$G0&X+X ADBHOM S;)B8G+B0G;
M 20 B&W^'S< __,0VR0NL5E2:LM6Z6VB&ZIW )O$Q,4W28AOWBPA(;H:)[H.
M2,AMEM][[+2DPH6K4OM"%8__G5&X1?./]RU*CKWL_2>NA=W9*KU3>9?*;JT#
MV@</Z1@8&AF?-#&U/&-E;7/6UL[IHK.+J]NER]Y_^5SW]?,/"(^(C(K&W8J)
MOYN0F'3O_H/,K$?9.;F/G^2]*'KYZG7QFY+2#Y55U36U'^OJ6]O:.SJ[/G_Y
MVM<_,#A$'1X9G60PIZ9G9G_.S7.6?Z^L<M>@]8U_=8D!XO\E_?^J2TZD:Y.$
MA+B$U+^ZQ#9%_WN#G,3FO<<DY4]?D+H:JK#O^-];%/_(*'S?LE7SA"-;Z5I8
MK_3._0:36IQ_I?VGLO\W87?^OY3]E[#_K6L4V"XN)OKSQ.4 -  +HM,M-\!4
MJYFVA0TBITRQ.WX )DZ>JF@@-8&/-W1.,N52$+\7S1@OGU^U4E1/J@;^>/HU
M,R8^&TTA>0@!AUL+"INZ9E/=XA_&R&T( 0SV,B&J1#OC^ZF%+LV_OZSP-ZZ3
MD<TGA4!+,/HJ8H3'P+;KWQ4"._@VG.-(9?Q1#L"F)D_V->]>&,W)O5KZ;GMA
MI-N+'79W=YQY2DW9\='D[;&3;_64:1UV1S%G1C\$CQV81KJK/8FR?SK3C_,@
M'BY[.I!R:]KAD<?T+D]>]W[! (L55,B35(/6X]!<+$<(F"B&@+\VP$4R _RR
M"X[2$@+Q12 ]J^>S1H@J/_"'Y%'49J@GC>_[;<_:=PN+X[8@_2<+VK]B@0_A
MO(E#;<;U%VOS;J\)I-;"O'F6TJN.R2O@M.:KJ4OU4;><(X923</J ZW+I_JQ
MFAO:3!ZYA"L$D ,$;;[4.B^6!Q=Q^/806@ALY@N!.W'X\-M82/PBU(O*[N=A
M+T)'F!9F]BH4?A7N\2J%'3H<[@CEPMNFA8#$"KLVM9PO%LL@WZ^%#P5J@K=\
MB_!ZU&KDXC=Y6:RGSY:(R"-?+CF'66/,Q7F6""& =H4ER.L:0L#U1($0^! H
M!.AU()%.H'J/H]&_6?"IEO0(T3M0R+.+QZ!"1@BDG\M7R&HY/P0?AYXRB-(>
MS&0+]U:GMM+?Q/5$W6\:>Y[]H4"QFYX2[=8]T5IYYXXT-:+,H/NEE/!!O 5[
MS(.SJ_KSG*;?]>G;"YDO,^9/;?IP*5%F28N,BT9NU+5C;I0VC%GM7',=,1(X
M5T5APM?<83&^@-RUBKPO!,0$F%HR>1Z-;/$TAF4M15OSU_P:]NI[#MC!_<B[
M5"G6+ U15-=G]^T+O4,(;IQ5TTT?0M-G29 6(9YQQ*8UC_: <-(_[WMN--?L
MVSGRWUX&N\(0?VB:.-I.5<2)E;M<30275]WYYX+)?MCYF;!J^ M)](QI,HVV
MT0,G'=W2EI'_C+ELT0#N7<+FH]D76*.ZG>1*5BM1Z@<DYY!\BZ/)T$\@J$W@
MS\6>&:@B)7@AAV9_1U)4,5LL<ZO8*Z8='44YH^A*]3/V8U[-^SBN_#VB/9=H
M84>@" U,1,K1/\36R^%MN.[TUR?OQW'B.S'7="F3HIW,$>UD!EK!D"3+-VCD
M*+>SY,9Q"^TQKO&'(^) ^LZFV*+Q^3PN23;A1=O; W7JO=LH)>VVD=?D;>]Y
MG0_IOMRLK)24H[KM<>N)P)QYVZ_4IAJ7I6+K5>.VZ5L5KO?3=%4>#4ZEU3S:
MC;%I^I7G7K42Y?'E=?]&F14[J?7+2MR!4%$9&D,+)5NKQE2LBX3 UN!$<HC\
MY7;&6@A?4PH9($7I=##_YP+V6A=O,]SUT/JA%<\,;Y%V\,*U-,/*@4U=>P+D
MY&SR;BI=/#C%-LW33>*9J8AJ*Y;?/1&>V+!6&BP$IB?LQ]<*0;+7Q@^>KA2/
M6 2FVN3 +-A<EZF&Y2X)LOGZO#_]:>_74E!Z/YOE!,\C4Z6LJ.:&='"G>P!*
M#;.GHMDGUZZ?KT):V(24P<6W)T3493<>V[P(ZXC+C[55YW]9K 6K$)_*S5P&
M#&2<F*ZMY6;MIKMG77M)A'V0==O%7N,WNH+*E[8,B;SMR,9@S=33WWN>_R(]
MW^@PC/VNZQYX\DAL[* S,8-YN.R8OZV/X4Q^W$L/OVL'\M7[4PK_>!$:=,G6
M6+7"*S@($5BF1/DY.I/,L#>EN?88VINY]E=D-W\KF:O-"##2%L]4/W3^UBYQ
M8$/^E*99\S7UM*3:";4XT]X(KC^?NI[_2SXY].:CRU&AH9FA@1']#_S+W_81
MSER\R,L=(%Q+VV+."[473-03_FIJQA1G7 I/,-%,Z^IAKK90:I7@:"+;"2'V
MA!R"'I/>T(U-CB_E8SA:<]MZU)(?2CW_:1KZ:3%0L.-W8J>J6)SLB>'9US%Q
M@9"YJ+[COU\3U) ##E[>WDK0GE>QJ%62R(^D3'<0W!D5NG)WORZOGV;=6QN-
M;=#KCN#QD/U8JY0F[X\4DY>+2ZW5!>6Q7J5WHJ(K&VL_K%*QT^%,J=OD256.
M6KL0N,HS;**&P+4009T/MB$3-T@=F'L32+9D-I=8&9!+Y)@T5,U=G037TQ;.
MI*RMSI#/@'XD*2'@[[F^QCTP!N-%OD.:IMB)K!$Z$-+"0T(8E$9 ;4]<\9_U
MO7Q]G^OH^9V1I+;G/;Q9\04O266SC1K,:I=>L@LKZ# KNMC]!H'T@+[=13]Y
MXL\7F6%A+FDY82$OJ*!1;%?'1U](E5WFP";=UB^OHD&O5YIV?FL;R@$Y3F#
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MQ:OB\YF29 F&GA+CAJO<S.//7\'AI0KGK;;&%?FE1RZ[5F>>\W(2'&7'=J*
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M<>><.7,^YYX[]U[.$&<<$+,RMS0'(! (<(,[ <X(8/I[]2^-WT'^U1@0#A6
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ML>XG;IB/J%K#@U8N65"QY=@2ZFKL3@B"#9O_OB5'/LL!0F9PK*^#?8I[0T/
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MQ3%=D?82M_0!V:=OE 2R1.K.;3MO>&76?1[=@%L/?_4/A$TC?W5(%IL!9AP
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M:XHO<Z(!N__(]G\1BC/\;U!+ P04    "  )BIM<1& 4Y2H)    "@  %0
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ML=OF6!YG_Q&F*^)*Z.NX_Z#]#V3_[X!%_O]"]K\"^]]PS0)8:*@HP:/A (
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M"5'4\1KN4^H'#"VT\&>#PH"X5<9]JA2)3X^[&5\D,_(;44@K7Z?E$!0#Q)I
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M!D4TF8"/JBK1NML8_B7E="\#*1Y5R8Z^D!LU1+XW5=BV%#!;NMPE4 WM XO
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M&^"VL[8:FYM;>\:463]W&W^78^JJ'ER1KV-=2H,NYHJ!AHO!8' P:7GI55_
M0]J@174?G5SAQ3,?K0D*H4;A6 2B3T<=COL/1+;A$<A:&DJQ6\3 -3ED ,0
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M@S2VTI4QO/#^B>5[RUY3SKQ^T\ZIA<\DIZP!Z"%#8#OIN*N+A!Z>LJC+L&"
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M[N/D26A6RZEZW3YTGY:,I"FW?B;*WR88098(C^3@?S!&>Y"2PL8;,_WF0CM
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M)$$'W<[U=)2](*E.U+!B,J;IC60A^@-=+6<W(YT>J7,FYE.E9?/4K,]OC/"
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MDJB:HR3=W3TVERPNY\ZFCKY+_+Y9[W-9HF+9P*Q%$9-:?U,\_75E/8?4?%[
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MYN;8)NKKZD->Q3.%9(M<T']6S;]+AO@SPQ%8JB627T+WT?HRA+I&I PQ<U-
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MO4C J+G($,Q$"9_"QDOA^/\!2$PK:W-TSAC"!>I1U__'+@!"90@F0R\+J?)
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MO=JZ;5W84EV7WZ;#I@R"$C/QJ;K"G+#QAQW[RTR^3G8</;AT[U%VI?-HI8'
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M#P(.1_)M.:_G3Z 46Y/HRXJ3UMFQ@W?J%4?C69W=T@LW_"&Y!<_073;!_4O
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M0#Q $^#;#_"+\PF(\W%; 1@ \&WY>P#PS\;'+R"X9:O0MNW"(KP!-6( /Y^
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MVK61$G4=:CW&81[;@CE@MLP+?>_:+"Z0SK;IJMKAHB7E+=55\4#/334P,2
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MT2;_6\G JWRL-VR6/,GW]T3_OCS2@ NX\*)&GM!J >[0_P)02P,$%     @
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M3F'R+-)9S[=JL .SFKLUBG4]L.SAE+:N:>[@OF;D^O)<!+,D\^(@=W=0-:7
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MN\\$45](G_=\(6PC%UM>+ ?5>/SC[A$]RP?1,2/CF#[QA8T]832, <2X*S"
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M#* )8\4 )MUT)R^Q6(C\S^9&?U-I\_+KD^9G 8'U#>S?GPQ).^V:L[P^\D/
M^L:#PJ<+^4NJQ?RBT\&C\705;)NL"1D3X]K?7M/NX KB;<:1&N?/.K/H!'AZ
MQ$I]-&7_,I8K8QN_8+"L!^<U,L0PJR#7;.\<)+,_--?&JZJO4&9<9U/GX%T_
M8::IU&QSZ:Q=O+G8)>)52[=LPV-M1>OWVO?N1@?5?F5NA,65A509V,_]CY7G
M-)2_/;]C8C,L>;H4[T$?O;:.-)9:-(WB;<>;W.B9[!T\^TR><"EK4BT'+_?
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MX)/?<%^\\#=T>VY(IS;OV:TH3H)T_TV]_>*AR8I;WU9@(KGV>G@S<OU M*2
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ML/[(8Q2.6/+B.PHHC/-@Q6.)7#.S;F/=Z++^3@:0#$DQ)8^1-^)*M1+4K<J
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M0PPMH(I26M&,L60EB.^39, >_ -02P,$%     @ "8J;7$6[+<L("P  Z L
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MFNRWBK]17GMWQ[J0\SP/9#Y-K,:Y8O$O9N/7:S*(A\H'7_4<2([1BN$C?P;
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M\DS!\:6?]56A5VA"^$O&5X9_ZUA4>3HT,XL@DBNO$<_K,NXN2TVF3<6S.MG
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M,1-J'K-:9TL.M57T&'ZY*C!4.\$;?FY&\::@Z$%M8E,,K"HH5]C '9HS[E)
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M<?>Z\^) D-8<ZU=VC@V?-GJ:=+NAU< FLGPC2FLT/J;+8,+XM,$4M_\-"?)
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MN] FMUH3HCUY>Q6GO></Q4,GBUY*F+0L2SG.S E6ZGX*-B3Z$ZQ #W&$UGU
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M!T/^/39BPC?+2!$P4]?(^45@0O*6BU[5]OBRYQLV_WIM]GYC*R36;7MU&W^
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M+B<!< !8-%I:E!D><OY0^F/I,]L&,BBUJ9G3+)'3((6I:5*;YEGN@JAP]4F
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M=9%E$!DJ1P QE=M:BH= 8RA#FHV=_?W%:9-X@2>H;4[S<$S'>#C7IQ2T6-1
M2S;;H@@J9!HU-W7GJ'!J,XTD+= J4" TWFR,H">1P02I,?BO@Z\@.T@#T,=<
MH$AL)4;*'.<A*]:H,;DC: 74JWA6/TC0E%!M B,US5"))G47WTEA*#B%69Q*
MXCER- +I 'S)&O9CI_V?HHP!<(W4I;/?;!S%P$>6G8ZRHHKN$\GA?;9.4F61
MTD$B0Q1_M?Z)^\O\QM?=T+:;(PGM 5$1A;!9%2F=EM0G4J2+P;+Z!0PM)(+%
M?D@_>DJ;J'N\PDV^^T'T9K1>[[%[925\$+^#18R/[\J+SFL1Q<G4#5=:DL7X
M0-F/OETS*O:76ZNAU^&#&,QG,-U6X@X#[X,X!7; :W4:XPKLEISJ^BM\\G1<
M_0^%MA5[VMTRCK<M8D.]B%W [3!.D<ECE$]LN(5=/91@-6_6NRA%Q4-)7II%
MR]MHI?ASBBV 8,FE;LJH^77.OWHWX00V3PLJY6TLHA6H,A/G@K^)0][$D]UL
MU+@;A>T]+'D"V?EGG(E XG 02_,RWDDS$_YF2_3+*UJL8[-1C)>6WRDO!8P+
MQ$3F_@#A"]Q!BHL@03<82&6P)/#5&!UN//0S-P_%L9MFY.(X.3D3&VKLI2>%
M1S=6%''8;HD!['(0L:;0(=F.>NX"C01L?52_,&2PR9I(QDH!2RM25,AM35-P
MTSH#IME0N\M^OE#14#GNPY2K9:LV?<I/:<PFKB-:O$SJX8)_R)*'L!>TVK$'
MBID*7I3D9=53M%L*:.@]TUW_Z;R 1O'9W=I9AR.PX%'"WDJG-E)0RRS*/(AW
M4_&?B3Z,Y2.[);[.8">5"[O94'P%3?0 SA52OS'RY$7@DU13+V'+:# 2'?HR
MA/.2S/7#NL[(/^5Y(/3I,Z64V02UM4-ZH1E'A:^0U9GRA]#ZS&(I]<R3EP ,
MB2(B(_UJ\(9?LCSSRA<^Q_-,0P&[SYW&.=@N-^!Z>,X3J9I9L'XJQN134CKQ
M .VNZP -E@?I>)^5B8 /7P%I*[JUV75A7)!(+:P+EUVM'LP.1I9P!Z#"I7'D
M#L,YR%,X1FF*3S (2$(DQR-D$^C][_2@=7C2$>T.",C6T5'W]/-?7VR_H+_[
M9ZVV_EN-[3+PLPD.;OL77OL;PW6NT[8'Y[JO"^0ZGAOJ2<&'""[_.#BJC&;O
MS=;V:_QX#U9S< 1M'!UHEMDVNH5Z]FIPCO\/)UU9]])JK@YWO\>#L[<>R5.L
M&1)NA:WUAC VUXI/X1&+S8^BQ*KQ>PP_Y--IE? QN%'1K$=Y. I"Y6F>)4%,
MW[/^5%):H _IX@$=5?270I.\TZC5O7/0#7?S%@E!D<%Y333YFXDFLQ$UH(#W
M55'G*KJF"#4O8CF,?,9PE4:!)!A0(UT!GB$9)0'(7"7O4Z6T+Y@^<:0M(-V_
M;>;!S\$(&O-E^45B^]C4_;/E.R6?X6V2C^$CIS&Z<@M. 7^S[4!(!$]*GTYS
M$%U(&-]882@L%RT<_5".@U3]R>1!T>LAQGV""#[+T,&'FBY(WDQ&[!V&YM$S
MZS<;[$T13'EY G;Y. ;!$B&] 1FY8\9F (_)LTE,81"[5^PJ]EF 1W_$ 8TO
M!3,HX$EP.A+JQ$,*8EF>8J"C*32/=E*SH=73>.14B5YI\(9-6DQTN7N2/ !V
M,T^,8+U;)%A#KV>&*)F)&>\U\[H6$-_,>N6G?,HJ3$I635FS#"A*SW\'D8?&
M%4G&1</;L,D4J"4=P<]Q@M$[37W*!D-T:<735-&!M8E/1XJ,O@M)8^-./;1Q
M9((P(*#2 +;*9:R"L@?YK+&6[,4SQ>R9AQ93(_?&G$(XMG*<H%,T?6ITZZ]!
M3FO)IIC&ET-D6*VNL"(QEK2^AJ=8 ?DRQO(L=(DO?9')&/9;T_$TCL;-1KNM
M?^_G0["Y/00<PU0N7-\MP9;I&P69<<3E)$;/5GR);!N)-T!H##D--,':?D[X
MUDR.X-'UG30;MI/,6@6Q /AV;)GBA2@RGA)!KA#OV7L.[91#.WO/H9V'1L9H
M"*_%@U0VA.N U[8U;%CLHC6LC9^?-X>7]&\DJJ4,* 7[V7R^B?DLUJ!/WJX!
MK:3@L_W\ .GGV7[^3^QGY]F ?M0&M+@G"UHL-: 147'+%G0UBE0.J]9;T C8
MOS43VO18MJ3%LR%]BPK?;9K24M3:G@_1Y'Q,,< E ) K H-+:E3L;W%]"HX8
MZD^7)05>K<Q5%/TM55MKQ?^C<=P2.>L?LGDHM16M?KN4")C0/[Y &K[9.#4'
M4FS8Z*TEE;6*\D"?TGL3DA]08;'E0=A;*@[RP/+*]M<3J&VQSO5OES&XG0@$
MEL?:C*BB'R9*BJ"X"-(@D\9E)L4LOE3^M4*+(XTM(Y2.PELO&*]@E:ZN7Z&>
MZH4YI8]B=GP49R(,ID'&.=(E3 3%E!F9H9V&94!1-0.<LZ(5T*: \9<$=DD_
MA'>"['HMT=(W,O7O0GWV,2E)+=B_:<I@<@%G+V ?BO4K$XN5@-'"X*(83/V$
M5 #U09#R-B6EI 3\@!VBA[&;^)3P18[4.$FU$ESQ#S0;E!(^H9-8U;=P0J1S
M\;?\!Z^]+;B,#E>=ND;7URPXNG;Q-=XT!<!?Q'II,*UE=V;\;V@@@*6DU$4R
M4>CM"SANC-<:!IR(O-S5(ODPD&O$';NH'"J\KWJA9D28>D C<A!A)X$A8)X?
M'!Q-J#!3,'AD L8)[D]&K<\25#9GH4K.=F>S$$06/AFZT8\DGV7>'*D_C<,+
MM);0!(J3L1NI@^LT&U,\AT!&^92-;R*&T+TDN:)[5 WSD6!(*JR + X]ONS!
M:@=($8H$-$A.-<*YBPN3HJX2B18;NO/5>70OW"!TAT%(5AVHI6"!(0Q0S&2"
MJC&GAP71'WG$\%AH(9 C"R)HUBB1F/:J5H@3#7%!1B[!EY%A3B-&&.H#3ZFN
MP3!GC[Z5N:YR@:S16RL.$[E_;>IN)<LN^@7:<32"-<@*[;39, S4*;@GP8Z+
MW:L>W5KF^K/<4U<$*+%//R;.3_H"GG#\ P^9IR8@-$>Z".*07$TP++/[E4-N
MW* JVZMO0D@% ZQ@5[&D@1>RP@;'MH@:85HIGSA-O?89A>.'1AL(F,R&!)+G
M@LY3:?ST<\&[0"P@8-S-0Y@K#57("[)-,=Q&$X9E"#P:8.C.4L;4(DP<?@#5
M>"(NXQQQ_]*+$3NN6U/53<BG@HTK-+J'KARU6K@LF!#:;.0S.ED&DHL^'LD%
M'G!,:2JS!;#.PKK2S,9XUM&UC,O$&?&*R^#G!0S>X80]Y<$&9BM#4]4"U@<)
M,%2NJ0V][?C?F-6# +E+[7)LDAO()%:P>L&<3X Q3PP+B7Y8Y*2B!-+N ;&A
ML,O(/UU[LL5$RU]?!JG<+"B#5AW]!+H8!A?VN'+E4*B[P,B @N@IG 55#H0)
M'/=B;G;BVHW YJCN!CTB:8!N/";'NO-4D B,@@^712) ^0XE2=K^0VR.R.N/
MW!]K'8Z9/3,5#S,2ZK)^=;/D,B22L9R&0 JVEEF_=I6IZM#(1J%$CJ3/8A%S
M!3,\WD5I)19HC,?5LTDY%T.O.[K'5USXREBT#UU7/K%WX(-6'/11=)EZ=;S%
M"]T<J[BP#$;%E;;+89>/BPP4#SIR1=*V:..,JX>0ZS/J"%?.VM+"L>_ZL-+0
M*>.-M>XYS-. 4P)POLJ$C>%4C."LPD%PPR+X4[5E'WOBQFJ![OWG0'<YT+W_
M'.B^W[RB_:V]=3@-?B<CJJNS=72"CN&=!:I;)ZXD<L'6+6P\2BABHXS*W8WB
MY8D]=B41TOZ&NF7XFHR[<*X:=##\#7]1FVPE1\B@P; >HI0:48TIM!-"Z5+.
M(IK>5/I"!%,*7BTHMYQ]-W$C6U2!BH@\$I78D4Q8U<0: VH>53>N%=&H>E?0
M%Y:@^Y_*$: M65TU3Q6!Y#IM[D)]-\HN*F5<TBBJ6\7;HA;^22:JX^'87XM'
MS:1]D:)X+L=N0MK&LN0NV),BT:O0/W#?=+;K0AY2D5IFY12E9 VP(TOGQZ7D
M$,("%'$HPWFA5,Q R66;W$VF9E"AC,9PU-37BVEQM8;=JN:; I$40].6&\$"
M,>D6+28%[8N3BA*AO0Z1AN6YE1);5;W+2K(EYU%M59%E!:PV+458^3**;+[J
MP%P]I*&,)%;K0UOO,C+%4/$#K-Z%6P/CW]G^13>Q+$O:R@]&.E!E0NA%GL:>
M_W)OD?$6A%24I]RWRU-N$L\I/%B%U] BJ"4[I0@)&Q.%S@?*8I#&M'&CP,\]
MC;XL[81BZ%8U%4V F\C&_S,J$Z9JH*KH@4,"7H<V9E1)=%=&$%KN65I"S5P0
M[TP(CI MB2O_U+A(WX=_T>'CB/+2A$\T<&<4/#8)JYH%V,=?[YH5/5D,F-1Z
M.<#@8B](V3=?F1J*(G+2#EU"<"C>H0P!Y*0S2>Q42"ICJ3TZ5;=TS1H_-1'S
M>DVH'JO"T!GH-RPB3F6@%)1B'Z(RR9NZA*EY,N-2A.IXXT[*B1N.\ L\U"HL
MP*PMH_JQE@L(E?1Q3" BI!K2M91_)W),+1VR-6?N7#]:5O+042:_F9OE&9CF
MD7;]X)C0% (&PL[F!Y4->[<$]F8]J%7@80%IC-^0]9VXES5:"&XX"@;E9_6U
M&TASV1+,JXPI4[$IXC;LO2G\2= L* XNT1$[+9?[+[A,\E6N"R3ZPG51A=[H
M*1C<S24(T@PX'SL/5:[^G'TK9HA/C<9^71,RFD37!_'-Q<B"(K!3#A&3J_"2
M'C@8G0&;BAWH%DB0MR9RLSSA<FW,*D;L#=$X1U(_YZ;0*6DR(5"4/X?='3(0
MUBG%2Y=@RE:.)E>-QAIP8?D5(^Q+ND3)CN2BRD4<)+A_(KS:&?;ZV1E6=H:]
M?K3.L-*2+"[(,Q0,N>3K-4#!5$6=/R<23%]T4 6".04*K%QA_AD%AE2V?A18
MH>B9NRA2<J6N /):J& 7:ZP *6(%UB8MO(X*?;60U[02IHHP:>X/R;DIRL-:
MJIICG*<K"/%FHU)]SP8Z* MJZ1Q^(H6 )W+ODOR.27@MB784DP""+&$8/]0"
M6TK*6BE\;'E-!8?9C2MD(<A0..4=JTJL1572+QO35@<4<"8,=P6>1O=A.%>B
MU*K97#4HM;(+N!8V%R3:Y49(C!)B31<@-BTS?&L1-:5A919\#0/5"-F:4V@8
MC]^-L6RB@+(YT!NTYA>8+E;QM1>Q!#H36(/2!-+QAP*QQBM2 ;I90UN&>>/X
M/P//*IC2ZR%1VN=8-1!H7:XBNF6(J6JC*_#($D+*CO8;8]88'Q6PDE41N41O
MJ\"5Q!*T$D]Z"5P)EN4&>*6?!!&)*S%$"A-D78GC".9@8&*RJ\H@@*[>0RM\
M4+OJ*Z%FF@T-FZ&X"(-E5L6OP!<Z*@%FF$A_Z-O=Z-1LVM1?J?"QB#\A&F'@
MB8K"#&/TXI$CCNM\*![KZ(VB >CRBKSM&I=":QJ ;<M528LHJ3N&91]3A<IZ
MEP^=G.M]/M16 3JU'>,KZ"-/31RO!2*PBHM:[<GM>ZB%[5.Y%P\U@1$#50Q8
MW9'$MSZRAKJ'5\N]VZR)X&'@3O/_)->(< N#9@77S$4(5D S,W2\^<#]Y(_)
M37!-U<@W1=7(EKIHBR[J5*;KG[!NY)OU&**'**KZ/^8%@JB<)#O%NMWX#^01
M.D4XD;,XR4J*8"D9J/#L*ENMD'RU\A('T6STRP+31.PS8DWJKZ\1Z<)]_M&J
M@EVNA^!@K8-U R$?G&AYLQY+[Y-43+$#6D&4:GQ,!_&QK#\SK2 W)P&@WY?J
M?2UI"+H HL6A,F6I#$D[Q'1KXWU222C_0H1OJG?183./*IN;Y]1P<7FK"AGQ
M>.Q,<AQ1! (I"UQ=AT'"6^J/5:R+!7OBJ5'56A06<[LRL0Q%4Y_H5J!*;1.@
MCR L*S "[_ UUP(CNZJ4[JZKHXY6&3$D]%]A@D<B69%EG>82$_08YI<"O\HX
M; I*.,A\D^9DZ0(&/*3S'SA# VOXZ*"F"JQ5W,OW33U7QY'>/,>1RG&D-\]Q
MI,>G(/Y:*(A?@I0<#I&,\S^C9OCK>C3#?NZA4S].6#"W@ N.=26-CO%;FE2K
M(GIN7T>\VL4[^IZ+")T^++*QBI%E7:)?RKAF*2LNFU0O.RZLN,+/FI8GX?(D
M3#H=?[\E3F,T'L<UE_%B2B8&ROB^5P3I*/ "7ZPL=8H]XM!-MIYV2!7@]9K1
MLA%==@O7#U>YR-BWXQCWJ%/V42<"C'CRP6 GK'AS[A2[=NKN.RK\SVJ6X;S8
MQX7%N'?!=<?':BW*]&?":"&QG;B7'\1O8 VE?J!N9(._YF* 3K:B^!)5"M+N
M9D]]JYW569(KU,V%"L<X):<[UUA2UR[:WN?Z&G0,("O2,.A3M*QM@XQL+_P#
MI_\]3GXX1@,:!W3WHG(,TI&<"V\2!ZQ%*ZB:]EW24/ W*U=87?NX<3F1='J6
M]6F Q?36']8JINJ.6O9^>N1")?^DE8JO6E6S8GQEJ8WJV5WH?TM8YH_&'8,E
M<A%[Y$--\^$T*&#"<-#"/,4C;G=3,G$YM4\YF"D),Q4IJ)&*+Y%IKORKQ<(?
MQNK&ZI'XXD83O"$L<HR#SO7_R'UKSCA-/TAGN=*M#9.H+S)!\&R^MAKK8%H9
M-76!#THD2+T\32T9H*]_K*P.X<P4.E!E4J!RC@0#GR>9 :_G :<AZ^"!74./
M:"MT@RGO-X@*A9MG[R6YNBOE.:N+;Y"&JDX>-40_4,^BKN-F ]-X:=G5."DI
M/;J048"'"18_GS)W5YAP>))+4R-L><LD5J:<WGH=??$*-AMZK@+SF-0QHQ93
M(W8-7EW_/I24G\*)3V:EKQ[:$,.1Y (26+AY-F>_)Q)PK.JFJ5!:IDC/)ZEI
M A8<?N+[]#*3!;( \+?R:M28U+P6HK?C..:(;9IC*@NMO7J9&(N]"BKVI89<
MR/NB,*>"^QE.Z..82+A3^%4OTZ4[+\)>-'5<1=.7>@LD0H1Y:1@1RRB*PO4Z
M@*F#[M1J'XNSUOG@NSCNG'<.OXON^7GG]UX;E-'OXENK^WNG+UJGW\5Y]_/Q
M0'0'XDL+7FW]WG'@YR/1^GS>@3=.>P,QZ(GSSO]\[?0'\$C\]O7\NQB<=ULG
MXE/O7 R..Z)U]-O7HVZ[->CV3D7O4[.![1YU^V=?!QWJ_>OI4>=<P-O=4]'N
MG9YVVO3JM^[@&']MG7?[H/:+WM<!? Y-=OO<_Y<."$9\X12[;)WV6_PAM#'H
M?#D[:0TZ1VIZ"J;UI#2'M3A,!D&FHQ/]?)C17U9AN^)IJI^*/*VM.8O9H?1H
MQ-*861<RCTAA+O -Q9&'K&F 2I@4M_*BXD$1%NM69]9+GK+"N);TQE-FG$HA
MI 03^L$QO%WCMJTZ*!@ORR,E^BVD=6QQ);6YG+55I.6QR5:#H9C"_/$#H #T
M;Y$HT"5A2AS3JCFE@3GO"0Z16Q<55LM-65+[ X>\:]Y.:2# 3$>N1Y 4T!2-
MO8)J99!82#!46'3$CG+"T$.(;@2.,<H0-(,DUK\P=B53>=$_T"["S!?L0VG#
MT#O)0A)TFZ0=P9.B&9*0'PH<0AQ)<:@R(<012@ZZNMR7LQ@4.ZU9"38(4)Z@
M%A(@VH;%&%\;B6H E:1@Q0 /*,M64X1-BUXJ+T%I%3Q<=ZK*LND/@%**A>-$
M9N6H?XE#+]ZS<08E0M+R\<'5&K^AZXDZ+_['/0Q*56.73O%GNKIEQE0>>1U
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MNAG*V)6+19\?_84A5V7'W&)ZC%UN 01QX@/K1"_*H:Y#GEBWQ)=.IITR4E-
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M_C2*PWBR8BT^EQD/Z[56G,SC1,'<'\?)3"3ABMU%\3+"W7OQ* ]9L\-P7>/
M@4U9/\IX(F/FVX^6)U' ;+0=0J4U%?[=(0!FW2QHT$Z=-.$BE+#3;,ZC%5"E
MW*98;N_4,$>I;L@3P=)X)C+B8R+&(D$2 8& (W(A@YR'<"HX#[=(?LN3;&7M
MCILZ@$L8"C^3"Q&NG'J-IVM/2)%:SS0,)>5_$" P,&5Y"A]'><:B.&-Q-A7)
M4J:"!6(L([@#WX6,6#H%G-B4+P2#)6PF>"2C"6"8^HD<*>S3W)^J3>LU> 37
MH9SL U)FMY$(X^5!XUN(][=3++ I[Z[=@=L<H@%Q%,=%Y L@4PJ[!@*IETUY
M!F8HR3C0SOWH3WDT$:5B.2S@&5#P41T:B6PI1+19]/:1*:6$&##UVD8%=M@\
M3]*<1QDBN)Q*X.]FB<:G20;@^" 7N4RGQ5F0&B- /1(IX:YW .U%J4H$7?2-
MAJ=9[-^5RQR0JM'O(.&X.0+U8] 15&* E\]C)6:M,$X!;$74E. >T$-B/%9*
MHLEG1-,V86ZQI@V$!N6^O]<WD9[O2FXO<^ #\KD5ST;WG$-5AF]X O*$D@OR
M^Y)XQV%5(,"L5<446%452X(] @M\SVE4Y/*9\VN(\@ST_Z5QLL\/ZC5+\.=)
M#'X&D"#NF:LSO@+S028<>8>< G+BW2SA4<IINQ15$(S//*05Z# $F![]+!_!
M(Z2<L"\X289.#L!)T'82%A >HZVH9VBUR*'D&7@]MDQDEH'Q A I' W%Q+(R
M@(QB,SF_Y\W<TBPJ+7C0+GZ>#70VTEX% 8I?$*5H3HF@7E/\+<0'-[3@&%$"
M@Y^'&6&E9&6F&;V3G#D6]FA,U&<P1VM'L3P:0099EPG9*XI(53RZZ4%F/8?J
M(62R13B?.(KYQL+6Z[^#W5#BKOH#5\F<!++BX<%R)!7^:@)Q0[J4I2)##Y]-
M30")3 "B@WU'U@/QP5B$8D(R-(ISC&4W2AM&^4QFJ0C'=/E&)!.1U&O#?'3
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M_U]02P$"% ,4    "  )BIM<)3C.JP 5  !#]@  $0              @ $
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M &5A,#(X-S8R,S Q7VEM9S$N:G!G4$L! A0#%     @ "8J;7+X_>JW3'@
M-"   !4              ( !*GX% &5A,#(X-S8R,S Q7VEM9S$P+FIP9U!+
M 0(4 Q0    (  F*FUQKP ([50\  (,0   5              "  3"=!0!E
M83 R.#<V,C,P,5]I;6<Q,2YJ<&=02P$"% ,4    "  )BIM<1& 4Y2H)
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M              "  :2'!@!E83 R.#<V,C,P,5]I;6<T+FIP9U!+ 0(4 Q0
M   (  F*FUS,4&ZX[@D  -@*   4              "  2*0!@!E83 R.#<V
M,C,P,5]I;6<U+FIP9U!+ 0(4 Q0    (  F*FUS?Y'\1?2P  .LN   4
M          "  4*:!@!E83 R.#<V,C,P,5]I;6<V+FIP9U!+ 0(4 Q0    (
M  F*FUPCQS#6A @  %\)   4              "  ?'&!@!E83 R.#<V,C,P
M,5]I;6<W+FIP9U!+ 0(4 Q0    (  F*FUQ%NRW+" L  .@+   4
M      "  :?/!@!E83 R.#<V,C,P,5]I;6<X+FIP9U!+ 0(4 Q0    (  F*
MFURK^ +4Z1P  !L>   4              "  >':!@!E83 R.#<V,C,P,5]I
M;6<Y+FIP9U!+ 0(4 Q0    (  F*FURX^V5J=08  -(?   5
M  "  ?SW!@!E83 R.#<V,C,P,65X,3(M,2YH=&U02P$"% ,4    "  )BIM<
M@TH#8FL&   J'P  %0              @ &D_@8 96$P,C@W-C(S,#%E>#$R
M+3(N:'1M4$L! A0#%     @ "8J;7*>#?KAR P  (0P  !4
M ( !0@4' &5A,#(X-S8R,S Q97@Q,RTQ+FAT;5!+ 0(4 Q0    (  F*FUS/
M=+*SU ,  '(,   5              "  ><(!P!E83 R.#<V,C,P,65X,34M
M,2YH=&U02P$"% ,4    "  )BIM<5&10KJ8"  !J"@  %0
M@ 'N# < 96$P,C@W-C(S,#%E>#$U+38N:'1M4$L! A0#%     @ "8J;7&G*
MK,.K)P  )?,  !4              ( !QP\' &5A,#(X-S8R,S Q97@T+3,Y
M+FAT;5!+ 0(4 Q0    (  F*FURS[9 !Y10  -!?   5              "
M :4W!P!E83 R.#<V,C,P,65X-"TT,"YH=&U02P4&     !H &@#&!@  O4P'
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>ea0287623-20f_checkcap_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:chek="http://check-cap.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="chek-20251231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">chek:CheckCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-08</startDate>
            <endDate>2024-09-08</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">chek:CheckCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-08</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:FirstApolloLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-08</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:SecondApolloLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-23</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:SecondApolloLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:FourthApolloLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chek:ComputersAndAuxiliaryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GhostKitchensARAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-04</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:DevelopmentAreaAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:RestOfCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chek:CheckCapUsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:DesignerRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:IsraelInnovationAuthorityMinistryOfEconomyAndIndustryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-07</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">chek:RoyaltiesToAnASICDesignerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">chek:RoyaltiesToAnASICDesignerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-04</startDate>
            <endDate>2025-09-04</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <instant>2025-12-30</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
        </entity>
        <period>
            <startDate>2025-09-04</startDate>
            <endDate>2025-09-04</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-04</startDate>
            <endDate>2025-09-04</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-04</startDate>
            <endDate>2025-09-04</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:NonExecutiveDirectorsCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesIncludingSharebasedCompensationAndReimbursementOfExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:ExchangeIndebtednessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chek:DebtforEquityExchangeNovemberFourteenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">chek:ApolloTechnologyCapitalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-19778">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-19779">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-19780">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-19781">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-19782">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-19783">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-19784">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-19785">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-19786">001-36848</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-76">Check-Cap Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-84">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-19787">29 Abba Hushi Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-19788">P.O. Box 1271</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-19789">Isfiya</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-19790">3009000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-19791">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-19792">David Lontini</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-19793">29 Abba Hushi Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-106">P.O. Box 1271</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-19794">Isfiya</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-19795">3009000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-19796">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-19797">+1 (647)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-19798">892-9516</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1" id="ixv-19799">david@londacorp.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="c0" id="ixv-133">Ordinary Shares, par value NIS 48.00</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-138">MBAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-19800">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-19801"
      unitRef="shares">7020502</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-19802">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-19803">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-19804">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-19805">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-19806">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-19807">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-19808">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-19809">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-19810">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-19811">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-19812">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-13018">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Board of Directors is
responsible for overseeing our risk management program and cybersecurity is a critical element of this program. Management is responsible
for the day-to-day administration of our risk management program and our cybersecurity policies, processes, and practices. Our cybersecurity
policies, standards, processes, and practices are based on recognized frameworks and other applicable industry standards are standalone
from our overall risk management system and processes. In general, we seek to address material cybersecurity threats through a company-wide
approach that addresses the confidentiality, integrity, and availability of our information systems or the information that the Company
collects and stores, by assessing, identifying and managing cybersecurity issues as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cybersecurity Risk Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Our cybersecurity risk management
strategy focuses on several areas:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Identification and Reporting&lt;/i&gt;: We have implemented a comprehensive, cross-functional approach to assessing, identifying and managing material cybersecurity threats and incidents. Our program includes controls and procedures to properly identify, classify and escalate certain cybersecurity incidents to provide management visibility and obtain direction from management as to the public disclosure and reporting of material incidents in a timely manner.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Technical Safeguards&lt;/i&gt;: We implements technical safeguards that are designed to protect the our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence, as well as outside audits and certifications.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Incident Response and Recovery Planning&lt;/i&gt;: We have established and maintains comprehensive incident response, business continuity, and disaster recovery plans designed to address our response to a cybersecurity incident. We conduct regular tabletop exercises to test these plans and ensure personnel are familiar with their roles in a response scenario.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Third-Party Risk Management&lt;/i&gt;: We maintain a comprehensive, risk-based approach to identifying and overseeing material cybersecurity threats presented by third parties, including vendors, service providers, and other external users of our systems, as well as the systems of third parties that could adversely impact our business in the event of a material cybersecurity incident affecting those third-party systems, including any outside auditors or consultants who advise on our cybersecurity systems.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Education and Awareness&lt;/i&gt;: We provide regular, mandatory training for all levels of employees regarding cybersecurity threats as a means to equip our employees with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes, and practices.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;We conduct periodic assessment
and testing of our policies, standards, processes, and practices in a manner intended to address cybersecurity threats and events. The
results of such assessments, audits, and reviews are evaluated by management and reported to the Audit Committee and the Board, and we
adjust our cybersecurity policies, standards, processes, and practices as necessary based on the information provided by these assessments,
audits, and reviews.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats. The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Senior management works collaboratively
across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond
to any material cybersecurity incidents in accordance with our incident response and recovery plans. To facilitate the success of our
cybersecurity program, cross-functional teams throughout the Company address cybersecurity threats and respond to cybersecurity incidents.
Through ongoing communications with these teams, our outsourced information technology team and senior management are informed about and
monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and report such threats
and incidents to the Audit Committee when appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Material Effects of Cybersecurity Incidents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have not materially affected and are not reasonably likely to
materially affect us, including our business strategy, results of operations, or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-19813">The Board of Directors is
responsible for overseeing our risk management program and cybersecurity is a critical element of this program</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-19814">Management is responsible
for the day-to-day administration of our risk management program and our cybersecurity policies, processes, and practices.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-19815">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-13122">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats. The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-19816">The Board, in coordination
with the Audit Committee, oversees our risk management program, including the management of cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-19817">The Board and the Audit
Committee each receive regular presentations and reports on developments in the cybersecurity space, including risk management practices,
recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological
trends, and information security issues encountered by our peers and third parties. The Board and the Audit Committee also receive prompt
and timely information regarding any cybersecurity risk that meets pre-established reporting thresholds, as well as ongoing updates regarding
any such risk. On an annual basis, the Board and the Audit Committee discuss our approach to overseeing cybersecurity threats with members
of senior management.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-19818">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-19819">Senior management works collaboratively
across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond
to any material cybersecurity incidents in accordance with our incident response and recovery plans. To facilitate the success of our
cybersecurity program, cross-functional teams throughout the Company address cybersecurity threats and respond to cybersecurity incidents.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-19820">Through ongoing communications with these teams, our outsourced information technology team and senior management are informed about and
monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and report such threats
and incidents to the Audit Committee when appropriate.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c0" id="ixv-19821">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-13135">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Material Effects of Cybersecurity Incidents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have not materially affected and are not reasonably likely to
materially affect us, including our business strategy, results of operations, or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-19822">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-14232">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Opinion on the Consolidated Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have audited the accompanying consolidated
balance sheets of Check-Cap Ltd. (the &#x201c;Company&#x201d;) as of December 31, 2025, 2024 and 2023, and the related consolidated statements
of operations, stockholders&#x2019; equity (deficit), and cash flows for each of the three years in the period ended December 31, 2025,
and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity
with accounting principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-19823">BCRG Group</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-19824">7158</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-19825">Irvine, CA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-19826" unitRef="usd">2000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="-3" id="ixv-19827" unitRef="usd">217000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="-3" id="ixv-19828" unitRef="usd">265000</us-gaap:ShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c2" decimals="-3" id="ixv-19829" unitRef="usd">219000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c3" decimals="-3" id="ixv-19830" unitRef="usd">265000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-19831" unitRef="usd">219000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-19832" unitRef="usd">265000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="-3" id="ixv-19833" unitRef="usd">726000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="-3" id="ixv-19834" unitRef="usd">6525000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-19835" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-19836" unitRef="usd">112000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-19837" unitRef="usd">7267000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-19838" unitRef="usd">112000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-19839" unitRef="usd">7486000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-19840" unitRef="usd">377000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="-3" id="ixv-19841" unitRef="usd">790000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" id="ixv-19842" unitRef="usd">492000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c2" decimals="-3" id="ixv-19843" unitRef="usd">2197000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="-3" id="ixv-19844" unitRef="usd">793000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-19845" unitRef="usd">406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-19846" unitRef="usd">406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-19847" unitRef="usd">640000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-19848" unitRef="usd">16000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-19849" unitRef="usd">120000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-19850" unitRef="usd">4049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-19851" unitRef="usd">1811000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-19852" unitRef="usd">16000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-19853" unitRef="usd">16000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="0"
      id="ix_8_fact"
      unitRef="ilsPershares">48</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="0"
      id="ix_9_fact"
      unitRef="ilsPershares">48</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ix_2_fact"
      unitRef="shares">18000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ix_3_fact"
      unitRef="shares">18000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">7020502</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">7020502</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ix_4_fact"
      unitRef="shares">5850906</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">5850906</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ix_0_fact" unitRef="usd">83918000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ix_1_fact" unitRef="usd">83751000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-19864" unitRef="usd">85389000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-19865" unitRef="usd">84809000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-19866" unitRef="usd">-165870000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-19867" unitRef="usd">-170010000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-19868" unitRef="usd">3437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-19869" unitRef="usd">-1450000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-19870" unitRef="usd">7486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-19871" unitRef="usd">377000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-19872" unitRef="usd">8311000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-19873" unitRef="usd">2373000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-19874" unitRef="usd">9462000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-19875" unitRef="usd">9550000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges contextRef="c5" decimals="-3" id="ixv-19876" unitRef="usd">1426000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-19877" unitRef="usd">-2373000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" id="ixv-19878" unitRef="usd">-9462000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" id="ixv-19879" unitRef="usd">-19287000</us-gaap:OperatingIncomeLoss>
    <chek:ImpairmentOfLoansReceivable contextRef="c4" decimals="-3" id="ixv-19880" unitRef="usd">16487000</chek:ImpairmentOfLoansReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="-3" id="ixv-19881" unitRef="usd">6525000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-19882" unitRef="usd">-12000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" id="ixv-19883" unitRef="usd">800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" id="ixv-19884" unitRef="usd">1719000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-19885" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-19886" unitRef="usd">-25149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-19887" unitRef="usd">-17568000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-19888" unitRef="usd">4140000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c4" decimals="-3" id="ixv-19889" unitRef="usd">-25149000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="-3" id="ixv-19890" unitRef="usd">-17568000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-19891"
      unitRef="usdPershares">0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-19892"
      unitRef="usdPershares">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-19893"
      unitRef="usdPershares">-4.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-19894"
      unitRef="usdPershares">-4.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-19895"
      unitRef="usdPershares">-3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-19896"
      unitRef="usdPershares">-3</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-19897"
      unitRef="shares">6232226</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-19898"
      unitRef="shares">6232226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-19899"
      unitRef="shares">5849013</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="0"
      id="ixv-19900"
      unitRef="shares">5849013</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-19901"
      unitRef="shares">5848737</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-19902"
      unitRef="shares">5848737</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-19903"
      unitRef="shares">5844463</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" id="ixv-19904" unitRef="usd">83664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" id="ixv-19905" unitRef="usd">84941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" id="ixv-19906" unitRef="usd">-127293000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-19907" unitRef="usd">41312000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c10"
      decimals="INF"
      id="ixv-19908"
      unitRef="shares">6092</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c10" decimals="-3" id="ixv-19909" unitRef="usd">82000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c11" decimals="-3" id="ixv-19910" unitRef="usd">-82000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c11" decimals="-3" id="ixv-19911" unitRef="usd">-57000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c5" decimals="-3" id="ixv-19912" unitRef="usd">57000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-19913" unitRef="usd">-17568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-19914" unitRef="usd">-17568000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c13"
      decimals="INF"
      id="ixv-19915"
      unitRef="shares">5850555</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-19916" unitRef="usd">83746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-19917" unitRef="usd">84802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-19918" unitRef="usd">-144861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-19919" unitRef="usd">23687000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c17"
      decimals="INF"
      id="ixv-19920"
      unitRef="shares">351</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c17" decimals="-3" id="ixv-19921" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c18" decimals="-3" id="ixv-19922" unitRef="usd">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c18" decimals="-3" id="ixv-19923" unitRef="usd">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c4" decimals="-3" id="ixv-19924" unitRef="usd">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-19925" unitRef="usd">-25149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-19926" unitRef="usd">-25149000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-19927"
      unitRef="shares">5850906</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-19928" unitRef="usd">83751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-19929" unitRef="usd">84809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-19930" unitRef="usd">-170010000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-19931" unitRef="usd">-1450000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c23"
      decimals="INF"
      id="ixv-19932"
      unitRef="shares">1169596</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="-3" id="ixv-19933" unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="-3" id="ixv-19934" unitRef="usd">592000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-19935" unitRef="usd">759000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c24" decimals="-3" id="ixv-19936" unitRef="usd">-12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-19937" unitRef="usd">-12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="-3" id="ixv-19938" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-19939" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      decimals="INF"
      id="ixv-19940"
      unitRef="shares">7020502</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-19941" unitRef="usd">83918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-19942" unitRef="usd">85389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-19943" unitRef="usd">-165870000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-19944" unitRef="usd">3437000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-19945" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-19946" unitRef="usd">-25149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-19947" unitRef="usd">-17568000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="-3" id="ixv-19948" unitRef="usd">161000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="-3" id="ixv-19949" unitRef="usd">212000</us-gaap:DepreciationDepletionAndAmortization>
    <chek:ImpairmentOfLoansReceivable contextRef="c4" decimals="-3" id="ixv-19950" unitRef="usd">16487000</chek:ImpairmentOfLoansReceivable>
    <us-gaap:AssetImpairmentCharges contextRef="c5" decimals="-3" id="ixv-19951" unitRef="usd">1426000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-19952" unitRef="usd">-12000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" id="ixv-19953" unitRef="usd">12000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" id="ixv-19954" unitRef="usd">-57000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="-3" id="ixv-19955" unitRef="usd">-305000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-19956" unitRef="usd">95000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-19957" unitRef="usd">-112000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-19958" unitRef="usd">49000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-19959" unitRef="usd">6491000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" id="ixv-19960" unitRef="usd">-100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" id="ixv-19961" unitRef="usd">-480000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-19962" unitRef="usd">2222000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" id="ixv-19963" unitRef="usd">497000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="-3" id="ixv-19964" unitRef="usd">-851000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c5" decimals="-3" id="ixv-19965" unitRef="usd">-856000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="c5" decimals="-3" id="ixv-19966" unitRef="usd">-94000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-19967" unitRef="usd">-46000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-19968" unitRef="usd">-8004000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-19969" unitRef="usd">-16954000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-19970" unitRef="usd">83000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireLoansReceivable contextRef="c4" decimals="-3" id="ixv-19971" unitRef="usd">16487000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c0" decimals="-3" id="ixv-19972" unitRef="usd">-48000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c4" decimals="-3" id="ixv-19973" unitRef="usd">-15647000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c5" decimals="-3" id="ixv-19974" unitRef="usd">-21439000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-19975" unitRef="usd">48000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-19976" unitRef="usd">-840000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-19977" unitRef="usd">21356000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-19978" unitRef="usd">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c4" decimals="-3" id="ixv-19979" unitRef="usd">-8844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="-3" id="ixv-19980" unitRef="usd">4402000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-19981" unitRef="usd">8844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="-3" id="ixv-19982" unitRef="usd">4442000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-19983" unitRef="usd">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-19984" unitRef="usd">8844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c5" decimals="-3" id="ixv-19985" unitRef="usd">35000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:IncomeTaxesPaid contextRef="c5" decimals="-3" id="ixv-19986" unitRef="usd">25000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="-3" id="ixv-19987" unitRef="usd">738000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="-3" id="ixv-19988" unitRef="usd">2023000</us-gaap:InterestPaidNet>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-19989" unitRef="usd">2000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c16" decimals="-3" id="ixv-19990" unitRef="usd">8844000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-19991" unitRef="usd">2000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c16" decimals="-3" id="ixv-19992" unitRef="usd">8844000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-16477">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &#x2013; GENERAL INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Check Cap Ltd. (the &#x201c;Company&#x201d;) was incorporated
under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Avenue, Isfiya 3009000, Israel.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company has three wholly-owned subsidiaries: Check-Cap
US, Inc., incorporated under the laws of the State of Delaware on May 15, 2015; Check-Cap Canada Inc., incorporated on April 9, 2024,
and CC Merger Sub Inc., incorporated under the laws of the State of Nevada on September 9, 2025.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company was engaged in a clinical-stage medical diagnostics
company that aimed to redefine colorectal cancer (CRC) screening through the introduction of C-Scan&#xae;, a screening test designed to
detect polyps before they may transform into colorectal cancer. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning,
control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan is non-invasive
and requires no preparation or sedation.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 21, 2023, the Company announced that the most recent
efficacy results from its calibration studies did not meet the goal required to proceed to the powered portion of the U.S. pivotal study.
On June 6, 2023, the Company&#x2019;s Board of Directors determined it was appropriate to pursue strategic options, approved a significant
reduction in workforce, discontinued the calibration studies, and concentrated resources on strategic alternatives.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(5)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 24, 2023, the Company received a notice terminating
the Keystone BCA pursuant to Section 10.1(e) thereof, in light of the failure by the Company&#x2019;s shareholders to approve the transaction
at the December 18, 2023 Annual General Meeting. At the same meeting, the then-existing Board of Directors was replaced by five new board
members.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(6)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Since its inception, the Company has devoted substantially
all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets, and raising
capital. The Company has not yet generated revenues from operations.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(7)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 25, 2024, the Company entered into a business combination
agreement (the &#x201c;Apollo BCA&#x201d;) with Apollo Technology Capital Corporation (formerly known as Nobul AI Corp.) (&#x201c;Apollo&#x201d;),
a private Ontario corporation. Subsequently, the Company&#x2019;s primary strategic focus shifted to a proposed business combination with
MBody AI Corp., a Nevada corporation (&#x201c;MBody AI&#x201d;) (the &#x201c;Merger&#x201d;). On November 17, 2025, the Company held a special
general meeting of shareholders at which approximately 98% of votes cast were in favor of the Merger. The Merger is expected to transform
the Company into a Nasdaq-listed embodied-AI enterprise, subject to final regulatory and procedural conditions. See Note 19 &#x2013; Subsequent
Events.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(8)&lt;/td&gt;&lt;td style="text-align: justify"&gt;During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo in connection with the Apollo BCA. On September 8, 2024, the Board approved the First
Apollo Loan ($6,000, 5% per annum) and an amendment to the Apollo BCA requiring the Company to deposit $11,000 into a segregated bank
account at the Royal Bank of Canada (the &#x201c;Segregated Account&#x201d;) for Apollo business activities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in"&gt;On December 23, 2024, the Board approved
the Second Apollo Loan ($6,000). As of December 31, 2024, $2,100 of the Segregated Account had been used by Apollo for acquisition targets
and growth initiatives; $700 had been used for certain Company expenses; and $2,200 remained in the Segregated Account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in"&gt;In July 2025, in connection with the
audit of the Company&#x2019;s December 31, 2024 financial statements, the Company reclassified the $2,100 as the Third Apollo Loan and
the $2,200 as the Fourth Apollo Loan, each on the same terms as the First Apollo Loan. See Note 19 &#x2013; Subsequent Events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify; text-indent: 0in"&gt;Also in July 2025, management evaluated
the recoverability of the Apollo Loans (First through Fourth) in accordance with ASC 326, Financial Instruments &#x2013; Credit Losses,
and recorded a full allowance for credit losses on the Apollo Loans as of December 31, 2024. As of the date of issuance of these financial
statements, the Apollo Loans are contractually current and not in default. See Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(9)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company&#x2019;s ordinary shares are listed on the Nasdaq
Capital Market under the symbol &#x201c;MBAI&#x201d; (formerly &#x201c;CHEK&#x201d;, prior to December 2, 2025). The Company has conducted
multiple registered direct offerings and warrant exercise transactions since its IPO on February 24, 2015. The Company&#x2019;s Series
A Warrants expired on February 24, 2020 and Series C Warrants expired on May 8, 2023.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(10)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The consolidated financial statements include the accounts
of Check Cap Ltd., Check-Cap US, Inc., and Check-Cap Canada Inc. All intercompany transactions and balances have been eliminated.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(11)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Effective November 23, 2022, the Company effected a 1-for-20
reverse share split. All share and per-share amounts in these financial statements have been retroactively adjusted.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.3in; text-align: left"&gt;(12)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Following the October 7, 2023 attacks in Israel, the country
has been involved in ongoing military conflicts. Although certain ceasefire agreements have been reached, the situation remains volatile
with potential for escalation. The Company continues to monitor developments and their potential impact on operations.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <chek:VotesCastPercentage contextRef="c29" decimals="2" id="ixv-19993" unitRef="pure">0.98</chek:VotesCastPercentage>
    <chek:AmountPayableForNonrefundableFee contextRef="c30" decimals="-3" id="ixv-19994" unitRef="usd">6000000</chek:AmountPayableForNonrefundableFee>
    <us-gaap:InvestmentInterestRate contextRef="c31" decimals="2" id="ixv-19995" unitRef="pure">0.05</us-gaap:InvestmentInterestRate>
    <us-gaap:Deposits contextRef="c32" decimals="-3" id="ixv-19996" unitRef="usd">11000000</us-gaap:Deposits>
    <us-gaap:LoansPayable contextRef="c33" decimals="-3" id="ixv-19997" unitRef="usd">6000000</us-gaap:LoansPayable>
    <us-gaap:SecuritiesSegregatedUnderOtherRegulations contextRef="c34" decimals="-3" id="ixv-19998" unitRef="usd">2100000</us-gaap:SecuritiesSegregatedUnderOtherRegulations>
    <us-gaap:OtherExpenses contextRef="c4" decimals="-3" id="ixv-19999" unitRef="usd">700000</us-gaap:OtherExpenses>
    <us-gaap:SecuritiesSegregatedUnderOtherRegulations contextRef="c3" decimals="-3" id="ixv-20000" unitRef="usd">2200000</us-gaap:SecuritiesSegregatedUnderOtherRegulations>
    <chek:ReclassifiedAcquisitionTarget contextRef="c3" decimals="-3" id="ixv-20001" unitRef="usd">2100000</chek:ReclassifiedAcquisitionTarget>
    <us-gaap:LoansPayable contextRef="c35" decimals="-3" id="ixv-20002" unitRef="usd">2200000</us-gaap:LoansPayable>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c36" id="ixv-20003">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-16594">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING
CONCERN&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The accompanying consolidated financial statements have been
prepared on a going concern basis. As of December 31, 2025, the Company had an accumulated deficit of approximately $165,870 and cash
and cash equivalents of approximately $2. The Company has not generated revenues from operations and has incurred substantial net losses
since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Notwithstanding net income of $4,140 for the year ended December
31, 2025, which arose primarily from a non-cash credit loss recovery of $6,525 recognized upon reinstatement of the Apollo loan receivable
during the first half of 2025 (see Note 14), the Company&#x2019;s operating cash flows remain negative. These conditions raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans include consummating the pending merger with MBody
AI Corp. and utilizing the ARC Equity Line of Credit facility. There is no assurance these plans will be successfully executed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s consolidated financial statements have
been prepared in accordance with U.S. GAAP. The functional currency of the Company is the U.S. dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Consolidation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The consolidated financial statements include the accounts
of Check Cap Ltd. and its wholly-owned subsidiaries, Check-Cap US, Inc. and Check-Cap Canada Inc. All intercompany transactions and balances
have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company considers all short-term, highly liquid investments
with original maturities of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Short-term Bank Deposit&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Bank deposits with original maturities of more than three
months but less than twelve months are included in short-term bank deposits and bear interest at market rates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over estimated useful lives: laboratory equipment 5&#x2013;7 years;
office furniture and equipment 5&#x2013;7 years; computers and auxiliary equipment 3 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Intangible assets are recorded at cost and amortized on a
straight-line basis over their estimated useful lives. The Ghost Kitchens ARA intangible asset, recorded at $759 upon issuance of shares
on September 4, 2025, is amortized over its estimated useful life. Amortization expense for the year ended December 31, 2025 was $34.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company reviews long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying
amount exceeds the fair value of the asset.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Investments in Equity Securities&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company accounts for investments in equity securities
without a readily determinable fair value under ASC 321, using the measurement alternative (cost less impairment, adjusted for observable
price changes in orderly transactions for identical or similar investments of the same issuer). The Apollo equity investment of $6,525
thousand, arising from the noncash debt-for-equity exchange recognized on November 14, 2025, is recorded at cost equal to the carrying
value of the loan receivable surrendered. No gain or loss was recognized on exchange. See Note 14.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Research and development expenses are charged to operations
as incurred, net of participation from the Israeli Innovation Authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company measures share-based compensation awards at grant-date
fair value using the Black-Scholes option-pricing model and recognizes compensation expense on a straight-line basis over the requisite
service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company uses the asset and liability method for income
taxes. A full valuation allowance has been established against all deferred tax assets given the Company&#x2019;s history of losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Loss (Earnings) Per Share&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Basic earnings (loss) per share is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share equals
basic in loss years as all potentially dilutive securities are anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company applies ASC 820, using a three-level hierarchy:
Level 1 (quoted prices), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company accounts for leases in accordance with ASC 842.
As of December 31, 2025, the Company has one operating lease for office facilities in Isfiya, Israel.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Tax
Disclosures) are effective for fiscal years beginning after December 15, 2023 and 2024, respectively. The Company is evaluating their
impact. No other recently issued but not yet effective pronouncements are expected to have a material impact.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Severance Pay&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;All Company employees are subject to Section 14 of the Israeli
Severance Pay Law. The Company&#x2019;s monthly deposits release it from future severance obligations; accordingly, no related assets or
liabilities are presented on the balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Deferred Income Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Deferred tax assets and liabilities are recognized for temporary
differences between carrying amounts and tax bases. Given the Company&#x2019;s history of losses, a full valuation allowance has been established
against all deferred tax assets, including net operating loss carryforwards.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <chek:GoingConcernPolicyTextBlock contextRef="c0" id="ixv-16598">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The accompanying consolidated financial statements have been
prepared on a going concern basis. As of December 31, 2025, the Company had an accumulated deficit of approximately $165,870 and cash
and cash equivalents of approximately $2. The Company has not generated revenues from operations and has incurred substantial net losses
since inception.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Notwithstanding net income of $4,140 for the year ended December
31, 2025, which arose primarily from a non-cash credit loss recovery of $6,525 recognized upon reinstatement of the Apollo loan receivable
during the first half of 2025 (see Note 14), the Company&#x2019;s operating cash flows remain negative. These conditions raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans include consummating the pending merger with MBody
AI Corp. and utilizing the ARC Equity Line of Credit facility. There is no assurance these plans will be successfully executed.&lt;/p&gt;</chek:GoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-20004" unitRef="usd">-165870000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-20005" unitRef="usd">2000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-20006" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="-3" id="ixv-20007" unitRef="usd">6525000</us-gaap:LongTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-16613">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s consolidated financial statements have
been prepared in accordance with U.S. GAAP. The functional currency of the Company is the U.S. dollar.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-16626">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Consolidation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The consolidated financial statements include the accounts
of Check Cap Ltd. and its wholly-owned subsidiaries, Check-Cap US, Inc. and Check-Cap Canada Inc. All intercompany transactions and balances
have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-16638">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company considers all short-term, highly liquid investments
with original maturities of three months or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <chek:ShortTermBankDepositPolicyTextBlock contextRef="c0" id="ixv-16650">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Short-term Bank Deposit&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Bank deposits with original maturities of more than three
months but less than twelve months are included in short-term bank deposits and bear interest at market rates.&lt;/p&gt;</chek:ShortTermBankDepositPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-16662">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over estimated useful lives: laboratory equipment 5&#x2013;7 years;
office furniture and equipment 5&#x2013;7 years; computers and auxiliary equipment 3 years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c37" id="ixv-20008">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c38" id="ixv-20009">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c39" id="ixv-20010">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c40" id="ixv-20011">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c41" id="ixv-20012">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0" id="ixv-16674">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Intangible assets are recorded at cost and amortized on a
straight-line basis over their estimated useful lives. The Ghost Kitchens ARA intangible asset, recorded at $759 upon issuance of shares
on September 4, 2025, is amortized over its estimated useful life. Amortization expense for the year ended December 31, 2025 was $34.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c42" decimals="-3" id="ixv-20013" unitRef="usd">759000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="-3" id="ixv-20014" unitRef="usd">34000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-16686">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company reviews long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying
amount exceeds the fair value of the asset.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-16713">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Investments in Equity Securities&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company accounts for investments in equity securities
without a readily determinable fair value under ASC 321, using the measurement alternative (cost less impairment, adjusted for observable
price changes in orderly transactions for identical or similar investments of the same issuer). The Apollo equity investment of $6,525
thousand, arising from the noncash debt-for-equity exchange recognized on November 14, 2025, is recorded at cost equal to the carrying
value of the loan receivable surrendered. No gain or loss was recognized on exchange. See Note 14.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:LoansReceivableFairValueDisclosure contextRef="c43" decimals="-3" id="ixv-20015" unitRef="usd">6525000</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-16725">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Research and development expenses are charged to operations
as incurred, net of participation from the Israeli Innovation Authority.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-16737">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company measures share-based compensation awards at grant-date
fair value using the Black-Scholes option-pricing model and recognizes compensation expense on a straight-line basis over the requisite
service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-16749">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company uses the asset and liability method for income
taxes. A full valuation allowance has been established against all deferred tax assets given the Company&#x2019;s history of losses.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-16761">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Loss (Earnings) Per Share&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Basic earnings (loss) per share is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding during the year. Diluted earnings (loss) per share equals
basic in loss years as all potentially dilutive securities are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c0" id="ixv-16773">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company applies ASC 820, using a three-level hierarchy:
Level 1 (quoted prices), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs).&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-16785">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;The Company accounts for leases in accordance with ASC 842.
As of December 31, 2025, the Company has one operating lease for office facilities in Isfiya, Israel.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-16797">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;ASU 2023-07 (Segment Reporting) and ASU 2023-09 (Income Tax
Disclosures) are effective for fiscal years beginning after December 15, 2023 and 2024, respectively. The Company is evaluating their
impact. No other recently issued but not yet effective pronouncements are expected to have a material impact.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PostemploymentBenefitPlansPolicy contextRef="c0" id="ixv-16809">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Severance Pay&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;All Company employees are subject to Section 14 of the Israeli
Severance Pay Law. The Company&#x2019;s monthly deposits release it from future severance obligations; accordingly, no related assets or
liabilities are presented on the balance sheet.&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <chek:DeferredIncomeTaxesPolicyTextBlock contextRef="c0" id="ixv-16821">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Deferred Income Taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;Deferred tax assets and liabilities are recognized for temporary
differences between carrying amounts and tax bases. Given the Company&#x2019;s history of losses, a full valuation allowance has been established
against all deferred tax assets, including net operating loss carryforwards.&lt;/p&gt;</chek:DeferredIncomeTaxesPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-16845">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &#x2013; PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government institutions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-16853">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Government institutions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-16946">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 4 &#x2013; PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computers and auxiliary equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Impairment of fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Depreciation expenses amounted to $0, $0, and $161 for the
years ended December 31, 2025, 2024, and 2023, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Impairment of fixed assets: The Company recorded an impairment
loss of $1,426 for the year ended December 31, 2023, following the decision to discontinue clinical studies. See Note 1(A)(4).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-16953">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Computers and auxiliary equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,336&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Impairment of fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c44" decimals="-3" id="ixv-20016" unitRef="usd">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c45" decimals="-3" id="ixv-20017" unitRef="usd">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c46" decimals="-3" id="ixv-20018" unitRef="usd">1938000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c47" decimals="-3" id="ixv-20019" unitRef="usd">1938000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c48" decimals="-3" id="ixv-20020" unitRef="usd">571000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" id="ixv-20021" unitRef="usd">571000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-20022" unitRef="usd">3336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" id="ixv-20023" unitRef="usd">3336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-20024" unitRef="usd">3336000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-20025" unitRef="usd">3336000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-20026" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c4" decimals="-3" id="ixv-20027" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="-3" id="ixv-20028" unitRef="usd">161000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges contextRef="c5" decimals="-3" id="ixv-20029" unitRef="usd">1426000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-17065">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 5 &#x2013; LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company&#x2019;s office lease in Isfiya, Israel (approximately
1,550 square meters, originally under the Amended Lease Agreement) expired December 31, 2023. Following expiry, the Company agreed to
lease a portion of the premises at a monthly fee of $8.3. On April 15, 2024, this lease was extended for two years commencing March 1,
2024, terminable upon 60 days&#x2019; notice.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Petach Tikva sub-lease (laboratory space) was terminated
effective September 8, 2023.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Petach Tikva office lease was terminated by the parties
in September 2023.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;As of December 31, 2025, operating lease right-of-use assets
and current lease liabilities were $16. The Company uses its incremental borrowing rate as the discount rate.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand contextRef="c50" decimals="0" id="ixv-20030" unitRef="sqm">1550</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1 contextRef="c0" id="ixv-20031">2023-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-2" id="ixv-20032" unitRef="usd">8300</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c51" id="ixv-20033">P2Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-20034" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-17107">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 &#x2013; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term employee benefits:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Benefits for vacation and recreation pay&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Liability for payroll, bonuses and wages&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Post-employment benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;All Company employees elected to be included under Section
14 of the Israeli Severance Pay Law. The Company&#x2019;s monthly deposits at a rate of 8.33% of salary release it from future severance
obligations. Related assets and liabilities are not presented in the balance sheet. The Company did not make contributions to pension
funds in 2025 or 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Short-term employee benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Employees are entitled to paid vacation days in accordance
with the Yearly Vacation Law-1951. Accrued but unused vacation days are payable upon termination.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock contextRef="c0" id="ixv-17122">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term employee benefits:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Benefits for vacation and recreation pay&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Liability for payroll, bonuses and wages&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock>
    <us-gaap:AccruedVacationCurrent contextRef="c2" decimals="-3" id="ixv-20035" unitRef="usd">142000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="c3" decimals="-3" id="ixv-20036" unitRef="usd">142000</us-gaap:AccruedVacationCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-20037" unitRef="usd">264000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-20038" unitRef="usd">264000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-20039" unitRef="usd">406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-20040" unitRef="usd">406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <chek:DepositsRate contextRef="c0" decimals="4" id="ixv-20041" unitRef="pure">0.0833</chek:DepositsRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-17205">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Check-Cap Ltd. is taxed according to Israeli tax laws:&lt;/p&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Corporate tax rates in Israel&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;The Israeli corporate tax rate in years 2022, 2023, 2024,
2025 and onwards is 23%.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;The Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Investments Law&#x201d;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Under the Investments Law, including Amendment No. 60 as
published in April 2005, by virtue of the &#x201c;Benefited Enterprise&#x201d; status, the Company is entitled to various tax benefits as
follows:&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 18pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Reduced tax rates&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company has one Benefited Enterprise program under the
Investments Law, which entitles it to certain tax benefits with respect to income to be derived from its Benefited Enterprise. The Company
chose 2010 as the year of election (the &#x201c;Year of Election&#x201d;). Due to the location of the Company&#x2019;s offices, the Company
believes it is entitled to a 10-year benefit period, subject to a 14-year limitation from the Year of Election. The tax benefit period
ended in 2023.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 18pt"&gt;&lt;b&gt;b)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The benefits available to a Benefited Enterprise are subject
to the fulfillment of conditions stipulated in the Investments Law and its regulations.&lt;/p&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 18pt"&gt;&lt;b&gt;c)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Amendment of the Investments Law&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Investments Law was amended as part of the Economic Policy
Law for the years 2011-2012, passed by the Israeli Knesset on December 29, 2010 (the &#x201c;Capital Investments Law Amendment&#x201d;).
The Capital Investments Law Amendment set alternative benefit tracks. Under the transitional provisions, the Company was entitled to elect
that the Capital Investments Law Amendment applies; however, the Company elected not to have the Capital Investments Law Amendment apply
to the Company.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;On December 22, 2016, the Knesset approved amendment number
73 to the Investments Law introducing reduced corporate tax rate tracks of 7.5% for Preferred Technological Enterprises located in Development
Area A and 12% for the rest of the country, and 6% for a Special Preferred Technological Enterprise.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In accordance with the Israeli Income Tax Ordinance [New
Version], 1961, as of December 31, 2025, all of the Company&#x2019;s tax assessments through tax year 2017 are considered final. Tax years
2018 through 2025 remain open to examination by the Israeli Tax Authority.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Check-Cap US, Inc.&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Check-Cap US, Inc. is taxed according to U.S. tax laws at
a federal rate of 21%.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Check-Cap US, Inc. had &lt;span style="-sec-ix-hidden: hidden-fact-119"&gt;no&lt;/span&gt; net operating loss carryforwards
as of December 31, 2025 (December 31, 2024: $177,107; December 31, 2023: $13).&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Utilization of any U.S. NOL carryforwards may be subject
to substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have
occurred or could occur in the future. The Company has not completed a detailed study to determine whether such ownership changes have
occurred.&lt;/p&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Deferred income taxes&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, Check-Cap Ltd. has accumulated
Israeli net operating loss carryforwards of approximately $129,559 (December 31, 2024: $127,162; December 31, 2023: $118,512). Under the
Israeli Income Tax Ordinance, these losses may be carried forward indefinitely to offset future Israeli taxable income. No Israeli NOL
carryforwards are subject to expiry.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, Check-Cap US, Inc. has &lt;span style="-sec-ix-hidden: hidden-fact-120"&gt;no&lt;/span&gt; U.S.
federal or state net operating loss carryforwards.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In assessing the realizability of deferred tax assets,
the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will be realized. Based on
the Company&#x2019;s history of losses, its cessation of operations in June 2023, the absence of revenue since that date, and the absence
of objectively verifiable projections of future taxable income, the Company has established a full valuation allowance against all net
operating loss carryforwards. The Company does not expect to pay taxes in Israel until it has taxable income sufficient to fully utilize
its carryforward tax losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Net deferred tax assets consist of the following components:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;NOL carryforwards &#x2013; Israel (at 23%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;NOL carryforwards &#x2013; U.S. (at 21%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total gross deferred tax asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,799&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,247&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,261&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;All amounts in USD thousands. The Israeli NOL DTA is
computed at the 23% Israeli statutory corporate tax rate on accumulated Israeli tax losses of $129,559, $127,162 and $118,512 at December
31, 2025, 2024 and 2023 respectively. The U.S. DTA of $3 at December 31, 2023 is computed at 21% on $13 of U.S. NOL and is immaterial.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Movement in accumulated Israeli net operating loss carryforwards:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Israeli NOL Rollforward (USD thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Opening accumulated Israeli NOL&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Current year estimated tax loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Closing accumulated Israeli NOL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;129,559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;127,162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;i&gt;The current year tax loss is estimated from the GAAP
net income/(loss) after the following adjustments applied consistently in both years: (i) the Apollo loan impairment charge of $16,487
recorded in 2024 and the related reversal/conversion gain of $6,525 recorded in 2025 are excluded from taxable income &#x2014; tax recognition
is deferred until all closing conditions for the debt-for-equity exchange are met, which requires completion of the merger ; (ii) share-based
compensation is added back ($12 charge in 2024; ($12) credit in 2025); and (iii) IIA grants are excluded from taxable income ($0 received
in both years). Depreciation timing differences are assumed &lt;span style="-sec-ix-hidden: hidden-fact-118"&gt;nil&lt;/span&gt; or immaterial.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Movement in valuation allowance:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Valuation Allowance Rollforward (USD thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Opening valuation allowance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(27,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Increase &#x2014; current year tax loss &#xd7; 23%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Closing accumulated Israeli NOL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(29,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has not recorded any liability for unrecognized
tax benefits under ASC 740 as of December 31, 2025 or 2024, and does not anticipate significant changes in uncertain tax positions within
the next 12 months. The Company&#x2019;s policy is to record interest and penalties related to income tax matters in income tax expense;
&lt;span style="-sec-ix-hidden: hidden-fact-121"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122"&gt;no&lt;/span&gt;&lt;/span&gt; such amounts were recognized in 2025 or 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Current tax provision&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The provision for income taxes consists of the following:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Federal (U.S.)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State (U.S.)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2014; Israel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total current tax provision&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Federal (U.S.)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State (U.S.)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2014; Israel&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total deferred tax benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Reconciliation of theoretical to actual tax expense&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table reconciles the statutory Israeli corporate
tax rate to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Statutory Israeli corporate tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of full valuation allowance on NOL carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other permanent differences (immaterial)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company generated no taxable income in Israel or the
United States in 2025 or 2024. No income taxes were paid in either jurisdiction in 2025 or 2024. The primary reconciling item between
the statutory rate and the effective rate is the full valuation allowance established against all net operating loss carryforwards, reflecting
management&#x2019;s conclusion that it is more likely than not that these assets will not be realized given the Company&#x2019;s history
of losses, absence of revenue since June 2023, and the uncertainty of future taxable income pending completion of the merger&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c52" decimals="2" id="ixv-20042" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c53" decimals="2" id="ixv-20043" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="2" id="ixv-20044" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-20045" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <chek:EntitledBenefitTerm contextRef="c0" id="ixv-20046">P10Y</chek:EntitledBenefitTerm>
    <chek:LimitationFromTheYearOfElectionTerm contextRef="c0" id="ixv-20047">P14Y</chek:LimitationFromTheYearOfElectionTerm>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c54" decimals="3" id="ixv-20048" unitRef="pure">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c55" decimals="2" id="ixv-20049" unitRef="pure">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <chek:ReductionInIncomeTaxRate contextRef="c56" decimals="2" id="ixv-20050" unitRef="pure">0.06</chek:ReductionInIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c57" decimals="2" id="ixv-20051" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards contextRef="c59" decimals="-3" id="ixv-20052" unitRef="usd">177107000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c60" decimals="-3" id="ixv-20053" unitRef="usd">13000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c61" decimals="-3" id="ixv-20054" unitRef="usd">129559000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c62" decimals="-3" id="ixv-20055" unitRef="usd">127162000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c63" decimals="-3" id="ixv-20056" unitRef="usd">118512000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-17333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Net deferred tax assets consist of the following components:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;NOL carryforwards &#x2013; Israel (at 23%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;NOL carryforwards &#x2013; U.S. (at 21%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total gross deferred tax asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,799&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;29,247&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;27,261&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-20057" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="2" id="ixv-20058" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" id="ixv-20059" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c2" decimals="-3" id="ixv-20060" unitRef="usd">29799000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c3" decimals="-3" id="ixv-20061" unitRef="usd">29247000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c16" decimals="-3" id="ixv-20062" unitRef="usd">27258000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="2" id="ixv-20063" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c4" decimals="2" id="ixv-20064" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c5" decimals="2" id="ixv-20065" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c16" decimals="-3" id="ixv-20066" unitRef="usd">3000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-20067" unitRef="usd">29799000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" id="ixv-20068" unitRef="usd">29247000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c16" decimals="-3" id="ixv-20069" unitRef="usd">27261000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-20070" unitRef="usd">29799000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-20071" unitRef="usd">29247000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c16" decimals="-3" id="ixv-20072" unitRef="usd">27261000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c64" decimals="2" id="ixv-20073" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c61" decimals="-3" id="ixv-20074" unitRef="usd">129559000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c62" decimals="-3" id="ixv-20075" unitRef="usd">127162000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c63" decimals="-3" id="ixv-20076" unitRef="usd">118512000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c16" decimals="-3" id="ixv-20077" unitRef="usd">3000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c5" decimals="2" id="ixv-20078" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:OperatingLossCarryforwards contextRef="c65" decimals="-3" id="ixv-20079" unitRef="usd">13000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c0" id="ixv-17443">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Movement in accumulated Israeli net operating loss carryforwards:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Israeli NOL Rollforward (USD thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Opening accumulated Israeli NOL&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;127,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Current year estimated tax loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Closing accumulated Israeli NOL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;129,559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;127,162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-20080" unitRef="usd">127162000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c16" decimals="-3" id="ixv-20081" unitRef="usd">118512000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss contextRef="c0" decimals="-3" id="ixv-20082" unitRef="usd">2397000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss contextRef="c4" decimals="-3" id="ixv-20083" unitRef="usd">8650000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="-3" id="ixv-20084" unitRef="usd">129559000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-20085" unitRef="usd">127162000</us-gaap:OperatingLossCarryforwards>
    <chek:ImpairmentOfLoansReceivable contextRef="c4" decimals="-3" id="ixv-20086" unitRef="usd">16487000</chek:ImpairmentOfLoansReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="-3" id="ixv-20087" unitRef="usd">6525000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" id="ixv-20088" unitRef="usd">12000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-20089" unitRef="usd">-12000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c0" decimals="-3" id="ixv-20090" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c4" decimals="-3" id="ixv-20091" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-17518">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Movement in valuation allowance:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Valuation Allowance Rollforward (USD thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Opening valuation allowance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(27,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Increase &#x2014; current year tax loss &#xd7; 23%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Closing accumulated Israeli NOL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(29,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(29,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" id="ixv-20092" unitRef="usd">-29247000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c16" decimals="-3" id="ixv-20093" unitRef="usd">-27258000</us-gaap:DeferredTaxAssetsOther>
    <chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance contextRef="c0" decimals="2" id="ixv-20094" unitRef="pure">0.23</chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance contextRef="c4" decimals="2" id="ixv-20095" unitRef="pure">0.23</chek:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" id="ixv-20096" unitRef="usd">-551000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c4" decimals="-3" id="ixv-20097" unitRef="usd">-1989000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOther contextRef="c2" decimals="-3" id="ixv-20098" unitRef="usd">-29799000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" id="ixv-20099" unitRef="usd">-29247000</us-gaap:DeferredTaxAssetsOther>
    <chek:UncertainTaxPositions contextRef="c4" id="ixv-20100">P12M</chek:UncertainTaxPositions>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-17586">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The provision for income taxes consists of the following:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Federal (U.S.)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State (U.S.)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2014; Israel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total current tax provision&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Federal (U.S.)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;State (U.S.)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2014; Israel&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total deferred tax benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-17765">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table reconciles the statutory Israeli corporate
tax rate to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Statutory Israeli corporate tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of full valuation allowance on NOL carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other permanent differences (immaterial)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-20101" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="2" id="ixv-20102" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="2" id="ixv-20103" unitRef="pure">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c4" decimals="2" id="ixv-20104" unitRef="pure">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-20105" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c4" decimals="2" id="ixv-20106" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-17834">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 &#x2013; COMMITMENTS AND CONTINGENT LIABILITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Royalties provision&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Royalties to an ASIC designer: The Company had a liability to
pay royalties of 50 euro cents per ASIC component sold, capped at &#x20ac;200 (~$213). As no future sales are expected following the C-Scan
discontinuation, the provision was derecognized in 2023 as a reduction of R&amp;amp;D expenses.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Royalties to an ASIC designer&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reimbursement liability to Predecessor Entity&#x2019;s unit holders:
The Company committed to reimburse unit holders of Check Cap LLC for tax burdens arising from the 2009 reorganization under Section 367(d)
of the Code. Since no profitability is expected, the liability based on discounted cash outflows is &lt;span style="-sec-ix-hidden: hidden-fact-127"&gt;$0&lt;/span&gt;.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Royalties &#x2013; IIA and BIRD Foundation: Since inception through
December 31, 2023, the Company received IIA funding of approximately $5,600 and BIRD Foundation funding of approximately $114. &lt;span style="-sec-ix-hidden: hidden-fact-128"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129"&gt;No&lt;/span&gt;&lt;/span&gt; grants
were received in 2024 or 2025. Contingent royalty obligations to the IIA (~$6,199) and BIRD Foundation (~$209) as of December 31, 2023
remain; these are not anticipated to be payable in the foreseeable future.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Rental agreements: See Note 5.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;From time to time, the Company is involved
in litigation arising in the ordinary course of business. The following legal proceedings were outstanding as of December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Derivative action. &lt;/b&gt;On October
7, 2024, a minority shareholder of the Company filed an application in the Haifa District Court seeking certification of a shareholders&#x2019;
derivative lawsuit against the Company, certain present and former directors, and a third party, seeking damages in excess of NIS 2,500
(approximately $784). The claims relate primarily to corporate governance matters and the legality of certain corporate decisions and
transactions. The Company filed a response requesting that certification be denied. The parties are currently engaged in mediation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Former executive compensation claims.
&lt;/b&gt;During 2024, two former senior executives filed separate claims against the Company seeking an aggregate of approximately NIS 620
(approximately $195) in respect of alleged unpaid compensation and contractual entitlements arising from the termination of their respective
engagements. The Company filed Statements of Defense rejecting all allegations in both matters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Legal fee dispute. &lt;/b&gt;During 2024,
a former legal services provider filed a claim against the Company seeking approximately NIS 175 (approximately $55) for alleged unpaid
fees. The Company filed a Statement of Defense rejecting all allegations. The parties are engaged in mediation proceedings concurrent
with the court process.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Lease and eviction proceedings. &lt;/b&gt;In
September 2024, the Company ceased making rent payments in respect of its leased premises in Usfiyeh, Israel. The landlord subsequently
commenced legal proceedings and an eviction order was granted by the court. The Company has ceased active business operations at the facility.
Certain Company property and documentation remain on the premises pending resolution of access and logistical matters. The landlord&#x2019;s
claim for unpaid rent and damages totals approximately NIS 207 (approximately $65). No impairment has been recorded against the related
right-of-use asset as proceedings remain ongoing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Management&#x2019;s assessment. &lt;/b&gt;For all of
the above matters, based on the information currently available and after consultation with legal counsel, management does not believe
an unfavorable outcome is probable for any of the above proceedings. Accordingly, no provision has been recorded in these consolidated
financial statements as of December 31, 2025. Management will reassess at each reporting date and will record a provision in the period
in which it becomes probable that a liability has been incurred and the amount can be reasonably estimated. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c66" decimals="0" id="ixv-20107" unitRef="eur">50</us-gaap:ProceedsFromRoyaltiesReceived>
    <chek:RoyaltiesSoldComponent contextRef="c66" decimals="0" id="ixv-20108" unitRef="eur">200</chek:RoyaltiesSoldComponent>
    <chek:RoyaltiesSoldComponent contextRef="c66" decimals="-3" id="ixv-20109" unitRef="usd">213000</chek:RoyaltiesSoldComponent>
    <us-gaap:OtherCommitmentsTableTextBlock contextRef="c0" id="ixv-20110">As no future sales are expected following the C-Scan
discontinuation, the provision was derecognized in 2023 as a reduction of R&amp;amp;D expenses.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Royalties to an ASIC designer&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <chek:FundReceivedInTotalAmount contextRef="c67" decimals="-3" id="ixv-20111" unitRef="usd">5600000</chek:FundReceivedInTotalAmount>
    <chek:FundReceivedInTotalAmount contextRef="c68" decimals="-3" id="ixv-20112" unitRef="usd">114000</chek:FundReceivedInTotalAmount>
    <chek:ContingentLiability contextRef="c69" decimals="-3" id="ixv-20113" unitRef="usd">6199000</chek:ContingentLiability>
    <chek:ContingentLiability contextRef="c70" decimals="-3" id="ixv-20114" unitRef="usd">209000</chek:ContingentLiability>
    <chek:DerivativeAmount contextRef="c71" decimals="0" id="ixv-20115" unitRef="ils">2500</chek:DerivativeAmount>
    <chek:DerivativeAmount contextRef="c71" decimals="-3" id="ixv-20116" unitRef="usd">784000</chek:DerivativeAmount>
    <us-gaap:PaymentsForLegalSettlements contextRef="c4" decimals="0" id="ixv-20117" unitRef="ils">620</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c4" decimals="-3" id="ixv-20118" unitRef="usd">195000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c4" decimals="0" id="ixv-20119" unitRef="ils">175</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c4" decimals="-3" id="ixv-20120" unitRef="usd">55000</us-gaap:ProceedsFromLegalSettlements>
    <chek:OutstandingAmountsOfLandlordClaim contextRef="c2" decimals="0" id="ixv-20121" unitRef="ils">207</chek:OutstandingAmountsOfLandlordClaim>
    <chek:OutstandingAmountsOfLandlordClaim contextRef="c2" decimals="-3" id="ixv-20122" unitRef="usd">65000</chek:OutstandingAmountsOfLandlordClaim>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-17973">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 &#x2013; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In accordance with ASC 820, the Company measures financial
instruments at fair value using a three-level hierarchy. As of December 31, 2025 and 2024, the Company had &lt;span style="-sec-ix-hidden: hidden-fact-130"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131"&gt;no&lt;/span&gt;&lt;/span&gt; financial instruments measured
at fair value on a recurring basis through the income statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Equity Investment in Apollo Technology
Capital Corporation &#x2014; ASC 321. The Company holds an equity investment in Apollo Technology Capital Corporation (&#x201c;Apollo&#x201d;),
representing approximately 7.5% of Apollo&#x2019;s issued and outstanding shares, arising from a debt-for-equity exchange recognized on
November 14, 2025 (see Note 14). Classification: The investment is classified as an equity security under ASC 321. The Company does not
have significant influence over Apollo: there is no board representation, no board nomination rights, no common directors or officers,
no shared management, and no governance, veto, or substantive participating rights. The equity method under ASC 323 does not apply. Measurement
alternative: Apollo&#x2019;s shares are not publicly traded and do not have a readily determinable fair value. The Company applies the
measurement alternative under ASC 321-10-35-2: the investment is carried at cost of $6,525 thousand, less any impairment, adjusted for
observable price changes in orderly transactions for identical or similar investments of the same issuer. No observable price changes
have occurred since initial recognition. Impairment assessment at December 31, 2025: Management performed a qualitative impairment assessment
supported by an independent external valuation (effective date December 31, 2025), which concluded a fair market value of CAD 124.0 million
for 100% of Apollo&#x2019;s equity. The implied value of the Company&#x2019;s 7.5% interest is approximately USD 6.8 million, exceeding
the carrying value of USD 6.5 million by USD 252,000. No impairment indicators were identified and &lt;span style="-sec-ix-hidden: hidden-fact-132"&gt;no&lt;/span&gt; impairment charge is required at
December 31, 2025. The carrying amounts of cash, short-term deposits, and current liabilities approximate fair value due to their short-term
nature.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c74" decimals="3" id="ixv-20123" unitRef="pure">0.075</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="-3" id="ixv-20124" unitRef="usd">6525000</us-gaap:LongTermInvestments>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c2" decimals="-5" id="ixv-20125" unitRef="cad">124000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities contextRef="c2" decimals="2" id="ixv-20126" unitRef="pure">1</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities>
    <chek:ImpliedInterestPercentage contextRef="c2" decimals="3" id="ixv-20127" unitRef="pure">0.075</chek:ImpliedInterestPercentage>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c2" decimals="-5" id="ixv-20128" unitRef="usd">6800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="c75" decimals="-5" id="ixv-20129" unitRef="usd">6500000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:AlternativeInvestment contextRef="c2" decimals="-3" id="ixv-20130" unitRef="usd">252000000</us-gaap:AlternativeInvestment>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-17986">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 &#x2013; SHAREHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Effective November 23, 2022, the Company effected a 1-for-20
reverse share split. Share and per-share amounts prior to November 23, 2022 have been retroactively adjusted. See Note 1(A)(11).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Ordinary shares&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Ordinary shares confer upon their holders the right to receive
dividends, to participate in liquidation distributions, and one vote per share at shareholder meetings.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Changes in ordinary share capital: The Company has conducted
multiple offerings from 2015 through 2022, including its IPO (February 2015), warrant exercises, and registered direct offerings. As
of December 31, 2024, 5,850,906 ordinary shares were issued and outstanding. On September 4, 2025, the Company issued 1,169,596 ordinary
shares in connection with the Ghost Kitchens ARA arrangement, resulting in 7,020,502 shares issued and outstanding as of December 31,
2025.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;CLA Warrants to purchase 370 ordinary
shares remain outstanding. Private Placement Warrants to purchase 84,626 ordinary shares remain outstanding.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c36" id="ixv-20131">1-for-20</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockVotingRights contextRef="c0" id="ixv-20132">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20"
      decimals="0"
      id="ixv-20133"
      unitRef="shares">5850906</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-20134"
      unitRef="shares">5850906</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c76"
      decimals="INF"
      id="ixv-20135"
      unitRef="shares">1169596</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="c26"
      decimals="0"
      id="ixv-20136"
      unitRef="shares">7020502</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-20137"
      unitRef="shares">7020502</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c77"
      decimals="INF"
      id="ixv-20138"
      unitRef="shares">370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c78"
      decimals="0"
      id="ixv-20139"
      unitRef="shares">84626</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-18025">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 &#x2013; SHARE-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company grants options and RSUs under the 2006 Plan and
the 2015 Equity Incentive Plan (including the 2015 U.S. Sub-Plan). No new options or RSUs were granted during 2025 or 2024. As of December
31, 2025, the same number of options and RSUs remain outstanding as at December 31, 2024, with no forfeitures or exercises occurring in
2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Details of share-based grants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The last options were granted on March 30, 2023 (903 options
at $2.82 exercise price). The last RSUs were granted in 2022. No share-based grants were made in 2024 or 2025.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Options Fair Value &#x2013; Black-Scholes parameters&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The parameters used in applying the Black-Scholes model are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt;
year ended&lt;br/&gt; December 31, &lt;br/&gt;
2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt;
year ended&lt;br/&gt; December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;117&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Effect of share-based compensation on statements of operations&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(57&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Option activity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Year ended December 31, 2025:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Remaining&lt;br/&gt; Life &lt;br/&gt;
(yrs)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value &lt;br/&gt;
($000s)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Options outstanding &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options outstanding &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6.34&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options exercisable &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;55,286&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;66.01&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5.87&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Year ended December 31, 2024:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;br/&gt; (yrs)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value &lt;br/&gt;
($000s)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Options outstanding &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options outstanding &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options exercisable &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;55,286&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;66.01&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6.87&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Weighted average grant date fair values: 2023: $1.17; 2022:
$4.50; 2021: $15.70. &lt;span style="-sec-ix-hidden: hidden-fact-170"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-171"&gt;No&lt;/span&gt;&lt;/span&gt; options granted in 2025 or 2024.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="text-align: justify"&gt;As of December 31, 2025, all outstanding options (102,288 at
$47.13 average exercise price) are out of the money.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;RSU activity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Unvested &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,092&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,644&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Unvested &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;No RSUs were granted in 2025 or 2024. Weighted average grant
date fair value of RSUs awarded during 2022 was $9.20.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: justify; width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;(4)&lt;/td&gt;&lt;td style="text-align: justify"&gt;As of December 31, 2025, unrecognized compensation cost related
to non-vested arrangements is approximately $&#x2013; (all prior grants are fully vested or their remaining cost is immaterial).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c79"
      decimals="0"
      id="ixv-20140"
      unitRef="shares">903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c80"
      decimals="2"
      id="ixv-20141"
      unitRef="usdPershares">2.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-18071">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The parameters used in applying the Black-Scholes model are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt;
year ended&lt;br/&gt; December 31, &lt;br/&gt;
2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt;
year ended&lt;br/&gt; December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;117&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk-free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;No grants&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="2" id="ixv-20142" unitRef="pure">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="3" id="ixv-20143" unitRef="pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" id="ixv-20144" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5" id="ixv-20145">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="c16"
      decimals="2"
      id="ixv-20146"
      unitRef="usdPershares">1.43</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-18171">&lt;b&gt;Effect of share-based compensation on statements of operations&lt;/b&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(144&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(57&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-20147" unitRef="usd">-144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c91" decimals="-3" id="ixv-20148" unitRef="usd">-12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c92" decimals="-3" id="ixv-20149" unitRef="usd">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c93" decimals="-3" id="ixv-20150" unitRef="usd">87000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-20151" unitRef="usd">-12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="-3" id="ixv-20152" unitRef="usd">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="-3" id="ixv-20153" unitRef="usd">-57000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-18240">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Year ended December 31, 2025:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Remaining&lt;br/&gt; Life &lt;br/&gt;
(yrs)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value &lt;br/&gt;
($000s)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Options outstanding &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options outstanding &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6.34&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options exercisable &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;55,286&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;66.01&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5.87&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Year ended December 31, 2024:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Exercise&lt;br/&gt; Price &lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Wtd. Avg.&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;br/&gt; (yrs)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value &lt;br/&gt;
($000s)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Options outstanding &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options outstanding &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;102,288&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;47.13&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;7.34&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Options exercisable &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;55,286&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;66.01&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6.87&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c94"
      decimals="INF"
      id="ixv-20154"
      unitRef="shares">102288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c94"
      decimals="2"
      id="ixv-20155"
      unitRef="usdPershares">47.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c95" id="ixv-20156">P7Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-20157"
      unitRef="shares">102288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-20158"
      unitRef="usdPershares">47.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c96" id="ixv-20159">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-20160"
      unitRef="shares">55286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-20161"
      unitRef="usdPershares">66.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c96" id="ixv-20162">P5Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c98"
      decimals="INF"
      id="ixv-20163"
      unitRef="shares">102288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c98"
      decimals="2"
      id="ixv-20164"
      unitRef="usdPershares">35.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c99" id="ixv-20165">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c94"
      decimals="INF"
      id="ixv-20166"
      unitRef="shares">102288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c94"
      decimals="2"
      id="ixv-20167"
      unitRef="usdPershares">47.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c100" id="ixv-20168">P7Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c94"
      decimals="INF"
      id="ixv-20169"
      unitRef="shares">55286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c94"
      decimals="2"
      id="ixv-20170"
      unitRef="usdPershares">66.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c100" id="ixv-20171">P6Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c81"
      decimals="2"
      id="ixv-20172"
      unitRef="usdPershares">1.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c82"
      decimals="2"
      id="ixv-20173"
      unitRef="usdPershares">4.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c83"
      decimals="2"
      id="ixv-20174"
      unitRef="usdPershares">15.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c86"
      decimals="0"
      id="ixv-20175"
      unitRef="shares">102288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c86"
      decimals="2"
      id="ixv-20176"
      unitRef="usdPershares">47.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-18574">&lt;b&gt;RSU activity&lt;/b&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Unvested &#x2013; beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,092&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,644&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Unvested &#x2013; end of year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,967&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c101"
      decimals="INF"
      id="ixv-20177"
      unitRef="shares">2967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-20178"
      unitRef="shares">2967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c103"
      decimals="INF"
      id="ixv-20179"
      unitRef="shares">19703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c106"
      decimals="INF"
      id="ixv-20180"
      unitRef="shares">6092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c106"
      decimals="INF"
      id="ixv-20181"
      unitRef="shares">10644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c107"
      decimals="INF"
      id="ixv-20182"
      unitRef="shares">2967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c101"
      decimals="INF"
      id="ixv-20183"
      unitRef="shares">2967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-20184"
      unitRef="shares">2967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c87"
      decimals="2"
      id="ixv-20185"
      unitRef="usdPershares">9.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-18684">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 &#x2013; RESEARCH AND DEVELOPMENT EXPENSES, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Subcontractors and consultants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cost for registration of patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less participation of the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total research and development expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock contextRef="c0" id="ixv-18688">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Subcontractors and consultants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-179"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-180"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-181"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cost for registration of patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-182"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-183"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-184"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-185"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-186"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-187"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,294&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less participation of the IIA&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-188"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-189"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total research and development expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-190"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-191"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</chek:ScheduleOfResearchAndDevelopmentExpensesNetTableTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c90" decimals="-3" id="ixv-20186" unitRef="usd">4926000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-20187" unitRef="usd">-144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SuppliesExpense contextRef="c90" decimals="-3" id="ixv-20188" unitRef="usd">1530000</us-gaap:SuppliesExpense>
    <chek:SubcontractorsAndConsultantFees contextRef="c90" decimals="-3" id="ixv-20189" unitRef="usd">800000</chek:SubcontractorsAndConsultantFees>
    <us-gaap:DepreciationNonproduction contextRef="c90" decimals="-3" id="ixv-20190" unitRef="usd">121000</us-gaap:DepreciationNonproduction>
    <chek:PaymentsExpensesForPatents contextRef="c90" decimals="-3" id="ixv-20191" unitRef="usd">78000</chek:PaymentsExpensesForPatents>
    <us-gaap:OtherExpenses contextRef="c90" decimals="-3" id="ixv-20192" unitRef="usd">983000</us-gaap:OtherExpenses>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c90" decimals="-3" id="ixv-20193" unitRef="usd">8294000</us-gaap:OtherResearchAndDevelopmentExpense>
    <chek:GrantedRevenue contextRef="c90" decimals="-3" id="ixv-20194" unitRef="usd">-17000</chek:GrantedRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c90" decimals="-3" id="ixv-20195" unitRef="usd">8311000</us-gaap:ResearchAndDevelopmentExpense>
    <chek:GeneralAndAdministrativeExpensesTextBlock contextRef="c0" id="ixv-18883">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 &#x2013; GENERAL AND ADMINISTRATIVE EXPENSES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional services*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office rent and maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,373&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The 2024 &#x201c;Others&#x201d; line includes amounts arising
from the Apollo (Apollo) loan arrangements.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</chek:GeneralAndAdministrativeExpensesTextBlock>
    <chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="c0" id="ixv-18887">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;799&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional services*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-192"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-193"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office rent and maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-194"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-195"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-196"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,373&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The 2024 &#x201c;Others&#x201d; line includes amounts arising
from the Apollo (Apollo) loan arrangements.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</chek:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c91" decimals="-3" id="ixv-20196" unitRef="usd">200000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c92" decimals="-3" id="ixv-20197" unitRef="usd">799000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c93" decimals="-3" id="ixv-20198" unitRef="usd">2055000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c91" decimals="-3" id="ixv-20199" unitRef="usd">-12000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c92" decimals="-3" id="ixv-20200" unitRef="usd">12000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c93" decimals="-3" id="ixv-20201" unitRef="usd">87000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="c93"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">4383000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:CostMaintenance contextRef="c91" decimals="-3" id="ixv-20203" unitRef="usd">105000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance contextRef="c92" decimals="-3" id="ixv-20204" unitRef="usd">81000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance contextRef="c93" decimals="-3" id="ixv-20205" unitRef="usd">235000</us-gaap:CostMaintenance>
    <us-gaap:Depreciation contextRef="c92" decimals="-3" id="ixv-20206" unitRef="usd">161000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c93" decimals="-3" id="ixv-20207" unitRef="usd">88000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization contextRef="c91" decimals="-3" id="ixv-20208" unitRef="usd">34000</us-gaap:AdjustmentForAmortization>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c91" decimals="-3" id="ixv-20209" unitRef="usd">2046000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c92" decimals="-3" id="ixv-20210" unitRef="usd">8409000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c93" decimals="-3" id="ixv-20211" unitRef="usd">2702000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c91" decimals="-3" id="ixv-20212" unitRef="usd">2373000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c92" decimals="-3" id="ixv-20213" unitRef="usd">9462000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c93" decimals="-3" id="ixv-20214" unitRef="usd">9550000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-19057">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 &#x2013; IMPAIRMENT OF LOANS RECEIVABLE AND GAIN ON DEBT
EXTINGUISHMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;During the year ended December 31, 2024, the Company entered
into a series of financing arrangements with Apollo (Apollo) totaling $16,400 (First through Fourth Apollo Loans). Management recorded
a full allowance for credit losses on all Apollo Loans as of December 31, 2024, in accordance with ASC 326. Notwithstanding the impairment,
the loans were contractually current and not in default. See Notes 1(A)(7) and 1(A)(8).&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;During the six months ended June 30, 2025, management reversed
the full impairment allowance and reinstated the loan receivable at $6,525 thousand (7.5% of the management-assessed equity value of Apollo
of $87,000 thousand at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during 2025. The reinstated receivable
was presented net of a payable owed by the Company to Apollo of $2,247 thousand pursuant to ASC 210-20-45, giving a net carrying value
of $4,278 thousand as reported in the Form 6-K filed December 30, 2025. On November 14, 2025, following the 98.01% shareholder vote in
favor of the Merger at the Annual General Meeting, the closing condition in the Exchange Agreement ceased to be substantive and the exchange
was recognized for accounting purposes. The Company derecognized the gross loan receivable of $6,525 thousand and recognized an equity
investment in Apollo at cost of $6,525 thousand, being the carrying value of the consideration surrendered in a noncash exchange. No gain
or loss was recognized on exchange; the estimated fair value of the equity received ($6,596,000) exceeded the carrying value by $71,000
(approximately 1.1%), which is not material. The Apollo payable of $2,247,000, previously netted against the loan receivable, was reclassified
as a standalone liability on November 14, 2025 and reduced to $1,400,000 through settlements and reallocations of $847,000 during the
second half of 2025. The Apollo equity investment is carried at $6,525,000 at December 31, 2025, accounted for under ASC 321 (Investments
in Equity Securities) using the measurement alternative. See Note 9 for classification, measurement, and impairment assessment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Impairment of loans receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on debt extinguishment and conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,525&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(6,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c4" decimals="-3" id="ixv-20216" unitRef="usd">16400000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable
      contextRef="c108"
      decimals="-3"
      id="ixv-20217"
      unitRef="usd">6525000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod
      contextRef="c108"
      decimals="3"
      id="ixv-20218"
      unitRef="pure">0.075</us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod>
    <us-gaap:EquityFairValueDisclosure
      contextRef="c109"
      decimals="-3"
      id="ixv-20219"
      unitRef="usd">87000000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable
      contextRef="c110"
      decimals="-3"
      id="ixv-20220"
      unitRef="usd">2247000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <chek:NetCarryingValue
      contextRef="c111"
      decimals="-3"
      id="ixv-20221"
      unitRef="usd">4278000</chek:NetCarryingValue>
    <chek:ShareholderVotingPercentage
      contextRef="c112"
      decimals="4"
      id="ixv-20222"
      unitRef="pure">0.9801</chek:ShareholderVotingPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="c113"
      decimals="-3"
      id="ixv-20223"
      unitRef="usd">6525000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="c113"
      decimals="-3"
      id="ixv-20224"
      unitRef="usd">6525000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure contextRef="c2" decimals="-3" id="ixv-20225" unitRef="usd">-6596000000</us-gaap:EquityFairValueDisclosure>
    <chek:ExceedingCarryingValue contextRef="c2" decimals="-3" id="ixv-20226" unitRef="usd">71000000</chek:ExceedingCarryingValue>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod contextRef="c0" decimals="3" id="ixv-20227" unitRef="pure">0.011</us-gaap:LoansReceivableBasisSpreadOnVariableRateDuringPeriod>
    <us-gaap:LoansPayable
      contextRef="c113"
      decimals="-3"
      id="ixv-20228"
      unitRef="usd">2247000000</us-gaap:LoansPayable>
    <us-gaap:NotesReduction contextRef="c0" decimals="-3" id="ixv-20229" unitRef="usd">1400000000</us-gaap:NotesReduction>
    <chek:NotesReallocation contextRef="c0" decimals="-3" id="ixv-20230" unitRef="usd">847000000</chek:NotesReallocation>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure contextRef="c2" decimals="-6" id="ixv-20231" unitRef="usd">6525000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c0" id="ixv-19069">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Impairment of loans receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-197"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-198"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on debt extinguishment and conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,525&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-199"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-200"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(6,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-201"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <chek:ImpairmentOfLoansReceivable contextRef="c4" decimals="-3" id="ixv-20232" unitRef="usd">16487000</chek:ImpairmentOfLoansReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c0" decimals="-3" id="ixv-20233" unitRef="usd">6525000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment contextRef="c0" decimals="-3" id="ixv-20234" unitRef="usd">6525000</chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment>
    <chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment contextRef="c4" decimals="-3" id="ixv-20235" unitRef="usd">-16487000</chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="c0" id="ixv-19148">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 &#x2013; FINANCE INCOME (EXPENSE), NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Composition:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Interest income on short-term deposits and other&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;809&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Bank fees and interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in provision for royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(188&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Changes in fair value of derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total financing income, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-19155">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Interest income on short-term deposits and other&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;809&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Bank fees and interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in provision for royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-202"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-203"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exchange rate differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-204"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-205"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(188&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Changes in fair value of derivatives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-206"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-207"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total financing income, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-20236" unitRef="usd">172000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c4" decimals="-3" id="ixv-20237" unitRef="usd">809000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="-3" id="ixv-20238" unitRef="usd">1770000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="-3" id="ixv-20239" unitRef="usd">185000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c4" decimals="-3" id="ixv-20240" unitRef="usd">9000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c5" decimals="-3" id="ixv-20241" unitRef="usd">13000</us-gaap:InterestExpenseOther>
    <chek:ChangesInLiabilityToPayRoyalties contextRef="c5" decimals="-3" id="ixv-20242" unitRef="usd">94000</chek:ChangesInLiabilityToPayRoyalties>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c5" decimals="-3" id="ixv-20243" unitRef="usd">-188000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c5" decimals="-3" id="ixv-20244" unitRef="usd">56000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-20245" unitRef="usd">-12000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" id="ixv-20246" unitRef="usd">800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" id="ixv-20247" unitRef="usd">1719000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-19289">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 16 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Basic earnings (loss) per share is computed based on the
weighted average number of shares outstanding during each year. Diluted earnings (loss) per share equals basic in periods of net loss,
as all potentially dilutive securities are anti-dilutive. In periods of net income, diluted EPS reflects the dilutive effect of outstanding
options and warrants, to the extent dilutive.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;All outstanding options and warrants were excluded from the
2024 and 2023 diluted loss per share calculations as their effect was anti-dilutive. For the year ended December 31, 2025, outstanding
options and warrants are out of the money and accordingly also excluded from diluted EPS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Computation of basic and diluted earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(25,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average ordinary shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,232,226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,849,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,848,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Earnings (loss) per ordinary share &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Note: Weighted average shares for 2025 reflect the issuance
of 1,169,596 shares on September 4, 2025 (246 pre-issuance days at 5,850,906 shares + 119 post-issuance days at 7,020,502 shares, divided
by 365 days).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Anti-dilutive instruments excluded from diluted EPS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(number)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Warrants and share options&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-19297">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Computation of basic and diluted earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(25,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average ordinary shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,232,226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,849,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,848,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Earnings (loss) per ordinary share &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.66&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-20248" unitRef="usd">4140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" id="ixv-20249" unitRef="usd">-25149000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-20250" unitRef="usd">-17568000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-20251"
      unitRef="shares">6232226</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-20252"
      unitRef="shares">6232226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-20253"
      unitRef="shares">5849013</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c4"
      decimals="0"
      id="ixv-20254"
      unitRef="shares">5849013</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-20255"
      unitRef="shares">5848737</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-20256"
      unitRef="shares">5848737</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-20257"
      unitRef="usdPershares">0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-20258"
      unitRef="usdPershares">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="ixv-20259"
      unitRef="usdPershares">-4.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c4"
      decimals="2"
      id="ixv-20260"
      unitRef="usdPershares">-4.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-20261"
      unitRef="usdPershares">-3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-20262"
      unitRef="usdPershares">-3</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c114"
      decimals="0"
      id="ixv-20263"
      unitRef="shares">1169596</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c115"
      decimals="0"
      id="ixv-20264"
      unitRef="shares">5850906</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c116"
      decimals="0"
      id="ixv-20265"
      unitRef="shares">7020502</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-19375">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Anti-dilutive instruments excluded from diluted EPS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(number)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Warrants and share options&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631,603&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c117"
      decimals="INF"
      id="ixv-20266"
      unitRef="shares">2631603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c118"
      decimals="INF"
      id="ixv-20267"
      unitRef="shares">2631603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      decimals="INF"
      id="ixv-20268"
      unitRef="shares">2631603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-19418">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 17 &#x2013; RELATED PARTIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Compensation to non-executive directors:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Fees, including reimbursement of expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Transactions with related parties:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Sigalit Kimchy: No consulting fees were paid to Sigalit Kimchy
(wife of Yoav Kimchy, the Company&#x2019;s Chief Technology Officer) during the year ended December 31, 2025. Ms. Kimchy had previously
served as marcom and user interface lead under an employment agreement dated April 4, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Consulting fees, including share-based compensation and reimbursement of expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;188&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c120" id="ixv-19428">&lt;b&gt;Compensation to non-executive directors:&lt;/b&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Fees, including reimbursement of expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-208"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-209"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c121"
      decimals="-3"
      id="ixv-20269"
      unitRef="usd">109000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c122"
      decimals="-3"
      id="ixv-20270"
      unitRef="usd">124000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c123"
      decimals="-3"
      id="ixv-20271"
      unitRef="usd">448000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c126"
      decimals="-3"
      id="ixv-20272"
      unitRef="usd">6000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c127"
      decimals="-3"
      id="ixv-20273"
      unitRef="usd">109000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c128"
      decimals="-3"
      id="ixv-20274"
      unitRef="usd">124000</chek:Compensationtothenon-executivedirectors>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c129"
      decimals="-3"
      id="ixv-20275"
      unitRef="usd">454000</chek:Compensationtothenon-executivedirectors>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c130" id="ixv-19513">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Sigalit Kimchy: No consulting fees were paid to Sigalit Kimchy
(wife of Yoav Kimchy, the Company&#x2019;s Chief Technology Officer) during the year ended December 31, 2025. Ms. Kimchy had previously
served as marcom and user interface lead under an employment agreement dated April 4, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Consulting fees, including share-based compensation and reimbursement of expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;188&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c131"
      decimals="-3"
      id="ixv-20276"
      unitRef="usd">188000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c132"
      decimals="-3"
      id="ixv-20277"
      unitRef="usd">95000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c133"
      decimals="-3"
      id="ixv-20278"
      unitRef="usd">19000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c134"
      decimals="-3"
      id="ixv-20279"
      unitRef="usd">188000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c135"
      decimals="-3"
      id="ixv-20280"
      unitRef="usd">95000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c136"
      decimals="-3"
      id="ixv-20281"
      unitRef="usd">19000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock contextRef="c0" id="ixv-19589">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 18 &#x2013; APOLLO TECHNOLOGY CAPITAL CORPORATION &#x2013; LOAN
RECEIVABLE, EXCHANGE, AND EQUITY INVESTMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"&gt;The Company holds an equity investment in Apollo Technology Capital
Corporation (&#x201c;Apollo&#x201d;, formerly Apollo AI Corp.), a technology-driven AI marketplace platform connecting homebuyers, real
estate agents, and mortgage providers across North American residential real estate markets. The investment arose from the conversion
of a series of loan receivables from Apollo (the &#x201c;Exchange Indebtedness&#x201d;) with aggregate principal of USD 16,648,253, pursuant
to the Exchange Agreement entered into on June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;Initial Impairment &#x2013; Year Ended December 31, 2024&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"&gt;During the year ended December 31, 2024, the Company fully impaired
its loan receivable from Apollo under ASC 310 and ASC 326, reducing the net carrying value to &lt;span style="-sec-ix-hidden: hidden-fact-216"&gt;nil&lt;/span&gt;, reflecting Apollo&#x2019;s financial
distress, recurring operating losses, and negative working capital at that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;Reversal of Impairment and Loan Reinstatement &#x2013; Six Months
Ended June 30, 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"&gt;During the six months ended June 30, 2025, management determined that
the impairment indicators no longer existed and reinstated the recoverable portion of the loan at USD 6,525,000 (7.5% of USD 87,000,000,
being the management-assessed equity value of Apollo at June 30, 2025) in accordance with ASC 310-10-35-23. No interest was charged during
2025. The reinstated receivable was presented net of a payable owed by Check-Cap to Apollo of USD 2,247,000, resulting in a net carrying
value of USD 4,278,000 as at June 30, 2025.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Debt-for-Equity Exchange &#x2013; November 14, 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;On June 30, 2025, the (the &#x201c;Exchange Agreement&#x201d;) with Apollo
under which the Exchange Indebtedness would be exchanged for common shares of Apollo representing a 7.5% shareholding. The Exchange Agreement
was conditional on the completion of the Merger . At the Annual General Meeting held on November 14, 2025, Check-Cap shareholders voted
98.01% in favor of the merger, at which point the closing condition ceased to be substantive and the exchange was recognized for accounting
purposes.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;On November 14, 2025, the Company derecognized the loan receivable
of USD 6,525,000 and recognized an equity investment in Apollo at cost of USD 6,525,000, being the carrying value of the consideration
surrendered. No gain or loss was recognized on exchange. Apollo&#x2019;s shares do not have a readily determinable fair value; accordingly,
the investment is carried at cost under the measurement alternative provided by ASC 321-10-35-2. The Apollo payable of USD 2,247,000,
previously netted against the loan receivable, was reclassified as a standalone liability.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Investment &#x2013; Classification and Subsequent Measurement&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;The equity investment is classified as an equity security under ASC
321. The Company holds 7.5% of Apollo&#x2019;s issued and outstanding shares and does not have significant influence, as evidenced by the
absence of board representation, shared management, governance rights, or substantive participating rights. The equity method under ASC
323 does not apply.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;The investment is carried at cost of USD 6,525,000 under the measurement
alternative (ASC 321-10-35-2), adjusted for observable price changes in orderly transactions for identical or similar investments. No
observable price changes have occurred since initial recognition.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Impairment Assessment &#x2013; December 31, 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;At December 31, 2025, management performed a qualitative impairment
assessment supported by an independent external valuation report, effective date December 31, 2025. The valuation concluded a Fair Market
Value of CAD 124.0 million for 100% of Apollo equity using a weighted average of the Discounted Cash Flow method (30% weight) and Comparable
Company Method (70% weight), with a cost of equity of 13.53%.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;Check-Cap&#x2019;s 7.5% interest implied by the valuation is CAD 9.3
million (USD 6.8 million approximately at the December 31, 2025 CAD/USD rate of 0.7287), which exceeds the carrying value of USD 6.5 million
by USD 252,000. No impairment indicators were identified and no impairment charge is required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Carrying Value Summary (USD)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended &lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loan receivable &#x2013; gross principal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,648,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,648,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loan receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity investment in Apollo (at cost)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Payable to Apollo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,399,579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</chek:ApolloTechnologyCapitalCorporationLoanReceivableExchangeAndEquityInvestmentTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c137"
      decimals="-3"
      id="ixv-20282"
      unitRef="usd">16648253000</us-gaap:DebtInstrumentIssuedPrincipal>
    <chek:ReinstatedRecoverableLoan
      contextRef="c108"
      decimals="-3"
      id="ixv-20283"
      unitRef="usd">6525000000</chek:ReinstatedRecoverableLoan>
    <chek:PercentageOfManagementAssessedEquity
      contextRef="c109"
      decimals="3"
      id="ixv-20284"
      unitRef="pure">0.075</chek:PercentageOfManagementAssessedEquity>
    <chek:AmountOfManagementAssessedEquity
      contextRef="c108"
      decimals="-3"
      id="ixv-20285"
      unitRef="usd">87000000000</chek:AmountOfManagementAssessedEquity>
    <us-gaap:LoansPayable
      contextRef="c139"
      decimals="-3"
      id="ixv-20286"
      unitRef="usd">2247000000</us-gaap:LoansPayable>
    <chek:CarryingValueOfReinstatedReceivable
      contextRef="c108"
      decimals="-3"
      id="ixv-20287"
      unitRef="usd">4278000000</chek:CarryingValueOfReinstatedReceivable>
    <chek:PercentageOfShareholding
      contextRef="c109"
      decimals="3"
      id="ixv-20288"
      unitRef="pure">0.075</chek:PercentageOfShareholding>
    <chek:ShareholderVotingPercentage
      contextRef="c112"
      decimals="4"
      id="ixv-20289"
      unitRef="pure">0.9801</chek:ShareholderVotingPercentage>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="c140"
      decimals="-3"
      id="ixv-20290"
      unitRef="usd">6525000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="c141"
      decimals="-3"
      id="ixv-20291"
      unitRef="usd">6525000000</us-gaap:EquityMethodInvestments>
    <us-gaap:PaymentsForLoans
      contextRef="c142"
      decimals="-3"
      id="ixv-20292"
      unitRef="usd">2247000000</us-gaap:PaymentsForLoans>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c75" decimals="3" id="ixv-20293" unitRef="pure">0.075</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c75" decimals="-3" id="ixv-20294" unitRef="usd">6525000000</us-gaap:EquityMethodInvestments>
    <chek:ValuationOfFairValueMarket contextRef="c0" decimals="-5" id="ixv-20295" unitRef="cad">124000000</chek:ValuationOfFairValueMarket>
    <chek:EquityPercentageOfWeightedAverage contextRef="c2" decimals="2" id="ixv-20296" unitRef="pure">1</chek:EquityPercentageOfWeightedAverage>
    <chek:PercentageOfDiscountedCashFlowMethod contextRef="c2" decimals="2" id="ixv-20297" unitRef="pure">0.30</chek:PercentageOfDiscountedCashFlowMethod>
    <chek:PercentageOfComparableCompanyMethod contextRef="c2" decimals="2" id="ixv-20298" unitRef="pure">0.70</chek:PercentageOfComparableCompanyMethod>
    <chek:PercentageOfCostEquity contextRef="c0" decimals="4" id="ixv-20299" unitRef="pure">0.1353</chek:PercentageOfCostEquity>
    <chek:PercentageOfValuationInterest contextRef="c2" decimals="3" id="ixv-20300" unitRef="pure">0.075</chek:PercentageOfValuationInterest>
    <chek:InterestImpliedValuation
      contextRef="c143"
      decimals="-5"
      id="ixv-20301"
      unitRef="cad">9300000</chek:InterestImpliedValuation>
    <chek:InterestImpliedValuation
      contextRef="c143"
      decimals="-5"
      id="ixv-20302"
      unitRef="usd">6800000</chek:InterestImpliedValuation>
    <chek:PercentageOfImpliedRate contextRef="c0" decimals="6" id="ixv-20303" unitRef="pure">0.007287</chek:PercentageOfImpliedRate>
    <chek:InterestImpliedValuation
      contextRef="c144"
      decimals="-5"
      id="ixv-20304"
      unitRef="usd">6500000</chek:InterestImpliedValuation>
    <chek:InterestImpliedValuation contextRef="c0" decimals="-3" id="ixv-20305" unitRef="usd">252000000</chek:InterestImpliedValuation>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-19648">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended &lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loan receivable &#x2013; gross principal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-210"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,648,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-211"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,648,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net loan receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-212"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-213"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity investment in Apollo (at cost)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-214"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Payable to Apollo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,399,579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-215"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesAndLoansReceivableGrossCurrent contextRef="c3" decimals="-3" id="ixv-20306" unitRef="usd">16648253000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent contextRef="c3" decimals="-3" id="ixv-20307" unitRef="usd">16648253000</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <us-gaap:EquityMethodInvestments contextRef="c75" decimals="-3" id="ixv-20308" unitRef="usd">6525000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LoansPayable contextRef="c75" decimals="-3" id="ixv-20309" unitRef="usd">1399579000</us-gaap:LoansPayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-19752">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 19 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span&gt;The Company has evaluated subsequent
events through January 1, 2026 and the date on which these consolidated financial statements were issued, and has determined that there
are no subsequent events requiring recognition or disclosure in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c3"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:RoyaltiesProvision
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:RoyaltiesProvision
      contextRef="c3"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="c2"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c0"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c4"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c0"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c4"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c0"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c5"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c4"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c5"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c12"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c5"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c10"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c19"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c4"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c17"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c5"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c4"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c4"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="c4"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="c4"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c4"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c4"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c5"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c3"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c3"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="c4"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
      contextRef="c0"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
      contextRef="c4"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
      contextRef="c5"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c4"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c3"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="c2"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="c3"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="c16"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="c3"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:PrepaidGovernmentInstitutions
      contextRef="c2"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:PrepaidGovernmentInstitutions
      contextRef="c3"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c2"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c3"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c2"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c3"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsCurrent
      contextRef="c2"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsCurrent
      contextRef="c3"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c2"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c3"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:AccumulatedImpairmentOnPropertyPlantAndEquipment
      contextRef="c2"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:AccumulatedImpairmentOnPropertyPlantAndEquipment
      contextRef="c3"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c2"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c3"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="c2"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="c3"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c16"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c0"
      id="hidden-fact-116"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c4"
      id="hidden-fact-117"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c58"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c58"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c0"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c4"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c72"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c73"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c0"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c4"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:RoyaltiesProvision
      contextRef="c2"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrantsReceivable
      contextRef="c3"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrantsReceivable
      contextRef="c2"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="c2"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="c3"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c0"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c0"
      id="hidden-fact-133"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c4"
      id="hidden-fact-134"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c0"
      id="hidden-fact-135"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c4"
      id="hidden-fact-136"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-137"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c4"
      id="hidden-fact-138"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="hidden-fact-139" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c4" id="hidden-fact-140" xsi:nil="true"/>
    <us-gaap:SharePrice
      contextRef="c2"
      id="hidden-fact-141"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharePrice
      contextRef="c3"
      id="hidden-fact-142"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c88"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c89"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c94"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c96"
      id="hidden-fact-146"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c96"
      id="hidden-fact-147"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c96"
      id="hidden-fact-148"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c96"
      id="hidden-fact-149"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c96"
      id="hidden-fact-150"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c96"
      id="hidden-fact-151"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c97"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c97"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c98"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c100"
      id="hidden-fact-155"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c100"
      id="hidden-fact-156"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c100"
      id="hidden-fact-157"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c100"
      id="hidden-fact-158"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c100"
      id="hidden-fact-159"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c100"
      id="hidden-fact-160"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c94"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c94"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c104"
      id="hidden-fact-163"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c105"
      id="hidden-fact-164"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c106"
      id="hidden-fact-165"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c104"
      id="hidden-fact-166"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c105"
      id="hidden-fact-167"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c104"
      id="hidden-fact-168"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c105"
      id="hidden-fact-169"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c84"
      id="hidden-fact-170"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c85"
      id="hidden-fact-171"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c88"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c89"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c88"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c89"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SuppliesExpense
      contextRef="c88"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SuppliesExpense
      contextRef="c89"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:SubcontractorsAndConsultantFees
      contextRef="c88"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:SubcontractorsAndConsultantFees
      contextRef="c89"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationNonproduction
      contextRef="c88"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationNonproduction
      contextRef="c89"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:PaymentsExpensesForPatents
      contextRef="c88"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:PaymentsExpensesForPatents
      contextRef="c89"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="c88"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="c89"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c88"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c89"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:GrantedRevenue
      contextRef="c88"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:GrantedRevenue
      contextRef="c89"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c88"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c89"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="c91"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="c92"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="c91"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentForAmortization
      contextRef="c92"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentForAmortization
      contextRef="c93"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c0"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoansReceivable
      contextRef="c5"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c4"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c5"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ImpairmentOfLoanReceivableAndGainOnDebtExtinguishment
      contextRef="c5"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ChangesInLiabilityToPayRoyalties
      contextRef="c0"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ChangesInLiabilityToPayRoyalties
      contextRef="c4"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c0"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c4"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="c0"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="c4"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c124"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:Compensationtothenon-executivedirectors
      contextRef="c125"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="c2"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="c2"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="c2"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="c3"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c145"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="c145"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <chek:ReducingCarryingValueNet
      contextRef="c138"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-20529">0001610590</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-20530">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-20531">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share amounts have been retroactively adjusted to reflect a 1-for-20 share reverse split, see Note 1(A)(11).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-192"
          xlink:label="hidden-fact-192"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-193"
          xlink:label="hidden-fact-193"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 2024 &#x201c;Others&#x201d; line includes amounts arising
from the Apollo (Apollo) loan arrangements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-192"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-193"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
